Compounds > meropenem
Page last updated: 2024-11-08

meropenem

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID441130
CHEMBL ID127
CHEBI ID43968
SCHEMBL ID34442
MeSH IDM0165499

Synonyms (118)

Synonym
BIDD:GT0851
AB00514051-02
ici-194660
meropen
NCGC00016962-01
NCGC00179259-01
meropenem anhydrous
meropenem
96036-03-2
BSPBIO_001212
PRESTWICK3_001106
BPBIO1_001334
PRESTWICK2_001106
smr000469184
AB00514051
MLS001401437
meropenemum [inn-latin]
brn 6940582
1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4r-(3(s*,5s*),4-alpha,5-beta,6-beta(r*)))-
1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3s,5s)-5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-, (4r,5s,6s)-
sm 7338
merrem
meronem
(1r,5s,6s)-2-[(3s,5s)-5-dimethylaminocarbonylpyrrolidin-3-ylthio]-6-[(r)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid
DB00760
mepm
(6s)-2-{[(3s,5s)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1r)-1-hydroxyethyl]-1beta-methyl-2,3-didehydro-1-carbapenam-3-carboxylic acid
CHEBI:43968 ,
(4r,5s,6s)-3-{[(3s,5s)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
antibiotic sm 7338
meropenemum
PRESTWICK1_001106
SPBIO_003086
PRESTWICK0_001106
HMS2051G08
HMS2090C05
CHEMBL127
meropenem, anhydrous
merrem i.v.
ici 194,660
meropenem (as trihydrate)
bdbm50129062
merrem iv
merrem i.v. (tn)
meropenem (inn)
D08185
meronem (tn)
(4r,5s,6s)-3-[(3s,5s)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
HMS1571M14
HMS2098M14
1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4r-(3(3s*,5s*),4alpha,5beta,6beta(r*)))-
hsdb 8019
meropenem [inn]
yop6px0bao ,
unii-yop6px0bao
tox21_110715
dtxsid7045526 ,
cas-96036-03-2
dtxcid5025526
AKOS015920140
(1r,5s,6s)-2-[(3s,5s)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(r)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid
CCG-100850
(4r,5s,6s)-3-{[(3s,5s)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
M05727
M-2780
meropenem [mi]
meropenem [who-dd]
(4r,5s,6s)-3-(((3s,5s)-5-(dimethylcarbamoyl)-3-pyrrolidinyl)thio)-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid
EPITOPE ID:195064
AB00698370-05
HY-13678
CS-1865
NC00100
(4r,5s,6s)-3-[[(3s,5s)-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(4r,5s,6s)-3-[[(3s,5s)-5-(dimethylaminocarbonyl)-3-pyrrolidinyl]thio]-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DMJNNHOOLUXYBV-PQTSNVLCSA-N
SCHEMBL34442
NCGC00262579-02
tox21_110715_1
tox21_113794
NCGC00253670-01
KS-5224
meropenem trihydrate, antibiotic for culture media use only
SR-01000762894-3
sr-01000762894
SR-01000762894-4
(4r,5s,6s)-3-(((3s,5s)-5-(dimethylcarbamoyl)pyrrolidin-3-yl)thio)-6-((r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
HMS3715M14
(4r,5s,6s)-3-((3s,5s)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(4r,6s)-3-((3s,5s)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
meropenem (closed form)
Q421670
pyrrolidin-3-ylthio)-6-((r)-1-hydroxyethyl)-
[3.2.0]hept-2-ene-2-carboxylic acid
4-methyl-7-oxo-1-azabicyclo
(4r,5s,6s)-3-((3s,5s)-5-(dimethylcarbamoyl)
meropenem,(s)
meropenem with sodium carbonate
AMY22192
NCGC00179259-06
gtpl10829
meropenem aslo known as meropenemum
(4r,5s,6s)-3-(((3s,5s)-5-(dimethylcarbamoyl)pyrrolidin-3-yl)thio)-6-((r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid
NCGC00179259-17
EN300-1721646
(4r,5s,6s)-3-
meropenem and sodium chloride in duplex container
j01dh02
meropenem (usp impurity)
meropenem trihydrate (ep monograph)
dtxcid00196578
meropenem (usp-rs)
(1r,5s,6s)-2-((3s,5s)-5-dimethylaminocarbonylpyrrolidin-3-ylthio)-6-((r)-1-hydroxyethyl)-1-methylcarbapen-2-em-3-carboxylic acid
(6s)-2-(((3s,5s)-5-(dimethylcarbamoyl)pyrrolidin-3-yl)sulfanyl)-6-((1r)-1-hydroxyethyl)-1beta-methyl-2,3-didehydro-1-carbapenam-3-carboxylic acid
meropenem (usp monograph)
meropenem (mart.)
(4r,5s,6s)-3-(((3s,5s)-5-(dimethylcarbamoyl)pyrrolidin-3-yl)thio)-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid
(1r,5s,6s)-2-

Research Excerpts

Toxicity

Of 200 subjects enrolled in the study, 99 (50%) experienced an adverse event, and 34 (17%) had serious adverse events. No adverse events were probably or definitely related to meropenem. Statistically significant trends were observed favoring cefotaxime plus metronidazole.

ExcerptReferenceRelevance
" Both treatments were well tolerated and only one patient had to withdraw from the trial because of an adverse effect (rash associated with ceftazidime)."( Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime, alone or combined with amikacin.
Sjursen, H; Solberg, CO, 1995)		0.29
" The overall pattern and frequency of adverse events with meropenem were similar to those of the other beta-lactam antibiotics with which it was compared."( Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem.
Faulkner, KL; Lesky, W; Newell, PA; Norrby, SR, 1995)		0.29
" Most drug-related adverse events were mild and self-limiting."( Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group.
Schuler, D, 1995)		0.29
" The possibility of administering meropenem in intravenous infusion or bolus injection with lower volumes of fluid, without increasing the incidence of these adverse reactions, may have practical advantages in special situations."( [Tolerance and safety of carbapenems: the use of meropenem].
Lizasoaín, M; Noriega, AR, 1997)		0.3
" Meropenem-related adverse events most frequently reported were diarrhoea (2."( Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem.
Gildon, KM; Norrby, SR, 1999)		0.3
" In conclusion, the present study showed that meropenem was safe and tolerable in children."( Efficacy and safety of meropenem as an empirical treatment for febrile neutropenia in children with cancer.
Buranachonapa, J; Mekmullica, J; Nuchprayoon, I; Pancharoen, C; Seksarn, P; Thisyakorn, U; Trongjit, D; Vanichsetakul, P, 2003)		0.32
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)		0.32
" In general, the incidence and pattern of adverse events occurring with meropenem were similar to those of the first carbapenem, imipenem/cilastatin, and to those of the cephalosporin- and clindamycin-based regimens to which it had been compared."( Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem.
Linden, P, 2007)		0.34
" The results obtained indicated that samples could be toxic in high concentration (2."( Thermal and alkaline stability of meropenem: degradation products and cytotoxicity.
Chagastelles, P; Mendez, A; Nardi, N; Palma, E; Schapoval, E, 2008)		0.35
" Although we have had extensive clinical experience since 1996 using meropenem safely in treating hundreds of patients with reported allergic reactions to penicillin without any adverse events, we have not published our experience."( Safety of meropenem in patients reporting penicillin allergy: lack of allergic cross reactions.
Cunha, BA; Eisenstein, L; Hamid, NS; Krol, V, 2008)		0.35
" Plasma concentrations (pc), interactions between drugs in the ICU context, adverse effects and seizure occurrences were observed and recorded."( Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage.
Bjeljac, M; Keller, E; Mink, S; Muroi, C; Seule, M, 2011)		0.37
"17), as well as adverse effects between the original and the generic groups."( Monitoring of effectiveness and safety of generic formulation of meropenem for treatment of infections at Siriraj Hospital.
Angkasekwinai, N; Chaiyasoot, K; Thamlikitkul, V; Werarak, P, 2011)		0.37
" There was no significant difference between CIP IV and MEM IV in terms of clinical efficacy, bacteriological efficacy, incidence of adverse drug reactions, duration of antimicrobial treatment, or relapse/reactivation."( Evaluation of the efficacy and safety of intravenous ciprofloxacin versus meropenem in the treatment of postoperative infection.
Kato, K; Kobayashi, S; Kusachi, S; Mashita, K; Oda, S; Sumiyama, Y; Takahashi, Y; Takeyama, H, 2012)		0.38
" No significant difference of adverse effect was found between two groups."( Effectiveness and safety of generic formulation of meropenem (Penem) for treatment of infections at Siriraj Hospital.
Angkasekwinai, N; Thamlikitkul, V; Tongsai, S; Werarak, P, 2012)		0.38
" Adverse events and serious adverse events were collected through 3 and 30 days following the last meropenem dose, respectively."( Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections.
Arrieta, A; Benjamin, DK; Berezny, K; Bidegain, M; Blumer, J; Brozanski, BS; Burchfield, D; Capparelli, EV; Cohen-Wolkowiez, M; Finer, N; Kantak, A; Kearns, GL; Laughon, M; Martz, K; Mehta, V; Poindexter, B; Randolph, DA; Rasmussen, M; Rich, W; Schelonka, RL; Smith, PB; Sullivan, JE; Valencia, G; van den Anker, J; Wade, K; Walsh, M; Ward, RM; Watt, KM; Weitkamp, JH, 2012)		0.38
"Of 200 subjects enrolled in the study, 99 (50%) experienced an adverse event, and 34 (17%) had serious adverse events; no adverse events were probably or definitely related to meropenem."( Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections.
Arrieta, A; Benjamin, DK; Berezny, K; Bidegain, M; Blumer, J; Brozanski, BS; Burchfield, D; Capparelli, EV; Cohen-Wolkowiez, M; Finer, N; Kantak, A; Kearns, GL; Laughon, M; Martz, K; Mehta, V; Poindexter, B; Randolph, DA; Rasmussen, M; Rich, W; Schelonka, RL; Smith, PB; Sullivan, JE; Valencia, G; van den Anker, J; Wade, K; Walsh, M; Ward, RM; Watt, KM; Weitkamp, JH, 2012)		0.38
" The incidence of adverse events was 93."( [A phase III study of the efficacy and safety of meropenem in patients with febrile neutropenia].
Akiyama, N; Chayama, K; Imajo, K; Ito, Y; Kamimura, T; Kawano, F; Miyamura, K; Morimatsu, Y; Mugitani, A; Nagai, H; Nagatoshi, Y; Ohara, A; Sao, H; Suzuki, K; Takaki, K; Tamura, K; Tanimoto, M; Ueda, Y; Uike, N; Urabe, M; Uski, K, 2012)		0.38
" The incidence of treatment-emergent adverse events was similar for ceftazidime/avibactam plus metronidazole (64."( Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial.
Lipka, J; Lucasti, C; Popescu, I; Ramesh, MK; Sable, C, 2013)		0.39
" We compared the incidence of adverse events in hospitalized infants receiving meropenem versus imipenem/cilastatin."( Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.
Benjamin, DK; Capparelli, EV; Clark, RH; Cohen-Wolkowiez, M; Herring, AH; Hornik, CP; Kearns, GL; Smith, PB; van den Anker, J, 2013)		0.39
" Multivariable conditional logistic regression was performed to evaluate the association between carbapenem therapy and adverse events, controlling for infant factors and severity of illness."( Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.
Benjamin, DK; Capparelli, EV; Clark, RH; Cohen-Wolkowiez, M; Herring, AH; Hornik, CP; Kearns, GL; Smith, PB; van den Anker, J, 2013)		0.39
"In this cohort of infants, meropenem was associated with more frequent but less severe adverse events when compared with imipenem/cilastatin."( Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.
Benjamin, DK; Capparelli, EV; Clark, RH; Cohen-Wolkowiez, M; Herring, AH; Hornik, CP; Kearns, GL; Smith, PB; van den Anker, J, 2013)		0.39
"Pharmacists have been involved in promoting the proper and safe use of antimicrobial drugs in our institution since 2010."( Outcome evaluation of an intervention to improve the effective and safe use of meropenem.
Higaki, H; Hirata, A; Miyamura, M; Nakai, M; Okazaki, M; Yagi, Y, 2014)		0.4
"Daily dose, frequency of administration, dose interval, duration of therapy, adverse events and cost reduction."( Outcome evaluation of an intervention to improve the effective and safe use of meropenem.
Higaki, H; Hirata, A; Miyamura, M; Nakai, M; Okazaki, M; Yagi, Y, 2014)		0.4
"05) in the intervention subgroup, there was no significant difference in the rate of adverse events between the two subgroups."( Outcome evaluation of an intervention to improve the effective and safe use of meropenem.
Higaki, H; Hirata, A; Miyamura, M; Nakai, M; Okazaki, M; Yagi, Y, 2014)		0.4
"Pharmacist intervention was associated with a shorter duration of therapy, lower drug costs, and decreased adverse effect."( Outcome evaluation of an intervention to improve the effective and safe use of meropenem.
Higaki, H; Hirata, A; Miyamura, M; Nakai, M; Okazaki, M; Yagi, Y, 2014)		0.4
" Eleven clinical and laboratory adverse events considered to be related to meropenem were observed in all patients, but no serious adverse event and no discontinuance of treatment due to adverse events occurred."( Open-label study to evaluate the pharmacodynamics, clinical efficacy, and safety of meropenem for adult bacterial meningitis in Japan.
Araki, N; Fukushima, Y; Hayashi, N; Hirayama, T; Iwasaki, Y; Iwata, S; Kamei, S; Kawabata, S; Kobayashi, R; Kuroda, H; Mikamo, H; Minami, M; Morita, A; Niwa, J; Ochiai, J; Sato, S; Sato, T; Shindo, K; Suzuki, Y; Takita, T; Ueda, M; Yamagishi, Y; Yoshida, K, 2014)		0.4
" The adverse event rates were similar in the groups (50."( Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.
Friedland, I; Hershberger, E; Lucasti, C; Miller, B; Solomkin, J; Steenbergen, J; Yankelev, S, 2014)		0.4
" Adverse patient outcomes including hemato-, hepato- and nephrotoxicity were infrequent."( Continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability.
Davis, TM; Dyer, J; Heath, CH; Ingram, PR; Manning, L; Manson, I; Page-Sharp, M; Salman, S; Whitmore, TJ; Wright, C, 2014)		0.4
" Adverse drug reactions were observed in 17 of the 48 patients (20."( Efficacy and safety of meropenem (3 g daily) in Japanese patients with refractory respiratory infections.
Akata, K; Ishimoto, H; Kawanami, T; Matsumoto, K; Morita, K; Mukae, H; Noguchi, S; Yamasaki, K; Yatera, K, 2014)		0.4
" Azithromycin was not associated with excess serious adverse events (SAEs)."( Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment.
Butler-Laporte, G; Menzies, D; Winters, N, 2015)		0.42
" The secondary end-points were the defervescence rates at 72 h, 7 days, 14 days and the incidence of adverse events."( The efficacy and safety of cefepime or meropenem in the treatment of febrile neutropenia in patients with lung cancer. A randomized phase II study.
Ebi, N; Fujita, M; Ichinose, Y; Inoue, Y; Ishida, M; Kishimoto, J; Matsumoto, T; Takayama, K; Wataya, H, 2016)		0.43
" Adverse events were similar between groups."( Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.
Armstrong, J; Broadhurst, H; Gasink, LB; Llorens, L; Mazuski, JE; Newell, P; Pachl, J; Rank, D; Stone, GG, 2016)		0.43
" Only six cases reported adverse events attributable to meropenem/clavulanate (four of them then restarting treatment)."( Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Abdo Arbex, M; Akkerman, OW; Alarcon Arrascue, E; Alarcon Guizado, V; Aleska, A; Alffenaar, JW; Avchinko, V; Bonini, EH; Caminero, JA; Centis, R; Chong Marín, FA; Collahuazo López, L; D'Ambrosio, L; De Lorenzo, S; de Vries, G; Dore, S; Gaga, M; Gualano, G; Kunst, H; Matteelli, A; Migliori, GB; Moschos, C; Palmieri, F; Papavasileiou, A; Payen, MC; Roby Arias, AJ; Scardigli, A; Skrahina, A; Solovic, I; Sotgiu, G; Spanevello, A; Sulis, G; Tadolini, M; Tiberi, S; Vargas Vasquez, D; Viggiani, P; White, V; Zumla, A, 2016)		0.43
" Adverse events were similar between the study groups."( A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia.
Chen, Q; Chow, JW; Kim, MJ; Laud, PJ; Nguyen, DA; Qin, X; Song, J; Stone, GG; Tran, BG; Wang, L, 2017)		0.46
"To determine the existence of concentration-toxicity relationships for common β-lactam antibiotic adverse effects and define thresholds above which toxicity is more likely."( Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships.
Buscher, H; Gentili, S; Imani, S; Marriott, D; Sandaradura, I, 2017)		0.46
" Adverse events investigated included neurotoxicity, nephrotoxicity, hepatotoxicity and opportunistic Clostridium difficile infection."( Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships.
Buscher, H; Gentili, S; Imani, S; Marriott, D; Sandaradura, I, 2017)		0.46
"Our data reveal an association between toxic concentrations for a number of β-lactam agents and neurotoxic/nephrotoxic effects."( Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships.
Buscher, H; Gentili, S; Imani, S; Marriott, D; Sandaradura, I, 2017)		0.46
" No subjects discontinued the study due to adverse events (AEs), and no serious AEs were observed."( Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects.
Bhavnani, SM; Dudley, MN; Griffith, DC; Loutit, JS; Morgan, EE; Rubino, CM; White, D, 2018)		0.48
" Overall, fewer adverse events were observed in the MV group than in the BAT group."( Efficacy and Safety of Meropenem-Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis.
Bassetti, M; Giacobbe, DR; Massey, J; Patel, N; Tillotson, G, 2019)		0.51
" The primary outcome was treatment success without modification; the secondary outcomes were adverse events (AEs), all-cause mortality, and new infections."( Comparative efficacy and safety of antipseudomonal β-lactams for pediatric febrile neutropenia: A systematic review and Bayesian network meta-analysis.
Chen, X; Guo, S; Li, Y; Liang, X; Su, H; Tan, X; Xi, J, 2021)		0.62
" Secondary endpoints included clinical and microbiologic responses at the TOC and end-of-treatment (≤24 hours after last dose) visits and adverse event rates."( A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections.
Bensaci, M; Bruno, CJ; Chen, G; Chen, X; Du, X; Fan, J; Huntington, JA; Johnson, MG; Sun, F; Sun, Y; Wang, H; Wang, Y, 2022)		0.72
"We conducted a meta-analysis of clinical trials comparing novel carbapenem-β-lactamase inhibitor combinations with comparators to assess the clinical and microbiological responses, mortality, and adverse events (AEs)."( Efficacy and safety of novel carbapenem-β-lactamase inhibitor combinations: Results from phase II and III trials.
Luo, Q; Shen, P; Xiao, Y; Xiong, L; Yu, W, 2022)		0.72
"We explored the adverse drug reaction signals of drug-induced neutropenia (DIN) and drug-induced agranulocytosis (DIA) in hospitalized patients and evaluated the novelty of these correlations."( Detection of drug safety signal of drug-induced neutropenia and agranulocytosis in all-aged patients using electronic medical records.
Liu, A; Sun, C; Xiang, Y; Yuan, Y; Zhao, L, 2023)		0.91
"Many antibiotics are well known for being associated with adverse events (AEs) of central nervous system, ceftazidime/avibactam (CAZ/AVI) is a novel β-lactam/β-lactamase inhibitor combinations."( Central nervous system adverse events of ceftazidime/avibactam: A retrospective study using Food and Drug Administration Adverse Event Reporting System.
Cui, X; Guo, M; Guo, X; Li, J, 2022)		0.72
" Rates of adverse events were similar between treatment groups (any: ceftolozane/tazobactam, 59."( Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial.
Ashouri, N; Bensaci, M; Bradley, JS; Bruno, CJ; De Anda, C; Huntington, JA; Johnson, MG; Lonchar, J; Popejoy, MW; Rhee, EG; Roilides, E; Su, FH, 2023)		0.91
" Ceftolozane/tazobactam is a safe and effective new treatment option for children with cUTI, especially due to antibacterial-resistant Gram-negative pathogens."( Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial.
Ashouri, N; Bensaci, M; Bradley, JS; Bruno, CJ; De Anda, C; Huntington, JA; Johnson, MG; Lonchar, J; Popejoy, MW; Rhee, EG; Roilides, E; Su, FH, 2023)		0.91
" Adverse events (AEs) occurred in 80."( Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection.
Bensaci, M; Bruno, CJ; De Anda, C; Dementieva, N; Huntington, JA; Jackson, CA; Johnson, MG; Lonchar, J; Newland, J; Popejoy, MW; Rhee, EG; Su, FH, 2023)		0.91
" Statistically significant trends were observed favoring cefotaxime plus metronidazole, which exhibited fewer discontinuations because of adverse events (AEs) when compared with eravacycline, meropenem and ceftolozane/tazobactam plus metronidazole (OR = 0."( Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
Deng, T; Kong, W; Li, S; Shu, Y; Wu, Y, 2023)		0.91
"In terms of adverse events, the safety of PTZ was higher than that of meropenem in the treatment of cUTIs."( Efficacy and safety of piperacillin-tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing
Cao, SS; Cui, B; Cui, F; Cui, J; Fan, BY; Fan, TT; Guan, Y; Ji, B; Li, MY; Li, SR; Wang, JW; Wang, L; Yan, CY; Zhang, W, 2023)		0.91

Pharmacokinetics

Meropenem 2000 mg every 8 hours was administered as a 3-hour infusion to maximize pharmacodynamic exposure. Oral minocycline 100 mg twice/day was also given. The pharmacokinetic parameters for meropenem are similar to those for imipenem/cilastatin.

ExcerptReferenceRelevance
" Pharmacokinetic parameters of unchanged meropenem were determined by using the HPLC data."( Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment.
Borsa-Lebas, F; Etienne, I; Fillastre, JP; Humbert, G; Leroy, A, 1992)		0.28
" Pharmacokinetic studies."( [Pharmacokinetic and clinical studies with meropenem in the pediatric field. Pediatric Study Group of Meropenem].
Chiba, S; Fujii, R; Fujita, K; Fukushima, N; Inyaku, F; Maruyama, S; Sakata, H; Tsutsumi, H; Wagatsuma, Y; Yoshioka, H, 1992)		0.28
" The pharmacokinetic studies on MEPM were done in 6 patients."( [Clinical and pharmacokinetic evaluation of meropenem and its effect on fecal flora in children].
Fujita, K; Inyaku, F; Maruyama, S; Murono, K; Saijyo, M; Sakata, H; Yoshioka, H, 1992)		0.28
" The mean plasma peak concentration of MEPM in 5 patients was 36."( [Clinical and pharmacokinetic evaluations of meropenem in children].
Satoh, K; Watanabe, A, 1992)		0.28
" Pharmacokinetic studies: Peak plasma concentrations of MEPM averaged 43."( [Pharmacokinetic, bacteriological and clinical studies on meropenem in children].
Abe, T; Hagiwara, N; Higa, A; Kawashima, S; Kondo, Y; Negishi, S; Niimi, R; Nishimura, S; Tajima, T, 1992)		0.28
" The terminal half-life of meropenem was approximately 1 h in subjects with normal kidney function and it was proportionately increased as renal function decreased."( Pharmacokinetics of meropenem in subjects with renal insufficiency.
Borsa-Lebás, F; Etienne, I; Fillastre, JP; Humbert, G; Leroy, A, 1992)		0.28
" In order to define meropenem dosing guidelines for children, an escalating, single-dose, pharmacokinetic study at 10, 20, and 40 mg/kg of body weight was performed."( Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children.
Blumer, JL; Ewing, BJ; Gooch, WM; Jacobs, RF; Kearns, GL; Reed, MD; Willims, K; Yogev, R, 1995)		0.29
" The elimination half-life (t1/2) is approximately 1 hour, and the area under the plasma concentration-time curve increases linearly in a dose-related manner."( Meropenem clinical pharmacokinetics.
Mouton, JW; van den Anker, JN, 1995)		0.29
" The terminal half-life is approximately 1 hour and the plasma clearance is approximately 15."( The pharmacokinetics of meropenem.
Drusano, GL; Hutchison, M, 1995)		0.29
" Twelve patients (one woman and 11 men) participated in the meropenem pharmacokinetic analysis."( Pharmacokinetics of meropenem in patients with intra-abdominal infections.
Appleman, MD; Bedikian, A; Berne, TV; Farino, J; Gill, MA; Heseltine, PN; Nakahiro, RK; Okamoto, MP; Yellin, AE, 1994)		0.29
" Serum meropenem concentrations were assayed by HPLC and fitted to a two compartment pharmacokinetic model."( The pharmacokinetics of meropenem in surgical patients with moderate or severe infections.
Leaper, D; Lovering, AM; MacGowan, AP; McMullin, CM; Reeves, DS; Vickery, CJ; Watkin, DS; White, LO, 1995)		0.29
" Plasma clearance, renal clearance, non-renal clearance, terminal half-life and volume of distribution were unchanged."( A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min.
Haworth, SJ; Hutchison, M; Kelly, HC, 1995)		0.29
"Plasma meropenem concentration versus time data collected during a single dose, pharmacokinetic study in infants and children were analysed using the population pharmacokinetics program NONMEM."( The pharmacokinetics of meropenem in infants and children: a population analysis.
Blumer, JL; Hutchison, M; Parker, EM, 1995)		0.29
"Several pharmacodynamic parameters are being studied and applied to the design of dosage regimens."( In vivo and in vitro study of several pharmacodynamic effects of meropenem.
Fuentes, F; Gomez-Lus, ML; Izquierdo, J; Martín, MM; Prieto, J, 1995)		0.29
" In conclusion, this chronic model of catheterized micropig is suitable for long term pharmacokinetic and pharmacodynamic investigations of antiinfective agents."( [Model of a miniature pig catheterized for pharmacokinetic and pharmacodynamic studies of anti-infective agents].
Cavalier, A; Elkhaïli, H; Jehl, F; Kaltenbach, G; Levêque, D; Monteil, H; Peter, JD; Salmon, J; Salmon, Y, 1996)		0.29
" Pharmacokinetic parameters were based on an open two-compartment model and a noncompartmental technique."( Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.
Borner, K; Dreetz, M; Eller, J; Hamacher, J; Koeppe, P; Lode, H; Schaberg, T, 1996)		0.29
" Pharmacodynamic parameters were compared by using the Wilcoxon signed-rank test."( Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa.
Bosso, J; Burgess, D; Friedrich, L; Warkentin, D; White, R, 1996)		0.29
" No statistically significant differences were found between the first dose and steady state or between groups for any plasma pharmacokinetic parameters-including the highest observed plasma concentrations, plasma concentrations at 6 hours after dosing (C6h), terminal half-life, area under the plasma concentration-time curve (AUC), area under the first moment of the curve, plasma clearance, steady-state volume of distribution, and accumulation ratios-on the basis of either AUC or C6h."( Pharmacokinetics of meropenem in patients with liver disease.
Birmingham, B; Lasseter, K; Thyrum, PT; Yeh, C, 1997)		0.3
" The pharmacokinetic parameters for meropenem are similar to those for imipenem/cilastatin, with the exception of meropenem's smaller volume of distribution."( Pharmacokinetics of meropenem in animals, healthy volunteers, and patients.
Chung, KC; Gill, MA; Moon, YS, 1997)		0.3
" A pharmacodynamic model equation, based on the concept that the killing rate depends on concentration and time, was fitted to the numbers of CFU."( Pharmacokinetic and pharmacodynamic models of the antistaphylococcal effects of meropenem and cloxacillin in vitro and in experimental infection.
Douwes-Idema, AE; Mattie, H; Sekh, BR; van Strijen, E; Zhang, LC, 1997)		0.3
" Plasma clearance, terminal half-life and volume of distribution were virtually unchanged."( A comparison of the pharmacokinetics of meropenem after intravenous administration by injection over 2, 3 and 5 minutes.
Freestone, S; Hutchison, M; Jones, HK; Kelly, HC; Lomax, C; Ross, F; Webb, D; Yates, RA, )		0.13
" The pharmacokinetic profile of meropenem in febrile neutropenic patients differs from earlier findings in healthy subjects."( Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish study group.
Ljungberg, B; Nilsson-Ehle, I; Nyhlén, A, 1997)		0.3
"The pharmacokinetic properties of meropenem were investigated in nine critically ill patients treated by continuous venovenous hemofiltration (CVVH)."( Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration.
Breyer, S; Burgmann, H; El Menyawi, I; Hollenstein, UM; Ratheiser, K; Rosenkranz, AR; Schenk, P; Sunder-Plassmann, G; Thalhammer, F, 1998)		0.3
"An in-vitro pharmacokinetic model was used to study the antibacterial activity of meropenem."( Comparative pharmacodynamics of meropenem using an in-vitro model to simulate once, twice and three times daily dosing in humans.
Bowker, KE; Holt, HA; Lewis, RJ; MacGowan, AP; Reeves, DS, 1998)		0.3
" The aim of this study was to assess pharmacokinetic data of meropenem in patients with acute renal failure and to determine the amount of drug removed by continuous venovenous hemofiltration, an often-used renal replacement therapy in patients with acute renal failure."( Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.
Bremer, F; Brune, K; Geisslinger, G; Lötsch, J; Neumann, F; Tegeder, I, 1999)		0.3
" Pharmacokinetic parameters were calculated for a 2-compartment open model and dose requirements were calculated."( Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.
Bremer, F; Brune, K; Geisslinger, G; Lötsch, J; Neumann, F; Tegeder, I, 1999)		0.3
"Meropenem concentrations were measured by high-performance liquid chromatography in serum taken at timed intervals and in ultrafiltrate/dialysate to determine serum concentration-time profiles, derive pharmacokinetic variable estimates, and determine sieving coefficients and filter clearances."( Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration.
Beale, RJ; Creed, G; Giles, LJ; Jennings, AC; McLuckie, A; Thomson, AH, 2000)		0.31
" The following pharmacokinetic variables for meropenem were obtained: mean peak plasma concentration was 24."( Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration.
Blankestijn, PJ; Boereboom, FT; Meulenbelt, J; Savelkoul, JF; van Dijk, A; Ververs, TF; Vinks, SA, 2000)		0.31
" The half-life of meropenem (approximately 1 hour in healthy volunteers) is prolonged up to 13."( Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy.
Hörl, WH; Thalhammer, F, 2000)		0.31
" response, when normalized by the MIC and corrected for drug degradation, these agents displayed similar pharmacodynamic parameter-response relationships."( Comparative in vitro pharmacodynamics of imipenem and meropenem against ATCC strains of Escherichia coli, Staphylococcus aureus and Bacteroides fragilis.
Bosso, JA; Friedrich, LV; Manduru, M; Mihm, LB; White, RL, 2001)		0.31
" These pharmacokinetic data were similar to those obtained in non-CF populations."( Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients.
Ambrose, PG; Bui, KQ; Lapin, CD; Nicolau, DP; Nightingale, CH; Quintiliani, R, )		0.13
" The purposes of this study were to evaluate the bactericidal effectiveness and the pharmacodynamic profile of moxifloxacin in cerebrospinal fluid (CSF) and to compare the bactericidal activity with that of ceftriaxone and meropenem therapy."( Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis.
Ghaffar, F; Hardy, RD; Jafri, HS; McCoig, CC; McCracken, GH; Michelow, IC; Olsen, K; Patel, C; Rodriguez-Cerrato, V, 2001)		0.31
" The pharmacokinetic parameters differed between the two groups as follows, Group I, maximal concentration 56."( Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients.
De Myttenaere-Bursztein, SA; Farin, D; Kitzes-Cohen, R; Piva, G, 2002)		0.31
" This study represents a successful application of the microdialysis technique, which is an effective method for pharmacokinetic and biliary drug excretion studies."( Determination and pharmacokinetic study of meropenem in rat bile using on-line microdialysis and liquid chromatography.
Chan, YL; Chen, CF; Chou, MH; Lin, MF; Tsai, TH, 2002)		0.31
"To estimate pharmacokinetic variables and measure tissue fluid concentrations of meropenem after IV and SC administration in dogs."( Plasma pharmacokinetics and tissue fluid concentrations of meropenem after intravenous and subcutaneous administration in dogs.
Bidgood, T; Papich, MG, 2002)		0.31
"Plasma data were analyzed by compartmental and noncompartmental pharmacokinetic methods."( Plasma pharmacokinetics and tissue fluid concentrations of meropenem after intravenous and subcutaneous administration in dogs.
Bidgood, T; Papich, MG, 2002)		0.31
"The economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts is described."( Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts.
Kuti, JL; Maglio, D; Nicolau, DP; Nightingale, CH, 2003)		0.32
"The pharmacokinetic disposition of meropenem, administered at 500 mg every 8 h, in plasma and cantharidin-induced blister fluid is described."( Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid.
Maglio, D; Nicolau, DP; Nightingale, CH; Teng, R; Thyrum, PT, 2003)		0.32
" The 3-hour infusion optimized the pharmacodynamic profile of meropenem and worked within the constraints of stability at room temperature stability."( Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.
Dandekar, PK; Maglio, D; Nicolau, DP; Nightingale, CH; Sutherland, CA, 2003)		0.32
" Monte Carlo simulation was employed to determine pharmacodynamic target attainment rates for several prolonged infusion (PI) meropenem dosage regimens as compared with the traditional 30-minute infusion (TI) against Enterobacteriaceae, Acinetobacter species, and Pseudomonas aeruginosa populations."( Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
Dandekar, PK; Kuti, JL; Nicolau, DP; Nightingale, CH, 2003)		0.32
" The pharmacokinetic analysis was based both on a noncompartmental approach and on a four-compartment modeling."( Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients.
Biollaz, J; Buclin, T; Decosterd, LA; Eckert, P; Robatel, C; Schaller, MD, 2003)		0.32
" Dosage recommendations are based on the correlation of plasma levels with pharmacodynamic requirements."( Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration.
Dieterich, HJ; Forst, H; Heininger, A; Hoffmann, E; Krueger, WA; Neeser, G; Schroeder, TH; Schuster, H; Unertl, KE, 2003)		0.32
"The probability of attaining lower pharmacodynamic targets for most gram-negative bacteria is similar for these carbapenems; however, differences become apparent as the pharmacodynamic requirement increases."( Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
Florea, NR; Kuti, JL; Nicolau, DP; Nightingale, CH, 2004)		0.32
" Although continuous infusion is the ideal method to maximize the pharmacodynamic properties of this betalactam antibiotic, meropenem is stable for only approximately 4 to 6 hours at room temperature, and its pharmacokinetic (PK) properties, when administered by continuous infusion to patients with CF, are largely unknown."( Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis.
Knauft, RF; Kuti, JL; Nicolau, DP; Nightingale, CH, 2004)		0.32
" Serum samples were collected throughout the infusion and then for 6 hours after infusion to determine the PK properties (volume of distribution [V(d)], elimination rate constant, total body clearance [CL], terminal half-life [t 1/2], and steady-state concentration [C(ss)])."( Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis.
Knauft, RF; Kuti, JL; Nicolau, DP; Nightingale, CH, 2004)		0.32
"The clinical and economic outcomes of a meropenem dosage strategy based on pharmacodynamic concepts are retrospectively reviewed."( Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts.
Kotapati, S; Kuti, JL; Nicolau, DP; Nightingale, CH, 2004)		0.32
" Consideration of pharmacodynamic principles in dosage regimens for these agents can maximize their antibacterial effectiveness and reduce the number of bacterial strains that survive to mutate or continue infection."( Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem.
Drusano, GL; Kuti, JL; Mattoes, HM; Nicolau, DP, 2004)		0.32
"When proper pharmacodynamic principles are applied to dosage strategies for meropenem, clinical and microbiological outcomes can be optimized."( Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem.
Drusano, GL; Kuti, JL; Mattoes, HM; Nicolau, DP, 2004)		0.32
" To circumvent these limitations, we propose an alternative approach to the quantification of pharmacodynamic drug interaction (PDI)."( Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents.
Boucher, AN; Lewis, RE; Melnick, DA; Schilling, AN; Tam, VH, 2004)		0.32
" Meropenem 2000 mg every 8 hours was administered as a 3-hour infusion to maximize pharmacodynamic exposure; oral minocycline 100 mg twice/day was also given."( Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy.
Knauft, RF; Kuti, JL; Moss, KM; Nicolau, DP, 2004)		0.32
" The pharmacodynamic index of percent time above MIC (% T>MIC) was analyzed for its association with clinical outcome."( Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia.
Ariano, RE; Donnelly, JP; Harding, GK; Nyhlén, A; Sitar, DS; Zelenitsky, SA, 2005)		0.33
"A 2-compartment pharmacokinetic model using patient covariates of body weight and renal function best described the pharmacokinetics of meropenem in febrile neutropenic patients."( Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia.
Ariano, RE; Donnelly, JP; Harding, GK; Nyhlén, A; Sitar, DS; Zelenitsky, SA, 2005)		0.33
"To our knowledge, this is the first published report of a relationship between a pharmacodynamic index and clinical outcome in a febrile neutropenic population."( Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia.
Ariano, RE; Donnelly, JP; Harding, GK; Nyhlén, A; Sitar, DS; Zelenitsky, SA, 2005)		0.33
" Monte Carlo simulation was used to construct pharmacodynamic models for imipenem, meropenem, ertapenem, levofloxacin, gatifloxacin, and ciprofloxacin."( Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Burgess, DS; Frei, CR; Moczygemba, LR, 2004)		0.32
" In the pharmacodynamic models, imipenem and meropenem had an equal likelihood of achieving a free T>MIC > or =40% against bacteria that produced ESBLs (> or =97%) and bacteria that did not produce ESBLs (> or =98%)."( Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Burgess, DS; Frei, CR; Moczygemba, LR, 2004)		0.32
" Pharmacodynamic modeling based on local ESBL-producing isolates and pharmacokinetic data from healthy humans indicated that imipenem and meropenem may have a greater likelihood of achieving pharmacodynamic targets against bacteria that produce ESBLs than ertapenem or fluoroquinolones."( Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Burgess, DS; Frei, CR; Moczygemba, LR, 2004)		0.32
" Pharmacokinetic calculations were done by use of a two-compartment open model, and the data were extrapolated by Monte Carlo simulations for 10,000 simulated subjects for pharmacodynamic evaluation."( Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.
Bulitta, J; Drusano, GL; Holzgrabe, U; Kinzig-Schippers, M; Krueger, WA; Landersdorfer, C; Naber, KG; Sörgel, F, 2005)		0.33
"To evaluate and compare the pharmacokinetic profiles of imipenem and meropenem in a population of critically ill patients with sepsis to find possible differences that may help in selecting the most appropriate drug and/or dosage in order to optimise empiric antimicrobial therapy."( Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis.
Adembri, C; De Gaudio, AR; Fallani, S; Livi, P; Mazzei, T; Novelli, A, 2005)		0.33
" Pharmacokinetic analysis was carried out through computerised programs using the least-square regression method and a two-compartment open model."( Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis.
Adembri, C; De Gaudio, AR; Fallani, S; Livi, P; Mazzei, T; Novelli, A, 2005)		0.33
"The following pharmacokinetic differences between the two drugs were observed: the imipenem mean peak serum concentration was significantly higher than for meropenem (90."( Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis.
Adembri, C; De Gaudio, AR; Fallani, S; Livi, P; Mazzei, T; Novelli, A, 2005)		0.33
"The more favourable pharmacokinetic profile of imipenem compared with meropenem in critically ill patients with sepsis might balance the possibly greater potency demonstrated in vitro for meropenem against Gram-negative strains."( Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis.
Adembri, C; De Gaudio, AR; Fallani, S; Livi, P; Mazzei, T; Novelli, A, 2005)		0.33
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005)		0.33
"Dosage recommendations for antibiotics in patients receiving continuous veno-venous hemofiltration (CVVH) should be based on pharmacodynamic requirements."( Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment.
Kuti, JL; Nicolau, DP, 2005)		0.33
"Meropenem 1,000 mg every 8 h optimizes the pharmacodynamic profile in patients undergoing CVVH."( Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment.
Kuti, JL; Nicolau, DP, 2005)		0.33
"Monte Carlo simulation based on published pharmacokinetic studies."( Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem.
Horowitz, S; Kuti, JL; Nicolau, DP; Nightingale, CH, 2005)		0.33
"One hundred and ninety-seven participants (75 healthy volunteers and 122 patients) from published pharmacokinetic studies of ceftazidime or meropenem."( Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem.
Horowitz, S; Kuti, JL; Nicolau, DP; Nightingale, CH, 2005)		0.33
" We calculated the likelihood of obtaining bactericidal exposures (50% time above the minimum inhibitory concentration [MIC] for ceftazidime and 40% time above the MIC for meropenem) for each combination of pharmacokinetic study data and MIC distribution."( Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem.
Horowitz, S; Kuti, JL; Nicolau, DP; Nightingale, CH, 2005)		0.33
"The pharmacodynamic target attainment calculated with healthy subject pharmacokinetic data was predictive of patient target target attainment for ceftazidime and meropenem."( Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem.
Horowitz, S; Kuti, JL; Nicolau, DP; Nightingale, CH, 2005)		0.33
" Pharmacokinetic parameters, obtained from previously published studies in healthy volunteers were used to simulate the %T > MIC for 10,000 patients receiving imipenem-cilastatin, meropenem, and piperacillin/tazobactam."( Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
Kotapati, S; Kuti, JL; Nicolau, DP, 2005)		0.33
"To compare the probability of achieving specific pharmacodynamic exposures of commonly used intravenous antibiotics for the empirical treatment of nosocomial pneumonia against those pathogens most commonly implicated in the disease."( Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
Kuti, JL; Nicolau, DP; Sun, HK, 2005)		0.33
" The probabilities of each drug and dosing regimen in achieving pharmacodynamic targets were calculated."( Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
Kuti, JL; Nicolau, DP; Sun, HK, 2005)		0.33
" An increase in total clearance and a decrease in elimination half-life were observed to the extent that the patient's creatinine clearance was higher."( Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients.
Arzuaga, A; Corral, E; Gascón, AR; Isla, A; Maynar, J; Pedraz, JL; Sánchez-Izquierdo, JA, 2005)		0.33
"The objective of this study was to determine the plasma and intrapulmonary pharmacokinetic parameters of intravenously administered meropenem in healthy volunteers."( Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem.
Conte, JE; Golden, JA; Kelley, MG; Zurlinden, E, 2005)		0.33
" In addition to the application of different methods to calculate pharmacokinetic parameters, the total dialysate concentration of both drugs was measured."( Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis.
Bode-Böger, SM; Czock, D; Fliser, D; Hafer, C; Keller, F; Kielstein, JT; Kuse, E; Schöpke, T, 2006)		0.33
"3 years) were used to develop a population pharmacokinetic model."( Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients.
Du, X; Kuti, JL; Li, C; Nicolau, DP; Nightingale, CH, 2006)		0.33
"The bactericidal exposures necessary for positive clinical outcomes among skin and soft tissue infections are largely dependent on interpatient pharmacokinetic variability and pathogen drug susceptibility."( Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
Kuti, JL; Nicolau, DP; Ong, CT, 2005)		0.33
" The exact mechanism of this pharmacokinetic interaction is unknown, although several experimental studies have been carried out in animals."( [Pharmacokinetic interaction between valproic acid and meropenem].
Balcells Ramírez, J; Cabañas Poy, MJ; Clemente Bautista, S; Hidalgo Albert, E; Oliveras Arenas, M; Padullés Zamora, N; Sala Piñol, F, 2006)		0.33
" Pediatric pharmacokinetic data were derived from the literature."( Pharmacodynamic evaluation of meropenem and cefotaxime for pediatric meningitis: a report from the OPTAMA program.
Ellis, JM; Kuti, JL; Nicolau, DP, 2006)		0.33
"The pharmacodynamic potency of imipenem, meropenem and ertapenem against extended-spectrum beta-lactamase (ESBL)-producing isolates was investigated."( Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil.
Eagye, KJ; Kiffer, CR; Kuti, JL; Mendes, C; Nicolau, DP, 2006)		0.33
"Population pharmacokinetic parameters of meropenem in 57 febrile neutropenic patients and minimal inhibitory concentration (MIC) data for clinically isolated Pseudomonas aeruginosa and Escherichia coli were applied to estimate the time above the MIC (T>MIC) using the Monte Carlo simulation method."( Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea.
Choi, SM; Lah, HO; Lee, DG; Shin, WS; Yim, DS, 2006)		0.33
"The objectives of this study were to develop a meropenem population pharmacokinetic model using patient data and use it to explore alternative dosage regimens that could optimize the currently used dosing regimen to achieve higher likelihood of pharmacodynamic exposure against pathogenic bacteria."( Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients.
Kuti, JL; Li, C; Nicolau, DP; Nightingale, CH, 2006)		0.33
"Owing to increasing resistance rates in Europe, pharmacodynamic analyses were proposed to determine optimal empirical antibiotic therapy against Pseudomonas aeruginosa isolated in Hungary."( Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Konkoly-Thege, M; Kuti, JL; Ludwig, E; Nicolau, DP, 2006)		0.33
" In this study, classification and regression tree (CART) and logistic regression analyses were used to identify which pharmacodynamic indices and magnitudes were significant predictors of meropenem efficacy for 101 adult patients with lower respiratory tract infections (LRTI)."( Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.
Du, X; Kuti, JL; Li, C; Nicolau, DP, 2007)		0.34
" A model employing the pharmacokinetic properties of meropenem, susceptibility results and Monte Carlo simulation was used to analyse four different dosing regimens of meropenem at pharmacodynamic endpoints."( Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy.
Eagye, KJ; Kuti, JL; Nicolau, DP; Santos Filho, L, 2007)		0.34
"Using an in vitro pharmacodynamic model, a multidrug-resistant strain of Acinetobacter baumannii was exposed to colistin methanesulfonate alone and in combination with ceftazidime."( Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.
Hovde, LB; Kroeger, LA; Mitropoulos, IF; Rotschafer, JC; Schafer, J, 2007)		0.34
"In this study we investigated the interplay of antibiotic pharmacokinetic profiles and the development of mutation-mediated resistance in wild-type and hypermutable Pseudomonas aeruginosa strains."( Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
Henrichfreise, B; Luhmer-Becker, I; Wiedemann, B; Wiegand, I, 2007)		0.34
"A pharmacokinetic (PK)/pharmacodynamic (PD) modeling strategy to simulate in vivo bactericidal effects for three carbapenem antibiotics, doripenem (DRPM), meropenem (MEPM)/cilastatin (CS), and imipenem (IPM)/CS, against a Pseudomonas aeruginosa (P."( Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model.
Katsube, T; Yamano, Y; Yano, Y, 2008)		0.35
" Although their dispositions in CSF have been described, the ability of these agents to achieve critical pharmacodynamic targets against the array of nosocomial CSF Gram-negative bacteria encountered in practice has not been reported."( Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.
Drusano, GL; Jones, RN; Kinzig, M; Lodise, TP; Nau, R; Sörgel, F, 2007)		0.34
"Serum and CSF pharmacokinetic data were obtained from hospital patients with external ventricular drains and who received ceftazidime or meropenem."( Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.
Drusano, GL; Jones, RN; Kinzig, M; Lodise, TP; Nau, R; Sörgel, F, 2007)		0.34
" The objective of this study was to develop a population pharmacokinetic model of meropenem in critically ill patients undergoing CRRT."( Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
Bueno, L; Isla, A; Maynar, J; Pedraz, JL; Rodríguez-Gascón, A; Sánchez-Izquierdo, JA; Solinís, MA; Trocóniz, IF, 2008)		0.35
"A population pharmacokinetic model of meropenem in intensive care patients undergoing CRRT was developed and validated."( Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
Bueno, L; Isla, A; Maynar, J; Pedraz, JL; Rodríguez-Gascón, A; Sánchez-Izquierdo, JA; Solinís, MA; Trocóniz, IF, 2008)		0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008)		0.35
"Prospective, open-label, steady-state pharmacokinetic study."( Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.
Cheatham, SC; Kays, MB; Smith, DW; Sowinski, KM; Wack, MF, 2008)		0.35
" Meropenem concentrations were determined by high-performance liquid chromatography, and pharmacokinetic data were analyzed by noncompartmental methods."( Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.
Cheatham, SC; Kays, MB; Smith, DW; Sowinski, KM; Wack, MF, 2008)		0.35
"Pharmacokinetic and pharmacodynamic profiles of antibiotics are important in determining effective dosing regimens."( Pharmacokinetic and pharmacodynamic properties of meropenem.
Nicolau, DP, 2008)		0.35
" The pharmacokinetic parameter of % time above MIC for tomopenem and meropenem was 16% and 17% in sera and 15% and 18% in lungs, respectively."( In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model.
Izumikawa, K; Kakeya, H; Kamihira, S; Kohno, S; Morinaga, Y; Nakamura, S; Seki, M; Yamada, Y; Yamamoto, K; Yamamoto, Y; Yanagihara, K, 2008)		0.35
"Rational dosing of antibiotics in neonates should be based on pharmacokinetic (PK) parameters assessed in specific populations."( Microanalysis of beta-lactam antibiotics and vancomycin in plasma for pharmacokinetic studies in neonates.
Ahsman, MJ; Mathot, RA; Tibboel, D; Wildschut, ED, 2009)		0.35
"5 g q8h achieved a >90% probability of pharmacodynamic target (50% of the time above MIC) attainment, and 1 g q8h was needed for a >90% probability of target (100% of the time above MIC) attainment."( The pharmacokinetics and pharmacodynamics of meropenem in the cerebrospinal fluid of neurosurgical patients.
Iida, K; Ikawa, K; Ikeda, K; Kurisu, K; Morikawa, N; Shibukawa, M; Tsumura, R, 2008)		0.35
"Because of the high frequency of multidrug resistant bacteria in our intensive care units (ICUs), we implemented a ventilator-associated pneumonia (VAP) clinical pathway based on unit-specific minimum inhibitory concentration (MIC) distributions and pharmacodynamic modeling in 3 of our ICUs."( Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia.
Eagye, KJ; Kuti, JL; Nicasio, AM; Nicolau, DP; Palter, M; Pepe, J; Shore, E, 2010)		0.36
"In our ICUs where multidrug resistant bacteria are common, an approach considering ICU-specific antibiotic MICs coupled with pharmacodynamic dosing strategies resulted in improved outcomes and shorter duration of treatments."( Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia.
Eagye, KJ; Kuti, JL; Nicasio, AM; Nicolau, DP; Palter, M; Pepe, J; Shore, E, 2010)		0.36
" Population pharmacokinetic parameter values were obtained by employing the BigNPAG program."( Meropenem pharmacokinetics in the newborn.
de Groot, R; Drusano, GL; Kinzig-Schippers, M; Martinkova, J; Pokorna, P; Sorgel, F; van den Anker, JN, 2009)		0.35
" Concerning the strain of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae (BLNAR), the killing rates of both meropenem and piperacillin were compared in an in vitro pharmacokinetic (PK) model, in which human pharmacokinetics in CSF were simulated."( Clinical significance of cerebrospinal fluid inhibitory titers of antibiotics, based on pharmacokinetic/pharmacodynamic parameters, in the treatment of bacterial meningitis.
Kitazato, M; Mitsuyama, J; Mizunaga, S; Morikawa, Y; Morita, T, 2009)		0.35
" An in vitro pharmacodynamic model was used to simulate human serum concentrations."( Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
Bulik, CC; Christensen, H; Kuti, JL; Li, P; Nicolau, DP; Sutherland, CA, 2010)		0.36
"5 h infusion therapy (TIT) with meropenem against Pseudomonas aeruginosa using an in vitro pharmacodynamic model and a Monte Carlo simulation."( Experimental verification of the efficacy of optimized two-step infusion therapy with meropenem using an in vitro pharmacodynamic model and Monte Carlo simulation.
Eguchi, K; Kaku, M; Kanazawa, K; Kanemitsu, K; Shimizudani, T, 2010)		0.36
"This study was a pharmacokinetic (PK)-pharmacodynamic (PD) target attainment analysis of meropenem in Japanese adult patients."( Pharmacokinetic–pharmacodynamic target attainment analysis of meropenem in Japanese adult patients.
Ikawa, K; Ikeda, K; Kurisu, K; Morikawa, N; Ohge, H; Sueda, T; Taniwaki, M, 2010)		0.36
"The aims of this study were to develop a population pharmacokinetic model for meropenem in Japanese pediatric patients, and to use this model to assess the pharmacodynamics of meropenem regimens against common bacterial populations."( Population pharmacokinetics and pharmacodynamics of meropenem in Japanese pediatric patients.
Ikawa, K; Ikeda, K; Kobayashi, M; Miki, M; Morikawa, N, 2010)		0.36
" The pharmacodynamic endpoint of interest was percent time that the unbound drug concentration exceeded the minimal inhibitory concentration for a bacterial pathogen."( Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review.
Ensom, MH; Mabasa, VH; Perrott, J, 2010)		0.36
"Sixteen studies were reviewed, which included 13 pharmacokinetic and dynamic assessments using Monte Carlo simulations, 5 clinical evaluations, and 3 pharmacoeconomic appraisals."( Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review.
Ensom, MH; Mabasa, VH; Perrott, J, 2010)		0.36
"Meropenem alternative dosing strategies provide similar pharmacodynamic target attainment rates compared with traditional dosing strategies."( Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review.
Ensom, MH; Mabasa, VH; Perrott, J, 2010)		0.36
" The sigmoid maximum-threshold-of-efficacy (E(max)) model fit the survival data, in which the free-drug area under the concentration-time curve (fAUC)/MIC ratio, the maximum concentration of free drug in plasma (fC(max))/MIC ratio, and the cumulative percentage of a 24-h period that the free-drug concentration exceeds the MIC under steady-state pharmacokinetic conditions (f %T(MIC)) were each evaluated."( Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
Ambrose, PG; Bassett, J; Beaudry, A; Bhavnani, SM; Critchley, I; Gill, SC; Heine, HS; Janjic, N; Li, J; Miller, L; Rubino, CM; Stone, KC, 2010)		0.36
" Lastly, we explain the combination of these three antibiotics administered to increase microbiologic and pharmacodynamic yield."( A combination of tigecycline, colistin, and meropenem against multidrug-resistant Acinetobacter baumannii bacteremia in a renal transplant recipient: pharmacodynamic and microbiological aspects.
Barrientos, A; Calvo, N; Candel, FJ; Culebras, E; Head, J; Matesanz, M; Picazo, J; Sánchez, A, 2010)		0.36
"To develop a population pharmacokinetic model of meropenem in burn patients and to explore the appropriateness of current dosage regimens."( Population pharmacokinetics of meropenem in burn patients.
Chae, H; Doh, K; Han, S; Hur, J; Kim, J; Woo, H; Yim, DS; Yim, H, 2010)		0.36
" The population pharmacokinetic parameters of meropenem in 59 burn patients were estimated, and concentrations were simulated by using a mixed effect method (NONMEM, ver."( Population pharmacokinetics of meropenem in burn patients.
Chae, H; Doh, K; Han, S; Hur, J; Kim, J; Woo, H; Yim, DS; Yim, H, 2010)		0.36
" The mean population pharmacokinetic parameters were clearance (L/h) =4."( Population pharmacokinetics of meropenem in burn patients.
Chae, H; Doh, K; Han, S; Hur, J; Kim, J; Woo, H; Yim, DS; Yim, H, 2010)		0.36
" Monte Carlo simulations were conducted for conventional and prolonged infusion regimens of doripenem, imipenem and meropenem using pharmacokinetic data from adult patients with conserved renal function."( Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
Gomersall, C; Kuti, JL; Kwa, A; Montakantikul, P; Nicolau, DP; Roberts, JA, 2011)		0.37
" An in vitro pharmacodynamic model was used to simulate adult steady-state epithelial lining fluid concentrations of tigecycline (50 mg every 12 h) given alone and in combination with either meropenem (2 g by 3-hour infusion every 8 h) or rifampin (600 mg every 12 h)."( In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.
Koomanachai, P; Kuti, JL; Nicasio, AM; Nicolau, DP; Wiskirchen, DE, 2011)		0.37
"Meropenem is frequently employed as an empirical treatment for serious infections, but there has been no report on its population pharmacokinetic parameters for Japanese patients."( Population pharmacokinetic analysis of meropenem in Japanese adult patients.
Higuchi, S; Hosaka, N; Kamimura, H; Karube, Y; Muro, T; Sasaki, T; Takemoto, S; Umeda, Y; Yamamoto, H, 2011)		0.37
" A comparison of the population pharmacokinetic parameters of meropenem in the final model estimated in NONMEM with original data, and 1000 bootstrap samples shows that both sets of estimates were comparable, thereby indicating the robustness of the proposed model."( Population pharmacokinetic analysis of meropenem in Japanese adult patients.
Higuchi, S; Hosaka, N; Kamimura, H; Karube, Y; Muro, T; Sasaki, T; Takemoto, S; Umeda, Y; Yamamoto, H, 2011)		0.37
"A population pharmacokinetic model that satisfactorily described the disposition and variability of meropenem in our Japanese population is described."( Population pharmacokinetic analysis of meropenem in Japanese adult patients.
Higuchi, S; Hosaka, N; Kamimura, H; Karube, Y; Muro, T; Sasaki, T; Takemoto, S; Umeda, Y; Yamamoto, H, 2011)		0.37
" The efficacies of simulated pharmacokinetic profiles for human 10-day clinical regimens of ampicillin, meropenem, moxifloxacin, ciprofloxacin, and gentamicin were compared with the gold standard, streptomycin, for killing of Yersinia pestis in an in vitro pharmacodynamic model."( Comparative efficacies of candidate antibiotics against Yersinia pestis in an in vitro pharmacodynamic model.
Brown, D; Drusano, GL; Heine, HS; Kulawy, R; Liu, W; Louie, A; Vanscoy, B, 2011)		0.37
"A population pharmacokinetic (PK) model for meropenem in Japanese pediatric patients with various infectious diseases was developed based on 116 plasma concentrations from 50 pediatric patients."( Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations.
Kozuki, T; Nakayama, M; Ohata, Y; Sunakawa, K; Tanigawara, Y; Tomita, Y, 2011)		0.37
"The objectives of this study were to develop a population pharmacokinetic (PK) model of meropenem, to simulate the percent time above minimum inhibitory concentration (%T > MIC) at various MICs, and to estimate effective dosage regimens by calculating the target attainment rates against various strains of bacteria."( Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis.
Nakayama, M; Ohata, Y; Tamura, K; Tanigawara, Y; Tomita, Y, 2011)		0.37
" Therefore, the pharmacodynamic (PD) parameter of the efficacy of β-lactam antibiotics, that is, the time that its concentration is above the bacteria minimal inhibitory concentration (T > MIC), cannot be safely extrapolated from data derived from the PK of healthy volunteers."( Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira, J; Póvoa, P, 2011)		0.37
" Consequently, in ICU patients, β-lactam antibiotic half-life and T > MIC were virtually unpredictable, especially in those patients with normal renal function."( Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira, J; Póvoa, P, 2011)		0.37
"The present study investigated the pharmacokinetics of meropenem and biapenem in bile and estimated their pharmacodynamic target attainment at the site."( Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
Derendorf, H; Ikawa, K; Ikeda, K; Morikawa, N; Murakami, Y; Nakashima, A; Ohge, H; Sueda, T, 2011)		0.37
"The aim of this study was to develop a pharmacokinetic model of meropenem using patient data and use this to explore the clinical pharmacodynamics of meropenem in the treatment of LRTIs in elderly Chinese patients."( Pharmacokinetics and pharmacodynamics of meropenem in elderly chinese with lower respiratory tract infections: population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics study.
He, B; Liu, ZY; Zhai, SD; Zhang, C; Zhang, J; Zhou, QT, 2011)		0.37
" The pharmacokinetic analysis of meropenem was performed using nonlinear mixed-effects modelling (NONMEM®) software."( Pharmacokinetics and pharmacodynamics of meropenem in elderly chinese with lower respiratory tract infections: population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics study.
He, B; Liu, ZY; Zhai, SD; Zhang, C; Zhang, J; Zhou, QT, 2011)		0.37
" Forty-five patients were enrolled in the pharmacodynamic study, including 25 clinical responders and 21 patients with bacteriological eradication."( Pharmacokinetics and pharmacodynamics of meropenem in elderly chinese with lower respiratory tract infections: population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics study.
He, B; Liu, ZY; Zhai, SD; Zhang, C; Zhang, J; Zhou, QT, 2011)		0.37
"This study was designed to simulate standard and optimized dosing regimens for intravenous antibiotics against contemporary populations of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa using MIC distribution data to determine which of the tested carbapenem regimens provided the greatest opportunity for obtaining maximal pharmacodynamic (PD) activity."( Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
Briceno, DF; Furtado, GH; Nicolau, DP; Ruiz, SJ; Villegas, MV, )		0.13
"To demonstrate the pharmacokinetic profile of meropenem when administered by 3-hour infusion in patients undergoing continuous veno-venous hemofiltration (CVVH)."( [Pharmacokinetics of meropenem administered with prolonged infusion time in patients receiving continuous veno-venous hemofiltration].
Bo, SN; He, B; Hu, YF; Li, HL; Lu, W; Wang, SY; Xu, YZ; Yao, GQ; Zhai, SD; Zhu, X, 2012)		0.38
" The elimination half-life (T1/2) was (3."( [Pharmacokinetics of meropenem administered with prolonged infusion time in patients receiving continuous veno-venous hemofiltration].
Bo, SN; He, B; Hu, YF; Li, HL; Lu, W; Wang, SY; Xu, YZ; Yao, GQ; Zhai, SD; Zhu, X, 2012)		0.38
"Based on these data, we concluded that satisfactory pharmacodynamic parameters could be attained in CVVH patients treated with meropenem by a prolonged infusion time of 3 hours with a dosage of 500 mg for every 6 hours."( [Pharmacokinetics of meropenem administered with prolonged infusion time in patients receiving continuous veno-venous hemofiltration].
Bo, SN; He, B; Hu, YF; Li, HL; Lu, W; Wang, SY; Xu, YZ; Yao, GQ; Zhai, SD; Zhu, X, 2012)		0.38
"Prospective, observational, multicenter, pharmacokinetic study."( Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
Bellomo, R; Cole, L; Lipman, J; Liu, X; Nair, P; Roberts, DM; Roberts, JA; Roberts, MS, 2012)		0.38
" In this study, pharmacodynamic profiles of doripenem, imipenem and meropenem were evaluated against Gram-negative bacteria isolated from hospitalised patients."( Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
Keel, RA; Kiratisin, P; Nicolau, DP, 2013)		0.39
" This was a prospective pharmacokinetic study of meropenem and piperacillin."( Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains.
Adnan, S; Jarrett, P; Li, JX; Lipman, J; Paterson, DL; Roberts, JA; Rudd, M; Udy, AA; Wallis, SC, 2013)		0.39
"This was a prospective, observational, pharmacokinetic study executed at the medical and surgical intensive care unit at a large academic medical center."( Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
Carlier, M; Carrette, S; De Waele, JJ; Decruyenaere, J; Depuydt, P; Hoste, E; Lipman, J; Roberts, JA; Stove, V; Verstraete, A; Wallis, SC, 2013)		0.39
"We obtained data from 61 patients and observed extensive pharmacokinetic variability."( Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
Carlier, M; Carrette, S; De Waele, JJ; Decruyenaere, J; Depuydt, P; Hoste, E; Lipman, J; Roberts, JA; Stove, V; Verstraete, A; Wallis, SC, 2013)		0.39
"The goal of this study was to evaluate our current dosing strategy for cefepime and the formulary carbapenem (imipenem) compared with meropenem and doripenem to determine the best dosing strategy for achieving maximal pharmacodynamic activity against an institution-specific population of P aeruginosa isolates."( When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Goff, DA; Nicolau, DP, 2013)		0.39
"Antimicrobial stewardship programs should consider pharmacodynamic modeling to select the optimal dosing strategies to guide therapy in an era of escalating antimicrobial resistance."( When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Goff, DA; Nicolau, DP, 2013)		0.39
"Antimicrobial pharmacokinetic and pharmacodynamic data are limited in obesity."( Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
Cheatham, SC; Chung, EK; Fleming, MR; Juenke, JM; Kays, MB, 2014)		0.4
" Differences in pharmacokinetic parameters were determined by unpaired t test."( Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
Cheatham, SC; Chung, EK; Fleming, MR; Juenke, JM; Kays, MB, 2014)		0.4
" However, currently approved dosing regimens provide adequate pharmacodynamic exposures for susceptible bacteria in obese patients."( Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
Cheatham, SC; Chung, EK; Fleming, MR; Juenke, JM; Kays, MB, 2014)		0.4
" The pharmacodynamic analysis of meropenem was performed to determine the PTA by using the Monte Carlo simulation and the study used susceptibility patterns obtained from EUCAST and MYSTIC for assessment of CFR."( Pharmacodynamics of meropenem in critically ill patients with ventilator-associated pneumonia.
Aeinlang, N; Jaruratanasirikul, S; Jullangkoon, M; Kositpantawong, N; Wongpoowarak, W, 2013)		0.39
" The probability of attaining the pharmacodynamic target (40% of the time above the minimum inhibitory concentration [MIC]) in pancreatic juice against MIC distributions for clinical isolates of Gram-negative bacteria was determined using a Monte Carlo simulation."( Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.
Hashimoto, Y; Ikawa, K; Kondo, N; Morikawa, N; Murakami, Y; Ohge, H; Sudo, T; Sueda, T; Uemura, K, )		0.13
"Regression analyses of published pharmacokinetic data."( The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*.
Jamal, JA; Lipman, J; Roberts, JA; Udy, AA, 2014)		0.4
" The available pharmacokinetic (PK) data has been mostly obtained from healthy volunteers as well as from clinical studies addressing selected populations, often excluding the elderly and also patients with renal failure."( Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients.
Goncalves-Pereira, J; Mateus, A; Pinho, C; Povoa, P; Silva, NE, 2014)		0.4
"Since antimicrobial resistance among uropathogens against current first line agents has affected the management of severe urinary tract infection, we determined the likelihood that antibiotic regimens achieve bactericidal pharmacodynamic exposures using Monte Carlo simulation for five antimicrobials (ciprofloxacin, ceftriaxone, piperacillin/tazobactam, ertapenem, and meropenem) commonly prescribed as initial empirical treatment of inpatients with severe community acquired urinary tract infections."( Pharmacodynamic profiling of commonly prescribed antimicrobial drugs against Escherichia coli isolates from urinary tract.
Cuba, GT; Kiffer, CR; Luchesi, LJ; Patekoski, KS; Pignatari, AC, )		0.13
" Significant pharmacokinetic differences were observed in median (interquartile range) Cmax for both meropenem (extended infusion 17 [12."( Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis.
Carlier, M; De Waele, J; Decruyenaere, J; Depuydt, P; Hoste, E; Lipman, J; Roberts, JA; Wallis, SC, 2014)		0.4
"This study confirms that extended infusion in critically ill patients result in advantageous pharmacokinetic profiles by increasing the fT>MIC for piperacillin and meropenem."( Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis.
Carlier, M; De Waele, J; Decruyenaere, J; Depuydt, P; Hoste, E; Lipman, J; Roberts, JA; Wallis, SC, 2014)		0.4
" Pharmacokinetic data to guide dosing in children, however, are limited to healthy volunteers or patients who are not in the ICU."( Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support.
Carella, D; Chopra, A; Cies, JJ; Dickerman, MJ; Moore, WS; Parker, J; Small, C, 2014)		0.4
" There was marked variability in the pharmacokinetic and hence the pharmacokinetic-pharmacodynamic parameters between individuals."( Pharmacokinetics of short versus extended infusion meropenem dosing in critically ill patients: a pilot study.
Bellomo, R; Howden, B; Jacob, J; Johnson, PD; Langan, KM; Li, J; Nation, RL, 2014)		0.4
" Meropenem pharmacokinetic parameters were calculated using a non-compartmental approach."( Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
Jamal, JA; Lipman, J; Mat-Nor, MB; Mohamad-Nor, FS; Roberts, JA; Udy, AA; Wallis, SC, 2015)		0.42
"Population pharmacokinetic analyses can be applied to predict optimized dosages for individual patients."( Comparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patients.
Daroczi, G; Farkas, A; Hope, WW; Lipman, J; Roberts, JA; Sussman, R; Wong, G, 2015)		0.42
" There were no significant differences in serum concentrations or pharmacokinetic parameters between ECMO and non-ECMO patients, including Vd [0."( β-Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: A case-control study.
Antonucci, E; Beumier, M; Cristallini, S; de Backer, D; Donadello, K; Jacobs, F; Roberts, JA; Rondelet, B; Scolletta, S; Taccone, FS; Vincent, JL, 2015)		0.42
" The bile drug concentration-time data were processed by software to figure out the pharmacokinetic parameters such as maximum concentration (C(max)), peak time (T(max)), half-life time (T(1/2)), clearance (CL) and apparent volume of distribution (VD)."( [Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential].
Lai, J; Li, S; Liang, L; Peng, B; Wang, Z; Zheng, J, 2014)		0.4
"To systematically assess the impact of pharmacodynamic interactions when adding either linezolid or vancomycin to meropenem on the antibacterial activity against methicillin-susceptible Staphylococcus aureus (MSSA)."( Pharmacodynamic and response surface analysis of linezolid or vancomycin combined with meropenem against Staphylococcus aureus.
Kees, MG; Kloft, C; Kuss, J; Wicha, SG, 2015)		0.42
" We newly elaborated a response surface analysis (RSA) to quantify the extent of the pharmacodynamic interactions."( Pharmacodynamic and response surface analysis of linezolid or vancomycin combined with meropenem against Staphylococcus aureus.
Kees, MG; Kloft, C; Kuss, J; Wicha, SG, 2015)		0.42
"Standard doses of linezolid and meropenem will provide inhibitory concentrations and thus pharmacodynamic antagonism throughout the whole dosing interval for MSSA."( Pharmacodynamic and response surface analysis of linezolid or vancomycin combined with meropenem against Staphylococcus aureus.
Kees, MG; Kloft, C; Kuss, J; Wicha, SG, 2015)		0.42
"Pathophysiological changes during the early phase of severe sepsis and septic shock in critically ill patients, resulting in altered pharmacokinetic (PK) patterns for antibiotics, are important factors influencing therapeutic success."( Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units.
Jaruratanasirikul, S; Jullangkoon, M; Samaeng, M; Sukarnjanaset, W; Tangkitwanitjaroen, K; Thengyai, S; Wattanavijitkul, T; Wongpoowarak, W, 2015)		0.42
"1 pharmacokinetic software was used to calculate non-compartment pharmacokinetics parameters."( [Pharmacokinetics study of injected doripenemin healthy volunteers].
Liu, W; Miao, J; Qin, YP; Shu, SQ; Wang, Y; Zhang, L; Zheng, J, 2015)		0.42
"0 g doripenemin 60 min produced the following respective parameters: Cmax (11."( [Pharmacokinetics study of injected doripenemin healthy volunteers].
Liu, W; Miao, J; Qin, YP; Shu, SQ; Wang, Y; Zhang, L; Zheng, J, 2015)		0.42
" The aim of this clinical investigation was to determine the pharmacokinetic parameters of meropenem in critically ill patients receiving CVVHD in order to estimate dosing regimens for the patient population in Japan."( Pharmacokinetics and dosing estimation of meropenem in Japanese patients receiving continuous venovenous hemodialysis.
Hara, R; Hori, S; Horino, T; Ikawa, K; Kawano, S; Kizu, J; Kuroda, Y; Matsumoto, K; Morikawa, N, 2015)		0.42
" Human fosfomycin pharmacokinetic profiles were simulated over 4 days."( Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.
Ballestero-Tellez, M; Conejo, MC; Docobo-Pérez, F; Drusano, GL; Goodwin, J; Hope, WW; Johnson, A; Pascual, A; Ramos-Martín, V; Rodríguez-Baño, J; Rodriguez-Martinez, JM; van Guilder, M; Whalley, S, 2015)		0.42
" Population pharmacokinetic models were developed using NONMEM(®) , which described total meropenem clearance and its relationship with several estimates of renal function (measured creatinine clearance CLCR , Cockcroft-Gault formula CLCG , Hoek formula, 1/plasma creatinine, 1/plasma cystatin C) and other patient characteristics."( Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients.
Beck, S; Kees, F; Kees, MG; Kloft, C; Minichmayr, IK; Moritz, S; Steinke, T; Wicha, SG, 2016)		0.43
"6 mg/kg of meropenem was administered, resulting in a mean peak concentration of 80."( Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation of clinical trial simulations.
Cox, S; Goldstein, SL; Mizuno, T; Nehus, EJ; Vinks, AA, 2016)		0.43
"5 with 3 h infusions to estimate the probability of pharmacodynamic target attainment (PTA) at 40% fT> MIC."( Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis.
Cies, JJ; Kuti, JL; Lapin, C; Muhlebach, MS; Neu, N; Nguyen, ST; Nicolau, DP; Novak, KJ; Pettit, RS; Saiman, L, 2016)		0.43
"This was a post hoc analysis of a prospective, multicentre pharmacokinetic point-prevalence study (DALI), which recruited a large cohort of critically ill patients from 68 ICUs across 10 countries."( Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DA
Abdul-Aziz, MH; Akova, M; Bassetti, M; De Waele, JJ; Dimopoulos, G; Dulhunty, J; Kaukonen, KM; Koulenti, D; Lipman, J; Martin, C; Montravers, P; Rello, J; Rhodes, A; Roberts, JA; Starr, T; Wallis, SC, 2016)		0.43
"The objective of this study was to determine the pharmacokinetic profile of meropenem in automated peritoneal dialysis (APD) patients."( An Open, Randomized, Single-Center, Crossover Pharmacokinetic Study of Meropenem after Intraperitoneal and Intravenous Administration in Patients Receiving Automated Peritoneal Dialysis.
Balcke, P; Burgmann, H; Kussmann, M; Pichler, P; Poeppl, W; Reznicek, G; Wiesholzer, M; Wimmer, M; Zeitlinger, M, 2016)		0.43
" The percentage of pharmacodynamic target attainment for isolates with different MICs was calculated for 350 ICU, surgical, and internal medicine patients."( Comparison of Short Versus Prolonged Infusion of Standard Dose of Meropenem Against Carbapenemase-Producing Klebsiella pneumoniae Isolates in Different Patient Groups: A Pharmacokinetic-Pharmacodynamic Approach.
Daikos, GL; Kotsakis, S; Meletiadis, J; Miriagou, V; Tsala, M; Tzouvelekis, L; Vourli, S; Zerva, L, 2016)		0.43
" Patient-specific data were used in conjunction with published population pharmacokinetic models to construct concentration-time profiles for each patient."( Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence.
Aubry, A; Chastre, J; Crandon, JL; Luyt, CE; Nicolau, DP, 2016)		0.43
"This study aimed to describe the pharmacokinetic (PK) characteristics of meropenem in children with severe infections and to assess the pharmacokinetic/pharmacodynamic (PK/PD) profiles of various meropenem dosage regimens in these patients."( Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.
Eakanunkul, S; Issaranggoon Na Ayuthaya, S; Kongthavonsakul, K; Lucksiri, A; Oberdorfer, P; Roongjang, S, 2016)		0.43
" The pharmacokinetic parameters used in the final model were Ke (elimination rate constant from the central compartment), Vc (volume of distribution of central compartment), KCP and KPC (intercompartmental rate constants), and IC2 (the fitted amount of meropenem in the peripheral compartment)."( A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients.
Fleming, DH; Jacob, GG; K, S; Mathew, BS; Mathew, SK; Naik, GS; Neely, MN; Prabha, R, 2016)		0.43
" A dynamic in vitro pharmacokinetic/pharmacodynamic (PK/PD) model that can simulate the pharmacokinetic profiles of antibiotics provides a powerful tool to compare antibacterial responses to different clinical dosage regimens."( Synergistic killing by meropenem and colistin combination of carbapenem-resistant Acinetobacter baumannii isolates from Chinese patients in an in vitro pharmacokinetic/pharmacodynamic model.
Bian, X; Chen, Y; Li, Y; Liu, X; Shi, J; Zhang, J; Zhao, M, 2016)		0.43
" push administration on the pharmacodynamic exposures of meropenem, cefepime, and aztreonam were evaluated."( Effects of i.v. push administration on β-lactam pharmacodynamics.
Burgner, K; Butterfield-Cowper, JM, 2017)		0.46
"Pharmacokinetic and pharmacodynamic analyses were conducted using previously published pharmacokinetic data for meropenem, cefepime, and aztreonam."( Effects of i.v. push administration on β-lactam pharmacodynamics.
Burgner, K; Butterfield-Cowper, JM, 2017)		0.46
" push over 5 minutes indicated that there would be minimal or no effect on pharmacodynamic exposures compared with the effect when administered by 30-minute infusions."( Effects of i.v. push administration on β-lactam pharmacodynamics.
Burgner, K; Butterfield-Cowper, JM, 2017)		0.46
" However, there are currently no pharmacokinetic (PK) and pharmacodynamic (PD) data to guide meropenem dosing in these patients."( Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation.
Kong, L; Lu, G; Shi, Q; Tang, Y; Wu, X; Yu, M; Zhang, X, 2017)		0.46
" Driven by these differences and recent legislation mandating the study of drugs in children and neonates, an increasing number of pharmacokinetic studies of antibiotics are being performed in neonates."( Dosing antibiotics in neonates: review of the pharmacokinetic data.
Cohen-Wolkowiez, M; Greenberg, RG; Rivera-Chaparro, ND, 2017)		0.46
"The selection and dose of antibiotic therapy for biofilm-related infections are based on traditional pharmacokinetic studies using planktonic bacteria."( Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms.
Engel, J; Haagensen, J; Huang, L; Spormann, AM; Verotta, D; Yang, K, 2017)		0.46
"To develop and externally validate a population pharmacokinetic model for continuous-infusion meropenem in critically ill patients and to establish a nomogram based on a routinely available marker of renal function."( Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model.
Brinkmann, A; Frey, OR; Kloft, C; Minichmayr, IK; Roberts, JA; Roehr, AC, 2018)		0.48
" The pharmacokinetics of meropenem and vaborbactam were similar when given alone or in combination; all evaluated plasma PK exposure measures (peak plasma concentration, area under the plasma concentration-time curve [AUC] from time zero to the last measurable concentration area under the plasma concentration-time curve, and AUC from time zero to infinity) were similar for the study drugs alone versus those in combination, indicating no pharmacokinetic interaction between meropenem and vaborbactam."( Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects.
Bhavnani, SM; Dudley, MN; Griffith, DC; Loutit, JS; Morgan, EE; Rubino, CM; White, D, 2018)		0.48
" For 24 patients with culture-proven Gram-negative LOS, pharmacodynamic target attainment was similar regardless of the test-of-cure visit outcome."( Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies.
Chazallon, C; Fournier, I; Germovsek, E; Heath, P; Karlsson, MO; Kipper, K; Lutsar, I; Metsvaht, T; Meyer, L; Planche, T; Sharland, M; Standing, JF; Trafojer, UMT, 2018)		0.48
" The biosensor PenP has been shown to have a dynamic range, sensitivity and specificity useful for pharmacokinetic (PK) tests in healthy subjects."( Evaluation of Meropenem Pharmacokinetics in an Experimental Acute Respiratory Distress Syndrome (ARDS) Model during Extracorporeal Membrane Oxygenation (ECMO) by Using a PenP
Alegria, L; Andresen, M; Araos, J; Bruhn, A; Cabrera, S; Leung, YC; Silva, C; So, LY; Soto, D; Wong, KY; Wong, WT, 2018)		0.48
"To describe, by using PenP Biosensor, the pharmacokinetic of meropenem in a 24-h animal ARDS/ECMO model."( Evaluation of Meropenem Pharmacokinetics in an Experimental Acute Respiratory Distress Syndrome (ARDS) Model during Extracorporeal Membrane Oxygenation (ECMO) by Using a PenP
Alegria, L; Andresen, M; Araos, J; Bruhn, A; Cabrera, S; Leung, YC; Silva, C; So, LY; Soto, D; Wong, KY; Wong, WT, 2018)		0.48
" Four strains were assessed in an in vitro, one-compartment pharmacokinetic (PK)/pharmacodynamic (PD) model for 96 h."( Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model.
Barber, KE; Bonomo, RA; Kaye, KS; Pogue, JM; Warnock, HD, 2018)		0.48
"An in vitro pharmacokinetic model was used to assess changes in bacterial load and profiles after exposure to mean human serum concentrations over 168 h."( Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR, 2018)		0.48
" In this study, we aimed to determine the optimum population pharmacokinetic model of meropenem in patients with sepsis with ARC, and evaluated dosing regimens based on renal function."( The exploration of population pharmacokinetic model for meropenem in augmented renal clearance and investigation of optimum setting of dose.
Dohi, K; Fukuda, K; Kobayashi, Y; Kogo, M; Kohyama, N; Miyake, Y; Nakamura, S; Ohbayashi, M; Tamatsukuri, T; Yamamoto, T, 2018)		0.48
"A pharmacokinetic analysis (NONMEM) was conducted with external model validation."( Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
Buclin, T; Burger, R; Calpini, V; Csajka, C; Decosterd, L; Guidi, M; Lamoth, F; Marchetti, O; Robatel, C, 2018)		0.48
"Several population pharmacokinetic (PopPK) models for meropenem dosing in ICU patients are available."( Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models.
Colin, P; De Waele, JJ; Dhaese, SAM; Farkas, A; Lipman, J; Roberts, JA; Stove, V; Verstraete, AG, 2019)		0.51
"Individualizing drug dosing regimens in critically ill patients on renal replacement therapy is a challenge to clinicians as guidelines are often imprecise and specific-validated pharmacokinetic software is unavailable."( Clinical Application of Pharmacokinetics: Basis for Rational Dose Selection in a Critically Ill Patient on Renal Replacement Therapy.
Janković, SM, 2019)		0.51
"A case of a septic patient on hemodialysis is presented, where a quick solution for antibiotic dose adjustment based on the application of pharmacokinetic principles was found."( Clinical Application of Pharmacokinetics: Basis for Rational Dose Selection in a Critically Ill Patient on Renal Replacement Therapy.
Janković, SM, 2019)		0.51
"Specific pharmacokinetic software and measuring plasma concentrations of the drugs should be used for calculation of total drug clearance and dose adjustment whenever possible."( Clinical Application of Pharmacokinetics: Basis for Rational Dose Selection in a Critically Ill Patient on Renal Replacement Therapy.
Janković, SM, 2019)		0.51
"The objective of this study was to develop a physiologically based pharmacokinetic model for meropenem using a retrograde approach, which could serve as a basis for prediction of the systemic and infection-site drug exposures in different populations and indications."( Towards a Generic Tool for Prediction of Meropenem Systemic and Infection-Site Exposure: A Physiologically Based Pharmacokinetic Model for Adult Patients with Pneumonia.
Marquet, P; Musuamba, FT; Thémans, P; Winkin, JJ, 2019)		0.51
"We developed a reduced physiologically based pharmacokinetic model with NONMEM software using a top-down approach."( Towards a Generic Tool for Prediction of Meropenem Systemic and Infection-Site Exposure: A Physiologically Based Pharmacokinetic Model for Adult Patients with Pneumonia.
Marquet, P; Musuamba, FT; Thémans, P; Winkin, JJ, 2019)		0.51
"We successfully fitted a reduced physiologically based pharmacokinetic model with six compartments (arterial and venous pools, infection site [lungs], liver, kidneys and rest of the body) to the data and adequately estimated model parameters."( Towards a Generic Tool for Prediction of Meropenem Systemic and Infection-Site Exposure: A Physiologically Based Pharmacokinetic Model for Adult Patients with Pneumonia.
Marquet, P; Musuamba, FT; Thémans, P; Winkin, JJ, 2019)		0.51
"We successfully developed a physiologically based pharmacokinetic model for meropenem in adult patients to be used as a basis for prediction of concentrations in different groups of patients, and eventually for effective dose individualisation in different subgroups of the population."( Towards a Generic Tool for Prediction of Meropenem Systemic and Infection-Site Exposure: A Physiologically Based Pharmacokinetic Model for Adult Patients with Pneumonia.
Marquet, P; Musuamba, FT; Thémans, P; Winkin, JJ, 2019)		0.51
"An open-label pilot pharmacokinetic study of meropenem and piperacillin-tazobactam."( The pharmacokinetics of meropenem and piperacillin-tazobactam during sustained low efficiency haemodiafiltration (SLED-HDF).
Donnellan, S; Duffull, SB; Putt, TL; Roberts, JA; Schollum, JBW; Walker, RJ; Wallis, SC; Wright, DFB, 2020)		0.56
"The pharmacokinetic data obtained from this pilot study demonstrate significant quantities of meropenem and piperacillin are removed during a SLED-HDF session."( The pharmacokinetics of meropenem and piperacillin-tazobactam during sustained low efficiency haemodiafiltration (SLED-HDF).
Donnellan, S; Duffull, SB; Putt, TL; Roberts, JA; Schollum, JBW; Walker, RJ; Wallis, SC; Wright, DFB, 2020)		0.56
" Due to pharmacodynamic reasons, the target concentration corresponds to the concentration producing the half-maximum effect."( [Pharmacokinetics and pharmacodynamics in extracorporeal renal replacement therapy].
Kächele, M; Keller, F, 2021)		0.62
"The aim of this study was to conduct a population pharmacokinetic (PK) analysis of meropenem and to explore the optimal dosing strategy for meropenem in critically ill patients with acute kidney injury receiving treatment with continuous hemodiafiltration (CHDF)."( Population Pharmacokinetic Analysis of Meropenem in Critically Ill Patients With Acute Kidney Injury Treated With Continuous Hemodiafiltration.
Hattori, N; Ishii, I; Nakada, TA; Niibe, Y; Oda, S; Suzuki, T; Takahashi, N; Yamazaki, S, 2020)		0.56
" Our aim was to evaluate the pharmacokinetic and pharmacodynamic (PK/PD) characteristics of meropenem and vancomycin in patients undergoing SLED."( Pharmacokinetic and Pharmacodynamic Characteristics of Vancomycin and Meropenem in Critically Ill Patients Receiving Sustained Low-efficiency Dialysis.
Cavani Jorge Santos, SR; Chaves, L; Levin, AS; Macedo, E; Machado, AS; Mendes, ET; Oliveira, MS; Perdigão Neto, LV; Sanches, C; Vieira da Silva, C, 2020)		0.56
" The aim of this study was to perform an external evaluation of published population pharmacokinetic models of MERO in order to test their predictive performance in a cohort of ICU adult patients."( External evaluation of population pharmacokinetic models for continuous administration of meropenem in critically ill adult patients.
Blin, O; Guilhaumou, R; Marsot, A; Velly, L; Wang, YL, 2020)		0.56
"The physiologically based pharmacokinetic (PBPK) models of meropenem and fosfomycin were developed from previously published pharmacokinetic studies in five populations: healthy subjects of Japanese origin, and healthy adults, geriatric, paediatric and renally impaired of primarily Caucasian origins."( Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics.
Heinrichs, MT; Martins, FS; Sy, SKB; Zhu, P, 2021)		0.62
"We sought to compare meropenem and fluconazole dosing in the neonatal intensive care unit with recommendations based on published pharmacokinetic (PK) studies in infants."( Dosing of Antimicrobials in the Neonatal Intensive Care Unit: Does Clinical Practice Reflect Pharmacokinetics-based Recommendations?
Benjamin, DK; Childers, J; Clark, RH; Cohen-Wolkowiez, M; England, M; Greenberg, RG; Laughon, M; Smith, PB; Stark, A; Wade, K, 2020)		0.56
"There has been increasing interest in incorporating β-lactam precision dosing into routine clinical care, but robust population pharmacokinetic models in critically ill children are needed for these purposes."( Demonstrating Feasibility of an Opportunistic Sampling Approach for Pharmacokinetic Studies of β-Lactam Antibiotics in Critically Ill Children.
Benken, LA; Chamberlain, AR; Jones, RL; Kaplan, JM; Murphy, ME; Stoneman, EM; Tang Girdwood, SC; Tang, PH; Vinks, AA, 2021)		0.62
"No study has been evaluated pharmacokinetic (PK) and pharmacodynamic (PD) properties of β-lactam antibiotics in patients with acute kidney injury (AKI), not requiring renal replacement therapy (RRT)."( Evaluation of pharmacokinetic and pharmacodynamic parameters of meropenem in critically ill patients with acute kidney disease.
Ahmadi Koomleh, A; Hassanpour, R; Kobarfard, F; Kouchek, M; Miri, M; Nezarat, F; Pourheidar, E; Salarian, S; Shojaei, S; Sistanizad, M; Ziaie, S, 2021)		0.62
"18 L), terminal half-life (T1/2) (4."( Evaluation of pharmacokinetic and pharmacodynamic parameters of meropenem in critically ill patients with acute kidney disease.
Ahmadi Koomleh, A; Hassanpour, R; Kobarfard, F; Kouchek, M; Miri, M; Nezarat, F; Pourheidar, E; Salarian, S; Shojaei, S; Sistanizad, M; Ziaie, S, 2021)		0.62
" We aimed to investigate the pharmacokinetic (PK) parameters of meropenem in children with sepsis receiving extracorporeal life support (ECLS)."( Pharmacokinetics of meropenem in children with sepsis undergoing extracorporeal life support: A prospective observational study.
Chen, C; Chen, W; Li, Z; Lu, G; Wang, G; Wang, Y; Yan, G, 2021)		0.62
"The data of 205 samples obtained from 59 patients treated with meropenem at the General Hospital Lahore, Pakistan, was used for the development of a population pharmacokinetic (-popPK) model by using nonlinear mixed-effects modeling software."( Population pharmacokinetics of meropenem among post-operative patients in Pakistan.
Abbas, M; Khan, HM; Khan, RR; Khokhar, MI; Rasheed, H; Saleem, R; Usman, M; Zaman, M, 2021)		0.62
" CF can modify both the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of antibiotics, therefore specific PK/PD endpoints should be determined in the context of CF."( Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.
Jullien, V; Launay, M; Magréault, S; Roy, C; Sermet-Gaudelus, I, 2021)		0.62
" Population pharmacokinetic (PK) models were developed to characterize the time course of meropenem and vaborbactam using pooled data from two phase 1 and two phase 3 studies."( Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients.
Ambrose, PG; Bhavnani, SM; Dudley, MN; Griffith, DC; Loutit, JS; Rubino, CM; Trang, M, 2021)		0.62
" We applied physiologically based pharmacokinetic (PBPK) modeling to characterize the disposition of meropenem in preterm and term infants."( Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term Infants.
Cohen-Wolkowiez, M; Edginton, AN; Ganguly, S; Gerhart, JG; Gonzalez, D; Greenberg, RG, 2021)		0.62
" Because critically ill patients are more prone to pharmacokinetic variability than other patients, ensuring an effective blood concentration can be complex."( Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
Djebli, N; Khier, S; Larcher, R; Le Souder, C; O'Jeanson, A, 2021)		0.62
" A population pharmacokinetic model was developed (using NONMEM software) and Monte Carlo simulations were performed with different dosing scenarios (bolus-like, extended, and continuous infusion) exploring the impact of clinical categories of residual diuresis (anuria, oliguria, and preserved diuresis) on the probability of target attainment (MIC: 1-45 mg/L)."( Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
Djebli, N; Khier, S; Larcher, R; Le Souder, C; O'Jeanson, A, 2021)		0.62
"The population pharmacokinetic model included five covariates with a significant impact on clearance: glomerular filtration rate, dialysis (continuous and semi-continuous), renal function status, and volume of residual diuresis."( Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
Djebli, N; Khier, S; Larcher, R; Le Souder, C; O'Jeanson, A, 2021)		0.62
" As critically ill patients often experience pharmacokinetic aberrations, and rates of antimicrobial resistance vary between hospital settings, reliance on tertiary sources or package labeling to guide empiric dosing often results in suboptimal β-lactam exposure."( Time Above All Else: Pharmacodynamic Analysis of β-Lactams in Critically Ill Patients.
Burgess, DS; Clark, JA; Landmesser, KB, 2022)		0.72
" Higher doses and extended infusion may be required to achieve optimal pharmacodynamic targets."( Identification of factors affecting meropenem pharmacokinetics in critically ill patients: Impact of inflammation on clearance.
Hattori, N; Ishii, I; Nakada, TA; Niibe, Y; Suzuki, T; Takahashi, N; Uchida, M; Yamazaki, S, 2022)		0.72
" However, the effect of Seraph 100 on achieving pharmacodynamic (PD) targets is not well described."( Hemoperfusion with Seraph 100 Microbind Affinity Blood Filter Unlikely to Require Increased Antibiotic Dosing: A Simulations Study Using a Pharmacokinetic/Pharmacodynamic Approach.
Chung, KK; DeLuca, JP; Kress, AT; Reed, T; Selig, DJ; Stewart, IJ, 2023)		0.91
" For vancomycin and gentamicin, published pharmacokinetic models were used to explore the effect of Seraph 100 on ability to achieve probability of target attainment (PTA)."( Hemoperfusion with Seraph 100 Microbind Affinity Blood Filter Unlikely to Require Increased Antibiotic Dosing: A Simulations Study Using a Pharmacokinetic/Pharmacodynamic Approach.
Chung, KK; DeLuca, JP; Kress, AT; Reed, T; Selig, DJ; Stewart, IJ, 2023)		0.91
"The aim of this study was to investigate the impact of therapeutic plasma exchange (TPE) on the plasma concentrations and pharmacokinetic (PK) patterns of meropenem."( Impact of therapeutic plasma exchange on meropenem pharmacokinetics.
Jaruratanasirikul, S; Jullangkoon, M; Neamrat, P; Samaeng, M, 2022)		0.72
" In this study, a population pharmacokinetic model of meropenem in infected critically ill patients was developed."( Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: a Prospective Two-Center Study.
Cotta, MO; Heffernan, AJ; Joynt, GM; Kumta, N; Lipman, J; Livermore, A; Roberts, JA; Starr, T; Wallis, SC; Wong, WT, 2022)		0.72
"An adult physiologically based pharmacokinetic model was developed for meropenem, colistin, and sulbactam and scaled to pediatrics accounting for both renal and non-renal clearances."( Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling.
Lv, Z; Oo, C; Sy, SKB; Yu, M; Zhang, J; Zhu, P; Zhu, S, 2022)		0.72
" In a virtual pediatric population aged from 2 to < 18 years, the interpretive breakpoints were achieved in 85-90% of subjects for their targeted pharmacodynamic indices after administration of pediatric dosing regimens consisting of 30 mg/kg of meropenem, and 40 mg/kg of sulbactam three times daily as a 3-h or continuous infusion and 5 mg/kg/day of colistin base activity."( Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling.
Lv, Z; Oo, C; Sy, SKB; Yu, M; Zhang, J; Zhu, P; Zhu, S, 2022)		0.72
"The optimal dosing regimen for meropenem in critically ill patients undergoing continuous renal replacement therapy (CRRT) remains undefined due to small studied sample sizes and uninformative pharmacokinetic (PK)/pharmacodynamic (PD) analyses in reported studies."( Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
Cheng, Z; Peng, Y; Xie, F, 2022)		0.72
" The pharmacokinetic profile is a beta-lactam one: no oral absorption, and with a wide distribution within the vascular space and the interstitial fluid of well vascularized tissues, reaching therapeutic concentrations in the alveolar lavage fluid and within the macrophage."( Pharmacokinetics/Pharmacodynamics and tolerability of cefiderocol in the clinical setting.
Azanza Perea, JR; Sádaba Díaz de Rada, B, 2022)		0.72
"Creatinine clearance (CCr) and pharmacokinetic parameters are markedly affected by pathophysiological changes in patients with sepsis."( Population Pharmacokinetic Model and Dosing Simulation of Meropenem Using Measured Creatinine Clearance for Patients with Sepsis.
Dohi, K; Fukumoto, S; Inoue, H; Kato, A; Kogo, M; Kohyama, N; Kotani, T; Ohbayashi, M; Okada, A; Sagara, H; Tamatsukuri, T, 2023)		0.91
"In the present study, population pharmacokinetic (PK) analysis was performed based on meropenem data from a prospective study conducted in 114 critically ill patients with a wide range of renal functions and various disease conditions."( Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis.
An, G; Creech, CB; Fishbane, N; Fissell, W; Gu, K; Jimenez-Truque, N; Kirkpatrick, CMJ; Landersdorfer, CB; Nalbant, D; Nation, RL; Patel, PC; Rolsma, S; Watanabe, A; Winokur, P; Wu, N, 2023)		0.91
" The practical limitations of pharmacokinetic studies requiring numerous plasma and effluent samples, and lack of generalizability of observations from specific CRRT prescriptions, highlight gaps in bedside assessment of CRRT drug elimination and individualized dosing needs."( Transdermal Detection of MB-102 and Correlation to Meropenem Pharmacokinetics During Continuous Renal Replacement Therapy: In Vivo Results.
Dorshow, RB; Goldstein, SL; Humes, HD; Johnson, JR; Johnston, KA; Nolin, TD; Pino, CJ; Riley, IR; Rogers, TE; Shieh, JJ; Tang, P, 2023)		0.91
" However, most population pharmacokinetic (PopPK) models developed to date have not yet been evaluated for MIPD."( Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.
Brinkmann, A; Frey, O; Greppmair, S; Hempel, G; Liebchen, U; Röhr, A; Scharf, C; Schatz, LM; Weinelt, F; Zoller, M, 2023)		0.91
" A sigmoidal maximum effect model was applied to determine the pharmacodynamic parameters (maximal effect, median effective concentration, and Hill factor) of each antibiotic to create a mathematical three-dimensional response surface plot."( Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm.
Badawy, MSEM; Elkhatib, WF; Shebl, RI, 2023)		0.91
" Synergistic anti-biofilm potentials were also detected via the simulated pharmacodynamic modeling, with higher anti-biofilm activity in the case of the in vitro observation compared to the simulated anti-biofilm profile."( Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm.
Badawy, MSEM; Elkhatib, WF; Shebl, RI, 2023)		0.91
" aeruginosa biofilms and the importance of the mathematical pharmacodynamic modeling in investigating the efficacy of antibiotics in combination as an effective strategy for successful antibiotic therapy to tackle the extensively growing resistance to the currently available antibiotics."( Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm.
Badawy, MSEM; Elkhatib, WF; Shebl, RI, 2023)		0.91
" However, pharmacokinetic data on meropenem in children with end-stage renal disease (ESRD) undergoing prolonged intermittent renal replacement therapy (PIRRT) is limited."( Meropenem Clearance in a Child With End-stage Renal Disease Undergoing Prolonged Intermittent Renal Replacement Therapy: A Case Report and Literature Review.
Anker, JVD; Cao, W; Chen, XY; Shi, HY; Zhang, W; Zhao, W, 2023)		0.91

Compound-Compound Interactions

Trovafloxacin alone and in combination with ceftazidime, meropenem, and amikacin was studied by determining the minimal inhibitory concentrations (MICs) for 111 gram-negative and 71 gram-positive bacteria. Tigecycline alone and combined with colistin and mer openem was tested against eight genetically unrelated KPC-producing clinical strains of Enterobacteriaceae.

ExcerptReferenceRelevance
"The kinetics of bacterial killing by meropenem alone and in combination with gentamicin (for Pseudomonas aeruginosa) and vancomycin (for Staphylococcus aureus) were studied for two strains of each species."( The antibacterial activity of meropenem in combination with gentamicin or vancomycin.
Andrews, JM; Ashby, JP; Wise, R, 1989)		0.28
" The efficacy and safety of meropenem was compared with that of ceftazidime (alone or in combination with amikacin) in 153 patients with septicaemia who were enrolled into identical, prospective, randomised studies."( Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime, alone or combined with amikacin.
Sjursen, H; Solberg, CO, 1995)		0.29
"The in vitro activity of trovafloxacin alone and in combination with ceftazidime, meropenem, and amikacin was studied by determining the minimal inhibitory concentrations (MICs) for 111 gram-negative and 71 gram-positive bacteria."( In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin.
Milatovic, D; Wallrauch, C, 1996)		0.29
" The 8 h SBTs for dosing schedule containing meropenem combined with amikacin were 1:4 and 1:16 after 30 min short infusion and continuous infusion respectively."( [In vivo pharmacokinetic of amikacin and its pharmacodynamic in combination with cefepime, cefpirome and meropenem in an in vitro/ex vivo micropig model].
Elkhaïli, H; Jehl, F; Levêque, D; Linger, L; Monteil, H; Niedergang, S; Peter, JD; Pompei, D; Salmon, J; Salmon, Y; Thierry, RC, 1997)		0.3
" The combination beta-lactam-ciprofloxacin-tobramycin was the combination with the most consistently synergistic effect."( Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis.
Bingen, E; Bonacorsi, S; Fitoussi, F; Lhopital, S, 1999)		0.3
"The in vitro activities of buforin II, cecropin P1, and magainin II, alone and in combination with six clinically used antimicrobial agents, against 12 clinical isolates of Stenotrophomonas maltophilia were investigated."( In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia.
Barchiesi, F; Cirioni, O; Del Prete, MS; Drenaggi, D; Fortuna, M; Giacometti, A; Scalise, G, 2000)		0.31
"To study the in vitro interaction of gatifloxacin in combination with gentamicin and with the beta-lactams cefepime, meropenem and piperacillin against clinical isolates of Stenotrophomonas maltophilia, Pseudomonas aeruginosa, Burkholderia cepacia, extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae, vancomycin-resistant Enterococcus faecium (VRE) and methicillin-resistant Staphylococcus aureus (MRSA)."( In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms.
Dawis, MA; France, KA; Isenberg, HD; Jenkins, SG, 2003)		0.32
"The mutant prevention concentrations (MPCs) of levofloxacin alone and in combination with ceftazidime, colistin (polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin were established against Pseudomonas aeruginosa."( Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa.
Adam, HJ; Laing, N; Mayer, M; Zhanel, GG, 2006)		0.33
"The activities of tigecycline alone and in combination with other antimicrobials are not well defined for carbapenem-intermediate or -resistant Acinetobacter baumannii (CIRA)."( In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
Noskin, GA; Obias, A; Postelnick, MJ; Qi, C; Scheetz, MH; Warren, JR; Zembower, T, 2007)		0.34
"The antimicrobial activity of meropenem combined with either polymyxin B or gatifloxacin was evaluated by the checkerboard method against Pseudomonas aeruginosa (10 strains) and Acinetobacter baumannii (10 strains)."( In vitro evaluation of the antimicrobial activity of meropenem in combination with polymyxin B and gatifloxacin against Pseudomonas aeruginosa and Acinetobacter baumannii.
Cardoso, CL; Carrara-Marrone, FE; Gales, AC; Garcia, LB; Guelfi, KC; Tognim, MC, 2008)		0.35
" The aims of this study was to determine the efficacies of meropenem alone and combined with rifampin against two Streptococcus pneumoniae strains with different susceptibility to beta-lactams using the guinea pig meningitis model and compare them with the standard ceftriaxone plus vancomycin therapy."( Evaluation of meropenem alone and combined with rifampin in the guinea pig model of pneumococcal meningitis.
Cabellos, C; Doménech, A; Force, E; Gudiol, F; Ribes, S; Taberner, F; Tubau, F; Viladrich, PF, 2009)		0.35
"We investigated the activity of BAL30072, a dihydroxypyridone monosulfactam, against carbapenem-resistant Enterobacteriaceae and non-fermenters (i) alone, (ii) combined with BAL29880 (to inhibit AmpC) and/or clavulanate [to inhibit extended-spectrum β-lactamases (ESBLs)] and (iii) combined 1:1 with meropenem."( Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters.
Adkin, R; Hope, R; Livermore, DM; Mushtaq, S; Woodford, N, 2013)		0.39
" In this study, the in vitro activity of the novel monosulfactam BAL30072 was investigated both alone and in combination with meropenem against a diverse collection of commonly encountered Gram-negative pathogens."( In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens.
Hornsey, M; Phee, L; Stubbings, W; Wareham, DW, 2013)		0.39
"5% of the strains for meropenem combination with tigecycline."( Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model.
Labrou, M; Manousaka, S; Michail, G; Pitiriga, V; Pournaras, S; Sakellaridis, N; Tsakris, A, 2013)		0.39
" The aim of this study was to determine in vitro synergy and postantibiotic effect (PAE) of colistin alone and combined with other antibiotics (vancomycin or meropenem) against eight carbapenem-non-susceptible Acinetobacter spp."( Postantibiotic effect of colistin alone and combined with vancomycin or meropenem against Acinetobacter spp. with well defined resistance mechanisms.
Beader, N; Bedenić, B; Ćačić, M; Godič-Torkar, K; Mihaljević, L; Prahin, E; Vraneš, J, 2016)		0.43
" Synergy was observed when plazomicin was combined with meropenem, colistin or fosfomycin against both isolates, whilst the combination with tigecycline resulted in indifference."( In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
Culebras, E; Pena, I; Picazo, JJ; Rodríguez-Avial, C; Rodríguez-Avial, I, 2015)		0.42
"2%) of the 121 MDR-TB strains were subjected to a synergistic effect when the drug was combined with sulbactam, tazobactam, or clavulanate, respectively."( In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates.
Lu, J; Pang, Y; Wang, Y; Zhang, D, 2016)		0.43
"The present study evaluates the synergistic effect of sulbactam/tazobactam in combination with meropenem or colistin against multidrug resistant (MDR) Acinetobacter baumannii isolated from hospitalized patients from a tertiary care hospital in Saudi Arabia."( A prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multidrug resistant Acinetobacter baumannii.
Alyousef, AA; Alzahrani, AJ; Krishnappa, LG; Marie, MA; Mubaraki, MA, 2015)		0.42
" Herein we describe the results of dose fractionation and dose-ranging studies carried out using a one-compartment in vitro infection model to determine the exposure measure for CB-618, a novel β-lactamase inhibitor, most predictive of the efficacy when given in combination with meropenem."( Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an In Vitro Infection Model.
Alexander, DC; Ambrose, PG; Bhavnani, SM; Conde, H; Friedrich, LV; McCauley, J; Trang, M; VanScoy, BD, 2016)		0.43
" Using a murine thigh-infection model, we examined the in vivo efficacy of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin, or sulbactam against 12 XDR-AB strains."( Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model.
Cong, Y; Fan, B; Guan, J; Wang, X, 2016)		0.43
" We investigated the activity of various antibiotics in combination with polymyxin B using time-kill studies (TKS)."( In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B.
Cai, Y; Chan, EC; Hong, Y; Hsu, LY; Koh, TH; Kwa, AL; Lee, W; Lim, TP; Sasikala, S; Tan, TT; Tan, TY; Teo, J, 2016)		0.43
" Imipenem, meropenem and doripenem were significantly more effective (reduced fold-change of MICs) when combined with rifampicin in bla VIM-negative isolates, especially in isolates with porin frameshift mutation."( In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
Hu, YF; Liu, CP; Shih, SC; Wang, NY, 2016)		0.43
" A retrospective analysis of VPA therapeutic drug monitoring (TDM) records was performed to investigate this VPA pharmacokinetics drug-drug interaction."( Drug-drug interaction between valproic acid and meropenem: a retrospective analysis of electronic medical records from neurosurgery inpatients.
Chen, XP; Chen, Y; Du, C; Fan, SS; Peng, ZF; Wen, ZP; Xiao, J; Xie, YY; Yin, T; Zhang, W; Zhou, BT, 2017)		0.46
"Human in vitro and dog in vitro/in vivo researches indicate that the drug-drug interaction (DDI) of decreased plasma valproic acid (VPA) concentration by co-administration of carbapenem antibiotics is caused by inhibition of acylpeptide hydrolase (APEH)-mediated VPA acylglucuronide (VPA-G) hydrolysis by carbapenems."( Observation of Clinically Relevant Drug Interaction in Chimeric Mice with Humanized Livers: The Case of Valproic Acid and Carbapenem Antibiotics.
Chiba, K; Goda, R; Koyama, K; Kuga, H; Nakai, D; Suzuki, E, 2017)		0.46
" The SBPI analysis showed that CAZ-AVI in combination with imipenem achieved higher SBPI values than other CAZ-AVI-based combinations."( In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.
Ambretti, S; Campoli, C; Gaibani, P; Giannella, M; Landini, MP; Lewis, RE; Re, MC; Viale, P; Volpe, SL, 2017)		0.46
" Treatments of colistin alone or combined with rifampicin or meropenem were started 1 h after infection."( Activity of colistin alone or in combination with rifampicin or meropenem in a carbapenem-resistant bioluminescent Pseudomonas aeruginosa intraperitoneal murine infection model.
Cai, Y; Wang, J; Wang, R; Yang, D, 2018)		0.48
"In vivo imaging showed that both low- and high-dose colistin combined with rifampicin resulted in a significant decrease in bioluminescence signals compared with monotherapy of colistin or rifampicin alone, whereas colistin and meropenem combination therapy did not show a greater bactericidal effect compared with monotherapy."( Activity of colistin alone or in combination with rifampicin or meropenem in a carbapenem-resistant bioluminescent Pseudomonas aeruginosa intraperitoneal murine infection model.
Cai, Y; Wang, J; Wang, R; Yang, D, 2018)		0.48
"To compare the incidence of nephrotoxicity in patients receiving intravenous vancomycin in combination with cefepime, meropenem, or piperacillin/tazobactam."( Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin/Tazobactam: A Prospective, Multicenter Study.
Bartel, BJ; Catlin, JS; Gilder, RE; Kramer, CJ; Mullins, BP, 2018)		0.48
"This was a prospective, multicenter observational study of patients receiving vancomycin in combination with piperacillin/tazobactam versus cefepime or meropenem."( Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin/Tazobactam: A Prospective, Multicenter Study.
Bartel, BJ; Catlin, JS; Gilder, RE; Kramer, CJ; Mullins, BP, 2018)		0.48
" Limited data regarding the impact of meropenem (MEM) combined with VAN exist."( Incidence of Acute Kidney Injury among Patients Treated with Piperacillin-Tazobactam or Meropenem in Combination with Vancomycin.
Burgess, DS; Rutter, WC, 2018)		0.48
" Drug combination assays indicated that these derivatives exhibited synergistic antimicrobial activity when used along with meropenem, effectively restoring the activity of carbapenems against the resistant strains tested in a Galleria mellonella larvae in vivo infection model."( Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
Chan, EWC; Chan, KF; Chan, TH; Chen, S; Cheng, Q; Gao, W; Jin, WB; Leung, YC; Qi, XL; Wong, KY; Xu, C; Zheng, Z, 2018)		0.48
" It is being developed in combination with meropenem."( In vitro activity of meropenem combined with vaborbactam against KPC-producing Enterobacteriaceae in China.
Chen, X; Kudinha, T; Lomovskaya, O; Sun, D; Xu, Y; Xu, Z; Yang, Q; Zhang, G; Zhou, M, 2018)		0.48
" Their antibacterial activities were tested in combination with meropenem (MEM) against several MBL (NDM and IMP type)-producing clinical isolates."( Dithiocarbamates: Efficient metallo-β-lactamase inhibitors with good antibacterial activity when combined with meropenem.
Chu, WC; Qin, SS; Wang, MM; Yang, QQ; Yang, Y; Zhang, E, 2018)		0.48
"Amikacin is administered with a carbapenem to treat serious infections caused by carbapenem-resistant Enterobacteriaceae (CRE)."( Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin.
Burgess, DS; Clark, JA; Kulengowski, B, 2019)		0.51
" In this study, the activity of colistin (COL) as monotherapy and in combination with other antibiotics against Acinetobacter baumannii in vitro was investigated."( In vitro and in vivo assessment of the antibacterial activity of colistin alone and in combination with other antibiotics against Acinetobacter baumannii and Escherichia coli.
Fu, L; Li, H; Li, X; Liu, J; Luo, S; Wan, Z; Wang, Y; Wu, X; Xie, X; Zhao, Z, 2020)		0.56
" SIGNIFICANCE AND IMPACT OF THE STUDY: Drug combination is an effective approach for the treatment of resistant bacterial infection."( In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant Acinetobacter baumannii.
Li, X; Lu, C; Sun, S; Wang, D; Wang, Y, 2020)		0.56
"To evaluate in vitro activity of the novel β-lactamase boronate inhibitor taniborbactam (VNRX-5133) combined with cefepime or meropenem against 500 urinary Gram-negative bacilli."( In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China.
Chen, H; Li, H; Li, S; Liang, X; Meng, H; Wang, H; Wang, Q; Wang, X; Wang, Z; Zhang, F; Zhang, Y; Zhao, C; Zhou, C, 2020)		0.56
"53 mg/kg combined with MEM 8 g using a 3-hr prolonged infusion every 8 hr and RIF 600 mg every 24 hr resulted in bacterial counts below the quantitative limit within 24 hr and remained undetectable throughout the 10-day experiment."( In pursuit of the triple crown: mechanism-based pharmacodynamic modelling for the optimization of three-drug combinations against KPC-producing Klebsiella pneumoniae.
Bulitta, JB; Bulman, ZP; Forrest, A; Holden, PN; Li, J; Nation, RL; Onufrak, NJ; Satlin, MJ; Smith, NM; Tan, X; Tsuji, BT, 2020)		0.56
" The purpose of the study was to assess the synergistic activity of fosfomycin in combination with other antimicrobial agents against CRKP isolated from patients in Songklanagarind Hospital, Thailand."( In vitro synergistic activity of fosfomycin in combination with other antimicrobial agents against carbapenem-resistant Klebsiella pneumoniae isolated from patients in a hospital in Thailand.
Charoenmak, B; Chukamnerd, A; Chusri, S; Hortiwakul, T; Paing Phoo, MT; Pomwised, R; Terbtothakun, P, 2021)		0.62
" The aim of this study was to evaluate the in vitro efficacy of aztreonam (ATM) in combination with CAZ/AVI, M/V, and I/R against 40 MDR, MBL-producing, and serine-β-lactamases co-producing Klebsiella pneumoniae using the Etest method."( Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae.
Kasimati, A; Magkafouraki, E; Maraki, S; Mavromanolaki, VE; Moraitis, P; Scoulica, E; Stafylaki, D, 2021)		0.62
"A total of 29 MRSA, including 6 VISA, 14 hVISA, and 9 VSSA isolates, were subjected to a microbroth dilu- tion-minimum inhibitory concentration (MIC) checkerboard using vancomycin combined with cefotaxime, imipenem, or meropenem."( Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin
Booncharoen, S; Chaiyapoke, C; Chanawong, A; Lulitanond, A; Srisrattakarn, A; Tavichakorntrakool, R; Tippayawat, P; Wongthong, S, 2021)		0.62
" Using time-kill assay, the vancomycin combined with either imipenem or cefotaxime demonstrated synergism against both VISA and hVISA isolates, while the synergistic effect with meropenem was obtained only in the VISA isolates."( Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin
Booncharoen, S; Chaiyapoke, C; Chanawong, A; Lulitanond, A; Srisrattakarn, A; Tavichakorntrakool, R; Tippayawat, P; Wongthong, S, 2021)		0.62
"The antimicrobial efficacy of meropenem (MEM), cefepime (FEP), and aztreonam (ATM), each in combination with NAC, were assessed in vitro and in vivo against Klebsiella pneumoniae and Escherichia coli."( Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection
Asai, N; Hagihara, M; Kato, H; Koizumi, Y; Mikamo, H; Okade, H; Sakanashi, D; Sato, N; Shibata, Y; Suematsu, H; Sugano, T; Yamagishi, Y, 2021)		0.62
" Teicoplanin can be preferred instead of VAN when combination with TZP is used particularly for patients with high AKI risk."( Comparison of teicoplanin versus vancomycin in combination with piperacillin-tazobactam or meropenem for the risk of acute kidney injury.
Akova, M; Aslan, AT; Dağ, O; Pashayev, T, 2021)		0.62
"Recent studies have shown that the incidence of nephrotoxicity increases when vancomycin is combined with a beta-lactam antibiotic."( Comparative incidence of acute kidney injury in patients on vancomycin therapy in combination with cefepime, piperacillin-tazobactam or meropenem.
Duong, L; Harriott, NG; Ives, AL; Pan-Chen, S; Rungkitwattanakul, D, 2022)		0.72
"To investigate the antibacterial activity of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales (CRE) in vivo and in vitro."( Synergistic effect of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales.
Liu, Q; Shi, S; Xu, M; Yao, Z; Ye, J; Zhang, X; Zhang, Y; Zhou, B; Zhou, C; Zhou, T, 2022)		0.72
"Twenty-five CRE strains, including Klebsiella pneumoniae (n = 10), Escherichia coli (n = 6) and Enterobacter cloacae (n = 9), were used in chequerboard assays to evaluate the synergistic effect of BLI-489 combined with imipenem or meropenem."( Synergistic effect of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales.
Liu, Q; Shi, S; Xu, M; Yao, Z; Ye, J; Zhang, X; Zhang, Y; Zhou, B; Zhou, C; Zhou, T, 2022)		0.72
"The novel β-lactamase inhibitor BLI-489 possesses a synergistic effect against diverse carbapenemase-producing CRE combined with imipenem or meropenem."( Synergistic effect of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales.
Liu, Q; Shi, S; Xu, M; Yao, Z; Ye, J; Zhang, X; Zhang, Y; Zhou, B; Zhou, C; Zhou, T, 2022)		0.72
"Evaluate the in vivo efficacy and resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam and meropenem using human-simulated regimens (HSR) in the murine infection model."( In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii.
Echols, R; Gill, CM; Longshaw, C; Nicolau, DP; Santini, D; Takemura, M; Yamano, Y, 2023)		0.91
" The results showed additivity when the substance was combined with ciprofloxacin and cefepime, indifference when associated with ceftazidime and synergistic effect when combined with meropenem and imipenem."( Effect of 2-chloro-N-(4-fluoro-3-nitrophenyl)acetamide in combination with antibacterial drugs against Klebsiella pneumoniae.
Andrade Júnior, FP; Athayde Filho, PF; Cordeiro, LV; Figueiredo, PTR; Lima, EO; Oliveira, RF; Oliveira-Filho, AA; Sousa, AP; Souza, HDS, 2023)		0.91
" In this study, we analyzed the in vitro activity of those novel antibacterial agents alone or in combination with polymyxin B against the CR-A."( In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii.
Gu, Y; Hu, D; Hu, M; Liang, R; Wang, D; Wang, M; Zhu, M, 2023)		0.91
"Synergistic effects of phages in combination with antibiotics have received increasing attention."( Synergistic Antibacterial Effect of Phage pB3074 in Combination with Antibiotics Targeting Cell Wall against Multidrug-Resistant Acinetobacter baumannii
Fan, J; Jin, J; Li, Q; Liu, M; Luo, C; Luo, J; Wang, P; Xie, L; Yang, M, 2023)		0.91
" Zinc in combination with aminoglycosides (kanamycin, gentamicin, and amikacin) reduced the expression of biofilm-related genes by 40-, 2602- and 20-folds, respectively, and by 2-folds in combination with ertapenem."( Modulating the transcriptomic profile of multidrug-resistant Klebsiella pneumoniae biofilm formation by antibiotics in combination with zinc sulfate.
Badawy, MSEM; Elkhatib, WF; Shebl, RI, 2023)		0.91
"Results revealed variable interaction patterns between different antibiotics in combination with zinc."( Modulating the transcriptomic profile of multidrug-resistant Klebsiella pneumoniae biofilm formation by antibiotics in combination with zinc sulfate.
Badawy, MSEM; Elkhatib, WF; Shebl, RI, 2023)		0.91
" Some studies have demonstrated promising results of IgG in combination with antimicrobial preparations against bacterial infections, in which the direct action of IgG has restored the immune system balance."( In vitro evaluation of human intravenous immunoglobulin in combination with antimicrobials and human serum against multidrug-resistant isolates of Acinetobacter baumannii.
Alves, LC; Bezerra Cavalcanti, CL; Brayner, FA; da Silva, EM; de Araújo, AR; de Freitas, CF; de Lima, FCG; do Nascimento, AV; Oliveira Júnior, JB; Sandes, JM; Veras, DL, 2023)		0.91

Bioavailability

ExcerptReferenceRelevance
"87%, and bioavailability after SC administration was 84%."( Plasma pharmacokinetics and tissue fluid concentrations of meropenem after intravenous and subcutaneous administration in dogs.
Bidgood, T; Papich, MG, 2002)		0.31
" Compounds 4 and 8 were well absorbed after oral administration to rats and beagles (bioavailability 18."( Novel prodrugs of meropenem with two lipophilic promoieties: synthesis and pharmacokinetics.
Kakeya, N; Kasai, M; Kunishiro, K; Matsui, H; Shirahase, H; Tanaka, S, 2011)		0.37
"3% bioavailability for enteral liquid applications."( Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage.
Bjeljac, M; Keller, E; Mink, S; Muroi, C; Seule, M, 2011)		0.37
"Though this finding needs further verification, the enteral liquid application of levetiracetam seems to be associated with lower bioavailability than the common oral application of levetiracetam."( Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage.
Bjeljac, M; Keller, E; Mink, S; Muroi, C; Seule, M, 2011)		0.37
" Strong binding of carbapenems to HSA may lead to decreased bioavailability of the drug."( Interaction of meropenem with 'N' and 'B' isoforms of human serum albumin: a spectroscopic and molecular docking study.
Ahmed, S; Khan, AU; Rehman, MT, 2016)		0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
" Reported here is a novel, orally bioavailable diazabicyclooctane (DBO) β-lactamase inhibitor."( Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
Carter, NM; Chen, A; Chen, Y; Comita-Prevoir, J; Durand-Réville, TF; Giacobbe, RA; Lahiri, SD; May-Dracka, TL; McLeod, SM; Miller, AA; Mueller, JP; O'Donnell, JP; Romero, JAC; Sacco, MD; Shapiro, AB; Tommasi, RA; Verheijen, JC; Wu, F; Wu, X; Zhang, J, 2020)		0.56
" In this review, we discuss strategies for improving the oral bioavailability of MER, such as inhibiting tubular secretion, prodrug formulations, and use of nanomedicine."( Oral meropenem for superbugs: challenges and opportunities.
Cabot, PJ; Falconer, JR; Kumeria, T; Ngieng, SC; Popat, A; Raza, A; Roberts, JA; Sime, FB, 2021)		0.62
" Delivery vehicles capable of versatile loading may improve local bioavailability and minimize systemic toxicities yet such vehicles are not clinically available."( Glutathione-Conjugated Hydrogels: Flexible Vehicles for Personalized Treatment of Bacterial Infections.
Gemeinhart, RA; Pham, HM; Sokolowski, K; Wenzler, E, 2021)		0.62
" However, conventional antibiotic combinations have some limitations such as the low bioavailability and the rise of resistant strains."( Nanosized Combined Antimicrobial Drugs Decreased Emergence of Resistance in
Abd El-Baky, RM; Aly, SA; Elsabahy, M; Hadiya, S; Ibrahem, RA, 2022)		0.72

Dosage Studied

Meropenem was tested against an experimental lethal meningitis model in guinea pigs with type b β-lactamase-nonproducing ampicillin-resistant Haemophilus influenzae. The superiority of bolus dosing over the infusions could be documented only for meropenem concentrations below the MIC.

ExcerptRelevanceReference
" Dosage adjustments of meropenem will be necessary in patients with severe renal impairment."( Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment.
Borsa-Lebas, F; Etienne, I; Fillastre, JP; Humbert, G; Leroy, A, 1992)		0.28
" The usual recommended dosage and administration should be 10 to 20 mg/kg of MEPM at a time, using intravenous drip infusion, 3 times a day."( [Bacteriological and clinical studies on meropenem in the pediatric field].
Akita, H; Iwata, S; Nitta, Y; Sato, Y; Sunakawa, K; Yokota, T, 1992)		0.28
" Five dialysis patients were dosed 2 h prior to hemodialysis, and four of them were also dosed between hemodialysis treatments."( Pharmacokinetics of meropenem in subjects with various degrees of renal impairment.
Christensson, BA; Haworth, SJ; Hutchison, M; Nilsson-Ehle, I; Norrby, SR; Oqvist, B, 1992)		0.28
"7 micrograms/ml after dosing 10 mg/kg, and that of 2 patients was 70."( [Clinical and pharmacokinetic evaluations of meropenem in children].
Satoh, K; Watanabe, A, 1992)		0.28
" A 4-year-6-month-old girl with suppurative meningitis (Haemophilus influenzae) was treated by intravenous drip infusion of MEPM in a daily dose of 29 mg/kg which was divided into 4 dosages, each dosage being infused over 30 minutes, and the drug concentration in cerebrospinal fluid was determined."( [Studies on meropenem in the field of pediatrics].
Haruta, T; Kobayashi, Y; Kuroki, S; Nikami, H; Nishio, T; Okura, K, 1992)		0.28
" Agents with longer half lives allowing twice daily dosing (cefmetazole and cefotetan) were as effective and less expensive than multiple doses of short-acting agents."( Adjunctive antimicrobials in surgery of soft tissue infections: evaluation of cephalosporins and carbapenems.
Hopkins, JA; Lami, JL; Wilson, SE, 1991)		0.28
" Diarrhoea occurred in rabbits and monkeys dosed with imipenem or meropenem."( Safety evaluation of meropenem in animals: studies on the kidney.
Goonetilleke, UR; Jones, DV; Murgatroyd, LB; Topham, JC; Wright, J, 1989)		0.28
" In order to define meropenem dosing guidelines for children, an escalating, single-dose, pharmacokinetic study at 10, 20, and 40 mg/kg of body weight was performed."( Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children.
Blumer, JL; Ewing, BJ; Gooch, WM; Jacobs, RF; Kearns, GL; Reed, MD; Willims, K; Yogev, R, 1995)		0.29
" Dosage adjustments in people with decreased creatinine clearance can, thus, be made on the basis of creatinine clearance."( Meropenem clinical pharmacokinetics.
Mouton, JW; van den Anker, JN, 1995)		0.29
" Hepatic functional impairment does not alter drug disposition and no dosing alterations are required here."( The pharmacokinetics of meropenem.
Drusano, GL; Hutchison, M, 1995)		0.29
", significantly lowered the convulsive threshold of pentylenetetrazol (PTZ) in mice and shifted the dose-response curve of PTZ."( Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem.
Day, IP; Goudie, J; Nishiki, K; Williams, PD, 1995)		0.29
"Whether PALE is confirmed, it must be taken into consideration in dosage schedules."( [Effect of ciprofloxacin on the phagocytosis of Escherichia coli by human polymorphonuclear leukocytes].
Gómez-Lus, ML; Herrera, I; Martín, M; Pérez, P; Prieto, J, 1993)		0.29
" Meropenem was the major radioactive component in urine up to 8 h after dosing and is therefore remarkably stable to human renal dehydropeptidase (DHP-1) compared with other carbapenems in clinical use."( The disposition and metabolic fate of 14C-meropenem in man.
Featherstone, A; Harrison, MP; Haworth, SJ; Moss, SR; Wilkinson, DM, 1993)		0.29
" The dosing interval of meropenem should be prolonged in a regular proportion to the decline in CLCR (12 h in group II patients and 24 h in group III patients)."( Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease.
Chimata, M; Kakuta, S; Nagase, M; Shimomura, M; Suzuki, Y, 1993)		0.29
" These factors, combined with the human plasma, tissue or urinary concentrations of meropenem which exceed modal MICs for the pathogens isolated in clinical trials for most or all of the recommended 8 h dosing interval, predict that meropenem should be efficacious in the treatment of infections at many body sites."( Meropenem: a microbiological overview.
Edwards, JR, 1995)		0.29
" In bacterial meningitis, the meropenem dosage in adults was 2 g 8 hourly and 40 mg/kg 8 hourly in children."( Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem.
Faulkner, KL; Lesky, W; Newell, PA; Norrby, SR, 1995)		0.29
" For both doses, administration over 5 rather than 30 min doubled the plasma concentrations observed at the end of the dosing period."( A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min.
Haworth, SJ; Hutchison, M; Kelly, HC, 1995)		0.29
" A higher dosage of 40 mg/kg or 2 g in adults given tds would be recommended for meningitis based on the penetration of meropenem into CSF."( A compilation of meropenem tissue distribution data.
Faulkner, KL; Haworth, SJ; Hutchison, M; Nadler, H; Pitkin, DH; Sheikh, W; Turner, PJ, 1995)		0.29
" The findings in the younger, lighter patients, if generally applicable, might have significance for the dosage recommendations for drugs with narrow therapeutic indices."( The pharmacokinetics of meropenem in infants and children: a population analysis.
Blumer, JL; Hutchison, M; Parker, EM, 1995)		0.29
"Several pharmacodynamic parameters are being studied and applied to the design of dosage regimens."( In vivo and in vitro study of several pharmacodynamic effects of meropenem.
Fuentes, F; Gomez-Lus, ML; Izquierdo, J; Martín, MM; Prieto, J, 1995)		0.29
" If the manufacturer's dosage recommendations are followed, the risk of seizures in patients receiving this combination is minimal."( Neurotoxicity of carbapenem antibacterials.
Norrby, SR, 1996)		0.29
"In a nonblind, randomised, parallel-group study, initial empirical monotherapy with meropenem 1 g intravenously every 8 h was compared to an identical dosage of imipenem/cilastatin for the treatment of 66 febrile episodes in 61 adult neutropenic patients."( Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients.
Böhme, A; Fuhr, HG; Halir, S; Heller, A; Jung, B; Köhler, A; Lips-Schulte, C; Schaumann, R; Shah, PM; Stille, W; Walther, F, )		0.13
" The superiority of bolus dosing over the infusions could be documented only for meropenem concentrations below the MIC."( Relationships between antimicrobial effect and area under the concentration-time curve as a basis for comparison of modes of antibiotic administration: meropenem bolus injections versus continuous infusions.
Firsov, AA; Mattie, H, 1997)		0.3
" No statistically significant differences were found between the first dose and steady state or between groups for any plasma pharmacokinetic parameters-including the highest observed plasma concentrations, plasma concentrations at 6 hours after dosing (C6h), terminal half-life, area under the plasma concentration-time curve (AUC), area under the first moment of the curve, plasma clearance, steady-state volume of distribution, and accumulation ratios-on the basis of either AUC or C6h."( Pharmacokinetics of meropenem in patients with liver disease.
Birmingham, B; Lasseter, K; Thyrum, PT; Yeh, C, 1997)		0.3
" Approximately 70% of meropenem is excreted via the kidneys, thus dosage adjustments are required for patients with renal impairment."( Pharmacokinetics of meropenem in animals, healthy volunteers, and patients.
Chung, KC; Gill, MA; Moon, YS, 1997)		0.3
" Dosage reduction is required in patients with reduced renal function; no dosage adjustment is required for patients with hepatic impairment."( The pharmacology of meropenem, a new carbapenem antibiotic.
Craig, WA, 1997)		0.3
" Dosage was reduced in patients with renal impairment."( [Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study].
Tonelli, F, 1997)		0.3
" For the six dosage regimens used in this study, the killing activities were similar and resulted in at least 4 log decrease at 6 h after drug exposure."( [In vivo pharmacokinetic of amikacin and its pharmacodynamic in combination with cefepime, cefpirome and meropenem in an in vitro/ex vivo micropig model].
Elkhaïli, H; Jehl, F; Levêque, D; Linger, L; Monteil, H; Niedergang, S; Peter, JD; Pompei, D; Salmon, J; Salmon, Y; Thierry, RC, 1997)		0.3
" Within 10 min after the start of the injection, the plasma concentrations from all three injections were very similar indicating that dosing over 2, 3 or 5 min would result in similar antimicrobial cover and, therefore, comparable efficacy."( A comparison of the pharmacokinetics of meropenem after intravenous administration by injection over 2, 3 and 5 minutes.
Freestone, S; Hutchison, M; Jones, HK; Kelly, HC; Lomax, C; Ross, F; Webb, D; Yates, RA, )		0.13
" Modification of the dosage is not necessary in patients with hepatic failure."( [Meropenem: pharmacologic advantages of clinical interest].
Domínguez-Gil Hurlé, A, 1997)		0.3
" Meropenem dosage depends on the patient weight, and the way of administration is potentially easier."( [Clinical pharmacology and indications of meropenem in severe pediatric infection].
Díaz, M; Honorato, J; Sádaba, B, 1997)		0.3
" Cost-avoidance with meropenem is, therefore, mainly the result of less frequent dosing and the ability to administer meropenem by rapid intravenous injection."( Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem.
Ambrose, PG; Nightingale, CH; Quintiliani, R; Richerson, MA, 1998)		0.3
" A dosage of 1,000 mg of meropenem twice a day provides plasma drug levels covering intermediately susceptible microorganisms."( Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration.
Dieterich, HJ; Erley, C; Heininger, A; Hoffmann, E; Hutchison, M; Krueger, WA; Schroeder, TH; Unertl, K; Wehrle, A, 1998)		0.3
" Each of these three dosing regimens produced a rapid reduction in viable bacterial count over the first 16 h after dosing."( Comparative pharmacodynamics of meropenem using an in-vitro model to simulate once, twice and three times daily dosing in humans.
Bowker, KE; Holt, HA; Lewis, RJ; MacGowan, AP; Reeves, DS, 1998)		0.3
" Plasma and hemofiltrate concentrations were determined during 1 dosing interval at steady state."( Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.
Bremer, F; Brune, K; Geisslinger, G; Lötsch, J; Neumann, F; Tegeder, I, 1999)		0.3
" Peak and trough concentrations for a dosing interval of 12 hours were 38."( Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.
Bremer, F; Brune, K; Geisslinger, G; Lötsch, J; Neumann, F; Tegeder, I, 1999)		0.3
" In patients with normal renal function, the recommended dosing interval is every 8 hours."( Carbapenems and monobactams: imipenem, meropenem, and aztreonam.
Brewer, NS; Hellinger, WC, 1999)		0.3
" Dosage recommendations derived from clinical studies might be appropriate when different filter materials, but similar operational settings of the continuous replacement therapy, are applied."( Elimination of meropenem by continuous hemo(dia) filtration: an in vitro one-compartment model.
Dieterich, HJ; Hansen, M; Hoffmann, E; Krueger, WA; Schroeder, TH; Unertl, K, 1999)		0.3
" In the mouse pentylenetetrazole (PTZ) convulsive model, intravenous pretreatment with cefazolin (800 mg/kg) or imipenem (200 mg/kg) shifted the dose-response curve of PTZ (i."( Low convulsive activity of a new carbapenem antibiotic, DK-35C, as compared with existing congeners.
Cho, JH; Jin, C; Jung, I; Kim, DH; Kim, M; Ku, HJ; Oh, CH; Yook, J, 1999)		0.3
" Serum meropenem concentrations were measured before dosing and at 30 min after each 30 min infusion."( Use of meropenem 3 g once daily for outpatient treatment of infective exacerbations of bronchiectasis.
Bowker, KE; Darley, ES; Harvey, JE; Lovering, AM; Macgowan, AP, 2000)		0.31
"To evaluate an intravenous meropenem dosage regimen in adult intensive care patients with acute renal failure treated by continuous renal replacement therapy."( Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration.
Beale, RJ; Creed, G; Giles, LJ; Jennings, AC; McLuckie, A; Thomson, AH, 2000)		0.31
" Serum concentrations exceeded 4 mg/L (MIC90 for Pseudomonas aeruginosa) during 67% of the dosage period in all patients."( Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration.
Beale, RJ; Creed, G; Giles, LJ; Jennings, AC; McLuckie, A; Thomson, AH, 2000)		0.31
" Plasma samples and ultrafiltrate aliquots were collected during one dosing interval."( Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration.
Blankestijn, PJ; Boereboom, FT; Meulenbelt, J; Savelkoul, JF; van Dijk, A; Ververs, TF; Vinks, SA, 2000)		0.31
" We recommend meropenem to be dosed at 500 mg intravenously every 12 hrs in patients receiving CWHF, according to our operational characteristics."( Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration.
Blankestijn, PJ; Boereboom, FT; Meulenbelt, J; Savelkoul, JF; van Dijk, A; Ververs, TF; Vinks, SA, 2000)		0.31
" Meropenem is predominately excreted unchanged in the urine, and thus dosage adjustments are necessary in patients with renal insufficiency and those undergoing intermittent haemodialysis (IHD) or various forms of continuous renal replacement therapy (CRRT), such as continuous venovenous haemodialysis, continuous venovenous haemodiafiltration (CVVHDF), continuous venovenous haemofiltration (CVVHF) or continuous ambulatory peritoneal dialysis (CAPD)."( Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy.
Hörl, WH; Thalhammer, F, 2000)		0.31
" administered every 8 h in clinically stable CF patients to determine if the recommended maximum doses could sustain adequate concentrations during the dosing interval."( Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients.
Ambrose, PG; Bui, KQ; Lapin, CD; Nicolau, DP; Nightingale, CH; Quintiliani, R, )		0.13
"A new, simple, precise and rapid high performance liquid chromatographic method was developed for the determination of meropenem in human serum, urine and pharmaceutical dosage forms."( A rapid, sensitive high performance liquid chromatographic method for the determination of meropenem in pharmaceutical dosage form, human serum and urine.
Aboul-Enein, HY; Küçükgüzel, I; Ozkan, SA; Ozkan, Y, 2001)		0.31
" Dosing simulations revealed that a daily dose of 25 mg/kg or an alternate day dose of 40 mg/kg would result in an acceptable pharmacodynamic profile."( Meropenem pharmacokinetics in children and adolescents receiving hemodialysis.
Aleksic, A; Blaney, S; Goldstein, SL; May, S; Murry, DJ; Sowinski, KM, 2001)		0.31
" In both groups, patients with susceptible pathogens (MIC<1 mg/l) had meropenem plasma levels which exceeded the MIC for the whole dosing interval."( Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients.
De Myttenaere-Bursztein, SA; Farin, D; Kitzes-Cohen, R; Piva, G, 2002)		0.31
" However, there are limited data available to substantial rational dosing decisions in this condition."( Determination of meropenem in plasma and filtrate-dialysate from patients under continuous veno-venous haemodiafiltration by SPE-LC.
Biollaz, J; Buclin, T; Decosterd, LA; Eckert, P; Robatel, C; Schaller, MD, 2002)		0.31
"The economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts is described."( Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts.
Kuti, JL; Maglio, D; Nicolau, DP; Nightingale, CH, 2003)		0.32
"47% of an 8 h dosing interval, respectively."( Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection.
Jaruratanasirikul, S; Sriwiriyajan, S, 2003)		0.32
"5 or 2 g every 8 hours as a 3-hour infusion for three doses and then crossed over to the other dosage regimen."( Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.
Dandekar, PK; Maglio, D; Nicolau, DP; Nightingale, CH; Sutherland, CA, 2003)		0.32
"Prolonging the infusion of meropenem over 3 hours increases the percentage of the dosing interval that drug concentrations remain above the minimum inhibitory concentration (MIC), thereby maximizing the pharmacodynamics of this agent and adhering to drug stability constraints."( Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
Dandekar, PK; Kuti, JL; Nicolau, DP; Nightingale, CH, 2003)		0.32
" Its disposition was studied over one dosage interval in 15 patients under CVVHDF on a steady regimen of 500 or 1000 mg every 8 to 12 hours."( Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients.
Biollaz, J; Buclin, T; Decosterd, LA; Eckert, P; Robatel, C; Schaller, MD, 2003)		0.32
" The proposed methods are highly sensitive, precise and accurate and can be used for the reliable quantitation of meropenem in pharmaceutical dosage form."( Validation of HPLC and UV spectrophotometric methods for the determination of meropenem in pharmaceutical dosage form.
Mendez, AS; Schapoval, EE; Steppe, M, 2003)		0.32
" Dosage recommendations are based on the correlation of plasma levels with pharmacodynamic requirements."( Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration.
Dieterich, HJ; Forst, H; Heininger, A; Hoffmann, E; Krueger, WA; Neeser, G; Schroeder, TH; Schuster, H; Unertl, KE, 2003)		0.32
" The minimal inhibitory concentration (MIC) for susceptible bacteria (4 mg/l) was covered for 40% of the dosing interval or longer in all patients."( Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration.
Dieterich, HJ; Forst, H; Heininger, A; Hoffmann, E; Krueger, WA; Neeser, G; Schroeder, TH; Schuster, H; Unertl, KE, 2003)		0.32
"A dosage of 500 mg twice daily provides appropriate serum levels for the treatment of infections caused by susceptible bacteria."( Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration.
Dieterich, HJ; Forst, H; Heininger, A; Hoffmann, E; Krueger, WA; Neeser, G; Schroeder, TH; Schuster, H; Unertl, KE, 2003)		0.32
" For the free drug concentrations, the percentage of the dosing interval that the drug concentrations remain above the MIC (%T>MIC) for each carbapenem-bacteria combination was calculated for 10,000 iterations, substituting a different ClT, Vdbeta, fraction of unbound drug, and MIC into the equation each time based on the probability distribution for each parameter."( Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
Florea, NR; Kuti, JL; Nicolau, DP; Nightingale, CH, 2004)		0.32
"The bactericidal activity of meropenem is determined by the time that concentrations in tissue and serum are above the MIC for the pathogens during the dosing interval."( Stability of meropenem in normal saline solution after storage at room temperature.
Jaruratanasirikul, S; Sriwiriyajan, S, 2003)		0.32
" The CSF meropenem concentrations exceeded the minimum inhibitory concentration of the pathogen for virtually the entire dosing interval in both cases."( Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections.
Byers, KE; Capitano, B; Horowitz, M; Nicolau, DP; Paterson, DL; Potoski, BA; Venkataramanan, R, 2004)		0.32
"The clinical and economic outcomes of a meropenem dosage strategy based on pharmacodynamic concepts are retrospectively reviewed."( Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts.
Kotapati, S; Kuti, JL; Nicolau, DP; Nightingale, CH, 2004)		0.32
" Patients were included if they were clinically evaluable, had no prior successful antibiotic therapy, and received a meropenem dosage appropriate for renal function."( Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts.
Kotapati, S; Kuti, JL; Nicolau, DP; Nightingale, CH, 2004)		0.32
"A pharmacodynamically designed meropenem dosage strategy of 500 mg every six hours yielded similar clinical outcomes to a regimen of 1000 mg every eight hours and reduced the daily drug acquisition costs associated with antibiotic therapy."( Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts.
Kotapati, S; Kuti, JL; Nicolau, DP; Nightingale, CH, 2004)		0.32
" Consideration of pharmacodynamic principles in dosage regimens for these agents can maximize their antibacterial effectiveness and reduce the number of bacterial strains that survive to mutate or continue infection."( Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem.
Drusano, GL; Kuti, JL; Mattoes, HM; Nicolau, DP, 2004)		0.32
"The objectives of this review were to highlight examples of the application of pharmacodynamics to the carbapenems (particularly meropenem) and to comment on clinical utility of these dosage regimens."( Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem.
Drusano, GL; Kuti, JL; Mattoes, HM; Nicolau, DP, 2004)		0.32
" All studies demonstrating the pharmacodynamics of the carbapenems by incorporating changes in dosage strategies were included."( Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem.
Drusano, GL; Kuti, JL; Mattoes, HM; Nicolau, DP, 2004)		0.32
" The dosage scheme for meropenem may be modified to maximize the percentage of the dosage interval that drug concentrations remain above the minimum inhibitory concentration, an important parameter related to the bacterial kill rate."( Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem.
Drusano, GL; Kuti, JL; Mattoes, HM; Nicolau, DP, 2004)		0.32
"When proper pharmacodynamic principles are applied to dosage strategies for meropenem, clinical and microbiological outcomes can be optimized."( Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem.
Drusano, GL; Kuti, JL; Mattoes, HM; Nicolau, DP, 2004)		0.32
" Concentrations above the mimimum inhibitory concentration (MIC) of 8 microg/ml were achieved for 52% of the dosing interval, which is greater than what is required for a bactericidal effect."( Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy.
Knauft, RF; Kuti, JL; Moss, KM; Nicolau, DP, 2004)		0.32
" Based on this relationship, dosing with intravenous meropenem 500 mg every 6 hours is predicted to be comparable to the currently recommended 1 g every 8 hours for serious infections."( Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia.
Ariano, RE; Donnelly, JP; Harding, GK; Nyhlén, A; Sitar, DS; Zelenitsky, SA, 2005)		0.33
" The proposed method allows the quantitation of meropenem in pharmaceutical dosage form and can be used for the drug analysis in routine quality control."( Microbiological assay for the determination of meropenem in pharmaceutical dosage form.
Mendez, AS; Oppe, TP; Schapoval, EE; Steppe, M; Weisheimer, V, 2005)		0.33
" In order to optimize levels in plasma relative to the MICs, the ideal dose level and dosage regimen need to be determined."( Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.
Bulitta, J; Drusano, GL; Holzgrabe, U; Kinzig-Schippers, M; Krueger, WA; Landersdorfer, C; Naber, KG; Sörgel, F, 2005)		0.33
"To evaluate and compare the pharmacokinetic profiles of imipenem and meropenem in a population of critically ill patients with sepsis to find possible differences that may help in selecting the most appropriate drug and/or dosage in order to optimise empiric antimicrobial therapy."( Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis.
Adembri, C; De Gaudio, AR; Fallani, S; Livi, P; Mazzei, T; Novelli, A, 2005)		0.33
"Randomized controlled trials of adult patients with severe infections treated with meropenem or imipenem plus cilastatin at an equal dose, on a gram-for-gram basis, and with the same dosing regimen."( Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections.
Campbell, HE; Edwards, SJ; Emmas, CE, 2005)		0.33
" We employed Monte Carlo simulation to calculate the bactericidal target attainment for various dosing regimens of meropenem against Pseudomonas aeruginosa and Acinetobacter species."( Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment.
Kuti, JL; Nicolau, DP, 2005)		0.33
" Lower doses or increased dosing intervals should not be advocated for inpatients receiving this renal replacement technique."( Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment.
Kuti, JL; Nicolau, DP, 2005)		0.33
" The probabilities of each drug and dosing regimen in achieving pharmacodynamic targets were calculated."( Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
Kuti, JL; Nicolau, DP; Sun, HK, 2005)		0.33
" By using minimum inhibitory concentration (MIC) data derived from a global surveillance study and Monte Carlo simulation, the Optimizing Pharmacodynamic Target Attainment using the MYSTIC Antibiogram (OPTAMA) Program was established to impart greater understanding of the ability to attain pharmacodynamic exposure for specific dosing regimens and their relationship with percent susceptibility."( Making the most of surveillance studies: summary of the OPTAMA Program.
Kuti, JL; Nicolau, DP, 2005)		0.33
" Dosing regimes for intermittent hemodialysis and continuous renal replacement therapy cannot be used for critically ill patients treated with EDD."( Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis.
Bode-Böger, SM; Czock, D; Fliser, D; Hafer, C; Keller, F; Kielstein, JT; Kuse, E; Schöpke, T, 2006)		0.33
"3 m; blood and dialysate flow, 160 mL/min; EDD time, 480 mins) and current dosing regimens run the risk of being significantly underdosed, which may have detrimental effects on critically ill patients with life-threatening infections."( Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis.
Bode-Böger, SM; Czock, D; Fliser, D; Hafer, C; Keller, F; Kielstein, JT; Kuse, E; Schöpke, T, 2006)		0.33
" The microbiological outcomes indicate that the current clinical dosage regimen provides sufficient drug exposure to eradicate the pathogens commonly involved in pediatric meningitis."( Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients.
Du, X; Kuti, JL; Li, C; Nicolau, DP; Nightingale, CH, 2006)		0.33
" Pharmacodynamic exposure, measured as percent of the dosing interval during which free drug was above the MIC (% fT>MIC), was modelled via a 5000-subject Monte Carlo simulation."( Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil.
Eagye, KJ; Kiffer, CR; Kuti, JL; Mendes, C; Nicolau, DP, 2006)		0.33
"5g or 1g every 8h, the proportions of patients who had a T>MIC less than 40% of the dosing interval were 46."( Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea.
Choi, SM; Lah, HO; Lee, DG; Shin, WS; Yim, DS, 2006)		0.33
"The objectives of this study were to develop a meropenem population pharmacokinetic model using patient data and use it to explore alternative dosage regimens that could optimize the currently used dosing regimen to achieve higher likelihood of pharmacodynamic exposure against pathogenic bacteria."( Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients.
Kuti, JL; Li, C; Nicolau, DP; Nightingale, CH, 2006)		0.33
" A 5000-subject Monte Carlo simulation was performed to calculate the bactericidal cumulative fraction of response (CFR) for standard dosing regimens of cefepime, ceftazidime, ciprofloxacin, imipenem, meropenem and piperacillin/tazobactam."( Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Konkoly-Thege, M; Kuti, JL; Ludwig, E; Nicolau, DP, 2006)		0.33
" Although the valproic acid dosage was increased, valproic acid levels did not return to the therapeutic range."( Meropenem -valproic acid interaction in patients with cefepime-associated status epilepticus.
Casteels, M; De Troy, E; Meersseman, W; Spriet, I; Willems, L; Wilmer, A, 2007)		0.34
" Pharmacodynamic indices [percentage of the dosing interval that free drug concentrations remain above the MIC (% fT > MIC), f(maximum concentration of drug in serum) (fC(max))/MIC, fC(min)/MIC, and f(area under the concentration-time curve) (fAUC)/MIC] were calculated based on the baseline pathogen with the highest drug MIC for each patient."( Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.
Du, X; Kuti, JL; Li, C; Nicolau, DP, 2007)		0.34
" A model employing the pharmacokinetic properties of meropenem, susceptibility results and Monte Carlo simulation was used to analyse four different dosing regimens of meropenem at pharmacodynamic endpoints."( Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy.
Eagye, KJ; Kuti, JL; Nicolau, DP; Santos Filho, L, 2007)		0.34
"047 microg/mL for 100% of the dosing interval."( Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem.
DeRyke, CA; Kuti, JL; Nicasio, AM; Nicolau, DP; Quintiliani, R, 2007)		0.34
"4% in this patient, resulting in 100% time above the MIC throughout the dosing interval."( Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem.
DeRyke, CA; Kuti, JL; Nicasio, AM; Nicolau, DP; Quintiliani, R, 2007)		0.34
" Compartment modeling with elimination from a peripheral compartment described the data adequately, and was used to simulate steady-state concentration profiles in plasma and PF during various dosing regimens."( Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock.
Couet, W; Karjagin, J; Kipper, K; Lefeuvre, S; Marchand, S; Oselin, K; Sawchuk, RJ; Starkopf, J; Tikkerberi, A, 2008)		0.35
" We explored the use of mathematical modelling to guide selection of dosing regimens."( Mathematical modelling response of Pseudomonas aeruginosa to meropenem.
Nikolaou, M; Poole, K; Schilling, AN; Tam, VH, 2007)		0.34
"Our results suggest that mathematical modelling may be used to predict microbial response to a large number of antimicrobial agent dosing regimens efficiently, and have the potential to be used to guide highly targeted investigation of dosing regimens in pre-clinical studies and clinical trials."( Mathematical modelling response of Pseudomonas aeruginosa to meropenem.
Nikolaou, M; Poole, K; Schilling, AN; Tam, VH, 2007)		0.34
" Meropenem was administrated intravenously in 30 min at dosage of 20 mg/kg every 12 h (every 8 h in Pseudomonas Aeruginosa infections)."( [Use of Meropenem in preterm newborns. Survey of the literature and case series].
Boccacci, S; De Cunto, A; Romagnoli, C; Tana, M; Tirone, C; Vendettuoli, V; Vento, G, 2007)		0.34
"To compare outcomes and cost for the traditional United States Food and Drug Administration-approved dosing regimen for meropenem versus an alternative dosing regimen providing similar pharmacodynamic exposure with a lower total daily dose."( Clinical outcomes and cost minimization with an alternative dosing regimen for meropenem in a community hospital.
Duquaine, SM; McKinnon, PS; Patel, GW, 2007)		0.34
"One hundred patients who received meropenem 1 g every 8 or 12 hours (traditional dosing regimen) between January 1 and September 30, 2004 (historical controls), and 192 patients who received meropenem 500 mg every 6 or 8 hours (alternative dosing regimen) between October 1, 2004, and September 30, 2005."( Clinical outcomes and cost minimization with an alternative dosing regimen for meropenem in a community hospital.
Duquaine, SM; McKinnon, PS; Patel, GW, 2007)		0.34
" Demographics, sources of infection, distributions of organisms, and Charlson Comorbidity Index scores were similar between patients in the traditionally and alternatively dosed groups."( Clinical outcomes and cost minimization with an alternative dosing regimen for meropenem in a community hospital.
Duquaine, SM; McKinnon, PS; Patel, GW, 2007)		0.34
"An alternative dosing regimen for meropenem with a lower total daily dose yielded patient outcomes, including success rates and duration of therapy, equivalent to those of the traditional dosing regimen."( Clinical outcomes and cost minimization with an alternative dosing regimen for meropenem in a community hospital.
Duquaine, SM; McKinnon, PS; Patel, GW, 2007)		0.34
" CI may be an effective alternative dosing regimen to IB."( Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy.
Glück, T; Kees, F; Langgartner, J; Reng, M; Vasold, A, 2008)		0.35
" These results suggest that our simple and rapid HPLC method for the determination of the serum concentrations of carbapenems is useful for pharmacokinetic/pharmacodynamic (PK/PD)-based determination of carbapenem dosage regimens."( Simple and rapid determination of serum carbapenem concentrations by high-performance liquid chromatography.
Hori, S; Kizu, J; Kurihara, Y, 2008)		0.35
"Recently, PK/PD (pharmacokinetics/pharmacodynamics) analysis for the antimicrobial dosage method became one of the popular categories in chemotherapy and infectious disease societies world wide."( [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Kobayashi, Y; Sumitani, Y, 2007)		0.34
" Monte Carlo simulations (10,000 patients) were performed to calculate the cumulative fraction of response (CFR) for a percentage of the dosing interval that free drug concentrations remain above the minimum inhibitory concentration (fT>MIC) of 40% by using pharmacokinetic data for each group and MIC data for seven gram-negative pathogens from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC, 2004-2005) database."( Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.
Cheatham, SC; Kays, MB; Smith, DW; Sowinski, KM; Wack, MF, 2008)		0.35
" However, more aggressive dosing or alternative dosing strategies may be necessary for Acinetobacter species."( Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.
Cheatham, SC; Kays, MB; Smith, DW; Sowinski, KM; Wack, MF, 2008)		0.35
"4 and (ii) sigmoidal dose-response curves with cloxacillin (0."( Restoration of susceptibility of intracellular methicillin-resistant Staphylococcus aureus to beta-lactams: comparison of strains, cells, and antibiotics.
Appelbaum, PC; Glupczynski, Y; Lemaire, S; Olivier, A; Tulkens, PM; Van Bambeke, F, 2008)		0.35
" Using Monte Carlo simulation (MCS), the probability of pharmacokinetic-pharmacodynamic target attainment was evaluated by computer modeling from predictions extrapolated from PPK data, using "virtual" dosing regimens of 10, 20, and 40 mg/kg administered every 8 or 12 hours against community- and hospital-acquired pathogens."( Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate.
Ambrose, PG; Bhavnani, SM; Bradley, JS; Capparelli, EV; Rasmussen, MR; Sauberan, JB, 2008)		0.35
" MCS demonstrated that in infants during the first 2 weeks of life, a dosage of 20 mg/kg/dose every 8 hours achieved the desired PD target in 95% of preterm neonates and 91% of term neonates against Pseudomonas aeruginosa isolated from patients managed in adult and pediatric intensive care units in the United States."( Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate.
Ambrose, PG; Bhavnani, SM; Bradley, JS; Capparelli, EV; Rasmussen, MR; Sauberan, JB, 2008)		0.35
"Pharmacokinetic and pharmacodynamic profiles of antibiotics are important in determining effective dosing regimens."( Pharmacokinetic and pharmacodynamic properties of meropenem.
Nicolau, DP, 2008)		0.35
" Alternative meropenem dosing strategies for the optimization of outcomes are under investigation."( Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections.
Mohr, JF, 2008)		0.35
"Rational dosing of antibiotics in neonates should be based on pharmacokinetic (PK) parameters assessed in specific populations."( Microanalysis of beta-lactam antibiotics and vancomycin in plasma for pharmacokinetic studies in neonates.
Ahsman, MJ; Mathot, RA; Tibboel, D; Wildschut, ED, 2009)		0.35
"Assesment of dosage deviations of three ss-lactam antibiotics eliminated through the kidneys (meropenem, piperacillin/tazobactam and cefepime) by comparison of two prediction formulae, Cockroft-Gault (CG) and Modification of Diet in Renal Disease (MDRD) with 24 h urinary creatinine clearance (CrCl(24h)), as a reference method."( [The impact of different renal function measuring methods on the dosages of meropenem, piperacillin/tazobactam and cefepime in critically ill patients].
Diego del Río, E; Gratacós Santanach, L; Ribas Sala, J; Soy Muner, D, )		0.13
" Dosage discrepancies for each antibiotic based on CG y MDRD were studied in reference to CrCl(24h) by percentage agreement and weighted kappa."( [The impact of different renal function measuring methods on the dosages of meropenem, piperacillin/tazobactam and cefepime in critically ill patients].
Diego del Río, E; Gratacós Santanach, L; Ribas Sala, J; Soy Muner, D, )		0.13
"To compare the plasma and subcutaneous tissue concentration-time profiles of meropenem administered by intermittent bolus dosing or continuous infusion to critically ill patients with sepsis and without renal dysfunction, and to use population pharmacokinetic modelling and Monte Carlo simulations to assess the cumulative fraction of response (CFR) against Gram-negative pathogens likely to be encountered in critical care units."( Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
Dalley, AJ; Kirkpatrick, CM; Lipman, J; Roberts, JA; Roberts, MS; Robertson, TA, 2009)		0.35
" All simulated intermittent bolus, extended and continuous infusion dosing achieved 100% of pharmacodynamic targets against most Gram-negative pathogens."( Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
Dalley, AJ; Kirkpatrick, CM; Lipman, J; Roberts, JA; Roberts, MS; Robertson, TA, 2009)		0.35
"In our ICUs where multidrug resistant bacteria are common, an approach considering ICU-specific antibiotic MICs coupled with pharmacodynamic dosing strategies resulted in improved outcomes and shorter duration of treatments."( Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia.
Eagye, KJ; Kuti, JL; Nicasio, AM; Nicolau, DP; Palter, M; Pepe, J; Shore, E, 2010)		0.36
"To compare clinical outcomes of patients receiving an alternative dosage of meropenem with those of patients receiving imipenem-cilastatin or the traditional dosage of meropenem after failure of or intolerance to cefepime for treatment of febrile neutropenia."( Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.
Arnold, HM; Augustin, KM; Casabar, E; Dubberke, ER; Hladnik, LM; McKinnon, PS; Reichley, RM; Ritchie, DJ; Westervelt, P, 2009)		0.35
"Of the 127 patients, 40 received imipenem-cilastatin 500 mg every 6 hours between September 1, 2005, and August 31, 2006; 87 patients received meropenem between September 1, 2006, and August 31, 2007: 29 received a traditional dosage of meropenem 1 g every 8 hours, and 58 received an alternative dosage of meropenem 500 mg every 6 hours."( Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.
Arnold, HM; Augustin, KM; Casabar, E; Dubberke, ER; Hladnik, LM; McKinnon, PS; Reichley, RM; Ritchie, DJ; Westervelt, P, 2009)		0.35
"The alternative meropenem dosage of 500 mg every 6 hours yielded similar patient outcomes, including time to defervescence, need for additional antibiotics, duration of therapy, and mortality, when compared with the traditional meropenem dosage and imipenem-cilastatin in adults with febrile neutropenia."( Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.
Arnold, HM; Augustin, KM; Casabar, E; Dubberke, ER; Hladnik, LM; McKinnon, PS; Reichley, RM; Ritchie, DJ; Westervelt, P, 2009)		0.35
"001) than were cefazolin, vancomycin, or linezolid based on the dose-response profiles."( In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
Abbanat, D; Bush, K; Fernandez, J; Flamm, RK; Hilliard, JJ; Melton, JL; Santoro, CM; Zhang, W, 2010)		0.36
" As a consequence, studies have recommended higher doses or more frequent dosing or both for some antibiotics in patients with major burns, but data are lacking for many of the antibiotics reserved for treatment of life-threatening infections."( Potential subtherapeutic linezolid and meropenem antibiotic concentrations in a patient with severe burns and sepsis.
Allen, JM; Davies, JG; Dheansa, BS; Donaldson, PM; Hallam, MJ; Hanlon, GW; James, SE, )		0.13
" aeruginosa was evaluated for 8 h, which is the usual dosing interval of meropenem."( Experimental verification of the efficacy of optimized two-step infusion therapy with meropenem using an in vitro pharmacodynamic model and Monte Carlo simulation.
Eguchi, K; Kaku, M; Kanazawa, K; Kanemitsu, K; Shimizudani, T, 2010)		0.36
"To systematically review evidence comparing traditional and alternative dosing strategies for meropenem, based on clinical and pharmacoeconomic outcomes."( Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review.
Ensom, MH; Mabasa, VH; Perrott, J, 2010)		0.36
" No studies have formally examined adverse effects with alternative dosing regimens."( Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review.
Ensom, MH; Mabasa, VH; Perrott, J, 2010)		0.36
"Meropenem alternative dosing strategies provide similar pharmacodynamic target attainment rates compared with traditional dosing strategies."( Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review.
Ensom, MH; Mabasa, VH; Perrott, J, 2010)		0.36
" Using a minimum inhibitory concentration (MIC) = 2 microg/mL as our reference point, we also evaluated the therapeutic adequacy of dosing meropenem as 1 g every 12 h during SLED."( Meropenem removal in critically ill patients undergoing sustained low-efficiency dialysis (SLED).
Chen, J; Deshpande, P; Gofran, A; Golestaneh, L; Murea, M, 2010)		0.36
" Dosing 1 g of meropenem every 12 h during a typical 8-h SLED session maintains adequate plasma concentrations."( Meropenem removal in critically ill patients undergoing sustained low-efficiency dialysis (SLED).
Chen, J; Deshpande, P; Gofran, A; Golestaneh, L; Murea, M, 2010)		0.36
" maltophilia did not exhibit a gene dosage effect on beta-lactamase expression."( AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
Chung, TC; Hu, RM; Huang, YW; Lin, CW; Lin, YT; Yang, TC, 2010)		0.36
" The probabilities of target achievement of drug concentrations over the MIC in PF for 40% of the dosing interval with 500 mg every 8 h and 1000 mg every 8 h, were 84% and 90% against Bacteroides spp."( Peritoneal pharmacokinetics and pharmacodynamic target attainment of meropenem in patients undergoing abdominal surgery.
Ikawa, K; Ikeda, K; Morikawa, N; Ohge, H; Soga, Y; Sueda, T, 2010)		0.36
" The objectives of this study were, firstly, to investigate the pharmacokinetics of meropenem in critically ill patients with severe sepsis who are receiving high-volume CVVHF with high-volume exchanges (> or = 4 liters/h); secondly, to determine whether standard dosing regimens (1,000 mg intravenously [i."( Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
Bilgrami, I; Davis, J; Fowler, S; Goldrick, PB; Lipman, J; Roberts, JA; Thomas, J; Wallis, SC, 2010)		0.36
" Confirmation of testing results is encouraged when an accurate MIC is required for antibiotic dosing optimization."( Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods.
Abuali, M; Bulik, CC; Fauntleroy, KA; Jenkins, SG; Kuti, JL; LaBombardi, VJ; Nicolau, DP, 2010)		0.36
" Serum concentrations remained above 4 times the minimal inhibitory concentration (T > 4 × MIC), corresponding to the clinical breakpoint for Pseudomonas aeruginosa defined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST), for 57% of the dosage interval for meropenem (target MIC = 8 μg/mL), 45% for ceftazidime (MIC = 32 μg/mL), 34% for cefepime (MIC = 32 μg/mL), and 33% for piperacillin-tazobactam (MIC = 64 μg/mL)."( Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
De Backer, D; Delattre, I; Dugernier, T; Jacobs, F; Laterre, PF; Layeux, B; Spapen, H; Taccone, FS; Vincent, JL; Wallemacq, P; Wittebole, X, 2010)		0.36
" Standard dosage regimens for piperacillin-tazobactam, ceftazidime and cefepime may, therefore, be insufficient to empirically cover less susceptible pathogens in the early phase of severe sepsis and septic shock."( Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
De Backer, D; Delattre, I; Dugernier, T; Jacobs, F; Laterre, PF; Layeux, B; Spapen, H; Taccone, FS; Vincent, JL; Wallemacq, P; Wittebole, X, 2010)		0.36
"019) than those with the genes chromosomally encoded, which is most likely due to increased gene dosage provided by the higher copy number of associated plasmids."( Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan.
Chang, FY; Chen, TL; Fung, CP; Hsueh, PR; Ko, WC; Kuo, SC; Lee, YT; Siu, LK, 2010)		0.36
"To develop a population pharmacokinetic model of meropenem in burn patients and to explore the appropriateness of current dosage regimens."( Population pharmacokinetics of meropenem in burn patients.
Chae, H; Doh, K; Han, S; Hur, J; Kim, J; Woo, H; Yim, DS; Yim, H, 2010)		0.36
" The simulation of 1000 virtual patients' plasma meropenem concentration treated with 1000 mg (30 min infusion) every 8 h based upon the model predicted the probability of achieving the time above MIC >40% of the dosing interval as 58."( Population pharmacokinetics of meropenem in burn patients.
Chae, H; Doh, K; Han, S; Hur, J; Kim, J; Woo, H; Yim, DS; Yim, H, 2010)		0.36
" Monte Carlo simulations using various dosage regimens at steady-state and 30-min and 3-h infusion rates were performed to evaluate the probabilities of attaining 20% (bacteriostatic), 30%, and 40% (maximum kill) time above the MIC."( Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
Bertino, JS; Drusano, GL; Jones, RN; Kinzig-Schippers, M; Lee, LS; Ma, L; Nafziger, AN; Sörgel, F, 2010)		0.36
"To develop a meropenem population pharmacokinetic model in critically ill patients with particular focus on optimizing dosing regimens based on renal function."( Optimization of meropenem dosage in the critically ill population based on renal function.
Ariano, RE; Crandon, JL; Kuti, JL; Nicasio, AM; Nicolau, DP; Zelenitsky, SA, 2011)		0.37
" A 5,000-patient Monte Carlo simulation was used to ascertain optimal dosing regimens for three CrCl ranges."( Optimization of meropenem dosage in the critically ill population based on renal function.
Ariano, RE; Crandon, JL; Kuti, JL; Nicasio, AM; Nicolau, DP; Zelenitsky, SA, 2011)		0.37
" Dating back to the first days of penicillin, it was noted that there was an observed benefit to prolonging the infusion time or dosing more frequently."( Pharmacodynamic approaches to optimizing beta-lactam therapy.
Crandon, JL; Nicolau, DP, 2011)		0.37
" This new lesion, which resulted from CSF dissemination from the primary abscess, was refractory to treatment, and eventually disappeared after the intraventricular VCM dosage was increased from 20 to 30 mg and continued for 30 days."( Fulminant ependymitis following intraventricular rupture of brain abscess.
Inamasu, J; Kuramae, T; Nakatsukasa, M; Tomiyasu, K, 2011)		0.37
" In the plasma samples which were taken in the end of the dosage regimen (8 h) in subsequent days the antibiotic was not fund."( [Application of HPLC to meropenem determination in plasma samples of patients with infections treated after coronary artery bypass graft surgery].
Bafeltowska, J; Białek, K; Pokorska, A; Wilczyński, M, 2010)		0.36
" The results of this study should help Japanese patients on meropenem by improving the prediction accuracy of dosing using the Bayesian method."( Population pharmacokinetic analysis of meropenem in Japanese adult patients.
Higuchi, S; Hosaka, N; Kamimura, H; Karube, Y; Muro, T; Sasaki, T; Takemoto, S; Umeda, Y; Yamamoto, H, 2011)		0.37
" The distribution ofthe sites of infection, causative microorganisms, the dosage ofmeropenem, and duration oftreatment were similar between the two groups."( Therapeutic effectiveness of a generic versus original meropenem in serious infections.
Chantarothorn, S; Jutivorakool, K; Munsakul, W; Nuntachit, N; Simaroj, S; Tangkosakul, T; Tansuphasawadikul, S; Wannasunthornchai, S; Yomtem, K, 2011)		0.37
" The population PK parameters developed in this analysis are useful for calculation of the percent time above minimum inhibitory concentration (%T>MIC) and for optimal dosing of meropenem in pediatric patients."( Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations.
Kozuki, T; Nakayama, M; Ohata, Y; Sunakawa, K; Tanigawara, Y; Tomita, Y, 2011)		0.37
"The objectives of this study were to develop a population pharmacokinetic (PK) model of meropenem, to simulate the percent time above minimum inhibitory concentration (%T > MIC) at various MICs, and to estimate effective dosage regimens by calculating the target attainment rates against various strains of bacteria."( Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis.
Nakayama, M; Ohata, Y; Tamura, K; Tanigawara, Y; Tomita, Y, 2011)		0.37
" We found that the IV group had significantly higher serum concentrations of meropenem during the first hour after dosing (P < 0."( Efficacy of intratracheal instillation of a meropenem/perfluorochemical suspension in acute lung injury.
Chiou, SY; Jeng, MJ; Lee, YS; Lin, CC; Soong, WJ; Tsai, TH; Tsao, PC; Wu, YT; Yang, CF, 2012)		0.38
" The purpose of this study was to determine the pharmacokinetics (PK) of meropenem in young infants as a basis for optimizing dosing and minimizing adverse events."( Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections.
Anand, R; Arrieta, A; Benjamin, DK; Bhatt-Mehta, V; Bidegain, M; Blumer, J; Brozanski, BS; Burchfield, D; Capparelli, EV; Castro, LM; Cohen-Wolkowiez, M; Finer, N; Kantak, A; Kearns, GL; Poindexter, B; Rasmussen, M; Sanchez, P; Schelonka, RL; Smith, PB; Sullivan, JE; Valencia, G; van den Anker, J; Wade, K; Walsh, M; Ward, RM; Weitkamp, JH, 2011)		0.37
"Meropenem dosing strategies based on postnatal and gestational age achieved therapeutic drug exposure in almost all infants."( Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections.
Anand, R; Arrieta, A; Benjamin, DK; Bhatt-Mehta, V; Bidegain, M; Blumer, J; Brozanski, BS; Burchfield, D; Capparelli, EV; Castro, LM; Cohen-Wolkowiez, M; Finer, N; Kantak, A; Kearns, GL; Poindexter, B; Rasmussen, M; Sanchez, P; Schelonka, RL; Smith, PB; Sullivan, JE; Valencia, G; van den Anker, J; Wade, K; Walsh, M; Ward, RM; Weitkamp, JH, 2011)		0.37
" Consequently, the dosing of antibiotics should be supported by PK concepts, including data derived from studies of the PK of ICU patients and therapeutic drug monitoring."( Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira, J; Póvoa, P, 2011)		0.37
" These results help to define the clinical pharmacokinetics of the two carbapenems in bile while also helping to rationalize and optimize the dosing regimens for biliary tract infections based on site-specific pharmacodynamic target attainment."( Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
Derendorf, H; Ikawa, K; Ikeda, K; Morikawa, N; Murakami, Y; Nakashima, A; Ohge, H; Sueda, T, 2011)		0.37
"This study was designed to simulate standard and optimized dosing regimens for intravenous antibiotics against contemporary populations of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa using MIC distribution data to determine which of the tested carbapenem regimens provided the greatest opportunity for obtaining maximal pharmacodynamic (PD) activity."( Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
Briceno, DF; Furtado, GH; Nicolau, DP; Ruiz, SJ; Villegas, MV, )		0.13
" A 5,000 patient Monte Carlo simulation was performed for each regimen and PD targets were defined as free drug concentrations above the MIC for at least 40% of the dosing interval."( Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
Briceno, DF; Furtado, GH; Nicolau, DP; Ruiz, SJ; Villegas, MV, )		0.13
" High MEM dosage may represent a valuable therapeutic option for infection due to multidrug-resistant (MDR) strains, and drug monitoring would allow rapid regimen adjustment in clinical practice."( Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock.
Cotton, F; Jacobs, F; Roisin, S; Taccone, FS; Vincent, JL, 2012)		0.38
"Based on these data, we concluded that satisfactory pharmacodynamic parameters could be attained in CVVH patients treated with meropenem by a prolonged infusion time of 3 hours with a dosage of 500 mg for every 6 hours."( [Pharmacokinetics of meropenem administered with prolonged infusion time in patients receiving continuous veno-venous hemofiltration].
Bo, SN; He, B; Hu, YF; Li, HL; Lu, W; Wang, SY; Xu, YZ; Yao, GQ; Zhai, SD; Zhu, X, 2012)		0.38
" Early and adequate antibiotic treatment at correct dosage levels is crucial."( [Dosage of antipseudomonal antibiotics in patients with acute kidney injury subjected to continuous renal replacement therapies].
Carcelero San Martín, E; Soy Muner, D, 2013)		0.39
"The study confirmed the significant link between the exposure to AMK and to β-lactams, and presented population models able to guide β-lactam dosage adjustments using renal biomarkers or TDM-related aminoglycoside data."( Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin.
Delattre, IK; Jacobs, F; Jacqmin, P; Laterre, PF; Musuamba, FT; Taccone, FS; Verbeeck, RK; Wallemacq, P, 2012)		0.38
"We obtained data from 40 dosing intervals and observed wide variability in trough concentrations (6."( Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
Bellomo, R; Cole, L; Lipman, J; Liu, X; Nair, P; Roberts, DM; Roberts, JA; Roberts, MS, 2012)		0.38
" Here, empirical dosing of antibiotics failed to achieve the target trough antibiotic concentration during 25% of the dosing intervals."( Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
Bellomo, R; Cole, L; Lipman, J; Liu, X; Nair, P; Roberts, DM; Roberts, JA; Roberts, MS, 2012)		0.38
" We compared the steady-state pharmacokinetics (PK) of meropenem given as a short (30-min) or prolonged (4-h) infusion to very-low-birth-weight (gestational age, <32 weeks; birth weight, <1,200 g) neonates to define the appropriate dosing regimen for a phase 3 efficacy study."( Short versus long infusion of meropenem in very-low-birth-weight neonates.
Germovsek, E; Herodes, K; Ilmoja, ML; Kipper, K; Kõrgvee, LT; Lutsar, I; Metsvaht, T; Oselin, K; Padari, H; Standing, JF, 2012)		0.38
" The goal of this study was to compare clinical and bacteriological efficacy of continuous meropenem infusion versus bolus administration in critically ill patients with severe infection, and to evaluate the safety of both dosing regimens."( Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.
Benes, J; Bergerova, T; Chytra, I; Kasal, E; Pelnar, P; Pradl, R; Stepan, M; Zidkova, A, 2012)		0.38
" Here we describe two cases of sepsis with subtherapeutic exposures with standard meropenem dosing in whom therapy could be optimised by therapeutic drug monitoring (TDM)."( Decreased meropenem levels in Intensive Care Unit patients with augmented renal clearance: benefit of therapeutic drug monitoring.
Bode-Böger, SM; Braun-Dullaeus, RC; Drust, A; Martens-Lobenhoffer, J; Tanev, I; Tröger, U, 2012)		0.38
" The aim of this study was to create dosing nomograms in relation to different creatinine clearance (CL(Cr)) estimates for use in daily clinical practice to target the steady-state concentrations (C(ss)s) of meropenem during continuous infusion at 8 to 16 mg/liter (after the administration of an initial loading dose of 1 to 2 g over 30 min)."( Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach.
Cojutti, P; Furlanut, M; Pea, F; Viale, P, 2012)		0.38
"73 m(2)), noting the effect this had on drug pharmacokinetics and leading to dosing requirements 2-3 times those recommended in standard regimens."( Antibacterial therapeutic drug monitoring in cerebrospinal fluid: difficulty in achieving adequate drug concentrations.
Lipman, J; Lonsdale, DO; Roberts, JA; Udy, AA, 2013)		0.39
"The purpose of this study was to investigate the relationship between efficacy and percentage of time above the MIC (%T>MIC) in the cerebrospinal fluid (CSF) for different dosing regimens of meropenem against an experimental lethal meningitis model in guinea pigs with type b β-lactamase-nonproducing ampicillin-resistant Haemophilus influenzae (Hib BLNAR)."( Therapeutic effect of meropenem on an experimental guinea pig model of meningitis with type b β-lactamase-nonproducing ampicillin-resistant Haemophilus influenzae.
Fujimoto, K; Kanazawa, K; Sunakawa, K; Takemoto, K; Ubukata, K; Ueda, Y; Urasaki, K, 2013)		0.39
" Studies suggest that to be effective, meropenem concentrations must be maintained above the inhibitory concentrations for the majority of a dosing interval."( Pharmacokinetics of meropenem in critically ill patients with severe infections.
Beckmann, A; Binder, L; Hoppe, S; Neumann, S; Oellerich, M; Schwörer, H; Streit, F; Wachter, R; Walson, PD, 2013)		0.39
"This study was designed to investigate meropenem PK in critically ill patients and to see how often standard dosing regimens produced adequate plasma concentrations."( Pharmacokinetics of meropenem in critically ill patients with severe infections.
Beckmann, A; Binder, L; Hoppe, S; Neumann, S; Oellerich, M; Schwörer, H; Streit, F; Wachter, R; Walson, PD, 2013)		0.39
"Meropenem plasma concentrations over time were measured using a high pressure liquid chromatography assay in febrile Hem/Onc and ICU patients who were treated with standard meropenem dosing schedules."( Pharmacokinetics of meropenem in critically ill patients with severe infections.
Beckmann, A; Binder, L; Hoppe, S; Neumann, S; Oellerich, M; Schwörer, H; Streit, F; Wachter, R; Walson, PD, 2013)		0.39
"Standard meropenem dosing regimens were inadequate in many critically ill febrile, neutropenic Hem/Onc, and septic ICU patients."( Pharmacokinetics of meropenem in critically ill patients with severe infections.
Beckmann, A; Binder, L; Hoppe, S; Neumann, S; Oellerich, M; Schwörer, H; Streit, F; Wachter, R; Walson, PD, 2013)		0.39
" Outcomes were compared between patients who received standardized dosing of meropenem, piperacillin-tazobactam, or cefepime as an intermittent infusion over 30 minutes (January 1, 2010, to June 30, 2010) and patients who received prolonged infusion over 3 hours (August 1, 2010, to January 31, 2011)."( Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.
Arnold, HM; Hampton, NB; Hoban, A; Hoffmann, J; Hollands, JM; Juang, PH; Kollef, MH; McCormick, S; Micek, ST; Reichley, RM; Skrupky, LP; Smith, JR, 2013)		0.39
" Based on pharmacokinetic/pharmacodynamic indexes reported for beta-lactams against other bacterial pathogens, a cumulative percentage of a 24-h period that the drug concentration exceeds the MIC under steady-state pharmacokinetic conditions (%TMIC) of 20 to 40% was achieved in mice using a suitable dosing regimen."( In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis.
Ahuja, V; Balasubramanian, V; Balganesh, M; Bhattacharjee, D; Dinesh, N; Ganguly, S; Kumar, N; Panduga, V; Parab, M; Ramachandran, V; Reddy, J; Shandil, R; Sharma, S; Solapure, S; Vishwas, KG, 2013)		0.39
" Serial plasma, urine and surgical drain fluid samples were collected over one dosing interval of antibiotic treatment in ten patients (meropenem, n = 5; piperacillin n = 5)."( Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains.
Adnan, S; Jarrett, P; Li, JX; Lipman, J; Paterson, DL; Roberts, JA; Rudd, M; Udy, AA; Wallis, SC, 2013)		0.39
"Correct antibiotic dosing remains a challenge for the clinician."( Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
Carlier, M; Carrette, S; De Waele, JJ; Decruyenaere, J; Depuydt, P; Hoste, E; Lipman, J; Roberts, JA; Stove, V; Verstraete, A; Wallis, SC, 2013)		0.39
"The goal of this study was to evaluate our current dosing strategy for cefepime and the formulary carbapenem (imipenem) compared with meropenem and doripenem to determine the best dosing strategy for achieving maximal pharmacodynamic activity against an institution-specific population of P aeruginosa isolates."( When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Goff, DA; Nicolau, DP, 2013)		0.39
" Cefepime dosing was increased from 2 g q12h SI to 2 g q8h PI, a 52% increase in drug acquisition cost."( When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Goff, DA; Nicolau, DP, 2013)		0.39
"Antimicrobial stewardship programs should consider pharmacodynamic modeling to select the optimal dosing strategies to guide therapy in an era of escalating antimicrobial resistance."( When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Goff, DA; Nicolau, DP, 2013)		0.39
" However, currently approved dosing regimens provide adequate pharmacodynamic exposures for susceptible bacteria in obese patients."( Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
Cheatham, SC; Chung, EK; Fleming, MR; Juenke, JM; Kays, MB, 2014)		0.4
" The predefined PK/pharmacodynamic (PK/PD) target was 100% fT>4MIC [percentage of time during a dosing interval that the free (f) drug concentration exceeded 4 times the MIC]."( Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial.
Boelens, J; Carlier, M; Carrette, S; Claeys, G; De Waele, JJ; Decruyenaere, J; Depuydt, P; Hoste, E; Leroux-Roels, I; Stove, V; Verstraete, AG, 2014)		0.4
" The developed analytical methods did not show any interference of the excipients when applied to pharmaceutical dosage form."( Ultraviolet spectrophotometry (dual wavelength and chemometric) and high performance liquid chromatography for simultaneous estimation of meropenem and sulbactam sodium in pharmaceutical dosage form.
Borkhatariya, DV; Marwada, KR; Patel, AJ; Patel, BD; Patel, JB; Patel, NS, 2014)		0.4
" This study of the clinical pharmacokinetics and pharmacodynamics of meropenem in human pancreatic juice was performed to establish a basis for the validation of dosing regimens for pancreatic infections."( Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.
Hashimoto, Y; Ikawa, K; Kondo, N; Morikawa, N; Murakami, Y; Ohge, H; Sudo, T; Sueda, T; Uemura, K, )		0.13
" However, a dosing regimen of 500 mg meropenem (0."( Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.
Hashimoto, Y; Ikawa, K; Kondo, N; Morikawa, N; Murakami, Y; Ohge, H; Sudo, T; Sueda, T; Uemura, K, )		0.13
"To describe the effect of different renal replacement therapy modalities and settings on the clearance of meropenem, piperacillin, and vancomycin in critically ill patients and to evaluate the frequency with which current dosing regimens achieve therapeutic concentrations."( The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*.
Jamal, JA; Lipman, J; Roberts, JA; Udy, AA, 2014)		0.4
" Current dosing regimens achieved target concentrations for meropenem (89%), piperacillin (83%), and vancomycin (60%) against susceptible pathogens."( The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*.
Jamal, JA; Lipman, J; Roberts, JA; Udy, AA, 2014)		0.4
" Higher dosing regimens maybe required in critically ill patients receiving renal replacement therapy, in the presence of high effluent flow rates and/or the presence of poorly susceptible pathogens, particularly for vancomycin."( The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*.
Jamal, JA; Lipman, J; Roberts, JA; Udy, AA, 2014)		0.4
" Meropenem has clinically insignificant protein binding and, as a carbapenem antibiotic, shows time-dependent bacterial killing, meaning that the unbound or free antibiotic concentration in blood should be maintained above the minimal inhibitory concentration of the pathogen for at least 40 % of the dosing interval."( Measurement of meropenem concentration in different human biological fluids by ultra-performance liquid chromatography-tandem mass spectrometry.
Alía, P; Cárdenas-Campos, P; Colom, H; Juvany-Roig, R; Leiva-Badosa, E; Pérez-Fernández, XL; Rigo-Bonnin, R; Sabater-Riera, J; Sospedra-Martínez, E, 2014)		0.4
"Meropenem infusers are likely to deliver ∼95% MDD and maintain effective plasma concentrations throughout the dosing period."( Continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability.
Davis, TM; Dyer, J; Heath, CH; Ingram, PR; Manning, L; Manson, I; Page-Sharp, M; Salman, S; Whitmore, TJ; Wright, C, 2014)		0.4
" This article aims to describe the current clinical scenario for beta-lactam dosing in critically ill patients with septic shock and CRRT, to highlight the sources of variability among the different studies that reduce extrapolation to clinical practice, and to identify the opportunities for future research and improvement in this field."( Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.
Calvo, G; Llauradó-Serra, M; Martín-Loeches, I; Pontes, C; Soy, D; Ulldemolins, M; Vaquer, S, 2014)		0.4
" Data including the dosage and duration of the drug use, occurrence of seizures and mortality outcome was collected from the electronic pharmacy records."( A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem.
Chen, K; Shi, Z; Wang, Q; Wu, Y, 2014)		0.4
" There was not further risk for patients with pre-existing seizures or creatinine clearance abnormalities when dosed appropriate."( A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem.
Chen, K; Shi, Z; Wang, Q; Wu, Y, 2014)		0.4
" We examined the compliance of the empirical antimicrobial treatment with the programme recommendations and the treatment optimisation achieved by reducing the antibiotic spectrum and adjusting the dose, dosing interval and duration of treatment."( The impact of an antimicrobial stewardship programme on the use of antimicrobials and the evolution of drug resistance.
de la Torre, J; Del Arco, A; Faus, V; Fernández, F; García-Alegría, J; Montiel, N; Olalla, J; Prada, JL; Rivas, F; Tortajada, B, 2015)		0.42
" Pharmacokinetic data to guide dosing in children, however, are limited to healthy volunteers or patients who are not in the ICU."( Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support.
Carella, D; Chopra, A; Cies, JJ; Dickerman, MJ; Moore, WS; Parker, J; Small, C, 2014)		0.4
" We determined serial plasma concentrations for each dosing episode and performed comparisons of %TMIC at different MICs."( Pharmacokinetics of short versus extended infusion meropenem dosing in critically ill patients: a pilot study.
Bellomo, R; Howden, B; Jacob, J; Johnson, PD; Langan, KM; Li, J; Nation, RL, 2014)		0.4
" Six meropenem dosage regimens (0."( Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.
Gong, WT; Li, X; Liu, W; Wang, L; Xu, B; Yang, Y; Zhang, XJ; Zhu, YQ, 2014)		0.4
"To develop a population model to describe the pharmacokinetics (PK) of intravenous meropenem in adult patients with severe burns and investigate potential relationships between dosage regimens and antimicrobial efficacy."( Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations.
Allen, JM; Davies, JG; Dheansa, BS; Hanlon, GW; James, SE; Ramon-Lopez, A; Stewart, B; Thomson, AH, 2015)		0.42
" Five plasma meropenem concentrations were typically measured over the dosage interval on one to four occasions."( Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations.
Allen, JM; Davies, JG; Dheansa, BS; Hanlon, GW; James, SE; Ramon-Lopez, A; Stewart, B; Thomson, AH, 2015)		0.42
"Data comprised 113 meropenem concentration measurements from 20 dosage intervals in 12 patients."( Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations.
Allen, JM; Davies, JG; Dheansa, BS; Hanlon, GW; James, SE; Ramon-Lopez, A; Stewart, B; Thomson, AH, 2015)		0.42
"The objective of this study was to describe the pharmacokinetics of meropenem, administered by continuous infusion (CI) or intermittent bolus (IB), in critically ill patients receiving continuous venovenous haemofiltration (CVVH) and to evaluate the frequency of pharmacokinetic/pharmacodynamic target attainment with each dosing strategy."( Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
Jamal, JA; Lipman, J; Mat-Nor, MB; Mohamad-Nor, FS; Roberts, JA; Udy, AA; Wallis, SC, 2015)		0.42
" We coded the published population pharmacokinetic models with covariate relationships into dosing software to predict unbound meropenem concentrations measured in a separate cohort of critically ill patients."( Comparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patients.
Daroczi, G; Farkas, A; Hope, WW; Lipman, J; Roberts, JA; Sussman, R; Wong, G, 2015)		0.42
" Drug concentrations were considered adequate if they remained 4-8× the clinical MIC breakpoint for Pseudomonas aeruginosa for 50% (TZP) or 40% (MEM) of the dosing interval."( β-Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: A case-control study.
Antonucci, E; Beumier, M; Cristallini, S; de Backer, D; Donadello, K; Jacobs, F; Roberts, JA; Rondelet, B; Scolletta, S; Taccone, FS; Vincent, JL, 2015)		0.42
"Standard doses of linezolid and meropenem will provide inhibitory concentrations and thus pharmacodynamic antagonism throughout the whole dosing interval for MSSA."( Pharmacodynamic and response surface analysis of linezolid or vancomycin combined with meropenem against Staphylococcus aureus.
Kees, MG; Kloft, C; Kuss, J; Wicha, SG, 2015)		0.42
" Currently, there are no clear guidelines for antibiotic dosing during ECMO."( The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study.
Fraser, JF; Lipman, J; Mullany, DV; Roberts, JA; Shekar, K; Taccone, FS; Wallis, SC; Welch, S, 2014)		0.4
" Routine target concentrations >2 mg/L are maintained with standard dosing (1 g IV 8-hourly)."( The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study.
Fraser, JF; Lipman, J; Mullany, DV; Roberts, JA; Shekar, K; Taccone, FS; Wallis, SC; Welch, S, 2014)		0.4
" However, dosing regimens are often extrapolated from data in adults and older children, increasing the risk for drug toxicity and lack of clinical efficacy because they fail to account for developmental changes in infant physiology."( New antibiotic dosing in infants.
Pineda, LC; Watt, KM, 2015)		0.42
" Therapeutic drug monitoring (TDM) may aid antibiotic prescription and implementation of initial empirical antimicrobial dosage recommendations."( Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
Decosterd, LA; Eggimann, P; Fournier, A; Marchetti, O; Pagani, JL; Pannatier, A; Que, YA; Revelly, JP; Voirol, P, 2015)		0.42
"Imipenem/cilastatin and meropenem use and daily empirical dosage at a five-bed burn ICU were analyzed retrospectively."( Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
Decosterd, LA; Eggimann, P; Fournier, A; Marchetti, O; Pagani, JL; Pannatier, A; Que, YA; Revelly, JP; Voirol, P, 2015)		0.42
"Real-time carbapenem TDM availability significantly altered the empirical daily dosage of imipenem/cilastatin at our burn ICU."( Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
Decosterd, LA; Eggimann, P; Fournier, A; Marchetti, O; Pagani, JL; Pannatier, A; Que, YA; Revelly, JP; Voirol, P, 2015)		0.42
" The user-friendly dosing nomogram based on CLCR estimated using ABW showed that optimal drug exposure [Css ≥ minimum inhibitory concentration (MIC)] may be obtained even against multi-drug resistant (MDR) pathogens when considering dosages up to 1250 mg every 6 h by continuous infusion."( Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infectio
Cojutti, P; Pai, MP; Pea, F, 2015)		0.42
" Application of our dosing nomogram may improve the care of overweight and obese patients with severe MDR Gram-negative infections treated with meropenem by continuous infusion."( Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infectio
Cojutti, P; Pai, MP; Pea, F, 2015)		0.42
" The aim of this clinical investigation was to determine the pharmacokinetic parameters of meropenem in critically ill patients receiving CVVHD in order to estimate dosing regimens for the patient population in Japan."( Pharmacokinetics and dosing estimation of meropenem in Japanese patients receiving continuous venovenous hemodialysis.
Hara, R; Hori, S; Horino, T; Ikawa, K; Kawano, S; Kizu, J; Kuroda, Y; Matsumoto, K; Morikawa, N, 2015)		0.42
" Meropenem was dosed at 40 mg/kg/dose intravenously every 6 hours, infused over 30 minutes, during which, simultaneous serum and CSF meropenem levels were measured."( Pharmacokinetics of continuous-infusion meropenem for the treatment of Serratia marcescens ventriculitis in a pediatric patient.
Brown, M; Calaman, S; Chopra, A; Cies, JJ; Moore, WS; Narayan, P; Parker, J, 2015)		0.42
" The device has the ability to simulate the changing antibiotic concentrations in humans associated with intravenous dosing on bacterial biofilms grown under continuous culture conditions."( New in vitro model to study the effect of human simulated antibiotic concentrations on bacterial biofilms.
Haagensen, JA; Huang, L; Spormann, A; Verotta, D; Yang, K, 2015)		0.42
" Meropenem serum concentrations were obtained and indicated that T>MIC was at least 75% of the dosing interval."( Success With Extended-Infusion Meropenem After Recurrence of Baclofen Pump-Related Achromobacter Xylosoxidans Meningitis in an Adolescent.
Christenson, JC; Jackson, NG; Knoderer, CA; Manaloor, JJ; Nichols, KR, 2015)		0.42
" Hepatic and renal APEH activity was negligible even at 24 h after dosing of MEPM to a dog."( In vivo inhibition of acylpeptide hydrolase by carbapenem antibiotics causes the decrease of plasma concentration of valproic acid in dogs.
Fusegawa, K; Goda, R; Ikenaga, H; Izumi, T; Kobayashi, N; Kuga, H; Nakai, D; Suzuki, E, 2016)		0.43
" A Monte Carlo simulation was performed to investigate the predictive performance of five dosing regimens (15 to 90 mg/kg of body weight/day) for the empirical treatment of severe Gram-negative-related infections in relation to four different categories of renal function."( Pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patients.
Cojutti, P; Maximova, N; Pea, F, 2015)		0.42
" These models can be used to predict dosing requirements or meropenem concentrations during continuous infusion."( Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients.
Beck, S; Kees, F; Kees, MG; Kloft, C; Minichmayr, IK; Moritz, S; Steinke, T; Wicha, SG, 2016)		0.43
" We previously used clinical trial simulations to evaluate dosing regimens of meropenem in this population and reported that a dose of 20 mg/kg every 12 hours optimizes target attainment."( Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation of clinical trial simulations.
Cox, S; Goldstein, SL; Mizuno, T; Nehus, EJ; Vinks, AA, 2016)		0.43
" All concentrations were analyzed simultaneously via population modeling, and target attainment probabilities predicted via Monte Carlo simulations using the target of unbound meropenem concentrations above the MIC for at least 40% of the dosing interval."( Population Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery.
Brockschmidt, C; Bulitta, JB; Hemper, E; Henne-Bruns, D; Kurlbaum, M; Scheele, J; Wittau, M; Wolf, AM, 2015)		0.42
" One of the reasons (carba)penems are seldom used for treatment of TB is the high dosage levels required, often at the therapeutic limits."( Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus.
Kaushik, A; Lamichhane, G; Makkar, N; Pandey, P; Parrish, N; Singh, U, 2015)		0.42
" From the clinical point of view, the prolongation of colistin PAE when combined with other antibiotics could provide a rationale for the modification of the dosing interval and could be important for the optimization of the treatment regimen and the minimization of drug-induced side effects."( Postantibiotic effect of colistin alone and combined with vancomycin or meropenem against Acinetobacter spp. with well defined resistance mechanisms.
Beader, N; Bedenić, B; Ćačić, M; Godič-Torkar, K; Mihaljević, L; Prahin, E; Vraneš, J, 2016)		0.43
" However, these findings are likely to be clinically insignificant and not affect dosing requirements."( Can we use an ex vivo continuous hemofiltration model to describe the adsorption and elimination of meropenem and piperacillin?
Jamal, JA; Lipman, J; McWhinney, BC; Ranganathan, D; Roberts, JA; Udy, AA; Ungerer, JP; Wallis, SC, 2015)		0.42
" The non-optimal drug dosage will provide a positive selection pressure on bacteria to develop resistance."( Interaction of meropenem with 'N' and 'B' isoforms of human serum albumin: a spectroscopic and molecular docking study.
Ahmed, S; Khan, AU; Rehman, MT, 2016)		0.43
"We utilized the database of the Defining Antibiotic Levels in Intensive care unit patients (DALI) study to statistically compare the pharmacokinetic/pharmacodynamic and clinical outcomes between prolonged-infusion and intermittent-bolus dosing of piperacillin/tazobactam and meropenem in critically ill patients using inclusion criteria similar to those used in previous prospective studies."( Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DA
Abdul-Aziz, MH; Akova, M; Bassetti, M; De Waele, JJ; Dimopoulos, G; Dulhunty, J; Kaukonen, KM; Koulenti, D; Lipman, J; Martin, C; Montravers, P; Rello, J; Rhodes, A; Roberts, JA; Starr, T; Wallis, SC, 2016)		0.43
" Additionally, in patients with a SOFA score of ≥9, administration by prolonged infusion compared with intermittent-bolus dosing demonstrated significantly better clinical cure [73."( Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DA
Abdul-Aziz, MH; Akova, M; Bassetti, M; De Waele, JJ; Dimopoulos, G; Dulhunty, J; Kaukonen, KM; Koulenti, D; Lipman, J; Martin, C; Montravers, P; Rello, J; Rhodes, A; Roberts, JA; Starr, T; Wallis, SC, 2016)		0.43
"A conventional nomogram, based on serum creatinine (sCr) and age, was developed in order to determine the correct initial dosage regimen for meropenem (MEPM) infusions in elderly patients with severe community-acquired pneumonia (CAP), using a target minimum inhibitory concentration (MIC) of 2 mg/L."( Development and Assessment of a Nomogram to Propose the Initial Dosage Regimen of a Meropenem Infusion Based on Serum Creatinine and Age Using a Monte Carlo Simulation.
Nomura, Y; Shino, N; Uchida, T; Yoshida, M, 2015)		0.42
" Drug dosing was similar in the two groups."( Serum β-lactam concentrations in critically ill patients with cirrhosis: a matched case-control study.
Cotton, F; Creteur, J; Gustot, T; Hites, M; Jacobs, F; Lheureux, O; Surin, R; Taccone, FS; Trepo, E; Vincent, JL; Wolff, F, 2016)		0.43
" The in vitro PK-PD target associated with bactericidal activity was estimated and the target attainment for different dosing regimens was calculated with Monte Carlo analysis."( Pharmacokinetic-pharmacodynamic modelling of meropenem against VIM-producing Klebsiella pneumoniae isolates: clinical implications.
Daikos, GL; Kotsakis, S; Meletiadis, J; Miriagou, V; Tsala, M; Tzouvelekis, L; Vourli, S; Zerva, L, 2016)		0.43
"The aim of this study was the evaluation of the influence of the susceptibility patterns of Escherichia coli and Klebsiella pneumoniae isolates, specifically the presence of extended-spectrum β-lactamases and the geographical area (Europe and USA), on the meropenem dosing requirements in critically ill patients with different degrees of renal function by estimation of the probability of pharmacokinetic/pharmacodynamic (PK/PD) target attainment."( Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases.
Arribas, J; Asín-Prieto, E; Canut, A; Isla, A; Rodríguez-Gascón, A, 2016)		0.43
"Antibiotic dose predictions based on PK/PD indices rely on that the index type and magnitude is insensitive to the pharmacokinetics (PK), the dosing regimen, and bacterial susceptibility."( Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs.
David-Pierson, P; Friberg, LE; Kristoffersson, AN; Kuhlmann, O; Lave, T; Nielsen, EI; Parrott, NJ, 2016)		0.43
" However, for increased dosing frequencies fAUC/MIC was found to be more predictive and the magnitude of the index was sensitive to drug susceptibility."( Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs.
David-Pierson, P; Friberg, LE; Kristoffersson, AN; Kuhlmann, O; Lave, T; Nielsen, EI; Parrott, NJ, 2016)		0.43
" Using data from dose fractionation studies and a challenge Klebsiella pneumoniae isolate (CB-618-potentiated meropenem MIC = 1 mg/liter), relationships between change from baseline in log10 CFU/ml at 24 h and each of CB-618 area under the concentration-time curve over 24 h (AUC0-24), maximum concentration (Cmax), and percentage of the dosing interval that CB-618 concentrations remained above a given threshold were evaluated in combination with meropenem at 2 g every 8 h (q8h)."( Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an In Vitro Infection Model.
Alexander, DC; Ambrose, PG; Bhavnani, SM; Conde, H; Friedrich, LV; McCauley, J; Trang, M; VanScoy, BD, 2016)		0.43
" Time-kill curves were constructed for each isolate and dosing regimen, and the %T > MIC associated with maximal bactericidal activity was estimated."( Comparison of Short Versus Prolonged Infusion of Standard Dose of Meropenem Against Carbapenemase-Producing Klebsiella pneumoniae Isolates in Different Patient Groups: A Pharmacokinetic-Pharmacodynamic Approach.
Daikos, GL; Kotsakis, S; Meletiadis, J; Miriagou, V; Tsala, M; Tzouvelekis, L; Vourli, S; Zerva, L, 2016)		0.43
" Therapeutic drug monitoring can be used to guide dosing so as to maximise therapeutic effect whilst reducing the likelihood of exposure-related toxicity."( Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?
Cotta, MO; Lipman, J; Little, PJ; McDonald, C; McWhinney, B; Roberts, JA; Ungerer, JP, 2016)		0.43
" Pharmacodynamic analyses of the MEM and FOF dosing schemes were performed by Monte Carlo simulation."( Strategies for the treatment of polymyxin B-resistant Acinetobacter baumannii infections.
Albiero, J; Alves, JL; Cardoso, CL; Carrara-Marroni, FE; Mazucheli, J; Menegucci, TC; Migliorini, LB; Tognim, MC; Viana, GF, 2016)		0.43
"5 g q6h, 2 g q8h) and fosfomycin (4 g q8h, 6 g q6h, 8 g q8h) by Monte Carlo simulation to evaluate the time above the MIC of the free drug concentration as a percentage of the dosing interval (fT>MIC)."( Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae.
Albiero, J; Alves, JL; Caparroz-Assef, SM; Costa, BB; Gales, AC; Mazucheli, J; Sy, SK; Tognim, MC, 2016)		0.43
" Population PK analysis and Monte Carlo dosing simulations were undertaken with Pmetrics."( Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients.
Alobaid, AS; Jarrett, P; Lassig-Smith, M; Lipman, J; Ordóñez Mejia, JL; Roberts, JA; Roberts, MS; Starr, T; Stuart, J; Wallis, SC, 2016)		0.43
"This study aimed to describe the pharmacokinetic (PK) characteristics of meropenem in children with severe infections and to assess the pharmacokinetic/pharmacodynamic (PK/PD) profiles of various meropenem dosage regimens in these patients."( Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.
Eakanunkul, S; Issaranggoon Na Ayuthaya, S; Kongthavonsakul, K; Lucksiri, A; Oberdorfer, P; Roongjang, S, 2016)		0.43
" Our aims were to (i) characterize meropenem PPK in plasma and CSF and (ii) recommend favorable dosing regimens in postneurosurgical meningitis patients."( Population Pharmacokinetics and Dosing Regimen Optimization of Meropenem in Cerebrospinal Fluid and Plasma in Patients with Meningitis after Neurosurgery.
Chen, M; Chen, Y; Lu, C; Wu, J; Wu, X; Yu, J; Zhang, J; Zhang, Y; Zhong, P, 2016)		0.43
"Controversies remain regarding optimal dosing and the need for plasma concentration measurements when treating intensive care patients with beta-lactam antibiotics."( Standard dosing of piperacillin and meropenem fail to achieve adequate plasma concentrations in ICU patients.
Eliasson, E; Giske, CG; Petersson, J, 2016)		0.43
" Antibiotic concentrations were measured at the mid and end of the dosing interval, and repeated after 2-3 days when feasible."( Standard dosing of piperacillin and meropenem fail to achieve adequate plasma concentrations in ICU patients.
Eliasson, E; Giske, CG; Petersson, J, 2016)		0.43
" Antibiotic concentrations at the mid and end of the dosing interval were for piperacillin, 27."( Standard dosing of piperacillin and meropenem fail to achieve adequate plasma concentrations in ICU patients.
Eliasson, E; Giske, CG; Petersson, J, 2016)		0.43
" A dynamic in vitro pharmacokinetic/pharmacodynamic (PK/PD) model that can simulate the pharmacokinetic profiles of antibiotics provides a powerful tool to compare antibacterial responses to different clinical dosage regimens."( Synergistic killing by meropenem and colistin combination of carbapenem-resistant Acinetobacter baumannii isolates from Chinese patients in an in vitro pharmacokinetic/pharmacodynamic model.
Bian, X; Chen, Y; Li, Y; Liu, X; Shi, J; Zhang, J; Zhao, M, 2016)		0.43
"Administration of higher-than-standard doses of meropenem and therapeutic drug monitoring in both serum and CSF should be considered to individualise meropenem dosing in neurocritical care patients with ventriculitis."( Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study.
Blassmann, U; Briegel, J; Frey, OR; Hope, W; Huge, V; Roehr, AC; Thon, N; Vetter-Kerkhoff, C, 2016)		0.43
" A higher dose and shorter dosing interval of meropenem may be more useful for clearance of pathogens."( Evaluation of Meropenem Penetration into Cerebrospinal Fluid in Patients with Meningitis After Neurosurgery.
Cao, G; Chen, M; Chen, Y; Wu, J; Wu, X; Yu, J; Zhang, J; Zhang, Y; Zhao, X, 2017)		0.46
"To compare the clinical and microbiologic efficacy and safety of prolonged infusions versus conventional dosing of meropenem in neonates with Gram-negative late-onset sepsis (GN-LOS)."( Conventional Versus Prolonged Infusion of Meropenem in Neonates With Gram-negative Late-onset Sepsis: A Randomized Controlled Trial.
Abdel-Hady, H; Elsayed Eldegla, H; Nasef, N; Nour, I; Shabaan, AE; Shouman, B, 2017)		0.46
" Patients were randomly assigned to receive either intravenous infusion of meropenem over 4 hours (infusion group) or 30 minutes (conventional group) at a dosing regimen of 20 mg/kg/dose every 8 hours and 40 mg/kg/dose every 8 hours in meningitis and Pseudomonas infection."( Conventional Versus Prolonged Infusion of Meropenem in Neonates With Gram-negative Late-onset Sepsis: A Randomized Controlled Trial.
Abdel-Hady, H; Elsayed Eldegla, H; Nasef, N; Nour, I; Shabaan, AE; Shouman, B, 2017)		0.46
" Designing rational dosage regimens for patients to maximize the antimicrobial activity and minimize the emergence and prevalence of resistance is recommended."( Systematic Review of Antimicrobial Resistance of Clinical Acinetobacter baumannii Isolates in Iran: An Update.
Ardebili, A; Mardaneh, J; Razavi Nikoo, H, 2017)		0.46
"We evaluated the clinical benefits of a strategy of meropenem dosing based on a population pharmacokinetics/pharmacodynamics (PK/PD) model in elderly patients with an LRTI."( Meropenem Dosing Based on a Population Pharmacokinetic-Pharmacodynamic Model in Elderly Patients with Infection of the Lower Respiratory Tract.
He, B; Liang, Y; Shen, N; Sun, LN; Zhou, QT, 2017)		0.46
" The SG received individualized meropenem therapy with a dosing strategy based on software developed from a meropenem population PK/PD model."( Meropenem Dosing Based on a Population Pharmacokinetic-Pharmacodynamic Model in Elderly Patients with Infection of the Lower Respiratory Tract.
He, B; Liang, Y; Shen, N; Sun, LN; Zhou, QT, 2017)		0.46
"A strategy for meropenem dosing based on a population PK/PD model can improve clinical response and avoid overtreatment in elderly patients with an LRTI."( Meropenem Dosing Based on a Population Pharmacokinetic-Pharmacodynamic Model in Elderly Patients with Infection of the Lower Respiratory Tract.
He, B; Liang, Y; Shen, N; Sun, LN; Zhou, QT, 2017)		0.46
"Meropenem is a carbapenem antibiotic that exhibits time-dependent bactericidal activity, traditionally dosed intravenously at 1 g every 8 h."( A Review of Clinical Outcomes Associated with Two Meropenem Dosing Strategies.
Elazzazy, S; Hamad, A; Lau, TT; Nasr, ZG; Wilby, KJ, 2017)		0.46
"The magnitude of persister levels from ACB planktonic and, particularly, biofilm cultures exposed to meropenem was independent of the antibiotic concentration, dosing regimen and biofilm biomass."( Effects of meropenem exposure in persister cells of Acinetobacter calcoaceticus-baumannii.
de Oliveira, SD; Donamore, BK; Ferreira, CA; Gallo, SW; Pagnussatti, VE, 2017)		0.46
" Optimized dosing is expected to reduce the likelihood of resistance development during antimicrobial therapy, but the target for clinical dose adjustment is not well established."( Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.
Cantón, R; Chang, KT; Gao, S; Ledesma, KR; Oliver, A; Phe, K; Sánchez-Díaz, AM; Tam, VH; Van Bambeke, F; Zamorano, L; Zhou, J, 2017)		0.46
" Various dosing exposures of cefepime, ceftazidime and meropenem were simulated in the hollow-fibre infection model."( Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.
Cantón, R; Chang, KT; Gao, S; Ledesma, KR; Oliver, A; Phe, K; Sánchez-Díaz, AM; Tam, VH; Van Bambeke, F; Zamorano, L; Zhou, J, 2017)		0.46
"The development of β-lactam resistance during therapy could be suppressed by an optimized dosing exposure."( Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.
Cantón, R; Chang, KT; Gao, S; Ledesma, KR; Oliver, A; Phe, K; Sánchez-Díaz, AM; Tam, VH; Van Bambeke, F; Zamorano, L; Zhou, J, 2017)		0.46
" The probability of target attainment (PTA) was assessed using Monte Carlo simulations for 30-minute and 5-minute infusions of approved dosing regimens and alternative dosing schemes often used in clinical practice, including 500 mg every 6 hours and 1 g every 8 hours for meropenem, 1 g every 6 hours and 2 g every 8 hours for cefepime, and 2 g every 8 hours for aztreonam."( Effects of i.v. push administration on β-lactam pharmacodynamics.
Burgner, K; Butterfield-Cowper, JM, 2017)		0.46
" Serial plasma meropenem concentrations for the first and third dosing periods (steady state) were also measured."( Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study.
An, YZ; Gu, J; Liu, D; Liu, F; Lyu, J; Wang, YT; Zhao, HY; Zhu, FX, 2017)		0.46
"000) and third dosing periods (Cmax: 12."( Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study.
An, YZ; Gu, J; Liu, D; Liu, F; Lyu, J; Wang, YT; Zhao, HY; Zhu, FX, 2017)		0.46
" However, there are currently no pharmacokinetic (PK) and pharmacodynamic (PD) data to guide meropenem dosing in these patients."( Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation.
Kong, L; Lu, G; Shi, Q; Tang, Y; Wu, X; Yu, M; Zhang, X, 2017)		0.46
"To investigate the PK/PD properties of meropenem in these patients and whether the usual dosing regimens of meropenem (2-hour infusion, 1 g, every 8 hours) was suitable."( Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation.
Kong, L; Lu, G; Shi, Q; Tang, Y; Wu, X; Yu, M; Zhang, X, 2017)		0.46
"The PK/PD profile of dosing regimens tested will assist in selecting the appropriate meropenem regimens for these patients."( Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation.
Kong, L; Lu, G; Shi, Q; Tang, Y; Wu, X; Yu, M; Zhang, X, 2017)		0.46
"Antibiotics are often used in neonates despite the absence of relevant dosing information in drug labels."( Dosing antibiotics in neonates: review of the pharmacokinetic data.
Cohen-Wolkowiez, M; Greenberg, RG; Rivera-Chaparro, ND, 2017)		0.46
"Appropriate antibiotic dosing is critical to improve outcomes in critically ill patients with sepsis."( Antibiotic Dosing in Continuous Renal Replacement Therapy.
Mueller, BA; Shaw, AR, 2017)		0.46
"To use a population pharmacokinetic approach to define maximally effective meropenem dosing recommendations for treatment of Acinetobacter baumannii and Pseudomonas aeruginosa infections in a large cohort of patients with septic shock."( Maximally effective dosing regimens of meropenem in patients with septic shock.
Alobaid, AS; Lipman, J; Perner, A; Roberts, JA; Sjövall, F; Wallis, SC, 2018)		0.48
" Seven blood samples were collected during a single dosing interval and meropenem concentrations were measured by a validated HPLC-MS/MS method."( Maximally effective dosing regimens of meropenem in patients with septic shock.
Alobaid, AS; Lipman, J; Perner, A; Roberts, JA; Sjövall, F; Wallis, SC, 2018)		0.48
" In patients with a CLCR of ≤ 100 mL/min, successful concentration targets could be reached with intermittent dosing of 1000 mg/8 h."( Maximally effective dosing regimens of meropenem in patients with septic shock.
Alobaid, AS; Lipman, J; Perner, A; Roberts, JA; Sjövall, F; Wallis, SC, 2018)		0.48
" In patients with normal renal function, however, standard dosing seems to be sufficient."( Maximally effective dosing regimens of meropenem in patients with septic shock.
Alobaid, AS; Lipman, J; Perner, A; Roberts, JA; Sjövall, F; Wallis, SC, 2018)		0.48
" Specifically, combinatory therapies resulting in synergistic interactions between antibiotics and adjuvant have been the main focus due to their effectiveness, sidelining the effects of additivity, which also lowers the minimal effective dosage of either antimicrobial agent."( Additivity vs Synergism: Investigation of the Additive Interaction of Cinnamon Bark Oil and Meropenem in Combinatory Therapy.
Lai, KS; Lim, SE; Lim, WM; Mai, CW; Yang, SK; Yap, WS; Yusoff, K, 2017)		0.46
"In older adults, few studies confirm that adequate concentrations of antibiotics are achieved using current dosage regimens of intravenous β-lactam antibiotics."( Considerable variation of trough β-lactam concentrations in older adults hospitalized with infection-a prospective observational study.
Hatti, M; Odenholt, I; Resman, F; Solomonidi, N; Tham, J, 2018)		0.48
" Colistin is one of the last available options, and there are increasing concerns about the dosage and resistance to this agent in long-term monotherapies."( Frequency Determination of Carbapenem-Resistant Klebsiella Pneumoniae (CRKP) Isolated from hospitals in Isfahan of Iran and Evaluation of Synergistic Effect of Colistin and Meropenem on them.
Fazeli, H; Gheitani, L; Moghim, S; Nasr Isfahani, B, 2018)		0.48
" After validation of the pharmacokinetic model with independent data, a dosing nomogram was developed, relating renal function to the daily doses required to achieve selected target concentrations (4/8/16 mg/L) in 90% of the patients."( Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model.
Brinkmann, A; Frey, OR; Kloft, C; Minichmayr, IK; Roberts, JA; Roehr, AC, 2018)		0.48
"A dosing nomogram was developed for continuous-infusion meropenem based on renal function in a critically ill population."( Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model.
Brinkmann, A; Frey, OR; Kloft, C; Minichmayr, IK; Roberts, JA; Roehr, AC, 2018)		0.48
" Meropenem, a broad-spectrum antibiotic, is not licensed for use in neonates and infants below 3 months of age and sufficient information on its plasma and CSF disposition and dosing in neonates and infants is lacking."( Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies.
Chazallon, C; Fournier, I; Germovsek, E; Heath, P; Karlsson, MO; Kipper, K; Lutsar, I; Metsvaht, T; Meyer, L; Planche, T; Sharland, M; Standing, JF; Trafojer, UMT, 2018)		0.48
" We observed a 56% decline in half-life with short-term meropenem dosing and an improvement in mental status shortly after administration."( Intentional use of carbapenem antibiotics for valproic acid toxicity: A case report.
Biggs, AD; Dudley, SW; Erstad, BL; French, RNE; Huckleberry, YC; Khobrani, MA; Kopp, BJ; Shirazi, FM, 2018)		0.48
"To use a pre-clinical infection model to assess the antibacterial effect of human simulations of dosing with ceftolozane/tazobactam (with or without amikacin) or meropenem against Enterobacteriaceae and Pseudomonas aeruginosa."( Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR, 2018)		0.48
"Administration of 500 mg meropenem resulted in highly variable concentrations between horses and achieved levels above clinically relevant minimum inhibitory concentration for a minor portion of a once-daily dosing interval."( Meropenem synovial fluid concentrations after intravenous regional limb perfusion in standing horses.
Fontenot, RL; Langston, VC; Mochal-King, CA; Sloan, PB; Wills, RW; Zimmerman, JA, 2018)		0.48
" In this study, we aimed to determine the optimum population pharmacokinetic model of meropenem in patients with sepsis with ARC, and evaluated dosing regimens based on renal function."( The exploration of population pharmacokinetic model for meropenem in augmented renal clearance and investigation of optimum setting of dose.
Dohi, K; Fukuda, K; Kobayashi, Y; Kogo, M; Kohyama, N; Miyake, Y; Nakamura, S; Ohbayashi, M; Tamatsukuri, T; Yamamoto, T, 2018)		0.48
" An understanding of the pharmacokinetics of meropenem when given in combination with vaborbactam is important to understanding the dosing of meropenem-vaborbactam."( Pharmacokinetics of the Meropenem Component of Meropenem-Vaborbactam in the Treatment of KPC-Producing Klebsiella pneumoniae Bloodstream Infection in a Pediatric Patient.
Chopra, A; Cies, JJ; Enache, A; Evangelista, AT; Hanretty, AM; Kaur, I; Moore, WS, 2018)		0.48
"Meropenem plasma concentration above a pathogen's MIC over the whole dosing interval (100% ƒT>MIC) is a determinant of outcome in severe infections."( Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
Buclin, T; Burger, R; Calpini, V; Csajka, C; Decosterd, L; Guidi, M; Lamoth, F; Marchetti, O; Robatel, C, 2018)		0.48
" Simulations evaluated the appropriateness of recommended dosing for achieving 100% fT>MIC in 90% of patients."( Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
Buclin, T; Burger, R; Calpini, V; Csajka, C; Decosterd, L; Guidi, M; Lamoth, F; Marchetti, O; Robatel, C, 2018)		0.48
" Modified dosing or infusion modalities achieve appropriate MIC coverage for optimized antibacterial efficacy in meropenem-susceptible life-threatening infections."( Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
Buclin, T; Burger, R; Calpini, V; Csajka, C; Decosterd, L; Guidi, M; Lamoth, F; Marchetti, O; Robatel, C, 2018)		0.48
" This effect was more pronounced if prolonged infusion of meropenem and high tigecycline dosing were used."( Triple combination of meropenem, colistin and tigecycline was bactericidal in a dynamic model despite mere additive interactions in chequerboard assays against carbapenemase-producing Klebsiella pneumoniae isolates.
Daikos, GRL; Georgiou, PC; Meletiadis, J; Mouton, JW; Pournaras, S; Tsala, M; Vourli, S, 2019)		0.51
"Several population pharmacokinetic (PopPK) models for meropenem dosing in ICU patients are available."( Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models.
Colin, P; De Waele, JJ; Dhaese, SAM; Farkas, A; Lipman, J; Roberts, JA; Stove, V; Verstraete, AG, 2019)		0.51
"Individualizing drug dosing regimens in critically ill patients on renal replacement therapy is a challenge to clinicians as guidelines are often imprecise and specific-validated pharmacokinetic software is unavailable."( Clinical Application of Pharmacokinetics: Basis for Rational Dose Selection in a Critically Ill Patient on Renal Replacement Therapy.
Janković, SM, 2019)		0.51
"High-dose meropenem can achieve CSF levels largely superior to those achieved with commonly recommended dosing regimens."( Cerebrospinal fluid penetration of very high-dose meropenem: a case report.
Kerz, T; Neulen, A; Ringel, F; Roberts, J; von Loewenich, FD, 2018)		0.48
"Antibiotic therapy is a crucial aspect of the management of hospitalized patients, however, current standard dosing protocols have been shown to often attain inadequate plasmatic concentrations which may impair the clinical outcome and promote the selection of multidrug-resistant bacteria."( LC-MS/MS method for simultaneous determination of linezolid, meropenem, piperacillin and teicoplanin in human plasma samples.
Banfi, G; Castagna, A; Ferrari, D; Locatelli, M; Premaschi, S; Ripa, M, 2019)		0.51
" Melioidosis presents with multisystem involvement with disseminated abscess, standard dosing of meropenem may not be sufficient in achieving therapeutic levels and TDM with increased dosing in these critically ill patients will improve outcome."( A case of septicaemic melioidosis: Utility of therapeutic drug monitoring and high-dose meropenem in successful management.
Amladi, A; Gunasekaran, K; Iyyadurai, R; Mathew, SK; Miraclin, TA, )		0.13
"To evaluate target attainment of empirically dosed continuous infusion piperacillin/tazobactam (TZP) and meropenem (MER) in critically ill patients."( Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study.
De Waele, JJ; Dhaese, SAM; Farkas, A; Lipman, J; Roberts, JA; Stove, V; Thooft, ADJ; Verstraete, AG, 2019)		0.51
" We intended this model to be a useful tool to inform (local) pharmacokinetic-based optimal dosing of meropenem in different settings."( Towards a Generic Tool for Prediction of Meropenem Systemic and Infection-Site Exposure: A Physiologically Based Pharmacokinetic Model for Adult Patients with Pneumonia.
Marquet, P; Musuamba, FT; Thémans, P; Winkin, JJ, 2019)		0.51
"Careful consideration of drug-circuit interactions during continuous renal replacement therapy is essential for appropriate drug dosing in critically ill children."( Antimicrobial Disposition During Pediatric Continuous Renal Replacement Therapy Using an Ex Vivo Model.
Drover, DR; Elkomy, MH; Frymoyer, A; Hammer, GB; Purohit, PJ; Su, F; Sutherland, SM, 2019)		0.51
"Therapeutic drug monitoring (TDM) is increasingly used to optimize the dosing of beta-lactam antibiotics in critically ill patients."( Preanalytical Stability of Piperacillin, Tazobactam, Meropenem, and Ceftazidime in Plasma and Whole Blood Using Liquid Chromatography-Tandem Mass Spectrometry.
Doogue, M; Jensen, BP; Mortensen, JS; Zhang, M, 2019)		0.51
"To develop a PK/pharmacodynamic (PD) model for meropenem in critically ill sepsis patients undergoing continuous venovenous haemodiafiltration (CVVHDF) with the oXiris® membrane, and to design an optimal dosing regimen assessed according to the PTA."( Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
Alía Ramos, P; Cárdenas Campos, P; Colom Codina, H; Juvany Roig, R; Leiva Badosa, E; Padullés Zamora, A; Pérez Fernández, XL; Rigo Bonin, R; Sabater Riera, J; Sospedra Martinez, E; Tubau Quintano, F, 2019)		0.51
" We evaluated the suitability of different dosage regimens using Monte Carlo simulations and calculated the PTA as the percentage of subjects achieving a given percentage of time above the MIC (fT>MIC)."( Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
Alía Ramos, P; Cárdenas Campos, P; Colom Codina, H; Juvany Roig, R; Leiva Badosa, E; Padullés Zamora, A; Pérez Fernández, XL; Rigo Bonin, R; Sabater Riera, J; Sospedra Martinez, E; Tubau Quintano, F, 2019)		0.51
" The objectives were to design a population pharmacokinetics model for meropenem in critically ill patients and to evaluate different dosage schemes that achieve the optimal PK/PD objectives."( Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation.
Aldaz Pastor, A; Idoate Grijalba, AI; Marquet, P; Woillard, JB, 2019)		0.51
" Monte Carlo simulations were performed to assess the probability of achieving the PK/PD target for different dosage regimens."( Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation.
Aldaz Pastor, A; Idoate Grijalba, AI; Marquet, P; Woillard, JB, 2019)		0.51
" The highest probability of achieving the pharmacodynamic objective was with 3-h infusion dosage regimens."( Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation.
Aldaz Pastor, A; Idoate Grijalba, AI; Marquet, P; Woillard, JB, 2019)		0.51
"This study proposed different dosing regimens depending on renal clearance strata and the MIC of the germ targeted."( Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation.
Aldaz Pastor, A; Idoate Grijalba, AI; Marquet, P; Woillard, JB, 2019)		0.51
"4% and 0% were susceptible standard dosing regimen (S), 55."( Variable performance of different commercial systems for testing carbapenem susceptibility of KPC carbapenemase-producing Escherichia coli.
Antonelli, A; Camarlinghi, G; Coppi, M; Giani, T; Mattei, R; Nardone, M; Parisio, EM; Riccobono, E; Rossolini, GM, 2019)		0.51
"To determine the percentage of patients given standard doses of piperacillin/tazobactam or meropenem by continuous  infusion who achieved the target pharmacokinetic/pharmacodynamic  (PK/PD) index, which was defined as free concentrations four times  more than the minimum inhibitory concentration (CMI) for 100% of the  dosing interval (100% fT≥ 4 x MIC)."( OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
Cobo-Sacristán, S; Colom-Codina, H; Esteve-Pitarch, E; Maisterra-Santos, K; Padullés-Zamora, A, 2019)		0.51
"Gram-negative infections are a serious concern among hospitalized patients and require innovative pharmacokinetic dosing strategies to achieve clinical success, especially as the emergence of resistant gram-negative pathogens has outpaced the development of new antibiotics."( Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics.
Buurma, V; Chen, M; Fahim, G; Shah, M, 2019)		0.51
"Therapeutic drug monitoring (TDM) of beta-lactam antibiotics has become a valuable tool to guide dosing in critically ill patients."( Comparative LC-MS/MS and HPLC-UV Analyses of Meropenem and Piperacillin in Critically Ill Patients.
Bertsch, T; Heilmann, M; Höhl, R; Kleine, FM; Koch, S; Liebchen, U; Paal, M; Schuster, C; Steinmann, J; Vogeser, M, 2019)		0.51
"A set of 80 sera/plasma samples from ICU patients receiving therapeutic meropenem or piperacillin dosage was investigated."( Comparative LC-MS/MS and HPLC-UV Analyses of Meropenem and Piperacillin in Critically Ill Patients.
Bertsch, T; Heilmann, M; Höhl, R; Kleine, FM; Koch, S; Liebchen, U; Paal, M; Schuster, C; Steinmann, J; Vogeser, M, 2019)		0.51
"There have been literature reports that some recommended meropenem dosage regimens may fail to meet therapeutic targets in some high-risk children and adults."( Dosage Regimens for Meropenem in Children with Pseudomonas Infections Do Not Meet Serum Concentration Targets.
Gobburu, J; Green, TP; Hassan, HE; Ivaturi, V, 2020)		0.56
" The significance of using drug combination is that it can reduce drug dosage requirements, reduce the toxic effects of agents and prevent or delay the emergence of drug resistance."( In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant Acinetobacter baumannii.
Li, X; Lu, C; Sun, S; Wang, D; Wang, Y, 2020)		0.56
"We analysed the pharmacokinetics of meropenem and piperacillin-tazobactam in patients undergoing a standardised session of sustained low efficiency haemodiafiltration (SLED-HDF) to inform the dosing of these drugs in an acute setting."( The pharmacokinetics of meropenem and piperacillin-tazobactam during sustained low efficiency haemodiafiltration (SLED-HDF).
Donnellan, S; Duffull, SB; Putt, TL; Roberts, JA; Schollum, JBW; Walker, RJ; Wallis, SC; Wright, DFB, 2020)		0.56
" Renal disease can contribute to baclofen overdose and encephalopathy, and there are currently no dosing recommendations for patient's on baclofen with renal impairment."( Encephalopathy of Unknown Origin in a Baclofen Patient: Case Report and Review of the Literature.
Abraham, M; Behmer Hansen, R; Gold, J; Lad, M; Mammis, A; Zhao, K, 2020)		0.56
" Immediately after prolonged daily dialysis, a loading dose should be given; with twice daily dosing the maintenance dose needs to be adjusted to kidney function."( [Pharmacokinetics and pharmacodynamics in extracorporeal renal replacement therapy].
Kächele, M; Keller, F, 2021)		0.62
"The aim of this study was to conduct a population pharmacokinetic (PK) analysis of meropenem and to explore the optimal dosing strategy for meropenem in critically ill patients with acute kidney injury receiving treatment with continuous hemodiafiltration (CHDF)."( Population Pharmacokinetic Analysis of Meropenem in Critically Ill Patients With Acute Kidney Injury Treated With Continuous Hemodiafiltration.
Hattori, N; Ishii, I; Nakada, TA; Niibe, Y; Oda, S; Suzuki, T; Takahashi, N; Yamazaki, S, 2020)		0.56
" Hence, there is a strong rationale to individualize anti-infective dosing in these patients by using therapeutic drug monitoring (TDM)."( Determination of Total and Unbound Meropenem, Imipenem/Cilastatin, and Cefoperazone/Sulbactam in Human Plasma: Application for Therapeutic Drug Monitoring in Critically Ill Patients.
Dang, ZL; Li, B; Qin, HY; Rao, Z; Wei, YH; Wu, XA; Zhu, L, 2020)		0.56
" This article aimed to describe the literature regarding spectrum of activity, dosing and administration, including pharmacokinetic and pharmacodynamics properties, safety profile, and efficacy end points."( An Update on Existing and Emerging Data for Meropenem-Vaborbactam.
Casapao, AM; Shoulders, BR; Venugopalan, V, 2020)		0.56
"The optimal dosing of antibiotics in critically ill patients receiving renal replacement therapy (RRT) remains unclear."( The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study.
Agbeve, J; Baptista, JP; Bekos, V; Bellomo, R; Boidin, C; Brinkmann, A; Buizen, L; Castro, P; Choi, G; Cole, CL; Creteur, J; De Waele, JJ; Deans, R; Eastwood, GM; Escobar, L; Gomersall, C; Gresham, R; Jamal, JA; Joynt, GM; Kanji, S; Kluge, S; König, C; Koulouras, VP; Lassig-Smith, M; Laterre, PF; Lee, A; Lefrant, JY; Lei, K; Leung, P; Lipman, J; Llauradó-Serra, M; Martin-Loeches, I; Mat Nor, MB; Mudaliar, MY; Ostermann, M; Parker, SL; Paul, SK; Peake, SL; Rello, J; Richards, B; Roberts, DM; Roberts, JA; Roberts, MS; Rodríguez, A; Roehr, AC; Roger, C; Seoane, L; Sinnollareddy, M; Sousa, E; Soy, D; Spring, A; Starr, T; Stephens, D; Taccone, FS; Thomas, J; Turnidge, J; Ulldemolins, M; Valkonen, MM; Wallis, SC; Williams, T; Wittebole, X; Zikou, XT, 2021)		0.62
" There was wide variability (4-8-fold) in antibiotic dosing regimens, RRT prescription, and estimated endogenous renal function."( The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study.
Agbeve, J; Baptista, JP; Bekos, V; Bellomo, R; Boidin, C; Brinkmann, A; Buizen, L; Castro, P; Choi, G; Cole, CL; Creteur, J; De Waele, JJ; Deans, R; Eastwood, GM; Escobar, L; Gomersall, C; Gresham, R; Jamal, JA; Joynt, GM; Kanji, S; Kluge, S; König, C; Koulouras, VP; Lassig-Smith, M; Laterre, PF; Lee, A; Lefrant, JY; Lei, K; Leung, P; Lipman, J; Llauradó-Serra, M; Martin-Loeches, I; Mat Nor, MB; Mudaliar, MY; Ostermann, M; Parker, SL; Paul, SK; Peake, SL; Rello, J; Richards, B; Roberts, DM; Roberts, JA; Roberts, MS; Rodríguez, A; Roehr, AC; Roger, C; Seoane, L; Sinnollareddy, M; Sousa, E; Soy, D; Spring, A; Starr, T; Stephens, D; Taccone, FS; Thomas, J; Turnidge, J; Ulldemolins, M; Valkonen, MM; Wallis, SC; Williams, T; Wittebole, X; Zikou, XT, 2021)		0.62
"In critically ill patients treated with RRT, antibiotic dosing regimens, RRT prescription, and eTRCL varied markedly and resulted in highly variable antibiotic concentrations that failed to meet therapeutic targets in many patients."( The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study.
Agbeve, J; Baptista, JP; Bekos, V; Bellomo, R; Boidin, C; Brinkmann, A; Buizen, L; Castro, P; Choi, G; Cole, CL; Creteur, J; De Waele, JJ; Deans, R; Eastwood, GM; Escobar, L; Gomersall, C; Gresham, R; Jamal, JA; Joynt, GM; Kanji, S; Kluge, S; König, C; Koulouras, VP; Lassig-Smith, M; Laterre, PF; Lee, A; Lefrant, JY; Lei, K; Leung, P; Lipman, J; Llauradó-Serra, M; Martin-Loeches, I; Mat Nor, MB; Mudaliar, MY; Ostermann, M; Parker, SL; Paul, SK; Peake, SL; Rello, J; Richards, B; Roberts, DM; Roberts, JA; Roberts, MS; Rodríguez, A; Roehr, AC; Roger, C; Seoane, L; Sinnollareddy, M; Sousa, E; Soy, D; Spring, A; Starr, T; Stephens, D; Taccone, FS; Thomas, J; Turnidge, J; Ulldemolins, M; Valkonen, MM; Wallis, SC; Williams, T; Wittebole, X; Zikou, XT, 2021)		0.62
"Antibiotic dosing is challenge in critically ill patients undergoing renal replacement therapy."( Pharmacokinetic and Pharmacodynamic Characteristics of Vancomycin and Meropenem in Critically Ill Patients Receiving Sustained Low-efficiency Dialysis.
Cavani Jorge Santos, SR; Chaves, L; Levin, AS; Macedo, E; Machado, AS; Mendes, ET; Oliveira, MS; Perdigão Neto, LV; Sanches, C; Vieira da Silva, C, 2020)		0.56
"Beta-lactam anti-infective levels after standard dosing have been shown to be subtherapeutic when renal clearance is augmented."( Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients.
Ahmad-Diaz, F; Aragones-Eroles, A; Cano-Marron, M; Miralbes-Torner, M; Palomar-Martinez, M; Schoenenberger-Arnaiz, JA, 2020)		0.56
"A 10-day HFIM was utilized to simulate human pharmacokinetics (PK) of various PMB, MEM and RIF dosing regimens against a clinical KPC-Kp isolate, with total and resistant subpopulations quantified to capture PD response."( In pursuit of the triple crown: mechanism-based pharmacodynamic modelling for the optimization of three-drug combinations against KPC-producing Klebsiella pneumoniae.
Bulitta, JB; Bulman, ZP; Forrest, A; Holden, PN; Li, J; Nation, RL; Onufrak, NJ; Satlin, MJ; Smith, NM; Tan, X; Tsuji, BT, 2020)		0.56
" Blood samples were collected from pediatric intensive care unit patients with severe infection treated with standard dosage regimens for meropenem."( Reappraisal of the Optimal Dose of Meropenem in Critically Ill Infants and Children: a Developmental Pharmacokinetic-Pharmacodynamic Analysis.
Bi, J; Chen, XY; Li, C; Shen, AD; Tang, BH; Wang, MY; Wang, ZM; Xu, BP; Zhao, W, 2020)		0.56
"β-lactams current dosing in critically ill septic children could be suboptimal."( Are β-lactam concentrations adequate in severe sepsis and septic shock in children?
Benaboud, S; Beranger, A; Chosidow, A; Dupic, L; Moulin, F; Oualha, M; Renolleau, S; Treluyer, JM; Zheng, Y, )		0.13
"The objective of the current study was to evaluate paediatric dosing regimens for meropenem plus fosfomycin that generate sufficient coverage against multidrug-resistant bacteria."( Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics.
Heinrichs, MT; Martins, FS; Sy, SKB; Zhu, P, 2021)		0.62
" Pharmacodynamic (PD) analyses were carried out by evaluating dosing regimens that achieved a ≥90% joint probability of target attainment (PTA), which was defined as the minimum of the marginal probabilities to achieve the target PD index of each antibiotic."( Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics.
Heinrichs, MT; Martins, FS; Sy, SKB; Zhu, P, 2021)		0.62
"The current study identified potentially effective paediatric dosing regimens for meropenem plus fosfomycin coadministration against multidrug-resistant bacteria."( Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics.
Heinrichs, MT; Martins, FS; Sy, SKB; Zhu, P, 2021)		0.62
"We sought to compare meropenem and fluconazole dosing in the neonatal intensive care unit with recommendations based on published pharmacokinetic (PK) studies in infants."( Dosing of Antimicrobials in the Neonatal Intensive Care Unit: Does Clinical Practice Reflect Pharmacokinetics-based Recommendations?
Benjamin, DK; Childers, J; Clark, RH; Cohen-Wolkowiez, M; England, M; Greenberg, RG; Laughon, M; Smith, PB; Stark, A; Wade, K, 2020)		0.56
" We calculated the percentage of appropriately dosed courses overall and by discharge year."( Dosing of Antimicrobials in the Neonatal Intensive Care Unit: Does Clinical Practice Reflect Pharmacokinetics-based Recommendations?
Benjamin, DK; Childers, J; Clark, RH; Cohen-Wolkowiez, M; England, M; Greenberg, RG; Laughon, M; Smith, PB; Stark, A; Wade, K, 2020)		0.56
"There was marked discordance between actual fluconazole and meropenem dosing and dosing recommendation in PK publications, yet adherence to PK-based doses showed improvement over time."( Dosing of Antimicrobials in the Neonatal Intensive Care Unit: Does Clinical Practice Reflect Pharmacokinetics-based Recommendations?
Benjamin, DK; Childers, J; Clark, RH; Cohen-Wolkowiez, M; England, M; Greenberg, RG; Laughon, M; Smith, PB; Stark, A; Wade, K, 2020)		0.56
"Optimal dosing of antibiotics is critical in immunocompromised patients suspected to have an infection."( A meropenem pharmacokinetics model in patients with haematological malignancies.
Benaboud, S; Boujaafar, S; Bouscary, D; Contejean, A; Gana, I; Gauzit, R; Grignano, E; Hirt, D; Jaffrelot, L; Kernéis, S; Tréluyer, JM; Willems, L, 2020)		0.56
"To optimize dosing regimens, we aimed to develop a PK population model for meropenem in this population."( A meropenem pharmacokinetics model in patients with haematological malignancies.
Benaboud, S; Boujaafar, S; Bouscary, D; Contejean, A; Gana, I; Gauzit, R; Grignano, E; Hirt, D; Jaffrelot, L; Kernéis, S; Tréluyer, JM; Willems, L, 2020)		0.56
" Initial meropenem dosing regimen ranged from 1 g q8h to 2 g q8h over 30 to 60 min."( A meropenem pharmacokinetics model in patients with haematological malignancies.
Benaboud, S; Boujaafar, S; Bouscary, D; Contejean, A; Gana, I; Gauzit, R; Grignano, E; Hirt, D; Jaffrelot, L; Kernéis, S; Tréluyer, JM; Willems, L, 2020)		0.56
" We aimed to describe meropenem PK in patients with decompensated cirrhosis and severe bacterial infections, identify the sources of PK variability and assess the performance of different dosing regimens to optimize the PK/pharmacodynamic (PD) target."( Meropenem population pharmacokinetics in patients with decompensated cirrhosis and severe infections.
Aziz, F; Bastida, C; Brunet, M; Espinosa, C; Fernández, J; Hernández-Tejero, M; López, E; Sanz, M; Soy, D, 2020)		0.56
" Dosing regimens are recommended to reach several PK/PD targets considering these clinical variables and any MIC within the susceptibility range."( Meropenem population pharmacokinetics in patients with decompensated cirrhosis and severe infections.
Aziz, F; Bastida, C; Brunet, M; Espinosa, C; Fernández, J; Hernández-Tejero, M; López, E; Sanz, M; Soy, D, 2020)		0.56
" Without TDM, prolonged infusion was judged to be the most appropriate dosing regimen for beta lactams."( The ONTAI study - a survey on antimicrobial dosing and the practice of therapeutic drug monitoring in German intensive care units.
Grabein, B; Liebchen, U; Paal, M; Scharf, C; Schroeder, I; Siebers, C; Zander, J; Zoller, M, 2020)		0.56
"To gather available meropenem pharmacokinetics and define drug dosing regimens for Asian critically ill patients receiving CRRT."( Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy.
Chaijamorn, W; Charoensareerat, T; Pattharachayakul, S; Rungkitwattanakul, D; Singhan, W; Srisawat, N, 2020)		0.56
"The recommended meropenem dosing regimen for Asian critically ill patients receiving CRRT with standard (20-25 mL/kg/h) and high (35 mL/kg/h) effluent rates was 750 mg q 8 h to manage Gram negative infections with expected MIC < 2 mg/L in virtual Asian patients."( Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy.
Chaijamorn, W; Charoensareerat, T; Pattharachayakul, S; Rungkitwattanakul, D; Singhan, W; Srisawat, N, 2020)		0.56
" The concentrations of the antibiotics showed a wide range because of the fixed dosing regimen in a mixed population with variable kidney function."( Measurement of Free Plasma Concentrations of Beta-Lactam Antibiotics: An Applicability Study in Intensive Care Unit Patients.
Dorn, C; Hitzenbichler, F; Kees, F; Kees, MG; Kratzer, A; Lubnow, M; Salzberger, B; Schießer, S, 2021)		0.62
" Mice were inoculated with ∼1 × 107 cfu/mL in each thigh 2 h prior to dosing and both thighs were harvested at 24 h."( Efficacy of human-simulated exposures of meropenem/vaborbactam and meropenem against OXA-48 β-lactamase-producing Enterobacterales in the neutropenic murine thigh infection model.
Asempa, TE; Gill, CM; Nicolau, DP, 2021)		0.62
"There has been increasing interest in incorporating β-lactam precision dosing into routine clinical care, but robust population pharmacokinetic models in critically ill children are needed for these purposes."( Demonstrating Feasibility of an Opportunistic Sampling Approach for Pharmacokinetic Studies of β-Lactam Antibiotics in Critically Ill Children.
Benken, LA; Chamberlain, AR; Jones, RL; Kaplan, JM; Murphy, ME; Stoneman, EM; Tang Girdwood, SC; Tang, PH; Vinks, AA, 2021)		0.62
"The proper dosage of antibiotics is a key element in the effective treatment of infection, especially in critically ill patients."( Effectiveness of Pharmacokinetic/Pharmacodynamic-Guided Meropenem Treatment in Critically Ill Patients: A Comparative Cohort Study.
Aldaz, A; Aquerreta, I; Idoate Grijalba, AI; Monedero, P; Ortega, A, 2021)		0.62
" In vivo efficacy was achieved in a mouse thigh infection model with meropenem/272 dosed subcutaneously."( Restoring carbapenem efficacy: a novel carbapenem companion targeting metallo-β-lactamases in carbapenem-resistant Enterobacterales.
Chalam-Judge, N; Cooper, IR; Lee, S; Lee, VE; Newman, R; Ooi, N; Orr, D; Savage, VJ; Wilkinson, AJ, 2021)		0.62
" Further investigations including PK modelling could provide evidence for appropriate meropenem dosing regimens during ECLS administration."( Pharmacokinetics of meropenem in children with sepsis undergoing extracorporeal life support: A prospective observational study.
Chen, C; Chen, W; Li, Z; Lu, G; Wang, G; Wang, Y; Yan, G, 2021)		0.62
" The model can be used for dosing simulations based on the CRCL of the patients in order to tailor the dose of meropenem in Pakistani patients."( Population pharmacokinetics of meropenem among post-operative patients in Pakistan.
Abbas, M; Khan, HM; Khan, RR; Khokhar, MI; Rasheed, H; Saleem, R; Usman, M; Zaman, M, 2021)		0.62
" It does so by indicating the appropriate dosage and preventing failure, toxicity and possible antimicrobial resistance."( Meropenem use and therapeutic drug monitoring in clinical practice: a literature review.
Brucker, N; Nichelle, SM; Steffens, NA; Zimmermann, ES, 2021)		0.62
" This study examined the synergistic killing and resistance suppression for meropenem-ciprofloxacin combination dosage regimens against Pseudomonas aeruginosa isolates within the context of ARC."( Evaluation of Meropenem-Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically Ill Patients With Augmented Renal Clearance.
Agyeman, AA; Bergen, PJ; Bulitta, JB; Kirkpatrick, CM; Landersdorfer, CB; Lipman, J; Nation, RL; Paterson, DL; Roberts, JA; Rogers, KE; Tait, JR; Wallis, SC, 2021)		0.62
" Little is known about the accurate dosage of meropenem needed to avoid central nervous system toxicity."( Meropenem at recommended dose is a potential risk for seizure in hemodialysis patient.
Abdul-Rahman, IS; Abdulkhani, A; Al-Harbi, A; Al-Hwiesh, A; Aldwaihi, A; Alhwiesh, A; AlKhaldi, D; Alqahtani, S; Beheri, H; Mousa, D; Radi, M; Skiker, S, )		0.13
" While all isolates were fully susceptible at standard dosing regimen to amoxicillin-clavulanate, most were only susceptible at increased exposure or resistant to piperacillin-tazobactam."( Antimicrobial susceptibility testing of Eggerthella lenta blood culture isolates at a university hospital in Belgium from 2004 to 2018.
De Geyter, D; Declerck, B; Piérard, D; Van der Beken, Y; Wybo, I, 2021)		0.62
" Our results suggest that in clinical use of the tested antibiotics during CRRT with the ATA hemofilter, the same factors have to be considered for determining the dosing strategy as with filters with other commonly applied membrane materials."( Antibiotics Removal by Continuous Venovenous Hemofiltration with a Novel Asymmetric Triacetate Membrane Hemofilter: An in vitro Study.
Heskamp, B; Körtge, A; Majcher-Peszynska, J; Mitzner, S; Wasserkort, R, 2021)		0.62
" Thus, a personalised dosing regimen is crucial for the achievement of adequate meropenem exposure."( Meropenem serum concentrations in intensive care patients: a retrospective analysis.
Brozmanová, H; Kacířová, I; Uricová, J, 2020)		0.56
" Population PK analysis with Monte Carlo simulations for different dosing regimens was performed."( Population pharmacokinetics and probability of target attainment in patients with sepsis under renal replacement therapy receiving continuous infusion of meropenem: Sustained low-efficiency dialysis and continuous veno-venous haemodialysis.
Bloos, F; Gastine, S; Hagel, S; Müller, C; Peters, F; Pletz, M; Rudolph, W; Westermann, I, 2021)		0.62
" This finding highlights the strong demand for personalized dosing in critically ill patients."( Population pharmacokinetics and probability of target attainment in patients with sepsis under renal replacement therapy receiving continuous infusion of meropenem: Sustained low-efficiency dialysis and continuous veno-venous haemodialysis.
Bloos, F; Gastine, S; Hagel, S; Müller, C; Peters, F; Pletz, M; Rudolph, W; Westermann, I, 2021)		0.62
" aeruginosa, 2 was shown to have dose-dependent efficacy at 50 and 100 mg/kg q6h dosing in a mouse thigh infection model."( A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
Bethel, CR; Bonomo, RA; Goldberg, JA; Hoyer, D; Hujer, AM; Hujer, KM; Jacobs, MR; Kreiswirth, BN; Kumar, V; Marshall, SH; Papp-Wallace, KM; Perez, F; Plummer, MS; Spencer, EJ; van den Akker, F; van Duin, D, 2021)		0.62
" Patients were stratified in groups according to their estimated glomerular filtration rate for drug dosing of vancomycin and meropenem."( Drug dosing using estimated glomerular filtration rate: Misclassification due to metamizole interference in a creatinine assay.
Bojko, L; Borato, DCK; Borges, CL; Dionísio, LM; Moss, MF; Ripka, GP, 2021)		0.62
"During the validity of metamizole treatment, the stratification for drug dosing by the estimated glomerular filtration rate is not reliable if the creatinine measurement is done through dry chemistry."( Drug dosing using estimated glomerular filtration rate: Misclassification due to metamizole interference in a creatinine assay.
Bojko, L; Borato, DCK; Borges, CL; Dionísio, LM; Moss, MF; Ripka, GP, 2021)		0.62
" Further evaluations with multiple dose in-vitro and in-vivo investigations are needed before specific MEM/VBR dosing recommendations can be made for clinical application with ECMO."( Oxygenator impact on meropenem/vaborbactam in extracorporeal membrane oxygenation circuits.
Chopra, A; Cies, JJ; Deacon, J; Enache, A; Giliam, N; Low, T; Marino, D; Moore, WS; Nikolos, P, 2022)		0.72
" With well-characterized stability, this assay can be used with residual specimens for pharmacokinetic modeling, which may lead to individualized dosing and improved patient care."( Stability and Validation of a High-Throughput LC-MS/MS Method for the Quantification of Cefepime, Meropenem, and Piperacillin and Tazobactam in Serum.
Barreto, EF; Bjergum, MW; Jannetto, PJ; Rule, AD; Scheetz, MH, 2021)		0.62
" ADVOS showed more efficient elimination of meropenem compared to CRRT which has to be considered when evaluating dosing regimens."( Pharmacokinetics of meropenem during advanced organ support (ADVOS
Fuhrmann, V; Jarczak, D; Kluge, S; König, C, 2021)		0.62
" For 90% of virtual infants, a 4-mg/L target plasma concentration was achieved for > 50% of the dosing interval following product label-recommended dosing."( Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term Infants.
Cohen-Wolkowiez, M; Edginton, AN; Ganguly, S; Gerhart, JG; Gonzalez, D; Greenberg, RG, 2021)		0.62
"Our PBPK model supports the meropenem dosing regimens recommended in the product label for infants <3 months of age."( Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term Infants.
Cohen-Wolkowiez, M; Edginton, AN; Ganguly, S; Gerhart, JG; Gonzalez, D; Greenberg, RG, 2021)		0.62
" aeruginosa isolates, the combined susceptibility rates (susceptible at standard dosing regimen plus susceptible at increased exposure) were highest to ceftazidime-avibactam, colistin and amikacin (≥82."( In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
Piérard, D; Stone, GG, 2021)		0.62
" The aims of this study were to describe the pharmacokinetics of meropenem in critically ill patients, to identify and quantify the patients' characteristics responsible for the observed pharmacokinetic variability, and to perform different dosing simulations in order to determine optimal individually adapted dosing regimens."( Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
Djebli, N; Khier, S; Larcher, R; Le Souder, C; O'Jeanson, A, 2021)		0.62
" A population pharmacokinetic model was developed (using NONMEM software) and Monte Carlo simulations were performed with different dosing scenarios (bolus-like, extended, and continuous infusion) exploring the impact of clinical categories of residual diuresis (anuria, oliguria, and preserved diuresis) on the probability of target attainment (MIC: 1-45 mg/L)."( Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
Djebli, N; Khier, S; Larcher, R; Le Souder, C; O'Jeanson, A, 2021)		0.62
" Performed dosing regimen simulations suggested that, for equivalent doses, the continuous infusion mode (with loading dose) allowed the obtaining of the pharmacokinetic/pharmacodynamic target for a larger number of patients (100% for MIC ≤ 20 mg/L)."( Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
Djebli, N; Khier, S; Larcher, R; Le Souder, C; O'Jeanson, A, 2021)		0.62
" The model highlighted the importance of considering the patient's overall condition (renal function and dialysis) and the pathogen's characteristics (MIC target) during the establishment of a patient's dosing regimen."( Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
Djebli, N; Khier, S; Larcher, R; Le Souder, C; O'Jeanson, A, 2021)		0.62
" Data on appropriate antimicrobial dosing are limited in this population and therapeutic drug monitoring (TDM) for beta-lactams is impractical at most facilities."( When More Is Still Not Enough: A Case of Ceftazidime-Avibactam Resistance in a Burn Patient.
Barber, KE; Baylor, AE; Dolman, HS; Faris, J; Herbin, SR; Isaacson, AR; McGee, JD; Tyburski, JG; White, MT, 2022)		0.72
" Dosing regimens were considered adequate if the 5th percentile of the concentration-time profile did not drop at any time below four times the S/I breakpoint (= 2 mg/L) of Pseudomonas aeruginosa according to the EUCAST definition."( Optimal loading dose of meropenem before continuous infusion in critically ill patients: a simulation study.
Huebner, L; Kallee, S; Liebchen, U; Salletmeier, H; Scharf, C; Weber, A; Zoller, M, 2021)		0.62
"Therapeutic drug monitoring (TDM) of β-lactam antibiotics may be used to optimize dosing for patients in the intensive care unit (ICU)."( Pilot study of oral fluid and plasma meropenem and piperacillin concentrations in the intensive care unit.
Colman, S; De Waele, JJ; Dhaese, S; Stove, V; Verstraete, AG, 2021)		0.62
"5% of the target site concentrations were below the clinical EUCAST breakpoint, indicating subtherapeutic dosing in high-risk patients receiving perioperative antibiotic prophylaxis in lung transplantation."( Target Site Pharmacokinetics of Meropenem: Measurement in Human Explanted Lung Tissue by Bronchoalveolar Lavage, Microdialysis, and Homogenized Lung Tissue.
Denninger, AK; Ilia, L; Kloft, C; Kneidinger, N; Liebchen, U; Michel, S; Paal, M; Scharf, C; Schneider, C; Schroeder, I; Schröpf, S; Schuster, C; Vogeser, M; Weinelt, F; Zander, J; Zoller, M, 2021)		0.62
" As critically ill patients often experience pharmacokinetic aberrations, and rates of antimicrobial resistance vary between hospital settings, reliance on tertiary sources or package labeling to guide empiric dosing often results in suboptimal β-lactam exposure."( Time Above All Else: Pharmacodynamic Analysis of β-Lactams in Critically Ill Patients.
Burgess, DS; Clark, JA; Landmesser, KB, 2022)		0.72
"Beta-lactam dosing is challenging in critically ill patients with slow extended daily dialysis (SLEDD)."( Trough concentrations of meropenem and piperacillin during slow extended dialysis in critically ill patients with intermittent and continuous infusion: A prospective observational study.
Bucher, V; Irlbeck, M; Liebchen, U; Paal, M; Scharf, C; Schroeder, I; Vogeser, M; Zoller, M, 2022)		0.72
" In septic patients with vasopressors, piperacillin dosing higher than 16 g may be needed to achieve the recommended target concentration."( β-lactam dosing at the early phase of sepsis: Performance of a pragmatic protocol for target concentration achievement in a prospective cohort study.
Besch, G; Capellier, G; Chaignat, C; Clairet, AL; Despres, C; Floury, SP; Labro, G; Lagoutte-Renosi, J; Montange, D; Piton, G; Puyraveau, M; Vettoretti, L; Vivet, B; Winiszewski, H, 2022)		0.72
" The increased use of RDD and the lack of standardization among available protocols in terms of formulation, starting dose, number of steps and dosing frequency make it essential to determine the safety and appropriate management of these protocols, especially regarding reconstitution, diluents, stability and drug administration in order to guarantee reproducibility."( Evaluation of desensitization protocols to betalactam antibiotics.
Albanell-Fernández, M; Aranda, L; Bartra, J; Gelis, S; González-García, R; López-Cabezas, C; Soy Muner, D, 2022)		0.72
" Secondary outcomes were: the use of increased dosage for non-meropenem anti-pseudomonal drugs, and IDs' consultations rates after susceptibility testing was made available."( Impact of 2020 EUCAST criteria on meropenem prescription for the treatment of Pseudomonas aeruginosa infections: an observational study in a university hospital.
Damas, J; Guery, B; Kritikos, A; Lhopitallier, L; Munting, A; Regina, J; Senn, L; Viala, B, 2022)		0.72
"For many antibiotics, the convenient one-fits-all dosing regimen had to be abandoned."( Quantification of Antibiotics in Patient Samples: State of the Art in Standardization and Proficiency Testing.
Hess, C; Kessler, A; Schneider, H; Steimer, W, 2022)		0.72
"The purpose of this study was to explore factors influencing meropenem pharmacokinetics (PKs) in critically ill patients by developing a population PK model and to determine the optimal dosing strategy."( Identification of factors affecting meropenem pharmacokinetics in critically ill patients: Impact of inflammation on clearance.
Hattori, N; Ishii, I; Nakada, TA; Niibe, Y; Suzuki, T; Takahashi, N; Uchida, M; Yamazaki, S, 2022)		0.72
"The findings of this study suggest that CRP might be helpful in managing meropenem dosing in critically ill patients."( Identification of factors affecting meropenem pharmacokinetics in critically ill patients: Impact of inflammation on clearance.
Hattori, N; Ishii, I; Nakada, TA; Niibe, Y; Suzuki, T; Takahashi, N; Uchida, M; Yamazaki, S, 2022)		0.72
" Four blood samples were obtained during a dosing interval to measure and determine attainment of therapeutic targets: unbound beta-lactam concentration above (i) minimum inhibitory concentration (MIC) at 40% (meropenem) or 50% (piperacillin) of dosing interval (40-50%fT > MIC) and (ii) 5 × MIC at 100% of dosing interval (100%fT > 5 × MIC)."( Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population - A prospective, multi-center, observational study (BLAST 1).
Chua, NG; Cove, M; Hee, DKH; Hoo, GSR; Kwa, AL; Lee, LS; Lee, W; Lim, TP; Ling, LM; Loo, L; Ng, TM; Ong, JCL; Soong, JL; Tang, SSL; Zhou, YP, 2022)		0.72
" Among 85 sets of blood samples, current dosing practices were able to achieve 94% success for 40-50%fT > MIC and 44% for 100%fT > 5 × MIC."( Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population - A prospective, multi-center, observational study (BLAST 1).
Chua, NG; Cove, M; Hee, DKH; Hoo, GSR; Kwa, AL; Lee, LS; Lee, W; Lim, TP; Ling, LM; Loo, L; Ng, TM; Ong, JCL; Soong, JL; Tang, SSL; Zhou, YP, 2022)		0.72
"Current dosing practices may be suboptimal for ICU patients."( Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population - A prospective, multi-center, observational study (BLAST 1).
Chua, NG; Cove, M; Hee, DKH; Hoo, GSR; Kwa, AL; Lee, LS; Lee, W; Lim, TP; Ling, LM; Loo, L; Ng, TM; Ong, JCL; Soong, JL; Tang, SSL; Zhou, YP, 2022)		0.72
"High-dose cefepime-tazobactam (WCK 4282) is currently under clinical development at a dosage of 2 grams/2 grams every 8 hours with prolonged infusion (90 minutes)."( Antimicrobial activity of high-dose cefepime-tazobactam (WCK 4282) against a large collection of gram-negative organisms collected worldwide in 2018 and 2019.
Carvalhaes, CG; Castanheira, M; Mendes, RE; Sader, HS, 2022)		0.72
" There are several guidelines recommending different dosing regimens of meropenem in neonates."( Optimal dose of meropenem for the treatment of neonatal sepsis: Dosing guideline variations and clinical practice deviations.
Hao, GX; Raza, MA; Shi, HY; Van Den Anker, J; Xu, HY; Yao, BF; Zhao, W, 2022)		0.72
" After defining the predictive performance of the model, Monte Carlo simulations were used to calculate the probability of target attainment of the currently existing dosing guidelines of meropenem and their use in daily clinical practice."( Optimal dose of meropenem for the treatment of neonatal sepsis: Dosing guideline variations and clinical practice deviations.
Hao, GX; Raza, MA; Shi, HY; Van Den Anker, J; Xu, HY; Yao, BF; Zhao, W, 2022)		0.72
"In critically ill children, severely altered pharmacokinetics may result in subtherapeutic β-lactam antibiotic concentrations when standard pediatric dosing regimens are applied."( Suboptimal Beta-Lactam Therapy in Critically Ill Children: Risk Factors and Outcome.
De Cock, PAJG; De Paepe, P; Delanghe, JR; Dhont, E; Herck, I; Stove, V; Van Der Heggen, T; Vanhaesebrouck, S; Verstraete, AG; Willems, J, 2022)		0.72
"Post hoc analysis of the "Antibiotic Dosing in Pediatric Intensive Care" study (NCT02456974, 2012-2019)."( Suboptimal Beta-Lactam Therapy in Critically Ill Children: Risk Factors and Outcome.
De Cock, PAJG; De Paepe, P; Delanghe, JR; Dhont, E; Herck, I; Stove, V; Van Der Heggen, T; Vanhaesebrouck, S; Verstraete, AG; Willems, J, 2022)		0.72
" For aminoglycosides, we recommend extended interval dosing and initiating Seraph 100 at least 30 min to 1 h after completion of infusion to avoid the possibility of interference with maximum concentrations."( Hemoperfusion with Seraph 100 Microbind Affinity Blood Filter Unlikely to Require Increased Antibiotic Dosing: A Simulations Study Using a Pharmacokinetic/Pharmacodynamic Approach.
Chung, KK; DeLuca, JP; Kress, AT; Reed, T; Selig, DJ; Stewart, IJ, 2023)		0.91
"This article is a narrative review of the articles that evaluated different dosing regimens of antibiotics in patients with ARC."( Are Antibiotics Appropriately Dosed in Critically Ill Patients with Augmented Renal Clearance? A Narrative Review.
Hassanpour, R; Pourheidar, E; Sistanizad, M, 2022)		0.72
"PK properties of antibiotics including lipophilicity or hydrophilicity, protein binding, the volume of distribution, and elimination rate that affect drug concentration should be considered along with PD parameters for drug dosing in critically ill patients with ARC."( Are Antibiotics Appropriately Dosed in Critically Ill Patients with Augmented Renal Clearance? A Narrative Review.
Hassanpour, R; Pourheidar, E; Sistanizad, M, 2022)		0.72
"This review recommends a dosing protocol for some antibiotics to help the appropriate dosing of antibiotics in ARC and decrease the risk of subtherapeutic exposure that may be observed while receiving conventional dosing regimens in critically ill patients with ARC."( Are Antibiotics Appropriately Dosed in Critically Ill Patients with Augmented Renal Clearance? A Narrative Review.
Hassanpour, R; Pourheidar, E; Sistanizad, M, 2022)		0.72
" Four indicators of performance of the TDM-guided real-time ECPA program were identified [total TDM-guided ECPAs July-December 2021/total TDM results July-December 2020; total ECPA dosing adjustments/total delivered ECPAs both at first assessment and overall; and turnaround time (TAT) of ECPAs, defined as optimal (< 12 h), quasi-optimal (12-24 h), acceptable (24-48 h), suboptimal (> 48 h)]."( Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients.
Ambretti, S; Bartoletti, M; Bianchini, A; Cojutti, PG; Gatti, M; Giannella, M; Mancini, R; Pea, F; Pizzilli, G; Ramirez, S; Siniscalchi, A; Tonetti, T; Viale, P, 2022)		0.72
" TDM-guided dosing adjustments were recommended at first assessment in 61."( Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients.
Ambretti, S; Bartoletti, M; Bianchini, A; Cojutti, PG; Gatti, M; Giannella, M; Mancini, R; Pea, F; Pizzilli, G; Ramirez, S; Siniscalchi, A; Tonetti, T; Viale, P, 2022)		0.72
" aeruginosa, quantitative reductions in bacterial density observed with the translational murine model suggest that the phenotypic profile of ceftazidime, ceftazidime/avibactam and meropenem is predictive of clinical efficacy when using the evaluated dosing regimens."( In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against Pseudomonas aeruginosa.
Fraile-Ribot, PA; Gill, CM; Nicolau, DP; Oliver, A, 2022)		0.72
" Here, we present a meropenem PK model in the central nervous system and simulate dosing regimens."( Meropenem Population Pharmacokinetics and Simulations in Plasma, Cerebrospinal Fluid, and Brain Tissue.
Alshaer, MH; Barlow, B; Burgmann, H; Gramss, L; Gruber, A; Hosmann, A; Jäger, W; Jalali, VA; Maranchick, N; Moser, M; Peloquin, CA; Plöchl, W; Poschner, S; Reinprecht, A; Rössler, K; Wölfl-Duchek, M; Zeitlinger, M, 2022)		0.72
" We applied the final model to determine optimal meropenem dosing regimens required to achieve targeted cerebrospinal fluid exposures."( Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: a Prospective Two-Center Study.
Cotta, MO; Heffernan, AJ; Joynt, GM; Kumta, N; Lipman, J; Livermore, A; Roberts, JA; Starr, T; Wallis, SC; Wong, WT, 2022)		0.72
" Target pharmacodynamic indices were used to evaluate whether pediatric and adult dosing regimens provided sufficient coverage."( Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling.
Lv, Z; Oo, C; Sy, SKB; Yu, M; Zhang, J; Zhu, P; Zhu, S, 2022)		0.72
" In a virtual pediatric population aged from 2 to < 18 years, the interpretive breakpoints were achieved in 85-90% of subjects for their targeted pharmacodynamic indices after administration of pediatric dosing regimens consisting of 30 mg/kg of meropenem, and 40 mg/kg of sulbactam three times daily as a 3-h or continuous infusion and 5 mg/kg/day of colistin base activity."( Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling.
Lv, Z; Oo, C; Sy, SKB; Yu, M; Zhang, J; Zhu, P; Zhu, S, 2022)		0.72
" Besides, the combination of bacteriophage and antimicrobials can effectively alleviate the generation of bacterial resistance and reduce the dosage of antimicrobials."( The identification of phage vB_1086 of multidrug-resistant Klebsiella pneumoniae and its synergistic effects with ceftriaxone.
Chen, L; Chen, T; Qian, C; Wang, L; Xu, W; Yao, Z; Ye, J; Zhang, Y; Zhao, Y; Zhou, T, 2022)		0.72
" To some extent, these results provide valuable information that phage vB_1086 can be combined with antibiotics to reduce the dosage of antimicrobials and alleviate the generation of bacterial resistance."( The identification of phage vB_1086 of multidrug-resistant Klebsiella pneumoniae and its synergistic effects with ceftriaxone.
Chen, L; Chen, T; Qian, C; Wang, L; Xu, W; Yao, Z; Ye, J; Zhang, Y; Zhao, Y; Zhou, T, 2022)		0.72
"The optimal dosing regimen for meropenem in critically ill patients undergoing continuous renal replacement therapy (CRRT) remains undefined due to small studied sample sizes and uninformative pharmacokinetic (PK)/pharmacodynamic (PD) analyses in reported studies."( Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
Cheng, Z; Peng, Y; Xie, F, 2022)		0.72
" Therefore, conventional or standard dosing regimens do not achieve satisfactory anti-infective effects."( A UPLC-MS/MS method for simultaneous determination of eight special-grade antimicrobials in human plasma and application in TDM.
Liu, G; Qi, Y, 2022)		0.72
" Ampicillin's inconvenient dosing schedule, drug instability, allergy potential, along with ceftriaxone's high risk for Clostridioides difficile infection and its promotion of vancomycin-resistant enterococci (VRE), led our team to explore alternative options."( Meropenem plus Ceftaroline Is Active against Enterococcus faecalis in an
Cusumano, JA; Daffinee, KE; Desbonnet, C; García-Solache, M; LaPlante, KL; Piehl, EC; Rice, LB, 2022)		0.72
" This study aimed to determine the population PK of meropenem and to propose optimized dosing regimens for the treatment of multidrug-resistant Klebsiella pneumoniae in critically ill patients."( Optimizing Meropenem in Highly Resistant Klebsiella pneumoniae Environments: Population Pharmacokinetics and Dosing Simulations in Critically Ill Patients.
Bui, VC; Cotta, MO; Dang, QT; Dao, XC; Do, THG; Lipman, J; Nguyen, GB; Nguyen, HA; Pham, HN; Roberts, JA; Tran, NM; Tran, NT; Trinh, TA; Truong, AQ; Vu, DH; Vu, NB, 2022)		0.72
" Therefore, this study was performed to construct a meropenem PPK model for patients with sepsis using the measured CCr and evaluate the optimized meropenem dosing regimen based on the CCr."( Population Pharmacokinetic Model and Dosing Simulation of Meropenem Using Measured Creatinine Clearance for Patients with Sepsis.
Dohi, K; Fukumoto, S; Inoue, H; Kato, A; Kogo, M; Kohyama, N; Kotani, T; Ohbayashi, M; Okada, A; Sagara, H; Tamatsukuri, T, 2023)		0.91
" The recommended dosing regimen to achieve a PTA of 50% T > MIC of 4 mcg/mL was 1 g every 8 hours as a 3-hour prolonged infusion for patients with CCr 85-130 mL/min and 1 g every 8 hours as an 8-hour continuous infusion for patients with CCr ≥ 130 mL/min."( Population Pharmacokinetic Model and Dosing Simulation of Meropenem Using Measured Creatinine Clearance for Patients with Sepsis.
Dohi, K; Fukumoto, S; Inoue, H; Kato, A; Kogo, M; Kohyama, N; Kotani, T; Ohbayashi, M; Okada, A; Sagara, H; Tamatsukuri, T, 2023)		0.91
" Extended dosing was demonstrated to be necessary to achieve a PTA of 50% T > MIC for patients with CCr ≥ 85 mL/min."( Population Pharmacokinetic Model and Dosing Simulation of Meropenem Using Measured Creatinine Clearance for Patients with Sepsis.
Dohi, K; Fukumoto, S; Inoue, H; Kato, A; Kogo, M; Kohyama, N; Kotani, T; Ohbayashi, M; Okada, A; Sagara, H; Tamatsukuri, T, 2023)		0.91
"The average body weight is smaller in Asian patients compared with Western patients, but influence of body weight in antibiotic dosing is unknown."( Optimal antipseudomonal ꞵ-lactam drug dosing recommendations in critically-ill Asian patients receiving CRRT.
Jang, SM; Lewis, SJ; Rhie, SJ, 2022)		0.72
" Various dosing regimens were assessed for the probability of target attainments using 60% fT > 1 × MIC or 4xMIC and neurotoxicity risk at 48-h using suggested neurotoxicity thresholds."( Optimal antipseudomonal ꞵ-lactam drug dosing recommendations in critically-ill Asian patients receiving CRRT.
Jang, SM; Lewis, SJ; Rhie, SJ, 2022)		0.72
"MCS enabled the prediction of optimal β-lactam dosing regimens for Asian patients receiving CVVH at varying Qeff."( Optimal antipseudomonal ꞵ-lactam drug dosing recommendations in critically-ill Asian patients receiving CRRT.
Jang, SM; Lewis, SJ; Rhie, SJ, 2022)		0.72
"Meropenem is a wide inter-individual variability in the pharmacokinetic, and standard dosing may not be adequate in critically ill patients."( Development and Validation of a Strong Cation Exchange Chromatographic Column Coupled with High-Performance Liquid Chromatography Method for Meropenem and Evaluation of Its Stability in Human Plasma: Application to the Therapeutic Drug Monitoring.
Chen, L; Li, Q; Liu, T; Lou, J; Yu, P, 2023)		0.91
" Precision dosing software programs may be used to improve probability of obtaining these target exposures."( Accuracy of a precision dosing software program for predicting antibiotic concentrations in critically ill patients.
Chai, MG; Cotta, MO; Farkas, A; Roberts, JA, 2023)		0.91
"To quantify the accuracy of a precision dosing software program for predicting antibiotic concentrations as well as to assess the impact of using software predictions on actual dosing adjustments."( Accuracy of a precision dosing software program for predicting antibiotic concentrations in critically ill patients.
Chai, MG; Cotta, MO; Farkas, A; Roberts, JA, 2023)		0.91
" The impact of these predictions on actual dosage adjustments was determined by using software predicted concentrations versus measured concentrations."( Accuracy of a precision dosing software program for predicting antibiotic concentrations in critically ill patients.
Chai, MG; Cotta, MO; Farkas, A; Roberts, JA, 2023)		0.91
" Dosing changes using predicted concentrations of piperacillin and meropenem with TDM data versus measured concentrations were matched on 89."( Accuracy of a precision dosing software program for predicting antibiotic concentrations in critically ill patients.
Chai, MG; Cotta, MO; Farkas, A; Roberts, JA, 2023)		0.91
"These data demonstrate that precision dosing software programs may have scope to reasonably predict antibiotic concentrations in critically ill patients with sepsis."( Accuracy of a precision dosing software program for predicting antibiotic concentrations in critically ill patients.
Chai, MG; Cotta, MO; Farkas, A; Roberts, JA, 2023)		0.91
" Thus, it is necessary to decide the antibiotic dosage considering the CRRT clearance in addition to residual renal function."( UHPLC-MS/MS method for simultaneous quantification of doripenem, meropenem, ciprofloxacin, levofloxacin, pazufloxacin, linezolid, and tedizolid in filtrate during continuous renal replacement therapy.
Goto, K; Itoh, H; Kai, M; Kitano, T; Ohchi, Y; Suzuki, Y; Tanaka, R; Tatsuta, R; Yasuda, N, 2023)		0.91
"The aim of this study was to compare the achievement of therapeutic pharmacokinetic-pharmacodynamic (PK-PD) exposure targets for beta-lactam antibiotics using product information dosing or guideline-based dosing for the treatment of serious infections."( In silico evaluation of a beta-lactam dosing guideline among adults with serious infections.
Abdul-Aziz, MH; Cotta, MO; Farkas, A; Roberts, JA; Wilks, K; Williams, P, 2023)		0.91
"In silico product information and guideline-based dosing simulations for cefepime, ceftazidime, flucloxacillin, meropenem, and piperacillin/tazobactam were performed using pharmacokinetic models from seriously ill patient populations."( In silico evaluation of a beta-lactam dosing guideline among adults with serious infections.
Abdul-Aziz, MH; Cotta, MO; Farkas, A; Roberts, JA; Wilks, K; Williams, P, 2023)		0.91
" Secondary outcomes were the use of increased dosage of non-meropenem anti-pseudomonal drugs, and IDs' consultations rates after the release of susceptibility testing results."( Impact of selective reporting of antibiotic susceptibility testing results on meropenem prescriptions for the treatment of Pseudomonas aeruginosa infections after 2020 EUCAST criteria update: an observational study in a university hospital.
Damas, J; Guery, B; Munting, A; Prod'hom, G; Senn, L; Viala, B, 2022)		0.72
" Based on the final model developed, comprehensive Monte Carlo simulations were performed to evaluate the probability of target attainment (PTA) of 16 different dosing regimens."( Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis.
An, G; Creech, CB; Fishbane, N; Fissell, W; Gu, K; Jimenez-Truque, N; Kirkpatrick, CMJ; Landersdorfer, CB; Nalbant, D; Nation, RL; Patel, PC; Rolsma, S; Watanabe, A; Winokur, P; Wu, N, 2023)		0.91
" We dosed IV MEM at 25 mg/kg every 8 h and inhaled AMK at 400 mg every 12 h."( Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia.
Artigas, A; Battaglini, D; Bobi, J; Cabrera, R; Camprubí-Rimblas, M; Fernández-Barat, L; Ferrer-Segarra, A; Frigola, G; Kiarostami, K; Li Bassi, G; Martinez, D; Meli, A; Motos, A; Nicolau, DP; Pagliara, F; Pelosi, P; Rigol, M; Torres, A; Vila, J; Yang, H; Yang, M, 2023)		0.91
" Four different dosing regimens were simulated: intermittent infusion in 30 min, prolonged infusion in 4 h, continuous infusion, and continuous infusion with a loading dose."( Optimization of β-Lactam Dosing Regimens in Neonatal Infections: Continuous and Extended Administration versus Intermittent Administration.
de Grauw, AM; Kruizinga, MD; Leegwater, E; Storm, BN; van Veen, M; Wewerinke, L, 2023)		0.91
"For all antibiotics except cefotaxime, continuous infusion with a loading dose resulted in a higher PTA compared with other dosing regimens."( Optimization of β-Lactam Dosing Regimens in Neonatal Infections: Continuous and Extended Administration versus Intermittent Administration.
de Grauw, AM; Kruizinga, MD; Leegwater, E; Storm, BN; van Veen, M; Wewerinke, L, 2023)		0.91
" Due to pathophysiological changes in critically ill children, the available evidence has demonstrated that the standard dosage regimens of meropenem could not meet an appropriate pharmacodynamic (PD) target attainment in severely infected children."( Meropenem for the Pharmacological Treatment of Severe Infections in Critically Ill Pediatric Patients: Breakthrough Standard Treatment Strategies Based on PK/PD.
Chen, F; Gong, X; He, X; Liu, X; Wang, L, 2023)		0.91
"To improve outcomes in patients with bacteremia treated with MEPM, support for appropriate antimicrobial use is necessary for compliance with the dosage and administration schedule according to severe infections in initial treatment."( Evaluation of the meropenem dosage and administration schedule in patients with bacteremia initial therapy.
Kosaka, S; Muraki, Y; Tai, T; Tanaka, H; Watanabe, M; Yamaguchi, K; Yamamoto, T, 2023)		0.91
" Few data exist regarding drug dosing requirements with contemporary CRRT modalities and effluent rates."( Transdermal Detection of MB-102 and Correlation to Meropenem Pharmacokinetics During Continuous Renal Replacement Therapy: In Vivo Results.
Dorshow, RB; Goldstein, SL; Humes, HD; Johnson, JR; Johnston, KA; Nolin, TD; Pino, CJ; Riley, IR; Rogers, TE; Shieh, JJ; Tang, P, 2023)		0.91
" Model-informed precision dosing (MIPD) is applied to individualize meropenem dosing."( Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.
Brinkmann, A; Frey, O; Greppmair, S; Hempel, G; Liebchen, U; Röhr, A; Scharf, C; Schatz, LM; Weinelt, F; Zoller, M, 2023)		0.91
"The optimal meropenem dosing regimens in critically ill patients receiving continuous renal replacement therapy (CRRT) based on pharmacokinetic and pharmacodynamic (PD) concepts are not well established."( Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations.
Boonpeng, A; Chaijamorn, W; Charoensareerat, T; Kerdnimith, P; Kosumwisaisakul, N; Pattharachayakul, S; Rungkitwattanakul, D; Srisawat, N; Teeranaew, P, 2023)		0.91
" PD target significantly contributed to meropenem dosage regimens in these patients."( Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations.
Boonpeng, A; Chaijamorn, W; Charoensareerat, T; Kerdnimith, P; Kosumwisaisakul, N; Pattharachayakul, S; Rungkitwattanakul, D; Srisawat, N; Teeranaew, P, 2023)		0.91
" pneumoniae bloodstream infection that was successfully treated with a continuous infusion of meropenem-vaborbactam at a dosage of 1 g/1 g q4h as a 4-h infusion."( Continuous infusion of meropenem-vaborbactam for a KPC-3-producing Klebsiella pneumoniae bloodstream infection in a critically ill patient with augmented renal clearance.
Bourgeois, PM; Gandon, C; Laffont-Lozes, P; Larcher, R; Magnan, C; Naciri, T; Pantel, A; Sotto, A, 2023)		0.91
" It could be appropriate for optimizing the management of critically ill patients with ARC, as it resulted in antibiotic concentrations above the minimum inhibitory concentration for susceptible carbapenem-resistant Enterobacterales (up to 8 mg/L) throughout the dosing interval."( Continuous infusion of meropenem-vaborbactam for a KPC-3-producing Klebsiella pneumoniae bloodstream infection in a critically ill patient with augmented renal clearance.
Bourgeois, PM; Gandon, C; Laffont-Lozes, P; Larcher, R; Magnan, C; Naciri, T; Pantel, A; Sotto, A, 2023)		0.91
"In recent years, numerous dosing studies have been conducted to optimize therapeutic antibiotic exposures in patients with serious infections."( International survey of antibiotic dosing and monitoring in adult intensive care units.
Cotta, MO; Elhadi, M; Farkas, A; Imani, S; Kanji, S; Luque-Pardos, S; Roberts, JA; Sanches, C; Sandaradura, I; Scheetz, MH; Schellack, N; Tabah, A; Timsit, JF; Wilks, K; Williams, PG; Xie, J, 2023)		0.91
" Respondents rarely used dosing software to guide therapy in clinical practice and was most frequently used with vancomycin (11%)."( International survey of antibiotic dosing and monitoring in adult intensive care units.
Cotta, MO; Elhadi, M; Farkas, A; Imani, S; Kanji, S; Luque-Pardos, S; Roberts, JA; Sanches, C; Sandaradura, I; Scheetz, MH; Schellack, N; Tabah, A; Timsit, JF; Wilks, K; Williams, PG; Xie, J, 2023)		0.91
" Nonetheless, there is a lack in pharmacokinetics information for this population, and dosing criteria may vary between healthcare centers."( Model-informed precision dosing of antimicrobial drugs in pediatrics: experiences from a pilot scale program.
Arriaga-García, FJ; Medellín-Garibay, SE; Milán-Segovia, RDC; Pérez-González, LF; Rodríguez-Báez, AS; Romano-Moreno, S; Velarde-Salcedo, R, 2023)		0.91
" Further studies are needed to explore the individual variability of meropenem clearance and optimize the dosing regimen."( Meropenem Clearance in a Child With End-stage Renal Disease Undergoing Prolonged Intermittent Renal Replacement Therapy: A Case Report and Literature Review.
Anker, JVD; Cao, W; Chen, XY; Shi, HY; Zhang, W; Zhao, W, 2023)		0.91
"Antibiotic therapy requires appropriate dosage of drugs for effective treatment."( A Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneously Determining Meropenem and Linezolid in Blood and Cerebrospinal Fluid.
Berska, J; Bugajska, J; Sztefko, K, 2024)		1.44
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
carbapenemcarboxylic acid
pyrrolidinecarboxamide
alpha,beta-unsaturated monocarboxylic acidA monocarboxylic acid in which the carbon of the carboxy group is directly attached to a C=C or C#C bond.
organic sulfideCompounds having the structure RSR (R =/= H). Such compounds were once called thioethers.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (46)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency3.34910.001022.650876.6163AID1224838
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency13.33320.001530.607315,848.9004AID1224841; AID1224842
GVesicular stomatitis virusPotency0.08710.01238.964839.8107AID1645842
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency0.01330.001024.504861.6448AID743215
aryl hydrocarbon receptorHomo sapiens (human)Potency33.49150.000723.06741,258.9301AID743085
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency13.33220.000627.21521,122.0200AID743202
lethal factor (plasmid)Bacillus anthracis str. A2012Potency0.50120.020010.786931.6228AID912
Interferon betaHomo sapiens (human)Potency0.08710.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency0.08710.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency0.08710.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency0.08710.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
streptokinase A precursorStreptococcus pyogenes M1 GASEC50 (µMol)0.12700.06008.9128130.5170AID1902
Beta-lactamase Klebsiella pneumoniaeKd0.85000.85000.85000.8500AID1320842
Beta-lactamase class B VIM-2 Pseudomonas aeruginosaKd12.00000.60000.60000.6000AID1254036
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-lactamase Aeromonas caviaeKm7.00007.00007.00007.0000AID374363
Beta-lactamase Burkholderia cenocepaciaKm2,500.000010.000010.000010.0000AID541022
Metallo-beta-lactamase type 2Klebsiella pneumoniaeKm49.00008.00009.333310.0000AID563972
Metallo-beta-lactamase VIM-11 Pseudomonas aeruginosaKm22.70004.50007.00009.4000AID520385
Metallo-beta-lactamase VIM-2Pseudomonas aeruginosaKm24.50005.50007.87509.9000AID520386
Beta-lactamase Aeromonas allosaccharophilaKm10.00001.50006.300010.0000AID584846
Metallo-beta-lactamaseStutzerimonas stutzeriKm20.00003.50004.75006.0000AID518728
Beta-lactamaseEnterobacter cloacaeKm9.80002.90006.43649.8000AID495693
Beta-lactamase SHV-1Klebsiella pneumoniaeKm4.20004.20004.25004.3000AID495687
Beta-lactamasePseudomonas aeruginosa PAO1Km1.40000.50004.24448.0000AID495747
Beta-lactamase TEMEscherichia coliKm15.00005.40006.30007.2000AID495686
B2 metallo-beta-lactamase Chryseobacterium indologenesKm145.00003.00003.00003.0000AID562337
Metallo-beta-lactamase VIM-2Klebsiella pneumoniaeKm5.00005.00007.500010.0000AID563976
Beta-lactamase Escherichia coliKm0.06000.00461.41494.5000AID495746
Metallo-beta-lactamaseEscherichia coliKm8.00002.00006.857110.0000AID583083; AID583084; AID583085; AID583094
Beta-lactamase Serratia marcescensKm5.80002.20004.60008.2000AID495696
Beta-lactamase Klebsiella pneumoniaeKm1.00001.00004.45007.9000AID1320835
Beta-lactamase IMP-1 Pseudomonas aeruginosaKm6.50006.50006.50006.5000AID495698
BlaVIM-1 Escherichia coliKm50.00001.50001.50001.5000AID495914
Beta-lactamase Escherichia coliKm11.00007.10008.16678.7000AID495688
Carbapenem-hydrolyzing beta-lactamase KPCKlebsiella pneumoniaeKm12.50001.60003.80006.0000AID374025; AID495695
Beta-lactamase class B VIM-2 Pseudomonas aeruginosaKm18.68002.00006.65009.4000AID1254040; AID495697; AID529659; AID531315; AID575015
Beta-lactamase Acinetobacter baumanniiKm66.25001.30003.80009.6000AID495699; AID495700
Beta-lactamase VIM-1 Pseudomonas aeruginosaKm72.00004.00004.00004.0000AID530340
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (86)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (40)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (32)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5006)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1763151Antibacterial activity against Acinetobacter sp. 121 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI based serial dilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Antibacterial and synergistic activity of 6β-hydroxy-3-oxolup-20(29)-en-28-oic acid (6β-hydroxy betunolic acid) isolated from Schumacheria castaneifolia vahl.
AID519820Induction of morphological changes in Pseudomonas aeruginosa 27853 assessed as increase in cell length at antimicrobial MIC after 240 mins by microscopy2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID524298Antibacterial activity against Pseudomonas aeruginosa P338 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID495838Hydrolytic activity of Escherichia coli BL21 DE3 beta-lactamase VIM-19 by microacidimetric method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID576529Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008136 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID1691833Antibacterial activity against Pseudomonas aeruginosa PAO1 infected in Caenorhabditis elegans N2 strain assessed as increase in Caenorhabditis elegans survival rate at 0.25 ug/ml after 120 hrs relative to control2020European journal of medicinal chemistry, May-15, Volume: 194Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1.
AID516142Antibacterial activity against Pulsotype L Acinetobacter genomosp. 3 isolate 7 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID517984Antimicrobial activity against Escherichia coli Libyien harboring beta-lactamase CMY-2 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID1318924Antibacterial activity against pandrug-resistant Pseudomonas aeruginosa isolate 914332016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID764540Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis in presence of clavulanate2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Synthesis, pH-dependent, and plasma stability of meropenem prodrugs for potential use against drug-resistant tuberculosis.
AID1407940Antibacterial activity against Pseudomonas aeruginosa ARC3504 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID562223Antimicrobial activity against Desulfovibrio desulfuricans MB by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Susceptibilities of 23 Desulfovibrio isolates from humans.
AID433370Antibacterial activity against Peptostreptococcus anaerobius isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID533125Antimicrobial activity against Bacteroides distasonis by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID508726Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1B2 RCA2 harboring acquired beta-lactamase PER-1 by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID584717Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2128 harboring cupA1 mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID425090Antimicrobial activity against Porphyromonas levii isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID295833Antibacterial activity against Pasteurella multocida after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID495719Activity of Klebsiella oxytoca Beta-lactamase K1 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID498835Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU4 deficient in SHV-1, DHA-1, ompK35/36 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID561385Antibacterial activity against Escherichia coli isolate ARL06-39 harboring beta-lactamase CMY 30 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
CMY-29 and CMY-30, two novel plasmid-mediated AmpC beta-lactamases.
AID1325282Induction of defects in chromosomal segregation in Escherichia coli SH3210 assessed as generation of anucleate cells at MIC after 2.5 hrs using beta-galactosidase substrate DDAOG by fluorescence assay2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
5-Alkyloxytryptamines are membrane-targeting, broad-spectrum antibiotics.
AID496009Antimicrobial activity against tobramycin resistant Pseudomonas aeruginosa isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID555235Antibacterial activity against Acinetobacter genomosp. 3 isolate 20 by Etest method in presence of efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID70111Compound was evaluated for its antibacterial activity against Escherichia coli CCARM 1111 MDR2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID323039Antimicrobial activity against extended-spectrum-beta-lactamase producing Klebsiella pneumoniae isolates2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
AID524100Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A8512010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1233138Antibacterial activity against patient-derived methicillin-resistant Staphylococcus aureus 7386 after 18 to 20 hrs by microbroth dilution method2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors.
AID425078Antimicrobial activity against beta lactamase-positive Bacteroides vulgatus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID433012Antibacterial activity against Staphylococcus haemolyticus isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID656445Antimicrobial activity against extended spectrum beta-lactamase-producing Klebsiella pneumoniae2011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID764529Chemical stability of the compound in simulated gastric fluid assessed as compound remaining at 10 uM after 60 mins at pH 1.22013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Synthesis, pH-dependent, and plasma stability of meropenem prodrugs for potential use against drug-resistant tuberculosis.
AID496007Antimicrobial activity against Ceftazidime resistant Pseudomonas aeruginosa isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID524311Antibacterial activity against Acinetobacter baumannii A848 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433156Antibacterial activity against Prevotella bivia isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID1757611Antibacterial activity against Enterobacter aerogenes 15-4 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID558324Antibacterial activity against bla gene-negative and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P835 by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID495912Hydrolytic activity of beta-lactamase VIM-19 expressed in Escherichia coli TOP10 by spectrophotometry2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID534701Antimicrobial activity against Fusobacterium sp. by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID164408Antibacterial activity against Pseudomonas aeruginosa 1771M1998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID523506Antimicrobial activity against Pseudomonas aeruginosa isolate 1712c from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID565515Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-20 harboring A residue at 105 position in PDC- 4 by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1905567Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 assessed as reduction of bacterial growth incubated for 18 hrs by CLSI protocol based broth microdilution method2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Novel β-Hairpin Antimicrobial Peptides Containing the β-Turn Sequence of -RRRF- Having High Cell Selectivity and Low Incidence of Drug Resistance.
AID423301Antibacterial activity against Pseudomonas aeruginosa isolate 340 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID584509Antimicrobial activity against Pseudomonas aeruginosa PA14 PA1348 harboring mutation in conserved hypothetical protein by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID564531Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid with entire blaAmpC gene by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID573600Antibacterial activity against Fusobacterium mortiferum assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID423104Antibacterial activity against penicillin-resistant Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID528817Antimicrobial activity against carbapenem-resistant Enterobacter cloacae isolated from ICU patient urine assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID322779Antimicrobial activity against Bacteroides caccae isolates by agar dilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID401690Antibacterial activity against Klebsiella oxytoca 10822005Journal of natural products, May, Volume: 68, Issue:5
Cytotoxic bisindole alkaloids from a marine sponge Spongosorites sp.
AID522660Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis BA1086 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID567472Antimicrobial activity against gBLNAR Haemophilus influenzae by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID656352Antibacterial activity against imipenem-sensitive Pseudomonas aeruginosa isolate 1091-05 infected in ip dosed SF-1 mouse assessed as survival of animal administered 0.5 and 4 hrs post infected measured on day 42011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID545413Antimicrobial activity against Pseudomonas aeruginosa PS21 with PFGE phenotype 11F obtained from skin of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID518816Antibacterial activity against Acinetobacter genomosp. 3 isolates by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID567475Antimicrobial activity against gBLPACR-2 Haemophilus influenzae by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID1539484Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa ATCC 1744 clinical isolates after 18 to 20 hrs in aerobic condition by CLSI-based broth microdilution assay
AID322777Antimicrobial activity against Bacteroides uniformis isolates by agar dilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID576262Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17829 harboring pSHA2-encoded porin OmpK36 gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID529484Antimicrobial activity against Enterobacter cloacae isolate 185 containing PFGE genetic clone A expressing qnrB2 aac(6')-Ib-cr and beta-lactamase KPC-2 and SHV-12 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID534416Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID534388Antibacterial activity against Escherichia coli JM109 harboring recombinant pKHM-1 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID564468Antimicrobial activity against Pseudomonas aeruginosa isolate 1093 by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID1757604Antibacterial activity against Enterobacter cloacae 17-10 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID532193Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii TJ15T harboring wild-type GyrA, ParC, GyrB genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID561478Antibacterial activity against Pseudomonas aeruginosa by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID369631Antimicrobial activity against beta-lactamase positive ampicillin-resistant Haemophilus influenzae by E-test2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
AID561492Antibacterial activity against Acinetobacter baumannii assessed as intermediate isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID1763160Antibacterial activity against Escherichia coli ATCC 35218 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI based serial dilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Antibacterial and synergistic activity of 6β-hydroxy-3-oxolup-20(29)-en-28-oic acid (6β-hydroxy betunolic acid) isolated from Schumacheria castaneifolia vahl.
AID545613Antimicrobial activity against Pseudomonas aeruginosa PS34 with PFGE phenotype 4A obtained from blood of ICU patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID524105Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A8492010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID532181Antimicrobial activity against aac(6')-Ib-cr-negative Klebsiella pneumoniae SY22T harboring qnrS gene by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID533417Antimicrobial activity against Micromonas micros by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID535368Antimicrobial activity against Pseudomonas aeruginosa isolated from ICU patient by broth microdilution method in presence of Tazobactam2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID95701Antibacterial activity against Klebsiella aerogenes 1522E2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID428273Antimicrobial activity against carbapenemase producing Enterobacter sp. assessed as susceptible isolates by CLSI breakpoint assay2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID534688Antimicrobial activity against Bacteroides caccae by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID289904Antibacterial activity against Salmonella give2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID533405Antimicrobial activity against Clostridium tertium by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID534476Antimicrobial activity against Sutterella wadsworthensis ATCC 51579 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534644Antimicrobial activity against Klebsiella pneumoniae assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1533855Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 3589 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID519471Antimicrobial activity against Stenotrophomonas maltophilia K279a expressing beta-lactamase L1 and L2 by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator.
AID520973Antibacterial activity against Klebsiella pneumoniae KN2303 by Etest method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID549041Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate KpSCMC1 harboring int1, bla IMP-4, bla SHV-12, armA and sul1 gene isolated from patient with pulmonary infection by Etest method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Two clinical strains of Klebsiella pneumoniae carrying plasmid-borne blaIMP-4, blaSHV-12, and armA isolated at a Pediatric Center in Shanghai, China.
AID518512Antimicrobial activity against Acinetobacter baumannii HPA74510 selected after 4 times MIC compound exposure2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID285690Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4036 isolate expressing carbapenemase KPC22007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID572146Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii unique clonal group isolate 40 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID324312Antimicrobial activity against Serratia marcescens AW isolated from parotidectomy patient2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
SME-2-producing Serratia marcescens isolate from Switzerland.
AID499118Antimicrobial activity against Pseudomonas aeruginosa OC 4351 infected in immunocompromized SKH1 mouse assessed as lesion volume at 1.6 mg/kg/day, sc measured after 48 hrs postinfection (Rvb = 2234 mm3)2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID545358Antibacterial activity against Staphylococcus aureus SIR2a selected at 2 times MIC of imipenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID523945Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E451 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID560078Antimicrobial activity against Pseudomonas aeruginosa isolate 956 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID534918Antimicrobial activity against Serratia marcescens by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID96094Compound was evaluated for its antibacterial activity against Klebsiella pneumoniae 9 ESBL2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID534601Antimicrobial activity against Enterobacteriaceae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1680062Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 4 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID289884Antibacterial activity against Staphylococcus aureus 5032007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID532098Antimicrobial against Pseudomonas aeruginosa 1494 harboring phnA allele by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID285995Antimicrobial activity against ESBL producing Klebsiella pneumoniae 264 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID528818Antimicrobial activity against carbapenem-resistant Enterobacter cloacae isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID524429Antibacterial activity against ciprofloxacin-resistant Enterobacteriaceae clinical isolates isolated from patient with complicated intra-abdominal infection assessed as cure rate at test-of-cure visit by mMITT analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID283390Antimicrobial activity against Nocardia cyriacigeorgica after 72 hrs by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID498822Antimicrobial activity against Klebsiella pneumoniae WH77 expressing IMP-4, TEM-1, SHV-14, CTX-M-3, qnrS1 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID534905Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID561496Antibacterial activity against Moraxella catarrhalis by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID559089Antimicrobial activity against carbapenem-susceptible Acinetobacter baumannii isolate A1 by Etest method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vivo selection of reduced susceptibility to carbapenems in Acinetobacter baumannii related to ISAba1-mediated overexpression of the natural bla(OXA-66) oxacillinase gene.
AID1373304Antimicrobial activity against Escherichia coli expressing beta-lactamase GIM-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1853614Antibacterial activity against Staphylococcus aureus clinical isolate 1088105 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution method2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
Design, synthesis, and antibacterial activity of
AID553670Chemical stability of the compound assessed as compound remaining after 24 hrs PBS buffer by HPLC analysis at pH 5.52008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Restoration of susceptibility of intracellular methicillin-resistant Staphylococcus aureus to beta-lactams: comparison of strains, cells, and antibiotics.
AID1853603Antibacterial activity against Enterococcus faecalis clinical isolate 1088051 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution method2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
Design, synthesis, and antibacterial activity of
AID567584Antimicrobial activity against Acinetobacter baumannii by broth dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.
AID576526Antimicrobial activity against Carbapenem-resistant Klebsiella pneumoniae isolate ART2008028 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID761206Antibacterial activity against Acinetobacter spp. by broth microdilution method2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Pyridone-conjugated monobactam antibiotics with gram-negative activity.
AID1757532Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-5 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID761212Antibacterial activity against Klebsiella pneumoniae expressing defined beta-lactamase by broth microdilution method2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Pyridone-conjugated monobactam antibiotics with gram-negative activity.
AID1879127Antibacterial activity against NDM-1 negative Escherichia coli BL21(DE3) pET28a isolates assessed as inhibition of bacterial growth incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1596889Antibacterial activity against methicillin-resistant Staphylococcus aureus NR100 incubated for 16 to 18 hrs by broth microdilution assay
AID372345Ratio of Cmax in in vitro PK/PD model at 1 g infused at every 8 hrs intervals to MIC for Pseudomonas aeruginosa PAO12007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID429077Antibacterial activity against Escherichia coli J53 by E test method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.
AID564947Antimicrobial activity against Acinetobacter baumannii isolate Ab12 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba92009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID1407960Antibacterial activity against Acinetobacter baumannii ARC2728 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID543270Antimicrobial activity against Streptococcus pneumoniae by broth microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID523764Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E4772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID528820Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1407948Antibacterial activity against Pseudomonas aeruginosa ARC3611 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID519803Antimicrobial activity against Escherichia coli MC4100 by CLSI protocol based broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID558046Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S9 by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID564956Antimicrobial activity against Acinetobacter baumannii isolate Ab108 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba92009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID524086Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3532010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534844AUC (0 to 8 hrs) in critically ill patient with sepsis receiving high-volume continuous venovenous hemofiltration at 1000 mg/kg, iv administered every 8 hrs by HPLC method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
AID68189In vitro antibacterial activity against Enterobacter cloacae 1321E2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.
AID576958Antimicrobial activity against Shewanella algae Sa10 harboring intI1, intI2, sul1 and sul2 genes by CLSI method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Reservoir of antimicrobial resistance determinants associated with horizontal gene transfer in clinical isolates of the genus Shewanella.
AID1757564Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-12 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID433194Antibacterial activity against Staphylococcus lugdunensis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID496474Antibacterial activity against Klebsiella pneumoniae isolate 354 in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID535372Antimicrobial activity against Pseudomonas aeruginosa isolated from ICU patient assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID575007Antimicrobial activity against Eubacterium sp. assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID576540Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate AIS080571 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID584688Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4109 harboring ampR mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID530814Antibacterial activity against Klebsiella pneumoniae 11978 harboring plasmid pA-1carrying beta-lactamase OXA-48 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID573599Antibacterial activity against Fusobacterium nucleatum assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1721008Synergistic Inhibition of beta lactamase NDM1 in Klebsiella pneumoniae K66-45 assessed colony formation by visual inspection in presence of 50 microM (5-((4-iodophenylsulfonamido)methyl)-1H-1,2,3-triazol-4-yl)methyl acetate incubated for 20 hrs by two-fol2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Structural studies of triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-β-lactamases.
AID562752Antimicrobial activity against Escherichia coli DH5alpha harboring pBC-CTX-M-15 plasmid by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID1229258Unbound fraction in human plasma after 16 hrs by LC-MS/MS analysis2015ACS medicinal chemistry letters, May-14, Volume: 6, Issue:5
SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of Pseudomonas aeruginosa PBP3.
AID531591Antibacterial activity against Salmonella spp. obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID559688Antibacterial activity against ESBL-positive and OmpF and OmpC porin-deficient Escherichia coli HB42009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
AID323612Ratio of fAUC to MIC in patient with lower respiratory tract infection2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.
AID574983Antimicrobial activity against Actinomyces naeslundii assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1546206Half life in rat2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID524271Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E509 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID519806Inhibition of Bocillin FL binding to PBP2 in Pseudomonas aeruginosa PAO1 membranes2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID533631Antimicrobial activity against Propionibacterium acnes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID535697Antimicrobial activity against Azide-resistant Escherichia coli J53 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
AID573595Antibacterial activity against Fusobacterium nucleatum assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID534642Antimicrobial activity against Non-ESBL Klebsiella pneumoniae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID534666Antimicrobial activity against Proteus mirabilis assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID535366Antimicrobial activity against Pseudomonas aeruginosa isolated from ICU patient by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID433191Antibacterial activity against methicillin-sensitive Staphylococcus aureus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID1680055Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 10 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID555454Antibacterial activity against Acinetobacter genomosp. 3 isolate 52 by Etest method in presence of cloxacillin and efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID69763Antibacterial activity against Escherichia coli 0782003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID496529fT>MIC in Klebsiella pneumoniae isolate 334 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 8-16 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID425084Antimicrobial activity against beta lactamase-positive Prevotella melaninogenica isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID573582Antibacterial activity against beta-lactamase producing Bacteroides caccae assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID533385Antimicrobial activity against Clostridium difficile by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID528839Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID423098Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID534881Antimicrobial activity against Enterobacter cloacae assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID496501fT>MIC in Pseudomonas aeruginosa isolate 1177 at 2 gram for every 8 hrs administered as 3 hrs infusion over 24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID1680050Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae clinical isolate 6 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID1407962Antibacterial activity against Acinetobacter baumannii ARC2780 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID520721Antibacterial activity against Escherichia coli DH10B harboring pOXA-972008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID555240Antibacterial activity against Acinetobacter genomosp. 3 isolate 52 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID249283Minimum inhibitory concentration against Moraxella catarrhalis (n=22); (Range=0.008-0.03)2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID574490Antimicrobial activity against Bacteroides vulgatus after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID576959Antimicrobial activity against Shewanella algae Sa82 harboring intI1, intI2, sul1 and sul2 genes by CLSI method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Reservoir of antimicrobial resistance determinants associated with horizontal gene transfer in clinical isolates of the genus Shewanella.
AID583026Antimicrobial activity against Escherichia coli TOP10 transformed with Escherichia coli EC-6 plasmid carrying AmpC-B2 by agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID517947Antimicrobial activity against Enterobacter aerogenes by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID524092Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3412010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID521994Antimicrobial activity against Escherichia coli isolate J53 harboring pBb containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID543427Antimicrobial activity against Escherichia coli XL-1 Blue harboring plasmid CL1920 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID545608Antimicrobial activity against Pseudomonas aeruginosa PS28 with PFGE phenotype 6 expressing beta-lactamase KPC-5 obtained from skin of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID534697Antimicrobial activity against Fusobacterium nucleatum by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID524282Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E453 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573591Antibacterial activity against Fusobacterium nucleatum by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1906417Antibacterial activity against imipenem resistant Klebsiella pneumoniae ATCC BAA 1705 assessed as reduction in microbial growth incubated for 24 hrs by microbroth dilution method2022European journal of medicinal chemistry, May-05, Volume: 235Amphiphilic cyclic peptide [W
AID524270Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E480 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID575946Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae assessed as susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.
AID553669Chemical stability of the compound assessed as compound remaining after 24 hrs in PBS buffer by HPLC analysis at pH 7.42008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Restoration of susceptibility of intracellular methicillin-resistant Staphylococcus aureus to beta-lactams: comparison of strains, cells, and antibiotics.
AID401686Antibacterial activity against Staphylococcus aureus SG5112005Journal of natural products, May, Volume: 68, Issue:5
Cytotoxic bisindole alkaloids from a marine sponge Spongosorites sp.
AID561630Antimicrobial activity against ampD1-, ampD2-deficient Stenotrophomonas maltophilia KJ by twofold serial agar dilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID523505Antimicrobial activity against Pseudomonas aeruginosa isolate 12142c from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1533876Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 1449 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID523557Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E460 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID295788Antibacterial activity against Streptococcus agalactiae 32 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID520976Antibacterial activity against Pseudomonas aeruginosa KG2505 harboring pCOL plasmid by Etest method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID560077Antimicrobial activity against Pseudomonas aeruginosa isolate 796 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID1905607Induction of drug resistance in Staphylococcus aureus ATCC 25923 assessed as increase in MIC after 10 passages by CLSI protocol based broth microdilution method2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Novel β-Hairpin Antimicrobial Peptides Containing the β-Turn Sequence of -RRRF- Having High Cell Selectivity and Low Incidence of Drug Resistance.
AID534479Antimicrobial activity against Prevotella corporis GAI 91000 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID373772Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh36 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID576308Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 29459 harboring porin OmpK36 gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID70119Compound was evaluated for its antibacterial activity against Escherichia coli DC 22003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID1443396Antibacterial activity against Klebsiella pneumoniae isolate 212232 after 18 hrs by broth microdilution method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections.
AID524079Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3272010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1628586Antibacterial activity against Pseudomonas aeruginosa PAO322 deficient in MexA/B/C/D/E/F incubated for 18 to 24 hrs by broth microdilution method2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
Discovery and Characterization of a Class of Pyrazole Inhibitors of Bacterial Undecaprenyl Pyrophosphate Synthase.
AID555263Antibacterial activity against Acinetobacter genomosp. 3 isolate 103 by Etest method in presence of efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID528974Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID203201Compound was evaluated for its antibacterial activity against Shigella sonnei ATCC 92902003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID565532Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-03 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID519629Antimicrobial activity against Escherichia coli JM83 without producing beta-lactamase OXA-63 after 3 days by Etest2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.
AID423496Antibacterial activity against Acinetobacter baumannii isolate 895 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID553679Ratio of intracellular to extracellular drug level in human THP1 cells at 250 mg/L after 24 hrs2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Restoration of susceptibility of intracellular methicillin-resistant Staphylococcus aureus to beta-lactams: comparison of strains, cells, and antibiotics.
AID545334Displacement of [14C]benzylpenicillin from PBP1 in Staphylococcus aureus ATCC 6538P2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID8399Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4)1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID534691Antimicrobial activity against Prevotella intermedia by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID1596888Antibacterial activity against methicillin-resistant Staphylococcus aureus NR10186 incubated for 16 to 18 hrs by broth microdilution assay
AID423323Antibacterial activity against Pseudomonas aeruginosa isolate 366 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID428246Antimicrobial activity against Proteus mirabilis2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID584694Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4946 harboring mutL mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1228697Antibacterial activity against Pseudomonas aeruginosa 1145 assessed as bacterial growth inhibition by susceptibility testing assay2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID433160Antibacterial activity against Clostridium clostridioforme isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID499123Antimicrobial activity against Pseudomonas aeruginosa OC 4354 infected in immunocompromized SKH1 mouse assessed as lesion volume at 6.2 mg/kg/day, sc measured after 48 hrs postinfection (Rvb = 2195 mm3)2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID1056844Antibacterial activity against TEM-1/CTX-M-15 expressing Enterobacter cloacae isolate 62 after 18 to 24 hrs by two-fold broth microdilution assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID279940Antibiotic susceptibility by resistance against MDR Pseudomonas aeruginosa from samples collected from patients2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
AID423491Antibacterial activity against Acinetobacter baumannii isolate 890 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID70109Compound was evaluated for its antibacterial activity against Escherichia coli CCARM 1109 MDR2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID511132Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 62010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID529663Activity of Pseudomonas aeruginosa 166301 beta-lactamase VIM-16 relative to cephaloridine2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID1763153Antibacterial activity against Acinetobacter sp. 126 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI based serial dilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Antibacterial and synergistic activity of 6β-hydroxy-3-oxolup-20(29)-en-28-oic acid (6β-hydroxy betunolic acid) isolated from Schumacheria castaneifolia vahl.
AID519816Inhibition of Bocillin FL binding to PBP5/6 in Pseudomonas aeruginosa 27853 membranes2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID656443Antimicrobial activity against CTX-M-positive extended spectrum beta-lactamase-producing Escherichia coli2011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID433354Antibacterial activity against Parabacteroides merdae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID565548Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-12 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID274727Antibacterial activity against methicillin-resistant Staphylococcus aureus 5032007Journal of natural products, Jan, Volume: 70, Issue:1
Bisindole alkaloids of the topsentin and hamacanthin classes from a marine sponge Spongosorites sp.
AID1278999Antibacterial activity against Staphylococcus aureus incubated for 20 hrs by microbroth dilution method2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
Synthesis of fluorinated carbazoles via C-H arylation catalyzed by Pd/Cu bimetal system and their antibacterial activities.
AID55863Compound was evaluated for its relative half life of hydrolysis to meropenem by partially purified porcine renal dihydropeptidase-I (DHP-I)2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID373031Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU4A22 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID656360Antimicrobial activity against Stenotrophomonas maltophilia2011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID295825Antibacterial activity against Serratia marcescens 370 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID495804Antimicrobial activity against Klebsiella pneumoniae 2878 strain expressing beta-lactamase VIM-19 by microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID545561Antibacterial activity against Escherichia coli EIR4a selected at 4 times MIC of imipenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID656357Antimicrobial activity against Enterobacter aerogenes2011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID529196Antibacterial activity against ESBL-producing Escherichia coli isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
AID1873912Antibacterial activity against Staphylococcus chromogenes incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID584719Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2963 harboring mutation in putative aminodeoxychorismate lyase by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID533638Antimicrobial activity against Propionibacterium sp. assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID545619Antimicrobial activity against Pseudomonas aeruginosa PS41 with PFGE phenotype 11D obtained from urine of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID574666Antimicrobial activity against Escherichia coli isolate 547T expressing beta-lactamase KPC2 and PFGE cluster 4 isolated from blood of patient by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID496004Antimicrobial activity against drug resistant Pseudomonas aeruginosa isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID519293Antimicrobial activity against Escherichia coli TOP10 by Etest2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp.
AID1762812Inhibition of Escherichia coli IMP-1 assessed as reduction in bacterial growth incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID68210In vitro antibacterial activity against Enterobacter cloacae 1321E by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13
Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID511162Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 18 assessed as zone of inhibition by disk diffusion assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID528835Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID523773Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3322010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534452Antimicrobial activity against Propionibacterium granulosum ATCC 25564 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID423326Antibacterial activity against Pseudomonas aeruginosa isolate 369 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID523572Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E472 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524304Antibacterial activity against Pseudomonas aeruginosa P349 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID425121Bactericidal activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID534097Antibacterial activity against Acinetobacter baumannii PFGE type A isolate by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
A plasmid-borne blaOXA-58 gene confers imipenem resistance to Acinetobacter baumannii isolates from a Lebanese hospital.
AID531590Antibacterial activity against Providencia stuartii obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID1318934Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 806212016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID533634Antimicrobial activity against Propionibacterium acnes assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID584838Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER2 by agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID495713Kcat/Km ratio of Pseudomonas aeruginosa IMP-12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID496536fT>MIC in Pseudomonas aeruginosa isolate 762 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 8-16 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID558042Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S5 by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID12711The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat2000Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13
Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID564533Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid carrying entire blaAmpC gene with alanine residue insertion at 215 position by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID517955Antimicrobial activity against Klebsiella pneumoniae by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID535638Antimicrobial activity against Group B streptococcus serotype VI R2 harboring F395L, V405A, R433H, H438Y, and G648A mutations in PBP 2X and T567I mutation in PBP 2B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID425108Antimicrobial activity against Clostridium paraputrificum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID565215Activity of VIM-1 in Klebsiella pneumoniae isolate A-17602009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID324864Antimicrobial activity against Acinetobacter baumannii A24D after 4 days by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID523762Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E4792010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID531780Antibacterial activity against Pseudomonas aeruginosa obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID236459Area under concentration time at a single intravenous administration of 5 mg/kg in dog2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID498838Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae SZ61 deficient in TEM-1, SHV-1a, CMY-2, ompK35/36 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID573572Antibacterial activity against beta-lactamase producing Bacteroides uniformis by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID495840Hydrolytic activity of beta-lactamase VIM-1 in Escherichia coli DH5alpha expressing pBCLL/39H by microacidimetric method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID423526Antibacterial activity against Acinetobacter baumannii isolate 925 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID518229Antimicrobial activity against Pseudomonas aeruginosa 860 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID555211Antibacterial activity against Acinetobacter genomosp. 3 isolate 109 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID534836Renal clearance in critically ill patient with sepsis at 1000 mg/kg, iv administered every 8 hrs by HPLC method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
AID519138Antimicrobial activity against community-acquired methicillin resistant Staphylococcus aureus expressing PVL and mec type IV gene by broth microdilution method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
AID529494Antimicrobial activity against Enterobacter cloacae isolate 837 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID558609Antimicrobial activity against Streptococcus pneumoniae isolate 1397 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID495685Antimicrobial activity against Acinetobacter baumannii OC 11738 expressing beta-lactamase OXA-23 and containing Carbapenemase assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID523912Antibacterial activity against Acinetobacter baumannii A896 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID274726Antibacterial activity against methicillin-resistant Staphylococcus aureus 2852007Journal of natural products, Jan, Volume: 70, Issue:1
Bisindole alkaloids of the topsentin and hamacanthin classes from a marine sponge Spongosorites sp.
AID1318933Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 791992016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID432994Antibacterial activity against Klebsiella oxytoca isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID511580Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 deficient in ampD, ampDh3 and ampDh3 gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID532208Antimicrobial activity against Escherichia coli J53 harboring wild-type GyrA, ParC, GyrB genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID535130Antimicrobial activity against imipenem non-susceptible Pseudomonas aeruginosa by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID237224Relative half life of hydrolysis to meropenem by partially purified porcine renal DHP-I2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID545563Antibacterial activity against Escherichia coli EIR4b selected at 4 times MIC of imipenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID533635Antimicrobial activity against Propionibacterium sp. by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID529460Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase TEM-1, SHV-12 and Oxa-9 by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID558325Antibacterial activity against bla gene-negative and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P850 by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID533377Antimicrobial activity against Bacteroides merdae by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID555253Antibacterial activity against Acinetobacter genomosp. 3 isolate 67 by Etest method in presence of efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID534672Antimicrobial activity against Porphyromonas asaccharolyticus ATCC 25260 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID560089Bactericidal activity against Enterobacter cloacae isolate 4073 at 1/4 times MIC after 24 hrs by time kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID369626Antimicrobial activity against beta-lactamase negative ampicillin-susceptible Haemophilus influenzae by broth microdilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
AID425093Antimicrobial activity against Fusobacterium varium isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID433014Antibacterial activity against Streptococcus agalactiae isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID283398Antimicrobial activity against Nocardia carnea after 72 hrs by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID534707Antimicrobial activity against Eggerthella lenta by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID565724Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-29 harboring A residue at 105 position in PDC- 8 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID425085Antimicrobial activity against beta lactamase-positive Prevotella denticola isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID534846Ultrafiltration flow rate in critically ill patient with sepsis receiving high-volume continuous venovenous hemofiltration at 1000 mg/kg, iv administered every 8 hrs by HPLC method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
AID498806Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ71 deficient in KPC-2, TEM-1, SHV-11, CTX-M-14, ompK35 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID373789Ratio of MIC for Acinetobacter baumannii ISAB ab1254(r) to MIC for Acinetobacter baumannii ISAB ab8(r) in presence of 2 ug/ml efflux pump inhibitor carbonyl cyanide m-chlorophenyl-hydrazone2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID560091Bactericidal activity against Klebsiella pneumoniae isolate 5427 at 1/4 times MIC after 24 hrs by time kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID534607Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID433371Antibacterial activity against Peptostreptococcus micros isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523924Antibacterial activity against Acinetobacter baumannii A903 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534692Antimicrobial activity against Prevotella sp. by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID565529Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-06 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID574782Antimicrobial activity against Actinomyces odontolyticus after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID534710Antimicrobial activity against Clostridium perfringens by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID285606Antimicrobial activity against Pseudomonas aeruginosa 2A7 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID518245Antimicrobial activity against Klebsiella pneumoniae 1338665 assessed as appearance of colony at 4 times MIC concentration2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID1417168Antibacterial activity against methicillin-resistant Staphylococcus aureus NR10192 by CLSI method2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis of 1,2,3-triazole linked 4(3H)-Quinazolinones as potent antibacterial agents against multidrug-resistant Staphylococcus aureus.
AID574482Antimicrobial activity against Bacteroides fragilis after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1680052Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae clinical isolate 4 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID517950Antimicrobial activity against Proteus vulgaris by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID245081Minimum inhibitory concentration against Escherichia coli 078 strain2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID285612Antimicrobial activity against Pseudomonas aeruginosa 65.68-4 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID529840Antibacterial activity against methicillin-resistant Staphylococcus aureus by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID574522Antimicrobial activity against Prevotella buccae after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID373038Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate NJ59 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID523515Antimicrobial activity against Pseudomonas aeruginosa isolate 1253 from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID555251Antibacterial activity against Acinetobacter genomosp. 3 isolate 65 by Etest method in presence of efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID575013Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase IMP-1 by UV spectrophotometric analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro potentiation of carbapenems with ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta-lactamase- producing Pseudomonas aeruginosa clinical isolates.
AID517963Antimicrobial activity against Pseudomonas aeruginosa by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID534929Antimicrobial activity against Ceftazidime non-susceptible Serratia marcescens assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID322789Antimicrobial activity against Bacteroides caccae assessed as percent resistant isolates2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID561490Antibacterial activity against Acinetobacter baumannii assessed as susceptible isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID574506Antimicrobial activity against Bacteroides distasonis assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID424859Antimicrobial activity against Pseudomonas aeruginosa PAO1 by E-test2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID523550Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E446 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523578Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E478 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523901Antibacterial activity against Acinetobacter baumannii A850 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID565216Activity of KPC-2 in Klebsiella pneumoniae isolate T-15042009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID656358Antimicrobial activity against extended spectrum beta-lactamase-producing Escherichia coli2011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID423493Antibacterial activity against Acinetobacter baumannii isolate 892 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID529574Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid BC-SK after 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID295804Antibacterial activity against Streptococcus durans D after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID531582Antibacterial activity against Enterobacter amnigenus obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID1373281Antimicrobial activity against Escherichia coli expressing beta-lactamase CTXM-3 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID535064Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pOXA-58-7 plasmid by agar dilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
AID761209Antibacterial activity against Escherichia coli expressing ESBL by broth microdilution method2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Pyridone-conjugated monobactam antibiotics with gram-negative activity.
AID531787Antibacterial activity against Enterobacter aerogenes obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID588127Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 5 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID323038Antimicrobial activity against extended-spectrum-beta-lactamase producing Escherichia coli assessed as percent resistant isolates2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
AID495725Activity of Klebsiella pneumoniae KPC-2 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1533857Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 3332 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID405820Antimicrobial activity against Acinetobacter baumannii 501 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-32007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID1559377Antibacterial activity against Klebsiella pneumoniae 11978 expressing OXA-48 after 16 to 20 hrs by CLSI-based microbroth dilution method2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID496541fT>MIC in Klebsiella pneumoniae isolate 351 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 16-24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID574051Antibacterial activity against beta-lactamase producing Finegoldia magna assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1407976Antibacterial activity against Acinetobacter baumannii ARC3659 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID423101Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID521996Antimicrobial activity against Escherichia coli isolate J53 harboring p3A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID528821Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID534623Antimicrobial activity against ESBL producing Escherichia coli by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID423534Antibacterial activity against Acinetobacter baumannii isolate 931 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID521991Antimicrobial activity against Klebsiella pneumoniae isolate Kp11978 expressing beta-lactamase OXA-48, SHV-2a and TEM-1 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID336779Antimicrobial activity against Pseudomonas aeruginosa 1592E isolate after 18 hrs2003Journal of natural products, Mar, Volume: 66, Issue:3
Bioactive sterols from the starfish Certonardoa semiregularis.
AID561476Antibacterial activity against Serratia marcescens assessed as resistant isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID533565Antimicrobial activity against Pseudomonas aeruginosa isolate PA399 expressing VIM-2 beta-lactamase2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID1782791Antibacterial activity against panel of 198 clinical isolates Acinetobacter baumannii assessed as inhibition of bacterial growth by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID531586Antibacterial activity against Morganella morganii obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID561271Antibacterial activity against Escherichia coli assessed as susceptible isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID573593Antibacterial activity against Fusobacterium necrophorum by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID574484Antimicrobial activity against Bacteroides thetaiotaomicron after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID576521Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate AIS081072 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID518228Antimicrobial activity against Pseudomonas aeruginosa 621 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID1846926Antibacterial activity against IMP4-producing multidrug resistant Pseudomonas aeruginosa assessed as reduction in bacterial growth incubated for 18 to 20 hrs by CLSI based microdilution method2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Design, Synthesis, and Biological Evaluation of Novel Pyrimido[4,5-
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID510509Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate MC4AC9-30 expressing KPC beta lactamase2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID534630Antimicrobial activity against ESBL producing Escherichia coli assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID518221Antimicrobial activity against Acinetobacter junii 15218 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID571914Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 21 expressing ampC, ompA, adeB, adeM, aacC2, blaSHV-5 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID289881Antibacterial activity against Enterobactor cloacae 1321E2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID523495Antimicrobial activity against Pseudomonas aeruginosa isolate 1693c from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID520975Antibacterial activity against Pseudomonas aeruginosa 2404 plasmid by Etest method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID558533Antibacterial activity against bla gene-positive and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P1698 by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID390333Antimicrobial activity against Haemophilus parainfluenzae 23192008Journal of natural products, Dec, Volume: 71, Issue:12
Citreamicins with potent gram-positive activity.
AID565220Activity of VIM-1 in Klebsiella pneumoniae isolate H-1406 assessed as compound hydrolysis in presence of EDTA2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID583084Activity of Escherichia coli BL21(DE3) VIM-2 W87F mutant beta-lactamase by spectrophotometer2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID584554Antimicrobial activity against Acinetobacter lwoffii isolate A expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID523516Antimicrobial activity against Pseudomonas aeruginosa isolate 13120 from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1596894Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated for 16 to 18 hrs by broth microdilution assay
AID373045Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZS15 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID520971Antibacterial activity against Klebsiella pneumoniae 633 by Etest method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID523579Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E481 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID535643Antimicrobial activity against Group B streptococcus serotype III N3 by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID249290Minimum inhibitory concentration against Streptococcus pneumoniae (n=22); (Range = 0.008-0.5)2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID423238Antibacterial activity against beta lactamase-negative Haemophilus influenzae ATCC 49247 isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID1863321Antibacterial activity against Klebsiella pneumoniae SI-518 assessed as reduction in microbial growth after 24 hrs by two-fold serial dilution method2022European journal of medicinal chemistry, Oct-05, Volume: 240A fragment-based drug discovery strategy applied to the identification of NDM-1 β-lactamase inhibitors.
AID518509Antimicrobial activity against Pseudomonas aeruginosa BA assessed as doubling time2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID534643Antimicrobial activity against ESBL producing Klebsiella pneumoniae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID535844Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTS harboring mexAB-oprM gene after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID499141fT>MIC in Pseudomonas aeruginosa OC 4354 infected sc dosed SKH1 mouse administered in 24 hrs dosing interval2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID1757593Antibacterial activity against ESBLs negative Carbapenem-sensitive Escherichia coli 17-19 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID547789Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237M mutant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID534841Renal extraction ratio in critically ill patient with sepsis receiving high-volume continuous venovenous hemofiltration at 1000 mg/kg, iv administered every 8 hrs by HPLC method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
AID433180Antibacterial activity against Pseudomonas aeruginosa isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID534842Hemofiltration clearance in critically ill patient with sepsis receiving high-volume continuous venovenous hemofiltration at 1000 mg/kg, iv administered every 8 hrs by HPLC method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
AID1757621Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-24 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID574041Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID532184Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae SY26 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrB genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID584564Antimicrobial activity against Acinetobacter lwoffii isolate K expressing beta-lactamase OXA-58 isolated from blood culture of patient by vitek 2 system2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID425075Antimicrobial activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID495813Antimicrobial activity against Escherichia coli 138 expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID656349Antibacterial activity against Klebsiella pneumoniae 1000-022011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID584515Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2023 harboring galU mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1767681Antibacterial activity against Escherichia coli EOL 931 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID532395Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A3 isolate NA-14X-34 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID558534Antibacterial activity against bla gene-positive and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P1699 by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID423299Antibacterial activity against Pseudomonas aeruginosa isolate 338 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID531314Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID423333Antibacterial activity against Pseudomonas aeruginosa isolate 376 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID520385Activity at Pseudomonas aeruginosa M5109 metallo-beta-lactamase VIM-11 by spectrometry2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID1757605Antibacterial activity against Enterobacter aerogenes 17-1 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID534609Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID425329Bactericidal activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID532205Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae WH99T harboring qnrB gene by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID528830Antimicrobial activity against CTX-M ESBL producing Escherichia coli isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID534706Antimicrobial activity against Peptoniphilus asaccharolyticus by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID433150Antibacterial activity against Bacteroides uniformis isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID531581Antibacterial activity against Citrobacter freundii obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID535365Antimicrobial activity against Pseudomonas aeruginosa isolated from non-ICU patient by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID535632Antimicrobial activity against Group B streptococcus R8 harboring T77I, S353F and A514V in PBP 2X; V80A and G613R in PBP 2B; and L45P, N163K, N723S and G527V in PBP 1A by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID1757547Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-11 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID529857Antibacterial activity against Pseudomonas aeruginosa N092 expressing MexE-MexD-OprN gene and OprD mutant gene and harboring nfxC mutant gene by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID495908Antimicrobial activity in Escherichia coli TOP10 harbouring recombinant plasmid VIM-1-N215K by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID582972Antimicrobial activity against ampD::lox and nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID584525Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3620 harboring mutS mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID560087Bactericidal activity against Pseudomonas aeruginosa isolate 1019 at 1/4 times MIC after 24 hrs by time kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID360050Antimicrobial activity against Enterococcus faecium M512 by agar dilution method after 48 hrs2007The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42
Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID533361Antimicrobial activity against Bacteroides thetaiotaomicron by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID575005Antimicrobial activity against Eubacterium sp. after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID532412Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B3 isolate PV-05X-07 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID558623Antimicrobial activity against Streptococcus pneumoniae isolate 3412 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID573795Antibacterial activity against Prevotella buccae assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID584306Antimicrobial activity against beta-lactamase ompC intact/ompF deficient Serratia marcescens isolate YMC0582 by agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID534879Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID573824Antibacterial activity against beta-lactamase producing Clostridium septicum by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1680051Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae clinical isolate 5 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID529656Ratio of Kcat to Km for Pseudomonas aeruginosa 9551 beta-lactamase VIM-152008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID534408Antimicrobial activity against methicillin-susceptible Staphylococcus aureus by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID583029Antimicrobial activity against Escherichia coli TOP10 transformed with Escherichia coli DH10B plasmid carrying DHA-1 by agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID522000Antimicrobial activity against Escherichia coli isolate J53 harboring p4A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID559821Antimicrobial activity against Pseudomonas aeruginosa PU21 harboring pCHE-A plasmid expressing blaGES-5 gene by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID289891Antibacterial activity against Pseudomonas aeruginosa 77/22007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID1291426Binding affinity to His-tagged Klebsiella pneumoniae NDM-1 expressed in Escherichia coli BL21-AI cells by surface plasmon resonance assay2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Fragment-based discovery of inhibitor scaffolds targeting the metallo-β-lactamases NDM-1 and VIM-2.
AID498872Antimicrobial activity against Acinetobacter baumannii B9 containing carbapenemase blaOXA-23 gene assessed as growth inhibition by Etest method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate.
AID571894Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 11 expressing ompA, adeB, adeM, blaSHV-5 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID529462Antimicrobial activity against Klebsiella pneumoniae isolate 11 expressing beta-lactamase Oxa-48, TEM-1 and Oxa-1 by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID528784Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID1407967Antibacterial activity against Acinetobacter baumannii ARC3486 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID1757578Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-8 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID374367Activity of Acinetobacter baumannii AC-54/97 metallo-beta-lactamase IMP-2 expressed in Escherichia coli DH5alpha2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID534899Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID433185Antibacterial activity against Corynebacterium urealyticum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID245141Minimum inhibitory concentration against Streptococcus aureus 285 strain2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID511581Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 deficient in ampD and dacB gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID520727Activity of Escherichia coli TOP10 beta-lactamase OXA-97 assessed as specific activity per mg of protein at 100 uM2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID524072Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3562010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534194Antimicrobial activity against Pseudomonas putida expressing beta-lactamase KPC-2 and SHV-12 obtained from criticall ill liver transplant recipient by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient.
AID555467Antibacterial activity against Acinetobacter genomosp. 3 isolate 90 by Etest method in presence of cloxacillin and efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID518187Antimicrobial activity against Acinetobacter baumannii HPA 4737 harboring beta-lactamase OXA-26 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID510502Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate C1AC9-24 expressing KPC beta lactamase2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID523951Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E358 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID535129Antimicrobial activity against imipenem susceptible Pseudomonas aeruginosa by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID546420Antimicrobial activity against Pseudomonas aeruginosa KG2505a harboring recombinant pBB-PDC-5 by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID285592Antimicrobial activity against Pseudomonas aeruginosa 65.38-3 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID522667Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis K8091 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID206734In vitro antibacterial activity against Staphylococcus aureus SG5112000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Synthesis and antibacterial activity of new carbapenems containing isoxazole moiety.
AID534622Antimicrobial activity against Non-ESBL Escherichia coli by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID322780Antimicrobial activity against Bacteroides eggerthii isolates by agar dilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID279815Antimicrobial activity against Escherichia coli DH5-alpha with pGEM-T EASY expressing TEM1 gene by agar dilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID324361Activity of Acinetobacter johnsonii SCO12007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.
AID286031Antimicrobial activity against ESBL producing Klebsiella pneumoniae 254 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID433011Antibacterial activity against Staphylococcus epidermidis isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID562760Antimicrobial activity against Klebsiella pneumoniae PFGE clone C expressing beta-lactamase KPC-2 by Etest2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID534771Antimicrobial activity against Acinetobacter baumannii-calcoaceticus obtained from war-wounded patient assessed as susceptible isolates2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.
AID583018Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Escherichia coli pGLK-1 plasmid carrying FOX-1 by agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID534490Antimicrobial activity against Stenotrophomonas maltophilia KJN2 harboring pRK-EcG plasmid and ampN with xylE-Gmomega cassette insertion by Etest2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID496481Antibacterial activity against Klebsiella pneumoniae isolate 361 in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID425100Antimicrobial activity against Peptoniphilus asaccharolyticus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID564945Antimicrobial activity against Acinetobacter baumannii isolate Ab150 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba92009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID369627Antimicrobial activity against beta-lactamase negative ampicillin-susceptible Haemophilus influenzae by E-test2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
AID535637Antimicrobial activity against Group B streptococcus serotype Ib R3 harboring Q557E, A400V mutations in PBP 2X and T567I, G539E mutations in PBP 2B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID560066Antimicrobial activity against Escherichia coli isolate 5411 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID574520Antimicrobial activity against Prevotella bivia after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID583085Activity of Escherichia coli BL21(DE3) wild-type VIM-2 beta-lactamase by spectrophotometer2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID584310Antimicrobial activity against beta-lactamase ompC intact/ompF deficient Serratia marcescens isolate YMC0564 by agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID584714Antimicrobial activity against Pseudomonas aeruginosa PA14 PA14_07490/07510 harboring mutation in intergenic region by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1407974Antibacterial activity against Acinetobacter baumannii ARC3657 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID534840Apparent volume of distribution in critically ill patient with sepsis at 1000 mg/kg, iv administered every 8 hrs by HPLC method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
AID1596882Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS12 incubated for 16 to 18 hrs by broth microdilution assay
AID565509Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-27 harboring A residue at 105 position in PDC- 7 by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID523889Antimicrobial activity against Acinetobacter baumannii 6AB15 harboring ISAba1-blaOXA-23 and blaOXA-66 gene by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
AID1762810Inhibition of Escherichia coli NDM-1 assessed as reduction in bacterial growth incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID286028Antimicrobial activity against ESBL producing Klebsiella pneumoniae 264 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID10440Half life of compound after iv administration of 20 mg/kg dose in rat2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.
AID341106Antibacterial activity against metallo-beta-lactamase VIM12 expressing Escherichia coli 28 isolate from decubitus ulcer infection patient by Etest2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12.
AID535847Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTL harboring oprD gene after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID565280Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
AID584307Antimicrobial activity against beta-lactamase ompC intact/ompF deficient Serratia marcescens isolate YMC0584 by agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID68022Antibacterial activity against Enterobacter cloacae 1321E2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.
AID1691831Antibacterial activity against Pseudomonas aeruginosa PAO1 infected in Caenorhabditis elegans N2 strain assessed as reduction in bacterial growth at 0.25 ug/ml after 120 hrs2020European journal of medicinal chemistry, May-15, Volume: 194Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1.
AID545607Antimicrobial activity against Pseudomonas aeruginosa PS26 with PFGE phenotype 3A expressing beta-lactamase OXA-2 obtained from sputum of ICU patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID1373287Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-4 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID423308Antibacterial activity against Pseudomonas aeruginosa isolate 350 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID565508Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-26 harboring T residue at 105 position in PDC- 6 and polymorphic OprD gene by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID433018Antibacterial activity against Bacteroides caccae isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID499128Antimicrobial activity against Pseudomonas aeruginosa OC 4351 infected in immunocompromized SKH1 mouse assessed as log change in bacterial colony forming units at 25 mg/kg/day, sc2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID323041Antimicrobial activity against extended-spectrum-beta-lactamase producing Proteus mirabilis isolates2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
AID1533860Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 2895 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID523891Antimicrobial activity against Acinetobacter baumannii ATCC 15151 harboring plasmid AT801 by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
AID558602Antimicrobial activity against Streptococcus pneumoniae isolate 33 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID1759648Antimicrobial activity against vancomycin-resistant Enterococcus faecium clinical isolate 1089544 by CLSI-based broth microdilution assay2021European journal of medicinal chemistry, Jul-05, Volume: 2194-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.
AID534409Antimicrobial activity against methicillin-resistant Staphylococcus aureus by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID573397Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron by by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID574488Antimicrobial activity against Bacteroides distasonis after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID374025Activity of Klebsiella pneumoniae KPC-1 beta lactamase expressed in Escherichia coli DH5alpha by SDS-PAGE2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID572134Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 34 expressing ampC, ompA, adeB, adeM by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID522187Antimicrobial activity against Klebsiella pneumoniae isolate KpL expressing beta-lactamase OXA-48 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID495677Antimicrobial activity against Enterobacter cloacae OC 4080 overexpressing beta-lactamase AmpC assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID425091Antimicrobial activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID573825Antibacterial activity against beta-lactamase producing Clostridium tertium by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID534687Antimicrobial activity against Bacteroides vulgatus by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID555468Antibacterial activity against Acinetobacter genomosp. 3 isolate 103 by Etest method in presence of cloxacillin and efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID425086Antimicrobial activity against beta lactamase-positive Prevotella corporis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID561460Antibacterial activity against Enterobacter cloacae assessed as resistant isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID558039Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S2 by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID1691822Antibacterial activity against Pseudomonas aeruginosa PAO1 biofilm cells assessed as reduction in bacterial growth after 2 days by resazurin dye based assay2020European journal of medicinal chemistry, May-15, Volume: 194Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1.
AID576305Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 287942 harboring porin OmpK36 gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID206152In vitro antibacterial activity against Staphylococcus aureus 5032001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.
AID520729Activity of Acinetobacter baumannii CIP7010 beta-lactamase OXA-97 assessed per mg of protein at 100 uM2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID522824Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis NH by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID549335Antimicrobial activity against Escherichia coli isolate Z1 harboring bla CTX-M-3a gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID562224Antimicrobial activity against Desulfovibrio piger by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Susceptibilities of 23 Desulfovibrio isolates from humans.
AID374021Ratio of Kcat to Km for Serratia fonticola UTAD54 SFC1 beta lactamase expressed in Escherichia coli BL21(DE3) by SDS-PAGE2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID510507Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-7 expressing KPC beta lactamase2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID532913Antimicrobial activity against Escherichia coli Genehogs by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID433186Antibacterial activity against Corynebacterium striatum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID582979Antimicrobial activity against ampR::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID523600Antibacterial activity against Pseudomonas aeruginosa P352 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID561468Antibacterial activity against Proteus mirabilis assessed as resistant isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID1757619Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-21 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID656356Antimicrobial activity against Citrobacter freundii2011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID517948Antimicrobial activity against Citrobacter freundii by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID529483Antimicrobial activity against Enterobacter cloacae isolate 151 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID534470Antimicrobial activity against Bacteroides ovatus ATCC 8483 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID499133Antimicrobial activity against Pseudomonas aeruginosa OC 4354 infected in immunocompromized SKH1 mouse assessed as log change in bacterial colony forming unit at 100 mg/kg/day, sc2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID496514fT>MIC in Klebsiella pneumoniae isolate 375 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 0-8 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID423304Antibacterial activity against Pseudomonas aeruginosa isolate 345 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID574467Antimicrobial activity against Escherichia coli isolate 386 expressing beta-lactamase KPC2, CTX-M-15, OXA-9, TEM and PFGE cluster 1 isolated from wound of patient by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID574492Antimicrobial activity against Bacteroides ovatus after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID496531fT>MIC in Klebsiella pneumoniae isolate 375 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 8-16 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID498802Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ18 deficient in KPC-2, SHV-28, DHA-1, ompK35 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID534849fT>MIC in patient with acute kidney injury infected with Burkholderia pseudomallei2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
AID517961Antimicrobial activity against Stenotrophomonas maltophilia by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID496005Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID1765580Antibacterial activity against Acinetobacter baumannii ATCC 19606 incubated for 18 hrs by CLSI based broth dilution method2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Novel Broad-Spectrum Antimicrobial Peptide Derived from Anoplin and Its Activity on Bacterial Pneumonia in Mice.
AID524102Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A9112010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID279816Antimicrobial activity against Escherichia coli DH5alpha by agar dilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID522648Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis Africa 33 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID535126Antimicrobial activity against Pseudomonas aeruginosa by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID289906Antibacterial activity against Enterobacter cloacae2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID559689Antibacterial activity against ESBL-positive and OmpF and OmpC porin-deficient Escherichia coli HB4 harboring plasmid AT5172009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
AID562812Antimicrobial activity against Escherichia coli DH5[alpha]2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID1407973Antibacterial activity against Acinetobacter baumannii ARC3515 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID423524Antibacterial activity against Acinetobacter baumannii isolate 923 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID433179Antibacterial activity against Proteus rettgeri isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID558538Antibacterial activity against bla-positive and beta-lactamase-weakly positive Campylobacter coli isolate P1627 by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID535128Antimicrobial activity against Ceftazidime non-susceptible Pseudomonas aeruginosa by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID495822Antimicrobial activity against Klebsiella pneumoniae 6828 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID1757555Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-3 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID584519Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3141 harboring wbpM mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID564958Antimicrobial activity against Acinetobacter baumannii isolate Ab181 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba92009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID285337Antimicrobial activity against Escherichia coli qnrA1 producing urinary specimen isolate 13.52 by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.
AID517951Antimicrobial activity against Providencia rettgeri by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID565217Activity of KPC-2 in Klebsiella pneumoniae isolate H-14062009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID286033Antimicrobial activity against ESBL producing Klebsiella pneumoniae 263 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID295814Antibacterial activity against Escherichia coli V6311/65 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID295820Antibacterial activity against Salmonella orion after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID558044Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S7 by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID289899Antibacterial activity against Escherichia coil 15072007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID564459Antimicrobial activity against Pseudomonas aeruginosa isolate 988 by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID555245Antibacterial activity against Acinetobacter genomosp. 3 isolate 56 by Etest method in presence of efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID534488Antimicrobial activity against Stenotrophomonas maltophilia KJN2 harboring pRK-G plasmid and ampN with xylE-Gmomega cassette insertion by Etest2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID1780306Antibacterial activity against wild type Pseudomonas aeruginosa LESB58 RS21000 and RS21005 mutant assessed as reduction in bacterial growth by broth microdilution assay
AID200859Compound was evaluated for its antibacterial activity against Salmonella Typhimurium 22003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID523754Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E3622010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID496525fT>MIC in Klebsiella pneumoniae isolate 354 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 8-16 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID528525Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B6 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID289915Antibacterial activity against Proteus rettgeri 9372007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID517957Antimicrobial activity against Proteus mirabilis by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID1757607Antibacterial activity against Enterobacter aerogenes 17-3 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID574746Antimicrobial activity against Peptostreptococcus anaerobius assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID425101Antimicrobial activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID1752489Antibacterial activity against Enterobacter cloacae SR36276 producing class C beta-lactamase, AmpC assessed as reduction in microbial growth incubated for 16 to 20 hrs in presence of vaborbactam by broth microdilution method2021Bioorganic & medicinal chemistry, 09-15, Volume: 46A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID1721007Synergistic Inhibition of beta lactamase VIM-2 in Pseudomonas aeruginosa K34-7 assessed colony formation by visual inspection in presence of 125 microM N-((4-((adamantylamino)methyl)-1H-1,2,3-triazol-5-yl)methyl)-4-iodobenzenesulfonamide incubated for 20 2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Structural studies of triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-β-lactamases.
AID285339Antimicrobial activity against streptomycin-resistant Escherichia coli J53 by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.
AID523510Antimicrobial activity against Pseudomonas aeruginosa isolate 16008 from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID524113Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A8972010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID549038Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate KpSCMC1 harboring int1, bla IMP-4, bla SHV-12, armA and sul1 gene isolated from patient with pulmonary infection by disk diffusion method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Two clinical strains of Klebsiella pneumoniae carrying plasmid-borne blaIMP-4, blaSHV-12, and armA isolated at a Pediatric Center in Shanghai, China.
AID656444Antimicrobial activity against Escherichia coli clinical isolate2011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID518249Antimicrobial activity against Pseudomonas aeruginosa 860 assessed as appearance of colony at 4 times MIC concentration2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID534883Antimicrobial activity against Enterobacter cloacae assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID531781Antibacterial activity against Acinetobacter baumannii obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID564524Antimicrobial activity against Acinetobacter baumannii KI by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID425081Antimicrobial activity against beta lactamase-positive Prevotella disiens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID564951Antimicrobial activity against Acinetobacter baumannii isolate Ab33 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba92009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID565717Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-22 harboring A residue at 105 position in PDC- 4 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1706294Elimination half life in human at 1 g, iv infusion for 30 mins2020European journal of medicinal chemistry, Dec-15, Volume: 208β-lactam antibiotics: An overview from a medicinal chemistry perspective.
AID584575Antimicrobial activity against Acinetobacter lwoffii isolate I expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID534832AUC (0 to 8 hrs) in critically ill patient with sepsis at 1000 mg/kg, iv administered every 8 hrs by HPLC method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
AID562340Ratio of Kcat to Km for Chryseobacterium indologenes 597 metallo-beta-lactamase IND-2 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID508728Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3C1 VAL6 by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID498826Antimicrobial activity against Citrobacter freundii SZ63 expressing IMP-4, qnrS1by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID564017Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID561627Antimicrobial activity against Stenotrophomonas maltophilia KJ by twofold serial agar dilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID423336Antibacterial activity against Acinetobacter baumannii isolate 883 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID545394Antimicrobial activity against OprD overproducing Pseudomonas aeruginosa PAO1 expressing mexA and oprD by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID1311364Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 29213 measured after 18 hrs by broth microdilution assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.
AID520707Antibacterial activity against Acinetobacter baumannii phenotype 2 by disk diffusion method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID522651Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis K5926 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID522665Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis BA0018 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID523939Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E446 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID289877Antibacterial activity against Escherichia coli TEM2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID534469Antimicrobial activity against Parabacteroides distasonis ATCC 8503 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID545610Antimicrobial activity against Pseudomonas aeruginosa PS30 with PFGE phenotype 11D obtained from sputum of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID322786Antimicrobial activity against Bacteroides thetaiotaomicron assessed as percent resistant isolates2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID285980Antimicrobial activity against ESBL producing Escherichia coli 312 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID1757592Antibacterial activity against ESBLs negative Carbapenem-sensitive Escherichia coli 17-16 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID546418Antimicrobial activity against Pseudomonas aeruginosa KG2505a harboring recombinant pBB-PDC-3 by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID428269Antimicrobial activity against Klebsiella sp. by CLSI broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID499131Antimicrobial activity against Pseudomonas aeruginosa OC 4354 infected in immunocompromized SKH1 mouse assessed as log change in bacterial colony forming unit at 6.2 mg/kg/day, sc2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID498808Antimicrobial activity against Klebsiella pneumoniae ZJ99 expressing KPC-2, CTX-M-3, qnrS1, ompK35 DE by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID575944Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae by broth microdilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.
AID531589Antibacterial activity against Proteus vulgaris obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID558583Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID545554Ratio of MIC for Escherichia coli ERR4a to MIC for Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID428270Antimicrobial activity against Klebsiella sp. assessed as susceptible isolates by CLSI breakpoint assay2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID495905Antimicrobial activity in Escherichia coli TOP10 hourbouring recombinant plasmid VIM-19 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID428272Antimicrobial activity against carbapenemase producing Enterobacter sp. by CLSI broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID535164Antimicrobial activity against imipenem non-susceptible Acinetobacter by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID574512Antimicrobial activity against Bacteroides vulgatus assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID522650Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis K7978 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID509870Antibacterial activity against Acinetobacter baumannii isolate 5191 isolated from human urine2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID499073Antimicrobial activity against carbapenem-resistant Enterobacter cloacae SZ93 deficient in ompC by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID559091Antimicrobial activity against bla OXA-66 gene-deficient Acinetobacter baumannii isolate A2 by Etest method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vivo selection of reduced susceptibility to carbapenems in Acinetobacter baumannii related to ISAba1-mediated overexpression of the natural bla(OXA-66) oxacillinase gene.
AID558624Antimicrobial activity against Streptococcus pneumoniae isolate 3455 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID396031Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pACYC184 plasmid by Etest2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID574464Antimicrobial activity against Escherichia coli isolate 339T expressing beta-lactamase KPC2 and PFGE cluster 5 isolated from peritoneal fluid of patient by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID529657Activity of Pseudomonas aeruginosa 166301 beta-lactamase VIM-162008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID1759642Antimicrobial activity against vancomycin-resistant Enterococcus faecium clinical isolate 1091720 by CLSI-based broth microdilution assay2021European journal of medicinal chemistry, Jul-05, Volume: 2194-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.
AID428274Antimicrobial activity against carbapenemase producing Enterobacter sp. assessed as resistant isolates by CLSI breakpoint assay2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID324854Antimicrobial activity against Acinetobacter baumannii A24 by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID533401Antimicrobial activity against Clostridium subterminale by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID1721002Synergistic Inhibition of beta lactamase VIM-29 in Escherichia coli 50639799 assessed colony formation by visual inspection in presence of 125 microM N-((4-((cyclohexylamino)methyl)-1H-1,2,3-triazol-5-yl)methyl)-4-iodobenzenesulfonamide incubated for 20 h2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Structural studies of triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-β-lactamases.
AID390331Antimicrobial activity against quinolone-resistant Streptococcus pneumoniae 3762008Journal of natural products, Dec, Volume: 71, Issue:12
Citreamicins with potent gram-positive activity.
AID576331Antibacterial activity against plasmid-mediated AmpC beta-Lactamase DHA-1 and ESBL-producing Klebsiella pneumoniae by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Microbiologic and clinical implications of bacteremia due to extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC beta-lactamase DHA-1.
AID495718Activity of Escherichia coli CTX-M-15 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID534396Ratio of Kcat to Km for Escherichia coli JM109 harboring recombinant pKHM-1 Beta-lactamase KHM-1 assessed as compound hydrolysis by UV-visible spectrophotometry2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID583094Activity of Escherichia coli XL1-Blue wild-type VIM-2 beta-lactamase by spectrophotometer2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID531580Antibacterial activity against Citrobacter braakii obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID1757591Antibacterial activity against ESBLs negative Carbapenem-sensitive Escherichia coli 17-9 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID535838Antimicrobial activity against wild-type Pseudomonas aeruginosa GP20 after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID520719Antibacterial activity against Escherichia coli DH10B2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID564463Antimicrobial activity against Pseudomonas aeruginosa isolate 927 by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID583088Ratio of Kcat to Km for Escherichia coli XL1-Blue wild-type IMP-1 beta-lactamase by spectrophotometer2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID1680064Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 2 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID535367Antimicrobial activity against Pseudomonas aeruginosa isolated from non-ICU patient by broth microdilution method in presence of Tazobactam2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID373752Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab3 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID533863Antibacterial activity against toxin-positive Clostridium difficile clinical isolate by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.
AID1311366Antibacterial activity against methicillin-sensitive Mycobacterium tuberculosis H37Rv measured after 14 days by broth microdilution assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.
AID295799Antibacterial activity against Staphylococcus aureus 209P after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID433016Antibacterial activity against Streptococcus pyogenes isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID587612Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID323611Ratio of fCmin to MIC in patient with lower respiratory tract infection2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.
AID535061Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pYMAb3 plasmid by agar dilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
AID535663Antimicrobial activity against aac(6')-Ib-cr-positive Enterobacter cloacae FJ63T harboring qnrS gene by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID535141Antimicrobial activity against imipenem susceptible Pseudomonas aeruginosa assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID535833Antimicrobial activity against Pseudomonas aeruginosa GP62KT41 harboring oprD gene after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID565512Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-30 harboring A residue at 105 position in PDC- 8 by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID373760Antibacterial activity against imipenem-intermediate Acinetobacter baumannii ab1297 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID521344Antimicrobial activity against Streptococcus pneumoniae ATCC BAA-3432008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID535651Antimicrobial activity against aac(6')-Ib-cr-positive Escherichia coli FJ3T harboring wild-type GyrA, ParC, GyrB and qnrB genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1373326Antimicrobial activity against ESBL, KPC and MBL producing Enterobacteriaceae by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID523913Antibacterial activity against Acinetobacter baumannii A928 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID555451Antibacterial activity against Acinetobacter genomosp. 3 isolate 109 by Etest method in presence of cloxacillin and efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID564943Antimicrobial activity against Acinetobacter baumannii isolate Ab11 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba92009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID586085Antimicrobial activity against verocytotoxin-producing Escherichia coli isolate O157 obtained from human assessed as percentage of resistant isolates by disk diffusion method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26.
AID522011Antimicrobial activity against Klebsiella pneumoniae isolate KpE expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID523944Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E459 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1533868Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 1717 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID534482Antimicrobial activity against Stenotrophomonas maltophilia KJG harboring ampG with xylE-Gmomega cassette insertion by Etest2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID423492Antibacterial activity against Acinetobacter baumannii isolate 891 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID401683Antibacterial activity against Streptococcus pyogenes 308A2005Journal of natural products, May, Volume: 68, Issue:5
Cytotoxic bisindole alkaloids from a marine sponge Spongosorites sp.
AID495695Activity of Klebsiella pneumoniae KPC-22010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID567471Antimicrobial activity against gLow-BLNAR Haemophilus influenzae by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID405818Antimicrobial activity against Acinetobacter sp. 5248 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-32007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID529847Binding affinity to PBP2a in methicillin-resistant Staphylococcus aureus 12386-1 by [14C]benzylpenicillin labelled competitive assay2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID574977Antimicrobial activity against Actinomyces meyeri assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID523750Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E3592010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID564222Antimicrobial activity against Escherichia coli TOP10 harboring plasmid PH1 by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
AID70910In vitro antibacterial activity against Escherichia coli 0782001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.
AID561386Antibacterial activity against Escherichia coli isolate ARL04-413 harboring beta-lactamase CMY 2 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
CMY-29 and CMY-30, two novel plasmid-mediated AmpC beta-lactamases.
AID523591Antibacterial activity against Pseudomonas aeruginosa P319 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID531317Activity of Escherichia coli beta-lactamase VIM-1 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID548036Antimicrobial activity against Escherichia coli DH10B by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID521489Antibacterial activity against Escherichia coli DH10B expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID528850Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID285978Antimicrobial activity against ESBL producing Escherichia coli 322 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID519804Inhibition of Bocillin FL binding to PBP1A in Pseudomonas aeruginosa PAO1 membranes2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID547785Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237L mutant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID425096Antimicrobial activity against Micromonas micros isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID496471Antibacterial activity against Klebsiella pneumoniae isolate 377 in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID533397Antimicrobial activity against Clostridium paraputrificum by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID509868Antibacterial activity against Acinetobacter baumannii isolate 2898 isolated from human ankle2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID524110Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A9082010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529855Antibacterial activity against Pseudomonas aeruginosa COR6 expressing MexC-MexD-OprJ gene by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID323605Antimicrobial activity against Pseudomonas aeruginosa2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.
AID498813Antimicrobial activity against Escherichia coli ZJ87T expressing KPC-2 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID511144Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 182010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID534889Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID534924Antimicrobial activity against Ceftazidime susceptible Serratia marcescens assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID574993Antimicrobial activity against Bifidobacterium sp. after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID583087Ratio of Kcat to Km for Escherichia coli XL1-Blue VIM-2 A64W mutant beta-lactamase by spectrophotometer2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID545404Antimicrobial activity against Pseudomonas aeruginosa PS11A with PFGE phenotype 7A obtained from sputum of ICU patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID584722Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3262 harboring fklB mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID555261Antibacterial activity against Acinetobacter genomosp. 3 isolate 103 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID528740Antimicrobial activity against penicillin-resistant Streptococcus agalactiae ATCC BAA-611 harboring PBP-2X Q557E mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID528826Antimicrobial activity against ESBL producing Klebsiella pneumoniae isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID529497Antimicrobial activity against Escherichia coli T-625 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID544490Antibacterial activity against Pseudomonas aeruginosa PR280 harboring beta-lactamase KPC-5 by agar dilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID433008Antibacterial activity against Corynebacterium xerosis isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID374368Ratio of Kcat to Km of Acinetobacter baumannii AC-54/97 metallo-beta-lactamase IMP-2 expressed in Escherichia coli DH5alpha2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID558582Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID69786Antibacterial activity against Escherichia coli 0782003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.
AID209565Antibacterial activity against Streptococcus faecium MD 8b1998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID532903Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 531 ST 376 expressing beta-lactamase SHV-1 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID534835Total clearance in critically ill patient with sepsis at 1000 mg/kg, iv administered every 8 hrs by HPLC method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
AID1879035Antibacterial activity against NDM-1 positive MCR1 carrying Escherichia coli ZJ487 isolates assessed as inhibition of bacterial growth incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1757573Antibacterial activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-20 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID201537Antibacterial activity against Salmonella Typhimurium1998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID433166Antibacterial activity against Anaerococcus tetradius isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523508Antimicrobial activity against Pseudomonas aeruginosa isolate 1726 from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID286022Antimicrobial activity against ESBL producing Klebsiella pneumoniae 230 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID285525Antibacterial activity against Neisseria meningitidis after 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID423338Antibacterial activity against Acinetobacter baumannii isolate 885 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID535660Antimicrobial activity against aac(6')-Ib-cr-positive Enterobacter cloacae FJ63 harboring GyrA S83I, GyrA D87A, ParC S80I mutant, wild-type GyrB and qnrS genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID535845Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTL1 harboring oprD, mexAB-oprM gene after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID565213Activity of VIM-1 in Klebsiella pneumoniae isolate A-17972009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID545332Antibacterial activity against Escherichia coli NIHJ by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID1373311Antimicrobial activity against Escherichia coli expressing beta-lactamase DHA by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID206733In vitro antibacterial activity against Staphylococcus aureus 5032000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Synthesis and antibacterial activity of new carbapenems containing isoxazole moiety.
AID323861Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 25923 after phagocytosis by human THP1 macrophages assessed as reduction in bacterial count at pH 7.4 after 24 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Role of acidic pH in the susceptibility of intraphagocytic methicillin-resistant Staphylococcus aureus strains to meropenem and cloxacillin.
AID519815Inhibition of Bocillin FL binding to PBP4 in Pseudomonas aeruginosa 27853 membranes2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID495738Kcat/Km ratio of Enterobacter cloacae AmpC relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID516146Antibacterial activity against Pulsotype J Acinetobacter genomosp. 3 isolate 15 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID529841Antibacterial activity against Pseudomonas aeruginosa clinical isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID528527Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B8 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID530324Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring pUCP carrying VIM-13 gene by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID545562Ratio of MIC for Escherichia coli EIR4a to MIC for Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID761214Antibacterial activity against Acinetobacter baumannii AB-3167 by broth microdilution method2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Pyridone-conjugated monobactam antibiotics with gram-negative activity.
AID545555Antibacterial activity against Escherichia coli ERR8a selected at 8 times MIC of tomopenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID390337Antimicrobial activity against Klebsiella pneumoniae 22392008Journal of natural products, Dec, Volume: 71, Issue:12
Citreamicins with potent gram-positive activity.
AID1533862Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 3267 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID531782Antibacterial activity against Pseudomonas fluorescens obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID534702Antimicrobial activity against Desulfovibrio desulfuricans by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID496496fT>MIC in Klebsiella pneumoniae isolate 368 at 2 gram for every 8 hrs administered as 3 hrs infusion over 24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID565722Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-27 harboring A residue at 105 position in PDC- 7 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID295817Antibacterial activity against Salmonella paratyphi A after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID1680039Antibacterial activity against NDM1 producing carbapenem-resistant Enterobacteriaceae clinical isolate 7 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID529661Activity of Pseudomonas aeruginosa 9551 beta-lactamase VIM-15 relative to cephaloridine2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID558536Antibacterial activity against bla gene-negative and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P854 by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID529653Antimicrobial activity against Escherichia coli DH5alpha by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID522028Antimicrobial activity against Escherichia coli isolate TOP10 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID1407938Antibacterial activity against Pseudomonas aeruginosa ARC3502 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID433363Antibacterial activity against Clostridium malenominatum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID1373297Antimicrobial activity against Escherichia coli expressing beta-lactamase VEB-7 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID394675Antibacterial activity against Pseudomonas aeruginosa blood isolate 1 carrying insertion sequence ISPa26 by disk susceptibility test2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.
AID518222Antimicrobial activity against Enterobacter cloacae S4741B by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID565223Activity of VIM-1 in Klebsiella pneumoniae isolate A-1760 assessed as compound hydrolysis in presence of EDTA2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID564456Antimicrobial activity against Pseudomonas aeruginosa isolate 22 by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID12151Area under curve of compound after iv administration of 20 mg/kg dose in rat2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.
AID522027Antimicrobial activity against Escherichia coli isolate J53 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID200849Antibacterial activity against Salmonella Typhimurium2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID495670Antimicrobial activity against Escherichia coli DH5-alpha expressing beta-lactamase TEM-1 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1706880Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS4 measured after 16 to 18 hrs2021European journal of medicinal chemistry, Feb-15, Volume: 212Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.
AID523741Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E4302010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1533851Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 231 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID1373298Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID425077Antimicrobial activity against beta lactamase-positive Bacteroides ovatus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID532418Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C3 isolate PG-12X-03 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID562738Antimicrobial activity against Escherichia coli K-12 by agar dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID535882Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae JN132T harboring qnrB gene by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID524120Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A9032010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID549334Antimicrobial activity against Escherichia coli isolate 100 harboring bla CTX-M-3a gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID523900Antibacterial activity against Acinetobacter baumannii A848 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1546207AUC in rat2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID1762803Antibacterial activity against Escherichia coli 01 assessed as reduction in bacterial growth incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID523755Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E4182010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID547996Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237C mutant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID576955Antimicrobial activity against Shewanella algae Sa9 harboring intI1, intI2, sul1 and sul2 genes by CLSI method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Reservoir of antimicrobial resistance determinants associated with horizontal gene transfer in clinical isolates of the genus Shewanella.
AID373037Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate DL34 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID519799Inhibition of Bocillin FL binding to PBP3 in Escherichia coli MC4100 membranes2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID523767Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E4172010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573601Antibacterial activity against Fusobacterium necrophorum assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID396026Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump by Etest2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID520968Antibacterial activity against Escherichia coli harboring pRYC plasmid expressing blaKPC gene by Etest method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID373036Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate BJ52 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID524301Antibacterial activity against Pseudomonas aeruginosa P353 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID165195In vitro antibacterial activity against Pseudomonas aeruginosa 1592E2000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Synthesis and antibacterial activity of new carbapenems containing isoxazole moiety.
AID1873895Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs using 10^4 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID511142Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 162010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID532912Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 557 transformant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID433154Antibacterial activity against Porphyromonas asaccharolyticus isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID524825Antibacterial activity against erythromycin susceptible Campylobacter sp. by agar plate dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID575683Antimicrobial activity against Acinetobacter baylyi ADP1 by microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
OXA-24 carbapenemase gene flanked by XerC/XerD-like recombination sites in different plasmids from different Acinetobacter species isolated during a nosocomial outbreak.
AID545331Antibacterial activity against Staphylococcus aureus ATCC 6538P by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID535858Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae GZ40T harboring qnrB gene by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID423503Antibacterial activity against Acinetobacter baumannii isolate 902 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID584839Antimicrobial activity against Escherichia coli DH10B by agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID576290Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 6267 harboring porin OmpK36V mutant gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID433167Antibacterial activity against Finegoldia magna isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID546416Antimicrobial activity against Pseudomonas aeruginosa KG2505a harboring recombinant pBB-PDC-1b by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID565541Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-05 harboring A residue at 105 position in PDC- 2 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID535694Antimicrobial activity against Azide-resistant Escherichia coli J53 transconjugant harboring Escherichia coli DH5alpha-5825 qnrB2 gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
AID586233Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 6 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID573796Antibacterial activity against Prevotella bivia assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID283217Antimicrobial activity against Burkholderia cepacia complex isolated from cystic fibrosis patient by broth microdilution assay2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
AID495668Antimicrobial activity against Escherichia coli OC 6697 expressing beta-lactamase CMY-2 and containing plasmid AmpC assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID545333Antibacterial activity against Pseudomonas aeruginosa ATCC 15692 by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID1757550Antibacterial activity against Carbapenem- resistant Pseudomonas aeruginosa 17-1 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID524297Antibacterial activity against Pseudomonas aeruginosa P337 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1320841Binding affinity to native signal deficient and TEV cleavage site containing His-tagged Klebsiella pneumoniae OXA-48 expressed in Escherichia coli assessed as dissociation rate constant by SPR assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.
AID561456Antibacterial activity against Enterobacter cloacae assessed as susceptible isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID534457Antimicrobial activity against Lactobacillus plantarum JCM 1149 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID433009Antibacterial activity against methicillin-resistant Staphylococcus aureus isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID558590Antimicrobial activity against Streptococcus pneumoniae 2 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID1757574Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-2 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID545557Antibacterial activity against Escherichia coli EIR2a selected at 2 times MIC of imipenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID558581Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID576956Antimicrobial activity against Shewanella algae Sa78 harboring sul2 gene by CLSI method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Reservoir of antimicrobial resistance determinants associated with horizontal gene transfer in clinical isolates of the genus Shewanella.
AID584706Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0420 harboring bioA mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID534865Antimicrobial activity against Non-ESBL Proteus mirabilis assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID534436Antimicrobial activity against Streptococcus constellatus ATCC 27923 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID528536Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B514 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID555247Antibacterial activity against Acinetobacter genomosp. 3 isolate 60 by Etest method in presence of efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID1757559Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-7 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID498836Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU5 deficient in SHV-12, DHA-1, aac(6')-Ib-cr, ompK35/36 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID372549Antibacterial activity against genetically beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b with an amino acid substitution in highly mutated locus Ser-385 of ftsI gene by broth microdilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.
AID11732Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4)1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID523588Antibacterial activity against Pseudomonas aeruginosa P369 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285596Antimicrobial activity against Pseudomonas aeruginosa 1C9 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID656347Antimicrobial activity against Serratia marcescens2011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID558626Antimicrobial activity against Streptococcus pneumoniae isolate 3481 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID1765579Antibacterial activity against Klebsiella pneumoniae ATCC 700603 incubated for 18 hrs by CLSI based broth dilution method2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Novel Broad-Spectrum Antimicrobial Peptide Derived from Anoplin and Its Activity on Bacterial Pneumonia in Mice.
AID561269Antibacterial activity against Escherichia coli by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID562737Antimicrobial activity against Escherichia coli K-12 transconjugant harboring blaCTX-M-71 gene by agar dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID1373323Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-181 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID496513fT>MIC in Klebsiella pneumoniae isolate 368 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 0-8 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID1906416Antibacterial activity against carbapenem and NDM-1 positive resistant Escherichia coli ATCC BAA 2452 assessed as reduction in microbial growth incubated for 24 hrs by microbroth dilution method2022European journal of medicinal chemistry, May-05, Volume: 235Amphiphilic cyclic peptide [W
AID495684Antimicrobial activity against wild type Acinetobacter baumannii OC 16708 deficient in beta-lactamase assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID499148Tmax in immunocompromized SKH1 mouse plasma at 50 mg/kg, sc2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID285591Antimicrobial activity against Pseudomonas aeruginosa 65.38-2 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID289872Antibacterial activity against Streptococcus pyogenes 308A2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID495723Activity of Enterobacter cloacae AmpC relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID574987Antimicrobial activity against Bifidobacterium adolescentis after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID534695Antimicrobial activity against Porphyromonas gingivalis by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID544491Antibacterial activity against Escherichia coli TOP10 by agar dilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID1721003Synergistic Inhibition of beta lactamase NDM1 in Klebsiella pneumoniae K66-45 assessed colony formation by visual inspection in presence of 125 microM N-((4-((cyclohexylamino)methyl)-1H-1,2,3-triazol-5-yl)methyl)-4-iodobenzenesulfonamide incubated for 20 2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Structural studies of triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-β-lactamases.
AID561277Antibacterial activity against Klebsiella pneumoniae by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID558319Antibacterial activity against Campylobacter coli by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID519805Inhibition of Bocillin FL binding to PBP1B in Pseudomonas aeruginosa PAO1 membranes2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID535163Antimicrobial activity against imipenem susceptible Acinetobacter by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID495682Antimicrobial activity against Pseudomonas aeruginosa OC 12115 expressing beta-lactamase SPM-1 and containing Carbapenemase assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID496485Antibacterial activity against Pseudomonas aeruginosa isolate 762 in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID529863Ratio of MIC for Pseudomonas aeruginosa N041 to MIC for Pseudomonas aeruginosa PAO12008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID584317Antimicrobial activity against azide-resistant Escherichia coli J53 by agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID1554005Antibacterial activity against Escherichia coli clinical isolates measured after 16 to 20 hrs by broth microdilution method2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Structural Basis for E. coli Penicillin Binding Protein (PBP) 2 Inhibition, a Platform for Drug Design.
AID295818Antibacterial activity against Salmonella Typhimurium after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID555456Antibacterial activity against Acinetobacter genomosp. 3 isolate 56 by Etest method in presence of cloxacillin and efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID576522Antimicrobial activity against Carbapenem-resistant Klebsiella pneumoniae isolate AIS080884 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID532417Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-12 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID1757609Antibacterial activity against Enterobacter aerogenes 17-5 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID560069Antimicrobial activity against Klebsiella pneumoniae isolate 5427 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID495716Activity of Escherichia coli TEM-1 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID561932Antibacterial activity against blaOXA-24-positive Acinetobacter baumannii isolate N50 by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii.
AID534462Antimicrobial activity against Bacteroides fragilis NCTC 10581 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID495699Activity of Pseudomonas aeruginosa SPM-12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID496507fT>MIC in Klebsiella pneumoniae isolate 351 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 0-8 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID322314Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID562759Antimicrobial activity against Klebsiella pneumoniae PFGE clone B expressing beta-lactamase KPC-2 by Etest2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID524283Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E457 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID532405Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone G isolate NA-14X-13 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID433177Antibacterial activity against Proteus mirabilis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID564455Antimicrobial activity against Pseudomonas aeruginosa isolate 1095 by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID533413Antimicrobial activity against Peptoniphilus asaccharolyticus by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID433003Antibacterial activity against Corynebacterium minutissimum isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID528916Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-14 and CTX-M-27 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID555215Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 14 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID574472Antimicrobial activity against Escherichia coli isolate 544 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from abscess of patient by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID571904Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 16 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID573822Antibacterial activity against beta-lactamase producing Clostridium perfringens by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID425079Antimicrobial activity against beta lactamase-positive Bacteroides distasonis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID495837Antimicrobial activity against Escherichia coli harbouring plasmidBK-CMV expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID529865Ratio of MIC for Pseudomonas aeruginosa N092 to MIC for Pseudomonas aeruginosa PAO12008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID528524Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B1 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID584697Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5002 harboring mutation in hypothetical protein by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1873940Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs in presence of 5% foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID524593Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolate Kpn-DK2 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.
AID534468Antimicrobial activity against Bacteroides vulgatus GAI 0673 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID1679970Growth inhibition of Escherichia coli TG1 transformed with IncX3 plasmid expressing blaNDM-1 incubated for overnight by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID585401Activity at Chryseobacterium meningosepticum NCTC 10585 metallo-beta-lactamase GOB-12010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID573592Antibacterial activity against Fusobacterium mortiferum by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID495732Kcat/Km ratio of Klebsiella pneumoniae SHV-1 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID528847Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID286025Antimicrobial activity against ESBL producing Klebsiella pneumoniae 268 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID529487Antimicrobial activity against Enterobacter cloacae isolate 622 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID524114Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A9292010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID495693Activity of Enterobacter cloacae AmpC2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID561931Antibacterial activity against blaOXA-24-positive Acinetobacter baumannii isolate VA-566/00 by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii.
AID565225Activity of KPC-2 in Klebsiella pneumoniae isolate H-1406 assessed as compound hydrolysis in presence of EDTA2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID555447Antibacterial activity against Acinetobacter genomosp. 3 isolate 243 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID523733Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E4152010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID521350Antimicrobial activity against Streptococcus pneumoniae isolate 40 obtained from blood of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID432993Antibacterial activity against Enterobacter cloacae isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523592Antibacterial activity against Pseudomonas aeruginosa P320 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID394676Antibacterial activity against Pseudomonas aeruginosa pus isolate 6 carrying insertion sequence ISPa26 by disk susceptibility test2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.
AID529495Antimicrobial activity against Enterobacter cloacae isolate 4469 containing PFGE genetic clone C expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID295811Antibacterial activity against Escherichia coli 086 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID496500fT>MIC in Pseudomonas aeruginosa isolate 1038 at 2 gram for every 8 hrs administered as 3 hrs infusion over 24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID433152Antibacterial activity against Parabacteroides distasonis isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID558537Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter coli isolate P321 by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID588078Ratio of MIC for Acinetobacter baumannii ATCC 17978 harboring plasmid pWHP825 to MIC for Acinetobacter baumannii ATCC 17978 harboring plasmid 12662011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
ISAba825, a functional insertion sequence modulating genomic plasticity and bla(OXA-58) expression in Acinetobacter baumannii.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID405817Antimicrobial activity against Pseudomonas putida 12346 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-32007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID529195Antibacterial activity against ESBL-producing Escherichia coli assessed as sensitive isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
AID1407955Antibacterial activity against Pseudomonas aeruginosa ARC4060 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID678448Antibacterial activity against penicillin-resistant, quinolone-sensitive Pseudomonas aeruginosa 1091-052012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID518186Antimicrobial activity against Acinetobacter baumannii HPA 327009 harboring beta-lactamase OXA-25 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID562331Antimicrobial activity against Escherichia coli DH5alpha harboring metallo-beta-lactamase IND-6 after 18 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID530326Antimicrobial activity against Escherichia coli XL1-Blue harboring pUCP carrying VIM-1 gene by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID432992Antibacterial activity against Enterobacter aerogenes isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID423518Antibacterial activity against Acinetobacter baumannii isolate 917 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID524279Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E481 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID425330Bactericidal activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID533393Antimicrobial activity against Clostridium innocuum by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID373039Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZJ32 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID534412Antimicrobial activity against methicillin-resistant coagulase-negative Staphylococcus by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID535059Antimicrobial activity against Acinetobacter genomic species 13TU by agar dilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
AID1628583Antibacterial activity against Haemophilus influenzae H128 deficient in AcrA incubated for 18 to 24 hrs by broth microdilution method2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
Discovery and Characterization of a Class of Pyrazole Inhibitors of Bacterial Undecaprenyl Pyrophosphate Synthase.
AID279562Antimicrobial activity against Haemophilus influenzae BLPAR strains2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.
AID1443405Antibacterial activity against Escherichia coli isolate 210737 after 18 hrs by broth microdilution method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections.
AID433153Antibacterial activity against Parabacteroides merdae isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID496489fT>MIC in Klebsiella pneumoniae isolate 328A at 2 gram for every 8 hrs administered as 3 hrs infusion over 24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID433010Antibacterial activity against methicillin-sensitive Staphylococcus aureus isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523937Antibacterial activity against beta-lactamase-negative Escherichia coli E424 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID562740Antimicrobial activity against Escherichia coli DH5[alpha] harboring pBC-CTX-M-15 plasmid by agar dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID1706879Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS1 measured after 16 to 18 hrs2021European journal of medicinal chemistry, Feb-15, Volume: 212Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.
AID521352Antimicrobial activity against Streptococcus pneumoniae ATCC BAA-6122008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID565540Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-04 harboring A residue at 105 position in PDC- 2 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID511156Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 12 assessed as zone of inhibition by disk diffusion assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID523566Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E361 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1320835Activity of native signal containing Klebsiella pneumoniae OXA-48 by Michaelis-Menten kinetics assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.
AID523748Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E3572010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1056836Antibacterial activity against CTX-15 expressing Escherichia coli isolate 235 after 18 to 24 hrs by two-fold broth microdilution assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID1680040Antibacterial activity against NDM1 producing carbapenem-resistant Enterobacteriaceae clinical isolate 6 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID518817Antibacterial activity against Acinetobacter genomosp. 3 isolates assessed as percent of resistance isolates by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID1407961Antibacterial activity against Acinetobacter baumannii ARC2779 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID1759644Antimicrobial activity against vancomycin-resistant Enterococcus faecium clinical isolate 1100440 by CLSI-based broth microdilution assay2021European journal of medicinal chemistry, Jul-05, Volume: 2194-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.
AID656361Antimicrobial activity against Acinetobacter sp.2011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID534487Antimicrobial activity against Stenotrophomonas maltophilia KJN2 harboring pRK415 plasmid and ampN with xylE-Gmomega cassette insertion by Etest2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID558323Antibacterial activity against Campylobacter jejuni isolate P270 harboring blaOXA-61::cat gene by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID285991Antimicrobial activity against ESBL producing Klebsiella pneumoniae 265 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID323604Antimicrobial activity against Escherichia coli2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.
AID423236Antibacterial activity against Haemophilus influenzae ATCC 49247 isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID571908Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 18 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID529845Antibacterial activity against methicillin-resistant Staphylococcus aureus 12386-1 expressing PBP 2a by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID498825Antimicrobial activity against Citrobacter freundii SZ62T expressing IMP-4, qnrS1by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID499064Antimicrobial activity against carbapenem-resistant Enterobacter cloacae GX56 deficient in ompC and expressing low levels of ompF DE by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID518199Antimicrobial activity against Pseudomonas aeruginosa BA(C2-107) selected after 25 ug/ml of compound exposure by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID523715Antibacterial activity against Acinetobacter baumannii A897 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534431Antimicrobial activity against Peptoniphilus asaccharolyticus WAL 3218 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID1533850Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 254 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID563601Antimicrobial activity against Escherichia coli isolate CKP048 transconjugant harboring beta-lactamase KPC-2, DHA-1, qnrB4 and armA by Etest2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA.
AID571211Antibacterial activity against Acinetobacter baumannii F264 by Etest method in presence of NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID575684Antimicrobial activity against Acinetobacter baylyi ADP1 harboring pMMCU1 plasmid expressing bla-OXA-24 gene by microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
OXA-24 carbapenemase gene flanked by XerC/XerD-like recombination sites in different plasmids from different Acinetobacter species isolated during a nosocomial outbreak.
AID1905564Antimicrobial activity against Enterococcus faecalis ATCC 29212 assessed as reduction of bacterial growth incubated for 18 hrs by CLSI protocol based broth microdilution method2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Novel β-Hairpin Antimicrobial Peptides Containing the β-Turn Sequence of -RRRF- Having High Cell Selectivity and Low Incidence of Drug Resistance.
AID289908Antibacterial activity against Serratia marcescens 3702007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID433006Antibacterial activity against Corynebacterium accolens isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID576062Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 71697 harboring porin OmpK36V mutant gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID521842Antibacterial activity against Escherichia coli J53 by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID524407Antibacterial activity against extended spectrum beta-lactamase-producing Enterobacteriaceae clinical isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID546620Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-2 by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID573394Antibacterial activity against Bacteroides fragilis by by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID423334Antibacterial activity against Pseudomonas aeruginosa isolate 379 expressing VIM2 beta-lactamase after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID531771Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4658 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID511680Antimicrobial activity against Pseudomonas aeruginosa clinical isolate assessed as resistant isolates selected in vitro after antipseudomonal treatment of intensive care unit patient by by CLSI method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID1759647Antimicrobial activity against vancomycin-resistant Enterococcus faecium clinical isolate 1088925 by CLSI-based broth microdilution assay2021European journal of medicinal chemistry, Jul-05, Volume: 2194-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.
AID498816Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae FZ49 deficient in IMP-8, TEM-1, SHV-11, CTX-M-14, qnrB2, aac(6')-Ib, ompK35/36 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID530339Activity of Pseudomonas aeruginosa VIM-13 beta-lactamase2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID374023Activity of Enterobacter cloacae IMI1 beta lactamase expressed in Escherichia coli DH5alpha by SDS-PAGE2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID573801Antibacterial activity against Prevotella intermedia assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID295803Antibacterial activity against Streptococcus agalactiae B after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID555260Antibacterial activity against Acinetobacter genomosp. 3 isolate 90 by Etest method in presence of efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID565214Activity of VIM-1 in Klebsiella pneumoniae isolate T-17802009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID572142Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 38 expressing ampC, ompA, adeB, adeM by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID534410Antimicrobial activity against methicillin-susceptible Staphylococcus aureus assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID576065Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 69928 harboring porin OmpK36V mutant gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID547765Antimicrobial activity against Escherichia coli DH10B harboring plasmid pBR322-catI carrying beta-lactamase KPC-2 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID571698Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 6 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1443399Antibacterial activity against extended spectrum beta-lactamase IMP-4 producing multidrug resistant Pseudomonas aeruginosa clinical isolates after 18 hrs by broth microdilution method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections.
AID1757530Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-2 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID764530Chemical stability of the compound in simulated gastric fluid assessed as drug degradation at 10 uM after 30 mins at pH 1.22013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Synthesis, pH-dependent, and plasma stability of meropenem prodrugs for potential use against drug-resistant tuberculosis.
AID518193Antimicrobial activity against mexAB-oprM protein and mexCD-oprJ deficient Pseudomonas aeruginosa PAO253 overexpressing MexEF-OprN gene by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID1691835Antibacterial activity against Pseudomonas aeruginosa PAO1 infected in Caenorhabditis elegans N2 strain assessed as increase in Caenorhabditis elegans survival rate at 0.25 ug/ml up to 240 hrs relative to control2020European journal of medicinal chemistry, May-15, Volume: 194Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1.
AID323609ft>MIC in patient with lower respiratory tract infection2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.
AID562220Antimicrobial activity against Desulfovibrio sp. by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Susceptibilities of 23 Desulfovibrio isolates from humans.
AID534449Antimicrobial activity against Bifidobacterium pseudolongum ATCC 25526 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID565504Antimicrobial activity against beta-lactamase negative ampicillin-resistant -Haemophilus influenzae by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re
AID520327Antimicrobial activity against Acinetobacter baumannii isolates by agar dilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Outbreak of Acinetobacter baumannii with chromosomally encoded VIM-1 undetectable by imipenem-EDTA synergy tests.
AID390324Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 292132008Journal of natural products, Dec, Volume: 71, Issue:12
Citreamicins with potent gram-positive activity.
AID523930Antibacterial activity against beta-lactamase-negative Escherichia coli E350 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID555449Antibacterial activity against Acinetobacter genomosp. 3 isolate 243 by Etest method in presence of efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID574965Antimicrobial activity against Actinomyces odontolyticus assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1757603Antibacterial activity against Enterobacter cloacae 17-9 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID25394Half life was calculated.1998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID433368Antibacterial activity against Finegoldia magna isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID564021Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring cloned pUCPOXA-2 by Etest2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID1311363Antibacterial activity against Pseudomonas aeruginosa PA14 measured after 18 hrs by broth microdilution assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.
AID286003Antimicrobial activity against ESBL producing Klebsiella pneumoniae 258 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID295796Antibacterial activity against Acinetobacter baumannii 2289 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID496498fT>MIC in Klebsiella pneumoniae isolate 361 at 2 gram for every 8 hrs administered as 3 hrs infusion over 24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID521486Antibacterial activity against Escherichia coli harboring pBC2303 expressing blaKPC gene plasmid by Etest method in presence of beta-lactamase inhibitor clavulanic acid2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID356631Antibacterial activity against methicillin-resistant Staphylococcus aureus KIST2 after 18 hrs2003Journal of natural products, Nov, Volume: 66, Issue:11
New bromotyrosine derivatives from an association of two sponges, Jaspis wondoensis and Poecillastra wondoensis.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID7656Half-life at a single subcutaneous administration of 40 mg/kg in mice2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Synthesis and antibacterial activity of 2alpha-functionalized 1beta-methylcarbapenems related to KR-21012.
AID405823Antimicrobial activity against Acinetobacter baumannii 9043 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-32007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID1706874Antibacterial activity against methicillin-resistant Staphylococcus aureus NR10192 measured after 16 to 18 hrs2021European journal of medicinal chemistry, Feb-15, Volume: 212Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.
AID369633Antimicrobial activity against beta-lactamase positive amoxicillin/clavulanate-resistant Haemophilus influenzae by E-test2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
AID1680056Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 9 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID1757562Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-10 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1883781Antibacterial activity against Mycobacterium tuberculosis H37Rv in acute Mtb infection BALB/c mouse model assessed as reduction in log10 CFU at 400 mg/kg, sc for 3 weeks in presence of Sodium clavulanate2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Tuberculosis Drug Discovery: Challenges and New Horizons.
AID495900Activity of Pseudomonas aeruginosa VIM-2 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID545621Antimicrobial activity against Pseudomonas aeruginosa PS44 with PFGE phenotype 13 expressing beta-lactamase IMP-18 obtained from blood of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID518517Microbicidal activity against Pseudomonas aeruginosa (560546)9 M.P. selected after MIC of compound exposure2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID582970Antimicrobial activity against nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID496557Antibacterial activity against Klebsiella pneumoniae isolate 353 assessed as reduction of bacterial count at 16 ug/ml within 6 hrs in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID529651Antimicrobial activity against Escherichia coli DH5alpha harboring beta-lactamase VIM-2 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID433020Antibacterial activity against Bacteroides stercoris isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID499070Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae GZ84 deficient in SHV-11, aac(6')-Ib-cr, ompK35 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID545401Antimicrobial activity against Pseudomonas aeruginosa PS7A with PFGE phenotype 11D obtained from urine of ICU patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID576330Antibacterial activity against ESBL-producing Klebsiella pneumoniae by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Microbiologic and clinical implications of bacteremia due to extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC beta-lactamase DHA-1.
AID656351Antibacterial activity against Pseudomonas aeruginosa2011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID200857Compound was evaluated for its antibacterial activity against Salmonella Typhimurium2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID535891Antimicrobial activity against aac(6')-Ib-cr-negative Citrobacter freundii JN64 harboring GyrA T83I, wild-type ParC, GyrB and qnrA genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID571397Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID573557Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID323256Antimicrobial activity against carbapenem-intermediate or resistant Acinetobacter baumannii assessed as percent susceptible isolates2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
AID531969Antibacterial activity against Klebsiella pneumoniae blood isolate A28008 PFGE pattern A expressing KPC-2, TEM-1, SHV-11, CTX-M-2 beta-lactamase by agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID425332Bactericidal activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID1706872Antibacterial activity against methicillin-resistant Staphylococcus aureus NR10129 measured after 16 to 18 hrs2021European journal of medicinal chemistry, Feb-15, Volume: 212Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.
AID423292Antibacterial activity against Pseudomonas aeruginosa isolate 329 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID1357428Antibacterial activity against Escherichia coli isolate 210737 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria.
AID1757606Antibacterial activity against Enterobacter aerogenes 17-2 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID433000Antibacterial activity against Corynebacterium amycolatum isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID1762811Inhibition of Escherichia coli VIM-2 assessed as reduction in bacterial growth incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID534632Antimicrobial activity against ESBL producing Escherichia coli assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1395496Antibacterial activity against carbapenem-resistant Enterobacter aerogenes 11-4 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, Apr-25, Volume: 150Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID574758Antimicrobial activity against Peptoniphilus asaccharolyticus after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574969Antimicrobial activity against Actinomyces israelii after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID571912Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 20 expressing ampC, ompA, adeB, adeM, aacC2 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID584723Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3433 harboring mutation in putative transcriptional regulator, LysR family by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1873942Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs in presence of 25% foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID524082Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3372010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID522645Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis Texas by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID576960Antimicrobial activity against Shewanella algae Sa392 harboring intI1, intI2, sul1 and sul2 genes by CLSI method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Reservoir of antimicrobial resistance determinants associated with horizontal gene transfer in clinical isolates of the genus Shewanella.
AID68034Compound was evaluated for in vitro antibacterial activity against Enterobacter cloacae P99 strain by agar dilution method2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Synthesis and antibacterial activity of 2alpha-functionalized 1beta-methylcarbapenems related to KR-21012.
AID532190Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii TJ15 harboring GyrA T83I, ParC S80I mutant, wild-type GyrB, qnrB genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID535166Antimicrobial activity against Acinetobacter assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID545615Antimicrobial activity against Pseudomonas aeruginosa PS36 with PFGE phenotype 11B obtained from urine of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID433189Antibacterial activity against Corynebacterium xerosis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID425118Bactericidal activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID543411Antimicrobial activity against Shigella sonnei UIH-1 expressing beta-lactamase CTX-M-64 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID516145Antibacterial activity against Pulsotype I Acinetobacter genomosp. 3 isolate 11 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID533425Antimicrobial activity against Peptostreptococcus sp. by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID584524Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3589 harboring mutation in acetyl-coenzyme A (CoA) acetyltransferase (thiolase) by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1853604Antibacterial activity against Enterococcus faecalis clinical isolate 1091563 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution method2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
Design, synthesis, and antibacterial activity of
AID249360Minimum inhibitory concentration against Streptococcus pneumoniae (n=22); (Range = 0.008-0.5)2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID372332Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as reduction of bacterial count in in vitro PK/PD model at 1 g infused every 8 hrs interval measured after second dose relative to initial inoculum2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID558337Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1650 by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID523599Antibacterial activity against Pseudomonas aeruginosa P328 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID519802Inhibition of Bocillin FL binding to PBP6 in Escherichia coli MC4100 membranes2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID574518Antimicrobial activity against Prevotella intermedia after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID529853Antibacterial activity against beta-lactamase and MexA-MexB-OprM-overproducing Pseudomonas aeruginosa N045 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID588124Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 2 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID209457In vitro antibacterial activity against Streptococcus pyogenes 308A2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.
AID565710Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-15 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1233136Antibacterial activity against patient-derived methicillin-resistant Staphylococcus aureus B19506 after 18 to 20 hrs by microbroth dilution method2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors.
AID1373299Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-10 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID425317Bactericidal activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID534843AUC (0 to 8 hrs) in critically ill patient with sepsis receiving high-volume continuous venovenous hemofiltration at 1000 mg/kg, iv administered every 8 hrs by HPLC method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
AID499048Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae GZ83 deficient in SHV-11, CTX-M-14, ompK35/36 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID530340Activity of Pseudomonas aeruginosa VIM-1 beta-lactamase2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID322791Antimicrobial activity against Bacteroides merdae assessed as percent resistant isolates2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID588132Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 3 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID545396Antimicrobial activity against Pseudomonas aeruginosa PS2 with PFGE phenotype 10B obtained from urine of ICU patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID532187Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae SY26T harboring wild-type GyrA, ParC, GyrB and qnrB genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID373757Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab1308 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID432990Antibacterial activity against Escherichia coli isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID529575Activity of Erwinia carotovora subsp. atroseptica DSM 30184 beta-lactamase CAR-12008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID1533872Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 774 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID495726Activity of Serratia marcescens SME-3 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID523928Antibacterial activity against beta-lactamase-negative Escherichia coli E347 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID518203Microbicidal activity against Enterobacter cloacae S4741B selected after 4 times MIC compound exposure2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID574760Antimicrobial activity against Peptoniphilus asaccharolyticus assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID425104Antimicrobial activity against Clostridium ramosum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID499071Antimicrobial activity against Klebsiella pneumoniae WH97 expressing SHV-33, aac(6')-Ib, ompK35 DE by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID574764Antimicrobial activity against Finegoldia magna after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID534921Antimicrobial activity against Serratia marcescens assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID543419Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID372326Half life in in vitro PK/PD model at 1 g infused thrice daily at 8 hrs interval2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID495839Ratio of Kcat to Km for Escherichia coli BL21 DE3 beta-lactamase VIM-19 by microacidimetric method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID582969Antimicrobial activity against Pseudomonas aeruginosa PAO1 by Etest method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID518510Antimicrobial activity against Pseudomonas aeruginosa BA(C2-107) mutant assessed as doubling time2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID432996Antibacterial activity against Proteus mirabilis isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523549Antibacterial activity against beta-lactamase-negative Escherichia coli E425 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433182Antibacterial activity against Corynebacterium aurimucosum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID532408Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B2 isolate VA-06X-28 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID1318925Antibacterial activity against pandrug-resistant Pseudomonas aeruginosa isolate 1012432016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID561484Antibacterial activity against Pseudomonas aeruginosa assessed as resistant isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID562811Antimicrobial activity against Escherichia coli J53 harboring pEK204 plasmid encoding CTX-M extended-spectrum beta-lactamases2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID523501Antimicrobial activity against Pseudomonas aeruginosa isolate 1352c from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID524296Antibacterial activity against Pseudomonas aeruginosa P334 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433004Antibacterial activity against Corynebacterium urealyticum isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID524313Antibacterial activity against Acinetobacter baumannii A864 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID518518Microbicidal activity against Stenotrophomonas maltophilia 1AC736 selected after 2 times MIC compound exposure2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID496567Antibacterial activity against Pseudomonas aeruginosa isolate 1030 assessed as reduction of bacterial count at 8 ug/ml within 6 hrs in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID574032Antibacterial activity against beta-lactamase producing Micromonas micros by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID542584Antimicrobial activity against Acinetobacter radioresistens 251-39C expressing beta-lactamase OXA-133 by CLSI method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.
AID519140Antimicrobial activity against community-acquired methicillin resistant Staphylococcus aureus expressing PVL and mec type IV gene assessed as resistant strains by broth microdilution method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
AID520711Antibacterial activity against Escherichia coli TOP10 harboring pOXA-582008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID295794Antibacterial activity against Enterobacter cloacae 34 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID289879Antibacterial activity against Salmonella Typhimurium2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID558599Antimicrobial activity against Streptococcus pneumoniae 11 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID71105In vitro antibacterial activity against Escherichia coli 078 by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13
Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID573581Antibacterial activity against beta-lactamase producing Bacteroides caccae by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID423529Antibacterial activity against Acinetobacter baumannii isolate 928 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID584584Antimicrobial activity against Acinetobacter baumannii ATCC 19606 harboring beta-lactamase OXA-164 by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID529491Antimicrobial activity against Enterobacter cloacae isolate 649 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID521992Antimicrobial activity against Escherichia coli isolate J53 harboring pA-1 containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID571696Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 5 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1554006Antibacterial activity against Pseudomonas aeruginosa clinical isolates measured after 16 to 20 hrs by broth microdilution method2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Structural Basis for E. coli Penicillin Binding Protein (PBP) 2 Inhibition, a Platform for Drug Design.
AID564948Antimicrobial activity against Acinetobacter baumannii isolate Ab30 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba92009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID1225786Antibacterial activity against Klebsiella pneumoniae KP1008 expressing KPC2 by broth microdilution method2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID555478Antibacterial activity against Acinetobacter genomosp. 3 isolate 14 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID543415Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 transconjugant by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID528823Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID587730Activity of Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP-18 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID585197Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-13 K104, N170 mutant by Etest method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID562813Antimicrobial activity against Escherichia coli DH5[alpha] harboring pEK516 plasmid encoding CTX-M extended-spectrum beta-lactamases2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID532900Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 588 transformant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID554989Antibacterial activity against Acinetobacter genomosp. 3 isolate 60 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID1296369Inhibition of Mycobacterium tuberculosis LdtMt1 expressed in Escherichia coli assessed as efficiency of acylation reaction by measuring ratio of K2 to Kapp by stopped-flow spectrofluorimetric method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Routes of Synthesis of Carbapenems for Optimizing Both the Inactivation of L,D-Transpeptidase LdtMt1 of Mycobacterium tuberculosis and the Stability toward Hydrolysis by β-Lactamase BlaC.
AID565525Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-10 harboring A residue at 105 position in PDC- 2 by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID523910Antibacterial activity against Acinetobacter baumannii A910 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID561486Antibacterial activity against Stenotrophomonas maltophilia by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID285598Antimicrobial activity against Pseudomonas aeruginosa 2C1 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID520966Antibacterial activity against Klebsiella pneumoniae YC by Etest method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID356638Antibacterial activity against ofloxacin-resistant Staphylococcus epidermidis 291 after 18 hrs2003Journal of natural products, Nov, Volume: 66, Issue:11
New bromotyrosine derivatives from an association of two sponges, Jaspis wondoensis and Poecillastra wondoensis.
AID70116Compound was evaluated for its antibacterial activity against Escherichia coli CCARM 1116 MDR2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID496546fT>MIC in Klebsiella pneumoniae isolate 334 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 16-24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID165196In vitro antibacterial activity against Pseudomonas aeruginosa 1771M2000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Synthesis and antibacterial activity of new carbapenems containing isoxazole moiety.
AID237259Half life at a single intravenous administration of 5 mg/kg in dog2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID373755Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab12 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID433015Antibacterial activity against Streptococcus dysgalactiae subsp. equisimilis isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID545402Antimicrobial activity against Pseudomonas aeruginosa PS9 with PFGE phenotype 3B obtained from sputum of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID574524Antimicrobial activity against Prevotella oralis after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID584571Antimicrobial activity against Acinetobacter lwoffii isolate E expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1443410Antibacterial activity against extended spectrum beta-lactamases producing Escherichia coli clinical isolates after 18 hrs by broth microdilution method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections.
AID533365Antimicrobial activity against Bacteroides uniformis by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID534919Antimicrobial activity against Ceftazidime susceptible Serratia marcescens by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID555448Antibacterial activity against Acinetobacter genomosp. 3 isolate 243 by Etest method in presence of efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID534906Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID572122Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 28 expressing ampC, ompA, adeM, aadB, aadA1 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID523932Antibacterial activity against beta-lactamase-negative Escherichia coli E409 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574975Antimicrobial activity against Actinomyces meyeri after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID531773Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4688 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID588126Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 4 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID558535Antibacterial activity against bla gene-negative and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P843 by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID524118Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A8942010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1373306Antimicrobial activity against Escherichia coli expressing beta-lactamase NDM-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1442620Antibacterial activity against Pseudomonas aeruginosa PA694 in CD-1 mouse model of thigh infection assessed as reduction in log10CFU per gram of thigh at 15 mg/kg, iv bid administered 2 to 12 hrs of post-infection measured after 24 hrs relative to untreat2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID496487Antibacterial activity against Pseudomonas aeruginosa isolate 988 in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID518823Antibacterial activity against Pulsotype C Acinetobacter genomosp. 3 isolate 1 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID535127Antimicrobial activity against Ceftazidime susceptible Pseudomonas aeruginosa by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID535169Antimicrobial activity against imipenem susceptible Acinetobacter assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID495828Antimicrobial activity against Escherichia coli C600 2878 transconjugate expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID496506fT>MIC in Klebsiella pneumoniae isolate 328A at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 0-8 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID573563Antibacterial activity against beta-lactamase producing Bacteroides vulgatus by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID558630Antimicrobial activity against Streptococcus pneumoniae isolate 4747 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID1395494Antibacterial activity against new delhi metallo-beta-lactamase-1 harboring Acinetobacter calcoaceticus 13-1 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, Apr-25, Volume: 150Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID523571Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E509 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID423303Antibacterial activity against Pseudomonas aeruginosa isolate 344 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1559371Antibacterial activity against methicillin resistant Staphylococcus aureus 33591 after 16 to 20 hrs by CLSI-based microbroth dilution method2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID286007Antimicrobial activity against Escherichia coli ATCC 25922 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID433159Antibacterial activity against Clostridium cadaveris isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID518190Antimicrobial activity against oprD protein deficient Pseudomonas aeruginosa C2 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID495797Activity at Pseudomonas fluorescens PF-1 beta-lactamase BIC-1 expressed in Escherichia coli DH10B carrying pSau12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID1225787Antibacterial activity against Klebsiella pneumoniae KP1082 expressing KPC2/SHV-1 by broth microdilution method2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID1757594Antibacterial activity against ESBLs negative Carbapenem-sensitive Escherichia coli 17-20 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID574776Antimicrobial activity against Clostridium difficile after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID508736Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring acquired beta-lactamase OXA-144 by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID1519342Antibacterial activity against multidrug resistant Pseudomonas aeruginosa H103 infected in BALB/c mouse infected assessed as survival rate at 25 mg/kg, ip measured on day 72020European journal of medicinal chemistry, Jan-01, Volume: 185Development of a novel hybrid antimicrobial peptide for targeted killing of Pseudomonas aeruginosa.
AID295822Antibacterial activity against Klebsiella pneumoniae 477 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID1853610Antibacterial activity against Enterococcus faecium clinical isolate 1088925 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution method2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
Design, synthesis, and antibacterial activity of
AID373041Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZJ36 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID564216Antimicrobial activity against Acinetobacter baumannii ATCC 19606 harboring plasmid PH98 by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
AID528845Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID425083Antimicrobial activity against beta lactamase-positive Prevotella nigrescens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID423099Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID571394Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 0.5 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID574042Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID678453Antibacterial activity against Acinetobacter baumannii2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections.
AID1680069Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae clinical isolate 1 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID761208Antibacterial activity against Escherichia coli expressing CTX-M by broth microdilution method2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Pyridone-conjugated monobactam antibiotics with gram-negative activity.
AID545548Ratio of MIC for Staphylococcus aureus SMR4a to MIC for Staphylococcus aureus ATCC 6538P2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID573783Antibacterial activity against Prevotella buccae by by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID531966Antibacterial activity against Klebsiella pneumoniae urine isolate A28009 PFGE pattern A expressing KPC-2, TEM-1, SHV-11, CTX-M-2 beta-lactamase by agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID558318Antibacterial activity against Campylobacter jejuni by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID534878Antimicrobial activity against Enterobacter cloacae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1407942Antibacterial activity against Pseudomonas aeruginosa ARC3506 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID1873905Antibacterial activity against Staphylococcus aureus incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID517982Antimicrobial activity against Stenotrophomonas maltophilia B715 harboring beta-lactamase L1and L2 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID546621Antimicrobial activity against Escherichia coli harboring plasmid pPCRScript by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID574668Antimicrobial activity against Escherichia coli isolate 1679T expressing beta-lactamase KPC2, TEM and PFGE cluster 6 isolated from peritoneal fluid of patient by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID401687Antibacterial activity against Staphylococcus aureus 2852005Journal of natural products, May, Volume: 68, Issue:5
Cytotoxic bisindole alkaloids from a marine sponge Spongosorites sp.
AID423290Antibacterial activity against Pseudomonas aeruginosa isolate 327 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID522026Antimicrobial activity against Escherichia coli isolate J53 harboring pEcA containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID524321Antibacterial activity against Acinetobacter baumannii A910 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID423103Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID545567Antibacterial activity against Escherichia coli EMR2a selected at 2 times MIC of meropenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID523933Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E458 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID561464Antibacterial activity against Proteus mirabilis assessed as susceptible isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID576286Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17049 harboring porin OmpK36V mutant gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID565715Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-20 harboring A residue at 105 position in PDC- 4 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID285610Antimicrobial activity against Pseudomonas aeruginosa 65.68-2 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID532911Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 557 ST 327 expressing beta-lactamase TEM-1 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID535640Antimicrobial activity against Group B streptococcus serotype Ib C2 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID574740Antimicrobial activity against Peptostreptococcus anaerobius after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID531584Antibacterial activity against Escherichia coli obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID528528Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B10 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID584320Antimicrobial activity against azide-resistant Escherichia coli J53 by agar dilution method in presence 4 ug/ml of clavulanic acid2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID425120Bactericidal activity against beta lactamase-positive Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID274723Antibacterial activity against methicillin-resistant Streptococcus pyogenes 308A2007Journal of natural products, Jan, Volume: 70, Issue:1
Bisindole alkaloids of the topsentin and hamacanthin classes from a marine sponge Spongosorites sp.
AID423100Antibacterial activity against penicillin-resistant Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID534621Antimicrobial activity against Escherichia coli by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID394679Antibacterial activity against Pseudomonas aeruginosa tracheal aspirate isolate 12 carrying insertion sequence ISPa26 by disk susceptibility test2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.
AID518463Antimicrobial activity against Klebsiella pneumoniae 1338665 assessed as number of passages required for MIC to rise above 4 times original MIC2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID523763Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E4732010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584512Antimicrobial activity against Pseudomonas aeruginosa PA14 PA14_43090 harboring mutation in hypothetical protein by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID295801Antibacterial activity against Micrococcus luteus ATCC 9341 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID523772Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E5112010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID531682Antimicrobial activity against Acinetobacter baumannii Ab290 containing plasmid harboring OXA-58-4 by broth dilution test2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID520386Activity at Pseudomonas aeruginosa COL-1 metallo-beta lactamase VIM-2 by spectrometry2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID529459Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase Oxa-48 by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID511153Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 9 assessed as zone of inhibition by disk diffusion assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID565520Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-15 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID373048Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate FZ84 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID555470Antibacterial activity against Acinetobacter genomosp. 3 isolate 109 by Etest method in presence of cloxacillin and efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID555244Antibacterial activity against Acinetobacter genomosp. 3 isolate 56 by Etest method in presence of efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID574754Antimicrobial activity against Anaerococcus prevotii assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID286040Bacteriostasis activity against ESBL producing Klebsiella pneumoniae 262 isolate at 8 ug/ml2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID245121Minimum inhibitory concentration against Escherichia coli 1507 E strain2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID517972Antimicrobial activity against Pseudomonas aeruginosa 1937E harboring beta-lactamase PSE-4 and class C enzymes by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID360049Antimicrobial activity against Enterococcus faecium D344S by agar dilution method after 48 hrs2007The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42
Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID545550Ratio of MIC for Escherichia coli ERR2a selected to MIC for Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID70112Compound was evaluated for its antibacterial activity against Escherichia coli CCARM 1112 MDR2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID520724Activity of Acinetobacter baumannii phenotype 2 beta-lactamase assessed per mg of protein at 100 uM2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID558587Antimicrobial activity against Streptococcus pneumoniae 19A by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID423306Antibacterial activity against Pseudomonas aeruginosa isolate 348 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID576957Antimicrobial activity against Shewanella algae Sa74 harboring intI1, intI2, sul1 and sul2 genes by CLSI method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Reservoir of antimicrobial resistance determinants associated with horizontal gene transfer in clinical isolates of the genus Shewanella.
AID372331Antibacterial activity against hypermutable Pseudomonas aeruginosa isolate 12-09-15 assessed as effect on bacterial count in in vitro PK/PD model at 1 g infused every 8 hrs interval measured after third dose relative to initial inoculum2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID528741Antimicrobial activity against penicillin-resistant Streptococcus agalactiae ATCC BAA-611 harboring PBP-2X V405A mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID558611Antimicrobial activity against Streptococcus pneumoniae isolate 1564 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID523903Antibacterial activity against Acinetobacter baumannii A865 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1680065Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 1 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID496537fT>MIC in Pseudomonas aeruginosa isolate 896 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 8-16 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID535135Antimicrobial activity against Ceftazidime susceptible Pseudomonas aeruginosa assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID423234Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as resistant isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID528783Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID517960Antimicrobial activity against Burkholderia sp. by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID498810Antimicrobial activity against carbapenem-resistant Escherichia coli ZJ86 deficient in KPC-2, TEM-1, ompC by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID534674Antimicrobial activity against Fusobacterium nucleatum ATCC 25586 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID555475Antibacterial activity against Acinetobacter genomosp. 3 isolate 195 by Etest method in presence of cloxacillin and efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID1680058Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 7 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID523730Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E4092010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID209602In vitro antibacterial activity against Streptococcus pyogenes 308A2000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Synthesis and antibacterial activity of new carbapenems containing isoxazole moiety.
AID1757497Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID433155Antibacterial activity against Porphyromonas somerae isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID1758330Antibacterial activity against KPC-2 producing Escherichia coli 111192021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Discovery of 3-aryl substituted benzoxaboroles as broad-spectrum inhibitors of serine- and metallo-β-lactamases.
AID529580Ratio of Kcat to Km for Caulobacter crescentus beta-Lactamase CAU-12008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID545549Antibacterial activity against Escherichia coli ERR2a selected at 2 times MIC of tomopenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID1318932Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 1085902016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID532095Antimicrobial against Pseudomonas aeruginosa 3208 harboring phzM allele by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID517971Antimicrobial activity against Pseudomonas aeruginosa 1973E harboring beta-lactamase PSE-1 and class C enzymes by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID533135Antimicrobial activity against Bacteroides ovatus by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID574730Antimicrobial activity against Porphyromonas asaccharolytica after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID433201Antibacterial activity against Bacteroides stercoris isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID564527Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID1757580Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-11 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID519067Antibacterial activity against multidrug resistant Streptococcus pneumoniae ATCC 49619 assessed as resistant strains by CLSI microdilution susceptibility testing method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Activity of the Diaminopyrimidine AR-709 against recently collected multidrug-resistant isolates of invasive Streptococcus pneumoniae from North America.
AID529488Antimicrobial activity against Enterobacter cloacae isolate 625 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID562749Antimicrobial activity against Escherichia coli K-12 transconjugant harboring blaCTX-M-71 gene by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID433007Antibacterial activity against Corynebacterium simulans isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID322778Antimicrobial activity against Bacteroides vulgatus isolates by agar dilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID520387Ratio of Kcat to Km for Pseudomonas aeruginosa M5109 metallo-beta-lactamase VIM-112008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID1443398In vivo antibacterial activity against multidrug resistant Klebsiella pneumoniae isolate 212232 infected in Kunming mouse systemic infection model assessed as increase in mouse survival at 100 mg/kg, sc administered 0.5 to 4 hrs post infection measured af2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections.
AID499051Antimicrobial activity against carbapenem-resistant Escherichia coli PU60 deficient in TEM-1, CMY-2, ompC/F by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID289902Antibacterial activity against Salmonella typhi2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID496516fT>MIC in Pseudomonas aeruginosa isolate 1030 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 0-8 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID1348996Antibacterial activity against Salmonella enterica ATCC 13076 after 16 to 20 hrs by broth microdilution method2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and antibacterial evaluation of novel cationic chalcone derivatives possessing broad spectrum antibacterial activity.
AID524093Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3582010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID571393Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 1 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID1543304Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 assessed as inhibition of microbial growth by CLSI based method2019Journal of natural products, 07-26, Volume: 82, Issue:7
Anthraquinone-Based Specialized Metabolites from Rhizomes of
AID1559376Antibacterial activity against Klebsiella pneumoniae A-1797 expressing KPC-2/VIM-4/CMY-4 after 16 to 20 hrs by CLSI-based microbroth dilution method2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID534900Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID586235Antimicrobial activity against Escherichia coli J532011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID574991Antimicrobial activity against Bifidobacterium adolescentis assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID373032Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate FW-F1 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID576542Antimicrobial activity against OmpK35,OmpK36-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008135 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID1318936Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 847452016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID528521Antimicrobial activity against penicillin-resistant Streptococcus agalactiae ATCC BAA-611 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID433175Antibacterial activity against Klebsiella oxytoca isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID534489Antimicrobial activity against Stenotrophomonas maltophilia KJN2 harboring pRK-NG plasmid and ampN with xylE-Gmomega cassette insertion by Etest2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID323610Ratio of fCmax to MIC in patient with lower respiratory tract infection2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.
AID533388Antimicrobial activity against Clostridium difficile assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID1906439Bactericidal activity against Pseudomonas aeruginosa ATCC BAA 1744 assessed as decrease of bacterial growth at MIC measured after 24 hrs by Time kill assay2022European journal of medicinal chemistry, May-05, Volume: 235Amphiphilic cyclic peptide [W
AID576535Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate AIS080792 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID584314Antimicrobial activity against beta-lactamase ompC intact/ompF deficient Serratia marcescens isolate YMC0579 by agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID511140Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 142010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID1758327Antibacterial activity against Escherichia coli ATCC 259222021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Discovery of 3-aryl substituted benzoxaboroles as broad-spectrum inhibitors of serine- and metallo-β-lactamases.
AID565723Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-28 harboring A residue at 105 position in PDC- 7 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID523502Antimicrobial activity against Pseudomonas aeruginosa isolate 1333c from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID498845Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU105 deficient TEM-1, SHV-12, CTX-M-14, DHA-1, qnrB10/B4-like, aac(6')-Ib-cr, ompK35/36 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID433188Antibacterial activity against Corynebacterium simulans isolated from patient with diabetic foot infection assessed as percent resistant isolates after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID425333Bactericidal activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID203176Compound was evaluated for its antibacterial activity against Shigella flexneri ATCC 91992003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID425113Antimicrobial activity against beta lactamase-positive Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID1906447Cytotoxicity against human HepaRG cells assessed as assessed as reduction in cell viability at 10 ug/ml incubated for 24 hrs by microplate reader analysis2022European journal of medicinal chemistry, May-05, Volume: 235Amphiphilic cyclic peptide [W
AID532404Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone F isolate RM-11X-09 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID574005Antibacterial activity against beta-lactamase producing Clostridium septicum assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID289911Antibacterial activity against Proteus mirabilis 112/32007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID517949Antimicrobial activity against Providencia stuartii by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID1320842Binding affinity to native signal deficient and TEV cleavage site containing His-tagged Klebsiella pneumoniae OXA-48 expressed in Escherichia coli assessed as dissociation constant by SPR assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.
AID340735Antimicrobial activity against Escherichia coli HB101 harboring pBC-IND-5 plasmid containing metallo-beta-lactamase IND5 assessed as drug level at which microbial resistance was observed by agar dilution method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID523744Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E4602010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID533389Antimicrobial activity against Clostridium perfringens by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID1765576Antibacterial activity against Staphylococcus epidermidis ATCC 12228 incubated for 18 hrs by CLSI based broth dilution method2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Novel Broad-Spectrum Antimicrobial Peptide Derived from Anoplin and Its Activity on Bacterial Pneumonia in Mice.
AID511669Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD3 harboring oprD spontaneous mutant and deficient in dacB gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID558041Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S4 by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID534683Antimicrobial activity against Bacteroides fragilis by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID545556Ratio of MIC for Escherichia coli ERR8a to MIC for Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID1318935Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 831822016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID520775Antibacterial activity against beta-lactamase KPC-2 producing Klebsiella pneumoniae isolate K1 to K9 by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID532898Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 523 transformant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID1373310Antimicrobial activity against Escherichia coli expressing beta-lactamase AmpC by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1853619Antibacterial activity against Staphylococcus aureus clinical isolate 1089106 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution method2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
Design, synthesis, and antibacterial activity of
AID9748Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4)1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID531783Antibacterial activity against Stenotrophomonas maltophilia obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID544497Ratio of MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-5 to MIC for Escherichia coli TOP102009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID560090Bactericidal activity against Enterobacter cloacae isolate 5420 at 1/4 times MIC after 24 hrs by time kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID1765578Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 incubated for 18 hrs by CLSI based broth dilution method2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Novel Broad-Spectrum Antimicrobial Peptide Derived from Anoplin and Its Activity on Bacterial Pneumonia in Mice.
AID499060Antimicrobial activity against Enterobacter aerogenes PU41T expressing CTX-M-14, DHA-1, qnrS1 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1757545Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-9 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID528492Antimicrobial activity against Pseudomonas aeruginosa clinical isolates assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID583098Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 beta-lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID519818Induction of morphological changes in Escherichia coli MC4100 assessed as induction of sphere formation at antimicrobial MIC after 4 hrs by microscopy2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID534455Antimicrobial activity against Lactobacillus casei subsp. casei JCM 1134 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID289885Antibacterial activity against Micrococcus luteus ATCC 93412007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID546417Antimicrobial activity against Pseudomonas aeruginosa KG2505a harboring recombinant pBB-PDC-2 by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID534704Antimicrobial activity against Parvimonas micra by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID495697Activity of Pseudomonas aeruginosa VIM-22010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID522003Antimicrobial activity against Klebsiella pneumoniae isolate Kp7A expressing beta-lactamase OXA-48 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID534904Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID95733Compound was evaluated for its antibacterial activity against Klebsiella oxytoca 1082E2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID575009Antimicrobial activity against Eubacterium sp. assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1873906Antibacterial activity against Staphylococcus aureus ATCC 25923 incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID571684Antimicrobial activity against ESBL producing Escherichia coli isolated from patient bloodstream assessed as resistant isolate by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy.
AID523714Antibacterial activity against Acinetobacter baumannii A931 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID518466Antimicrobial activity against Pseudomonas aeruginosa 621 assessed as number of passages required for MIC to rise above 4 times original MIC2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID571209Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method in presence of 0.125 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID583083Activity of Escherichia coli BL21(DE3) VIM-2 W87A mutant beta-lactamase by spectrophotometer2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID532414Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-02 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID1533869Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 2224 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID285979Antimicrobial activity against ESBL producing Escherichia coli 310 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID524280Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E417 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1762808Antibacterial activity against Klebsiella pneumoniae assessed as reduction in bacterial growth incubated for 24 hrs by by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID545606Antimicrobial activity against Pseudomonas aeruginosa PS25 with PFGE phenotype 1A obtained from sputum of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID555232Antibacterial activity against Acinetobacter genomosp. 3 isolate 20 by Etest method in presence of cloxacillin and efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID285604Antimicrobial activity against Pseudomonas aeruginosa 2A6 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID565510Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-28 harboring A residue at 105 position in PDC- 7 by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1759655Antimicrobial activity against against methicillin-resistant Staphylococcus aureus clinical isolate 1088610 by CLSI-based broth microdilution assay2021European journal of medicinal chemistry, Jul-05, Volume: 2194-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.
AID575015Activity of Pseudomonas aeruginosa beta-lactamase VIM-2 by UV spectrophotometric analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro potentiation of carbapenems with ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta-lactamase- producing Pseudomonas aeruginosa clinical isolates.
AID584555Antimicrobial activity against Acinetobacter lwoffii isolate B expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID285989Antimicrobial activity against ESBL producing Klebsiella pneumoniae 230 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID532092Antimicrobial against Pseudomonas aeruginosa 33410 harboring phoU allele by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID1862391Antibacterial activity against Klebsiella pneumoniae harboring KPC-3/NMD-1 assessed as bacterial growth inhibition at 0.06 to 64 ug/ml incubated for 16 to 20 hrs by microdilution method2022European journal of medicinal chemistry, Oct-05, Volume: 240Triazole-substituted phenylboronic acids as tunable lead inhibitors of KPC-2 antibiotic resistance.
AID423320Antibacterial activity against Pseudomonas aeruginosa isolate 363 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID535641Antimicrobial activity against Group B streptococcus serotype V C1 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID12324Half life was determined2000Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13
Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID555217Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 56 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID372328Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as maximum bactericidal effect in in vitro PK/PD model by measuring change in bacterial count at 1 g infused every 8 hrs interval measured 1 hr after first dose relative to initial inocul2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID521425Antibacterial activity against Stenotrophomonas maltophilia isolate KJ by Etest2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID495686Activity of Escherichia coli TEM-12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID495825Antimicrobial activity against Providencia stuartii 6858 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID565198Antimicrobial activity against Klebsiella pneumoniae isolate A-1797 expressing VIM-1 and KPC-2 genes by microdilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID585195Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-2 E104, N170 mutant by Etest method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID1407947Antibacterial activity against Pseudomonas aeruginosa ARC3607 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID425319Bactericidal activity against beta lactamase-positive Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as 99.9% bacterial killing at 2 times MIC after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID322313Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID520384Antimicrobial activity Escherichia coli DH5alpha expressing beta lactamase VIM-2 by agar macrodilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID1873909Antibacterial activity against Klebsiella pneumoniae ATCC 13883 incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID533421Antimicrobial activity against Anaerococcus prevotii by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID555256Antibacterial activity against Acinetobacter genomosp. 3 isolate 69 by Etest method in presence of efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID1853616Antibacterial activity against Staphylococcus aureus clinical isolate 1088064 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution method2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
Design, synthesis, and antibacterial activity of
AID523897Antibacterial activity against Pseudomonas aeruginosa P358 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523560Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E484 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID561281Antibacterial activity against Klebsiella pneumoniae assessed as intermediate isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID584315Antimicrobial activity against beta-lactamase ompC/ompF deficient Serratia marcescens ATCC 8100 by agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID534690Antimicrobial activity against Odoribacter splanchnicus by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID588125Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 3 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID534866Antimicrobial activity against Non-ESBL Proteus mirabilis assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID516140Antibacterial activity against Pulsotype M Acinetobacter genomosp. 3 isolate 5 containing IMP-1, OXA-58, ADC-43, ISAba2, ISAba3, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID528967Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID433168Antibacterial activity against Peptoniphilus asaccharolyticus isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID530330Antimicrobial activity against Escherichia coli XL1-Blue by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID571918Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 23 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, aphA6 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID523574Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E475 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1759651Antimicrobial activity against against methicillin-sensitive Staphylococcus aureus clinical isolate 1088060 by CLSI-based broth microdilution assay2021European journal of medicinal chemistry, Jul-05, Volume: 2194-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.
AID532409Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B2 isolate VA-06X-38 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID533131Antimicrobial activity against Bacteroides fragilis by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID508730Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3C9 GM1 harboring acquired beta-lactamase OXA-144 by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID565226Activity of KPC-2 in Klebsiella pneumoniae isolate A-1797 assessed as compound hydrolysis in presence of EDTA2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID560057Antimicrobial activity against ESBL-producing Escherichia coli by broth microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID372560Antibacterial activity against genetically beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b with an amino acid substitution in variable mutated locus Asn-526 or Arg-517 of ftsI gene assessed as resistance rate by broth microdilut2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.
AID433360Antibacterial activity against Clostridium cadaveris isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID498807Antimicrobial activity against Klebsiella pneumoniae ZJ71T expressing KPC-2 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID523543Antibacterial activity against beta-lactamase-negative Escherichia coli E409 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1678791Antibacterial activity against Escherichia coli BL21 (DE3) assessed as inhibition of bacterial growth incubated for 16 hrs by CLSI broth microdilution method2020RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2
AID572130Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 32 expressing ampC, ompA, adeB, adeM, aadB, aadA2 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1873913Antibacterial activity against Escherichia coli incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID372547Antibacterial activity against genetically beta-lactamase-negative ampicillin-susceptible Haemophilus influenzae type b without amino acid substitutions in ftsI gene and bla gene by broth microdilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.
AID1846927Antibacterial activity against wild type Pseudomonas aeruginosa ATCC 27853 assessed as reduction in bacterial growth incubated for 18 to 20 hrs by CLSI based microdilution method2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Design, Synthesis, and Biological Evaluation of Novel Pyrimido[4,5-
AID535843Antimicrobial activity against Pseudomonas aeruginosa PAO1 IPM46 harboring oprD gene after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID519292Antimicrobial activity against Escherichia coli TOP10 harboring Beta-lactamase OXA-105 by Etest2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp.
AID534437Antimicrobial activity against Streptococcus intermedius ATCC 27335 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID584716Antimicrobial activity against Pseudomonas aeruginosa PA14 PA1483 harboring cycH mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID564229Ratio of Kcat to Km for Escherichia coli TOP10 beta-lactamase OXA-1432009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
AID574461Antimicrobial activity against Escherichia coli isolate 329 expressing beta-lactamase KPC2, CTX-M-2, TEM and PFGE cluster 2 isolated from blood of patient by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID1225784Antibacterial activity against Klebsiella oxytoca KX1017 expressing KPC2/OXA2/SHV30 by broth microdilution method2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID545341Displacement of [14C]benzylpenicillin from PBP3 in Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID534662Antimicrobial activity against Non-ESBL Proteus mirabilis by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID555249Antibacterial activity against Acinetobacter genomosp. 3 isolate 65 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID1373307Antimicrobial activity against Escherichia coli expressing beta-lactamase NDM-5 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID528976Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient urine assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID495683Antimicrobial activity against Pseudomonas aeruginosa OC 4083 expressing beta-lactamase OXA-10 and containing Oxacillinase assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID496008Antimicrobial activity against piperacillin-tazobactam resistant Pseudomonas aeruginosa isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID511586Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD2 harboring oprD spontaneous mutant and deficient in ampD gene by selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution metho2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID576299Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 25008 by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID521968Antibacterial activity against Campylobacter sp. assessed as resistance breakpoint by CLSI method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID1443408Antibacterial activity against extended spectrum beta-lactamase OXA-23 producing multidrug resistant Acinetobacter baumannii clinical isolates after 18 hrs by broth microdilution method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections.
AID533381Antimicrobial activity against Bacteroides nordii by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID573799Antibacterial activity against Prevotella buccae assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID529303Antimicrobial activity against Acinetobacter genospecies 3 isolate Ac057 expressing beta-lactamase Oxa-58 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate.
AID496556Antibacterial activity against Klebsiella pneumoniae isolate 357 assessed as reduction of bacterial count at 16 ug/ml within 6 hrs in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID562758Antimicrobial activity against Klebsiella pneumoniae PFGE clone A expressing beta-lactamase KPC-2 by Etest2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID396029Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by Etest2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID531587Antibacterial activity against Proteus mirabilis obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID279564Antimicrobial activity against Haemophilus influenzae BLPACR strains2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.
AID423531Antibacterial activity against Acinetobacter baumannii isolate 930 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID523758Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E5092010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID545343Displacement of [14C]benzylpenicillin from PBP5 in Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID558051Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S14 by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID558603Antimicrobial activity against Streptococcus pneumoniae isolate 37 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID571900Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 14 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID532895Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 469 ST 277 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID523558Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E465 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534678Antimicrobial activity against Desulfovibrio desulfuricans ATCC 29577 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID584513Antimicrobial activity against Pseudomonas aeruginosa PA14 PA14_06490 harboring mutation in hypothetical protein by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID523490Antimicrobial activity against Pseudomonas aeruginosa AHP Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID433164Antibacterial activity against Propionibacterium acnes isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID535879Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae JN132 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrB genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID532175Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae SH39T harboring qnrA gene by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID68020Antibacterial activity against Enterobacter cloacae 1321E2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID423530Antibacterial activity against Acinetobacter baumannii isolate 929 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID574742Antimicrobial activity against Peptostreptococcus micros after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID534192Antimicrobial activity against Enterobacter cloacae expressing beta-lactamase KPC-2 and SHV-12 obtained from criticall ill liver transplant recipient by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient.
AID511136Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 102010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID373769Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh20 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID517973Antimicrobial activity against Serratia marcescens S6 harboring beta-lactamase SME-1.AmpC by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID528848Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID533130Antimicrobial activity against Bacteroides distasonis assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID520725Activity of Acinetobacter baumannii MAD beta-lactamase assessed per mg of protein at 100 uM2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID522657Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis V770 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID583096Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 W87F mutant beta-lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID529659Activity of Pseudomonas aeruginosa COL-1 beta-lactamase VIM-22008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID433356Antibacterial activity against Porphyromonas somerae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID495809Antimicrobial activity against Escherichia coli DH5alpha harbouring plasmid BK-VIM-19 expressing beta-lactamase VIM-19 by microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID524284Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E507 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534661Antimicrobial activity against Proteus mirabilis by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID534880Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID283391Antimicrobial activity against Nocardia farcinica after 72 hrs by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID286023Antimicrobial activity against ESBL producing Escherichia coli 130 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID373767Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh17 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID529655Activity of Pseudomonas aeruginosa 9551 beta-lactamase VIM-152008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID423331Antibacterial activity against Pseudomonas aeruginosa isolate 374 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID541023Ratio of Kcat to Km for Burkholderia cenocepacia 07-34 beta-lactamase PenB1 expressed in Escherichia coli Top102009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
AID562949Antimicrobial activity against Klebsiella pneumoniae PFGE clone F expressing beta-lactamase KPC-2 by Etest2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID555267Antibacterial activity against Acinetobacter genomosp. 3 isolate 128 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID560092Bactericidal activity against Klebsiella pneumoniae isolate 5436 at 1/4 times MIC after 24 hrs by time kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID1902204Antibacterial activity against Escherichia coli expressing NDM-1 measured by broth microdilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Stereochemically altered cephalosporins as potent inhibitors of New Delhi metallo-β-lactamases.
AID573800Antibacterial activity against Prevotella bivia assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID322792Antimicrobial activity against Bacteroides stercoris assessed as percent resistant isolates2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID576532Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008143 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID584511Antimicrobial activity against Pseudomonas aeruginosa PA14 PA14_23420 harboring mutation in putative zinc-binding dehydrogenase by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID528978Antimicrobial activity against methicillin-susceptible Staphylococcus aureus assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID534675Antimicrobial activity against Fusobacterium varium ATCC 8501 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID499156fAUC (0-infinity) in immunocompromized SKH1 mouse plasma at 50 mg/kg, sc2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID133976In vivo protective activity administered sc 1 hr after ip Enterobacter cloacae P strain infection in mice; Not determined2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Synthesis and antibacterial activity of 2alpha-functionalized 1beta-methylcarbapenems related to KR-21012.
AID534907Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID582924Ratio of Kcat to Km for Escherichia coli BL21(DE3) VIM-2 W87A mutant beta-lactamase by spectrophotometer2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID1757584Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-17 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID496568Antibacterial activity against Pseudomonas aeruginosa isolate 1038 assessed as reduction of bacterial count at 8 ug/ml within 6 hrs in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID560073Antimicrobial activity against Enterobacter cloacae isolate 4073 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID561474Antibacterial activity against Serratia marcescens assessed as intermediate isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID761207Antibacterial activity against Escherichia coli expressing defined beta-lactamase by broth microdilution method2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Pyridone-conjugated monobactam antibiotics with gram-negative activity.
AID207163Antibacterial activity against Staphylococcus aureus SG 5112003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID545604Antimicrobial activity against Pseudomonas aeruginosa PS22 with PFGE phenotype 3A obtained from urine of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID524107Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A8842010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID561629Antimicrobial activity against ampD2-deficient Stenotrophomonas maltophilia KJ by twofold serial agar dilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID12343Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.
AID534447Antimicrobial activity against Bifidobacterium breve ATCC 15700 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID373768Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh18 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID533360Antimicrobial activity against Bacteroides ovatus assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID424864Antimicrobial activity against carbapenem-susceptible Pseudomonas aeruginosa clinical isolate2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID656359Antimicrobial activity against carbapenemase-producing Klebsiella pneumoniae2011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID534442Antimicrobial activity against Clostridium sordellii ATCC 9714 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID336780Antimicrobial activity against Pseudomonas aeruginosa 1771 isolate after 18 hrs2003Journal of natural products, Mar, Volume: 66, Issue:3
Bioactive sterols from the starfish Certonardoa semiregularis.
AID1757883Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-30 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID432995Antibacterial activity against Klebsiella pneumoniae isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID496563Antibacterial activity against Klebsiella pneumoniae isolate 334 assessed as reduction of bacterial count at 32 ug/ml within 6 hrs in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID336781Antimicrobial activity against Pseudomonas aeruginosa 1771M isolate after 18 hrs2003Journal of natural products, Mar, Volume: 66, Issue:3
Bioactive sterols from the starfish Certonardoa semiregularis.
AID524827Antibacterial activity against erythromycin susceptible Campylobacter sp. assessed as resistance breakpoint by CLSI method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID585398Ratio of Kcat to Km for Stenotrophomonas maltophilia 1SML metallo-beta-lactamase L12010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID524319Antibacterial activity against Acinetobacter baumannii A892 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID561934Antibacterial activity against blaOXA-24-positive Acinetobacter baumannii isolate RUH134 harboring plasmid ABVA01 by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii.
AID323254Antimicrobial activity against carbapenem-intermediate or resistant Acinetobacter baumannii isolates by agar dilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
AID533408Antimicrobial activity against Clostridium tertium assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID245020Minimum inhibitory concentration against Salmonella Typhimurium2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID534602Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID546425Antimicrobial activity against Pseudomonas aeruginosa 12B harboring recombinant pBB-PDC-5 by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID558622Antimicrobial activity against Streptococcus pneumoniae isolate 3374 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID164537Compound was evaluated for its antibacterial activity against Pseudomonas aeruginosa 2 MDR2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID522653Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis K9724 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID531592Antibacterial activity against Serratia marcescens obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID584687Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3721 harboring nalC mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID576289Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 16855 harboring porin OmpK36 and OmpK35 genes by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID582974Antimicrobial activity against dacB::lox and nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID534298Antimicrobial activity against Pseudomonas aeruginosa isolate PA500 expressing VIM-1 beta-lactamase2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID323690Antibacterial activity against TEM92 ESBL-producing Acinetobacter baumannii by CLSI method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase.
AID531677Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid containing OXA-58-4 by broth dilution test2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID511161Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 17 assessed as zone of inhibition by disk diffusion assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID432998Antibacterial activity against Proteus rettgeri isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID558625Antimicrobial activity against Streptococcus pneumoniae isolate 3458 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID573784Antibacterial activity against Prevotella bivia by by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID285981Antimicrobial activity against ESBL producing Escherichia coli 118 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID1906446Induction of membrane disruption in Staphylococcus aureus ATCC BAA -1556 assessed as increase in PI positive cells at 4 times of MIC incubated for 2 hrs by Propidium iodide staining based FACS cytometry analysis relative to control2022European journal of medicinal chemistry, May-05, Volume: 235Amphiphilic cyclic peptide [W
AID522654Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis K4539 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID205547Minimum inhibitory concentration against Staphylococcus aureus SG 511 was determined by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID1757597Antibacterial activity against Enterobacter cloacae 17-3 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1225781Antibacterial activity against Escherichia coli EC1007 expressing KPC3 by broth microdilution method2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID425082Antimicrobial activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID576519Antimicrobial activity against Carbapenem-resistant Klebsiella pneumoniae isolate AIS081058 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID565507Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-25 harboring T residue at 105 position in PDC- 6 by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID423501Antibacterial activity against Acinetobacter baumannii isolate 900 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID574003Antibacterial activity against beta-lactamase producing Clostridium perfringens assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID279563Antimicrobial activity against Haemophilus influenzae BLNAR strains2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID390340Antimicrobial activity against Serratia marcescens 16352008Journal of natural products, Dec, Volume: 71, Issue:12
Citreamicins with potent gram-positive activity.
AID528966Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient urine assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID496483Antibacterial activity against Pseudomonas aeruginosa isolate 1038 in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID535170Antimicrobial activity against imipenem susceptible Acinetobacter assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID424857Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring pV2GY3 with blaVIM-2 and aac(6)'-32 by E-test2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID518003Antibacterial activity against Nocardia brasiliensis isolated from actinomycetoma patient by broth dilution method in presence of clavulanic acid2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro activity of ACH-702, a new isothiazoloquinolone, against Nocardia brasiliensis compared with econazole and the carbapenems imipenem and meropenem alone or in combination with clavulanic acid.
AID1759640Antimicrobial activity against vancomycin-resistant Enterococcus faecium clinical isolate 1088051 by CLSI-based broth microdilution assay2021European journal of medicinal chemistry, Jul-05, Volume: 2194-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.
AID295791Antibacterial activity against Escherichia coli 04 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID561933Antibacterial activity against blaOXA-24-positive Acinetobacter baumannii isolate RUH134 by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii.
AID564228Activity of Escherichia coli TOP10 beta-lactamase OXA-1432009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
AID565227Activity of KPC-2 in Klebsiella pneumoniae isolate T-1780 assessed as compound hydrolysis in presence of EDTA2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID322782Antimicrobial activity against Bacteroides merdae isolates by agar dilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID498840Antimicrobial activity against Klebsiella pneumoniae GZ66T expressing SHV-11, DHA-1 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1680071Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID1311361Antibacterial activity against Enterobacter cloacae ATCC 13047 measured after 18 hrs by broth microdilution assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.
AID499066Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ88 deficient in CTX-M-14, ompC/F by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID323037Antimicrobial activity against extended-spectrum-beta-lactamase producing Escherichia coli isolates2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
AID374024Ratio of Kcat to Km for Enterobacter cloacae IMI1 beta lactamase Escherichia coli DH5alpha by SDS-PAGE2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID295819Antibacterial activity against Salmonella typhi after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID356633Antibacterial activity against methicillin-resistant Staphylococcus aureus KIST4 after 18 hrs2003Journal of natural products, Nov, Volume: 66, Issue:11
New bromotyrosine derivatives from an association of two sponges, Jaspis wondoensis and Poecillastra wondoensis.
AID1533861Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 2516 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID584517Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2621 harboring clpS mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID423237Antibacterial activity against beta lactamase-positive Haemophilus influenzae ATCC 49247 isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID1373301Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-24 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID508725Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1E3 PpA2 harboring acquired beta-lactamase OXA-101 by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID495675Antimicrobial activity against wild type Serratia marcescens OC 7555 deficient in beta-lactamase assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID574687Antimicrobial activity against Escherichia coli DH10B by Etest2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID390334Antimicrobial activity against Escherichia coli 14112008Journal of natural products, Dec, Volume: 71, Issue:12
Citreamicins with potent gram-positive activity.
AID574532Antimicrobial activity against Prevotella bivia assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID561283Antibacterial activity against Klebsiella pneumoniae assessed as resistant isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID499120Antimicrobial activity against Pseudomonas aeruginosa OC 4351 infected in immunocompromized SKH1 mouse assessed as lesion volume at 25 mg/kg/day, sc measured after 48 hrs postinfection (Rvb = 2234 mm3)2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID545411Antimicrobial activity against Pseudomonas aeruginosa PS19A with PFGE phenotype 11C obtained from urine of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID423239Antibacterial activity against Haemophilus influenzae ATCC 49247 isolated from respiratory tract infected patients assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID433005Antibacterial activity against Corynebacterium striatum isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523926Antibacterial activity against beta-lactamase-negative Escherichia coli E345 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID423318Antibacterial activity against Pseudomonas aeruginosa isolate 361 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID1533863Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 757 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID423514Antibacterial activity against Acinetobacter baumannii isolate 913 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID518185Antimicrobial activity against Serratia marcescens 1T9 harboring beta-lactamase Class C by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID534686Antimicrobial activity against Bacteroides uniformis by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID576274Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18260 by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID534709Antimicrobial activity against Clostridium difficile by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID425080Antimicrobial activity against beta lactamase-positive Prevotella bivia isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID531683Antimicrobial activity against Acinetobacter baumannii ATCC 15151T by broth dilution test2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID584704Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0401 harboring mutation in Noncatalytic dihydroorotase-like protein by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID561466Antibacterial activity against Proteus mirabilis assessed as intermediate isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID323608fAUC in patient with lower respiratory tract infection2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.
AID496006Antimicrobial activity against imipenem resistant Pseudomonas aeruginosa isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID565519Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-16 harboring A residue at 105 position in PDC- 3 by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID564466Antimicrobial activity against Pseudomonas aeruginosa isolate 821 by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID583019Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Escherichia coli DH10B plasmid carrying DHA-1 by agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID563974Activity of Klebsiella pneumoniae 05-560 beta-lactamase IMP1 by spectrophotometry2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID531769Antimicrobial activity against Pseudomonas aeruginosa urine isolate 4698 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID576277Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17834 harboring porin OmpK36V mutant gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID285983Antimicrobial activity against ESBL producing Escherichia coli 285 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID373765Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh13 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID565279Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A1 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
AID405427Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID524101Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A8672010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID528831Antimicrobial activity against CTX-M ESBL producing Escherichia coli isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID559859Antimicrobial activity against Streptococcus agalactiae clinical isolates by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections.
AID1846924Antibacterial activity agains OXA23-producing multidrug resistant Acinetobacter baumannii assessed as reduction in bacterial growth incubated for 18 to 20 hrs by CLSI based microdilution method2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Design, Synthesis, and Biological Evaluation of Novel Pyrimido[4,5-
AID283220Antimicrobial activity against Pseudomonas aeruginosa PA09052007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil.
AID576533Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate AIS080949 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID584505Antimicrobial activity against wild type Pseudomonas aeruginosa PA14 by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID534708Antimicrobial activity against Eubacterium limosum by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID523585Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E511 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534415Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1318918Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 1000362016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1592957Antibacterial activity against multi-drug resistant Escherichia coli NMI 3548/14 assessed as reduction in microbial growth incubated for 20 hrs2019European journal of medicinal chemistry, Apr-15, Volume: 168Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae.
AID534831Cmin in critically ill patient with sepsis at 1000 mg/kg, iv administered every 8 hrs by HPLC method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
AID372548Antibacterial activity against genetically beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b with an amino acid substitution in variable mutated locus Asn-526 or Arg-517 of ftsI gene by broth microdilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.
AID495720Activity of Klebsiella pneumoniae Beta-lactamase TEM-26 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID588084Antibacterial activity against Acinetobacter baumannii Ab880 overexpressing beta-lactamase OXA-58 under the control of ISAba825 insertion sequence2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
ISAba825, a functional insertion sequence modulating genomic plasticity and bla(OXA-58) expression in Acinetobacter baumannii.
AID496484Antibacterial activity against Pseudomonas aeruginosa isolate 1177 in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID498362Antimicrobial activity against rifampin resistant Klebsiella pneumoniae 52deltaacrR containing isogenic acrR knockout assessed as growth inhibition by Etest method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence.
AID96088Compound was evaluated for its antibacterial activity against Klebsiella pneumoniae 3 ESBL2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID1780305Antibacterial activity against wild type Pseudomonas aeruginosa LESB58 LpxA Gly120Ala mutant assessed as reduction in bacterial growth by broth microdilution assay
AID574772Antimicrobial activity against Clostridium perfringens assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID565709Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-14 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1559379Antibacterial activity against Enterobacter aerogenes 188548 expressing AmpC after 16 to 20 hrs by CLSI-based microbroth dilution method2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID584699Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5005 harboring mutation in putative carbamoyltransferase by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID529463Antimicrobial activity against Klebsiella pneumoniae isolate 21 expressing beta-lactamase Oxa-48, TEM-1 and Oxa-9 by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID573583Antibacterial activity against beta-lactamase producing Bacteroides caccae assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID236463Area under concentration time at a single intravenous administration of 20 mg/kg in rat2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID1589225Effect on growth of NDM4-positive Escherichia coli assessed as bacterial growth at 0.03125 ug/mL after 24 hrs by broth microdilution method relative to control2019European journal of medicinal chemistry, Apr-01, Volume: 167H
AID207376In vivo antibacterial activity against Staphylococcus aureus SG 5111999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID1373319Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-48 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373322Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-160 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID423506Antibacterial activity against Acinetobacter baumannii isolate 905 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID559822Antimicrobial activity against Pseudomonas aeruginosa PU21 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID555268Antibacterial activity against Acinetobacter genomosp. 3 isolate 128 by Etest method in presence of efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID560079Antimicrobial activity against Pseudomonas aeruginosa isolate 1019 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID222237In vivo therapeutic efficacy was determined against Staphylococcus aureus Y-80-1953 by a single sc administration in mice1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID1596890Antibacterial activity against methicillin-resistant Staphylococcus aureus NR10192 incubated for 16 to 18 hrs by broth microdilution assay
AID433359Antibacterial activity against Clostridium aminovalericum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID1691825Ratio of MIC for antibacterial activity against Pseudomonas aeruginosa PAO1 biofilm cells to antibacterial activity against Pseudomonas aeruginosa PAO1 planktonic cells2020European journal of medicinal chemistry, May-15, Volume: 194Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1.
AID495736Kcat/Km ratio of Escherichia coli CMY-2 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID555219Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 69 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID584698Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5003 harboring mutation in conserved hypothetical protein by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1318930Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 861412016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID583651Antibacterial activity against Escherichia coli isolate 2712010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia.
AID521488Antibacterial activity against Pseudomonas aeruginosa KG2505 harboring pCOL plasmid by Etest method in presence of beta-lactamase inhibitor clavulanic acid2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID524305Antibacterial activity against Pseudomonas aeruginosa P363 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534484Antimicrobial activity against ampN deficient Stenotrophomonas maltophilia KJ harboring ampG with xylE-Gmomega cassette insertion by Etest2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID510503Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M2AC9-31 expressing KPC beta lactamase2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID555455Antibacterial activity against Acinetobacter genomosp. 3 isolate 52 by Etest method in presence of cloxacillin and efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID295789Antibacterial activity against Streptococcus pneumoniae 0025 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID495705Kcat/Km ratio of Klebsiella pneumoniae Beta-lactamase TEM-262010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID528788Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID528840Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID565547Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-11 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID425099Antimicrobial activity against Anaerococcus tetradius isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID534684Antimicrobial activity against Bacteroides thetaiotaomicron by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID571396Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 0.125 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID528534Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B503 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID1680067Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial growth incubated 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID574510Antimicrobial activity against Bacteroides vulgatus assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID96092Compound was evaluated for its antibacterial activity against Klebsiella pneumoniae 7 ESBL2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID534473Antimicrobial activity against Bacteroides eggerthii ATCC 27754 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID283392Antimicrobial activity against Nocardia otitidiscaviarum after 72 hrs by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID584712Antimicrobial activity against Pseudomonas aeruginosa PA14 PA1011 harboring mutation in putative lipoprotein by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID558336Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1618 by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID496472Antibacterial activity against Klebsiella pneumoniae isolate 328A in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID1759643Antimicrobial activity against vancomycin-resistant Enterococcus faecium clinical isolate 1094112 by CLSI-based broth microdilution assay2021European journal of medicinal chemistry, Jul-05, Volume: 2194-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.
AID209288Compound was evaluated for in vitro antibacterial activity against Streptococcus pyogenes 77A strain by agar dilution method2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Synthesis and antibacterial activity of 2alpha-functionalized 1beta-methylcarbapenems related to KR-21012.
AID1873897Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs using 10^3 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID511584Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD3 harboring oprD spontaneous mutant selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID523582Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E453 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285974Antimicrobial activity against Escherichia coli ATCC 25922 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID521348Antimicrobial activity against Streptococcus pneumoniae isolate 187 obtained from bronchoalveolar lavage fluid of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID498803Antimicrobial activity against Klebsiella pneumoniae ZJ18T expressing KPC-2, DHA-1 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID565212Activity of VIM-1 in Klebsiella pneumoniae isolate H-14062009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID531680Antimicrobial activity against Acinetobacter baumannii Ab290 harboring TVICU53 plasmid by broth dilution test2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID534651Antimicrobial activity against ESBL producing Klebsiella pneumoniae assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1373302Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-47 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1757601Antibacterial activity against Enterobacter cloacae 17-7 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID528522Antimicrobial activity against Streptococcus pneumoniae ATCC 49619 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1311358Antibacterial activity against Acinetobacter baumannii 6M-1b measured after 18 hrs by broth microdilution assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.
AID425076Antimicrobial activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID496492fT>MIC in Klebsiella pneumoniae isolate 353 at 2 gram for every 8 hrs administered as 3 hrs infusion over 24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID574534Antimicrobial activity against Prevotella buccae assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID425102Antimicrobial activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID574752Antimicrobial activity against Anaerococcus prevotii after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1475190Antibacterial activity against Pseudomonas aeruginosa clinical isolate after 18 to 24 hrs2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
AID285590Antimicrobial activity against Pseudomonas aeruginosa 65.38-1 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID561494Antibacterial activity against Acinetobacter baumannii assessed as resistant isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID573594Antibacterial activity against Fusobacterium varium assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID532905Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 525 ST 376 expressing beta-lactamase SHV-1 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID522023Antimicrobial activity against Citrobacter freundii isolate expressing beta-lactamase OXA-48 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID524272Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E472 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534304Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA4942010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID523500Antimicrobial activity against Pseudomonas aeruginosa isolate 1681c from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID528841Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID574967Antimicrobial activity against Actinomyces odontolyticus assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1853613Antibacterial activity against Staphylococcus aureus clinical isolate 1088060 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution method2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
Design, synthesis, and antibacterial activity of
AID322784Antimicrobial activity against Bacteroides distasonis assessed as percent resistant isolates2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID528822Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolated from ICU patient urine assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID529861Ratio of MIC for Pseudomonas aeruginosa N044 to MIC for Pseudomonas aeruginosa PAO12008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID545395Antimicrobial activity against Pseudomonas aeruginosa PS1 with PFGE phenotype 9C expressing beta-lactamase IMP-18 and OXA-2 obtained from sputum of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID1373325Chemical stability in pH 7.4 potassium phosphate buffer assessed as half life for compound hydrolysis at 37 degC by UPLC and mass spectrometry2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID495704Kcat/Km ratio of Klebsiella oxytoca Beta-lactamase K12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID558615Antimicrobial activity against Streptococcus pneumoniae isolate 2874 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID574526Antimicrobial activity against Prevotella intermedia assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1533849Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 2490 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID555464Antibacterial activity against Acinetobacter genomosp. 3 isolate 90 by Etest method in presence of cloxacillin and efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID433151Antibacterial activity against Bacteroides vulgatus isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID521490Antibacterial activity against Escherichia coli harboring pCOL plasmid expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID532907Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 526 ST 376 expressing beta-lactamase SHV-1 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID534485Antimicrobial activity against Stenotrophomonas maltophilia KJ harboring pRK415 plasmid by Etest2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID1407946Antibacterial activity against Pseudomonas aeruginosa ARC3606 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID524302Antibacterial activity against Pseudomonas aeruginosa P365 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID564451Antimicrobial activity against Pseudomonas aeruginosa isolate 1036 by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID495802Antimicrobial activity against Escherichia coli 138 expressing beta-lactamase VIM-19 by microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID548008Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237Q mutant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID574460Antimicrobial activity against Escherichia coli isolate 157T expressing beta-lactamase KPC2 and PFGE cluster 3 isolated from urine of patient by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID495672Antimicrobial activity against Klebsiella pneumoniae OC 4094 expressing extended-spectrum Beta-lactamase TEM-26 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1628576Antibacterial activity against Staphylococcus aureus OXFORD incubated for 18 to 24 hrs by broth microdilution method2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
Discovery and Characterization of a Class of Pyrazole Inhibitors of Bacterial Undecaprenyl Pyrophosphate Synthase.
AID206745In vitro antibacterial activity against Staphylococcus aureus SG 503 by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13
Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID574023Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1873893Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs using 10^6 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID761217Antibacterial activity against Pseudomonas aeruginosa 1091-05 by broth microdilution method2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Pyridone-conjugated monobactam antibiotics with gram-negative activity.
AID1311368Antibacterial activity against Mycobacterium tuberculosis 124R measured after 14 days by broth microdilution assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.
AID1592958Antibacterial activity against multi-drug resistant Escherichia coli NMI 3898/15 assessed as reduction in microbial growth incubated for 20 hrs2019European journal of medicinal chemistry, Apr-15, Volume: 168Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae.
AID496552fT>MIC in Pseudomonas aeruginosa isolate 1177 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 16-24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID531585Antibacterial activity against Klebsiella pneumoniae obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID1442618Antibacterial activity against Pseudomonas aeruginosa PA694 in CD-1 mouse model of thigh infection administered as iv bid for 2 to 12 hrs of post-infection measured after 24 hrs2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID1320840Binding affinity to native signal deficient and TEV cleavage site containing His-tagged Klebsiella pneumoniae OXA-48 expressed in Escherichia coli assessed as association rate constant by SPR assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.
AID587729Antimicrobial activity against Escherichia coli DH5alpha carrying empty pBC-SK after 18 hrs by microdilution broth method2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID1596900Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 incubated for 16 to 18 hrs by broth microdilution assay
AID523597Antibacterial activity against Pseudomonas aeruginosa P337 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523753Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E3612010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID525036Activity of Acinetobacter baumannii Beta-lactamase OXA2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Updated functional classification of beta-lactamases.
AID560086Bactericidal activity against Pseudomonas aeruginosa isolate 956 at 1/4 times MIC after 24 hrs by time kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID567473Antimicrobial activity against gBLPAR-TEM1 Haemophilus influenzae by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID586234Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 7 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1906443Induction of membrane disruption in Pseudomonas aeruginosa ATCC BAA 1744 assessed as increase in PI positive cells at MIC incubated for 2 hrs by Propidium iodide staining based FACS cytometry analysis relative to control2022European journal of medicinal chemistry, May-05, Volume: 235Amphiphilic cyclic peptide [W
AID534306Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA5092010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID53764Compound was evaluated for DHP-1 stability by using purified porcine renal enzyme2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Synthesis and antibacterial activity of 2alpha-functionalized 1beta-methylcarbapenems related to KR-21012.
AID70118Compound was evaluated for its antibacterial activity against Escherichia coli DC 02003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID372335Antibacterial activity against hypermutable Pseudomonas aeruginosa isolate 12-09-15 assessed as change in bacterial count in in vitro PK/PD model at 1 g infused every 8 hrs interval measured after 8 hrs relative to initial inoculum2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID423332Antibacterial activity against Pseudomonas aeruginosa isolate 375 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID499052Antimicrobial activity against Escherichia coli PU60T expressing CMY-2 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID523769Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E4532010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584727Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3978 harboring mutation in hypothetical protein by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID433352Antibacterial activity against Bacteroides vulgatus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID499058Antimicrobial activity against carbapenem-resistant Enterobacter cloacae GX24 deficient in TEM-1, DHA-1, aac(6')-Ib, ompC by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID522024Antimicrobial activity against Escherichia coli isolate J53 harboring pCF containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID545337Displacement of [14C]benzylpenicillin from PBP4 in Staphylococcus aureus ATCC 6538P2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID1782792Antibacterial activity against 98 member subset of carbapenem resistant Acinetobacter baumannii assessed as assessed as inhibition of bacterial growth by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID523494Antimicrobial activity against Pseudomonas aeruginosa isolate 1530c from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID574981Antimicrobial activity against Actinomyces naeslundii after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID524081Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3342010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1662231Binding affinity to recombinant bacteria NDM-1 (I31 to K268 residues)expressed in Escherichia coli BL21 (DE3) cells by SPR assay2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
A novel potent metal-binding NDM-1 inhibitor was identified by fragment virtual, SPR and NMR screening.
AID511287Antibacterial activity against Pseudomonas aeruginosa NL68 expressing GES-13 beta lactamase2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID584556Antimicrobial activity against Acinetobacter lwoffii isolate C expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID517967Antimicrobial activity against Klebsiella pneumoniae 1357E harboring beta-lactamase TEM-10 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID573565Antibacterial activity against beta-lactamase producing Bacteroides vulgatus assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1757570Antibacterial activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-17 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID499065Antimicrobial activity against carbapenem-resistant Enterobacter aerogenes WH85 deficient in TEM-1, CTX-M-3, ompC/F by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID341596Antibacterial activity against carbapenem-resistant blaKPC-encoding plasmid harboring Klebsiella pneumoniae 490 isolate producing KPC3 and TEM1 carbapenemases2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID522012Antimicrobial activity against Escherichia coli isolate J53 harboring pE containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID534475Antimicrobial activity against Campylobacter gracilis JCM 8538 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID545617Antimicrobial activity against Pseudomonas aeruginosa PS39 with PFGE phenotype 8 expressing beta-lactamase IMP-18 obtained from urine of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID498832Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae CY1 deficient in SHV-11, DHA-1, ompK35/36 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID519472Antimicrobial activity against Stenotrophomonas maltophilia K279a harboring -121 frameshift mutation in ampR gene by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator.
AID1407957Antibacterial activity against Pseudomonas aeruginosa ARC4068 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID559820Antimicrobial activity against Escherichia coli J53 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID522013Antimicrobial activity against Klebsiella pneumoniae isolate KpBEL expressing beta-lactamase OXA-48 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID565713Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-18 harboring A residue at 105 position in PDC- 3 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID574985Antimicrobial activity against Actinomyces naeslundii assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID554991Antibacterial activity against Acinetobacter genomosp. 3 isolate 67 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID424858Antimicrobial activity against Pseudomonas aeruginosa GY3 producing blaVIM-2 by E-test2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID574766Antimicrobial activity against Finegoldia magna assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1225783Antibacterial activity against Klebsiella oxytoca KX1019 expressing KPC2/OXA2 by broth microdilution method2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID583092Activity of Escherichia coli XL1-Blue VIM-2 A64W mutant beta-lactamase by spectrophotometer2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID534898Antimicrobial activity against Citrobacter by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID495746Inhibition of Escherichia coli CMY-2 assessed as inhibition of nitrocefin hydrolysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID496499fT>MIC in Pseudomonas aeruginosa isolate 1030 at 2 gram for every 8 hrs administered as 3 hrs infusion over 24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID584738Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5288 harboring glnK mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1706881Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS12 measured after 16 to 18 hrs2021European journal of medicinal chemistry, Feb-15, Volume: 212Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.
AID534847Antimicrobial activity against Burkholderia pseudomallei2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
AID433355Antibacterial activity against Porphyromonas asaccharolyticus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID533409Antimicrobial activity against Finegoldia magna by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID404954Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii BM4547 by agar dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID286017Antimicrobial activity against ESBL producing Klebsiella pneumoniae 225 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID533128Antimicrobial activity against Bacteroides caccae by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID1780309Antibacterial activity against wild type Pseudomonas aeruginosa LESB58 RS21000 and RS21005 mutant assessed as resistance development by measuring fold increase in MIC
AID356634Antibacterial activity against methicillin-resistant Staphylococcus aureus 004 after 18 hrs2003Journal of natural products, Nov, Volume: 66, Issue:11
New bromotyrosine derivatives from an association of two sponges, Jaspis wondoensis and Poecillastra wondoensis.
AID295834Antibacterial activity against Corynebacterium pyogenes after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID565538Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-02 harboring T residue at 105 position in PDC- 1, and polymorphic OprD gene by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID70108Compound was evaluated for its antibacterial activity against Escherichia coli CCARM 1108 MDR2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID523929Antibacterial activity against beta-lactamase-negative Escherichia coli E348 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1543305Antimicrobial activity against Escherichia coli ATCC 35218 assessed as inhibition of microbial growth by CLSI based method2019Journal of natural products, 07-26, Volume: 82, Issue:7
Anthraquinone-Based Specialized Metabolites from Rhizomes of
AID495702Kcat/Km ratio of Klebsiella pneumoniae SHV-12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID523892Antimicrobial activity against Acinetobacter baumannii ATCC 15151 harboring ISAba1-blaOXA-23 gene by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
AID535903Antimicrobial activity against aac(6')-Ib-cr-negative Escherichia coli PU12 harboring GyrA S83L mutant, wild-type GyrB, ParC and qnrS genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID535162Antimicrobial activity against Acinetobacter by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID587732Activity of Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP-1 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID534417Antimicrobial activity against methicillin-susceptible Streptococcus pneumoniae assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID524116Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A8852010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523740Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E4562010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534612Antimicrobial activity against Ceftazidime non-susceptible Enterobacteriaceae assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID555237Antibacterial activity against Acinetobacter genomosp. 3 isolate 21 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID1752486Antibacterial activity against Escherichia coli NIHJ JC-2 strain assessed as reduction in microbial growth incubated for 16 to 20 hrs in presence of vaborbactam by broth microdilution method2021Bioorganic & medicinal chemistry, 09-15, Volume: 46A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID524293Antibacterial activity against Pseudomonas aeruginosa P322 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID546618Antimicrobial activity against Pseudomonas aeruginosa isolate 243-31C expressing beta-lactamase VIM-18 isolated from sputum of patient by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID533364Antimicrobial activity against Bacteroides thetaiotaomicron assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID574043Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID295795Antibacterial activity against Serratia marcescens 3349 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID531679Antimicrobial activity against Acinetobacter baumannii Ab290 by broth dilution test2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID558422Antimicrobial activity against Burkholderia pseudomallei by agar dilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
In vitro activity of doripenem against Burkholderia pseudomallei.
AID1757590Antibacterial activity against ESBLs negative Carbapenem-sensitive Escherichia coli 17-7 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID324868Antimicrobial activity against Acinetobacter baumannii B46 by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID521487Antibacterial activity against Pseudomonas aeruginosa 2404 plasmid by Etest method in presence of beta-lactamase inhibitor clavulanic acid2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID576538Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008026 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID1407970Antibacterial activity against Acinetobacter baumannii ARC3493 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID1417166Antibacterial activity against methicillin-resistant Staphylococcus aureus NR10129 by CLSI method2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis of 1,2,3-triazole linked 4(3H)-Quinazolinones as potent antibacterial agents against multidrug-resistant Staphylococcus aureus.
AID289916Antibacterial activity against Pasteurella multocida2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID1649582Antimicrobial activity against Pseudomonas aeruginosa clinical isolates by standard broth microdilution method2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID1417164Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213 by CLSI method2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis of 1,2,3-triazole linked 4(3H)-Quinazolinones as potent antibacterial agents against multidrug-resistant Staphylococcus aureus.
AID534778Antimicrobial activity against Acinetobacter baumannii-calcoaceticus by disk diffusion method in presence of meropenem2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.
AID584569Antimicrobial activity against Acinetobacter lwoffii isolate C expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID286012Antimicrobial activity against ESBL producing Escherichia coli 310 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID207770Compound was evaluated for in vitro antibacterial activity against Staphylococcus aureus SG511 strain by agar dilution method2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Synthesis and antibacterial activity of 2alpha-functionalized 1beta-methylcarbapenems related to KR-21012.
AID425103Antimicrobial activity against Clostridium innocuum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID561275Antibacterial activity against Escherichia coli assessed as resistant isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID558052Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S15 by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID564213Antimicrobial activity against Acinetobacter baumannii ATCC 135040 by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
AID528828Antimicrobial activity against ESBL producing Klebsiella pneumoniae isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID496482Antibacterial activity against Pseudomonas aeruginosa isolate 1030 in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID523905Antibacterial activity against Acinetobacter baumannii A867 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523756Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E4762010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID511583Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD2 harboring oprD spontaneous mutant selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID565533Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-02 harboring T residue at 105 position in PDC- 1 and polymorphic OprD gene by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1853607Antibacterial activity against Enterococcus faecalis clinical isolate 1100440 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution method2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
Design, synthesis, and antibacterial activity of
AID572126Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 30 expressing ampC, ompA, adeB, adeM, aadB, aadA1 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID530341Ratio of Kcat to Km for Pseudomonas aeruginosa VIM-1 beta-lactamase2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID532091Antimicrobial against Pseudomonas aeruginosa PAO1 by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID1533875Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 85 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID286000Antimicrobial activity against ESBL producing Klebsiella pneumoniae 263 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID565666Antimicrobial activity against beta-lactamase positive (amoxicillin)clavulanate-resistant Haemophilus influenzae by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re
AID517969Antimicrobial activity against Klebsiella pneumoniae 26768WU harboring beta-lactamase SHV-5 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID95704Compound was evaluated for in vitro antibacterial activity against Klebsiella aerogenes 1522 E strain by agar dilution method2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Synthesis and antibacterial activity of 2alpha-functionalized 1beta-methylcarbapenems related to KR-21012.
AID523909Antibacterial activity against Acinetobacter baumannii A849 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1680045Antibacterial activity against NDM1 producing carbapenem-resistant Enterobacteriaceae clinical isolate 1 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID524417Antibacterial activity against ciprofloxacin-resistant Enterobacteriaceae clinical isolates isolated from patient with complicated intra-abdominal infection assessed as cure rate at test-of-cure visit2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1680057Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 8 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID322781Antimicrobial activity against Bacteroides stercoris isolates by agar dilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID390332Antimicrobial activity against ampicillin-resistant Haemophilus influenzae 17422008Journal of natural products, Dec, Volume: 71, Issue:12
Citreamicins with potent gram-positive activity.
AID1533866Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 2919 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID70097Compound was evaluated for in vitro antibacterial activity against Escherichia coli 078 strain by agar dilution method2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Synthesis and antibacterial activity of 2alpha-functionalized 1beta-methylcarbapenems related to KR-21012.
AID1824273Antimicrobial activity against Escherichia coli clinical isolate T2228 expressing VIM-1 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID428266Antimicrobial activity against carbapenemase producing Enterobacteriaceae by CLSI broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID523561Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E357 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID583016Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Escherichia coli EC-6 plasmid carrying AmpC-B2 by agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID1762814Inhibition of Escherichia coli L1 assessed as reduction in bacterial growth incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID285987Antimicrobial activity against ESBL producing Escherichia coli 133 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID584737Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5174 harboring mutation in putative beta-ketoacyl synthase by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID548004Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237P mutant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID1417175Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS12 by CLSI method2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis of 1,2,3-triazole linked 4(3H)-Quinazolinones as potent antibacterial agents against multidrug-resistant Staphylococcus aureus.
AID523724Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E3452010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534606Antimicrobial activity against Enterobacteriaceae assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1757553Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-1 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1905561Antimicrobial activity against Staphylococcus aureus ATCC 25923 assessed as reduction of bacterial growth incubated for 18 hrs by CLSI protocol based broth microdilution method2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Novel β-Hairpin Antimicrobial Peptides Containing the β-Turn Sequence of -RRRF- Having High Cell Selectivity and Low Incidence of Drug Resistance.
AID495806Antimicrobial activity against Providencia stuartii 6858 strain expressing beta-lactamase VIM-19 by microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID584319Antimicrobial activity against beta-lactamase AmpC producing meropenem-resistant Serratia marcescens by agar dilution method in presence of 4 ug/ml of clavulanic acid2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID560059Antimicrobial activity against AmpC-depressed Enterobacter cloacae by broth microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID283218Antimicrobial susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patient assessed as percent susceptible isolates2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
AID428271Antimicrobial activity against Klebsiella sp. assessed as resistant isolates by CLSI breakpoint assay2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID1906432Bactericidal activity against methicillin resistant Staphylococcus aureus ATCC BAA 1556 assessed as reduction in bacterial growth at MIC measured after 16 hrs by Time kill assay2022European journal of medicinal chemistry, May-05, Volume: 235Amphiphilic cyclic peptide [W
AID289896Antibacterial activity against Escherichia coli 01142007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID562951Antimicrobial activity against Enterobacter cloacae expressing beta-lactamase KPC-2 by Etest2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID584836Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER6 by agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID1906420Antibacterial activity against Klebsiella pneumoniae ATCC 13883 assessed as reduction in microbial growth incubated for 24 hrs by microbroth dilution method2022European journal of medicinal chemistry, May-05, Volume: 235Amphiphilic cyclic peptide [W
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID210400In vivo antibacterial activity against Streptococcus pyogenes 77A1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID523547Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E437 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1233139Antibacterial activity against patient-derived methicillin-resistant Staphylococcus aureus K1 after 18 to 20 hrs by microbroth dilution method2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors.
AID1559370Antibacterial activity against wild type Staphylococcus aureus ATCC 29213 after 16 to 20 hrs by CLSI-based microbroth dilution method2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID545553Antibacterial activity against Escherichia coli ERR4a selected at 4 times MIC of tomopenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID574762Antimicrobial activity against Peptoniphilus asaccharolyticus assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID7823Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4)1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID340733Antimicrobial activity against Chryseobacterium indologenes NF16 isolate assessed as drug level at which microbial resistance was observed by agar dilution method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID523563Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E359 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID571922Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 25 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID496494fT>MIC in Klebsiella pneumoniae isolate 360 at 2 gram for every 8 hrs administered as 3 hrs infusion over 24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID584576Antimicrobial activity against Acinetobacter lwoffii isolate J expressing beta-lactamase OXA-58 isolated from bedsore by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID519810Antimicrobial activity against Pseudomonas aeruginosa PAO1 by CLSI protocol based broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID529461Antimicrobial activity against Escherichia coli J53 by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID554986Antibacterial activity against Acinetobacter genomosp. 3 isolate 21 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID285688Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA2404 isolate expressing carbapenemase KPC22007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID529662Ratio of Kcat to Km for Pseudomonas aeruginosa 9551 beta-lactamase VIM-15 relative to cephaloridine2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID533372Antimicrobial activity against Bacteroides vulgatus assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID574748Antimicrobial activity against Peptostreptococcus micros assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID532392Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A2 isolate NA-14X-21 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID1762787Inhibition of bacterial NDM-1 expressed in Escherichia coli BL21 (DE3) at 20 uM using meropenem as substrate incubated for 1 hr by spectrometry analysis relative to control2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID163606Compound was tested for in vivo protective activity against Pseudomonas aeruginosa 1771M at a single subcutaneous administration in mice.1998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID373774Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh39 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID563976Activity of Klebsiella pneumoniae 05-560 beta-lactamase VIM2 by spectrophotometry2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID151539In vitro antibacterial activity against ATCC 27853 strain of Pseudomonas aeruginosa2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID573785Antibacterial activity against Prevotella intermedia by by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID425087Antimicrobial activity against beta lactamase-positive Prevotella buccae isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1906414Antibacterial activity against Methicillin resistant Staphylococcus aureus ATCC BAA -1556 assessed as reduction in microbial growth incubated for 24 hrs by microbroth dilution method2022European journal of medicinal chemistry, May-05, Volume: 235Amphiphilic cyclic peptide [W
AID200855Compound was evaluated for in vitro antibacterial activity against Salmonella Typhimurium by agar dilution method2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Synthesis and antibacterial activity of 2alpha-functionalized 1beta-methylcarbapenems related to KR-21012.
AID495714Kcat/Km ratio of Pseudomonas aeruginosa SPM-12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1680037Antibacterial activity against NDM1 producing carbapenem-resistant Enterobacteriaceae clinical isolate 10 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID534430Antimicrobial activity against Parvimonas micra VPI 5464-1 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID561470Antibacterial activity against Serratia marcescens by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID574995Antimicrobial activity against Bifidobacterium sp. assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID582977Antimicrobial activity against ampD::lox, ampDh2::lox and ampDh3::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID523938Antibacterial activity against beta-lactamase-negative Escherichia coli E425 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534605Antimicrobial activity against Enterobacteriaceae assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID433162Antibacterial activity against Clostridium malenominatum isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID562810Antimicrobial activity against Escherichia coli J53 harboring pEK499 plasmid encoding CTX-M extended-spectrum beta-lactamases2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID1504340Antibacterial activity against Enterococcus faecalis after 16 to 20 hrs by broth microdilution method2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and bioactivities study of new antibacterial peptide mimics: The dialkyl cationic amphiphiles.
AID295784Antibacterial activity against Staphylococcus aureus 1218 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID322783Antimicrobial activity against Bacteroides fragilis assessed as percent resistant isolates2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID404955Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii 183 isolate carrying one bla-OXA58 gene copy by agar dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID587500Antibacterial activity against drug-resistant Citrobacter freundii isolate producing metallo-beta-lactamase NDM-1 with carbapenemase activity isolated from urine culture of cerebral vascular malformation patient2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Extremely drug-resistant Citrobacter freundii isolate producing NDM-1 and other carbapenemases identified in a patient returning from India.
AID544495Ratio of MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-2 to MIC for Escherichia coli TOP102009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID1757622Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-26 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1533874Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 2973 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID433197Antibacterial activity against Streptococcus pyogenes isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID565528Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-07 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID588083Antibacterial activity against Acinetobacter baumannii ATCC 17978 harboring pAB8802011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
ISAba825, a functional insertion sequence modulating genomic plasticity and bla(OXA-58) expression in Acinetobacter baumannii.
AID518223Antimicrobial activity against Enterobacter cloacae S9369 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID1296368Inhibition of Mycobacterium tuberculosis LdtMt1 expressed in Escherichia coli assessed as second order rate constant for acylenzyme formation by stopped-flow spectrofluorimetric method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Routes of Synthesis of Carbapenems for Optimizing Both the Inactivation of L,D-Transpeptidase LdtMt1 of Mycobacterium tuberculosis and the Stability toward Hydrolysis by β-Lactamase BlaC.
AID1539482Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae ATCC BAA-2146 clinical isolates after 18 to 20 hrs in aerobic condition by CLSI-based broth microdilution assay
AID518200Antimicrobial activity against Pseudomonas aeruginosa BA(C1-106) selected after 25 ug/ml of compound exposure by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID656442Antibacterial activity against Pseudomonas aeruginosa cystic fibrosis isolate2011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID322776Antimicrobial activity against Bacteroides thetaiotaomicron isolates by agar dilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID534677Antimicrobial activity against Bilophila wadsworthia WAL 7959 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID425107Antimicrobial activity against Clostridium sordellii isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID496559Antibacterial activity against Klebsiella pneumoniae isolate 351 assessed as reduction of bacterial count at 8 ug/ml within 6 hrs in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID498843Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae XJ81 deficient in TEM-1, SHV-12, DHA-1, aac(6')-Ib, ompK35/36 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID519291Antimicrobial activity against Escherichia coli TOP10 harboring Beta-lactamase OXA-103 by Etest2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp.
AID356630Antibacterial activity against methicillin-resistant Staphylococcus aureus KIST1 after 18 hrs2003Journal of natural products, Nov, Volume: 66, Issue:11
New bromotyrosine derivatives from an association of two sponges, Jaspis wondoensis and Poecillastra wondoensis.
AID534467Antimicrobial activity against carbapenemase-producing Bacteroides fragilis GAI 30144 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID555234Antibacterial activity against Acinetobacter genomosp. 3 isolate 20 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID1680007Induction of outer membrane permeabilization in Escherichia coli ATCC 25922 at 20 ug/ml measured for 12 mins by NPN dye based fluorescence assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID518191Antimicrobial activity against Pseudomonas aeruginosa PAO1 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID495831Antimicrobial activity against Escherichia coli DH5alpha 2878 transformant expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID70117Compound was evaluated for its antibacterial activity against Escherichia coli CCARM 1117 MDR2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID535654Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae FJ61 harboring GyrA S83I, GyrA D87A, ParC S80I mutant, wild-type GyrB and qnrS genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID545571Antibacterial activity against Pseudomonas aeruginosa PIR2a selected at 2 times MIC of imipenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID584733Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4393 harboring mutation in putative permease by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID563970Antibacterial activity against Escherichia coli J53 harboring beta-lactamase NDM-1 by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID584703Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0011 harboring mutation in putative 2-OH-lauroyltransferase by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID534603Antimicrobial activity against Ceftazidime non-susceptible Enterobacteriaceae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID433002Antibacterial activity against Corynebacterium jeikeium isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID495915Ratio of Kcat to Km for beta-lactamase VIM-1 expressed in Escherichia coli TOP10 by spectrophotometry2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID548012Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237S mutant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID532401Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D3 isolate VA-06X-65 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID295827Antibacterial activity against Serratia marcescens 14273 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID433165Antibacterial activity against Anaerococcus prevotii isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID1559378Antibacterial activity against Enterobacter cloacae 144200 expressing p99 AmpC after 16 to 20 hrs by CLSI-based microbroth dilution method2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID534624Antimicrobial activity against Escherichia coli assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID295790Antibacterial activity against Haemophilus influenzae 1210 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID560065Antimicrobial activity against Escherichia coli isolate 5401 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID573798Antibacterial activity against Prevotella melaninogenica assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID564452Antimicrobial activity against Pseudomonas aeruginosa isolate 944 by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID423502Antibacterial activity against Acinetobacter baumannii isolate 901 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID496540fT>MIC in Klebsiella pneumoniae isolate 328A at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 16-24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID496478Antibacterial activity against Klebsiella pneumoniae isolate 334 in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID584521Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3247 harboring mutation in putative aspartyl aminopeptidase by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1757557Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-5 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID545338Displacement of [14C]benzylpenicillin from PBP1A in Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID517952Antimicrobial activity against Enterobacter cloacae by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID521353Antimicrobial activity against Streptococcus pneumoniae isolate k-421 obtained from ear of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID761247Antibacterial activity against Pseudomonas aeruginosa from cystic fibrosis patients by broth microdilution method2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Pyridone-conjugated monobactam antibiotics with gram-negative activity.
AID496526fT>MIC in Klebsiella pneumoniae isolate 353 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 8-16 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID518196Antimicrobial activity against fpvA, fpvB, fptA and pirA gene deficient Pseudomonas aeruginosa 860 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID396033Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pBGS18 plasmid by Etest2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID433187Antibacterial activity against Corynebacterium accolens isolated from patient with diabetic foot infection assessed as percent resistant isolates after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID1757572Antibacterial activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-19 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID286001Antimicrobial activity against ESBL producing Klebsiella pneumoniae 266 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID433358Antibacterial activity against Clostridium perfringens isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID532390Antibacterial activity against VIM-1 producing Pseudomonas putida isolate RM-11X-11 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID373027Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PUA6 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID433013Antibacterial activity against Staphylococcus lugdunensis isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID496561Antibacterial activity against Klebsiella pneumoniae isolate 377 assessed as reduction of bacterial count at 2 ug/ml within 6 hrs in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID545573Antibacterial activity against Pseudomonas aeruginosa PMR2a selected at 2 times MIC of meropenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID588079Antibacterial activity against Acinetobacter baumannii ATCC 17978 harboring plasmid directed expression of beta-lactamase OXA-58 under an ISAba825-ISAba3 hybrid and ISAba3-derived promoter sequence2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
ISAba825, a functional insertion sequence modulating genomic plasticity and bla(OXA-58) expression in Acinetobacter baumannii.
AID423498Antibacterial activity against Acinetobacter baumannii isolate 897 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID498360Antimicrobial activity against rifampin resistant Klebsiella pneumoniae 52145R assessed as growth inhibition by Etest method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence.
AID341089Antimicrobial activity against Clostridium difficile clinical isolates by agar dilution method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
AID529843Antibacterial activity against meropenem-resistant Pseudomonas aeruginosa clinical isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID1056842Antibacterial activity against TEM-1/SHV-12/CTX-15 expressing Enterobacter intermedius isolate 243 after 18 to 24 hrs by two-fold broth microdilution assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID521351Antimicrobial activity against Streptococcus pneumoniae isolate k-585 obtained from bronchoalveolar lavage fluid of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID533569Antimicrobial activity against Pseudomonas aeruginosa isolate PA475 expressing VIM-2 beta-lactamase2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID558047Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S10 by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID279560Antimicrobial activity against Haemophilus influenzae strains that are normal flora2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.
AID523487Antimicrobial activity against Pseudomonas aeruginosa M1251 by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1780308Antibacterial activity against wild type Pseudomonas aeruginosa LESB58 LpxA Gly120Ala mutant assessed as resistance development by measuring fold increase in MIC
AID165037In vitro antibacterial activity against Pseudomonas aeruginosa 1771M by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13
Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID520979Antibacterial activity against Pseudomonas aeruginosa KG2505 by Etest method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID523728Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E3502010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID425116Antimicrobial activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID584696Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5001 harboring mutation in conserved hypothetical protein by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1905562Antimicrobial activity against Bacillus subtilis ATCC 23857 assessed as reduction of bacterial growth incubated for 18 hrs by CLSI protocol based broth microdilution method2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Novel β-Hairpin Antimicrobial Peptides Containing the β-Turn Sequence of -RRRF- Having High Cell Selectivity and Low Incidence of Drug Resistance.
AID495715Kcat/Km ratio of Acinetobacter baumannii OXA-232010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID433170Antibacterial activity against Peptostreptococcus micros isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID565281Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A2 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
AID534845Mean residence time in critically ill patient with sepsis receiving high-volume continuous venovenous hemofiltration at 1000 mg/kg, iv administered every 8 hrs by HPLC method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
AID423288Antibacterial activity against Pseudomonas aeruginosa isolate 324 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID576537Antimicrobial activity against Carbapenem-resistant Klebsiella pneumoniae isolate ART2008024 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID528829Antimicrobial activity against ESBL producing Klebsiella pneumoniae assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID523954Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E419 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534887Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID583015Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 by agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID1757586Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-21 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID564535Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid carrying entire blaAmpC gene with alanine residue insertion at 215 position and R210P substitution by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID521356Antimicrobial activity against Streptococcus pneumoniae isolate 2907 obtained from sinusitis of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID571916Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 22 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID69764Antibacterial activity against Escherichia coli 1507E2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID495689Activity of Klebsiella oxytoca Beta-lactamase K12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID545552Ratio of MIC for Escherichia coli ERR2b to MIC for Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID285338Antimicrobial activity against streptomycin-resistant Escherichia coli J53 transconjugant with qnrA1 producing urinary specimen isolate 13.52 by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.
AID285576Antimicrobial activity against Pseudomonas aeruginosa 65.18-3 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID373785Antibacterial activity against imipenem-resistant Acinetobacter baumannii ISAB ab1254(r) by broth dilution method in presence of 2 ug/ml efflux pump inhibitor carbonyl cyanide m-chlorophenyl-hydrazone2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID498829Antimicrobial activity against carbapenem-resistant Enterobacter cloacae RJ94 deficient in IMP-4, TEM-1, CTX-M-3, ompC by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID523589Antibacterial activity against Pseudomonas aeruginosa P373 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID531583Antibacterial activity against Enterobacter cloacae obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID558331Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P338 by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID565711Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-16 harboring A residue at 105 position in PDC- 3 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID574463Antimicrobial activity against Escherichia coli isolate 339 expressing beta-lactamase KPC2, TEM and PFGE cluster 5 isolated from peritoneal fluid of patient by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID574756Antimicrobial activity against Anaerococcus prevotii assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1357438Antibacterial activity against extended-spectrum beta-lactamase producing Escherichia coli isolate 106342 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria.
AID584508Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0958 harboring oprD mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID433001Antibacterial activity against Corynebacterium aurimucosum isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1559381Antibacterial activity against Pseudomonas aeruginosa Ps296 AmpC/VIM-2/TEM-1 after 16 to 20 hrs by CLSI-based microbroth dilution method2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID574724Antimicrobial activity against Prevotella buccae assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1504350Hemolytic activity in sheep RBC after 1 hr2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and bioactivities study of new antibacterial peptide mimics: The dialkyl cationic amphiphiles.
AID496527fT>MIC in Klebsiella pneumoniae isolate 357 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 8-16 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID524089Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3492010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1596893Antibacterial activity against methicillin-resistant Staphylococcus aureus NR10198 incubated for 16 to 18 hrs by broth microdilution assay
AID519801Inhibition of Bocillin FL binding to PBP5 in Escherichia coli MC4100 membranes2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID532415Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-10 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID495914Hydrolytic activity of beta-lactamase VIM-1 expressed in Escherichia coli TOP10 by spectrophotometry2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID545558Ratio of MIC for Escherichia coli EIR2a to MIC for Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID222236In vivo therapeutic efficacy was determined against Pseudomonas aeruginosa 1771M by a single sc administration in mice1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID531676Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid containing OXA-58-3 by broth dilution test2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID535861Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae GZ47 harboring qnrB and qnrS genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID523721Antibacterial activity against Acinetobacter baumannii A901 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1225785Antibacterial activity against Klebsiella pneumoniae KP1004 expressing KPC2/TEM1/SHV11 by broth microdilution method2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID531315Activity of Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID534885Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID394678Antibacterial activity against Pseudomonas aeruginosa tracheal aspirate isolate 8 carrying insertion sequence ISPa26 inserted into oprD gene by disk susceptibility test2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.
AID523551Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E450 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1348993Antibacterial activity against Staphylococcus aureus ATCC 29213 after 16 to 20 hrs by broth microdilution method2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and antibacterial evaluation of novel cationic chalcone derivatives possessing broad spectrum antibacterial activity.
AID200852Antibacterial activity against Salmonella Typhimurium2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.
AID423339Antibacterial activity against Acinetobacter baumannii isolate 886 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID1680008Induction of inner membrane permeabilization in Escherichia coli ATCC 25922 at 20 ug/ml measured for 12 mins by propidium iodide staining based fluorescence microscopic analysis2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID533369Antimicrobial activity against Bacteroides vulgatus by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID523559Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E483 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523594Antibacterial activity against Pseudomonas aeruginosa P327 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID531777Antimicrobial activity against Pseudomonas aeruginosa urine isolate 4663 expressing beta-lactamase IMP-15 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID565539Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-03 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1759646Antimicrobial activity against vancomycin-resistant Enterococcus faecium clinical isolate 1088228 by CLSI-based broth microdilution assay2021European journal of medicinal chemistry, Jul-05, Volume: 2194-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.
AID582975Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 harboring dacB gene by Etest method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID1056850Antibacterial activity against TEM-1/SHV-12 expressing Klebsiella pneumoniae isolate 303 after 18 to 24 hrs by two-fold broth microdilution assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID1373316Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-18 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID524824Antibacterial activity against erythromycin resistant Campylobacter sp. by agar plate dilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID545348Displacement of [14C]benzylpenicillin from PBP3 in Pseudomonas aeruginosa ATCC 156922009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID496510fT>MIC in Klebsiella pneumoniae isolate 357 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 0-8 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID532104Antimicrobial against Pseudomonas aeruginosa 312 harboring PBPP allele by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID1373313Antimicrobial activity against Escherichia coli expressing beta-lactamase MIR-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID584321Antimicrobial activity against Serratia marcescens ATCC 8100 by agar dilution method in presence of 4 ug/ml of clavulanic acid2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID510511Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate N2AC9-19 expressing KPC beta lactamase2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID425106Antimicrobial activity against Clostridium clostridioforme isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID571910Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 19 expressing ampC, ompA, adeB, adeM, aacC2 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID524074Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3732010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584711Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0770 harboring rnc mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID534433Antimicrobial activity against Peptostreptococcus anaerobius ATCC 27337 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID1296367Inhibition of Mycobacterium tuberculosis LdtMt1 expressed in Escherichia coli assessed as first order rate constant for oxyanion formation by stopped-flow spectrofluorimetric method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Routes of Synthesis of Carbapenems for Optimizing Both the Inactivation of L,D-Transpeptidase LdtMt1 of Mycobacterium tuberculosis and the Stability toward Hydrolysis by β-Lactamase BlaC.
AID574979Antimicrobial activity against Actinomyces meyeri assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID586057Antimicrobial activity against Acinetobacter baumannii clinical isolate harboring plasmid encoded ISAba1-blaOXA-51-like gene with nuc upstream sequence by agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan.
AID285595Antimicrobial activity against Pseudomonas aeruginosa 1B9 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID522025Antimicrobial activity against Escherichia coli isolate A expressing beta-lactamase OXA-48 and TEM-150 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID555252Antibacterial activity against Acinetobacter genomosp. 3 isolate 67 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID571428Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method in presence of 0.5 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID584568Antimicrobial activity against Acinetobacter lwoffii isolate B expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID528819Antimicrobial activity against carbapenem-resistant Enterobacter cloacae assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID535846Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID523586Antibacterial activity against Pseudomonas aeruginosa P332 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523575Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E479 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID429080Activity at Klebsiella pneumoniae Greece Carbapenem-Hydrolyzing-Lactamase KPC-2 assessed per mg of total protein by spectrophotometrically2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.
AID529482Antimicrobial activity against Enterobacter cloacae isolate 140 containing PFGE genetic clone A expressing beta-lactamase KPC-2 and SHV-12 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID518192Antimicrobial activity against mexAB-oprM protein and mexCD-oprJ deficient Pseudomonas aeruginosa PAO238 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID531766Antimicrobial activity against Pseudomonas aeruginosa blood isolate 4677 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID534294Antimicrobial activity against Stenotrophomonas maltophilia KJ by Etest2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID564526Antimicrobial activity against Acinetobacter baumannii AYE expressing VEB-1 gene by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID573573Antibacterial activity against beta-lactamase producing Bacteroides uniformis assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID544496Ratio of MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-4 to MIC for Escherichia coli TOP102009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID523923Antibacterial activity against Acinetobacter baumannii A901 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID510508Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate MC1AC9-26 expressing KPC beta lactamase2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID496545fT>MIC in Klebsiella pneumoniae isolate 360 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 16-24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID523562Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E358 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523935Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E415 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID495834Antimicrobial activity against Escherichia coli DH5alpha harbouring plasmid BK-VIM-19 expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID519066Antibacterial activity against multidrug resistant Streptococcus pneumoniae ATCC 49619 by CLSI microdilution susceptibility testing method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Activity of the Diaminopyrimidine AR-709 against recently collected multidrug-resistant isolates of invasive Streptococcus pneumoniae from North America.
AID495708Kcat/Km ratio of Enterobacter cloacae AmpC2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1311359Antibacterial activity against Acinetobacter baumannii ATCC 19606 measured after 18 hrs by broth microdilution assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.
AID295830Antibacterial activity against Proteus vulgaris 868 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID532407Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B2 isolate VA-06X-20 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID520778Antibacterial activity against beta-lactamase KPC-2 producing Escherichia coli isolate E1 by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID518462Antimicrobial activity against Enterobacter cloacae S9369 assessed as number of passages required for MIC to rise above 4 times original MIC2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID524108Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A8962010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1873896Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs using 10^5 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1417174Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS4 by CLSI method2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis of 1,2,3-triazole linked 4(3H)-Quinazolinones as potent antibacterial agents against multidrug-resistant Staphylococcus aureus.
AID423289Antibacterial activity against Pseudomonas aeruginosa isolate 326 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID585397Activity at Stenotrophomonas maltophilia 1SML metallo-beta-lactamase L12010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID1767685Antibacterial activity against Escherichia coli EIEC E20851 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID423521Antibacterial activity against Acinetobacter baumannii isolate 920 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID533566Antimicrobial activity against Pseudomonas aeruginosa isolate PA462 expressing VIM-2 beta-lactamase2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID496479Antibacterial activity against Klebsiella pneumoniae isolate 368 in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID289880Antibacterial activity against Klebsiella aerogenes 1522E2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID285573Antimicrobial activity against Pseudomonas aeruginosa P21.21 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1698705Antibacterial activity against genotype penicillin-resistant Streptococcus pneumoniae by CLSI method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID285996Antimicrobial activity against ESBL producing Escherichia coli 311 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID523894Antibacterial activity against Pseudomonas aeruginosa P363 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1628584Antibacterial activity against Klebsiella pneumoniae 1161486a deficient in tolC incubated for 18 to 24 hrs by broth microdilution method2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
Discovery and Characterization of a Class of Pyrazole Inhibitors of Bacterial Undecaprenyl Pyrophosphate Synthase.
AID1296371Activity at Mycobacterium tuberculosis beta lactamase BlaC expressed in Escherichia coli assessed as ratio of Kcat to Km by spectrophotometric method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Routes of Synthesis of Carbapenems for Optimizing Both the Inactivation of L,D-Transpeptidase LdtMt1 of Mycobacterium tuberculosis and the Stability toward Hydrolysis by β-Lactamase BlaC.
AID522646Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis Ohio by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID534411Antimicrobial activity against methicillin-susceptible coagulase-negative Staphylococcus by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1873914Antibacterial activity against Pseudomonas aeruginosa LTP-3 incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID322317Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID531788Antibacterial activity against Klebsiella oxytoca obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID572136Antimicrobial activity against Acinetobacter baumannii eta clonal group isolate 35 expressing ampC, ompA, adeB, adeM by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID518728Activity of Pseudomonas stutzeri beta-lactamase DIM-1 by UV-spectrophotometry2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands.
AID1505215Antibacterial activity in Escherichia coli BL21 (DE3) expressing pET-24a-blaNDM-1 incubated at 37 degC for 18 hrs by spectrophotometry2018ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1
Structure-Based Virtual Screening for the Discovery of Novel Inhibitors of New Delhi Metallo-β-lactamase-1.
AID496533fT>MIC in Pseudomonas aeruginosa isolate 1030 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 8-16 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID577429Antimicrobial activity against Acinetobacter baumannii2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Serum and cerebrospinal fluid levels of colistin in pediatric patients.
AID279941Antibiotic susceptibility by resistance against non-MDR Pseudomonas aeruginosa from samples collected from patients2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
AID1757558Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-6 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID519796Inhibition of Bocillin FL binding to PBP1A in Escherichia coli MC4100 membranes2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID534700Antimicrobial activity against Fusobacterium mortiferum by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID518824Antibacterial activity against Pulsotype L Acinetobacter genomosp. 3 isolate 2 containing IMP-8, OXA-58, ADC-43, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID530817Antibacterial activity against Escherichia coli J53 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID572144Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 39 expressing ampC, ompA, adeM by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID423517Antibacterial activity against Acinetobacter baumannii isolate 916 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID523713Antibacterial activity against Acinetobacter baumannii A898 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584572Antimicrobial activity against Acinetobacter lwoffii isolate F expressing beta-lactamase OXA-164 isolated from tracheostoma of patient by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID523770Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E4572010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1357441Antibacterial activity against KPC-2 producing Klebsiella pneumoniae isolate 212423 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria.
AID584523Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3520 harboring mutation in putative periplasmic metal-binding protein by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID523493Antimicrobial activity against Pseudomonas aeruginosa 1405-con D2 by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID523723Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E3442010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID531313Activity of Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID1757508Antibacterial activity against Acinetobacter baumannii NCTC 13304 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID433161Antibacterial activity against Clostridium innocuum isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID1056841Antibacterial activity against TEM-1/SHV-12 expressing Aeromonas hydrophila isolate 268 after 18 to 24 hrs by two-fold broth microdilution assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID1539481Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae ATCC BAA-1705 clinical isolates after 18 to 20 hrs in aerobic condition by CLSI-based broth microdilution assay
AID534465Antimicrobial activity against Bacteroides fragilis GAI 10150 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID1906444Induction of membrane disruption in Staphylococcus aureus ATCC BAA -1556 assessed as increase in PI positive cells at MIC incubated for 2 hrs by Propidium iodide staining based FACS cytometry analysis relative to control2022European journal of medicinal chemistry, May-05, Volume: 235Amphiphilic cyclic peptide [W
AID499130Antimicrobial activity against Pseudomonas aeruginosa OC 4354 infected in immunocompromized SKH1 mouse assessed as log change in bacterial colony forming unit at 1.6 mg/kg/day, sc2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID511127Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 12010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID1680054Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae clinical isolate 2 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID575003Antimicrobial activity against Eubacterium lentum assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID423284Antibacterial activity against Pseudomonas aeruginosa isolate 319 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID1225782Antibacterial activity against Enterobacter cloacae ECL1058 expressing KPC3/SHV-11/TEM-1 by broth microdilution method2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID495674Antimicrobial activity against wild type Klebsiella oxytoca OC 4076 expressing Beta-lactamase K1 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID433157Antibacterial activity against Clostridium perfringens isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID528824Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID1417171Antibacterial activity against methicillin-resistant Staphylococcus aureus NR10194 by CLSI method2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis of 1,2,3-triazole linked 4(3H)-Quinazolinones as potent antibacterial agents against multidrug-resistant Staphylococcus aureus.
AID576068Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 69036 harboring porin OmpK36V mutant gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID1395482Antibacterial activity against new delhi metallo-beta-lactamase-1 harboring Klebsiella pneumoniae ATCC BAA-2146 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, Apr-25, Volume: 150Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID289890Antibacterial activity against Bacillus megaterium2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID433198Antibacterial activity against Bacteroides fragilis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523507Antimicrobial activity against Pseudomonas aeruginosa isolate 1495c from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID561480Antibacterial activity against Pseudomonas aeruginosa assessed as susceptible isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID534920Antimicrobial activity against Ceftazidime non-susceptible Serratia marcescens by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID576323Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008226 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID394681Antibacterial activity against Pseudomonas aeruginosa cystic fibrosis sputum isolate 529 carrying insertion sequence ISPa26 by disk susceptibility test2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.
AID523722Antibacterial activity against Acinetobacter baumannii A903 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534667Antimicrobial activity against Prevotella intermedia ATCC 25611 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID1752488Antibacterial activity against Enterobacter cloacae IR32 producing class B beta-lactamase, NDM-1 assessed as reduction in microbial growth incubated for 16 to 20 hrs in presence of vaborbactam by broth microdilution method2021Bioorganic & medicinal chemistry, 09-15, Volume: 46A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID496551fT>MIC in Pseudomonas aeruginosa isolate 1038 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 16-24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID574486Antimicrobial activity against Bacteroides caccae after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID523768Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E4202010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID585400Ratio of Kcat to Km for Fluoribacter gormanii 1K07 metallo-beta-lactamase FEZ-12010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID279814Antimicrobial activity against Escherichia coli DH5-alpha with pYW2 expressing KPC2 and TEM1 gene by agar dilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID523914Antibacterial activity against Acinetobacter baumannii A908 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1720997Synergistic Inhibition of beta lactamase VIM-29 in Escherichia coli 50639799 assessed colony formation by visual inspection in presence of 50 microM 2,5-Dichloro-N-((4-((cyclohexylamino)methyl)-1H-1,2,3-triazol-5-yl)methyl)benzenesulfonamide incubated for2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Structural studies of triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-β-lactamases.
AID499140fT>MIC in Pseudomonas aeruginosa OC 4351 infected sc dosed SKH1 mouse administered in 24 hrs dosing interval2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID528535Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B513 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID499067Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ89 deficient in CTX-M-14, ompC/F by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1757544Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-8 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID565536Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-32 harboring A residue at 105 position in PDC- 10 by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID574466Antimicrobial activity against Escherichia coli isolate 360T expressing beta-lactamase KPC2, OXA-9 and PFGE cluster 1 isolated from urine of patient by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID341108Antibacterial activity against Escherichia coli 26R793 by Etest2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12.
AID535852Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae FJ67T harboring qnrS gene by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID524098Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A8642010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID555265Antibacterial activity against Acinetobacter genomosp. 3 isolate 109 by Etest method in presence of efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID289882Antibacterial activity against Staphylococcus aureus giorgio2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID1361169Antimicrobial activity against IMP-1 producing Pseudomonas aeruginosa SR27060 in presence of human apo-transferrin by broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.
AID547777Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237G mutant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID564219Antimicrobial activity against Acinetobacter baumannii ATCC 19606 by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
AID324862Antimicrobial activity against Acinetobacter baumannii A24C after 4 days by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID564946Antimicrobial activity against Acinetobacter baumannii isolate Ab168 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba92009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID535140Antimicrobial activity against imipenem susceptible Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID587727Antimicrobial activity against Escherichia coli DH5alpha carrying Pseudomonas aeruginosa strain PS 297 IMP-18-pLBII after 18 hrs by microdilution broth method2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID53769Stability to porcine renal DHP-I was determined2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID535143Antimicrobial activity against imipenem non-susceptible Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID520726Activity of Escherichia coli TOP10 beta-lactamase OXA-58 assessed per mg of protein at 100 uM2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID524314Antibacterial activity against Acinetobacter baumannii A865 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574462Antimicrobial activity against Escherichia coli isolate 329T expressing beta-lactamase KPC2 and PFGE cluster 2 isolated from blood of patient by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID1883770Antibacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth incubated for 14 days2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Tuberculosis Drug Discovery: Challenges and New Horizons.
AID534361Antibacterial activity against Acinetobacter baumannii GIL1 isolate harboring intrinsic blaOXA-51/69-like gene by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Carbapenem-resistant Acinetobacter baumannii isolates expressing the blaOXA-23 gene associated with ISAba4 in Belgium.
AID285599Antimicrobial activity against Pseudomonas aeruginosa 2A2 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID535633Antimicrobial activity against Group B streptococcus serotype Ia R7 harboring T77I, F395V and S353F in PBP 2X; V80A and G613R in PBP 2B; and L45P, N163K, N723S and Y470F in PBP 1A by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID560060Antimicrobial activity against Pseudomonas aeruginosa by broth microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID200507Compound was evaluated for its antibacterial activity against Staphylococcus enteritidis 22003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID165039In vitro antibacterial activity against Pseudomonas aeruginosa 9027 by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13
Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID495701Kcat/Km ratio of Escherichia coli TEM-12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID555208Antibacterial activity against Acinetobacter genomosp. 3 isolate 69 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID584311Antimicrobial activity against beta-lactamase ompC intact/ompF deficient Serratia marcescens isolate YMC0566 by agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID545356Antibacterial activity against Staphylococcus aureus SRR2a selected at 2 times MIC of tomopenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID372329Antibacterial activity against hypermutable Pseudomonas aeruginosa isolate 12-09-15 assessed as maximum bactericidal effect in in vitro PK/PD model by measuring change in bacterial count at 1 g infused every 8 hrs interval measured 3 hrs after first dose 2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID573835Antibacterial activity against beta-lactamase producing Clostridium paraputrificum assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID565518Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-17 harboring A residue at 105 position in PDC- 3 by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID433017Antibacterial activity against Bacteroides fragilis isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID528968Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID558608Antimicrobial activity against Streptococcus pneumoniae isolate 1394 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID495843Ratio of Kcat to Km for Escherichia coli DH10B beta-lactamase VIM-2 by microacidimetric method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID524287Antibacterial activity against Pseudomonas aeruginosa P356 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1720998Inhibition of beta lactamase VIM-2 in Pseudomonas aeruginosa K34-7 assessed colony formation by visual inspection incubated for 20 hrs by two-fold dilution method2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Structural studies of triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-β-lactamases.
AID576280Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17830 harboring porin OmpK36V mutant gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID495667Antimicrobial activity against wild type Klebsiella pneumoniae OC 15263 expressing beta-lactamase SHV-1 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID564953Antimicrobial activity against Acinetobacter baumannii isolate Ab91 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba92009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID433195Antibacterial activity against Streptococcus agalactiae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID496554fT>MIC in Pseudomonas aeruginosa isolate 896 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 16-24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID573819Antibacterial activity against Veillonella parvula by by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID560080Antimicrobial activity against Pseudomonas aeruginosa isolate 1037 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID70115Compound was evaluated for its antibacterial activity against Escherichia coli CCARM 1115 MDR2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID524091Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3702010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID560070Antimicrobial activity against Klebsiella pneumoniae isolate 5436 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID574999Antimicrobial activity against Eubacterium lentum after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1706875Antibacterial activity against methicillin-resistant Staphylococcus aureus NR10186 measured after 16 to 18 hrs2021European journal of medicinal chemistry, Feb-15, Volume: 212Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.
AID545397Antimicrobial activity against Pseudomonas aeruginosa PS3 with PFGE phenotype 12 obtained from sputum of ICU patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID535131Antimicrobial activity against Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID295835Antibacterial activity against Corynebacterium diphtheriae after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID532894Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 475 transformant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID528523Antimicrobial activity against penicillin-resistant Streptococcus agalactiae ATCC 12403 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID518460Antimicrobial activity against Acinetobacter junii 15218 assessed as number of passages required for MIC to rise above 4 times original MIC2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID520713Antibacterial activity against Escherichia coli TOP10 harboring pOXA-972008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID535657Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae FJ61T harboring qnrS gene by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID555473Antibacterial activity against Acinetobacter genomosp. 3 isolate 128 by Etest method in presence of cloxacillin and efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID404958Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii T193 isolate carrying two bla-OXA58 gene copies by agar dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID523936Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E437 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573574Antibacterial activity against beta-lactamase producing Bacteroides uniformis assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID544493Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase KPC-4 by agar dilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID433369Antibacterial activity against Peptoniphilus asaccharolyticus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID555220Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 103 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID534625Antimicrobial activity against Escherichia coli assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID555221Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 109 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID534441Antimicrobial activity against Clostridium septicum ATCC 12464 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520717Antibacterial activity against Acinetobacter baumannii CIP7010 harboring pOXA-97 by disk diffusion method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID562755Activity of Klebsiella pneumoniae AH27 CTX-M-15 beta-lactamase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID529576Ratio of Kcat to Km for Erwinia carotovora subsp. atroseptica DSM 30184 beta-Lactamase CAR-12008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID558423Antimicrobial activity against Burkholderia pseudomallei by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
In vitro activity of doripenem against Burkholderia pseudomallei.
AID573590Antibacterial activity against Fusobacterium varium by by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID573786Antibacterial activity against Prevotella melaninogenica by by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1706295Chemical stability of compound assessed as compound degradation at 37 degreeC measured for 24 hrs2020European journal of medicinal chemistry, Dec-15, Volume: 208β-lactam antibiotics: An overview from a medicinal chemistry perspective.
AID423233Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as resistant isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID532394Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A2 isolate NA-14X-32 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID529860Ratio of MIC for Pseudomonas aeruginosa OCR1 to MIC for Pseudomonas aeruginosa PAO12008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID567470Antimicrobial activity against gBLNAS Haemophilus influenzae by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID286013Antimicrobial activity against ESBL producing Escherichia coli 312 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID518184Antimicrobial activity against Pseudomonas aeruginosa 18S/H harboring beta-lactamase Class C by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID545570Ratio of MIC for Pseudomonas aeruginosa PRR4a to MIC for Pseudomonas aeruginosa ATCC 156922009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID499151Tmax in immunocompromized SKH1 mouse plasma at 12.5 mg/kg, sc2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID373026Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PUA1 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID534694Antimicrobial activity against Porphyromonas asaccharolyticus by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID545612Antimicrobial activity against Pseudomonas aeruginosa PS33 with PFGE phenotype 9A obtained from blood of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID496519fT>MIC in Pseudomonas aeruginosa isolate 762 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 0-8 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID529666Ratio of Kcat to Km for Pseudomonas aeruginosa COL-1 beta-lactamase VIM-2 relative to cephaloridine2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID1765577Antibacterial activity against Escherichia coli ATCC 25922 incubated for 18 hrs by CLSI based broth dilution method2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Novel Broad-Spectrum Antimicrobial Peptide Derived from Anoplin and Its Activity on Bacterial Pneumonia in Mice.
AID558621Antimicrobial activity against Streptococcus pneumoniae isolate 3346 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID1902630Antibacterial activity against Methicillin-drug resistant Staphylococcus aureus C0621 incubated for 18 hrs by by disc diffusion method2022ACS medicinal chemistry letters, Feb-10, Volume: 13, Issue:2
Antibacterial Activity of Metergoline Analogues: Revisiting the Ergot Alkaloid Scaffold for Antibiotic Discovery.
AID373759Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab1316 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID517970Antimicrobial activity against Klebsiella oxytoca 1028E harboring beta-lactamase K1 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID96093Compound was evaluated for its antibacterial activity against Klebsiella pneumoniae 8 ESBL2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID1649583Antimicrobial activity against Klebsiella pneumoniae clinical isolates by standard broth microdilution method2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID289894Antibacterial activity against Pseudomonas cepacia2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID558597Antimicrobial activity against Streptococcus pneumoniae 9 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID1759656Antimicrobial activity against against methicillin-resistant Staphylococcus aureus clinical isolate 1088888 by CLSI-based broth microdilution assay2021European journal of medicinal chemistry, Jul-05, Volume: 2194-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.
AID545614Antimicrobial activity against Pseudomonas aeruginosa PS35 with PFGE phenotype 11A obtained from urine of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID423337Antibacterial activity against Acinetobacter baumannii isolate 884 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID571391Antibacterial activity against Acinetobacter baumannii F264 by Etest method in presence of 0.125 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID1767680Antibacterial activity against Escherichia coli STEC 2C1 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID499062Antimicrobial activity against carbapenem-resistant Escherichia coli HX74 deficient in TEM-1, CTX-M-14, CTX-M-3, aac(6')-Ibcr, ompC/F by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID323864Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 25923 after phagocytosis by human THP1 macrophages assessed as reduction in bacterial count at pH 5.5 after 24 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Role of acidic pH in the susceptibility of intraphagocytic methicillin-resistant Staphylococcus aureus strains to meropenem and cloxacillin.
AID558595Antimicrobial activity against Streptococcus pneumoniae 7 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID95702Antibacterial activity against Klebsiella aerogenes 1522E2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.
AID522644Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis SK57 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID558539Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter coli isolate P1826 by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID558620Antimicrobial activity against Streptococcus pneumoniae isolate 3282 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID656448Antibacterial activity against Pseudomonas aeruginosa clinical isolate2011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID356632Antibacterial activity against methicillin-resistant Staphylococcus aureus KIST3 after 18 hrs2003Journal of natural products, Nov, Volume: 66, Issue:11
New bromotyrosine derivatives from an association of two sponges, Jaspis wondoensis and Poecillastra wondoensis.
AID523766Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E4812010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1887614Synergistic antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as fractional inhibitory concentration incubated for 24 hrs in presence of artocarpin by checkerboard method2022Journal of natural products, 10-28, Volume: 85, Issue:10
Developing the Natural Prenylflavone Artocarpin from
AID423309Antibacterial activity against Pseudomonas aeruginosa isolate 352 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID510506Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-6 expressing KPC beta lactamase2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID511130Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 42010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID1846921Antibacterial activity against KPC2-producing multidrug resistant Klebsiella pneumoniae assessed as reduction in bacterial growth incubated for 18 to 20 hrs by CLSI based microdilution method2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Design, Synthesis, and Biological Evaluation of Novel Pyrimido[4,5-
AID535145Antimicrobial activity against imipenem non-susceptible Pseudomonas aeruginosa assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID511137Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 112010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID574050Antibacterial activity against beta-lactamase producing Finegoldia magna by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID425089Antimicrobial activity against Porphyromonas gingivalis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID524324Antibacterial activity against Acinetobacter baumannii A928 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID531588Antibacterial activity against Proteus penneri obtained from complicated skin and skin structure infections by agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID558596Antimicrobial activity against Streptococcus pneumoniae 8 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID761210Antibacterial activity against Klebsiella pneumoniae expressing KPC by broth microdilution method2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Pyridone-conjugated monobactam antibiotics with gram-negative activity.
AID521346Antimicrobial activity against Streptococcus pneumoniae isolate 2904 obtained from blood of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID535063Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pOXA-58-6 plasmid by agar dilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
AID761218Antibacterial activity against Pseudomonas aeruginosa 1042-06 by broth microdilution method2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Pyridone-conjugated monobactam antibiotics with gram-negative activity.
AID209575In vivo antibacterial activity against Streptococcus faecium MD 8b1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID532166Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii PU55 harboring GyrA T83I, ParC S80I mutant, wild-type GyrB, qnrA genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID496528fT>MIC in Klebsiella pneumoniae isolate 360 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 8-16 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID495724Activity of Pseudomonas aeruginosa OXA-10 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID584510Antimicrobial activity against Pseudomonas aeruginosa PA14 PA14_15600 harboring mutation in conserved hypothetical protein by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID555474Antibacterial activity against Acinetobacter genomosp. 3 isolate 195 by Etest method in presence of cloxacillin and efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID285691Antimicrobial susceptibility of Citrobacter freundii CF6010 isolate expressing carbapenemase KPC22007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID1759652Antimicrobial activity against against methicillin-sensitive Staphylococcus aureus clinical isolate 1088105 by CLSI-based broth microdilution assay2021European journal of medicinal chemistry, Jul-05, Volume: 2194-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.
AID498823Antimicrobial activity against Klebsiella pneumoniae WH77T expressing IMP-4, TEM-1, CTX-M-3, qnrS1 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID285993Antimicrobial activity against ESBL producing Klebsiella pneumoniae 270 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID517959Antimicrobial activity against Acinetobacter sp. by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID562757Ratio of Kcat to Km for Klebsiella pneumoniae AH27 CTX-M-15 beta-lactamase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID523544Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E458 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID68209In vitro antibacterial activity against Enterobacter cloacae 1321E2000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Synthesis and antibacterial activity of new carbapenems containing isoxazole moiety.
AID1442619Antibacterial activity against Pseudomonas aeruginosa PA694 in CD-1 mouse model of thigh infection assessed as reduction in log10CFU per gram of thigh at 5 mg/kg, iv bid administered 2 to 12 hrs of post-infection measured after 24 hrs relative to untreate2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID509867Antibacterial activity against Acinetobacter baumannii isolate 2824 isolated from human urine2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID295785Antibacterial activity against coagulase negative Staphylococcus after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID372354Antibacterial activity against Pseudomonas aeruginosa PAO1 in in vitro PK/PD model assessed as AAC (0 to 8 hrs) at 1 g infused thrice daily at 8 hrs interval measured after first dose2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID545357Ratio of MIC for Staphylococcus aureus SRR2a to MIC for Staphylococcus aureus ATCC 6538P2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID531316Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID565716Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-21 harboring A residue at 105 position in PDC- 4 and polymorphic OprD gene by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1407969Antibacterial activity against Acinetobacter baumannii ARC3492 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID520383Antimicrobial activity Escherichia coli DH5alpha expressing metallo-beta-lactamase VIM-11 by agar macrodilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID560591Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ799 by microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID585402Ratio of Kcat to Km for Chryseobacterium meningosepticum NCTC 10585 metallo-beta-lactamase GOB-12010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID584720Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2970 harboring rpmF mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID495906Antimicrobial activity in Escherichia coli TOP10 hourbouring recombinant plasmid VIM-4 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID519627Antimicrobial activity against Brachyspira pilosicoli 80.10 without producing beta-lactamase OXA-63 by disc diffusion method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.
AID283397Antimicrobial activity against Nocardia transvalensis after 72 hrs by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID519289Antimicrobial activity against Escherichia coli TOP10 harboring Beta-lactamase OXA-23 by Etest2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp.
AID423525Antibacterial activity against Acinetobacter baumannii isolate 924 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID528832Antimicrobial activity against CTX-M ESBL producing Escherichia coli isolated from ICU patient urine assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID576541Antimicrobial activity against OmpK35,OmpK36-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008141 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID495710Kcat/Km ratio of Klebsiella pneumoniae KPC-22010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1407963Antibacterial activity against Acinetobacter baumannii ARC2781 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID496502fT>MIC in Pseudomonas aeruginosa isolate 762 at 2 gram for every 8 hrs administered as 3 hrs infusion over 24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID523946Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E460 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534435Antimicrobial activity against Staphylococcus saccharolyticus ATCC 14953 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID495816Antimicrobial activity against Escherichia coli 2603 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID554987Antibacterial activity against Acinetobacter genomosp. 3 isolate 52 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID206732In vitro antibacterial activity against Staphylococcus aureus 2852000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Synthesis and antibacterial activity of new carbapenems containing isoxazole moiety.
AID518002Antibacterial activity against Nocardia brasiliensis isolated from actinomycetoma patient by broth dilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro activity of ACH-702, a new isothiazoloquinolone, against Nocardia brasiliensis compared with econazole and the carbapenems imipenem and meropenem alone or in combination with clavulanic acid.
AID524117Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A8912010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1533867Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 2728 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID560088Bactericidal activity against Pseudomonas aeruginosa isolate 1037 at 1/4 times MIC after 24 hrs by time kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID206272In vitro antibacterial activity against Staphylococcus aureus SG 5112001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.
AID322788Antimicrobial activity against Bacteroides vulgatus assessed as percent resistant isolates2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID545342Displacement of [14C]benzylpenicillin from PBP4 in Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID285579Antimicrobial activity against Pseudomonas aeruginosa IA5 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID518241Antimicrobial activity against Acinetobacter junii 15218 assessed as appearance of colony at 4 times MIC concentration2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID283395Antimicrobial activity against Nocardia nova after 72 hrs by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID405819Antimicrobial activity against Acinetobacter sp. 5227 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-32007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID1757608Antibacterial activity against Enterobacter aerogenes 17-4 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1311362Antibacterial activity against Klebsiella pneumoniae ATCC 35657 measured after 18 hrs by broth microdilution assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.
AID1373318Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-40 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID584560Antimicrobial activity against Acinetobacter lwoffii isolate G expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID561628Antimicrobial activity against ampD1-deficient Stenotrophomonas maltophilia KJ by twofold serial agar dilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID1407952Antibacterial activity against Pseudomonas aeruginosa ARC3756 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID576311Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 29830 harboring porin OmpK36V mutant gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID529854Antibacterial activity against MexA-MexB-OprM-overproducing and OprD-deficient Pseudomonas aeruginosa N041 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID584691Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4527 harboring pilC mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID531974Antibacterial activity against Escherichia coli DH10B by agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID574496Antimicrobial activity against Bacteroides fragilis assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID529194Antibacterial activity against AmpC-producing Escherichia coli isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
AID373040Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZJ58 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID532105Antimicrobial against Pseudomonas aeruginosa 46396 harboring katA allele by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID565516Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-19 harboring A residue at 105 position in PDC- 3 wild-type OprD porin gene by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID511138Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 122010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID583082Ratio of Kcat to Km for Escherichia coli BL21(DE3) wild-type VIM-2 beta-lactamase by spectrophotometer2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID373024Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU4A1 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID495696Activity of Serratia marcescens SME-32010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID207639Antibacterial activity against Staphylococcus aureus SG 5111998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID522009Antimicrobial activity against Klebsiella pneumoniae isolate KpBIC expressing beta-lactamase OXA-48 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID433202Antibacterial activity against Bacteroides thetaiotaomicron isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID423317Antibacterial activity against Pseudomonas aeruginosa isolate 360 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID534628Antimicrobial activity against Non-ESBL Escherichia coli assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID295826Antibacterial activity against Serratia marcescens 6093 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID524073Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3692010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574774Antimicrobial activity against Clostridium perfringens assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID524320Antibacterial activity against Acinetobacter baumannii A849 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534908Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1546208Clearance in rat2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID523729Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E4082010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID373035Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate BJ55 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID390322Antimicrobial activity against methicillin-resistant Staphylococcus aureus 433002008Journal of natural products, Dec, Volume: 71, Issue:12
Citreamicins with potent gram-positive activity.
AID517958Antimicrobial activity against Serratia marcescens by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID495793Antimicrobial activity against Escherichia coli DH10B by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID524267Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E362 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID564534Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid carrying entire blaAmpC gene with alanine residue deletion at 215 position and R210P substitution by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID563155Antibacterial activity against Pseudomonas aeruginosa isolate 9BR by Etest2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
AID532906Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 525 transformant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID565534Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-01 harboring T residue at 105 position in PDC- 1 by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID499049Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU104 deficient in TEM-1, SHV-11, CTX-M-15, qnrS1, ompK35/36 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID522669Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis B133 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID575001Antimicrobial activity against Eubacterium lentum assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID565506Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-24 harboring A residue at 105 position in PDC- 5 by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1846922Antibacterial activity agains wild type Klebsiella pneumoniae ATCC BAA-1705 assessed as reduction in bacterial growth incubated for 18 to 20 hrs by CLSI based microdilution method2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Design, Synthesis, and Biological Evaluation of Novel Pyrimido[4,5-
AID286038Antimicrobial activity against ESBL producing Klebsiella pneumoniae 256 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID529480Antimicrobial activity against Enterobacter cloacae isolate 1 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID423295Antibacterial activity against Pseudomonas aeruginosa isolate 332 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID549332Antimicrobial activity against Escherichia coli isolate 86 harboring bla CTX-M-3a gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID560834Antimicrobial activity against Acinetobacter baumannii isolate Ab5 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba92009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID373028Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU86 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID496550fT>MIC in Pseudomonas aeruginosa isolate 1030 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 16-24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID1596892Antibacterial activity against methicillin-resistant Staphylococcus aureus NR10129 incubated for 16 to 18 hrs by broth microdilution assay
AID496515fT>MIC in Klebsiella pneumoniae isolate 361 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 0-8 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID286008Antimicrobial activity against Escherichia coli 120 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID496569Antibacterial activity against Pseudomonas aeruginosa isolate 1177 assessed as reduction of bacterial count at 8 ug/ml within 6 hrs in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID511141Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 152010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID558329Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P305 by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID423522Antibacterial activity against Acinetobacter baumannii isolate 921 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID565197Antimicrobial activity against Klebsiella pneumoniae isolate H-1406 expressing VIM-1 and KPC-2 genes by microdilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID425095Antimicrobial activity against Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID561454Antibacterial activity against Enterobacter cloacae by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID563973Ratio of Kcat to Km for Klebsiella pneumoniae 05-560 beta-lactamase NDM-12009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID584573Antimicrobial activity against Acinetobacter lwoffii isolate G expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID523513Antimicrobial activity against Pseudomonas aeruginosa isolate 3149 from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID534480Antimicrobial activity against Prevotella heparinolytica ATCC 35895 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534641Antimicrobial activity against Klebsiella pneumoniae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID396030Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP2 plasmid containing Enterobacter cloacae acrA gene by Etest2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID523927Antibacterial activity against beta-lactamase-negative Escherichia coli E346 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID374363Activity of Aeromonas caviae A324R metallo-beta-lactamase IMP-19 expressed in Escherichia coli DH5alpha by computerized microacidimetric method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID433169Antibacterial activity against Peptostreptococcus anaerobius isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID521997Antimicrobial activity against Klebsiella pneumoniae isolate Kp4A expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID555242Antibacterial activity against Acinetobacter genomosp. 3 isolate 52 by Etest method of efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID495731Kcat/Km ratio of Escherichia coli TEM-1 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID373042Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZJ49 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID1906415Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in microbial growth incubated for 24 hrs by microbroth dilution method2022European journal of medicinal chemistry, May-05, Volume: 235Amphiphilic cyclic peptide [W
AID534884Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID534699Antimicrobial activity against Fusobacterium varium by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID533384Antimicrobial activity against Bacteroides nordii assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID535139Antimicrobial activity against Ceftazidime non-susceptible Pseudomonas aeruginosa assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID534478Antimicrobial activity against Prevotella buccae ATCC 33574 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID207158Antibacterial activity against Staphylococcus aureus 5032003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID548024Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237H mutant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID1863326Antibacterial activity against Escherichia coli SI-004M assessed as reduction in microbial growth after 24 hrs by two-fold serial dilution method2022European journal of medicinal chemistry, Oct-05, Volume: 240A fragment-based drug discovery strategy applied to the identification of NDM-1 β-lactamase inhibitors.
AID531765Antimicrobial activity against Pseudomonas aeruginosa blood isolate 4667 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID656447Antibacterial activity against metallo-beta-lactamase producing Pseudomonas aeruginosa2011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID519813Inhibition of Bocillin FL binding to PBP2 in Pseudomonas aeruginosa 27853 membranes2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID533134Antimicrobial activity against Bacteroides fragilis assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID535837Antimicrobial activity against Pseudomonas aeruginosa GP20KT21 harboring oprD gene after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID761213Antibacterial activity against Pseudomonas aeruginosa expressing metallo-beta-lactamase by broth microdilution method2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Pyridone-conjugated monobactam antibiotics with gram-negative activity.
AID373030Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU78 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID528816Antimicrobial activity against carbapenem-resistant Enterobacter cloacae isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID495721Activity of Escherichia coli CMY-2 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1757539Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-13 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID521354Antimicrobial activity against Streptococcus pneumoniae isolate 4134 obtained from sputum of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID286011Antimicrobial activity against ESBL producing Escherichia coli 322 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID373758Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab1254 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID495673Antimicrobial activity against Klebsiella pneumoniae OC 5367 expressing beta-lactamase KPC-2 and containing Carbapenemase assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID433375Antibacterial activity against Anaerococcus vaginalis isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID535836Antimicrobial activity against wild-type Pseudomonas aeruginosa GP37 after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID1752487Antibacterial activity against Escherichia coli SR34100 producing class A beta lactamase, CTX-M-15 assessed as reduction in microbial growth incubated for 16 to 20 hrs in presence of vaborbactam by broth microdilution method2021Bioorganic & medicinal chemistry, 09-15, Volume: 46A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID1906413Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in microbial growth incubated for 24 hrs by microbroth dilution method2022European journal of medicinal chemistry, May-05, Volume: 235Amphiphilic cyclic peptide [W
AID528787Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID564464Antimicrobial activity against Pseudomonas aeruginosa isolate 968 by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID534689Antimicrobial activity against Bacteroides stercoris by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534848Plasma protein binding in patient with acute kidney injury2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
AID517974Antimicrobial activity against Escherichia coli nmcA harboring beta-lactamase NMCA by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID562950Antimicrobial activity against Klebsiella oxytoca expressing beta-lactamase KPC-2 by Etest2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID532402Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D4 isolate VA-06X-47 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID534705Antimicrobial activity against Peptostreptococcus anaerobius by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID565201Antimicrobial activity against Klebsiella pneumoniae isolate T-1504 expressing VIM-1 and KPC-2 genes by microdilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID574778Antimicrobial activity against Clostridium difficile assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1373295Antimicrobial activity against Escherichia coli expressing beta-lactamase VEB-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID587728Antimicrobial activity against Escherichia coli DH5alpha carrying Pseudomonas aeruginosa strain PS 297 IMP-1-pLBII after 18 hrs by microdilution broth method2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID423512Antibacterial activity against Acinetobacter baumannii isolate 911 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID534434Antimicrobial activity against Gemella morbillorum ATCC 27824 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID283394Antimicrobial activity against Nocardia beijingensis after 72 hrs by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID520983Antibacterial activity against Klebsiella pneumoniae GR by Etest method in presence of beta-lactamase inhibitor clavulanic acid2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID245210Minimum inhibitory concentration against Pseudomonas aeruginosa 1592E strain2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID522652Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis 02AS-1 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID582980Antimicrobial activity against ampC::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID561285Antibacterial activity against Klebsiella oxytoca by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID565821Antimicrobial activity against Klebsiella pneumoniae2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae.
AID1373291Antimicrobial activity against Escherichia coli expressing beta-lactamase PER-2 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID511666Antimicrobial activity against beta-lactam resistant beta-lactam resistant Pseudomonas aeruginosa PAOD3 harboring oprD spontaneous mutant and deficient in ampD gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth 2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1188387Antibacterial activity against Acinetobacter baumannii ATCC BAA-1605 assessed as reduction in CFU at 4 ug/ml after 6 hrs by time kill assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Small-molecule suppression of β-lactam resistance in multidrug-resistant gram-negative pathogens.
AID1757537Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-11 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID534864Antimicrobial activity against Non-ESBL Proteus mirabilis assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1763162Antibacterial activity against Klebsiella pneumoniae ATCC BAA-1705 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI based serial dilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Antibacterial and synergistic activity of 6β-hydroxy-3-oxolup-20(29)-en-28-oic acid (6β-hydroxy betunolic acid) isolated from Schumacheria castaneifolia vahl.
AID423291Antibacterial activity against Pseudomonas aeruginosa isolate 328 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID495690Activity of Klebsiella pneumoniae Beta-lactamase TEM-262010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID531684Antimicrobial activity against Acinetobacter baumannii ATCC 15151T containing plasmid harboring OXA-58-3 by broth dilution test2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID520985Antibacterial activity against Klebsiella pneumoniae 633 by Etest method in presence of beta-lactamase inhibitor clavulanic acid2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID324310Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolate2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.
AID532901Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 365 ST 376 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1407958Antibacterial activity against Acinetobacter baumannii ARC2674 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID586236Antimicrobial activity against Escherichia coli J53 harboring Klebsiella pneumoniae Kp7 beta-lactamase NDM-12011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID396032Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP3 plasmid containing Enterobacter aerogenes acrR gene by Etest2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID533373Antimicrobial activity against Bacteroides eggerthii by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID561462Antibacterial activity against Proteus mirabilis by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID564015Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring Pseudomonas aeruginosa plasmid DNA lung biopsy specimen of patient by Etest2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID564461Antimicrobial activity against Pseudomonas aeruginosa isolate 856 by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID495687Activity of Klebsiella pneumoniae SHV-12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID390335Antimicrobial activity against Escherichia coli 25922 QC2008Journal of natural products, Dec, Volume: 71, Issue:12
Citreamicins with potent gram-positive activity.
AID522662Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis K7038 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID1873908Antibacterial activity against Cronobacter sakazakii ATCC 29544 incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID678718Metabolic stability in human liver microsomes assessed as high signal/noise ratio (S/N of >100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID286002Antimicrobial activity against ESBL producing Klebsiella pneumoniae 257 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID1691821Antibacterial activity against Pseudomonas aeruginosa PAO1 planktonic cells assessed as reduction in bacterial growth after 18 hrs by resazurin dye based assay2020European journal of medicinal chemistry, May-15, Volume: 194Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1.
AID574034Antibacterial activity against beta-lactamase producing Micromonas micros assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID425092Antimicrobial activity against Fusobacterium necrophorum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID524292Antibacterial activity against Pseudomonas aeruginosa P320 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1533852Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 417 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID563971Antibacterial activity against Escherichia coli NF-NDM-1 by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID95721In vitro antibacterial activity against Klebsiella aerogenes 1522E2000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Synthesis and antibacterial activity of new carbapenems containing isoxazole moiety.
AID1780304Antibacterial activity against wild type Pseudomonas aeruginosa LESB58 LpxA Ser150Ala mutant assessed as reduction in bacterial growth by broth microdilution assay
AID549042Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate KpSCMC2 harboring int1, bla IMP-4, bla SHV-12, armA and sul1 gene isolated from patient with pulmonary infection by Etest method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Two clinical strains of Klebsiella pneumoniae carrying plasmid-borne blaIMP-4, blaSHV-12, and armA isolated at a Pediatric Center in Shanghai, China.
AID285156Antimicrobial activity against Streptococcus pneumoniae ATCC 496192007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.
AID423245Antibacterial activity against Moraxella catarrhalis isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID574971Antimicrobial activity against Actinomyces israelii assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID535897Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii JS33 harboring GyrA T83I mutant, wild-type ParC, GyrB, qnrA and qnrB genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1873920Bactericidal activity against Escherichia coli ATCC 25922 assessed as reduction in number of viable bacteria at 4 times MIC measured after 2 hrs by time kill assay (Rvb = 10^4.85 CFU/ml)2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID534685Antimicrobial activity against Parabacteroides distasonis by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID498828Antimicrobial activity against carbapenem-resistant Enterobacter cloacae SZ92 deficient in IMP-4, TEM-1, CTX-M-14, DHA-1, qnrB10/B4-like, aac(6')-Ib, ompC by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524405Antibacterial activity against carbapenemase-producing Klebsiella pneumoniae by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID423520Antibacterial activity against Acinetobacter baumannii isolate 919 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID584702Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5443 harboring uvrD mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1757546Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-10 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID165022In vitro antibacterial activity against Pseudomonas aeruginosa 1771M2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.
AID1762804Antibacterial activity against against Escherichia coli 04 assessed as reduction in bacterial growth incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID535165Antimicrobial activity against Acinetobacter assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID565200Antimicrobial activity against Klebsiella pneumoniae isolate A-1760 expressing VIM-1 and KPC-2 genes by microdilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID584938Antimicrobial activity against Pseudomonas aeruginosa PA14 PA14_23430 harboring mutation in putative heparinase by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID495698Activity of Pseudomonas aeruginosa IMP-12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID584709Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0764 harboring mucB mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1757587Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-22 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID534703Antimicrobial activity against Finegoldia magna by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID508734Antibacterial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID573558Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID425094Antimicrobial activity against beta lactamase-positive Fusobacterium mortiferum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID433019Antibacterial activity against Bacteroides ovatus isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID516143Antibacterial activity against Pulsotype B Acinetobacter genomosp. 3 isolate 8 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID423322Antibacterial activity against Pseudomonas aeruginosa isolate 365 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID523918Antibacterial activity against Acinetobacter baumannii A929 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID517954Antimicrobial activity against Klebsiella oxytoca by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID534472Antimicrobial activity against Bacteroides uniformis ATCC 8492 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID423510Antibacterial activity against Acinetobacter baumannii isolate 909 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID496542fT>MIC in Klebsiella pneumoniae isolate 354 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 16-24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID496560Antibacterial activity against Klebsiella pneumoniae isolate 328A assessed as reduction of bacterial count at 8 ug/ml within 6 hrs in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID1228698Antibacterial activity against Pseudomonas aeruginosa 1145 infected in immunocompetent BALB/c mouse lung infection model assessed as log reduction in colony forming units at 40 mg/kg, iv bid administered at 2 hrs and 12 hrs post-infection measured 24 hrs 2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.
AID1559372Antibacterial activity against wild type Escherichia coli ATCC 25922 after 16 to 20 hrs by CLSI-based microbroth dilution method2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID423316Antibacterial activity against Pseudomonas aeruginosa isolate 359 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID433357Antibacterial activity against Prevotella bivia isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID286032Antimicrobial activity against ESBL producing Klebsiella pneumoniae 259 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID425320Bactericidal activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as 99.9% bacterial killing at 2 times MIC after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID523498Antimicrobial activity against Pseudomonas aeruginosa isolate 14169c from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID423097Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID432999Antibacterial activity against Pseudomonas aeruginosa isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID532406Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B1 isolate SS-09X-45 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID518461Antimicrobial activity against Enterobacter cloacae S4741B assessed as number of passages required for MIC to rise above 4 times original MIC2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID524312Antibacterial activity against Acinetobacter baumannii A850 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID545405Antimicrobial activity against Pseudomonas aeruginosa PS12 with PFGE phenotype 7B obtained from sputum of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID545560Ratio of MIC for Escherichia coli EIR2b to MIC for Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID588129Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 7 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID1361170Antimicrobial activity against Pseudomonas aeruginosa 27060deltaR1 harboring deletion of R1 plasmid in presence of human apo-transferrin by broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.
AID562472Antimicrobial activity against Klebsiella pneumoniae isolate 2641/08 obtained from urine of patient with ischemic cardiomyopathy and several comorbidities by Etest2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.
AID520715Antibacterial activity against Acinetobacter baumannii CIP7010 by disk diffusion method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID530322Antimicrobial activity against Pseudomonas aeruginosa isolate PA-SL2 harboring blaVIM-13 gene by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID533412Antimicrobial activity against Finegoldia magna assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID532910Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 549 transformant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID523899Antibacterial activity against Pseudomonas aeruginosa P326 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID558327Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P285 by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID433149Antibacterial activity against Bacteroides thetaiotaomicron isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID1752491Antibacterial activity against Klebsiella pneumoniae JMI:211 producing class A beta-lactamase, KPC-2 assessed as reduction in microbial growth incubated for 16 to 20 hrs in presence of vaborbactam by broth microdilution method2021Bioorganic & medicinal chemistry, 09-15, Volume: 46A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID1318921Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 260-971032016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID534439Antimicrobial activity against Clostridium difficile GAI 10029 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID279559Antimicrobial activity against Haemophilus influenzae strains causing clinical infections2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.
AID584559Antimicrobial activity against Acinetobacter lwoffii isolate F expressing beta-lactamase OXA-164 isolated from tracheostoma of patient by vitek 2 system2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID584690Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4459 harboring mutation in Conserved hypothetical protein by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID323606fCmax in patient with lower respiratory tract infection2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.
AID373773Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh37 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID428268Antimicrobial activity against carbapenemase producing Enterobacteriaceae assessed as resistant isolates by CLSI breakpoint assay2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID558616Antimicrobial activity against Streptococcus pneumoniae isolate 2880 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID495669Antimicrobial activity against Escherichia coli OC 11732 expressing extended-spectrum beta-lactamase CTX-M-15 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID289889Antibacterial activity against Bacillus subtilts ATCC 66332007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID438298Inhibition of penicillin-resistant Streptococcus pneumoniae 5204 PBP2X preincubated for 4 hrs before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID496566Antibacterial activity against Klebsiella pneumoniae isolate 361 assessed as reduction of bacterial count at 64 ug/ml within 6 hrs in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID405453Antibacterial activity against Pseudomonas aeruginosa PAOdeltamutS by Etest2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID565544Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-08 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID565719Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-24 harboring A residue at 105 position in PDC- 5 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID535172Antimicrobial activity against imipenem non-susceptible Acinetobacter assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID295787Antibacterial activity against Streptococcus pyogenes 9889 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID524087Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3652010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID495744Kcat/Km ratio of Pseudomonas aeruginosa SPM-1 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1357429Antibacterial activity against extended-spectrum beta-lactamase producing Escherichia coli isolate 208687 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria.
AID524285Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E511 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID565726Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-31 harboring A residue at 105 position in PDC- 9 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1906521Hemolytic activity in human Red blood cell incubated for 2 hrs by spectrophotometric analysis2022European journal of medicinal chemistry, May-05, Volume: 235Amphiphilic cyclic peptide [W
AID528834Antimicrobial activity against CTX-M ESBL producing Escherichia coli assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID573823Antibacterial activity against beta-lactamase producing Clostridium paraputrificum by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID534646Antimicrobial activity against Klebsiella pneumoniae assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID559819Antimicrobial activity against Escherichia coli J53 harboring pCHE-B plasmid expressing blaSHV-5 gene by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID1628582Antibacterial activity against Haemophilus influenzae H128 incubated for 18 to 24 hrs by broth microdilution method2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
Discovery and Characterization of a Class of Pyrazole Inhibitors of Bacterial Undecaprenyl Pyrophosphate Synthase.
AID565545Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-09 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID574770Antimicrobial activity against Clostridium perfringens after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID286009Antimicrobial activity against ESBL producing Escherichia coli 320 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID761211Antibacterial activity against Klebsiella pneumoniae expressing ESBL by broth microdilution method2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Pyridone-conjugated monobactam antibiotics with gram-negative activity.
AID555450Antibacterial activity against Escherichia coli DH5alpha by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID530321Antimicrobial activity against Pseudomonas aeruginosa isolate PA-SD2 harboring blaVIM-1 gene by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID564950Antimicrobial activity against Acinetobacter baumannii isolate Ab177 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba92009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID1757565Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-13 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID583030Antimicrobial activity against Escherichia coli TOP10 transformed with Enterobacter asburiae CIP 105006 plasmid carrying ACT-1 by agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID584732Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4269 harboring rpoC mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID517953Antimicrobial activity against Escherichia coli by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID571392Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID423327Antibacterial activity against Pseudomonas aeruginosa isolate 370 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID561488Antibacterial activity against Acinetobacter baumannii by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID433158Antibacterial activity against Clostridium aminovalericum isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID534838Elimination rate constant in critically ill patient with sepsis at 1000 mg/kg, iv administered every 8 hrs by HPLC method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
AID495743Kcat/Km ratio of Pseudomonas aeruginosa IMP-1 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID274725Antibacterial activity against methicillin-resistant Staphylococcus aureus SG5112007Journal of natural products, Jan, Volume: 70, Issue:1
Bisindole alkaloids of the topsentin and hamacanthin classes from a marine sponge Spongosorites sp.
AID532893Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 475 ST 277 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID532413Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C1 isolate AV-13X-28 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID1757531Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-3 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID322773Antimicrobial activity against Bacteroides fragilis isolates by agar dilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID559090Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii isolate A2 by Etest method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vivo selection of reduced susceptibility to carbapenems in Acinetobacter baumannii related to ISAba1-mediated overexpression of the natural bla(OXA-66) oxacillinase gene.
AID524268Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E418 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID295815Antibacterial activity against Escherichia coli TEM after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID558322Antibacterial activity against bla gene-positive and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni NCTC 11168 by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID1361166Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa SR24-12 in presence of human apo-transferrin by broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.
AID523765Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E4782010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID324866Antimicrobial activity against Acinetobacter baumannii A24D after 4 days in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID425097Antimicrobial activity against Peptostreptococcus anaerobius isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID1680049Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae clinical isolate 7 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID565224Activity of KPC-2 in Klebsiella pneumoniae isolate T-1504 assessed as compound hydrolysis in presence of EDTA2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID249280Minimum inhibitory concentration against Klebsiella pneumoniae (n=30); (Range = 0.015-0.06)2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID524303Antibacterial activity against Pseudomonas aeruginosa P340 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID563975Ratio of Kcat to Km for Klebsiella pneumoniae 05-560 beta-lactamase IMP12009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID523564Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E360 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1395493Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 12-12 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, Apr-25, Volume: 150Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID508722Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1C3 PTOL1 harboring acquired beta-lactamase OXA-17 by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID517956Antimicrobial activity against Proteus penneri by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID521345Antimicrobial activity against Streptococcus pneumoniae isolate k-637 obtained from CSF of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID283400Antimicrobial activity against Nocardia sp. after 72 hrs by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID405825Antimicrobial activity against Acinetobacter baumannii 694 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-32007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID555480Antibacterial activity against Acinetobacter genomosp. 3 isolate 14 by Etest method in presence of cloxacillin and efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID520980Antibacterial activity against Klebsiella pneumoniae YC by Etest method in presence of beta-lactamase inhibitor clavulanic acid2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID1504342Antibacterial activity against Salmonella enterica after 16 to 20 hrs by broth microdilution method2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and bioactivities study of new antibacterial peptide mimics: The dialkyl cationic amphiphiles.
AID584312Antimicrobial activity against beta-lactamase ompC intact/ompF deficient Serratia marcescens isolate YMC0570 by agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID576271Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18567 harboring porin OmpK36V mutant gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID1395490Antibacterial activity against extended-spectrum beta-lactamase harboring Escherichia coli CDC1001728 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, Apr-25, Volume: 150Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID549337Antimicrobial activity against Escherichia coli ATCC 25922 harboring bla CTX-M-3a gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID1417167Antibacterial activity against methicillin-resistant Staphylococcus aureus NR10198 by CLSI method2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis of 1,2,3-triazole linked 4(3H)-Quinazolinones as potent antibacterial agents against multidrug-resistant Staphylococcus aureus.
AID1765574Antibacterial activity against Bacillus subtilis ATCC 23857 incubated for 18 hrs by CLSI based broth dilution method2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Novel Broad-Spectrum Antimicrobial Peptide Derived from Anoplin and Its Activity on Bacterial Pneumonia in Mice.
AID534445Antimicrobial activity against Bifidobacterium adolescentis ATCC 15703 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID564460Antimicrobial activity against Pseudomonas aeruginosa isolate 1006 by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID573598Antibacterial activity against Fusobacterium varium assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1628578Antibacterial activity against Streptococcus pneumoniae 1629 incubated for 18 to 24 hrs by broth microdilution method2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
Discovery and Characterization of a Class of Pyrazole Inhibitors of Bacterial Undecaprenyl Pyrophosphate Synthase.
AID498809Antimicrobial activity against Klebsiella pneumoniae ZJ99T expressing KPC-2, CTX-M-3, qnrS1 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID499047Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ69 deficient in SHV-28, ompK35/36 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID528739Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B516 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID534671Antimicrobial activity against Prevotella oris ATCC 33573 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID511143Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 172010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID8579Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Synthesis and antibacterial activity of 2alpha-functionalized 1beta-methylcarbapenems related to KR-21012.
AID528975Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID582978Antimicrobial activity against ampD::lox, ampDh2::lox,ampDh3::lox and nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID576074Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18260 harboring pSHA2-encoded porin OmpK36 gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID534663Antimicrobial activity against ESBL producing Proteus mirabilis by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID433163Antibacterial activity against Clostridium sphenoides isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID496497fT>MIC in Klebsiella pneumoniae isolate 375 at 2 gram for every 8 hrs administered as 3 hrs infusion over 24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID1853611Antibacterial activity against Enterococcus faecium clinical isolate 1089544 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution method2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
Design, synthesis, and antibacterial activity of
AID499122Antimicrobial activity against Pseudomonas aeruginosa OC 4354 infected in immunocompromized SKH1 mouse assessed as lesion volume at 1.6 mg/kg/day, sc measured after 48 hrs postinfection (Rvb = 2195 mm3)2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID535645Antimicrobial activity against Group B Streptococcus serotype Ia N1 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID560074Antimicrobial activity against Enterobacter cloacae isolate 5420 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID563966Antibacterial activity against Klebsiella pneumoniae 05-560 by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID585396Ratio of Kcat to Km for Bradyrhizobium japonicum metallo-beta-lactamase BJP-12010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID522020Antimicrobial activity against Escherichia coli isolate J53 harboring pEnc1 containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID1373305Antimicrobial activity against Escherichia coli expressing beta-lactamase IMP-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID528792Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 and other bla gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID524316Antibacterial activity against Acinetobacter baumannii A867 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID565718Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-23 harboring A residue at 105 position in PDC- 5 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID405090Antimicrobial activity against integron carrying Enterobacteriaceae assessed as percent resistant isolates2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome.
AID206746In vitro antibacterial activity against Staphylococcus aureus SG 511 by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13
Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID396027Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by Etest2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID517965Antimicrobial activity against Escherichia coli K802N harboring beta-lactamase TEM-3 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID495739Kcat/Km ratio of Pseudomonas aeruginosa OXA-10 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID520776Antibacterial activity against beta-lactamase KPC-2 producing Serratia marcescens isolate S1 to S21 by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID562474Antimicrobial activity against rifampicin-resistant Escherichia coli A15 transconjugant expressing beta-lactamase SHV-12 by Etest2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.
AID574516Antimicrobial activity against Bacteroides ovatus assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID423312Antibacterial activity against Pseudomonas aeruginosa isolate 355 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID523950Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E357 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584837Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER1 by agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID560592Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa isolate IMCJ2S1 by microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID279561Antimicrobial activity against Haemophilus influenzae BLNAS strains2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.
AID372322Antibacterial activity against Pseudomonas aeruginosa PAO1 by CLSI broth microdilution method2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID1554003Antibacterial activity against Escherichia coli UFR39 measured after 16 to 20 hrs by broth microdilution method2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Structural Basis for E. coli Penicillin Binding Protein (PBP) 2 Inhibition, a Platform for Drug Design.
AID1853608Antibacterial activity against Enterococcus faecium clinical isolate 1088168 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution method2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
Design, synthesis, and antibacterial activity of
AID69477Minimum inhibitory concentration against Escherichia coli 055 was determined by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID433376Antibacterial activity against Anaerococcus vaginalis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID498820Antimicrobial activity against Klebsiella pneumoniae WH76 expressing IMP-4, TEM-1, SHV-14, CTX-M-3, qnrS1 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID545605Antimicrobial activity against Pseudomonas aeruginosa PS23 with PFGE phenotype 4A expressing beta-lactamase KPC-2 obtained from blood of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID561279Antibacterial activity against Klebsiella pneumoniae assessed as susceptible isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID423324Antibacterial activity against Pseudomonas aeruginosa isolate 367 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID1649584Antimicrobial activity against Escherichia coli clinical isolates by standard broth microdilution method2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID372357%T>MIC against hypermutable Pseudomonas aeruginosa isolate 12-09-15 in in vitro PK/PD model at 1 g infused thrice daily at 8 hrs interval2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID373763Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh9 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID583027Antimicrobial activity against Escherichia coli TOP10 transformed with Escherichia coli ECB-1 plasmid carrying ACC-1 by agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID496509fT>MIC in Klebsiella pneumoniae isolate 353 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 0-8 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID534414Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID584514Antimicrobial activity against Pseudomonas aeruginosa PA14 PA1553 harboring mutation in putative cytochrome c oxidase, cbb3 type, subunit II by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1758328Antibacterial activity against AmpC/TEM-1 producing Klebsiella pneumoniae C6922021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Discovery of 3-aryl substituted benzoxaboroles as broad-spectrum inhibitors of serine- and metallo-β-lactamases.
AID68378In vivo antibacterial activity against Enterobacter cloacae 1321E1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID401689Antibacterial activity against Pseudomonas aeruginosa 1771M2005Journal of natural products, May, Volume: 68, Issue:5
Cytotoxic bisindole alkaloids from a marine sponge Spongosorites sp.
AID64741In vitro antibacterial activity against ATCC 25922 strain of Escherichia coli2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID523732Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E4122010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID558618Antimicrobial activity against Streptococcus pneumoniae isolate 3263 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID584721Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3050 harboring pyrD mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID571888Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 8 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID530818Antibacterial activity against amoxicillin and amoxicillin-clavulanate resistant Klebsiella pneumoniae UCL-1 assessed as zone of inhibition by disk diffusion method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID545564Ratio of MIC for Escherichia coli EIR4b to MIC for Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID1596891Antibacterial activity against methicillin-resistant Staphylococcus aureus NR119 incubated for 16 to 18 hrs by broth microdilution assay
AID423296Antibacterial activity against Pseudomonas aeruginosa isolate 334 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID524826Antibacterial activity against erythromycin resistant Campylobacter sp. assessed as resistance breakpoint by CLSI method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID522658Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis V770-NP1-R by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID528917Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-14 and CTX-M-27 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID496539fT>MIC in Klebsiella pneumoniae isolate 377 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 16-24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID519822Induction of morphological changes in Pseudomonas aeruginosa 27853 assessed as increase in cell length at antimicrobial MIC after 60 mins by microscopy2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID499152fCmax in immunocompromized SKH1 mouse plasma at 50 mg/kg, sc2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID510514Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 expressing KPC beta lactamase2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID523514Antimicrobial activity against Pseudomonas aeruginosa isolate 12102 from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID524408Antibacterial activity against ciprofloxacin-resistant Enterobacteriaceae clinical isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID496504fT>MIC in Pseudomonas aeruginosa isolate 988 at 2 gram for every 8 hrs administered as 3 hrs infusion over 24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID587731Ratio of Kcat to Km for Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP18 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID531772Antimicrobial activity against Pseudomonas aeruginosa pleural fluid isolate 4679 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID563157Antibacterial activity against Pseudomonas aeruginosa isolate 213BR by Etest2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
AID423507Antibacterial activity against Acinetobacter baumannii isolate 906 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID518224Antimicrobial activity against Escherichia coli W3110 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID534867Antimicrobial activity against ESBL producing Proteus mirabilis assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID382591Antimicrobial activity against Escherichia coli ATCC 259222008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
Synthesis and antimicrobial activity of some novel derivatives of benzofuran: part 2. The synthesis and antimicrobial activity of some novel 1-(1-benzofuran-2-yl)-2-mesitylethanone derivatives.
AID561450Antibacterial activity against Klebsiella oxytoca assessed as intermediate isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID373047Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate FZ4A18 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID555453Antibacterial activity against Acinetobacter genomosp. 3 isolate 21 by Etest method in presence of cloxacillin and efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID531681Antimicrobial activity against Acinetobacter baumannii Ab290 containing plasmid harboring OXA-58-3 by broth dilution test2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID423511Antibacterial activity against Acinetobacter baumannii isolate 910 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID535646Antimicrobial activity against Group B Streptococcus serotype III NEM 316 by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID560058Antimicrobial activity against ESBL-producing Klebsiella pneumoniae by broth microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID70088Antibacterial activity against Escherichia coli 1507E1998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID532396Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A3 isolate FG-17X-08 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID1846920Antibacterial activity against multidrug resistant wild type Escherichia coli NCTC 13353 assessed as reduction in bacterial growth incubated for 18 to 20 hrs by CLSI based microdilution method2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Design, Synthesis, and Biological Evaluation of Novel Pyrimido[4,5-
AID295792Antibacterial activity against Klebsiella pneumoniae 523 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID209566Compound was evaluated for in vitro antibacterial activity against Streptococcus faecium MD strain by agar dilution method2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Synthesis and antibacterial activity of 2alpha-functionalized 1beta-methylcarbapenems related to KR-21012.
AID520779Antibacterial activity against Escherichia coli EC600 by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID555465Antibacterial activity against Acinetobacter genomosp. 3 isolate 69 by Etest method in presence of cloxacillin and efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID1680061Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 5 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID433362Antibacterial activity against Clostridium innocuum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID524088Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3402010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID423298Antibacterial activity against Pseudomonas aeruginosa isolate 337 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID1395492Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 12-11 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, Apr-25, Volume: 150Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID433172Antibacterial activity against Escherichia coli isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523751Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E3602010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID373029Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PUA7 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID1407966Antibacterial activity against Acinetobacter baumannii ARC3485 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID521491Antibacterial activity against Pseudomonas aeruginosa KG2505 by Etest method in presence of beta-lactamase inhibitor clavulanic acid2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID583024Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Escherichia coli ECB2 plasmid carrying CMY-2 by agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID1373290Antimicrobial activity against Escherichia coli expressing beta-lactamase PER-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID372554Antibacterial activity against genetically beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b with an amino acid substitution in variable mutated locus Asn-526 or Arg-517 of ftsI gene assessed as susceptibility rate by broth microd2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.
AID495711Kcat/Km ratio of Serratia marcescens SME-32010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID524288Antibacterial activity against Pseudomonas aeruginosa P369 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID511129Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 32010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID1559373Antibacterial activity against Escherichia coli J53 expressing SHV5/ AmpC/TEM-1 after 16 to 20 hrs by CLSI-based microbroth dilution method2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID499045Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ68T deficient in CTX-M-15, ompK35/36 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID520978Antibacterial activity against Escherichia coli harboring pCOL plasmid expressing blaKPC gene by Etest method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID545351Displacement of [14C]benzylpenicillin from PBP 6 in Pseudomonas aeruginosa ATCC 156922009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID495841Ratio of Kcat to Km for beta-lactamase VIM-1 in Escherichia coli DH5alpha expressing pBCLL/39H by microacidimetric method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID1318901Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 860522016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID533126Antimicrobial activity against Bacteroides caccae assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID524300Antibacterial activity against Pseudomonas aeruginosa P352 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID322790Antimicrobial activity against Bacteroides eggerthii assessed as percent resistant isolates2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID1056845Antibacterial activity against TEM-1/SHV-12 expressing Enterobacter cloacae isolate 306 after 18 to 24 hrs by two-fold broth microdilution assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID531318Ratio of Kcat to Km for Escherichia coli beta-lactamase VIM-1 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID1533858Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 3411 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID523590Antibacterial activity against Pseudomonas aeruginosa P335 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID423293Antibacterial activity against Pseudomonas aeruginosa isolate 330 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID10449Half life was calculated at a single intravenous administration of 20 mg/kg in rat2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.
AID1311360Antibacterial activity against Acinetobacter baumannii ACBA measured after 18 hrs by broth microdilution assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.
AID1395489Antibacterial activity against extended-spectrum beta-lactamase harboring Escherichia coli 13-1 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, Apr-25, Volume: 150Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID1311369Antibacterial activity against Mycobacterium abscessus ATCC 19977 measured after 3 days by broth microdilution assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.
AID573552Antibacterial activity against Bacteroides fragilis assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID372559Antibacterial activity against genetically beta-lactamase-negative ampicillin-susceptible Haemophilus influenzae type b without amino acid substitutions in ftsI gene and bla gene assessed as resistance rate by broth microdilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.
AID1853618Antibacterial activity against Staphylococcus aureus clinical isolate 1088888 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution method2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
Design, synthesis, and antibacterial activity of
AID524322Antibacterial activity against Acinetobacter baumannii A884 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1765575Antibacterial activity against Enterococcus faecalis ATCC 29212 incubated for 18 hrs by CLSI based broth dilution method2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Novel Broad-Spectrum Antimicrobial Peptide Derived from Anoplin and Its Activity on Bacterial Pneumonia in Mice.
AID433174Antibacterial activity against Enterobacter cloacae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID535832Antimicrobial activity against wild-type Pseudomonas aeruginosa GP61 after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID561387Antibacterial activity against Escherichia coli isolate ARL05-705 harboring beta-lactamase CMY 7 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
CMY-29 and CMY-30, two novel plasmid-mediated AmpC beta-lactamases.
AID524084Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3282010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1762802Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as reduction in bacterial growth incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID517966Antimicrobial activity against Escherichia coli CF102 harboring beta-lactamase TEM-3 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID584516Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2487 harboring mutation in hypothetical protein by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID576265Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 19039 harboring porin OmpK36V mutant gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID585194Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-7 K104, G170 mutant by Etest method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID584736Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5130 harboring mutation in putative rhodanese-like domain protein by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1846923Antibacterial activity agains wild type Klebsiella pneumoniae ATCC BAA-2470 assessed as reduction in bacterial growth incubated for 18 to 20 hrs by CLSI based microdilution method2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Design, Synthesis, and Biological Evaluation of Novel Pyrimido[4,5-
AID523602Antibacterial activity against Pseudomonas aeruginosa P365 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID558601Antimicrobial activity against Streptococcus pneumoniae isolate 24 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID584322Antimicrobial activity against Serratia marcescens ATCC 8100 by agar dilution method in presence of 300 ug/ml of boronic acid2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID1395495Antibacterial activity against carbapenem-resistant Acinetobacter calcoaceticus 12-6 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, Apr-25, Volume: 150Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID534681Antimicrobial activity against Veillonella parvula ATCC 10790 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID1757620Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-22 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID534301Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA4602010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID534443Antimicrobial activity against Clostridium ramosum ATCC 25582 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID523906Antibacterial activity against Acinetobacter baumannii A911 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID571906Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 17 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1443409In vivo antibacterial activity against Escherichia coli isolate 210737 infected in Kunming mouse systemic infection model assessed as increase in mouse survival administered subcutaneously 0.5 to 4 hrs post infection measured after 48 hrs by Bliss method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections.
AID522642Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis Vollum 1B by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID523418Antibacterial activity against beta-lactamase-negative Escherichia coli E345 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1757577Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-6 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID576952Antimicrobial activity against Shewanella putrefaciens Sp117 harboring intI1,sul1,sul2 and beta-lactamase OXA-48 like genes by CLSI method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Reservoir of antimicrobial resistance determinants associated with horizontal gene transfer in clinical isolates of the genus Shewanella.
AID341597Antibacterial activity against sEscherichia coli GeneHogs harboring blaKPC-encoding plasmids2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID523601Antibacterial activity against Pseudomonas aeruginosa P353 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1680006Induction of cytoplasmic membrane depolarization in Escherichia coli ATCC 25922 at 20 ug/ml measured for 12 mins by DiSC35 dye-based fluorescence assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID518225Antimicrobial activity against Klebsiella pneumoniae 1338665 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID1357435Antibacterial activity against extended-spectrum beta-lactamase producing Escherichia coli isolate 209285 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria.
AID1407959Antibacterial activity against Acinetobacter baumannii ARC2675 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID495803Antimicrobial activity against Escherichia coli 2603 strain expressing beta-lactamase VIM-19 by microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID341595Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 490 isolate producing KPC3 and TEM1 carbapenemases2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID286016Antimicrobial activity against ESBL producing Escherichia coli 285 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID499053Antimicrobial activity against carbapenem-resistant Escherichia coli PU96 deficient in TEM-1, CTX-M-14, CMY-2, ompC/F by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524099Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A8652010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID559818Antimicrobial activity against Escherichia coli J53 harboring pCHE-A plasmid expressing blaGES-5 gene by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID584693Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4748 harboring tpiA mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID495807Antimicrobial activity against Escherichia coli C600 2878 transconjugate expressing beta-lactamase VIM-19 by microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID164538Compound was evaluated for its antibacterial activity against Pseudomonas aeruginosa 3 MDR2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID584503Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0667 harboring mutation in putative metallopeptidase by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID545399Antimicrobial activity against Pseudomonas aeruginosa PS5 with PFGE phenotype 7A expressing beta-lactamase KPC-2 obtained from sputum of ICU patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID1905566Antimicrobial activity against Escherichia coli ATCC 25922 assessed as reduction of bacterial growth incubated for 18 hrs by CLSI protocol based broth microdilution method2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Novel β-Hairpin Antimicrobial Peptides Containing the β-Turn Sequence of -RRRF- Having High Cell Selectivity and Low Incidence of Drug Resistance.
AID285578Antimicrobial activity against Pseudomonas aeruginosa P21.23 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID534693Antimicrobial activity against Prevotella melaninogenica by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID496512fT>MIC in Klebsiella pneumoniae isolate 334 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 0-8 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID534471Antimicrobial activity against Bacteroides thetaiotaomicron ATCC 29741 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID508723Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1E1 PpA1 harboring acquired beta-lactamase OXA-144 by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID274728Antibacterial activity against methicillin-resistant Escherichia coli DC22007Journal of natural products, Jan, Volume: 70, Issue:1
Bisindole alkaloids of the topsentin and hamacanthin classes from a marine sponge Spongosorites sp.
AID95728Minimum inhibitory concentration against Klebsiella aerogenes 1522E was determined by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID164536Compound was evaluated for its antibacterial activity against Pseudomonas aeruginosa 1 MDR2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID425115Antimicrobial activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID534610Antimicrobial activity against Ceftazidime non-susceptible Enterobacteriaceae assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID576539Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate AIS081042 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID534909Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1373317Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-23 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID496538fT>MIC in Pseudomonas aeruginosa isolate 988 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 8-16 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID532399Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D2 isolate VA-06X-16 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID534882Antimicrobial activity against Enterobacter cloacae assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID283399Antimicrobial activity against Nocardia brasiliensis after 72 hrs by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID576267Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18918 harboring porin OmpK36V mutant gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID382590Antimicrobial activity against Staphylococcus aureus ATCC 65382008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
Synthesis and antimicrobial activity of some novel derivatives of benzofuran: part 2. The synthesis and antimicrobial activity of some novel 1-(1-benzofuran-2-yl)-2-mesitylethanone derivatives.
AID289912Antibacterial activity against Proteus mirabilis 174/32007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID1311370Antibacterial activity against Mycobacterium avium 104 measured after 7 days by broth microdilution assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.
AID373784Antibacterial activity against imipenem-resistant Acinetobacter baumannii ISAB ab8(r) by broth dilution method in presence of 2 ug/ml efflux pump inhibitor carbonyl cyanide m-chlorophenyl-hydrazone2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID496493fT>MIC in Klebsiella pneumoniae isolate 357 at 2 gram for every 8 hrs administered as 3 hrs infusion over 24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID423505Antibacterial activity against Acinetobacter baumannii isolate 904 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID562736Antimicrobial activity against Klebsiella pneumoniae AH24-270 expressing blaCTX-M-71 gene by agar dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID390339Antimicrobial activity against Moraxella catarrhalis 5572008Journal of natural products, Dec, Volume: 71, Issue:12
Citreamicins with potent gram-positive activity.
AID522017Antimicrobial activity against Providencia rettgeri isolate expressing beta-lactamase OXA-48 and TEM-101 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID574027Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1759654Antimicrobial activity against against methicillin-resistant Staphylococcus aureus clinical isolate 1088064 by CLSI-based broth microdilution assay2021European journal of medicinal chemistry, Jul-05, Volume: 2194-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.
AID558627Antimicrobial activity against Streptococcus pneumoniae isolate 3587 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID523948Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E483 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID562753Antimicrobial activity against Escherichia coli DH5alpha by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID585196Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-6 K104, S170 mutant by Etest method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID523735Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E4242010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1056835Antibacterial activity against SIM-1 expressing Acinetobacter baumannii isolate 170 after 18 to 24 hrs by two-fold broth microdilution assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID583091Activity of Escherichia coli XL1-Blue wild-type IMP-1 beta-lactamase by spectrophotometer2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID562221Antimicrobial activity against Desulfovibrio fairfieldensis by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Susceptibilities of 23 Desulfovibrio isolates from humans.
AID524103Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A9122010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524295Antibacterial activity against Pseudomonas aeruginosa P323 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID570791Antimicrobial activity against Acinetobacter baumannii HE130 expressing bla-OXA-23 gene by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania.
AID582764Antimicrobial activity against eaeA negative verocytotoxin-producing non-O157 Escherichia coli isolates obtained from human assessed as percentage of resistant isolates2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26.
AID533420Antimicrobial activity against Micromonas micros assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID764539Lipophilicity, log D of the compound2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Synthesis, pH-dependent, and plasma stability of meropenem prodrugs for potential use against drug-resistant tuberculosis.
AID249354Minimum inhibitory concentration against Moraxella catarrhalis (n=22); (Range=0.008-0.03)2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID533392Antimicrobial activity against Clostridium perfringens assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID534604Antimicrobial activity against Enterobacteriaceae assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID535371Antimicrobial activity against Pseudomonas aeruginosa isolated from non-ICU patient assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID286026Antimicrobial activity against ESBL producing Klebsiella pneumoniae 270 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID518464Antimicrobial activity against Pseudomonas aeruginosa BA assessed as number of passages required for MIC to rise above 4 times original MIC2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID249352Minimum inhibitory concentration against Klebsiella pneumoniae (n=30); (Range = 0.015-0.06)2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID535900Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii JS33T harboring qnrA gene by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID558606Antimicrobial activity against Streptococcus pneumoniae isolate 1147 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID1407939Antibacterial activity against Pseudomonas aeruginosa ARC003 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID520777Antibacterial activity against beta-lactamase KPC-2 producing Klebsiella pneumoniae isolate K10 by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID523720Antibacterial activity against Acinetobacter baumannii A894 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285999Antimicrobial activity against ESBL producing Klebsiella pneumoniae 259 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID558612Antimicrobial activity against Streptococcus pneumoniae isolate 2617 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID133977In vivo protective activity administered sc 1 hr after ip Escherichia coli 078 strain infection in mice2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Synthesis and antibacterial activity of 2alpha-functionalized 1beta-methylcarbapenems related to KR-21012.
AID1543302Antimicrobial activity against Aspergillus fumigatus ATCC 90906 assessed as inhibition of microbial growth by CLSI based method2019Journal of natural products, 07-26, Volume: 82, Issue:7
Anthraquinone-Based Specialized Metabolites from Rhizomes of
AID1759645Antimicrobial activity against vancomycin-resistant Enterococcus faecium clinical isolate 1088168 by CLSI-based broth microdilution assay2021European journal of medicinal chemistry, Jul-05, Volume: 2194-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.
AID423294Antibacterial activity against Pseudomonas aeruginosa isolate 331 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID495680Antimicrobial activity against Pseudomonas aeruginosa OC 13996 expressing beta-lactamase IMP-1 and containing Carbapenemase assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID534394Activity of Beta-lactamase KHM-1 in Escherichia coli JM109 harboring recombinant pKHM-1 assessed as compound hydrolysis by UV-visible spectrophotometry2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID322774Antimicrobial activity against Bacteroides distasonis isolates by agar dilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID559687Antibacterial activity against ESBL-positive Escherichia coli Top10 harboring plasmid AT5172009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
AID534451Antimicrobial activity against Propionibacterium acnes ATCC 11828 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID524308Antibacterial activity against Pseudomonas aeruginosa P358 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1533853Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 1344 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID498833Antimicrobial activity against Klebsiella pneumoniae CY1T expressing SHV-11, DHA-1 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID523745Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E4652010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523771Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E5072010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID564225Antimicrobial activity against Escherichia coli TOP10 by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
AID1680060Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 6 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID374026Ratio of Kcat to Km for Klebsiella pneumoniae KPC-1 beta lactamase expressed in Escherichia coli DH5alpha by SDS-PAGE2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID1887586Synergistic antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial growth incubated for 24 hrs in presence of artocarpin by checkerboard method2022Journal of natural products, 10-28, Volume: 85, Issue:10
Developing the Natural Prenylflavone Artocarpin from
AID496534fT>MIC in Pseudomonas aeruginosa isolate 1038 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 8-16 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID528977Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID555460Antibacterial activity against Acinetobacter genomosp. 3 isolate 65 by Etest method in presence of cloxacillin and efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID585193Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-1 E104, G170 mutant by Etest method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID286035Antimicrobial activity against ESBL producing Klebsiella pneumoniae 257 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID1762840In vivo antibacterial activity against Klebsiella pneumoniae producing NDM-1 infected in mouse assessed as reduction in bacterial load in liver at 10 mg/kg, ip2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID295786Antibacterial activity against Enterococcus faecalis 2347 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID498817Antimicrobial activity against Klebsiella pneumoniae FZ49T expressing IMP-8, TEM-1, CTX-M-14, qnrB2, aac(6')-Ib by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1757585Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-18 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID323601Antimicrobial activity against methicillin-susceptible Staphylococcus aureus2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.
AID520969Antibacterial activity against Klebsiella pneumoniae GR by Etest method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID372348Antibacterial activity against hypermutable Pseudomonas aeruginosa 12-09-15/MEM mutant by broth microdilution method2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID495734Kcat/Km ratio of Klebsiella oxytoca Beta-lactamase K1 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID289873Antibacterial activity against Streptococcus pyogenes 77A2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID209456In vitro antibacterial activity against Streptococcus pyogenes 308A by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13
Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID549043Antimicrobial activity against carbapenem susceptible Klebsiella pneumoniae isolate KpSCMC2c harboring bla SHV-12 gene isolated from patient with pulmonary infection by Etest method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Two clinical strains of Klebsiella pneumoniae carrying plasmid-borne blaIMP-4, blaSHV-12, and armA isolated at a Pediatric Center in Shanghai, China.
AID546423Antimicrobial activity against Pseudomonas aeruginosa 12B harboring recombinant pBB-PDC-3 by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID583089Ratio of Kcat to Km for Escherichia coli XL1-Blue wild-type VIM-2 beta-lactamase by spectrophotometer2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID520974Antibacterial activity against Escherichia coli harboring pBC2303 expressing blaKPC gene plasmid by Etest method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID572140Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 37 expressing ampC, ompA, adeB, adeM by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1680066Antibacterial activity against Salmonella enterica ATCC 8387 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID521841Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA375 containing qnrA1, blaTEM-1, blaSHV-11genes by Etest method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID423515Antibacterial activity against Acinetobacter baumannii isolate 914 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID678450Antibacterial activity against Pseudomonas aeruginosa2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections.
AID528532Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B68 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID285975Antimicrobial activity against Escherichia coli 120 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID558049Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S12 by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID571892Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 10 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1757540Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-4 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID498824Antimicrobial activity against Citrobacter freundii SZ62 expressing IMP-4, TEM-1, CMY-2, qnrS1, aac(6')-Ib-cr by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1873904Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs in absence of foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID529582Ratio of Kcat to Km for Bradyrhizobium japonicum beta-Lactamase BJP-12008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID584585Antimicrobial activity against Acinetobacter baumannii ATCC 19606 harboring beta-lactamase OXA-58 by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID565219Activity of KPC-2 in Klebsiella pneumoniae isolate T-17802009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID1357468Antibacterial activity against IMP-4 producing Pseudomonas aeruginosa isolate 207272 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria.
AID529850Antibacterial activity against OprD-deficient Pseudomonas aeruginosa MR08 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID534679Antimicrobial activity against Desulfovibrio piger DSM 749 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID10999Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.
AID372555Antibacterial activity against genetically beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b with an amino acid substitution in highly mutated locus Ser-385 of ftsI gene assessed as susceptibility rate by broth microdilution metho2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.
AID495730Activity of Acinetobacter baumannii OXA-23 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID523761Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E4752010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID558594Antimicrobial activity against Streptococcus pneumoniae 6 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID518246Antimicrobial activity against Pseudomonas aeruginosa BA assessed as appearance of colony at 4 times MIC concentration2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID369643Antibacterial activity against Acinetobacter haemolyticus expressing carbapenemase-encoding blaOXA-40 gene by Etest method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital.
AID523568Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E418 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID69787Antibacterial activity against Escherichia coli 1507E2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.
AID164581Antibacterial activity against Pseudomonas aeruginosa 90272003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.
AID584557Antimicrobial activity against Acinetobacter lwoffii isolate D expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID285994Antimicrobial activity against ESBL producing Klebsiella pneumoniae 260 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID533368Antimicrobial activity against Bacteroides uniformis assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID562756Ratio of Kcat to Km for Klebsiella pneumoniae AH24-270 CTX-M-71 beta-lactamase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID529864Ratio of MIC for Pseudomonas aeruginosa COR6 to MIC for Pseudomonas aeruginosa PAO12008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID133978In vivo protective activity administered sc 1 hr after ip Streptococcus pyogenes 77A strain infection in mice2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Synthesis and antibacterial activity of 2alpha-functionalized 1beta-methylcarbapenems related to KR-21012.
AID565530Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-05 harboring A residue at 105 position in PDC- 2 by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID423315Antibacterial activity against Pseudomonas aeruginosa isolate 358 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID1407944Antibacterial activity against Pseudomonas aeruginosa ARC3511 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID572060Antibacterial activity against abeS-deficient Acinetobacter baumannii AC0037 by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID522659Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis 003BS by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID405824Antimicrobial activity against Acinetobacter baumannii 696 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-32007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID517975Antimicrobial activity against Klebsiella pneumoniae CRE harboring beta-lactamase KPC-2 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID519628Antimicrobial activity against beta-lactamase OXA-63 producing Brachyspira pilosicoli isolate BM4442 isolated from feces of patient with diarrhea by disc diffusion method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.
AID511134Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 82010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID562947Antimicrobial activity against Klebsiella pneumoniae PFGE clone D expressing beta-lactamase KPC-2 by Etest2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID369641Antibacterial activity against Acinetobacter baumannii B clone by Etest method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital.
AID286020Antimicrobial activity against ESBL producing Escherichia coli 133 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID518247Antimicrobial activity against Pseudomonas aeruginosa 527 assessed as appearance of colony at 4 times MIC concentration2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID495700Activity of Acinetobacter baumannii OXA-232010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID584730Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4069 harboring mutation in putative dTDP-4-rhamnose reductase-related protein by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID423341Antibacterial activity against Acinetobacter baumannii isolate 888 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID562334Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid pBC-SK after 18 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID529848Antibacterial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID511290Antibacterial activity against Escherichia coli DH5alpha2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID1373309Antimicrobial activity against Escherichia coli expressing beta-lactamase VIM-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1407949Antibacterial activity against Pseudomonas aeruginosa ARC3612 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID1757613Antibacterial activity against Enterobacter aerogenes 15-6 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID588080Antibacterial activity against Acinetobacter baumannii ATCC 17978 harboring plasmid 12662011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
ISAba825, a functional insertion sequence modulating genomic plasticity and bla(OXA-58) expression in Acinetobacter baumannii.
AID562809Antimicrobial activity against Escherichia coli J532009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID222238In vivo therapeutic efficacy was determined against Streptococcus pyogenes 77A by a single sc administration in mice1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID534481Antimicrobial activity against Stenotrophomonas maltophilia KJN2 harboring ampN with xylE-Gmomega cassette insertion by Etest2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID1757579Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-10 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID573837Antibacterial activity against beta-lactamase producing Clostridium tertium assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID237262Half life at a single intravenous administration of 20 mg/kg in rat2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID286039Antimicrobial activity against ESBL producing Klebsiella pneumoniae 261 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID289892Antibacterial activity against Pseudomonas aeruginosa 110/22007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID558628Antimicrobial activity against Streptococcus pneumoniae isolate 3681 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID1853609Antibacterial activity against Enterococcus faecium clinical isolate 1088228 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution method2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
Design, synthesis, and antibacterial activity of
AID1757602Antibacterial activity against Enterobacter cloacae 17-8 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID372324Cmax in PK/PD in vitro model infused with 1g at 8hr intervals2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID523552Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E452 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID289900Antibacterial activity against Salmonella paratyphi A2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID1757566Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-14 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID520388Ratio of Kcat to Km for Pseudomonas aeruginosa COL-1 metallo-beta lactamase VIM-22008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID534629Antimicrobial activity against Non-ESBL Escherichia coli assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID555262Antibacterial activity against Acinetobacter genomosp. 3 isolate 103 by Etest method in presence of efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID571890Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 9 expressing ampC, ompA, adeB, adeM by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID523942Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E456 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID496490fT>MIC in Klebsiella pneumoniae isolate 351 at 2 gram for every 8 hrs administered as 3 hrs infusion over 24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID523488Antimicrobial activity against Pseudomonas aeruginosa R70 Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID523739Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E4522010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523896Antibacterial activity against Pseudomonas aeruginosa P341 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID496570Antibacterial activity against Pseudomonas aeruginosa isolate 762 assessed as reduction of bacterial count at 16 ug/ml within 6 hrs in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID523541Antibacterial activity against beta-lactamase-negative Escherichia coli E350 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID423241Antibacterial activity against beta lactamase-negative Haemophilus influenzae ATCC 49247 isolated from respiratory tract infected patients assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID286037Antimicrobial activity against ESBL producing Klebsiella pneumoniae 262 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID528983Antimicrobial activity against Haemophilus influenzae isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID576531Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008139 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID289909Antibacterial activity against Serratia marcescens 60932007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID423319Antibacterial activity against Pseudomonas aeruginosa isolate 362 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID574498Antimicrobial activity against Bacteroides thetaiotaomicron assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1407954Antibacterial activity against Pseudomonas aeruginosa ARC3925 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID524269Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E476 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524003Antimicrobial activity against Acinetobacter baumannii ATCC 15151 harboring ISAba1-blaOXA-66 gene by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
AID523895Antibacterial activity against Pseudomonas aeruginosa P370 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID528825Antimicrobial activity against ESBL producing Klebsiella pneumoniae isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1361168Antimicrobial activity against VIM-2 producing Pseudomonas aeruginosa SBRKM-28 in presence of human apo-transferrin by broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.
AID70114Compound was evaluated for its antibacterial activity against Escherichia coli CCARM 1114 MDR2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID496565Antibacterial activity against Klebsiella pneumoniae isolate 375 assessed as reduction of bacterial count at 32 ug/ml within 6 hrs in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID529647Antimicrobial activity against Escherichia coli DH5alpha harboring beta-lactamase VIM-15 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID584313Antimicrobial activity against beta-lactamase ompC intact/ompF deficient Serratia marcescens isolate YMC0573 by agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID511158Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 14 assessed as zone of inhibition by disk diffusion assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID519807Inhibition of Bocillin FL binding to PBP3 in Pseudomonas aeruginosa PAO1 membranes2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID423499Antibacterial activity against Acinetobacter baumannii isolate 898 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID498886Antimicrobial activity against Pseudomonas aeruginosa OC 4354 assessed as inhibition of growth by broth microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID1279001Antibacterial activity against methicillin-resistant Staphylococcus aureus incubated for 20 hrs by microbroth dilution method2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
Synthesis of fluorinated carbazoles via C-H arylation catalyzed by Pd/Cu bimetal system and their antibacterial activities.
AID495737Kcat/Km ratio of Pseudomonas aeruginosa AmpC relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID518465Antimicrobial activity against Pseudomonas aeruginosa 527 assessed as number of passages required for MIC to rise above 4 times original MIC2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID555241Antibacterial activity against Acinetobacter genomosp. 3 isolate 52 by Etest method in presence of efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID324858Antimicrobial activity against Acinetobacter baumannii A24A after 4 days by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID534429Antimicrobial activity against Finegoldia magna ATCC 29328 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID558589Antimicrobial activity against Streptococcus pneumoniae 1 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID1229261Half life of the compound at pH 7.4 at 37 degC2015ACS medicinal chemistry letters, May-14, Volume: 6, Issue:5
SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of Pseudomonas aeruginosa PBP3.
AID584563Antimicrobial activity against Acinetobacter lwoffii isolate J expressing beta-lactamase OXA-58 isolated from bedsore by vitek 2 system2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID495703Kcat/Km ratio of Escherichia coli CTX-M-152010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID70087Antibacterial activity against Escherichia coli 0781998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID584507Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0908 harboring mutation in hypothetical protein by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1373288Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-8 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID404957Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii 193 isolate carrying two bla-OXA58 gene copies by agar dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID1757588Antibacterial activity against ESBLs negative Carbapenem-sensitive Escherichia coli 17-1 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID429078Antibacterial activity against Escherichia coli J53 expressing Klebsiella pneumoniae Greece blaKPC-2 gene by E test method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.
AID574470Antimicrobial activity against Escherichia coli isolate 543 expressing beta-lactamase KPC2, CTX-M-15, TEM and PFGE cluster 4 isolated from synovial fluid of patient by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID545340Displacement of [14C]benzylpenicillin from PBP2 in Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID496532fT>MIC in Klebsiella pneumoniae isolate 361 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 8-16 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID584715Antimicrobial activity against Pseudomonas aeruginosa PA14 PA14_59780 harboring rcsC mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID524289Antibacterial activity against Pseudomonas aeruginosa P373 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID525038Activity of Klebsiella pneumoniae Beta-lactamase OXA2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Updated functional classification of beta-lactamases.
AID433173Antibacterial activity against Enterobacter aerogenes isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID565338Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-23 harboring A residue at 105 position in PDC- 5 by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID495712Kcat/Km ratio of Pseudomonas aeruginosa VIM-22010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1318929Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 860792016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID423235Antibacterial activity against penicillin-resistant Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as resistant isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID495792Antimicrobial activity against Escherichia coli DH10B harbouring recombinant plasmid pSau1 expressing beta-lactamase BIC-1 from Pseudomonas fluorescens PF-1 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID1373296Antimicrobial activity against Escherichia coli expressing beta-lactamase VEB-4 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID405089Antibacterial activity against blaVIM2-harboring integrons containing Pseudomonas aeruginosa 42 isolate from ventilator-associated pneumonia patient2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
blaVIM-2-harboring integrons isolated in India, Russia, and the United States arise from an ancestral class 1 integron predating the formation of the 3' conserved sequence.
AID584522Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3259 harboring mutation in conserved hypothetical protein by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID565662Antimicrobial activity against beta-lactamase negative ampicillin-resistant Haemophilus influenzae assessed as susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re
AID573564Antibacterial activity against beta-lactamase producing Bacteroides vulgatus assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID517985Antimicrobial activity against Pseudomonas aeruginosa BA harboring beta-lactamase Class C by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID336778Antimicrobial activity against Streptococcus pyogenes 77A isolate after 18 hrs2003Journal of natural products, Mar, Volume: 66, Issue:3
Bioactive sterols from the starfish Certonardoa semiregularis.
AID535642Antimicrobial activity against Group B streptococcus serotype VI N4 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID555238Antibacterial activity against Acinetobacter genomosp. 3 isolate 21 by Etest method in presence of efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID576530Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008022 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID1757610Antibacterial activity against Enterobacter aerogenes 15-3 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID323602Antimicrobial activity against Haemophilus influenzae2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.
AID544492Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase KPC-2 by agar dilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID535144Antimicrobial activity against imipenem non-susceptible Pseudomonas aeruginosa assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID572132Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 33 expressing ampC, ompA, adeB, adeM by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1680044Antibacterial activity against NDM1 producing carbapenem-resistant Enterobacteriaceae clinical isolate 2 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID498841Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae SX67 deficient in SHV-2, CTX-M-14, DHA-1, qnrB6/S1, aac(6')-Ib-cr, ompK35/36 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID10736Area under the curve was calculated for the compound.1998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID498821Antimicrobial activity against Klebsiella pneumoniae WH76T expressing IMP-4, TEM-1, CTX-M-3, qnrS1 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID295832Antibacterial activity against Proteus rettgeri 937 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID549336Antimicrobial activity against Escherichia coli isolate 49 harboring bla CTX-M-3a gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID555213Antibacterial activity against Acinetobacter genomosp. 3 isolate 195 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID117666In vivo therapeutic efficacy in systemic infections caused by Escherichia coli 078 in mice, at a single subcutaneous administration2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.
AID425111Antimicrobial activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID534459Antimicrobial activity against Lactobacillus salivarius subsp. salivarius JCM 1231 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID563967Antibacterial activity against Escherichia coli TOP10 by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID95720In vitro antibacterial activity against Klebsiella aerogenes 1522E2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.
AID340736Activity of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID423495Antibacterial activity against Acinetobacter baumannii isolate 894 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID295828Antibacterial activity against Proteus mirabilis 112/3 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID532397Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D isolate VA-06X-69 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID1361172Antimicrobial activity against OXA-23/OXA-58 producing Acinetobacter baumannii SR27323 in presence of human apo-transferrin by broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.
AID423500Antibacterial activity against Acinetobacter baumannii isolate 899 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID523734Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E4372010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1443397In vivo antibacterial activity against multidrug resistant Klebsiella pneumoniae isolate 212232 infected in Kunming mouse systemic infection model assessed as increase in mouse survival administered subcutaneously 0.5 to 4 hrs post infection measured afte2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections.
AID1395498Antibacterial activity against new delhi metallo-beta-lactamase-1 harboring Enterobacter cloacae 13-1 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, Apr-25, Volume: 150Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID522649Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis Colorado by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID511139Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 132010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID433192Antibacterial activity against Staphylococcus epidermidis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID1680043Antibacterial activity against NDM1 producing carbapenem-resistant Enterobacteriaceae clinical isolate 3 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID521995Antimicrobial activity against Klebsiella pneumoniae isolate Kp3A expressing beta-lactamase OXA-48 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID562750Antimicrobial activity against Escherichia coli K-12 by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID535840Antimicrobial activity against Pseudomonas aeruginosa GP4KT111 harboring oprD gene after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID1905563Antimicrobial activity against Staphylococcus epidermidis ATCC 12228 assessed as reduction of bacterial growth incubated for 18 hrs by CLSI protocol based broth microdilution method2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Novel β-Hairpin Antimicrobial Peptides Containing the β-Turn Sequence of -RRRF- Having High Cell Selectivity and Low Incidence of Drug Resistance.
AID1417169Antibacterial activity against methicillin-resistant Staphylococcus aureus NR10186 by CLSI method2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis of 1,2,3-triazole linked 4(3H)-Quinazolinones as potent antibacterial agents against multidrug-resistant Staphylococcus aureus.
AID548040Antimicrobial activity against Escherichia coli DH10B harboring plasmid pBK SK(+) by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID524318Antibacterial activity against Acinetobacter baumannii A912 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID547781Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237I mutant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID56123Relative hydrolysis to meropenem by partially purified porcine renal Dehydropeptidase-1 was reported.1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID524090Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3632010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID508731Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3D2 GM2 harboring acquired beta-lactamase BEL-3 by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID534444Antimicrobial activity against Actinomyces odontolyticus GAI 91002 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID274724Antibacterial activity against methicillin-resistant Streptococcus pyogenes 77A2007Journal of natural products, Jan, Volume: 70, Issue:1
Bisindole alkaloids of the topsentin and hamacanthin classes from a marine sponge Spongosorites sp.
AID1824272Antimicrobial activity against Klebsiella pneumoniae clinical isolate T2301 expressing NDM-1 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID576296Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 16830 harboring porin OmpK36 gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID95703Antibacterial activity against Klebsiella aerogenes 1522E1998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1407956Antibacterial activity against Pseudomonas aeruginosa ARC4063 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID322315Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID1628580Antibacterial activity against Streptococcus pyogenes 1307006P incubated for 18 to 24 hrs by broth microdilution method2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
Discovery and Characterization of a Class of Pyrazole Inhibitors of Bacterial Undecaprenyl Pyrophosphate Synthase.
AID523496Antimicrobial activity against Pseudomonas aeruginosa isolate 17145c from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID555214Antibacterial activity against Acinetobacter genomosp. 3 isolate 243 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID531678Antimicrobial activity against Acinetobacter baumannii TVICU53 by broth dilution test2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID495904Antimicrobial activity in Klebsiella pneumoniae DIH-2 clinical isolate expressing beta-lactamase VIM-19 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID1879069Antibacterial activity against NDM-1 negative Escherichia coli ATCC25922 isolates assessed as inhibition of bacterial growth incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID573834Antibacterial activity against beta-lactamase producing Clostridium perfringens assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID529645Antimicrobial activity against Pseudomonas aeruginosa 166301 expressing beta-lactamase VIM-16 obtained from urine of patient by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID1373294Antimicrobial activity against Escherichia coli expressing beta-lactamase SME-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1752490Antibacterial activity against Klebsiella pneumoniae PLE producing class D beta-lactamase, OXA-48 assessed as reduction in microbial growth incubated for 16 to 20 hrs in presence of vaborbactam by broth microdilution method2021Bioorganic & medicinal chemistry, 09-15, Volume: 46A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID532909Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 549 ST 327 expressing beta-lactamase TEM-1 and CTX-M-2 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID574500Antimicrobial activity against Bacteroides thetaiotaomicron assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID584566Antimicrobial activity against Acinetobacter lwoffii isolate M expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1757614Antibacterial activity against Enterobacter aerogenes 15-7 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID529578Ratio of Kcat to Km for Chryseobacterium meningosepticum beta-Lactamase GOB-12008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID1862390Antibacterial activity against Klebsiella pneumoniae harboring OXA-48 assessed as bacterial growth inhibition incubated for 16 to 20 hrs by microdilution method2022European journal of medicinal chemistry, Oct-05, Volume: 240Triazole-substituted phenylboronic acids as tunable lead inhibitors of KPC-2 antibiotic resistance.
AID1767683Antibacterial activity against Escherichia coli EHEC 933 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID1357450Antibacterial activity against KPC-2 producing Klebsiella pneumoniae isolate 212232 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria.
AID289886Antibacterial activity against Streptococcus faecium 77A2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID1757543Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-7 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID369628Antimicrobial activity against beta-lactamase negative ampicillin-resistant Haemophilus influenzae by broth microdilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
AID524080Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3232010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID432997Antibacterial activity against Proteus vulgaris isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID574052Antibacterial activity against beta-lactamase producing Finegoldia magna assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID574494Antimicrobial activity against Bacteroides fragilis assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID520780Antibacterial activity against Escherichia coli EC600 transconjugant harboring beta-lactamase KPC-2 by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID524317Antibacterial activity against Acinetobacter baumannii A911 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID423286Antibacterial activity against Pseudomonas aeruginosa isolate 322 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID351198Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii expressing ISAba12007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Global challenge of multidrug-resistant Acinetobacter baumannii.
AID563972Activity of Klebsiella pneumoniae 05-560 beta-lactamase NDM-1 by spectrophotometry2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID529862Ratio of MIC for Pseudomonas aeruginosa N045 to MIC for Pseudomonas aeruginosa PAO12008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID545544Ratio of MIC for Staphylococcus aureus SIR2a selected at 2 times MIC of imipenem to MIC for Staphylococcus aureus ATCC 6538P2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID555446Antibacterial activity against Acinetobacter genomosp. 3 isolate 195 by Etest method in presence of efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID495678Antimicrobial activity against wild type Pseudomonas aeruginosa ATCC 27853 expressing beta-lactamase AmpC assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID495681Antimicrobial activity against Pseudomonas aeruginosa OC 7052 expressing beta-lactamase VIM-2 and containing Carbapenemase assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID516147Antibacterial activity against Pulsotype D Acinetobacter genomosp. 3 isolate 18 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, repAcil, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID576524Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate AIS070446 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID564952Antimicrobial activity against Acinetobacter baumannii isolate Ab63 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba92009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID534650Antimicrobial activity against ESBL producing Klebsiella pneumoniae assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID535888Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae JN41T harboring qnrB gene by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1533859Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 1136 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID559684Antibacterial activity against Acinetobacter baumannii BM46522009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
AID285584Antimicrobial activity against Pseudomonas aeruginosa 65.33-3 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID496508fT>MIC in Klebsiella pneumoniae isolate 354 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 0-8 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID529517Antibacterial activity against Pseudomonas aeruginosa isolates by Etest2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
IMP-15-producing Pseudomonas aeruginosa strain isolated in a U.S. medical center: a recent arrival from Mexico.
AID523719Antibacterial activity against Acinetobacter baumannii A891 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574530Antimicrobial activity against Prevotella bivia assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID70162Compound was tested for in vivo protective activity against Escherichia coli 078 at a single subcutaneous administration in mice.1998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID283393Antimicrobial activity against Nocardia abscessus after 72 hrs by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID1765573Antibacterial activity against Staphylococcus aureus ATCC 25923 incubated for 18 hrs by CLSI based broth dilution method2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Novel Broad-Spectrum Antimicrobial Peptide Derived from Anoplin and Its Activity on Bacterial Pneumonia in Mice.
AID547773Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237A mutant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID511157Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 13 assessed as zone of inhibition by disk diffusion assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID529643Antimicrobial activity against Pseudomonas aeruginosa 9551 expressing beta-lactamase VIM-15 obtained from urine of patient by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID295837Antibacterial activity against Salmonella oranienburg after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID523931Antibacterial activity against beta-lactamase-negative Escherichia coli E408 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID396028Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate by Etest2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID564467Antimicrobial activity against Pseudomonas aeruginosa isolate 1080 by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID496486Antibacterial activity against Pseudomonas aeruginosa isolate 896 in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID518195Antimicrobial activity against mexAB-oprM, mexCD-oprJ, mexEF-oprN, mexJK, mexXY, opmH and pscC gene deficient Pseudomonas aeruginosa PAO750 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID516141Antibacterial activity against Pulsotype K Acinetobacter genomosp. 3 isolate 6 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID561472Antibacterial activity against Serratia marcescens assessed as susceptible isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID524307Antibacterial activity against Pseudomonas aeruginosa P341 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID562337Activity at Chryseobacterium indologenes 597 metallo-beta-lactamase IND-6 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID586231Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 4 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID71100In vitro antibacterial activity against Escherichia coli 0782000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Synthesis and antibacterial activity of new carbapenems containing isoxazole moiety.
AID584705Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0402 harboring pyrB mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID423232Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as resistant isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID1757541Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-5 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID374366Antimicrobial activity against Escherichia coli DH5alpha by broth dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID521999Antimicrobial activity against Klebsiella pneumoniae isolate Kp6A expressing beta-lactamase OXA-48 and TEM-150 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID499068Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ90 deficient in CTX-M-14, ompC/F by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID545347Displacement of [14C]benzylpenicillin from PBP2 in Pseudomonas aeruginosa ATCC 156922009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID1628587Antibacterial activity against Acinetobacter baumannii ACM1010 incubated for 18 to 24 hrs by broth microdilution method2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
Discovery and Characterization of a Class of Pyrazole Inhibitors of Bacterial Undecaprenyl Pyrophosphate Synthase.
AID1373280Antimicrobial activity against wild type Escherichia coli by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID576324Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008142 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID584747Antimicrobial activity against Acinetobacter baumannii ATCC 17978 harboring beta-lactamase OXA-164 by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID585395Activity at Bradyrhizobium japonicum metallo-beta-lactamase BJP-12010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID495907Antimicrobial activity in Escherichia coli TOP10 strain harbouring recombinant plasmid VIM-1 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID522010Antimicrobial activity against Escherichia coli isolate TOP10 harboring pBIC containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID69478Minimum inhibitory concentration against Escherichia coli 1507E was determined by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID529489Antimicrobial activity against Enterobacter cloacae isolate 656 containing PFGE genetic clone A expressing beta-lactamase KPC-2 and SHV-12 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID95726In vivo antibacterial activity against Klebsiella aerogenes 1522E1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID70106Compound was evaluated for its antibacterial activity against Escherichia coli 0157:H72003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID564529Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID528842Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID528979Antimicrobial activity against carbapenem-resistant Enterobacter cloacae isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID565727Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-32 harboring A residue at 105 position in PDC- 10 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID423519Antibacterial activity against Acinetobacter baumannii isolate 918 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID1361167Antimicrobial activity against IMP-1 producing Pseudomonas aeruginosa SR27001 in presence of human apo-transferrin by broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.
AID523576Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E473 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1504344Antibacterial activity against carbapenemase-producing Klebsiella pneumoniae after 16 to 20 hrs by broth microdilution method2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and bioactivities study of new antibacterial peptide mimics: The dialkyl cationic amphiphiles.
AID1554004Antibacterial activity against Pseudomonas aeruginosa UFR49 measured after 16 to 20 hrs by broth microdilution method2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Structural Basis for E. coli Penicillin Binding Protein (PBP) 2 Inhibition, a Platform for Drug Design.
AID534923Antimicrobial activity against Serratia marcescens assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1706871Antibacterial activity against methicillin-resistant Staphylococcus aureus NR119 measured after 16 to 18 hrs2021European journal of medicinal chemistry, Feb-15, Volume: 212Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.
AID423310Antibacterial activity against Pseudomonas aeruginosa isolate 353 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID423102Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID656350Antibacterial activity against Acinetobacter baumannii AB-31672011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID574768Antimicrobial activity against Finegoldia magna assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID532178Antimicrobial activity against aac(6')-Ib-cr-negative Klebsiella pneumoniae SY22 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrS genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID584735Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4753 harboring mutation in putative RNA-binding protein by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID534869Antimicrobial activity against ESBL producing Proteus mirabilis assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1296370Activity at Mycobacterium tuberculosis beta lactamase BlaC expressed in Escherichia coli by spectrophotometric method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Routes of Synthesis of Carbapenems for Optimizing Both the Inactivation of L,D-Transpeptidase LdtMt1 of Mycobacterium tuberculosis and the Stability toward Hydrolysis by β-Lactamase BlaC.
AID523893Antibacterial activity against Pseudomonas aeruginosa P349 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID374362Ratio of Kcat to Km of Aeromonas caviae A324R metallo-beta-lactamase IMP-19 expressed in Escherichia coli DH5alpha by computerized microacidimetric method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID496520fT>MIC in Pseudomonas aeruginosa isolate 896 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 0-8 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID533424Antimicrobial activity against Anaerococcus prevotii assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID534460Antimicrobial activity against Bacteroides fragilis GAI 5562 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID519817Antimicrobial activity against Pseudomonas aeruginosa 27853 by CLSI protocol based broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID286027Antimicrobial activity against ESBL producing Klebsiella pneumoniae 260 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID564462Antimicrobial activity against Pseudomonas aeruginosa isolate 913 by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID1279000Antibacterial activity against Escherichia coli incubated for 20 hrs by microbroth dilution method2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
Synthesis of fluorinated carbazoles via C-H arylation catalyzed by Pd/Cu bimetal system and their antibacterial activities.
AID341594Antibacterial activity against carbapenem-resistant blaKPC-encoding plasmid harboring Klebsiella pneumoniae 469 transformants producing KPC2, OXA4 and CTX-M-10 carbapenemases2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID524306Antibacterial activity against Pseudomonas aeruginosa P370 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584309Antimicrobial activity against beta-lactamase ompC intact/ompF deficient Serratia marcescens isolate YMC0547 by agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID522008Antimicrobial activity against Escherichia coli isolate J53 harboring pI-2 containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID1318927Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 860532016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID584558Antimicrobial activity against Acinetobacter lwoffii isolate E expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1905565Antimicrobial activity against Klebsiella pneumoniae ATCC 700603 assessed as reduction of bacterial growth incubated for 18 hrs by CLSI protocol based broth microdilution method2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Novel β-Hairpin Antimicrobial Peptides Containing the β-Turn Sequence of -RRRF- Having High Cell Selectivity and Low Incidence of Drug Resistance.
AID1757536Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-10 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID565542Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-06 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID511582Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD1 harboring oprD spontaneous mutant selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID523934Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E412 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433184Antibacterial activity against Corynebacterium minutissimum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID555210Antibacterial activity against Acinetobacter genomosp. 3 isolate 103 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID518242Antimicrobial activity against Enterobacter cloacae S4741B assessed as appearance of colony at 4 times MIC concentration2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID495729Activity of Pseudomonas aeruginosa SPM-1 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID534927Antimicrobial activity against Ceftazidime non-susceptible Serratia marcescens assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID341593Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 469 isolate producing KPC2, OXA4 and CTX-M-10 carbapenemases2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID1504341Antibacterial activity against Escherichia coli ATCC 25922 after 16 to 20 hrs by broth microdilution method2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and bioactivities study of new antibacterial peptide mimics: The dialkyl cationic amphiphiles.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1757504Antibacterial activity against Klebsiella pneumoniae ATCC BAA-1705 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID285977Antimicrobial activity against ESBL producing Escherichia coli 321 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID495722Activity of Pseudomonas aeruginosa AmpC relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1757499Antibacterial activity against Escherichia coli NCTC 13353 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID544488Antibacterial activity against Pseudomonas aeruginosa PR100 harboring beta-lactamase KPC-2 by agar dilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID324856Antimicrobial activity against Acinetobacter baumannii A24 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID423340Antibacterial activity against Acinetobacter baumannii isolate 887 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID423329Antibacterial activity against Pseudomonas aeruginosa isolate 372 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID545568Ratio of MIC for Escherichia coli EMR2a to MIC for Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID545410Antimicrobial activity against Pseudomonas aeruginosa PS18A with PFGE phenotype 11D obtained from CSF of ICU patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID555258Antibacterial activity against Acinetobacter genomosp. 3 isolate 90 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID496503fT>MIC in Pseudomonas aeruginosa isolate 896 at 2 gram for every 8 hrs administered as 3 hrs infusion over 24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID582763Antimicrobial activity against eaeA positive verocytotoxin-producing non-O157 Escherichia coli isolates obtained from human assessed as percentage of resistant isolates2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26.
AID565537Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-01 harboring T residue at 105 position in PDC- 1 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1278998Antibacterial activity against Bacillus subtilis incubated for 20 hrs by microbroth dilution method2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
Synthesis of fluorinated carbazoles via C-H arylation catalyzed by Pd/Cu bimetal system and their antibacterial activities.
AID423240Antibacterial activity against beta lactamase-positive Haemophilus influenzae ATCC 49247 isolated from respiratory tract infected patients assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID555557Antimicrobial activity against Pseudomonas aeruginosa isolate 27135 expressing VIM-2 beta lactamase gene by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
AID511160Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 16 assessed as zone of inhibition by disk diffusion assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID548016Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237D mutant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID1373282Antimicrobial activity against Escherichia coli expressing beta-lactamase CTXM-15 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID533416Antimicrobial activity against Peptoniphilus asaccharolyticus assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID164378Antibacterial activity against Pseudomonas aeruginosa 1771M2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID511159Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 15 assessed as zone of inhibition by disk diffusion assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID521426Antibacterial activity against Stenotrophomonas maltophilia isolate KJ deficient in L1 beta lactamase gene by Etest2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID584748Antimicrobial activity against Acinetobacter baumannii ATCC 17978 harboring beta-lactamase OXA-58 by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID495910Antimicrobial activity in Escherichia coli TOP10 strain2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID425112Antimicrobial activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID495728Activity of Pseudomonas aeruginosa IMP-1 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID574469Antimicrobial activity against Escherichia coli isolate 540 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from synovial fluid of patient by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID531770Antimicrobial activity against Pseudomonas aeruginosa urine isolate 4706 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID561452Antibacterial activity against Klebsiella oxytoca assessed as resistant isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID584846Activity at Aeromonas allosaccharophila AL-1 beta-lactamase PER62010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID496521fT>MIC in Pseudomonas aeruginosa isolate 988 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 0-8 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID511151Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 7 assessed as zone of inhibition by disk diffusion assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID96091Compound was evaluated for its antibacterial activity against Klebsiella pneumoniae 6 ESBL2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID535894Antimicrobial activity against aac(6')-Ib-cr-negative Citrobacter freundii JN64T harboring qnrA gene by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1395497Antibacterial activity against new delhi metallo-beta-lactamase-1 harboring Enterobacter cloacae CDC1000654 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, Apr-25, Volume: 150Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID576954Antimicrobial activity against Shewanella putrefaciens Sp31 harboring intI1 and beta-lactamase OXA-48 like genes by CLSI method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Reservoir of antimicrobial resistance determinants associated with horizontal gene transfer in clinical isolates of the genus Shewanella.
AID164379Antibacterial activity against Pseudomonas aeruginosa 90272003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID656355Chemical stability of the compound in phosphate buffer at pH 8 assessed as drug degradation at 1 uM after 100 hrs by HPLC analysis2011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID584570Antimicrobial activity against Acinetobacter lwoffii isolate D expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID585434Antimicrobial activity against Pseudomonas aeruginosa PA14 by EUCAST method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa.
AID528791Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 and other bla gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID373046Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZS5 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID496475Antibacterial activity against Klebsiella pneumoniae isolate 353 in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID678451Antibacterial activity against Klebsiella pneumoniae2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections.
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1757598Antibacterial activity against Enterobacter cloacae 17-4 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID576528Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate HIP14474 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID1233135Antibacterial activity against patient-derived methicillin-resistant Staphylococcus aureus 7419 after 18 to 20 hrs by microbroth dilution method2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors.
AID528529Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B12 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID1373292Antimicrobial activity against Escherichia coli expressing beta-lactamase PER-4 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID562741Antimicrobial activity against Escherichia coli DH5[alpha] by agar dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID285982Antimicrobial activity against ESBL producing Escherichia coli 243 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID1853605Antibacterial activity against Enterococcus faecalis clinical isolate 1091720 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution method2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
Design, synthesis, and antibacterial activity of
AID405821Antimicrobial activity against Acinetobacter baumannii 695 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-32007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID584734Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4745 harboring nusA mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID548020Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237E mutant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID1373289Antimicrobial activity against Escherichia coli expressing beta-lactamase NMC-A by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1862387Antibacterial activity against Escherichia coli expressing CMY-4/TEM-1 assessed as bacterial growth inhibition at 0.06 to 64 ug/ml incubated for 16 to 20 hrs by microdilution method2022European journal of medicinal chemistry, Oct-05, Volume: 240Triazole-substituted phenylboronic acids as tunable lead inhibitors of KPC-2 antibiotic resistance.
AID583020Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Enterobacter asburiae CIP 105006 plasmid carrying ACT-1 by agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID1596886Antibacterial activity against methicillin-resistant Staphylococcus aureus NR10191 incubated for 16 to 18 hrs by broth microdilution assay
AID1417172Antibacterial activity against methicillin-resistant Staphylococcus aureus NR10191 by CLSI method2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis of 1,2,3-triazole linked 4(3H)-Quinazolinones as potent antibacterial agents against multidrug-resistant Staphylococcus aureus.
AID165028In vitro antibacterial activity against Pseudomonas aeruginosa 90272001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.
AID532416Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-11 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID390323Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 65382008Journal of natural products, Dec, Volume: 71, Issue:12
Citreamicins with potent gram-positive activity.
AID533380Antimicrobial activity against Bacteroides merdae assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID555554Antimicrobial activity against Pseudomonas aeruginosa isolate M136074 expressing IMP-22 beta lactamase gene by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
AID289917Antibacterial activity against Corynebacterium diphtheriae2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID517977Antimicrobial activity against Acinetobacter baumannii HPA74510 harboring beta-lactamase IMP-4 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID524325Antibacterial activity against Acinetobacter baumannii A908 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523725Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E3462010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID521355Antimicrobial activity against Streptococcus pneumoniae isolate 657 obtained from sputum of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID584581Antimicrobial activity against Escherichia coli NEB 5-alpha harboring beta-lactamase OXA-164 by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1759650Antimicrobial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213 by CLSI-based broth microdilution assay2021European journal of medicinal chemistry, Jul-05, Volume: 2194-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.
AID587531Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse in presence of 4 ug/ml Tazobactam beta-lactamase inhibitor2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID1721009Synergistic Inhibition of beta lactamase VIM-29 in Escherichia coli 50639799 assessed colony formation by visual inspection in presence of 50 microM (5-((4-iodophenylsulfonamido)methyl)-1H-1,2,3-triazol-4-yl)methyl acetate incubated for 20 hrs by two-fold2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Structural studies of triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-β-lactamases.
AID245228Minimum inhibitory concentration against Streptococcus pyogenes SG 511 strain2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID562948Antimicrobial activity against Klebsiella pneumoniae PFGE clone E expressing beta-lactamase KPC-2 by Etest2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID70098Compound was evaluated for in vitro antibacterial activity against Escherichia coli 1507 E strain by agar dilution method2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Synthesis and antibacterial activity of 2alpha-functionalized 1beta-methylcarbapenems related to KR-21012.
AID438297Inhibition of penicillin-sensitive Streptococcus pneumoniae R6 PBP2X preincubated for 1 hr before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID534300Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA4592010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID546424Antimicrobial activity against Pseudomonas aeruginosa 12B harboring recombinant pBB-PDC-4 by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID562748Antimicrobial activity against Klebsiella pneumoniae AH24-270 expressing blaCTX-M-71 gene by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID545407Antimicrobial activity against Pseudomonas aeruginosa PS14 with PFGE phenotype 10C obtained from sputum of ICU patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID560085Bactericidal activity against Pseudomonas aeruginosa isolate 796 at 1/4 times MIC after 24 hrs by time kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID1740671In vivo antibacterial activity against multidrug-resistant Escherichia coli ARC 2687 infected in CD-1 mouse model of neutropenic thigh infection assessed as colony forming unit at 600 mg/kg, sc administered at 6 hrs interval relative to pretreatment2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1056834Antibacterial activity against GIM-1 expressing Pseudomonas aeruginosa isolate 197 after 18 to 24 hrs by two-fold broth microdilution assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID498818Antimicrobial activity against Klebsiella pneumoniae GZ64 expressing IMP-4, ompK35/36 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID563602Antimicrobial activity against lacZ-negative, Nalidixic acid-, rifampicin-resistant Escherichia coli EC600 by Etest2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA.
AID495819Antimicrobial activity against Klebsiella pneumoniae 2878 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID576317Antimicrobial activity against ESBL-negative Klebsiella pneumoniae 30018 harboring porin OmpK35 gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID534385Antibacterial activity against Escherichia coli K-12 W1895 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID534696Antimicrobial activity against Porphyromonas uenonis by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID545336Displacement of [14C]benzylpenicillin from PBP3 in Staphylococcus aureus ATCC 6538P2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID555254Antibacterial activity against Acinetobacter genomosp. 3 isolate 67 by Etest method in presence of efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID423313Antibacterial activity against Pseudomonas aeruginosa isolate 356 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID534440Antimicrobial activity against Clostridium perfringens ATCC 13124 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID558610Antimicrobial activity against Streptococcus pneumoniae isolate 1424 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID533568Antimicrobial activity against Pseudomonas aeruginosa isolate PA469 expressing VIM-2 beta-lactamase2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID567474Antimicrobial activity against gBLPACR-1 Haemophilus influenzae by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID1225850Antibacterial activity against Klebsiella pneumoniae KP1074 in Swiss webster neutropenic mouse lung infection model assessed as change in log10 CFU in lung at 100 mg/kg, ip administered every 2 hrs starting at 2 hrs postinfection measured after 24 hrs rel2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID1533871Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 3580 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID285986Antimicrobial activity against ESBL producing Escherichia coli 315 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID423285Antibacterial activity against Pseudomonas aeruginosa isolate 320 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID545572Ratio of MIC for Pseudomonas aeruginosa PIR2a to MIC for Pseudomonas aeruginosa ATCC 156922009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID530813Antibacterial activity against Escherichia coli J53 harboring plasmid pA-1carrying beta-lactamase OXA-48 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID535867Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae GZ51 harboring qnrA gene by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID560601Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa by microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID511578Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 deficient in ampD gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID401685Antibacterial activity against Streptococcus faecium MD 8b2005Journal of natural products, May, Volume: 68, Issue:5
Cytotoxic bisindole alkaloids from a marine sponge Spongosorites sp.
AID390338Antimicrobial activity against ampC beta-lactamase producing multidrug-resistant Klebsiella pneumoniae 22622008Journal of natural products, Dec, Volume: 71, Issue:12
Citreamicins with potent gram-positive activity.
AID545345Displacement of [14C]benzylpenicillin from PBP1A in Pseudomonas aeruginosa ATCC 156922009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID523757Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E4802010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID571695Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 4 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID498842Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae CY75 deficient in SHV-11, DHA-1, ompK35/36 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1373320Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-51 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID495791Antimicrobial activity against Pseudomonas fluorescens isolate PF-1 expressing beta-lactamase BIC-1 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID520972Antibacterial activity against Escherichia coli harboring pBC633 plasmid expressing blaKPC gene by Etest method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID1873907Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID286006Antimicrobial activity against ESBL producing Klebsiella pneumoniae 261 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID1757548Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-12 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID521838Antibacterial activity against Klebsiella pneumoniae isolate VA375 with blaKPC-3, qnrA1, blaTEM-1, blaSHV-11 genes by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID523746Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E4832010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID544489Antibacterial activity against Enterobacter cancerogenus E624 harboring beta-lactamase KPC-4 by agar dilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID1846918Antibacterial activity against ESBL-producing multidrug resistant Escherichia coli assessed as reduction in bacterial growth incubated for 18 to 20 hrs by CLSI based microdilution method2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Design, Synthesis, and Biological Evaluation of Novel Pyrimido[4,5-
AID285990Antimicrobial activity against ESBL producing Escherichia coli 130 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID495741Kcat/Km ratio of Serratia marcescens SME-3 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID571208Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method in presence of 0.25 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID495805Antimicrobial activity against Klebsiella pneumoniae 6828 strain expressing beta-lactamase VIM-19 by microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID523749Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E3582010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID528969Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID558591Antimicrobial activity against Streptococcus pneumoniae 3 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID588123Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 1 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID1373284Antimicrobial activity against Escherichia coli expressing beta-lactamase IMI-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID425117Bactericidal activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID511149Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 5 assessed as zone of inhibition by disk diffusion assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID562328Antimicrobial activity against Chryseobacterium indologenes 597 expressing metallo-beta-lactamase IND-6 after 18 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID195304In vitro DHP-I stability of the compound, expressed as relative t1/2 of hydrolysis to meropenem by partially purified porcine renal DHP-I2000Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13
Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID524106Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A9102010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523417Antibacterial activity against beta-lactamase-negative Escherichia coli E344 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524310Antibacterial activity against Pseudomonas aeruginosa P326 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID549331Antimicrobial activity against Escherichia coli isolate 32 harboring bla CTX-M-3a gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID519811Inhibition of Bocillin FL binding to PBP1A in Pseudomonas aeruginosa 27853 membranes2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID1056837Antibacterial activity against TEM-1/SHV-12 expressing Escherichia coli isolate 237 after 18 to 24 hrs by two-fold broth microdilution assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID1649595Stability in pH 7.5 phosphate buffer assessed as compound hydrolysis measured 24 hrs after reconstitution2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID222235In vivo therapeutic efficacy was determined against Escherichia coli 078 by a single sc administration in mice1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID372336Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as bacterial count in in vitro PK/PD model at 1 g infused every 8 hrs interval measured 40 hrs after first dose relative to initial inoculum2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID433176Antibacterial activity against Klebsiella pneumoniae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID401684Antibacterial activity against Streptococcus pyogenes 77A2005Journal of natural products, May, Volume: 68, Issue:5
Cytotoxic bisindole alkaloids from a marine sponge Spongosorites sp.
AID532908Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 526 transformant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID555257Antibacterial activity against Acinetobacter genomosp. 3 isolate 69 by Etest method in presence of efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID1407951Antibacterial activity against Pseudomonas aeruginosa ARC3729 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID563600Antimicrobial activity against Klebsiella pneumoniae isolate 048 expressing beta-lactamase KPC-2, DHA-1, qnrB4 and armA by Etest2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA.
AID588131Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 2 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID563156Antibacterial activity against Pseudomonas aeruginosa isolate 19BR by Etest2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
AID523947Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E465 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1504345Antibacterial activity against NDM-1-producing Enterobacteriaceae after 16 to 20 hrs by broth microdilution method2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and bioactivities study of new antibacterial peptide mimics: The dialkyl cationic amphiphiles.
AID524115Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A8902010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1906418Antibacterial activity against Pseudomonas aeruginosa ATCC 27883 assessed as reduction in microbial growth incubated for 24 hrs by microbroth dilution method2022European journal of medicinal chemistry, May-05, Volume: 235Amphiphilic cyclic peptide [W
AID508727Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1D5 SA1 harboring acquired beta-lactamase VIM-2 by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID523577Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E477 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1504343Antibacterial activity against methicillin-resistant Staphylococcus aureus after 16 to 20 hrs by broth microdilution method2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and bioactivities study of new antibacterial peptide mimics: The dialkyl cationic amphiphiles.
AID1407965Antibacterial activity against Acinetobacter baumannii ARC3484 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID528837Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient urine assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID560055Antibacterial activity against Acinetobacter baumannii A9844 infected in Galleria mellonella caterpillar assessed as prolonged survival rate at 60 mg/kg administered as single dose2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics.
AID585399Activity at Fluoribacter gormanii 1K07 metallo-beta-lactamase FEZ-12010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID373753Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab4 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID529577Ratio of Kcat to Km for Pseudomonas maltophilia ULA-511 beta-Lactamase L-12008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID555239Antibacterial activity against Acinetobacter genomosp. 3 isolate 21 by Etest method in presence of efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID285609Antimicrobial activity against Pseudomonas aeruginosa 65.68-1 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID495709Kcat/Km ratio of Pseudomonas aeruginosa OXA-102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID524299Antibacterial activity against Pseudomonas aeruginosa P328 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID499063Antimicrobial activity against Escherichia coli HX74T expressing CTX-M-3 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID531776Antimicrobial activity against Pseudomonas aeruginosa catheter isolate 4680 containing PFGE clone A2 expressing beta-lactamase IMP-15 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID523759Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E4722010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID356636Antibacterial activity against methicillin-resistant Staphylococcus aureus Y-80-12-844 after 18 hrs2003Journal of natural products, Nov, Volume: 66, Issue:11
New bromotyrosine derivatives from an association of two sponges, Jaspis wondoensis and Poecillastra wondoensis.
AID423321Antibacterial activity against Pseudomonas aeruginosa isolate 364 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID534676Antimicrobial activity against Fusobacterium necrophorum ATCC 25286 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID1906448Cytotoxicity against HEK293 cells assessed as effect on cell viability at 10 ug/ml incubated for 24 hrs by microplate reader analysis2022European journal of medicinal chemistry, May-05, Volume: 235Amphiphilic cyclic peptide [W
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID372333Antibacterial activity against hypermutable Pseudomonas aeruginosa isolate 12-09-15 assessed as reduction of bacterial count in in vitro PK/PD model at 1 g infused every 8 hrs interval measured after third dose relative to initial inoculum2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID508729Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3C8 GM1 harboring acquired beta-lactamase OXA-144 by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID522002Antimicrobial activity against Escherichia coli isolate J53 harboring p6A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID534302Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA4792010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID534464Antimicrobial activity against Bacteroides fragilis GAI 7955 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID656353Antibacterial activity against imipenem-sensitive Pseudomonas aeruginosa isolate 1091-05 infected in sc dosed neutropenic-C3H/HeN mouse assessed as mouse survival administered 4 hrs post infection followed by BID dosing for two days measured on day 102011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID532904Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 531 transformant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID425318Bactericidal activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID545618Antimicrobial activity against Pseudomonas aeruginosa PS40 with PFGE phenotype 5 expressing beta-lactamase KPC-2, OXA-2 obtained from urine of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID587532Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse in presence of 4 ug/ml cavulanate beta-lactamase inhibitor2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID521998Antimicrobial activity against Klebsiella pneumoniae isolate Kp5A expressing beta-lactamase OXA-48 and SHV-5 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID510513Antibacterial activity against Escherichia coli ATCC 25922 expressing KPC beta lactamase2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID1373324Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-225 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID529859Ratio of MIC for Pseudomonas aeruginosa MR08 to MIC for Pseudomonas aeruginosa PAO12008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID535072Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pOXA-58-6 plasmid by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
AID249279Minimum inhibitory concentration against Pseudomonas aeruginosa (n=60); (Range=0.06-128)2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID425334Bactericidal activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID1357444Antibacterial activity against KPC-2 producing Klebsiella pneumoniae isolate 209632 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria.
AID562473Antimicrobial activity against rifampicin-resistant Escherichia coli A15 transconjugant expressing beta-lactamase KPC-2/TEM-1 by Etest2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.
AID372334Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as change in bacterial count in in vitro PK/PD model at 1 g infused every 8 hrs interval measured after 8 hrs relative to initial inoculum2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID518729Ratio of Kcat to Km for Pseudomonas stutzeri beta-lactamase DIM-1by UV-spectrophotometry2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands.
AID535870Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae GZ51T harboring qnrA gene by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID374365Antimicrobial activity against Escherichia coli DH5alpha expressing pIP19 containing Aeromonas caviae A324R metallo-beta-lactamase blaIMP-19 gene by broth dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID524278Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E478 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID522006Antimicrobial activity against Klebsiella pneumoniae isolate KpI-2 expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID558604Antimicrobial activity against Streptococcus pneumoniae isolate 1055 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID588082Antibacterial activity against Acinetobacter baumannii ATCC 179782011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
ISAba825, a functional insertion sequence modulating genomic plasticity and bla(OXA-58) expression in Acinetobacter baumannii.
AID558045Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S8 by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID424865Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa clinical isolate2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID535835Antimicrobial activity against Pseudomonas aeruginosa GP37KT31 harboring oprD gene after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID545559Antibacterial activity against Escherichia coli EIR2b selected at 2 times MIC of imipenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID524109Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A9282010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID522668Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis B126 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID356637Antibacterial activity against ofloxacin-resistant Staphylococcus epidermidis 178 after 18 hrs2003Journal of natural products, Nov, Volume: 66, Issue:11
New bromotyrosine derivatives from an association of two sponges, Jaspis wondoensis and Poecillastra wondoensis.
AID200865In vitro antibacterial activity against Salmonella Typhimurium2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.
AID1680009Induction of inner membrane permeabilization in Staphylococcus aureus ATCC 29213 at 20 ug/ml measured for 12 mins by propidium iodide staining based fluorescence microscopic analysis2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID495842Hydrolytic activity of Escherichia coli DH10B beta-lactamase VIM-2 by microacidimetric method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID565526Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-09 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID545339Displacement of [14C]benzylpenicillin from PBP1B in Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID555556Antimicrobial activity against Pseudomonas aeruginosa isolate 22843 expressing VIM-2 beta lactamase gene by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
AID656446Antimicrobial activity against Klebsiella pneumoniae clinical isolate2011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID521485Antibacterial activity against Klebsiella pneumoniae KN2303 by Etest method in presence of beta-lactamase inhibitor clavulanic acid2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID1862389Antibacterial activity against Proteus mirabilis producing CTX-M-14/CMY-2 assessed as bacterial growth inhibition incubated for 16 to 20 hrs by microdilution method2022European journal of medicinal chemistry, Oct-05, Volume: 240Triazole-substituted phenylboronic acids as tunable lead inhibitors of KPC-2 antibiotic resistance.
AID517968Antimicrobial activity against Escherichia coli A harboring beta-lactamase CTX-M 15 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID534611Antimicrobial activity against Ceftazidime non-susceptible Enterobacteriaceae assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID499147Half life in immunocompromized SKH1 mouse plasma at 12.5 mg/kg, sc2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID289883Antibacterial activity against Staphylococcus aureus 209P2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID285580Antimicrobial activity against Pseudomonas aeruginosa IC7 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID521839Antibacterial activity against Klebsiella pneumoniae isolate VA375 with blaKPC-3, qnrA1, blaTEM-1, blaSHV-11 genes by Etest method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID423528Antibacterial activity against Acinetobacter baumannii isolate 927 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID518240Antimicrobial activity against Acinetobacter baumannii HPA74510 assessed as appearance of colony at 4 times MIC concentration2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID562338Ratio of Kcat to Km for Chryseobacterium indologenes 597 metallo-beta-lactamase IND-6 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID554985Antibacterial activity against Acinetobacter genomosp. 3 isolate 20 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID560593Antimicrobial activity against rifampin-resistant Pseudomonas aeruginosa ATCC 27853 by microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID531774Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4703 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID1533864Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 1749 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID1757534Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-8 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID529658Ratio of Kcat to Km for Pseudomonas aeruginosa 166301 beta-lactamase VIM-162008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID560835Antimicrobial activity against Acinetobacter baumannii isolate Ab23 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba92009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID286018Antimicrobial activity against ESBL producing Klebsiella pneumoniae 60 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID286030Antimicrobial activity against ESBL producing Klebsiella pneumoniae 255 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID495733Kcat/Km ratio of Escherichia coli CTX-M-15 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID584713Antimicrobial activity against Pseudomonas aeruginosa PA14 PA1195 harboring mutation in putative dimethylarginine dimethylaminohydrolase by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID523922Antibacterial activity against Acinetobacter baumannii A894 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID10756Clearance of compound after iv administration of 20 mg/kg dose in rat2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.
AID518220Antimicrobial activity against Acinetobacter baumannii HPA74510 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID340737Ratio of Kcat to Km of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID567582Antimicrobial activity against Acinetobacter baumannii assessed as susceptible isolate by broth dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.
AID1763161Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI based serial dilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Antibacterial and synergistic activity of 6β-hydroxy-3-oxolup-20(29)-en-28-oic acid (6β-hydroxy betunolic acid) isolated from Schumacheria castaneifolia vahl.
AID524427Antibacterial activity against Enterobacteriaceae clinical isolates isolated from patient with complicated intra-abdominal infection assessed as cure rate at test-of-cure visit by mMITT analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID564957Antimicrobial activity against Acinetobacter baumannii isolate Ab114 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba92009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID372330Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as effect on bacterial count in in vitro PK/PD model at 1 g infused every 8 hrs interval measured after second dose relative to initial inoculum2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID562339Ratio of Kcat to Km for Chryseobacterium indologenes 597 metallo-beta-lactamase IND-5 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID511128Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 22010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID555445Antibacterial activity against Acinetobacter genomosp. 3 isolate 195 by Etest method in presence of efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID535647Antimicrobial activity against Group B Streptococcus serotype V 2603 V/R harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID201539In vitro antibacterial activity against Salmonella Typhimurium by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13
Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID554984Antibacterial activity against Acinetobacter genomosp. 3 isolate 14 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID1757623Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-29 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID532099Antimicrobial against Pseudomonas aeruginosa 40198 harboring nirJ allele by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID518511Antimicrobial activity against Pseudomonas aeruginosa BA(C1-106) mutant assessed as doubling time2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID1905609Induction of drug resistance in Escherichia coli ATCC 25922 assessed as increase in MIC measured after 20 passages by CLSI protocol based broth microdilution method2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Novel β-Hairpin Antimicrobial Peptides Containing the β-Turn Sequence of -RRRF- Having High Cell Selectivity and Low Incidence of Drug Resistance.
AID1680041Antibacterial activity against NDM1 producing carbapenem-resistant Enterobacteriaceae clinical isolate 5 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID534477Antimicrobial activity against Prevotella bivia ATCC 29303 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID555483Ratio of MIC for Acinetobacter genomosp. 3 isolate 103 to MIC for Acinetobacter genomosp. 3 isolate 103 in presence of efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID571886Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 7 expressing ampC, ompA, adeB, adeM, blaSHV-5 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID519798Inhibition of Bocillin FL binding to PBP2 in Escherichia coli MC4100 membranes2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID565712Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-17 harboring A residue at 105 position in PDC- 3 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID535634Antimicrobial activity against Group B streptococcus serotype VI R6 harboring F395L, V405A, R433H, H438Y, A374V and G648A mutations in PBP 2X and T567I mutation in PBP 2B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID535639Antimicrobial activity against Group B streptococcus serotype VI R1 harboring F395L, V405A, R433H, H438Y, and G648A mutations in PBP 2X and T567I mutation in PBP 2B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID1757582Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-14 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757583Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-15 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1762806Antibacterial activity against Escherichia coli 08 assessed as reduction in bacterial growth incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID510504Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-2 expressing KPC beta lactamase2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID534463Antimicrobial activity against Bacteroides fragilis GAI 0558 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID545346Displacement of [14C]benzylpenicillin from PBP1B in Pseudomonas aeruginosa ATCC 156922009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID576534Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate HIP14358 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID1846925Antibacterial activity against wild type Acinetobacter baumannii NCTC 13304 assessed as reduction in bacterial growth incubated for 18 to 20 hrs by CLSI based microdilution method2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Design, Synthesis, and Biological Evaluation of Novel Pyrimido[4,5-
AID555255Antibacterial activity against Acinetobacter genomosp. 3 isolate 69 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID524276Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E473 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID535691Antimicrobial activity against beta-lactamase CTX-M-15-producing fluoroquinolone-resistant Escherichia coli FMV5825 expressing qnrB2 and aac(6')-Ib-cr and harboring gyrA Ser83Ile and Asp87Asn mutant gene and ParC Ser80Ile and Glu84Val mutant gene obtained2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
AID555462Antibacterial activity against Acinetobacter genomosp. 3 isolate 67 by Etest method in presence of cloxacillin and efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID584582Antimicrobial activity against Escherichia coli NEB 5-alpha harboring beta-lactamase OXA-58 by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID522022Antimicrobial activity against Escherichia coli isolate J53 harboring pEnc2 containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID523716Antibacterial activity against Acinetobacter baumannii A929 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID528533Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B502 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID562341Ratio of Kcat to Km for Chryseobacterium meningosepticum CCUG 4310 beta-lactamase BlaB1 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID286004Antimicrobial activity against ESBL producing Klebsiella pneumoniae 262 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID545400Antimicrobial activity against Pseudomonas aeruginosa PS6A with PFGE phenotype 11A obtained from sputum of ICU patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID1407975Antibacterial activity against Acinetobacter baumannii ARC3658 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID433361Antibacterial activity against Clostridium clostridioforme isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID286010Antimicrobial activity against ESBL producing Escherichia coli 321 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID584527Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3704 harboring wspE mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID162790In vivo antibacterial activity against Pseudomonas aeruginosa 1771M1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID236207Clearance value at a single intravenous administration of 20 mg/kg in rat2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID285992Antimicrobial activity against ESBL producing Klebsiella pneumoniae 268 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID532403Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone E isolate VA-06X-29 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID524119Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A9012010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1879068Antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as inhibition of bacterial growth incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID423297Antibacterial activity against Pseudomonas aeruginosa isolate 335 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID498831Antimicrobial activity against Escherichia coli C600 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID559415Antimicrobial activity against Acinetobacter baumannii 3208 expressing multiple-antibiotic resistance gene AbaR5 by Viek 2 system2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
AbaR5, a large multiple-antibiotic resistance region found in Acinetobacter baumannii.
AID285607Antimicrobial activity against Pseudomonas aeruginosa 2A9 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID531768Antimicrobial activity against Pseudomonas aeruginosa catheter isolate 4696 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID563598Antimicrobial activity against ESBL producing Escherichia coli assessed as susceptible isolates by Etest2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers.
AID423494Antibacterial activity against Acinetobacter baumannii isolate 893 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID584324Antimicrobial activity against Serratia marcescens ATCC 8100 by agar dilution method in presence of 250 ug/ml of cloxacillin2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID279812Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZR01 from patient sputum by agar dilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID560093Bactericidal activity against Escherichia coli isolate 5401 at 1/4 times MIC after 24 hrs by time kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID524415Antibacterial activity against Enterobacteriaceae clinical isolates isolated from patient with complicated intra-abdominal infection assessed as cure rate at test-of-cure visit2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID322316Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID565420Antimicrobial activity against ESBL- and MBL-producing and ceftazidime-resistant Pseudomonas aeruginosa isolated from patients with bloodstream infection assessed as resistant isolates by agar dilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Diversity of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil.
AID1757556Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-4 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1533865Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 1402 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID523940Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E450 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584724Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3649 harboring mutation in putative membrane-associated zinc metalloprotease by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1757571Antibacterial activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-18 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID498834Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU3 deficient in DHA-1, aac(6')-Ib-cr, ompK35/36 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID528833Antimicrobial activity against CTX-M ESBL producing Escherichia coli isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID534305Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA5072010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID10762Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat2000Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13
Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID1757533Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-6 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID555461Antibacterial activity against Acinetobacter genomosp. 3 isolate 65 by Etest method in presence of cloxacillin and efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID1357456Antibacterial activity against IMP-4 producing Pseudomonas aeruginosa isolate 212886 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria.
AID423335Antibacterial activity against Acinetobacter baumannii isolate 882 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID547793Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237V mutant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID572124Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 29 expressing ampC, ompA, adeM, aadB, aadA1 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1373283Antimicrobial activity against Escherichia coli expressing beta-lactamase GES-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID562754Activity of Klebsiella pneumoniae AH24-270 CTX-M-71 beta-lactamase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID1543301Antimicrobial activity against Candida albicans ATCC 90028 assessed as inhibition of microbial growth by CLSI based method2019Journal of natural products, 07-26, Volume: 82, Issue:7
Anthraquinone-Based Specialized Metabolites from Rhizomes of
AID511668Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD2 harboring oprD spontaneous mutant and deficient in dacB gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID521837Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA367 containing blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, aac(6')-1b genes by Etest method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID558614Antimicrobial activity against Streptococcus pneumoniae isolate 2688 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID523489Antimicrobial activity against Pseudomonas aeruginosa R20 Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID532102Antimicrobial against Pseudomonas aeruginosa 8666 by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID1628579Antibacterial activity against Streptococcus pneumoniae Ery2 incubated for 18 to 24 hrs by broth microdilution method2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
Discovery and Characterization of a Class of Pyrazole Inhibitors of Bacterial Undecaprenyl Pyrophosphate Synthase.
AID584692Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4550 harboring fimU mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID201242In vitro antibacterial activity against SG 511 strain of Staphylococcus aureus2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID1628577Antibacterial activity against Staphylococcus aureus WCUH29 incubated for 18 to 24 hrs by broth microdilution method2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
Discovery and Characterization of a Class of Pyrazole Inhibitors of Bacterial Undecaprenyl Pyrophosphate Synthase.
AID1318923Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 264-1043542016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID433196Antibacterial activity against Streptococcus dysgalactiae subsp. equisimilis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID163105Minimum inhibitory concentration against Pseudomonas aeruginosa 1771M was determined by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID532103Antimicrobial against Pseudomonas aeruginosa 3465 harboring tsaA allele by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID323860Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 25923 after phagocytosis by human THP1 macrophages assessed as reduction in bacterial count after 24 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Role of acidic pH in the susceptibility of intraphagocytic methicillin-resistant Staphylococcus aureus strains to meropenem and cloxacillin.
AID499127Antimicrobial activity against Pseudomonas aeruginosa OC 4351 infected in immunocompromized SKH1 mouse assessed as log change in bacterial colony forming unit at 25 mg/kg/day, sc2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID245177Minimum inhibitory concentration against Enterobacter cloacae 1321E strain2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID678452Antibacterial activity against Escherichia coli2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections.
AID1357447Antibacterial activity against KPC-2 producing Klebsiella pneumoniae isolate 209735 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria.
AID423523Antibacterial activity against Acinetobacter baumannii isolate 922 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID511289Antibacterial activity against Escherichia coli DH5alpha pB-ges-12010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID274732Antibacterial activity against methicillin-resistant Klebsiella oxytoca 1082E2007Journal of natural products, Jan, Volume: 70, Issue:1
Bisindole alkaloids of the topsentin and hamacanthin classes from a marine sponge Spongosorites sp.
AID582973Antimicrobial activity against dacB::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID534458Antimicrobial activity against Lactobacillus reuteri JCM 1112 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID522001Antimicrobial activity against Escherichia coli isolate J53 harboring p5A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID534456Antimicrobial activity against Lactobacillus fermentum JCM 1173 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID495735Kcat/Km ratio of Klebsiella pneumoniae Beta-lactamase TEM-26 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID523593Antibacterial activity against Pseudomonas aeruginosa P322 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID496572Antibacterial activity against Pseudomonas aeruginosa isolate 988 assessed as reduction of bacterial count at 16 ug/ml within 6 hrs in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID522661Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis K1938 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID96089Compound was evaluated for its antibacterial activity against Klebsiella pneumoniae 4 ESBL2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID555250Antibacterial activity against Acinetobacter genomosp. 3 isolate 65 by Etest method in presence of efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID1407945Antibacterial activity against Pseudomonas aeruginosa ARC3514 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID210068Compound was tested for in vivo protective activity against Streptococcus pyogenes 77A at a single subcutaneous administration in mice.1998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID571389Antibacterial activity against Acinetobacter baumannii F264 by Etest method in presence of 0.25 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID498885Antimicrobial activity against Pseudomonas aeruginosa OC 4351 assessed as inhibition of growth by broth microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID1706873Antibacterial activity against methicillin-resistant Staphylococcus aureus NR10198 measured after 16 to 18 hrs2021European journal of medicinal chemistry, Feb-15, Volume: 212Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.
AID520709Antibacterial activity against Acinetobacter baumannii MAD by disk diffusion method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID523738Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E4502010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534926Antimicrobial activity against Ceftazidime susceptible Serratia marcescens assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID767761Antibacterial activity against Klebsiella pneumoniae ATCC BAA-2146 after 24 hrs by spectrophotometry2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Polyketides with New Delhi metallo-β-lactamase 1 inhibitory activity from Penicillium sp.
AID295805Antibacterial activity against Bacillus megaterium after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID498884Antimicrobial activity against methicillin-resistant Staphylococcus aureus OC 8525 assessed as inhibition of growth by broth microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID584728Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4005 harboring mutation in conserved hypothetical protein by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1596887Antibacterial activity against methicillin-resistant Staphylococcus aureus NR10193 incubated for 16 to 18 hrs by broth microdilution assay
AID529858Ratio of MIC for Pseudomonas aeruginosa N043 to MIC for Pseudomonas aeruginosa PAO12008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID285985Antimicrobial activity against ESBL producing Klebsiella pneumoniae 60 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID423311Antibacterial activity against Pseudomonas aeruginosa isolate 354 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID496549fT>MIC in Klebsiella pneumoniae isolate 361 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 16-24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID528827Antimicrobial activity against ESBL producing Klebsiella pneumoniae isolated from ICU patient urine assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID286005Antimicrobial activity against ESBL producing Klebsiella pneumoniae 256 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID523509Antimicrobial activity against Pseudomonas aeruginosa isolate 15107 from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID523598Antibacterial activity against Pseudomonas aeruginosa P338 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID572901Antibacterial activity against blaVIM-2-positive Pseudomonas aeruginosa by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Molecular epidemiology of outbreak-related pseudomonas aeruginosa strains carrying the novel variant blaVIM-17 metallo-beta-lactamase gene.
AID1762841In vivo antibacterial activity against Klebsiella pneumoniae producing NDM-1 infected in mouse assessed as reduction in bacterial load in spleen at 10 mg/kg, ip2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID499057Antimicrobial activity against Escherichia coli PU102T expressing TEM-1, CTX-M-14, CMY-2 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID544494Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase KPC-5 by agar dilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID571896Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 12 expressing ompA, adeB, adeM, aacA4, aacC2, blaSHV-5 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID584565Antimicrobial activity against Acinetobacter lwoffii isolate L expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID573836Antibacterial activity against beta-lactamase producing Clostridium septicum assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID529573Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid pLBII carrying beta-lactamase CAR-1 gene after 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID529660Ratio of Kcat to Km for Pseudomonas aeruginosa COL-1 beta-lactamase VIM-22008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID165036In vitro antibacterial activity against Pseudomonas aeruginosa 1592E by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13
Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID372347Antibacterial activity against Pseudomonas aeruginosa PAO1/MEM mutant by CLSI broth microdilution method2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID207181Antibacterial activity against Staphylococcus aureus 5032003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.
AID373761Antibacterial activity against imipenem-resistant Acinetobacter baumannii ab1265 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID558334Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1093 by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID1443407Antibacterial activity against extended spectrum beta-lactamase KPC-2 producing multidrug resistant Klebsiella pneumoniae clinical isolates after 18 hrs by broth microdilution method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections.
AID285689Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4012 isolate expressing carbapenemase KPC22007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID496480Antibacterial activity against Klebsiella pneumoniae isolate 375 in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID575948Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae assessed as resistant isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.
AID555466Antibacterial activity against Acinetobacter genomosp. 3 isolate 69 by Etest method in presence of cloxacillin and efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID322787Antimicrobial activity against Bacteroides uniformis assessed as percent resistant isolates2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID555476Antibacterial activity against Acinetobacter genomosp. 3 isolate 243 by Etest method in presence of cloxacillin and efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID1757599Antibacterial activity against Enterobacter cloacae 17-5 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID534486Antimicrobial activity against Stenotrophomonas maltophilia KJ harboring pRK-NG plasmid by Etest2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID558425Antimicrobial activity against Pseudomonas aeruginosa by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
In vitro activity of doripenem against Burkholderia pseudomallei.
AID559817Antimicrobial activity against Enterobacter cloacae CHE-2 harboring blaGES-5 and blaSHV-5 gene by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID1716778Toxicity in Galleria mellonella larvae assessed as larval mortality at 100 mg/kg measured after 24 hrs2019European journal of medicinal chemistry, Jul-15, Volume: 174Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID584689Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4402 harboring argJ mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID200874Minimum inhibitory concentration against Salmonella Typhimurium was determined by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID574736Antimicrobial activity against Fusobacterium nucleatum after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID373764Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh11 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID574504Antimicrobial activity against Bacteroides caccae assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID564530Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid with entire blaAmpC gene by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID534698Antimicrobial activity against Fusobacterium necrophorum by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID495911Antimicrobial activity in Escherichia coli J53 strain2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID94143In vitro antibacterial activity against ATCC 100331 strain of Klebsiella pneumoniae2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID1543303Antimicrobial activity against Cryptococcus neoformans ATCC 90113 assessed as inhibition of microbial growth by CLSI based method2019Journal of natural products, 07-26, Volume: 82, Issue:7
Anthraquinone-Based Specialized Metabolites from Rhizomes of
AID151540In vitro antibacterial activity against SG 137 strain of Pseudomonas aeruginosa2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID1533854Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 2901 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID530815Antibacterial activity against human urinary Klebsiella pneumoniae UCL-1 harboring plasmid-encoded beta-lactamase OXA-48 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID1680005Induction of cytoplasmic membrane depolarization in Staphylococcus aureus ATCC 29213 at 20 ug/ml measured for 12 mins by DiSC35 dye-based fluorescence assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID564458Antimicrobial activity against Pseudomonas aeruginosa isolate 896 by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID519139Antimicrobial activity against community-acquired methicillin resistant Staphylococcus aureus expressing PVL gene and mec type IV gene assessed as susceptible strains by broth microdilution method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
AID1225789Antibacterial activity against Klebsiella pneumoniae KP1083 expressing KPC3/SHV-1/TEM-1 by broth microdilution method2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID286014Antimicrobial activity against ESBL producing Escherichia coli 318 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID519812Inhibition of Bocillin FL binding to PBP1B in Pseudomonas aeruginosa 27853 membranes2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID528980Antimicrobial activity against Haemophilus influenzae assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID535136Antimicrobial activity against Ceftazidime susceptible Pseudomonas aeruginosa assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID516144Antibacterial activity against Pulsotype I Acinetobacter genomosp. 3 isolate 10 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID285588Antimicrobial activity against Pseudomonas aeruginosa 65.36-3 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID587527Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID285589Antimicrobial activity against Pseudomonas aeruginosa 65.36-4 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID523497Antimicrobial activity against Pseudomonas aeruginosa isolate 1529c from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1680053Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae clinical isolate 3 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID295793Antibacterial activity against Citrobacter freundii 323 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID521427Antibacterial activity against Stenotrophomonas maltophilia isolate KJ deficient in L2 beta lactamase gene by Etest2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID279813Antimicrobial activity against Escherichia coli DH5-alpha pYW1 transformants expressing KPC2 gene by agar dilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID1417165Antibacterial activity against methicillin-resistant Staphylococcus aureus NR119 by CLSI method2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis of 1,2,3-triazole linked 4(3H)-Quinazolinones as potent antibacterial agents against multidrug-resistant Staphylococcus aureus.
AID70113Compound was evaluated for its antibacterial activity against Escherichia coli CCARM 1113 MDR2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID336789Antimicrobial activity against Streptococcus pyogenes 308A isolate after 18 hrs2003Journal of natural products, Mar, Volume: 66, Issue:3
Bioactive sterols from the starfish Certonardoa semiregularis.
AID499124Antimicrobial activity against Pseudomonas aeruginosa OC 4354 infected in immunocompromized SKH1 mouse assessed as lesion volume at 25 mg/kg/day, sc measured after 48 hrs postinfection (Rvb = 2195 mm3)2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID498883Antimicrobial activity against methicillin-susceptible Staphylococcus aureus OC 4172 assessed as inhibition of growth by broth microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID522666Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis Texas 2 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID274729Antibacterial activity against methicillin-resistant Pseudomonas aeruginosa 1592E2007Journal of natural products, Jan, Volume: 70, Issue:1
Bisindole alkaloids of the topsentin and hamacanthin classes from a marine sponge Spongosorites sp.
AID571213Antibacterial activity against Acinetobacter baumannii F264 by Etest method in presence of 0.5 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID1373300Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-16 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID510512Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate W2AC8-S10 expressing OXA-512010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID534670Antimicrobial activity against Prevotella oralis ATCC 33269 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534648Antimicrobial activity against Non-ESBL Klebsiella pneumoniae assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID518198Antimicrobial activity against pfeA deficient Pseudomonas aeruginosa 134 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID516139Antibacterial activity against Pulsotype F Acinetobacter genomosp. 3 isolate 4 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS18, IS1008, intI1 genetic elements by broth micro dilution2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID534673Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID524077Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3202010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID279939Antibiotic susceptibility by resistance against Pseudomonas aeruginosa from samples collected from patients2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
AID496524fT>MIC in Klebsiella pneumoniae isolate 351 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 8-16 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID558617Antimicrobial activity against Streptococcus pneumoniae isolate 3260 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID521834Antibacterial activity against Klebsiella pneumoniae isolate VA367 with blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, blaSHV-12, aac(6')-1b genes by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID499072Antimicrobial activity against Citrobacter freundii RJ78 expressing CMY-2, qnrA1, aac(6')-Ib-cr, ompC by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID555458Antibacterial activity against Acinetobacter genomosp. 3 isolate 60 by Etest method in presence of cloxacillin and efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID534627Antimicrobial activity against Non-ESBL Escherichia coli assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID565218Activity of KPC-2 in Klebsiella pneumoniae isolate A-17972009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID564019Antibacterial activity against Pseudomonas aeruginosa isolated from lung biopsy specimen of patient by Etest2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID1781724Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID529516Antibacterial activity against Pseudomonas aeruginosa 1750J expressing beta-lactamase IMP-15 by Etest2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
IMP-15-producing Pseudomonas aeruginosa strain isolated in a U.S. medical center: a recent arrival from Mexico.
AID324870Antimicrobial activity against Acinetobacter baumannii B46 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID535635Antimicrobial activity against Group B streptococcus serotype VI R5 harboring F395L, V405A, R433H, H438Y, and G648A mutations in PBP 2X and T567I mutation in PBP 2B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID68030Antibacterial activity against Enterobacter cloacae 1321E1998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID499129Antimicrobial activity against Pseudomonas aeruginosa OC 4351 infected in immunocompromized SKH1 mouse assessed as log change in bacterial colony forming unit at 100 mg/kg/day, sc2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID286029Antimicrobial activity against ESBL producing Escherichia coli 311 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID555270Antibacterial activity against Acinetobacter genomosp. 3 isolate 195 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID1853606Antibacterial activity against Enterococcus faecalis clinical isolate 1094112 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution method2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
Design, synthesis, and antibacterial activity of
AID373780Antibacterial activity against imipenem-resistant Acinetobacter baumannii ISAB ab8(r) by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID374364Antimicrobial activity against Aeromonas caviae A324R expressing metallo-beta-lactamase IMP-19 by broth dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID584701Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5192 harboring pckA mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID509866Antibacterial activity against Acinetobacter baumannii isolate 510 isolated from human sputum2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID14075Maximum concentration was calculated.1998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID576071Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 50748 harboring porin OmpK36 gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID584318Antimicrobial activity against Serratia marcescens ATCC 8100 by agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID373766Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh14 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID558600Antimicrobial activity against Streptococcus pneumoniae 12 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID517983Antimicrobial activity against Enterobacter cloacae 908R harboring beta-lactamase AmpC by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID565721Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-26 harboring T residue at 105 position in PDC- 6 and polymorphic OprD gene by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID523553Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E456 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529649Antimicrobial activity against Escherichia coli DH5alpha harboring beta-lactamase VIM-16 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID295806Antibacterial activity against Pseudomonas aeruginosa 9027 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID498814Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae FZ47 deficient in IMP-8, TEM-1, SHV-11, CTX-M-14, qnrB2, aac(6')-Ib, ompK35/36 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1407941Antibacterial activity against Pseudomonas aeruginosa ARC3505 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID1592959Antibacterial activity against multi-drug resistant Klebsiella pneumoniae NMI 2697/14 assessed as reduction in microbial growth incubated for 20 hrs2019European journal of medicinal chemistry, Apr-15, Volume: 168Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae.
AID545609Antimicrobial activity against Pseudomonas aeruginosa PS29 with PFGE phenotype 11D obtained from sputum of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID1757595Antibacterial activity against Enterobacter cloacae 17-1 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID9759Peak concentration at a single subcutaneous administration of 40 mg/kg in mice2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Synthesis and antibacterial activity of 2alpha-functionalized 1beta-methylcarbapenems related to KR-21012.
AID586232Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 5 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID423302Antibacterial activity against Pseudomonas aeruginosa isolate 341 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID584718Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2615 harboring ftsK mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID496518fT>MIC in Pseudomonas aeruginosa isolate 1177 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 0-8 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID1348995Antibacterial activity against Escherichia coli ATCC 25922 after 16 to 20 hrs by broth microdilution method2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and antibacterial evaluation of novel cationic chalcone derivatives possessing broad spectrum antibacterial activity.
AID534600Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1680038Antibacterial activity against NDM1 producing carbapenem-resistant Enterobacteriaceae clinical isolate 8 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID520970Antibacterial activity against Escherichia coli harboring pNGR plasmid expressing blaKPC gene by Etest method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID373781Antibacterial activity against imipenem-resistant Acinetobacter baumannii ISAB ab1254(r) by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID545349Displacement of [14C]benzylpenicillin from PBP4 in Pseudomonas aeruginosa ATCC 156922009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID583025Antimicrobial activity against Escherichia coli TOP10 transformed by agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID96090Compound was evaluated for its antibacterial activity against Klebsiella pneumoniae 5 ESBL2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID584847Ratio of Kcat to Km for Aeromonas allosaccharophila AL-1 beta-lactamase PER62010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID1757549Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-13 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1680048Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae clinical isolate 8 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID423314Antibacterial activity against Pseudomonas aeruginosa isolate 357 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID1417170Antibacterial activity against methicillin-resistant Staphylococcus aureus NR10193 by CLSI method2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis of 1,2,3-triazole linked 4(3H)-Quinazolinones as potent antibacterial agents against multidrug-resistant Staphylococcus aureus.
AID285976Antimicrobial activity against ESBL producing Escherichia coli 320 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID511155Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 11 assessed as zone of inhibition by disk diffusion assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1539483Antibacterial activity against carbapenem-resistant Acinetobacter baumannii ATCC BAA 1605 clinical isolates after 18 to 20 hrs in aerobic condition by CLSI-based broth microdilution assay
AID1757600Antibacterial activity against Enterobacter cloacae 17-6 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID164528Compound was evaluated for in vitro antibacterial activity against Pseudomonas aeruginosa 1771 M strain by agar dilution method2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Synthesis and antibacterial activity of 2alpha-functionalized 1beta-methylcarbapenems related to KR-21012.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1320836Activity of native signal containing Klebsiella pneumoniae OXA-48 assessed as ratio of Kcat to Km by Michaelis-Menten kinetics assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.
AID496495fT>MIC in Klebsiella pneumoniae isolate 334 at 2 gram for every 8 hrs administered as 3 hrs infusion over 24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID499136fT>MIC in Pseudomonas aeruginosa OC 4351 infected sc dosed SKH1 mouse at 50 mg/kg, sc administered twice at 1 and 3 hrs after infection2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID534466Antimicrobial activity against carbapenemase-producing Bacteroides fragilis GAI 30079 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID518188Antimicrobial activity against Acinetobacter baumannii HPA I-16 harboring beta-lactamase OXA-27 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID565720Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-25 harboring T residue at 105 position in PDC- 6 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1706878Antibacterial activity against methicillin-resistant Staphylococcus aureus NR10191 measured after 16 to 18 hrs2021European journal of medicinal chemistry, Feb-15, Volume: 212Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.
AID531775Antimicrobial activity against Pseudomonas aeruginosa blood isolate 4659 containing PFGE clone A2 expressing beta-lactamase IMP-15 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID564944Antimicrobial activity against Acinetobacter baumannii isolate Ab133 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba92009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID285608Antimicrobial activity against Pseudomonas aeruginosa 3B1 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID528971Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient urine assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1373293Antimicrobial activity against Escherichia coli expressing beta-lactamase SHV-12 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1680046Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae clinical isolate 10 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID373776Antibacterial activity against Escherichia coli TOP10 expressing imipenem-susceptible Acinetobacter baumannii ab1254 blaoxa-66 gene by Etest2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID574468Antimicrobial activity against Escherichia coli isolate 386T expressing beta-lactamase KPC2, OXA-9 and PFGE cluster 1 isolated from wound of patient by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID1373314Antimicrobial activity against Escherichia coli expressing beta-lactamase P99 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID558048Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S11 by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID1407953Antibacterial activity against Pseudomonas aeruginosa ARC3916 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID373034Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate BJ3-9 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID534474Antimicrobial activity against Bacteroides ureolyticus NCTC 10941 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID535834Antimicrobial activity against wild-type Pseudomonas aeruginosa GP62 after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID520730Activity of Escherichia coli DH10B beta-lactamase assessed per mg of protein at 100 uM2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID1906445Induction of membrane disruption in Pseudomonas aeruginosa ATCC BAA 1744 assessed as increase in PI positive cells at 4 times of MIC incubated for 2 hrs by Propidium iodide staining based FACS cytometry analysis relative to control2022European journal of medicinal chemistry, May-05, Volume: 235Amphiphilic cyclic peptide [W
AID369632Antimicrobial activity against beta-lactamase positive amoxicillin/clavulanate-resistant Haemophilus influenzae by broth microdilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
AID549039Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate KpSCMC2 harboring int1, bla IMP-4, bla SHV-12, armA and sul1 gene isolated from patient with pulmonary infection by disk diffusion method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Two clinical strains of Klebsiella pneumoniae carrying plasmid-borne blaIMP-4, blaSHV-12, and armA isolated at a Pediatric Center in Shanghai, China.
AID534297Antimicrobial activity against Pseudomonas aeruginosa isolate PA481 expressing VIM-2 beta-lactamase2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID534837Clearance not mediated by CVVHF in critically ill patient with sepsis at 1000 mg/kg, iv administered every 8 hrs by HPLC method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
AID561384Antibacterial activity against Escherichia coli isolate ARL05-909 harboring beta-lactamase CMY 29 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
CMY-29 and CMY-30, two novel plasmid-mediated AmpC beta-lactamases.
AID1762813Inhibition of Escherichia coli ImiS assessed as reduction in bacterial growth incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID524097Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A8502010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID761215Antibacterial activity against Klebsiella pneumoniae 1487-07 by broth microdilution method2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Pyridone-conjugated monobactam antibiotics with gram-negative activity.
AID533404Antimicrobial activity against Clostridium subterminale assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID1596883Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS4 incubated for 16 to 18 hrs by broth microdilution assay
AID517979Antimicrobial activity against Pseudomonas aeruginosa HPA10586 harboring beta-lactamase VIM-1 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID574514Antimicrobial activity against Bacteroides ovatus assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID425109Antimicrobial activity against Clostridium cadaveris isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID373788Ratio of MIC for Acinetobacter baumannii ISAB ab8(r) to MIC for Acinetobacter baumannii ISAB ab8(r) in presence of 2 ug/ml efflux pump inhibitor carbonyl cyanide m-chlorophenyl-hydrazone2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID534450Antimicrobial activity against Eggerthella lenta ATCC 25559 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534902Antimicrobial activity against Citrobacter assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID529851Antibacterial activity against MexA-MexB-OprM-overproducing Pseudomonas aeruginosa OCR1 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID562475Antimicrobial activity against rifampicin-resistant Escherichia coli A15 by Etest2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.
AID405091Antimicrobial activity against non-integron carrying Enterobacteriaceae assessed as percent resistant isolates2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome.
AID524286Antibacterial activity against Pseudomonas aeruginosa P332 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID532896Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 469 transformant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID571430Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method in presence of 2 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID576527Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008137 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID496488fT>MIC in Klebsiella pneumoniae isolate 377 at 2 gram for every 8 hrs administered as 3 hrs infusion over 24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID1720995Synergistic Inhibition of beta lactamase VIM-2 in Pseudomonas aeruginosa K34-7 assessed colony formation by visual inspection in presence of 50 microM 2,5-Dichloro-N-((4-((cyclohexylamino)methyl)-1H-1,2,3-triazol-5-yl)methyl)benzenesulfonamide incubated f2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Structural studies of triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-β-lactamases.
AID523419Antibacterial activity against beta-lactamase-negative Escherichia coli E346 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID564536Antimicrobial activity against Escherichia coli TOP10 harboring pTOPO plasmid by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID558332Antibacterial activity against Campylobacter jejuni isolate P338 harboring blaOXA-61::cat gene by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID585198Antimicrobial activity against Escherichia coli DH5[alpha] by Etest method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID523542Antibacterial activity against beta-lactamase-negative Escherichia coli E408 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID374022Activity of Serratia fonticola UTAD54 SFC1 beta lactamase expressed in Escherichia coli BL21(DE3) by SDS-PAGE2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID532897Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 523 ST 340 expressing beta-lactamase TEM-1, SHV-11 and OXA-2 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID582925Ratio of Kcat to Km for Escherichia coli BL21(DE3) VIM-2 W87F mutant beta-lactamase by spectrophotometer2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID69019In vivo antibacterial activity against Escherichia coli 1507E1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID495903Antimicrobial activity in Escherichia coli DIH-1 expressing beta-lactamase VIM-19 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID576314Antimicrobial activity against ESBL-negative Klebsiella pneumoniae 299332 harboring porin OmpK36 gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID523567Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E362 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524111Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A8982010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285574Antimicrobial activity against Pseudomonas aeruginosa 65.18-1 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID523499Antimicrobial activity against Pseudomonas aeruginosa isolate 1247c from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID561482Antibacterial activity against Pseudomonas aeruginosa assessed as intermediate isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID555266Antibacterial activity against Acinetobacter genomosp. 3 isolate 109 by Etest method in presence of efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID576283Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17829 by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID96085Compound was evaluated for its antibacterial activity against Klebsiella pneumoniae 1 ESBL2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID524323Antibacterial activity against Acinetobacter baumannii A896 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID564453Antimicrobial activity against Pseudomonas aeruginosa isolate 1050 by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID394677Antibacterial activity against Pseudomonas aeruginosa tracheal aspirate isolate 7 carrying insertion sequence ISPa26 by disk susceptibility test2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.
AID545620Antimicrobial activity against Pseudomonas aeruginosa PS43 with PFGE phenotype 2 expressing beta-lactamase KPC-2, OXA-2 obtained from skin of ICU patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID517981Antimicrobial activity against Providencia rettgeri J96 harboring beta-lactamase IMP-1 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID373770Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh26 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID433353Antibacterial activity against Parabacteroides distasonis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID558607Antimicrobial activity against Streptococcus pneumoniae isolate 1384 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID564018Antibacterial activity against Pseudomonas aeruginosa isolated from wound infection of patient by Etest2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID286034Antimicrobial activity against ESBL producing Klebsiella pneumoniae 266 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID295809Antibacterial activity against Pseudomonas aeruginosa 880/2 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID574465Antimicrobial activity against Escherichia coli isolate 360 expressing beta-lactamase KPC2, CTX-M-15, OXA-9, TEM and PFGE cluster 1 isolated from urine of patient by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID534668Antimicrobial activity against Prevotella melaninogenica JCM 6325 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID499125Antimicrobial activity against Pseudomonas aeruginosa OC 4354 infected in immunocompromized SKH1 mouse assessed as lesion volume at 100 mg/kg/day, sc measured after 48 hrs postinfection (Rvb = 2195 mm3)2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID423328Antibacterial activity against Pseudomonas aeruginosa isolate 371 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID533376Antimicrobial activity against Bacteroides eggerthii assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID495692Activity of Pseudomonas aeruginosa AmpC2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID588081Antibacterial activity against Acinetobacter baumannii ATCC 17978 harboring plasmid directed expression of beta-lactamase OXA-58 under an ISAba3 promoter2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
ISAba825, a functional insertion sequence modulating genomic plasticity and bla(OXA-58) expression in Acinetobacter baumannii.
AID1543306Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of microbial growth by CLSI based method2019Journal of natural products, 07-26, Volume: 82, Issue:7
Anthraquinone-Based Specialized Metabolites from Rhizomes of
AID1767684Antibacterial activity against Escherichia coli EAEC I 4913 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID1533873Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 200 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID390336Antimicrobial activity against extended spectrum beta-lactamase producing Escherichia coli 22692008Journal of natural products, Dec, Volume: 71, Issue:12
Citreamicins with potent gram-positive activity.
AID511135Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 92010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID523742Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E4592010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID372356%T>MIC against Pseudomonas aeruginosa PAO1 in in vitro PK/PD model at 1 g infused thrice daily at 8 hrs interval2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID530327Antimicrobial activity against Escherichia coli XL1-Blue harboring pUCP carrying VIM-13 gene by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID71108In vitro antibacterial activity against Escherichia coli 1507E by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13
Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID295810Antibacterial activity against Pseudomonas cepacia after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID496547fT>MIC in Klebsiella pneumoniae isolate 368 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 16-24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID583652Antibacterial activity against Escherichia coli TOP10 expressing metallo-beta-lactamase NDM-12010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia.
AID289887Antibacterial activity against Streptococcus agalactiae B2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID372346Ratio of Cmax in in vitro PK/PD model at 1 g infused at every 8 hrs intervals to MIC for hypermutable Pseudomonas aeruginosa isolate 12-09-152007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID529457Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone B expressing beta-lactamase Oxa-48, TEM-1, CTX-M-15 and Oxa-1 by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID521966Antibacterial activity against Campylobacter jejuni assessed as resistant isolates by disk diffusion method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID519630Antimicrobial activity against Escherichia coli JM83 harboring beta-lactamase OXA-63 after 3 days by Etest2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.
AID560836Antimicrobial activity against Acinetobacter baumannii isolate Ab3 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba92009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID1505214Antibacterial activity in Escherichia coli clinical isolates endogenously expressing NDM1 incubated at 37 degC for 18 hrs by spectrophotometry2018ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1
Structure-Based Virtual Screening for the Discovery of Novel Inhibitors of New Delhi Metallo-β-lactamase-1.
AID295800Antibacterial activity against Staphylococcus aureus 503 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID498827Antimicrobial activity against Citrobacter freundii SZ63T expressing IMP-4, qnrS1by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1706876Antibacterial activity against methicillin-resistant Staphylococcus aureus NR10193 measured after 16 to 18 hrs2021European journal of medicinal chemistry, Feb-15, Volume: 212Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.
AID1757554Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-2 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID560590Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ798 by microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID564465Antimicrobial activity against Pseudomonas aeruginosa isolate 971 by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID534649Antimicrobial activity against Non-ESBL Klebsiella pneumoniae assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID555555Antimicrobial activity against Pseudomonas aeruginosa isolate 26285 expressing IMP-13 beta lactamase gene by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
AID1757589Antibacterial activity against ESBLs negative Carbapenem-sensitive Escherichia coli 17-4 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID533567Antimicrobial activity against Pseudomonas aeruginosa isolate PA465 expressing VIM-2 beta-lactamase2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID163104Minimum inhibitory concentration against Pseudomonas aeruginosa 1592E was determined by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID496558Antibacterial activity against Klebsiella pneumoniae isolate 354 assessed as reduction of bacterial count at 8 ug/ml within 6 hrs in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID1757552Antibacterial activity against Carbapenem- resistant Pseudomonas aeruginosa 17-8 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID423533Antibacterial activity against Acinetobacter baumannii isolate 934 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID522005Antimicrobial activity against Klebsiella pneumoniae isolate KpI-1 expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID561287Antibacterial activity against Klebsiella oxytoca assessed as susceptible isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID565535Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-31 harboring A residue at 105 position in PDC- 9 by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID425088Antimicrobial activity against Porphyromonas asaccharolyticus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID324311Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa assessed as percent resistant isolates2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.
AID529849Antibacterial activity against beta-lactamase-overproducing Pseudomonas aeruginosa N043 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID1504339Antibacterial activity against Staphylococcus aureus ATCC 29213 after 16 to 20 hrs by broth microdilution method2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and bioactivities study of new antibacterial peptide mimics: The dialkyl cationic amphiphiles.
AID373033Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate BJ3-23 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID433199Antibacterial activity against Bacteroides caccae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID495909Antimicrobial activity in Escherichia coli J53 transconjugate with Escherichia coli DIH-1 expressing natural plasmid containing beta-lactamase VIM-192010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1757560Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-8 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID535137Antimicrobial activity against Ceftazidime non-susceptible Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID573551Antibacterial activity against Bacteroides fragilis assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID245211Minimum inhibitory concentration against Pseudomonas aeruginosa 1771M strain2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID545406Antimicrobial activity against Pseudomonas aeruginosa PS13 with PFGE phenotype 11E obtained from sputum of ICU patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID1229259Antibacterial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method2015ACS medicinal chemistry letters, May-14, Volume: 6, Issue:5
SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of Pseudomonas aeruginosa PBP3.
AID1407972Antibacterial activity against Acinetobacter baumannii ARC3513 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID522004Antimicrobial activity against Escherichia coli isolate J53 harboring p7A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID165197In vitro antibacterial activity against Pseudomonas aeruginosa 90272000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Synthesis and antibacterial activity of new carbapenems containing isoxazole moiety.
AID324860Antimicrobial activity against Acinetobacter baumannii A24B after 4 days by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID574459Antimicrobial activity against Escherichia coli isolate 157 expressing beta-lactamase KPC2, CTX-M-15, TEM and PFGE cluster 3 isolated from urine of patient by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID532100Antimicrobial against Pseudomonas aeruginosa 8564 harboring pyrX allele by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID555246Antibacterial activity against Acinetobacter genomosp. 3 isolate 60 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID558631Antimicrobial activity against Streptococcus pneumoniae isolate 4755 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID425331Bactericidal activity against beta lactamase-positive Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID535842Antimicrobial activity against Pseudomonas aeruginosa PAO1 SO20 harboring mexAB-oprM gene after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID584323Antimicrobial activity against Serratia marcescens ATCC 8100 by agar dilution method in presence of 20 ug/ml of phenyl-arginine-beta-naphthylamide2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID295813Antibacterial activity against Escherichia coli 0126 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID534925Antimicrobial activity against Ceftazidime susceptible Serratia marcescens assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID498815Antimicrobial activity against Klebsiella pneumoniae FZ47T expressing IMP-8, TEM-1, CTX-M-14, qnrB2, aac(6')-Ib by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID565222Activity of VIM-1 in Klebsiella pneumoniae isolate T-1780 assessed as compound hydrolysis in presence of EDTA2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID529458Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase TEM-1, CTX-M-15 and Oxa-1 by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID528526Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B7 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID289907Antibacterial activity against Enterobacter cloacae 4172007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID571390Antibacterial activity against Acinetobacter baumannii F264 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID200508Compound was evaluated for its antibacterial activity against Staphylococcus enteritidis 32003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID523736Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E4252010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523925Antibacterial activity against beta-lactamase-negative Escherichia coli E344 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1373315Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-10 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID373049Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate JN45 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID373762Antibacterial activity against imipenem-resistant Acinetobacter baumannii ab1266 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID521835Antibacterial activity against Klebsiella pneumoniae isolate VA367 with blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, blaSHV-12, aac(6')-1b genes by Etest method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID1873943Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs in presence of 50% foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID521836Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA367 containing blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, aac(6')-1b genes by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID532411Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B3 isolate PV-05X-02 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID534834Mean residence time in critically ill patient with sepsis at 1000 mg/kg, iv administered every 8 hrs by HPLC method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
AID285158Antimicrobial susceptibility of tetracycline-resistant Streptococcus pneumoniae from respiratory tract disease patient assessed as percent resistant isolates2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.
AID323607fCmin in patient with lower respiratory tract infection2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.
AID532899Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 588 ST 340 expressing beta-lactamase TEM-1 and SHV-11 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID1533856Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 256 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID499121Antimicrobial activity against Pseudomonas aeruginosa OC 4351 infected in immunocompromized SKH1 mouse assessed as lesion volume at 100 mg/kg/day, sc measured after 48 hrs postinfection (Rvb = 2234 mm3)2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID1373285Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-2 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID285611Antimicrobial activity against Pseudomonas aeruginosa 65.68-3 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID584739Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5366 harboring pstB mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID524273Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E474 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID521993Antimicrobial activity against Klebsiella pneumoniae isolate KpB expressing OXA-48 and CTX-M-15 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID584504Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0479 harboring mutation in putative transcriptional regulator, LysR family by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID534682Antimicrobial activity against Veillonella dispar ATCC 17748 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID545565Antibacterial activity against Escherichia coli EIR8a selected at 8 times MIC of imipenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID564454Antimicrobial activity against Pseudomonas aeruginosa isolate 1060 by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID565521Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-14 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID576523Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008140 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID523718Antibacterial activity against Acinetobacter baumannii A885 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID323863Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 25923 after phagocytosis by human THP1 macrophages assessed as reduction in bacterial count at pH 5.5 after 24 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Role of acidic pH in the susceptibility of intraphagocytic methicillin-resistant Staphylococcus aureus strains to meropenem and cloxacillin.
AID289903Antibacterial activity against Salmonella orion2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID1533870Antibacterial activity against multidrug-resistant Staphylococcus aureus isolate 358 by broth microdilution assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID356628Antibacterial activity against methicillin-resistant Staphylococcus aureus 003 after 18 hrs2003Journal of natural products, Nov, Volume: 66, Issue:11
New bromotyrosine derivatives from an association of two sponges, Jaspis wondoensis and Poecillastra wondoensis.
AID1407964Antibacterial activity against Acinetobacter baumannii ARC2782 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID520728Activity of Acinetobacter baumannii CIP7010 beta-lactamase assessed per mg of protein at 100 uM2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID521967Antibacterial activity against Campylobacter coli assessed as resistant isolates by disk diffusion method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID1757561Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-9 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID574004Antibacterial activity against beta-lactamase producing Clostridium paraputrificum assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID558619Antimicrobial activity against Streptococcus pneumoniae isolate 3275 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID523726Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E3472010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID245178Minimum inhibitory concentration against Klebsiella aerogenes 1522E strain2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID535841Antimicrobial activity against wild-type Pseudomonas aeruginosa GP4 after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID584583Antimicrobial activity against Acinetobacter baumannii ATCC 19606 harboring plasmid WH1266 by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID295824Antibacterial activity against Enterobacter cloacae 417 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID523727Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E3482010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID541022Activity at Burkholderia cenocepacia 07-34 beta-lactamase PenB1 expressed in Escherichia coli Top10 by UV-spectrophotometry2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID509865Antibacterial activity against Acinetobacter baumannii ATCC 17978 isolated from human CSF2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID534652Antimicrobial activity against ESBL producing Klebsiella pneumoniae assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID522656Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis 17T5 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID510510Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate N2AC9-18 expressing KPC beta lactamase2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID531675Antimicrobial activity against Escherichia coli DH5alpha by broth dilution test2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID70911In vitro antibacterial activity against Escherichia coli 1507E2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.
AID499137fT>MIC in Pseudomonas aeruginosa OC 4354 infected sc dosed SKH1 mouse at 50 mg/kg, sc administered twice at 1 and 3 hrs after infection2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID523517Antimicrobial activity against Pseudomonas aeruginosa isolate 1665 from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID564954Antimicrobial activity against Acinetobacter baumannii isolate Ab153 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba92009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID1763152Antibacterial activity against Acinetobacter sp. 122 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI based serial dilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Antibacterial and synergistic activity of 6β-hydroxy-3-oxolup-20(29)-en-28-oic acid (6β-hydroxy betunolic acid) isolated from Schumacheria castaneifolia vahl.
AID574734Antimicrobial activity against Fusobacterium necrogenes after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID433193Antibacterial activity against Staphylococcus haemolyticus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID532097Antimicrobial against Pseudomonas aeruginosa 3894 by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID1767682Antibacterial activity against Escherichia coli ETEC 2589093 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID1757551Antibacterial activity against Carbapenem- resistant Pseudomonas aeruginosa 17-5 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID117668In vivo therapeutic efficacy in systemic infections caused by Streptococcus pyogenes 77A in mice, at a single subcutaneous administration2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.
AID521349Antimicrobial activity against Streptococcus pneumoniae isolate 909 obtained from bronchoalveolar lavage fluid of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID558038Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S1 by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID576525Antimicrobial activity against Carbapenem-resistant Klebsiella pneumoniae isolate HIP10924 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID522664Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis BA1024 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID1225788Antibacterial activity against Klebsiella pneumoniae KP1087 expressing KPC2/CTX-M-15/SHV-11/TEM-1 by broth microdilution method2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID1757569Antibacterial activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-16 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID390330Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae 9402008Journal of natural products, Dec, Volume: 71, Issue:12
Citreamicins with potent gram-positive activity.
AID528846Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolated from ICU patient urine assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID530342Ratio of Kcat to Km for Pseudomonas aeruginosa VIM-13 beta-lactamase2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID523747Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E4842010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID545574Ratio of MIC for Pseudomonas aeruginosa PMR2a to MIC for Pseudomonas aeruginosa ATCC 156922009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID517976Antimicrobial activity against Klebsiella pneumoniae YC harboring beta-lactamase KPC-2,TEM-1and SHV-2 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID517980Antimicrobial activity against Pseudomonas aeruginosa HPA996 harboring beta-lactamase VIM-2 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID545546Ratio of MIC for Staphylococcus aureus SMR2a to MIC for Staphylococcus aureus ATCC 6538P2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID200858Compound was evaluated for its antibacterial activity against Salmonella Typhimurium 12003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID508741Antibacterial activity against Pseudomonas aeruginosa assessed as percent nonsusceptible isolates by broth microdilution assay2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID1762801Antibacterial activity against vancomycin-resistant Enterococcus faecium assessed as reduction in bacterial growth incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID1357421Antibacterial activity against extended-spectrum beta-lactamase producing Escherichia coli isolate 212648 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria.
AID565725Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-30 harboring A residue at 105 position in PDC- 8 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID423497Antibacterial activity against Acinetobacter baumannii isolate 896 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID534453Antimicrobial activity against Lactobacillus acidophilus JCM 1132 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID1757535Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-9 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID495671Antimicrobial activity against wild type Escherichia coli ATCC 25922 deficient in beta-lactamase assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID496625fT>MIC in Klebsiella pneumoniae isolate 360 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 0-8 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID496555fT>MIC in Pseudomonas aeruginosa isolate 988 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 16-24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID1373303Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-121 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID529499Antimicrobial activity against Escherichia coli GeneHogs by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID546419Antimicrobial activity against Pseudomonas aeruginosa KG2505a harboring recombinant pBB-PDC-4 by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID289878Antibacterial activity against Pseudomonas aeruginosa 90272007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID522018Antimicrobial activity against Escherichia coli isolate TOP10 harboring pPR containing beta-lactamase and TEM-101 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID496505fT>MIC in Klebsiella pneumoniae isolate 377 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 0-8 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID1407971Antibacterial activity against Acinetobacter baumannii ARC3495 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID1357453Antibacterial activity against KPC-2 producing Klebsiella pneumoniae isolate 212229 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria.
AID575012Activity of Pseudomonas aeruginosa beta-lactamase IMP-1 by UV spectrophotometric analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro potentiation of carbapenems with ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta-lactamase- producing Pseudomonas aeruginosa clinical isolates.
AID404960Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii T186 isolate carrying three bla-OXA58 gene copies by agar dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID495740Kcat/Km ratio of Klebsiella pneumoniae KPC-2 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID574997Antimicrobial activity against Bifidobacterium sp. assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID535876Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii JN1T by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID555248Antibacterial activity against Acinetobacter genomosp. 3 isolate 60 by Etest method in presence of efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID289876Antibacterial activity against Escherichia coli DC22007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID511152Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 8 assessed as zone of inhibition by disk diffusion assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID323862Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 25923 after phagocytosis by human THP1 macrophages assessed as reduction in bacterial count at pH 7.4 after 24 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Role of acidic pH in the susceptibility of intraphagocytic methicillin-resistant Staphylococcus aureus strains to meropenem and cloxacillin.
AID95722In vitro antibacterial activity against Klebsiella aerogenes 1522E by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13
Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID1757596Antibacterial activity against Enterobacter cloacae 17-2 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID574528Antimicrobial activity against Prevotella intermedia assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID372342Antibacterial activity against Pseudomonas aeruginosa PAO1 in in vitro PK/PD model assessed as AAC (0 to 24 hrs) at 1 g infused thrice daily at 8 hrs interval2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID532410Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B3 isolate CR-04X-14 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID555264Antibacterial activity against Acinetobacter genomosp. 3 isolate 109 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID565543Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-07 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID373043Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate CY7 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID535370Antimicrobial activity against Pseudomonas aeruginosa isolated from non-ICU patient assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID499061Antimicrobial activity against carbapenem-resistant Escherichia coli PU43 deficient in TEM-1, CTX-M-14, aac(6')-Ib, ompC/F by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID576536Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008138 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID511147Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 3 assessed as zone of inhibition by disk diffusion assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID584708Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0503 harboring mutation in Putative biotin synthesis protein BioC by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID523546Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E415 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID518227Antimicrobial activity against Pseudomonas aeruginosa 527 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID496477Antibacterial activity against Klebsiella pneumoniae isolate 360 in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID433351Antibacterial activity against Bacteroides uniformis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID547801Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237W mutant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID499050Antimicrobial activity against Klebsiella pneumoniae PU104T expressing TEM-1, CTX-M-15 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID565670Antimicrobial activity against beta-lactamase positive (amoxicillin)clavulanate-resistant Haemophilus influenzae assessed as susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re
AID523545Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E412 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID572128Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 31 expressing ampC, ompA, adeB, adeM, aadB, aadA2 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1853612Antibacterial activity against Enterococcus faecium clinical isolate 1091282 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution method2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
Design, synthesis, and antibacterial activity of
AID573596Antibacterial activity against Fusobacterium mortiferum assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID499046Antimicrobial activity against Klebsiella pneumoniae ZJ68T expressing CTX-M-15 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID584710Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0766 harboring mucD mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID587525Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse in presence of 4 ug/ml Tazobactam beta-lactamase inhibitor2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID495810Antimicrobial activity against Escherichia coli harbouring plasmid BK-CMV expressing beta-lactamase VIM-19 by microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID289895Antibacterial activity against Escherichia coli 0862007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID163106Minimum inhibitory concentration against Pseudomonas aeruginosa 9027 was determined by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID1311367Antibacterial activity against Mycobacterium tuberculosis 115R measured after 14 days by broth microdilution assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1757542Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-6 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID583017Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Escherichia coli ECB-1 plasmid carrying ACC-1 by agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID523570Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E480 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID249351Minimum inhibitory concentration against Pseudomonas aeruginosa (n=60); (Range=0.06-128)2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID498819Antimicrobial activity against Klebsiella pneumoniae GZ64T expressing IMP-4 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524274Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E475 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID555209Antibacterial activity against Acinetobacter genomosp. 3 isolate 90 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID1757563Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-11 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID295831Antibacterial activity against Proteus rettgeri 936 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID498812Antimicrobial activity against Escherichia coli ZJ87 expressing KPC-2, TEM-1, ompC by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID518248Antimicrobial activity against Pseudomonas aeruginosa 621 assessed as appearance of colony at 4 times MIC concentration2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID495691Activity of Escherichia coli CMY-22010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID373754Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab8 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID522663Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis SPS 0053 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID524078Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3222010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574473Antimicrobial activity against Escherichia coli isolate 547 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from blood of patient by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID555477Antibacterial activity against Acinetobacter genomosp. 3 isolate 243 by Etest method in presence of cloxacillin and efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID499155fCmax in immunocompromized SKH1 mouse plasma at 12.5 mg/kg, sc2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID563977Ratio of Kcat to Km for Klebsiella pneumoniae 05-560 beta-lactamase VIM22009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID565282Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A3 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
AID564457Antimicrobial activity against Pseudomonas aeruginosa isolate 878 by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID518467Antimicrobial activity against Stenotrophomonas maltophilia 1AC736 assessed as number of passages required for MIC to rise above 4 times original MIC2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID524309Antibacterial activity against Pseudomonas aeruginosa P376 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID324874Antimicrobial activity against Acinetobacter baumannii C75 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID560094Bactericidal activity against Escherichia coli isolate 5411 at 1/4 times MIC after 24 hrs by time kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID1680068Antibacterial activity against Enterococcus faecalis ATCC 29212 assessed as reduction in bacterial growth incubated 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID496530fT>MIC in Klebsiella pneumoniae isolate 368 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 8-16 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID517978Antimicrobial activity against Pseudomonas aeruginosa HPA101-1477 harboring beta-lactamase IMP-1 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID567580Antimicrobial activity against Acinetobacter baumannii assessed as resistant isolate by broth dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.
AID523556Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E451 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID207769Compound was evaluated for in vitro antibacterial activity against Staphylococcus aureus 285 strain by agar dilution method2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Synthesis and antibacterial activity of 2alpha-functionalized 1beta-methylcarbapenems related to KR-21012.
AID286036Antimicrobial activity against ESBL producing Klebsiella pneumoniae 258 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID285597Antimicrobial activity against Pseudomonas aeruginosa 2A1 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID528921Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-14 and CTX-M-27 gene and other bla gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID205544Minimum inhibitory concentration against Staphylococcus aureus 285 was determined by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID1758329Antibacterial activity against KPC-2 producing Escherichia coli BAA23402021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Discovery of 3-aryl substituted benzoxaboroles as broad-spectrum inhibitors of serine- and metallo-β-lactamases.
AID529496Antimicrobial activity against Escherichia coli T-622 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID1680042Antibacterial activity against NDM1 producing carbapenem-resistant Enterobacteriaceae clinical isolate 4 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID425105Antimicrobial activity against Clostridium bifermentans isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID535369Antimicrobial activity against Pseudomonas aeruginosa isolated from non-ICU patient assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID236206Clearance value at a single intravenous administration of 5 mg/kg in dog2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID285593Antimicrobial activity against Pseudomonas aeruginosa 65.38-4 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID574667Antimicrobial activity against Escherichia coli isolate 1679 expressing beta-lactamase KPC2, SHV-12, TEM and PFGE cluster 6 isolated from peritoneal fluid of patient by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID1780307Antibacterial activity against wild type Pseudomonas aeruginosa LESB58 LpxA Ser150Ala mutant assessed as resistance development by measuring fold increase in MIC
AID323600Antimicrobial activity against Streptococcus pneumoniae2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.
AID523540Antibacterial activity against beta-lactamase-negative Escherichia coli E348 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1357462Antibacterial activity against IMP-4 producing Pseudomonas aeruginosa isolate 208247 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria.
AID1757575Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-3 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID520984Antibacterial activity against Escherichia coli harboring pNGR plasmid expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID584562Antimicrobial activity against Acinetobacter lwoffii isolate I expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1056838Antibacterial activity against CTX-15 expressing Escherichia coli isolate 4024 after 18 to 24 hrs by two-fold broth microdilution assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID1767686Antibacterial activity against Escherichia coli EPEC E234969 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID574471Antimicrobial activity against Escherichia coli isolate 543T expressing beta-lactamase KPC2 and PFGE cluster 4 isolated from synovial fluid of patient by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID1559380Antibacterial activity against wild type Pseudomonas aeruginosa 27853 after 16 to 20 hrs by CLSI-based microbroth dilution method2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID201540In vivo antibacterial activity against Salmonella Typhimurium1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID289918Antibacterial activity against Corynebacterium pyogenes2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID496562Antibacterial activity against Klebsiella pneumoniae isolate 360 assessed as reduction of bacterial count at 16 ug/ml within 6 hrs in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID523731Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E4582010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID323040Antimicrobial activity against extended-spectrum-beta-lactamase producing Klebsiella pneumoniae assessed as percent resistant isolates2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
AID564528Antimicrobial activity against Escherichia coli TOP10 harboring pADC-50 plasmid by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID285601Antimicrobial activity against Pseudomonas aeruginosa 2A3 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1407968Antibacterial activity against Acinetobacter baumannii ARC3489 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID535644Antimicrobial activity against Group B streptococcus serotype Ib N2 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID531972Antibacterial activity against Klebsiella pneumoniae blood isolate A28006 PFGE pattern A expressing KPC-2, TEM-1, SHV-11, CTX-M-2 beta-lactamase by agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID496491fT>MIC in Klebsiella pneumoniae isolate 354 at 2 gram for every 8 hrs administered as 3 hrs infusion over 24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID1680047Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae clinical isolate 9 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID523941Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E452 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1883727Half life in mouse2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Tuberculosis Drug Discovery: Challenges and New Horizons.
AID558335Antibacterial activity against Campylobacter jejuni isolate P1093 harboring blaOXA-61::cat gene by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID496473Antibacterial activity against Klebsiella pneumoniae isolate 351 in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID534413Antimicrobial activity against methicillin-susceptible coagulase-negative Staphylococcus assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID496476Antibacterial activity against Klebsiella pneumoniae isolate 357 in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID523902Antibacterial activity against Acinetobacter baumannii A864 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523890Antimicrobial activity against Acinetobacter baumannii ATCC 15151 by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
AID511585Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD1 harboring oprD spontaneous mutant and deficient in ampD gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID323603Antimicrobial activity against Klebsiella pneumoniae2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.
AID535167Antimicrobial activity against Acinetobacter assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID535636Antimicrobial activity against Group B streptococcus serotype VI R4 harboring Q557E mutation in PBP 2X and T567I, Y262N mutations in PBP 2B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID340738Ratio of Kcat to Km of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis relative to control2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID1853615Antibacterial activity against Staphylococcus aureus clinical isolate 1088626 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution method2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
Design, synthesis, and antibacterial activity of
AID534454Antimicrobial activity against Lactobacillus brevis subsp. brevis JCM 1059 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID529856Antibacterial activity against Pseudomonas aeruginosa N091 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID499126Antimicrobial activity against Pseudomonas aeruginosa OC 4351 infected in immunocompromized SKH1 mouse assessed as log change in bacterial colony forming unit at 1.6 mg/kg/day, sc2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID549040Antimicrobial activity against carbapenem susceptible Klebsiella pneumoniae isolate KpSCMC2c harboring bla SHV-12 gene isolated from patient with pulmonary infection by disk diffusion method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Two clinical strains of Klebsiella pneumoniae carrying plasmid-borne blaIMP-4, blaSHV-12, and armA isolated at a Pediatric Center in Shanghai, China.
AID1757615Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-7 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID528531Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B60 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID522643Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis Sterne by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID498811Antimicrobial activity against Escherichia coli ZJ86T expressing KPC-2 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1373312Antimicrobial activity against Escherichia coli expressing beta-lactamase CMY-2 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID656348Antibacterial activity against Pseudomonas aeruginosa isolate 1091-052011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.
AID423325Antibacterial activity against Pseudomonas aeruginosa isolate 368 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID584578Antimicrobial activity against Acinetobacter lwoffii isolate L expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID523904Antibacterial activity against Acinetobacter baumannii A851 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524275Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E479 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1757617Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-10 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID520389Ratio of Kcat to Km for Pseudomonas aeruginosa COL-1 metallo-beta lactamase VIM-2 over Kcat to Km for Pseudomonas aeruginosa M5109 metallo-beta-lactamase VIM-112008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID545412Antimicrobial activity against Pseudomonas aeruginosa PS20A with PFGE phenotype 11D obtained from skin of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID390329Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae 9752008Journal of natural products, Dec, Volume: 71, Issue:12
Citreamicins with potent gram-positive activity.
AID523573Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E474 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID164580Antibacterial activity against Pseudomonas aeruginosa 1771M2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.
AID283396Antimicrobial activity against Nocardia veterana after 72 hrs by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID528984Antimicrobial activity against Haemophilus influenzae isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID518244Antimicrobial activity against Escherichia coli W3110 assessed as appearance of colony at 4 times MIC concentration2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID498844Antimicrobial activity against Klebsiella pneumoniae XJ81T expressing TEM-1, SHV-12, aac(6')-Ib by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID555216Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 20 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID555269Antibacterial activity against Acinetobacter genomosp. 3 isolate 128 by Etest method in presence of efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID524428Antibacterial activity against extended spectrum beta-lactamase-producing Enterobacteriaceae clinical isolates isolated from patient with complicated intra-abdominal infection assessed as cure rate at test-of-cure visit by mMITT analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID1056852Antibacterial activity against CTX-15 expressing Stenotrophomonas maltophilia isolate 125 after 18 to 24 hrs by two-fold broth microdilution assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID565283Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring plasmid pA1 by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
AID532196Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae WH42 harboring wild-type GyrA, ParC, GyrB and qnrA genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID495676Antimicrobial activity against wild type Serratia marcescens OC 7554 expressing beta-lactamase SME-3 and containing Carbapenemase assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID571210Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID519808Inhibition of Bocillin FL binding to PBP4 in Pseudomonas aeruginosa PAO1 membranes2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID1680063Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 3 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID207156Antibacterial activity against Staphylococcus aureus 2852003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID535060Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 by agar dilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
AID521840Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA375 containing qnrA1, blaTEM-1, blaSHV-11genes by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID285583Antimicrobial activity against Pseudomonas aeruginosa 65.33-2 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID534631Antimicrobial activity against ESBL producing Escherichia coli assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID535133Antimicrobial activity against Pseudomonas aeruginosa assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID535727Antibacterial activity against Klebsiella pneumoniae urine isolate A28011 PFGE pattern A expressing KPC-2 CTX-M-2 beta-lactamase by agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID245192Minimum inhibitory concentration against Streptococcus pyogenes 308A strain2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID1233142Antibacterial activity against methicillin-resistant Staphylococcus aureus after 18 to 20 hrs by microbroth dilution method2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors.
AID200867In vitro antibacterial activity against Salmonella Typhimurium2000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Synthesis and antibacterial activity of new carbapenems containing isoxazole moiety.
AID532391Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A1 isolate FG-17X-14 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID164377Antibacterial activity against Pseudomonas aeruginosa 1529E2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID535848Antimicrobial activity against Pseudomonas aeruginosa GP61KT51 harboring oprD,mexAB-oprM gene after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID532101Antimicrobial against Pseudomonas aeruginosa 9256 harboring ybhO allele by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID369629Antimicrobial activity against beta-lactamase negative ampicillin-resistant Haemophilus influenzae by E-test2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
AID495742Kcat/Km ratio of Pseudomonas aeruginosa VIM-2 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID529198Antibacterial activity against AmpC-producing Escherichia coli assessed as sensitive isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
AID520731Activity of Escherichia coli DH10B beta-lactamase OXA-97 assessed per mg of protein at 100 uM2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID534379Antibacterial activity against Citrobacter freundii KHM243 clinical isolate by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID534428Antimicrobial activity against Atopobium parvulum VPI 0546 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID289901Antibacterial activity against Salmonella oranienberg2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID425119Bactericidal activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID1757581Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-12 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1318919Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 1018852016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID564016Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring Pseudomonas aeruginosa plasmid DNA isolated from wound infection of patient by Etest2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID534432Antimicrobial activity against Peptoniphilus indolicus GAI 0915 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID574726Antimicrobial activity against Prevotella oralis assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1763154Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI based serial dilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Antibacterial and synergistic activity of 6β-hydroxy-3-oxolup-20(29)-en-28-oic acid (6β-hydroxy betunolic acid) isolated from Schumacheria castaneifolia vahl.
AID535171Antimicrobial activity against imipenem non-susceptible Acinetobacter assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID559683Antibacterial activity against Acinetobacter baumannii BM4674 isolated from the tibia fracture of a patient by Etest method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
AID574744Antimicrobial activity against Peptostreptococcus anaerobius assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID573597Antibacterial activity against Fusobacterium necrophorum assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID558613Antimicrobial activity against Streptococcus pneumoniae isolate 2686 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID523917Antibacterial activity against Acinetobacter baumannii A897 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID70120Compound was evaluated for its antibacterial activity against Escherichia coli TEM2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID543423Antimicrobial activity against Escherichia coli XL-1 Blue transconjugant harboring beta-lactamase CTX-M-64 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID401688Antibacterial activity against Escherichia coli DC22005Journal of natural products, May, Volume: 68, Issue:5
Cytotoxic bisindole alkaloids from a marine sponge Spongosorites sp.
AID1188392Antibacterial activity against Pseudomonas aeruginosa PA53 assessed as reduction in CFU at 4 ug/ml after 6 hrs by time kill assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Small-molecule suppression of β-lactam resistance in multidrug-resistant gram-negative pathogens.
AID576293Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 11932 harboring porin OmpK36 gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID529844Antibacterial activity against methicillin-resistant Staphylococcus aureus 123-1 expressing PBP 2a by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID524290Antibacterial activity against Pseudomonas aeruginosa P335 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523898Antibacterial activity against Pseudomonas aeruginosa P376 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529456Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone A expressing beta-lactamase Oxa-48, TEM-1, SHV-12 and Oxa-9 by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID558598Antimicrobial activity against Streptococcus pneumoniae 10 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID570790Antimicrobial activity against Acinetobacter baumannii AB026 transformant harboring bla-OXA-23 gene by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania.
AID508721Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1C2 PTOL1 harboring beta-lactamase OXA-17 by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID495688Activity of Escherichia coli CTX-M-152010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID433178Antibacterial activity against Proteus vulgaris isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523554Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E430 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID68522Minimum inhibitory concentration against Enterobacter cloacae 1321E was determined by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID289875Antibacterial activity against Staphylococcus aureus 2852007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID295812Antibacterial activity against Escherichia coli 0114 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID563969Antibacterial activity against Escherichia coli J53 by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID1348994Antibacterial activity against Enterococcus faecalis ATCC 29212 after 16 to 20 hrs by broth microdilution method2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and antibacterial evaluation of novel cationic chalcone derivatives possessing broad spectrum antibacterial activity.
AID571898Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 13 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID511131Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 52010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID201605In vitro antibacterial activity against GN 12873 strain of Stenotrophomonas maltophilia2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID499119Antimicrobial activity against Pseudomonas aeruginosa OC 4351 infected in immunocompromized SKH1 mouse assessed as lesion volume at 6.2 mg/kg/day, sc measured after 48 hrs postinfection (Rvb = 2234 mm3)2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID558629Antimicrobial activity against Streptococcus pneumoniae isolate 3791 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID323859Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 25923 after phagocytosis by human THP1 macrophages assessed as reduction in bacterial count after 24 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Role of acidic pH in the susceptibility of intraphagocytic methicillin-resistant Staphylococcus aureus strains to meropenem and cloxacillin.
AID518197Antimicrobial activity against fpvA deficient Pseudomonas aeruginosa (560546)9 M.P. by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID533400Antimicrobial activity against Clostridium paraputrificum assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID518194Antimicrobial activity against mexAB-oprM protein and mexZ deficient Pseudomonas aeruginosa PAO267 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID495798Ratio of Kcat to Km of Pseudomonas fluorescens PF-1 beta-lactamase BIC-1 expressed in Escherichia coli DH10B using nitrocefin hydrolysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID558330Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P316 by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID535134Antimicrobial activity against Ceftazidime susceptible Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1373308Antimicrobial activity against Escherichia coli expressing beta-lactamase SPM-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID520977Antibacterial activity against Escherichia coli DH10B expressing blaKPC gene by Etest method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID522016Antimicrobial activity against Escherichia coli isolate J53 harboring pL containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID523760Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E4742010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID545408Antimicrobial activity against Pseudomonas aeruginosa PS15A with PFGE phenotype 10A obtained from blood of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID547761Antimicrobial activity against Klebsiella pneumoniae 1534 expressing beta-lactamase KPC-2 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID545398Antimicrobial activity against Pseudomonas aeruginosa PS4 with PFGE phenotype 9B expressing beta-lactamase IMP-18 obtained from sputum of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID533396Antimicrobial activity against Clostridium innocuum assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID545547Antibacterial activity against Staphylococcus aureus SMR4a selected at 2 times MIC of meropenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID433365Antibacterial activity against Propionibacterium acnes isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID520382Antimicrobial activity Escherichia coli DH5alpha harboring bacteriophage T4 plasmid alpha omega by agar macrodilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID523555Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E459 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID565513Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-22 harboring A residue at 105 position in PDC- 4 by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID529665Activity of Pseudomonas aeruginosa COL-1 beta-lactamase VIM-2 relative to cephaloridine2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID498805Antimicrobial activity against Klebsiella pneumoniae ZJ70T expressing KPC-2 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID528920Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-14 and CTX-M-27 and other bla gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID341107Antibacterial activity against Escherichia coli transconjugant carrying pEC28 isolate eby Etest2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12.
AID423509Antibacterial activity against Acinetobacter baumannii isolate 908 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID1721005Synergistic Inhibition of beta lactamase VIM-29 in Escherichia coli 50639799 assessed colony formation by visual inspection in presence of 125 microM N-((4-((adamantylamino)methyl)-1H-1,2,3-triazol-5-yl)methyl)-4-iodobenzenesulfonamide incubated for 20 hr2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Structural studies of triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-β-lactamases.
AID200505Compound was evaluated for its antibacterial activity against Staphylococcus enteritidis2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID554988Antibacterial activity against Acinetobacter genomosp. 3 isolate 56 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID519287Antimicrobial activity against Acinetobacter radioresistens isolates by Etest2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp.
AID1254036Reversible binding affinity to Pseudomonas aeruginosa 301-5473 metallo-beta-lactamase VIM-2 expressed in Escherichia coli BL21(DE3) measured for 15 secs by SPR analysis2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Discovery of Novel Inhibitor Scaffolds against the Metallo-β-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening.
AID523565Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E419 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID429079Antibacterial activity against Klebsiella pneumoniae Greece producing KPC-2 beta-lactamase by E test method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.
AID523712Antibacterial activity against Pseudomonas aeruginosa P340 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID401691Antibacterial activity against Staphylococcus aureus 5032005Journal of natural products, May, Volume: 68, Issue:5
Cytotoxic bisindole alkaloids from a marine sponge Spongosorites sp.
AID534446Antimicrobial activity against Bifidobacterium bifidum JCM 1255 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID584700Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5038 harboring aroB mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID555479Antibacterial activity against Acinetobacter genomosp. 3 isolate 14 by Etest method in presence of efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID523548Antibacterial activity against beta-lactamase-negative Escherichia coli E424 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID555472Antibacterial activity against Acinetobacter genomosp. 3 isolate 128 by Etest method in presence of cloxacillin and efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID508724Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1E2 PpA1 harboring acquired beta-lactamase OXA-144 by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID523584Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E507 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573802Antibacterial activity against Prevotella melaninogenica assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID425114Antimicrobial activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID532398Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D1 isolate VA-06X-63 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID496543fT>MIC in Klebsiella pneumoniae isolate 353 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 16-24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID96087Compound was evaluated for its antibacterial activity against Klebsiella pneumoniae 2 ESBL2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID1846919Antibacterial activity against multidrug resistant wild type Escherichia coli ATCC BAA-2340 assessed as reduction in bacterial growth incubated for 18 to 20 hrs by CLSI based microdilution method2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Design, Synthesis, and Biological Evaluation of Novel Pyrimido[4,5-
AID534608Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID532400Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D2 isolate VA-06X-17 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID1373321Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-146 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID200506Compound was evaluated for its antibacterial activity against Staphylococcus enteritidis 12003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID428267Antimicrobial activity against carbapenemase producing Enterobacteriaceae assessed as susceptible isolates by CLSI breakpoint assay2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID564949Antimicrobial activity against Acinetobacter baumannii isolate Ab58 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba92009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID499132Antimicrobial activity against Pseudomonas aeruginosa OC 4354 infected in immunocompromized SKH1 mouse assessed as log change in bacterial colony forming unit at 25 mg/kg/day, sc2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID1318928Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 860672016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID351199Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii expressing ISAba32007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Global challenge of multidrug-resistant Acinetobacter baumannii.
AID1879067Antibacterial activity against pET28a-NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as inhibition of bacterial growth incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID585199Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-5 E104, S170 mutant by Etest method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID523492Antimicrobial activity against Pseudomonas aeruginosa 2779-con by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID523581Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E420 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID545569Antibacterial activity against Pseudomonas aeruginosa PRR4a selected at 4 times MIC of tomopenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID555469Antibacterial activity against Acinetobacter genomosp. 3 isolate 103 by Etest method in presence of cloxacillin and efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID558333Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P790 by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID523921Antibacterial activity against Acinetobacter baumannii A891 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1906518Cytotoxicity against HEK293 cells assessed as effect on cell viability at 10 to 200 ug/ml incubated for 24 hrs by microplate reader analysis2022European journal of medicinal chemistry, May-05, Volume: 235Amphiphilic cyclic peptide [W
AID518243Antimicrobial activity against Enterobacter cloacae S9369 assessed as appearance of colony at 4 times MIC concentration2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID511150Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 6 assessed as zone of inhibition by disk diffusion assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID587733Ratio of Kcat to Km for Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP-1 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID545545Antibacterial activity against Staphylococcus aureus SMR2a selected at 2 times MIC of meropenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID535138Antimicrobial activity against Ceftazidime non-susceptible Pseudomonas aeruginosa assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID523920Antibacterial activity against Acinetobacter baumannii A885 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID289897Antibacterial activity against Escherichia coli 01262007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID1887539Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial growth incubated for 16 to 18 hrs by broth microdilution method2022Journal of natural products, 10-28, Volume: 85, Issue:10
Developing the Natural Prenylflavone Artocarpin from
AID274730Antibacterial activity against methicillin-resistant Pseudomonas aeruginosa 17712007Journal of natural products, Jan, Volume: 70, Issue:1
Bisindole alkaloids of the topsentin and hamacanthin classes from a marine sponge Spongosorites sp.
AID518515Antimicrobial activity against Pseudomonas aeruginosa HPA10586 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID523952Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E359 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1318931Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 920142016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID524281Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E420 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584586Antimicrobial activity against Acinetobacter baumannii ATCC 17978 harboring plasmid WH1266 by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID95732Compound was evaluated for in vitro antibacterial activity against Klebsiella oxytoca 1082 E strain by agar dilution method2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Synthesis and antibacterial activity of 2alpha-functionalized 1beta-methylcarbapenems related to KR-21012.
AID532096Antimicrobial against Pseudomonas aeruginosa 3434 by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID1757612Antibacterial activity against Enterobacter aerogenes 15-5 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID523511Antimicrobial activity against Pseudomonas aeruginosa isolate 13167 from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID534886Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID521843Antibacterial activity against Escherichia coli J53 by Etest method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID499144Half life in immunocompromized SKH1 mouse plasma at 50 mg/kg, sc2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID523919Antibacterial activity against Acinetobacter baumannii A890 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1056839Antibacterial activity against TEM-1/CTX-M-15 expressing Aeromonas caviae isolate 260 after 18 to 24 hrs by two-fold broth microdilution assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID372343Antibacterial activity against hypermutable Pseudomonas aeruginosa isolate 12-09-15 in in vitro PK/PD model assessed as AAC (0 to 24 hrs) at 1 g infused thrice daily at 8 hrs interval2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID549330Antimicrobial activity against Escherichia coli isolate 16 harboring bla CTX-M-3a gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID532202Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae WH99 harboring wild-type GyrA, ParC, GyrB and qnrB genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID423307Antibacterial activity against Pseudomonas aeruginosa isolate 349 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID496682Antibacterial activity against Klebsiella pneumoniae isolate 368 assessed as reduction of bacterial count at 32 ug/ml within 6 hrs in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID295829Antibacterial activity against Proteus mirabilis 174/3 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID295797Antibacterial activity against Pseudomonas aeruginosa 5455 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID1447478Antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by microtiter dilution assay2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID519800Inhibition of Bocillin FL binding to PBP4 in Escherichia coli MC4100 membranes2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID524094Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3762010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1225791Antibacterial activity against Klebsiella pneumoniae KP1088 expressing KPC3/SHV-11/TEM-1 by broth microdilution method2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID571693Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 2 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID588128Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 6 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID1762805Antibacterial activity against against Escherichia coli 06 assessed as reduction in bacterial growth incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID498804Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ70 deficient in KPC-2, SHV-11, CTX-M-14, ompK35/36 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1906438Bactericidal activity against Escherichia coli ATCC BAA 2452 assessed as decrease of bacterial growth at MIC measured after 15 hrs by Time kill assay2022European journal of medicinal chemistry, May-05, Volume: 235Amphiphilic cyclic peptide [W
AID574006Antibacterial activity against beta-lactamase producing Clostridium tertium assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID423300Antibacterial activity against Pseudomonas aeruginosa isolate 339 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID1759649Antimicrobial activity against vancomycin-resistant Enterococcus faecium clinical isolate 1091282 by CLSI-based broth microdilution assay2021European journal of medicinal chemistry, Jul-05, Volume: 2194-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.
AID535873Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii JN1 harboring GyrA T83I, ParC S80I mutant, wild-type GyrB and qnrA genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID286015Antimicrobial activity against ESBL producing Escherichia coli 243 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID555452Antibacterial activity against Acinetobacter genomosp. 3 isolate 21 by Etest method in presence of cloxacillin and efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID583093Antimicrobial activity against Escherichia coli XL1-Blue harboring pBC-SK plasmid by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID209265Antibacterial activity against Streptococcus pyogenes 308A2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.
AID289888Antibacterial activity against Streptococcus durans D2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID564525Antimicrobial activity against Acinetobacter baumannii CIP70.10 by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID523955Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E361 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID519814Inhibition of Bocillin FL binding to PBP3 in Pseudomonas aeruginosa 27853 membranes2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID524294Antibacterial activity against Pseudomonas aeruginosa P327 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529304Antimicrobial activity against Acinetobacter baumannii isolate Ac058 expressing beta-lactamase Oxa-58 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate.
AID534599Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID584574Antimicrobial activity against Acinetobacter lwoffii isolate H expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1254040Activity of Pseudomonas aeruginosa metallo-beta-lactamase VIM-2 expressed in Escherichia coli BL21(DE3) by UV-Vis spectrophotometric analysis2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Discovery of Novel Inhibitor Scaffolds against the Metallo-β-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening.
AID425098Antimicrobial activity against Anaerococcus prevotii isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID523503Antimicrobial activity against Pseudomonas aeruginosa isolate 1248c from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID499056Antimicrobial activity against carbapenem-resistant Escherichia coli PU102 deficient in TEM-1, CTX-M-14, CMY-2, aac(6')-Ib, ompC DEc, ompF by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1720999Inhibition of beta lactamase NDM1 in Klebsiella pneumoniae K66-45 assessed colony formation by visual inspection incubated for 20 hrs by two-fold dilution method2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Structural studies of triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-β-lactamases.
AID523595Antibacterial activity against Pseudomonas aeruginosa P323 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID324852Antimicrobial activity against Acinetobacter baumannii D54 by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID586086Antimicrobial activity against verocytotoxin-producing Escherichia coli isolate O157 obtained from animals and food assessed as percentage of resistant isolates by disk diffusion method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26.
AID68037Compound was evaluated for its antibacterial activity against Enterobacter cloacae P992003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID534626Antimicrobial activity against Escherichia coli assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1407977Antibacterial activity against Acinetobacter baumannii ARC3882 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID423330Antibacterial activity against Pseudomonas aeruginosa isolate 373 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID71102In vitro antibacterial activity against Escherichia coli 1507E2000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Synthesis and antibacterial activity of new carbapenems containing isoxazole moiety.
AID495679Antimicrobial activity against Pseudomonas aeruginosa OC 4352 overexpressing beta-lactamase AmpC assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID531976Antibacterial activity against Escherichia coli DH10B expressing KPC-2 CTX-M-2 by agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID521484Antibacterial activity against Escherichia coli harboring pBC633 plasmid expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID164407Compound was evaluated for antibacterial activity against Pseudomonas aeruginosa 1592E1998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID511145Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 1 assessed as zone of inhibition by disk diffusion assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID534382Antibacterial activity against Escherichia coli K-12 W1895 transconjugant harboring pCF243 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID574732Antimicrobial activity against Fusobacterium varium after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID584580Antimicrobial activity against Escherichia coli NEB 5-alpha harboring plasmid WH1266 by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID520967Antibacterial activity against Escherichia coli harboring pNYC plasmid expressing blaKPC gene by Etest method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID532902Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 365 transformant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID369640Antibacterial activity against Acinetobacter baumannii A clone expressing carbapenemase-encoding blaOXA-40 gene by Etest method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital.
AID495717Activity of Klebsiella pneumoniae SHV-1 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID562222Antimicrobial activity against Desulfovibrio desulfuricans Essex 6 by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Susceptibilities of 23 Desulfovibrio isolates from humans.
AID1442621Antibacterial activity against Pseudomonas aeruginosa PA694 in CD-1 mouse model of thigh infection assessed as reduction in log10CFU per gram of thigh at 40 mg/kg, iv bid administered 2 to 12 hrs of post-infection measured after 24 hrs relative to untreat2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID373756Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab20 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID285998Antimicrobial activity against ESBL producing Klebsiella pneumoniae 254 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID423532Antibacterial activity against Acinetobacter baumannii isolate 932 expressing OXA-24 and OXA-51 beta-lactamase after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID523569Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E476 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1188388Antibacterial activity against Acinetobacter baumannii ATCC BAA-1605 assessed as reduction in CFU at 1 ug/ml after 6 hrs by time kill assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Small-molecule suppression of β-lactam resistance in multidrug-resistant gram-negative pathogens.
AID511577Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 by broth microdilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID534669Antimicrobial activity against Prevotella denticola GAI 5490 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID372323Antibacterial activity against hypermutable Pseudomonas aeruginosa isolate 12-09-15 by CLSI broth microdilution method2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID164529Compound was evaluated for in vitro antibacterial activity against Pseudomonas aeruginosa 1771 strain by agar dilution method2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Synthesis and antibacterial activity of 2alpha-functionalized 1beta-methylcarbapenems related to KR-21012.
AID511687Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PA01 deficient in dacB gene by broth microdilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID555481Antibacterial activity against Acinetobacter genomosp. 3 isolate 14 by Etest method in presence of cloxacillin and efflux pump inhibitor CCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID423504Antibacterial activity against Acinetobacter baumannii isolate 903 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID425328Bactericidal activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID424863Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa clinical isolate assessed as resistant isolates2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID546422Antimicrobial activity against Pseudomonas aeruginosa 12B harboring recombinant pBB-PDC-2 by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID561458Antibacterial activity against Enterobacter cloacae assessed as intermediate isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID11762Stability to porcine renal DHP-I2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.
AID495745Kcat/Km ratio of Acinetobacter baumannii OXA-23 relative to Cephaloridine2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID70110Compound was evaluated for its antibacterial activity against Escherichia coli CCARM 1110 MDR2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID511148Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 4 assessed as zone of inhibition by disk diffusion assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID534903Antimicrobial activity against Citrobacter assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID574502Antimicrobial activity against Bacteroides caccae assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID425110Antimicrobial activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID495694Activity of Pseudomonas aeruginosa OXA-102010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID545350Displacement of [14C]benzylpenicillin from PBP 5 in Pseudomonas aeruginosa ATCC 156922009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID518459Antimicrobial activity against Acinetobacter baumannii HPA74510 assessed as number of passages required for MIC to rise above 4 times original MIC2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID584308Antimicrobial activity against beta-lactamase ompC intact/ompF deficient Serratia marcescens isolate YMC0583 by agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID1873910Antibacterial activity against Enterococcus faecium incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID283219Antimicrobial susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patient assessed as percent resistant isolates2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
AID522007Antimicrobial activity against Escherichia coli isolate J53 harboring pI-1 containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID529498Antimicrobial activity against Escherichia coli T-781 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID571694Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 3 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID583095Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 W87A mutant beta-lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID428245Antimicrobial activity against Enterobacteriaceae2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID528972Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID499055Antimicrobial activity against Escherichia coli PU101T expressing CMY-2 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1357459Antibacterial activity against IMP-4 producing Pseudomonas aeruginosa isolate 209471 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria.
AID534665Antimicrobial activity against Proteus mirabilis assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID295823Antibacterial activity against Enterobacter cloacae after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID529486Antimicrobial activity against Enterobacter cloacae isolate 533 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID1757512Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID555459Antibacterial activity against Acinetobacter genomosp. 3 isolate 60 by Etest method in presence of cloxacillin and efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID555471Antibacterial activity against Acinetobacter genomosp. 3 isolate 14 by Etest method in presence of efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID1883786Antibacterial activity against Mycobacterium tuberculosis in acute Mtb infection 129sv dehydropeptidase-1 KO mouse model assessed as reduction in log10 CFU administered twice daily for 6 days in presence of clavulanate2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Tuberculosis Drug Discovery: Challenges and New Horizons.
AID519797Inhibition of Bocillin FL binding to PBP1B in Escherichia coli MC4100 membranes2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1225790Antibacterial activity against Klebsiella pneumoniae KP1084 expressing KPC3/SHV-11/TEM-1 by broth microdilution method2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID523752Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E4192010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529493Antimicrobial activity against Enterobacter cloacae isolate 781 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID518516Microbicidal activity against Pseudomonas aeruginosa 527 selected after 8 times MIC compound exposure2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID523737Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E4462010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584579Antimicrobial activity against Acinetobacter lwoffii isolate M expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID523587Antibacterial activity against Pseudomonas aeruginosa P356 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523916Antibacterial activity against Acinetobacter baumannii A931 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534299Antimicrobial activity against Pseudomonas aeruginosa isolate PA510 expressing VIM-2 beta-lactamase2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID70107Compound was evaluated for its antibacterial activity against Escherichia coli ATCC 259222003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID558592Antimicrobial activity against Streptococcus pneumoniae 4 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID1407950Antibacterial activity against Pseudomonas aeruginosa ARC3727 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID285594Antimicrobial activity against Pseudomonas aeruginosa 1A9 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID508735Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring acquired beta-lactamase OXA-2 by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID535062Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pOXA-58-5 plasmid by agar dilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
AID433367Antibacterial activity against Anaerococcus tetradius isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID583653Antibacterial activity against Escherichia coli TOP102010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia.
AID530816Antibacterial activity against Escherichia coli J53 harboring plasmid-encoded beta-lactamase OXA-48 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID423490Antibacterial activity against Acinetobacter baumannii isolate 889 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID286019Antimicrobial activity against ESBL producing Escherichia coli 315 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID495913Ratio of Kcat to Km for beta-lactamase VIM-19 expressed in Escherichia coli TOP10 by spectrophotometry2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID274731Antibacterial activity against methicillin-resistant Pseudomonas aeruginosa 1771M2007Journal of natural products, Jan, Volume: 70, Issue:1
Bisindole alkaloids of the topsentin and hamacanthin classes from a marine sponge Spongosorites sp.
AID523512Antimicrobial activity against Pseudomonas aeruginosa isolate 1240 from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID117669In vivo therapeutic efficacy in systemic infections caused by Staphylococcus aureus Y-80-1953 in mice, at a single subcutaneous administration2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.
AID562751Antimicrobial activity against Escherichia coli DH5alpha harboring pBC-CTX-M-71 plasmid by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID583014Antimicrobial activity against Escherichia coli TOP10 transformed with Escherichia coli ECB2 plasmid carrying CMY-2 by agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID1906419Antibacterial activity against carbapenem resistant Pseudomonas aeruginosa ATCC BAA 1744 assessed as reduction in microbial growth incubated for 24 hrs by microbroth dilution method2022European journal of medicinal chemistry, May-05, Volume: 235Amphiphilic cyclic peptide [W
AID571924Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 26 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID584577Antimicrobial activity against Acinetobacter lwoffii isolate K expressing beta-lactamase OXA-58 isolated from blood culture of patient by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID205545Minimum inhibitory concentration against Staphylococcus aureus 503 was determined by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID286021Antimicrobial activity against ESBL producing Klebsiella pneumoniae 101 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID295821Antibacterial activity against Salmonella give after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID285984Antimicrobial activity against ESBL producing Klebsiella pneumoniae 225 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID565531Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-04 harboring A residue at 105 position in PDC- 2 by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID534647Antimicrobial activity against Non-ESBL Klebsiella pneumoniae assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID528970Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1706869Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213 measured after 16 to 18 hrs2021European journal of medicinal chemistry, Feb-15, Volume: 212Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.
AID209764Minimum inhibitory concentration against Streptococcus pyogenes 308A was determined by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID584518Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2797 harboring mutation in putative anti-anti-sigma factor by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID207312Antibacterial activity against Staphylococcus aureus SG 5112003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.
AID560833Antimicrobial activity against Acinetobacter baumannii isolate Ab2 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba92009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID206150In vitro antibacterial activity against Staphylococcus aureus 2852001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.
AID534680Antimicrobial activity against Capnocytophaga ochracea GAI 5586 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID295808Antibacterial activity against Pseudomonas aeruginosa 110/2 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID524315Antibacterial activity against Acinetobacter baumannii A851 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529481Antimicrobial activity against Enterobacter cloacae isolate 18 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID546421Antimicrobial activity against Pseudomonas aeruginosa 12B harboring recombinant pBB-PDC-1 by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID373771Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh29 by broth dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID534461Antimicrobial activity against Bacteroides fragilis ATCC 25285 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID1229260Activity of Pseudomonas aeruginosa PBP3 assessed as acylation rate constant2015ACS medicinal chemistry letters, May-14, Volume: 6, Issue:5
SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of Pseudomonas aeruginosa PBP3.
AID558328Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P286 by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID523888Antimicrobial activity against Acinetobacter baumannii 6AB11 harboring ISAba1-blaOXA-66 gene by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
AID584695Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5000 harboring wapR mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1759653Antimicrobial activity against against methicillin-sensitive Staphylococcus aureus clinical isolate 1088626 by CLSI-based broth microdilution assay2021European journal of medicinal chemistry, Jul-05, Volume: 2194-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.
AID571920Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 24 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID534391Antibacterial activity against Escherichia coli JM109 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID529579Ratio of Kcat to Km for Legionella gormanii ATCC 33297T beta-Lactamase FEZ-12008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID1706870Antibacterial activity against methicillin-resistant Staphylococcus aureus NR100 measured after 16 to 18 hrs2021European journal of medicinal chemistry, Feb-15, Volume: 212Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.
AID1780303Antibacterial activity against wild type Pseudomonas aeruginosa LESB58 assessed as reduction in bacterial growth by broth microdilution assay
AID562739Antimicrobial activity against Escherichia coli DH5[alpha] harboring pBC-CTX-M-71 plasmid by agar dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID206067Antibacterial activity against Streptococcus pyogenes 308A2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID584835Antimicrobial activity against Aeromonas allosaccharophila AL-1 expressing beta-lactamase PER6 by agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID520723Activity of Acinetobacter baumannii phenotype 1 beta-lactamase assessed per mg of protein at 100 uM2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID1318937Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 853222016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID295807Antibacterial activity against Pseudomonas aeruginosa 77/2 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID584506Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0807 harboring ampDh3 mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID285988Antimicrobial activity against ESBL producing Klebsiella pneumoniae 101 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID1559374Antibacterial activity against wild type Klebsiella pneumoniae CI 09 after 16 to 20 hrs by CLSI-based microbroth dilution method2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID519290Antimicrobial activity against Escherichia coli TOP10 harboring Beta-lactamase OXA-102 by Etest2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp.
AID523943Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E430 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523949Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E484 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1721001Synergistic Inhibition of beta lactamase VIM-2 in Pseudomonas aeruginosa K34-7 assessed colony formation by visual inspection in presence of 50 microM (5-((4-iodophenylsulfonamido)methyl)-1H-1,2,3-triazol-4-yl)methyl acetate incubated for 20 hrs by two-fo2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Structural studies of triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-β-lactamases.
AID548000Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237N mutant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID7830Tmax at a single subcutaneous administration of 40 mg/kg in mice2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Synthesis and antibacterial activity of 2alpha-functionalized 1beta-methylcarbapenems related to KR-21012.
AID532163Antimicrobial activity against aac(6')-Ib-cr-negative Escherichia coli PU12T harboring wild-type GyrA, GyrB, ParC and qnrS genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID369642Antibacterial activity against Acinetobacter baumannii C clone by Etest method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital.
AID583097Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 A64W mutant beta-lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID433181Antibacterial activity against Corynebacterium amycolatum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID534833AUC (0 to 8 hrs) in critically ill patient with sepsis at 1000 mg/kg, iv administered every 8 hrs by HPLC method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
AID584526Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3667 harboring mutation in putative cysteine sulfinate desulfinase by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1056843Antibacterial activity against CTX-15 expressing Enterobacter cloacae isolate 51 after 18 to 24 hrs by two-fold broth microdilution assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID1680059Antibacterial activity against NDM1 producing carbapenem-resistant Enterobacteriaceae clinical isolate 9 assessed as reduction in bacterial growth incubated for 16 to 20 hrs by CLSI-based broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and antibacterial bioactivities of cationic deacetyl linezolid amphiphiles.
AID547797Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237F mutant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID529485Antimicrobial activity against Enterobacter cloacae isolate 293 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID289874Antibacterial activity against Staphylococcus aureus SG5112007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID1757567Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-15 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID524085Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3522010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID518513Antimicrobial activity against Enterobacter cloacae S9369 selected after MIC of compound exposure by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID548032Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237R mutant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID373025Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU73 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID555236Antibacterial activity against Acinetobacter genomosp. 3 isolate 20 by Etest method in efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID555259Antibacterial activity against Acinetobacter genomosp. 3 isolate 90 by Etest method in presence of efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID523580Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E417 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID394680Antibacterial activity against Pseudomonas aeruginosa cystic fibrosis sputum isolate 286 carrying insertion sequence ISPa26 by disk susceptibility test2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.
AID528973Antimicrobial activity against methicillin-resistant Staphylococcus aureus assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID575016Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamaseVIM-2 by UV spectrophotometric analysis2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro potentiation of carbapenems with ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta-lactamase- producing Pseudomonas aeruginosa clinical isolates.
AID584567Antimicrobial activity against Acinetobacter lwoffii isolate A expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID584707Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0427 harboring oprM mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID520705Antibacterial activity against Acinetobacter baumannii phenotype 1 by disk diffusion method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID584561Antimicrobial activity against Acinetobacter lwoffii isolate H expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID322318Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID511579Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 deficient in ampD and ampDh3 gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID1188371Antibacterial activity against Acinetobacter baumannii ATCC BAA-1605 assessed as complete inhibition of bacterial growth after 16 hrs by microdilution method2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Small-molecule suppression of β-lactam resistance in multidrug-resistant gram-negative pathogens.
AID573797Antibacterial activity against Prevotella intermedia assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID495808Antimicrobial activity against Escherichia coli DH5alpha 2878 transformant expressing beta-lactamase VIM-19 by microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID558605Antimicrobial activity against Streptococcus pneumoniae isolate 1146 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID1757538Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-12 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID528838Antimicrobial activity against vancomycin-resistant Enterococcus sp. assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1762809Antibacterial activity against Carbapenem-resistant Pseudomonas aeruginosa assessed as reduction in bacterial growth incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID295836Antibacterial activity against Bacillus subtilis ATCC 6633 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID522641Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis Ames by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID533428Antimicrobial activity against Peptostreptococcus sp. assessed as resistant isolates by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID20775Time taken by the compound to reach maximum concentration.1998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID496553fT>MIC in Pseudomonas aeruginosa isolate 762 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 16-24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID524112Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A9312010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534438Antimicrobial activity against Clostridium clostridioforme NCTC 11224 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID545409Antimicrobial activity against Pseudomonas aeruginosa PS17B with PFGE phenotype 11D expressing beta-lactamase KPC-2 obtained from blood of ICU patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID1720996Synergistic Inhibition of beta lactamase NDM1 in Klebsiella pneumoniae K66-45 assessed colony formation by visual inspection in presence of 50 microM 2,5-Dichloro-N-((4-((cyclohexylamino)methyl)-1H-1,2,3-triazol-5-yl)methyl)benzenesulfonamide incubated fo2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Structural studies of triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-β-lactamases.
AID356635Antibacterial activity against methicillin-resistant Staphylococcus aureus Y-80-12-1999 after 18 hrs2003Journal of natural products, Nov, Volume: 66, Issue:11
New bromotyrosine derivatives from an association of two sponges, Jaspis wondoensis and Poecillastra wondoensis.
AID524416Antibacterial activity against extended spectrum beta-lactamase-producing Enterobacteriaceae clinical isolates isolated from patient with complicated intra-abdominal infection assessed as cure rate at test-of-cure visit2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID324872Antimicrobial activity against Acinetobacter baumannii C75 by broth microdilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID433190Antibacterial activity against methicillin-resistant Staphylococcus aureus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID524104Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A8922010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID390327Antimicrobial activity against linezolid-resistant methicillin-resistant Staphylococcus aureus 17252008Journal of natural products, Dec, Volume: 71, Issue:12
Citreamicins with potent gram-positive activity.
AID498830Antimicrobial activity against carbapenem-resistant Enterobacter cloacae WH103 deficient in IMP-4, TEM-1, CTX-M-3, qnrS1, ompC by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1539479Antibacterial activity against carbapenem-resistant Escherichia coli BAA-2452 clinical isolates after 18 to 20 hrs in aerobic condition by CLSI-based broth microdilution assay
AID1361173Antimicrobial activity against KPC-2 producing Klebsiella pneumoniae ATCC BAA-1705 in presence of human apo-transferrin by broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.
AID1757568Antibacterial activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumonia 15-2 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID545616Antimicrobial activity against Pseudomonas aeruginosa PS37 with PFGE phenotype 11D obtained from sputum of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID555482Ratio of MIC for Acinetobacter genomosp. 3 isolate 103 to MIC for Acinetobacter genomosp. 3 isolate 103 in presence of efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID356629Antibacterial activity against methicillin-resistant Staphylococcus aureus Y-80-12-1109 after 18 hrs2003Journal of natural products, Nov, Volume: 66, Issue:11
New bromotyrosine derivatives from an association of two sponges, Jaspis wondoensis and Poecillastra wondoensis.
AID534448Antimicrobial activity against Bifidobacterium longum subsp. longum ATCC 15707 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID1853617Antibacterial activity against Staphylococcus aureus clinical isolate 1088610 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution method2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
Design, synthesis, and antibacterial activity of
AID285157Antimicrobial susceptibility of tetracycline-resistant Streptococcus pneumoniae from respiratory tract disease patient assessed as percent susceptible isolates2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.
AID528836Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient wound assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID496517fT>MIC in Pseudomonas aeruginosa isolate 1038 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 0-8 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID523583Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E457 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID528530Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B40 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID373044Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate CY6 by CLSI agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID498837Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU8 deficient in SHV-11, DHA-1, aac(6')-Ib-cr, ompK35/36 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID563968Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase NDM-1 by Etest method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID535168Antimicrobial activity against imipenem susceptible Acinetobacter assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID545566Ratio of MIC for Escherichia coli EIR8a to MIC for Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID565523Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-12 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1311365Antibacterial activity against Enterococcus faecalis ATCC 19433 measured after 18 hrs by broth microdilution assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.
AID496544fT>MIC in Klebsiella pneumoniae isolate 357 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 16-24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID162789In vivo antibacterial activity against Pseudomonas aeruginosa 1592E1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID531767Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4682-1 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID495706Kcat/Km ratio of Escherichia coli CMY-22010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID528844Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID495666Antimicrobial activity against Klebsiella pneumoniae OC 4238 overexpressing beta-lactamase SHV-1 assessed as inhibition of growth by broth dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID396025Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing pAP1 containing Escherichia coli ampD by Etest2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID529581Ratio of Kcat to Km for Janthinobacterium lividum THIN-B2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID520982Antibacterial activity against Escherichia coli harboring pRYC plasmid expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID69018In vivo antibacterial activity against Escherichia coli 0781999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID588130Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 1 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID585435Antimicrobial activity against Pseudomonas aeruginosa PA14 mutS gene hypermutant by EUCAST method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa.
AID496548fT>MIC in Klebsiella pneumoniae isolate 375 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 16-24 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID565527Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-08 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID571429Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method in presence of 1 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID117667In vivo therapeutic efficacy in systemic infections caused by Pseudomonas aeruginosa 1771M in mice, at a single subcutaneous administration2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.
AID523539Antibacterial activity against beta-lactamase-negative Escherichia coli E347 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1361174Antimicrobial activity against SHV-4 producing Escherichia coli ATCC BAA-200 in presence of human apo-transferrin by broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.
AID535142Antimicrobial activity against imipenem susceptible Pseudomonas aeruginosa assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID285602Antimicrobial activity against Pseudomonas aeruginosa 2A5 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID529846Binding affinity to PBP2a in methicillin-resistant Staphylococcus aureus 123-1 by [14C]benzylpenicillin labelled competitive assay2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID1762807Antibacterial activity against against Escherichia coli 24 assessed as reduction in bacterial growth incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID534295Antimicrobial activity against Stenotrophomonas maltophilia KJN1 harboring ampN with xylE-Gmomega cassette insertion by Etest2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID535855Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae GZ40 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrB genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID534664Antimicrobial activity against Proteus mirabilis assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID545335Displacement of [14C]benzylpenicillin from PBP2 Staphylococcus aureus ATCC 6538P2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID545611Antimicrobial activity against Pseudomonas aeruginosa PS31 with PFGE phenotype 11B obtained from skin of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID522014Antimicrobial activity against Escherichia coli isolate J53 harboring pBEL containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID523908Antibacterial activity against Acinetobacter baumannii A892 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523911Antibacterial activity against Acinetobacter baumannii A884 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID535132Antimicrobial activity against Pseudomonas aeruginosa assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID560056Antibacterial activity against carbapenem-resistant Acinetobacter baumannii A3587 infected in Galleria mellonella caterpillar assessed as prolonged survival rate at 60 mg/kg administered as single dose2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics.
AID164579Antibacterial activity against Pseudomonas aeruginosa 1592E2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.
AID518514Microbicidal activity against Pseudomonas aeruginosa BA selected after 4 times MIC compound exposure2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID524291Antibacterial activity against Pseudomonas aeruginosa P319 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529852Antibacterial activity against beta-lactamase-overproducing and OprD-deficient Pseudomonas aeruginosa N044 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID582971Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID404956Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii T183 isolate carrying one bla-OXA58 gene copy by agar dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID523518Antimicrobial activity against Pseudomonas aeruginosa isolate 17112 from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID433364Antibacterial activity against Clostridium sphenoides isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID390325Antimicrobial activity against methicillin-resistant Staphylococcus aureus 11372008Journal of natural products, Dec, Volume: 71, Issue:12
Citreamicins with potent gram-positive activity.
AID555218Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 65 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID523717Antibacterial activity against Acinetobacter baumannii A890 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524083Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3382010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID495707Kcat/Km ratio of Pseudomonas aeruginosa AmpC2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID498361Antimicrobial activity against rifampin resistant Klebsiella pneumoniae 52deltaacrB containing isogenic acrB knockout assessed as growth inhibition by Etest method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence.
AID496571Antibacterial activity against Pseudomonas aeruginosa isolate 896 assessed as reduction of bacterial count at 16 ug/ml within 6 hrs in vitro pharmacodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID1318926Antibacterial activity against Pseudomonas aeruginosa PAO12016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1721000Inhibition of beta lactamase VIM-29 in Escherichia coli 50639799 assessed colony formation by visual inspection incubated for 20 hrs by two-fold dilution method2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Structural studies of triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-β-lactamases.
AID1559375Antibacterial activity against Klebsiella pneumoniae UMM expressing SHV5/KPC-2/TEM-1 after 16 to 20 hrs by CLSI-based microbroth dilution method2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID523915Antibacterial activity against Acinetobacter baumannii A898 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID555463Antibacterial activity against Acinetobacter genomosp. 3 isolate 67 by Etest method in presence of cloxacillin and efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID286024Antimicrobial activity against ESBL producing Klebsiella pneumoniae 265 isolate infected thigh infection model ICR mouse2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID1373286Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-3 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1757576Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-5 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID433200Antibacterial activity against Bacteroides ovatus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID534645Antimicrobial activity against Klebsiella pneumoniae assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID561273Antibacterial activity against Escherichia coli assessed as intermediate isolates by CLSI M100-S17 method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
AID1706877Antibacterial activity against methicillin-resistant Staphylococcus aureus NR10194 measured after 16 to 18 hrs2021European journal of medicinal chemistry, Feb-15, Volume: 212Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.
AID390328Antimicrobial activity against vancomycin-resistant Enterococcus faecium 700221 clinical isolate2008Journal of natural products, Dec, Volume: 71, Issue:12
Citreamicins with potent gram-positive activity.
AID564022Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring cloned pUCPOXA-161 by Etest2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID1357465Antibacterial activity against IMP-4 producing Pseudomonas aeruginosa isolate 209321 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, May-10, Volume: 151Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria.
AID498839Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae GZ66 deficient in SHV-11, DHA-1, ompK35/36 by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID522019Antimicrobial activity against Enterobacter cloacae isolate 1 expressing beta-lactamase OXA-48 and SHV-5 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID532093Antimicrobial against Pseudomonas aeruginosa 30848 harboring phoU allele by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID574508Antimicrobial activity against Bacteroides distasonis assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574780Antimicrobial activity against Clostridium difficile assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID423305Antibacterial activity against Pseudomonas aeruginosa isolate 346 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID520981Antibacterial activity against Escherichia coli harboring pNYC plasmid expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID523953Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E360 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534483Antimicrobial activity against ampN deficient Stenotrophomonas maltophilia KJ by Etest2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID423287Antibacterial activity against Pseudomonas aeruginosa isolate 323 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID584725Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3800 harboring mutation in conserved hypothetical protein by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1318922Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 262-1018562016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID555212Antibacterial activity against Acinetobacter genomosp. 3 isolate 128 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID164539Compound was evaluated for its antibacterial activity against Pseudomonas aeruginosa ATCC 278532003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID285605Antimicrobial activity against Pseudomonas aeruginosa 2F6 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID535885Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae JN41 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrB genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1757618Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-11 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID340734Antimicrobial activity against Escherichia coli HB101 harboring pBC-SK plasmid assessed as drug level at which microbial resistance was observed by agar dilution method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID565517Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-18 harboring A residue at 105 position in PDC- 3 by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID525039Activity of pseudomonas aeruginosa Beta-lactamase OXA2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Updated functional classification of beta-lactamases.
AID535839Antimicrobial activity against Pseudomonas aeruginosa GP4KT111 harboring oprD,mexAB-oprM gene after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID576320Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 31750 harboring porin OmpK36 gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID534830Cmax in critically ill patient with sepsis at 1000 mg/kg, iv administered every 8 hrs by HPLC method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
AID571212Antibacterial activity against Acinetobacter baumannii F264 by Etest method in presence of 1 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID534839Elimination half life in critically ill patient with sepsis at 1000 mg/kg, iv administered every 8 hrs by HPLC method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
AID523596Antibacterial activity against Pseudomonas aeruginosa P334 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1763150Antibacterial activity against Acinetobacter sp. 103 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI based serial dilution method2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Antibacterial and synergistic activity of 6β-hydroxy-3-oxolup-20(29)-en-28-oic acid (6β-hydroxy betunolic acid) isolated from Schumacheria castaneifolia vahl.
AID565221Activity of VIM-1 in Klebsiella pneumoniae isolate A-1797 assessed as compound hydrolysis in presence of EDTA2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID390341Antimicrobial activity against Pseudomonas aeruginosa 14732008Journal of natural products, Dec, Volume: 71, Issue:12
Citreamicins with potent gram-positive activity.
AID555222Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 195 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID582976Antimicrobial activity against ampD::lox and nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 harboring dacB gene by Etest method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID289898Antibacterial activity against Escherichia coil V6311/652007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID499054Antimicrobial activity against carbapenem-resistant Escherichia coli PU101 deficient in TEM-1, CTX-M-14, CMY-2, ompC by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID96086Compound was evaluated for its antibacterial activity against Klebsiella pneumoniae 10 ESBL2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID534303Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA4832010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID587526Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse in presence of 4 ug/ml cavulanate beta-lactamase inhibitor2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID245280Minimum inhibitory concentration against was determined against Pseudomonas aeruginosa 9027 strain2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID56139Relative t1/2 hydrolysis to meropenem by partially purified porcine renal DHP-12000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Synthesis and antibacterial activity of new carbapenems containing isoxazole moiety.
AID374361Antimicrobial activity against Escherichia coli DH5alpha expressing pJDB2 containing Aeromonas caviae A324R metallo-beta-lactamase gene by broth dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID423508Antibacterial activity against Acinetobacter baumannii isolate 907 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID555457Antibacterial activity against Acinetobacter genomosp. 3 isolate 56 by Etest method in presence of cloxacillin and efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID565514Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-21 harboring A residue at 105 position in PDC- 4 and polymorphic OprD gene by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID535173Antimicrobial activity against imipenem non-susceptible Acinetobacter assessed as resistant isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID545551Antibacterial activity against Escherichia coli ERR2b selected at 2 times MIC of tomopenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID761216Antibacterial activity against Klebsiella pneumoniae 1000-02 by broth microdilution method2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Pyridone-conjugated monobactam antibiotics with gram-negative activity.
AID558043Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S6 by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID295802Antibacterial activity against Streptococcus faecium 77A after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID524096Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A8482010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID559686Antibacterial activity against Escherichia coli Top102009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
AID565511Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-29 harboring A residue at 105 position in PDC- 8 by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID206744In vitro antibacterial activity against Staphylococcus aureus SG 285 by agar dilution method using Mueller-Hinton2000Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13
Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID574728Antimicrobial activity against Prevotella oralis assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID565522Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-13 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID523743Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E4512010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID530824Compound hydrolyzing activity of Klebsiella pneumoniae beta-lactamase OXA-482008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID534928Antimicrobial activity against Ceftazidime non-susceptible Serratia marcescens assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID532389Antibacterial activity against VIM-1 producing Enterobacter cloacae isolate TO-16X-51 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID423516Antibacterial activity against Acinetobacter baumannii isolate 915 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID584316Antimicrobial activity against beta-lactamase AmpC producing meropenem-resistant Serratia marcescens by agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID576543Antimicrobial activity against OmpK35,OmpK36-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008027 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID1873941Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs in presence of 10% foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID207180Antibacterial activity against Staphylococcus aureus 2852003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.
AID323042Antimicrobial activity against extended-spectrum-beta-lactamase producing Proteus mirabilis assessed as percent resistant isolates2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
AID1056840Antibacterial activity against CTX-15 expressing Aeromonas caviae isolate 258 after 18 to 24 hrs by two-fold broth microdilution assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID576961Antimicrobial activity against Shewanella algae Sa2 harboring intI1, intI2 and sul1 genes by CLSI method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Reservoir of antimicrobial resistance determinants associated with horizontal gene transfer in clinical isolates of the genus Shewanella.
AID678449Antibacterial activity against beta-lactam- and quinolone-resistant Pseudomonas aeruginosa 1042-062012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections.
AID523504Antimicrobial activity against Pseudomonas aeruginosa isolate 15110c from fibrosis patient by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID524075Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3352010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID571688Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 1 expressing ampC, ompA, adeB, adeM by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID404959Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii 186 isolate carrying three bla-OXA58 gene copies by agar dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID554990Antibacterial activity against Acinetobacter genomosp. 3 isolate 65 by Etest method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID565546Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-10 harboring A residue at 105 position in PDC- 2 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID564955Antimicrobial activity against Acinetobacter baumannii isolate Ab185 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba92009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID549333Antimicrobial activity against Escherichia coli isolate 36 harboring bla CTX-M-3a gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID289914Antibacterial activity against Proteus rettgeri 9362007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID558050Antimicrobial activity against blaKPC-positive Klebsiella oxytoca S13 by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID1407943Antibacterial activity against Pseudomonas aeruginosa ARC3509 after 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID518189Antimicrobial activity against Pseudomonas aeruginosa B4 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID534296Antimicrobial activity against Pseudomonas aeruginosa isolate PA477 expressing VIM-2 beta-lactamase2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID524095Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3262010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1873911Antibacterial activity against Streptococcus dysgalactiae incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID522655Antibacterial activity against beta-lactamase Bla1 and Bla2-producing Bacillus anthracis BA1007 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
AID524076Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P3192010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID56119Compound was evaluated for relative rate of hydrolysis to imipenem by partially purified porcine renal Dehydropeptidase-11998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID1233137Antibacterial activity against patient-derived methicillin-resistant Staphylococcus aureus 7425 after 18 to 20 hrs by microbroth dilution method2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors.
AID1759641Antimicrobial activity against vancomycin-resistant Enterococcus faecium clinical isolate 1091563 by CLSI-based broth microdilution assay2021European journal of medicinal chemistry, Jul-05, Volume: 2194-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.
AID499059Antimicrobial activity against carbapenem-resistant Enterobacter aerogenes PU41 deficient in CTX-M-14, DHA-1, qnrS1, ompC DEc, ompF by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID534901Antimicrobial activity against Citrobacter assessed as susceptible isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID532393Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A2 isolate NA-14X-26 by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID542585Antimicrobial activity against plasmid encoded beta-lactamase OXA-58 deficient Acinetobacter radioresistens by CLSI method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.
AID369576Antibacterial activity against multidrug-resistant Acinetobacter baumannii 06-74 isolate by CLSI microdilution test2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.
AID530325Antimicrobial activity against Pseudomonas aeruginosa PAO1 by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID574750Antimicrobial activity against Peptostreptococcus micros assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID576520Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate AIS070654 expressing KPC beta lactamase by broth microdilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID496522fT>MIC in Klebsiella pneumoniae isolate 377 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 8-16 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID510505Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-4 expressing KPC beta lactamase2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID535648Antimicrobial activity against aac(6')-Ib-cr-positive Escherichia coli FJ3 harboring GyrA S83L, ParC S80R mutant, wild-type GyrB and qnrB genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1318920Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 259-969182016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1395491Antibacterial activity against new delhi metallo-beta-lactamase-1 harboring Klebsiella pneumoniae 13-1 after 18 hrs by CLSI broth microdilution method2018European journal of medicinal chemistry, Apr-25, Volume: 150Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.
AID295798Antibacterial activity against Staphylococcus aureus giorgio after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID511154Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 10 assessed as zone of inhibition by disk diffusion assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID535666Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae FJ67 harboring wild-type GyrA S83I and qnrS genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID433183Antibacterial activity against Corynebacterium jeikeium isolated from patient with diabetic foot infection assessed as percent resistant isolates after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID1361165Antimicrobial activity against Pseudomonas aeruginosa SR24 in presence of human apo-transferrin by broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.
AID372553Antibacterial activity against genetically beta-lactamase-negative ampicillin-susceptible Haemophilus influenzae type b without amino acid substitutions in ftsI gene and bla gene assessed as susceptibility rate by broth microdilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.
AID518226Antimicrobial activity against Pseudomonas aeruginosa BA by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID574026Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID511667Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD1 harboring oprD spontaneous mutant and deficient in dacB gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID545344Displacement of [14C]benzylpenicillin from PBP6 Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID559685Antibacterial activity against Acinetobacter baumannii BM4652 harboring plasmid IP8472009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
AID511146Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 2 assessed as zone of inhibition by disk diffusion assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID574973Antimicrobial activity against Actinomyces israelii assessed as percent resistant isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID584731Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4088 harboring mutation in putative aminotransferase by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID523907Antibacterial activity against Acinetobacter baumannii A912 incubated up to 7 days by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID535864Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae GZ47T harboring qnrB gene by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID528981Antimicrobial activity against Haemophilus influenzae isolated from ICU patient blood assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID558593Antimicrobial activity against Streptococcus pneumoniae 5 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID1873894Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs using 10^7 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID574989Antimicrobial activity against Bifidobacterium adolescentis assessed as percent susceptible isolates after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID209284Antibacterial activity against Streptococcus pyogenes 77A1998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID289893Antibacterial activity against Pseudomonas aeruginosa 880/22007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID369630Antimicrobial activity against beta-lactamase positive ampicillin-resistant Haemophilus influenzae by broth microdilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
AID534888Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID289913Antibacterial activity against Proteus vulgaris 8682007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID1721004Synergistic Inhibition of beta lactamase VIM-2 in Pseudomonas aeruginosa K34-7 assessed colony formation by visual inspection in presence of 125 microM N-((4-((cyclohexylamino)methyl)-1H-1,2,3-triazol-5-yl)methyl)-4-iodobenzenesulfonamide incubated for 202020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Structural studies of triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-β-lactamases.
AID555233Antibacterial activity against Acinetobacter genomosp. 3 isolate 20 by Etest method in presence of cloxacillin and efflux pump inhibitor PAN2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID499069Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ91 deficient in CTX-M-14, ompC/F by CLSI method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID530323Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring pUCP carrying VIM-1 gene by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID423513Antibacterial activity against Acinetobacter baumannii isolate 912 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID523491Antimicrobial activity against Pseudomonas aeruginosa Z799/61 by Etest2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID558040Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S3 by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID528849Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID511133Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 72010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID521347Antimicrobial activity against Streptococcus pneumoniae isolate k-598 obtained from bronchoalveolar lavage fluid of patient2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.
AID1361171Antimicrobial activity against L-1 producing Stenotrophomonas maltophilia SR21970 in presence of human apo-transferrin by broth microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.
AID547992Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237Y mutant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID1757616Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-9 assessed as reduction in bacterial growth2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID572138Antimicrobial activity against Acinetobacter baumannii eta clonal group isolate 36 expressing ampC, ompA, adeB, adeM by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID564532Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid with entire blaAmpC gene with alanine residue deletion at 215 position by Etest method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID1539480Antibacterial activity against carbapenem-resistant Escherichia coli BAA-2469 clinical isolates after 18 to 20 hrs in aerobic condition by CLSI-based broth microdilution assay
AID372337Antibacterial activity against hypermutable Pseudomonas aeruginosa isolate 12-09-15 assessed as bacterial count in in vitro PK/PD model at 1 g infused every 8 hrs interval measured 40 hrs after first dose relative to initial inoculum2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID1596884Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS1 incubated for 16 to 18 hrs by broth microdilution assay
AID534868Antimicrobial activity against ESBL producing Proteus mirabilis assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID534922Antimicrobial activity against Serratia marcescens assessed as intermediate isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID522021Antimicrobial activity against Enterobacter cloacae isolate 2 expressing beta-lactamase OXA-48 and SHV-5 by Etest method2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID570782Antimicrobial activity against multidrug-resistant Acinetobacter baumannii assessed as resistant isolates by disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania.
AID1348997Hemolytic activity in sheep RBC after 1 hr2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and antibacterial evaluation of novel cationic chalcone derivatives possessing broad spectrum antibacterial activity.
AID1628581Antibacterial activity against Moraxella catarrhalis 1502 incubated for 18 to 24 hrs by broth microdilution method2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
Discovery and Characterization of a Class of Pyrazole Inhibitors of Bacterial Undecaprenyl Pyrophosphate Synthase.
AID1596885Antibacterial activity against methicillin-resistant Staphylococcus aureus NR10194 incubated for 16 to 18 hrs by broth microdilution assay
AID532094Antimicrobial against Pseudomonas aeruginosa 32455 harboring phzS allele by Etest method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID1417173Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS1 by CLSI method2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis of 1,2,3-triazole linked 4(3H)-Quinazolinones as potent antibacterial agents against multidrug-resistant Staphylococcus aureus.
AID372561Antibacterial activity against genetically beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b with an amino acid substitution in highly mutated locus Ser-385 of ftsI gene assessed as resistance rate by broth microdilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.
AID571395Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 0.25 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID532169Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii PU55T harboring wild-type GyrA, ParC, GyrB and qnrA genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID565549Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-13 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID565714Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-19 harboring A residue at 105 position in PDC- 3 and wild type OprD gene by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID584729Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4007 harboring proA mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID545403Antimicrobial activity against Pseudomonas aeruginosa PS10 with PFGE phenotype 1A expressing beta-lactamase KPC-2 obtained from blood of patient by agar dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID548028Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237K mutant by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID285997Antimicrobial activity against ESBL producing Klebsiella pneumoniae 255 isolate2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID517964Antimicrobial activity against Escherichia coli HB101 harboring beta-lactamase TEM-5 by broth dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID1592960Antibacterial activity against multi-drug resistant Klebsiella pneumoniae NMI 3081/09 assessed as reduction in microbial growth incubated for 20 hrs2019European journal of medicinal chemistry, Apr-15, Volume: 168Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae.
AID511288Antibacterial activity against Escherichia coli DH5alpha pB-ges-13 plasmid2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID524277Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E477 assessed as mutant prevention concentration after overnight incubation2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID496523fT>MIC in Klebsiella pneumoniae isolate 328A at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 8-16 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID323865Reversal bacterial susceptibility against methicillin-resistant Staphylococcus aureus ATCC 33591 after phagocytosis by human THP1 macrophages assessed as bacterial count in presence of 10 mM ammonium chloride after 24 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Role of acidic pH in the susceptibility of intraphagocytic methicillin-resistant Staphylococcus aureus strains to meropenem and cloxacillin.
AID529572Antimicrobial activity against Erwinia carotovora subsp. atroseptica DSM 30184 after 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID555243Antibacterial activity against Acinetobacter genomosp. 3 isolate 56 by Etest method in presence of cloxacillin2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID1188393Antibacterial activity against Pseudomonas aeruginosa PA53 assessed as reduction in CFU at 1 ug/ml after 6 hrs by time kill assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Small-molecule suppression of β-lactam resistance in multidrug-resistant gram-negative pathogens.
AID576302Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 26077 harboring porin OmpK36V mutant gene by Etest2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID558338Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1730 by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID390326Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus 20122008Journal of natural products, Dec, Volume: 71, Issue:12
Citreamicins with potent gram-positive activity.
AID574738Antimicrobial activity against Fusobacterium mortiferum after 48 hrs by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID534427Antimicrobial activity against Anaerococcus prevotii ATCC 9321 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID574033Antibacterial activity against beta-lactamase producing Micromonas micros assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID529492Antimicrobial activity against Enterobacter cloacae isolate 658 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID532199Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae WH42T harboring qnrA gene by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1628585Antibacterial activity against Escherichia coli 120 deficient in AcrAB incubated for 18 to 24 hrs by broth microdilution method2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
Discovery and Characterization of a Class of Pyrazole Inhibitors of Bacterial Undecaprenyl Pyrophosphate Synthase.
AID423527Antibacterial activity against Acinetobacter baumannii isolate 926 after 24 hrs by CLSI microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID433366Antibacterial activity against Anaerococcus prevotii isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID584520Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3145 harboring wbpL mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID529664Ratio of Kcat to Km for Pseudomonas aeruginosa 166301 beta-lactamase VIM-16 relative to cephaloridine2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID1759657Antimicrobial activity against against methicillin-resistant Staphylococcus aureus clinical isolate 1089106 by CLSI-based broth microdilution assay2021European journal of medicinal chemistry, Jul-05, Volume: 2194-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.
AID496535fT>MIC in Pseudomonas aeruginosa isolate 1177 at 2 gram for every 8 hrs administered as 3 hrs infusion measured over 8-16 hrs in in vitro pharmcodynamic model2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
AID547769Antimicrobial activity against Escherichia coli DH10B harboring plasmid pBC SK(+) carrying wild type beta-lactamase KPC-2 by agar dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID201742In vitro antibacterial activity against SG 621 strain of Serratia marcescens2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.
AID1721006Synergistic Inhibition of beta lactamase NDM1 in Klebsiella pneumoniae K66-45 assessed colony formation by visual inspection in presence of 125 microM N-((4-((adamantylamino)methyl)-1H-1,2,3-triazol-5-yl)methyl)-4-iodobenzenesulfonamide incubated for 20 h2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Structural studies of triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-β-lactamases.
AID499159fAUC (0-infinity) in immunocompromized SKH1 mouse plasma at 12.5 mg/kg, sc2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
AID289910Antibacterial activity against Serratia marcescens 142732007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID529490Antimicrobial activity against Enterobacter cloacae isolate 354 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID565199Antimicrobial activity against Klebsiella pneumoniae isolate T-1780 expressing VIM-1 and KPC-2 genes by microdilution method2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID584726Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3818 harboring suhB mutant gene by Etest method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID295816Antibacterial activity against Escherichia coli 1507 after 18 to 24 hrs by agar dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID289905Antibacterial activity against Klebsiella pneumonise 4772007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID571902Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 15 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID558326Antibacterial activity against bla gene-negative and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P1962 by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID565524Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-11 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID583028Antimicrobial activity against Escherichia coli TOP10 transformed with Escherichia coli pGLK-1 plasmid carrying FOX-1 by agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID226084DHP-I stability of compound relative to t1/2 of hydrolysis to meropenem2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.
AID509869Antibacterial activity against Acinetobacter baumannii isolate 4860 isolated from human urine2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID546619Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-18 by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID576953Antimicrobial activity against Shewanella putrefaciens Sp95 harboring intI1,sul1,sul2 and beta-lactamase OXA-48 like genes by CLSI method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Reservoir of antimicrobial resistance determinants associated with horizontal gene transfer in clinical isolates of the genus Shewanella.
AID519809Inhibition of Bocillin FL binding to PBP5/6 in Pseudomonas aeruginosa PAO1 membranes2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID572120Antimicrobial activity against Acinetobacter baumannii lambda clonal group isolate 27 expressing ampC, ompA, adeB, adeM, aadB, aadA1 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID532172Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae SH39 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrA genes by agar dilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID495747Inhibition of Pseudomonas aeruginosa AmpC assessed as inhibition of nitrocefin hydrolysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,643)

TimeframeStudies, This Drug (%)All Drugs %
pre-199038 (1.04)18.7374
1990's391 (10.73)18.2507
2000's810 (22.23)29.6817
2010's1552 (42.60)24.3611
2020's852 (23.39)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials284 (7.47%)5.53%
Reviews219 (5.76%)6.00%
Case Studies631 (16.59%)4.05%
Observational61 (1.60%)0.25%
Other2,608 (68.58%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (161)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomised Controlled Trial of Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Due to Enterobacteriaceae Showing Resistance to Third Generation Cephalosporins [NCT04478721]Phase 3334 participants (Anticipated)Interventional2020-12-15Recruiting
How to Optimize the Combined Antibiotic Therapy for Carbapenem Resistant Klebsiella Pneumoniae [NCT03950544]Early Phase 180 participants (Anticipated)Interventional2019-01-01Recruiting
A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Versus Meropenem in Pediatric Subjects With Complicated Urinary Tract Infection, Including [NCT03230838]Phase 2134 participants (Actual)Interventional2018-04-26Completed
A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Pediatric Subjects With Complicated Intra-Abdominal [NCT03217136]Phase 294 participants (Actual)Interventional2018-04-03Completed
An Open-label, Randomized Equivalence Trial and Cost-effectiveness Analysis of Ertapenem Versus Other Carbapenems for Treatment of Extended -Spectrum Beta-Lactamase (ESBL)-Producing Gram-negative Bacterial Infections [NCT01297842]Phase 4100 participants (Anticipated)Interventional2011-05-31Recruiting
A Multicenter, Randomized, Double-blind, Parallel-group, Clinical Study of S-649266 Compared With Meropenem for the Treatment of Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, or Healthcare-associated Bacterial Pneumonia [NCT03032380]Phase 3300 participants (Actual)Interventional2017-10-24Completed
The Effect of Colistin Inhalation on the Clinical Outcome of Patients With Ventilator Associated Pneumonia [NCT03622450]Phase 2/Phase 340 participants (Actual)Interventional2016-01-02Completed
A suPAR Guided Double-blind Randomized Clinical Trial of Initiation of Antibiotics for Presumed Infection at the Emergency Department [NCT03717350]Phase 2/Phase 3220 participants (Anticipated)Interventional2018-10-27Recruiting
Pharmacokinetics/Pharmacodynamics and Clinical Outcomes of β-lactams in Critically Ill Patients [NCT03858387]102 participants (Anticipated)Observational2018-09-01Recruiting
Randomized, Open Label, Multicenter, Non-inferiority Trial to Compare Safety and Efficacy of Colistin vs. Meropenem in VAP Caused by CR-GNB [NCT01292031]Phase 3232 participants (Actual)Interventional2012-05-31Completed
A Phase 3, Randomized, Double-blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-zidebactam vs. Meropenem in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults [NCT04979806]Phase 3528 participants (Anticipated)Interventional2022-08-28Recruiting
Population Pharmacokinetics of Anti-infective Drugs in Children in Anti-infectious Therapies [NCT03113344]800 participants (Anticipated)Observational [Patient Registry]2017-06-21Recruiting
A Phase 2 Trial to Evaluate the Early Bactericidal Activity and Safety of Meropenem With Amoxicillin/Clavulanate Plus Either Pyrazinamde or Bedaquiline in Adults With Newly Diagnosed Rifampicin-susceptible Pulmonary Tuberculosis [NCT04629378]Phase 222 participants (Actual)Interventional2020-08-17Completed
Efficacy and Pharmacokinetics of Meropenem in Different Administration for Patients With Severe Sepsis [NCT03645668]Phase 480 participants (Actual)Interventional2018-01-30Completed
Continuous Infusion Versus Intermittent Administration of Meropenem in Critically Ill Patients: A Multicenter Randomized Double Blind Trial [NCT03452839]Phase 4607 participants (Actual)Interventional2018-06-05Completed
Pharmacokinetics of Meropenem During High-dose Continuous Renal Replacement Therapy in Critically Ill Patients [NCT03507751]19 participants (Actual)Observational2018-04-02Completed
A Randomized, Placebo- and Positive-Controlled, Crossover Study to Evaluate the Effect of Meropenem-Vaborbactam on the QT/QTc Interval in Healthy Volunteers [NCT03564158]Phase 153 participants (Actual)Interventional2018-05-01Completed
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
What Duration of Intravenous Antibiotic Therapy Should be Used in the Treatment of Infective Exacerbations of Cystic Fibrosis Chronically Colonised With Pseudomonas Aeruginosa [NCT01044719]Phase 4240 participants (Anticipated)Interventional2010-01-31Not yet recruiting
An Investigator Initiated, Phase II Single-Center, Randomized, Open-Label, Prospective, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftolozane-Tazobactam Plus Vancomycin, Linezolid Versus Standard of Care Plus Vancomycin, Lin [NCT03485950]Phase 2100 participants (Actual)Interventional2018-05-16Completed
A Pilot Study for Optimizing Meropenem Administration in the Intensive Care Unit - Short Six Times vs Prolonged Three Times Courses Daily [NCT05578586]50 participants (Anticipated)Interventional2021-12-14Recruiting
Optimisation, Valorisation and Application of UPLC-MS/MS Based Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients - Part 3: Non-blank Sputum Samples for Method Optimisation and Validation [NCT02840136]40 participants (Actual)Interventional2016-02-29Terminated(stopped due to Lack of staff)
A Non-Randomized, Open Label, One Treatment, One Group Study to Investigate the Intrapulmonary Lung Penetration of RO7079901 in Healthy Volunteers [NCT03182504]Phase 121 participants (Actual)Interventional2017-06-15Completed
Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy [NCT04370145]Phase 4160 participants (Actual)Interventional2021-05-01Completed
A Phase III, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-Tazobactam vs. Meropenem Followed by Optional Oral Therapy in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephrit [NCT03630081]Phase 31,004 participants (Anticipated)Interventional2024-01-31Not yet recruiting
Efficacy and Safety of the Administration of Betalactam Antibiotics in Continuous or Extended Infusion Compared to Intermittent Infusion in Patients With Sepsis in Two Pediatric Third-level Care Hospitals [NCT03019965]426 participants (Actual)Interventional2017-02-01Completed
Population Pharmacokinetics of Meropenem and Linezolid in Children With Severe Infectious Diseases [NCT03643497]800 participants (Anticipated)Observational [Patient Registry]2018-07-01Recruiting
Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy in Biliary Atresia: a Randomized Controlled Trial [NCT05925309]356 participants (Anticipated)Interventional2023-07-01Recruiting
Randomized Controlled Trial of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Due to Ceftriaxone Non-susceptible E. Coli and Klebsiella Species. [NCT02176122]Phase 4391 participants (Actual)Interventional2014-02-28Terminated(stopped due to Secondary to third interim analysis by the study DSMB.)
COMPARING THE OUTCOME IN PATIENTS OF ACUTE PANCREATITIS, WITH AND WITHOUT PROPHYLACTIC ANTIBIOTICS. [NCT02212392]Phase 1/Phase 290 participants (Actual)Interventional2013-01-31Completed
Randomized, Double-blind, Double-dummy, Active-controlled, Multi-centre Trial to Compare the Efficacy and Safety of CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) With Meropenem in Infections Caused by β-Lactamase (ESBL and MBL) Producing Gram-Negative Bacteria [NCT03477422]Phase 3230 participants (Actual)Interventional2014-01-11Completed
Bacterial Load Guided Therapy for Severe Exacerbations of Bronchiectasis Requiring IntraVenous Antibiotic Therapy- BLT Br IV Study [NCT02047773]Phase 490 participants (Actual)Interventional2014-01-31Completed
Is Combination Antibiotic Therapy Superior to Monotherapy in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease [NCT04879030]Phase 2/Phase 3170 participants (Actual)Interventional2020-01-01Completed
An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial Infections [NCT02687906]Phase 167 participants (Anticipated)Interventional2016-07-31Recruiting
Computer-basierte Dosierungsregime Von Antiinfektiva Bei eingeschränkter Nierenfunktion Und Kontinuierlichen Nierenersatztherapieverfahren (Computer-based Dosage Calculation for Antibiotics in Patients With Impaired Renal Function or Renal Replacement The [NCT03036826]0 participants (Actual)Observational2019-06-30Withdrawn(stopped due to due to organisational changes)
Рrospective Multicenter Randomized 3 Phase Study Evaluating the Role of Prolonged Antibiotic Prophylaxis as a Measure to Reduce the Incidence of Postoperative Complications After Radical Cystectomy With ERAS Protocol [NCT05392634]Phase 398 participants (Anticipated)Interventional2022-02-02Recruiting
Population Pharmacokinetics and Pharmacodynamics of Beta-lactams of Interest in Adult Patients From Intensive Care Units [NCT03440216]20 participants (Anticipated)Interventional2018-03-15Recruiting
Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With Fever of Unknown Origin: a Randomized Multicenter Non-inferiority Trial. [NCT02149329]Phase 4276 participants (Actual)Interventional2014-12-31Completed
Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single- and Multiple-Ascending Doses of Intravenous ANT3310 Alone and in Combination With Meropenem in Healthy Subjects [NCT05905913]Phase 172 participants (Anticipated)Interventional2023-04-12Recruiting
To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase - A Randomized Controlled Study [NCT02788240]14 participants (Actual)Interventional2016-05-01Terminated
Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia [NCT03108690]Phase 40 participants (Actual)Interventional2017-10-01Withdrawn(stopped due to Logistics)
Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic Urinary Tract Infections Due to Extended-spectrum β-lactamase (ESBL)-Producing Escherichia Coli or Klebsiella Pneumoniae - (CAPITIS Study) [NCT03891433]Phase 4198 participants (Anticipated)Interventional2019-04-01Recruiting
The Role of Second-generation Sequencing in the Treatment of Severe Pneumonia With Initial Treatment Failure [NCT03884881]400 participants (Actual)Interventional2018-01-01Active, not recruiting
A Study the Population Pharmacokinetics of Children Receiving the Anti-infective Drugs for Treatment of Infectious Disease in Central Nervous System [NCT03960905]800 participants (Anticipated)Observational2019-01-01Recruiting
Pharmacokinetic Study of Extended Infusion Meropenem in Adult Cystic Fibrosis Patient With Exacerbation of Pulmonary Infection [NCT01158937]2 participants (Actual)Interventional2010-05-31Terminated(stopped due to Inadequate enrolment and lack of resources)
Efficacy and Safety of Antibiotics in the Treatment of Early Onset Neonatal Sepsis [NCT03932123]500 participants (Anticipated)Observational2019-05-05Recruiting
A Multicentre, Parallel Group Open-label Randomised Controlled Non-Inferiority Phase 3 Trial, of Ceftolozane-tazobactam Versus Meropenem for Definitive Treatment of Bloodstream Infection Due to Extended-Spectrum Beta-Lactamase (ESBL) and AmpC-producing En [NCT04238390]Phase 30 participants (Actual)Interventional2022-01-31Withdrawn(stopped due to The decision to withdraw the study was made due to delayed logistics of the supply chain of ceftolozane-tazobactam along with the immense complexities of conducting clinical research felt because of the COVID-19 pandemic.)
Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial [NCT05977868]Phase 4135 participants (Anticipated)Interventional2023-08-04Enrolling by invitation
A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study to Assess the Efficacy, Safety and Tolerability of Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Intensive Phase Therapy of Melioidosis in Hospitalized Pa [NCT05105035]Phase 2100 participants (Anticipated)Interventional2022-06-14Recruiting
Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Haematologic Patients: a Randomised, Multicentre, Open-label, Superiority Clinical Trial (BEATLE) [NCT04233996]Phase 4150 participants (Anticipated)Interventional2019-06-05Recruiting
Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia [NCT05102162]Phase 435 participants (Actual)Interventional2021-12-17Terminated(stopped due to Low recruitment.)
Alterations of Glycocalyx in Critical Illness and During Major Surgery and Approaches for Glycocalyx Protection [NCT03136796]20 participants (Actual)Observational2017-05-02Completed
Single- and Multiple-dose Pharmacokinetics of Meropenem in Spontaneous Bacterial Peritonitis and Liver Cirrhosis [NCT03571711]15 participants (Anticipated)Observational2018-06-28Recruiting
Bolus Versus Prolonged Infusion of Meropenem in Newborn With Late Onset Sepsis: A Randomized Control Trial [NCT02503761]Phase 3100 participants (Actual)Interventional2013-08-31Completed
Target Attainment and Pharmacokinetics of Antimicrobials in Non-critically Ill Surgery Patients [NCT03120663]120 participants (Anticipated)Observational2016-11-30Recruiting
First Dose Pharmacokinetics for Piperacillin and Meropenem in ICU Patients [NCT05134298]50 participants (Anticipated)Observational2019-11-01Recruiting
Prospective Unblinded Randomized Trial to Examine Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia [NCT02463747]Phase 4110 participants (Anticipated)Interventional2015-06-30Not yet recruiting
A Multi-centre Study to Define Novel Individualised Dosing Regimens to Maximise Antibiotic Effectiveness for Treatment of Pneumonia in Intensive Care Units [NCT04986254]80 participants (Anticipated)Observational2019-10-17Recruiting
Phase 3, Randomized, Controlled Multicentric, Open-label Clinical Trial to Prove Non-Inferiority of Fosfomycin vs Meropenem or Ceftriaxone in the Treatment of Bacteriemic Urinary Infection Due to Multidrug Resistance in E.Coli [NCT02142751]Phase 3161 participants (Actual)Interventional2014-07-31Completed
Antibiotic Dosing in Pediatric Intensive Care [NCT02456974]640 participants (Anticipated)Observational [Patient Registry]2012-05-31Recruiting
A Non-Randomized, Open-Label, One Treatment, One Group Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Patients With a Complicated Urinary Tract Infection [NCT03174795]Phase 120 participants (Actual)Interventional2017-07-11Completed
Cefiderocol and Ampicillin-sulbactam vs. Colistin or Colistin-meropenem for Carbapenem Resistant Acinetobacter Baumannii Bacteremia or Hospital-acquired Pneumonia: Controlled Clinical Study With Historical Controls (CASCADE) [NCT05922124]Phase 4734 participants (Anticipated)Interventional2024-01-31Not yet recruiting
Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of Injectable TQD3606 in a Single Center, Randomized, Double-blind, Placebo-controlled, Single, Multiple Dosing in Healthy Subjects, and to Explore Urinary Ex [NCT05340530]Phase 156 participants (Anticipated)Interventional2022-04-30Not yet recruiting
A Multicenter, Randomized, Double Blind, Comparative Trial of Intravenous MERREM (Meropenem, ICI 194,660) vs PRIMAXIN I.V. (Imipenem-cilastatin) in the Treatment of Hospitalised Subjects With Complicated Skin and Skin Structure Infections. [NCT00619710]Phase 31,000 participants (Anticipated)Interventional2001-02-28Completed
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs [NCT04278404]5,000 participants (Anticipated)Observational2020-03-05Recruiting
Temocillin Versus a Carbapenem as Initial Intravenous Treatment for Extended-spectrum Beta-lactamase Related Urinary Tract Infections, a Non-inferiority Study [NCT03543436]Phase 329 participants (Actual)Interventional2019-01-04Completed
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections [NCT02784704]Phase 3500 participants (Actual)Interventional2016-10-13Completed
Dose Optimization by PK/PD of Antibiotics to Improve Clinical Outcome of CRKP Bloodstream Infections in Critically Ill Patients and in Vitro Study of Monotherapy, Combination Therapy and Molecular Biology of Drug Resistance at Phramongkutklao Hospital: Pr [NCT05862402]Phase 476 participants (Anticipated)Interventional2023-05-07Recruiting
Antibiotic Pharmacokinetics in Critically Ill Patients [NCT02609646]1,500 participants (Actual)Observational2016-01-31Completed
Prospective Study Evaluating Plasma Exposure of Optimized Antibiotic Therapy According to TDM in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC) [NCT04132115]104 participants (Anticipated)Observational2019-10-01Recruiting
A Multicentre, Randomised, Double-blind, Placebo-controlled, Study on the Use of Prophylactic Meropenem Therapy in Subjects With Severe Acute Necrotizing Pancreatitis [NCT00061438]Phase 4240 participants Interventional2003-02-28Completed
Monitoring of Piperacillin-Tazobactam and Meropenem Plasmatic Levels in Critical Patients [NCT04257838]200 participants (Anticipated)Observational2020-02-15Not yet recruiting
Validation of Uncertainty Quantifying Machine Learning Models to Predict Beta-lactam Antimicrobial Concentrations in ICU Patients [NCT06026852]600 participants (Anticipated)Interventional2023-12-20Not yet recruiting
The Pharmacodynamics of Meropenem in Patient With Ventilator-associated Pneumonia [NCT02615041]Phase 49 participants (Actual)Interventional2004-01-31Completed
A Randomised Controlled Crossover Pilot Study of Meropenem Standard 30 Minute Infusion Versus Prolonged 3 Hour Infusion in Intensive Care Patients [NCT00891423]10 participants (Actual)Interventional2009-04-30Completed
Pharmacokinetics and Pharmacodynamic (PK/PD) of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock [NCT02820987]Phase 3129 participants (Anticipated)Interventional2016-09-01Recruiting
Randomized, Multicenter, Phase III, Controlled Clinical Trial, to Demonstrate the no Inferiority of Reduced Antibiotic Treatment vs a Broad Spectrum Betalactam Antipseudomonal Treatment in Patients With Bacteremia by Enterobacteriaceae [NCT02795949]Phase 3344 participants (Actual)Interventional2016-10-31Completed
A Prospective, Multicenter, Double-blind, Randomized, Comparative Study to Estimate the Safety, Tolerability and Efficacy of NXL104/Ceftazidime Plus Metronidazole vs. Meropenem in the Treatment of Complicated Intra-abdominal Infections in Hospitalized Adu [NCT00752219]Phase 2204 participants (Actual)Interventional2009-03-31Completed
Development of a Method to Extract Interstitial Lung Fluid and Epithelial Lining Fluid for Antibiotic Concentration Measurement in Explanted Lung Tissue (Feasibility Study) [NCT03970265]30 participants (Actual)Observational2019-08-15Completed
A Phase 3 Study to Evaluate Cefepime-taniborbactam Compared to Meropenem in Adults With Ventilator Associated Bacterial Pneumonia (VABP) or Ventilated Hospital Acquired Bacterial Pneumonia (vHABP) [NCT06168734]Phase 3316 participants (Anticipated)Interventional2023-12-31Not yet recruiting
A Phase 2a Study of the Early Bactericidal Activity of Rifampin (RIF) in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampin-resistant or Rifampin-susceptible Pulmonary Tuberculosis [NCT03174184]Phase 2112 participants (Actual)Interventional2017-08-23Completed
Escalade or Deseacalade Antibiotic Use in Severe Acute Pancreatitis [NCT01992198]Phase 460 participants (Anticipated)Interventional2012-07-31Recruiting
Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units [NCT02213796]Phase 49 participants (Actual)Interventional2013-01-31Completed
A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis [NCT00579956]750 participants (Anticipated)Interventional2007-12-31Recruiting
A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Meropenem in Hospitalized Children With Complicated Intra-Abdominal Infections [NCT01110382]Phase 341 participants (Actual)Interventional2010-12-31Terminated(stopped due to Trial terminated early per business decision)
Population Pharmacokinetics and Dosage Individualization of Biapenem,Meropenem,Piperacillin and Tazobactam,Tigecycline,Levofloxacin .Etc in Elderly Patients Who Was Hospitalized in Intensive Care Unit [NCT04799626]500 participants (Anticipated)Observational [Patient Registry]2021-04-01Recruiting
The Immunoadsorption Effect of Arterio-venous ECMO in Refractory Septic Shock With ARDS Following Severe Lung Contusion [NCT04555798]Phase 1/Phase 2100 participants (Actual)Interventional2022-02-01Completed
A Multicenter, Double-Blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA 101/ Tazobactam and Metronidazole With That of Meropenem in Complicated Intraabdominal Infections [NCT01147640]Phase 2122 participants (Actual)Interventional2010-06-25Completed
Piperacillin Tazobactam Versus Meropenem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae- a Non-inferiority Randomized Controlled Trial [NCT03671967]Phase 41,084 participants (Anticipated)Interventional2019-05-01Recruiting
Treatment of 21st Century Typhoid Fever in Children;Open Label Mono vs Combination Drug Therapy [NCT04154722]Phase 4126 participants (Actual)Interventional2019-06-20Completed
Prospective, Randomized, Open, Multicentre Study About the Effect of an Empirical Antibiotic Monotherapy With Meropenem (Meronem®) Versus a Combination Therapy With Moxifloxacin (Avalox®) on Organ Dysfunction in Patients With Severe Sepsis and Septic Shoc [NCT00534287]Phase 3600 participants (Actual)Interventional2007-10-31Completed
An Investigator Initiated, Phase IV Single-Center, Randomized, Open-Label, Prospective Study to Determine the Impact of Serial Procalcitonin on Improving Antimicrobial Stewardship and on the Efficacy, Safety, and Tolerability of Imipenem - Relebactam Plus [NCT04983901]Phase 2100 participants (Actual)Interventional2021-09-14Active, not recruiting
Fast-track Absolute Neutrophil Count in Suspected Neutropenic Fever (The FRANCiS-NF Trial): A Single-centre, Pragmatic, Open-label, Randomised, Controlled Trial [NCT05393505]Phase 4344 participants (Anticipated)Interventional2022-10-24Recruiting
A Phase 3, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK0826 and Meropenem in Patients With Complicated Urinary Tract Infection [NCT00771316]Phase 36 participants (Actual)Interventional2008-12-31Terminated(stopped due to feasibility and low enrollment)
Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (EMPRESS) Trial [NCT06184659]Phase 45,800 participants (Anticipated)Interventional2024-03-01Not yet recruiting
Translational PKPD Modeling of Anti-infective Drugs in Children Treated in Pediatric Units on the Example of Selected Antibiotics and Antifungals. [NCT05426499]150 participants (Anticipated)Observational2021-10-01Active, not recruiting
Appropriate Antimicrobial Therapy in Critical Care: A Pilot Randomized Controlled Trial [NCT00438269]Phase 280 participants Interventional2003-02-28Completed
MERONEM: Observational Study About Efficacy of Meropenem in Comparison of Meropenem and Glycopeptide in Treatment of Neutropenia Febrile in Allogenic Blood Stem Cell Transplantation Patients [NCT00462878]392 participants (Anticipated)Observational2002-11-30Completed
Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged Ventilation [NCT06072222]Phase 1/Phase 2200 participants (Actual)Interventional2020-07-02Completed
Meropenem vs Cefotaxime as Empirical Treatment of Spontaneous Bacterial Peritonitis :Prospective Randomized Clinical Trial [NCT05427747]Phase 4286 participants (Anticipated)Interventional2023-01-01Not yet recruiting
Randomized, Multi-Center, Comparative Trial of Short-Course Empiric Antibiotic Therapy Versus Standard Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the Intensive Care Unit (ICU): Impact on Antimicrobial Resistance, Superinfections, Length [NCT00307099]Phase 3460 participants (Anticipated)Interventional2006-10-31Terminated
A Phase IIIb, Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in the Treatment of Hospital-Acquired Bacterial Pneumonia and Ventilator-Asso [NCT03006679]Phase 30 participants (Actual)Interventional2018-08-31Withdrawn(stopped due to Sponsor Decision)
Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis [NCT00318994]Phase 46 participants Interventional2002-02-28Completed
Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients [NCT03344627]76 participants (Actual)Interventional2017-11-27Completed
Antibiotic Concentrations in Serum and Epithelial Lining Fluid Under Continous Infusion [NCT00435305]40 participants (Anticipated)Observational2006-11-30Terminated(stopped due to difficulties by enrolling patients fundings consumed, no staff could be recruited and payed to continue enrolling patients,)
Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age (Inclusive) With Clinical or Confirmed Late-onset Sepsis : a European Multicenter Randomised Phase III Trial [NCT01551394]Phase 3272 participants (Actual)Interventional2012-09-30Completed
Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age (Inclusive) With Probable and Confirmed Meningitis: A European Multicenter Phase I-II Trial [NCT01554124]Phase 1/Phase 251 participants (Actual)Interventional2013-02-28Completed
Impact of Aggressive Empiric Antibiotic Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Ventilator-associated Pneumonia [NCT00050401]Phase 3500 participants Interventional2002-07-31Completed
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of RO7079901 Administered Intravenously Both Alone and in Combination With Meropenem in Adult Healthy Volunteers [NCT02972255]Phase 146 participants (Actual)Interventional2016-10-31Completed
Standard vs. Biofilm Susceptibility Testing in CF [NCT00153634]75 participants (Actual)Interventional2004-03-31Completed
Randomized, Multi-Center, Comparative Trial of Short-Course Empiric Antibiotic Therapy Versus Standard Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the Intensive Care Unit (ICU) [NCT00410527]Phase 40 participants Interventional2006-08-11Completed
A Study to Assess the Safety, Tolerability and Preliminary Efficacy of GSK2251052 in the Treatment of Complicated Intra-abdominal Infection in Adults [NCT01381562]Phase 215 participants (Actual)Interventional2011-10-03Terminated(stopped due to Microbiological findings of resistance on therapy in patients with complicated urinary tract infection)
The Effect of Gut Sterilisation on Macrophage Activation in Patients With Alcoholic Hepatitis. [NCT03157388]15 participants (Actual)Interventional2017-06-01Completed
Clinical Evaluation of a Meropenem Dosage Strategy Based on a Population Pharmacokinetic-pharmacodynamic Model in Lower Respiratory Tract Infection Patients [NCT01944319]Phase 479 participants (Actual)Interventional2013-07-31Completed
Antidote for Valproic Acid Toxicity: a New Indication for Meropenem Antibiotic. A Randomized Placebo-controlled Trial [NCT04671589]Phase 448 participants (Anticipated)Interventional2021-06-30Not yet recruiting
Phase 2 Trial to Evaluate the Early EBA, Safety and Tolerability of Amoxicillin/Clavulanate With or Without Meropenem, Ertapenem or Rifampicin in Adults With Newly Diagnosed, Smear-Positive Rifampicin-Susceptible Pulmonary Tuberculosis [NCT05896930]Phase 2134 participants (Actual)Interventional2017-11-09Completed
Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients. An Open, Randomized Multi-center Study. [NCT00318552]Phase 4160 participants Interventional2002-01-31Completed
Eradication of Gut Microbiota - Effects on Postprandial Gut Hormone Secretion, Glucose Metabolism, Bone Metabolism and Gut Microbiome [NCT01633762]Early Phase 112 participants (Actual)Interventional2012-04-30Completed
Continuous-infusion Anti-pseudomonal β-lactams for the Treatment of Acute, Infective Pulmonary Exacerbations in Cystic Fibrosis [NCT01667094]Phase 450 participants (Actual)Interventional2012-09-30Active, not recruiting
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects [NCT05226923]Phase 1123 participants (Actual)Interventional2022-01-12Completed
Nosocomial Infections in Patients With Acute Respiratory Distress Syndrome Treated With Extracorporeal Membrane Oxygenation [NCT05566665]200 participants (Anticipated)Observational2023-01-01Recruiting
Multicenter Open-label RCT to Compare Colistin Alone vs. Colistin Plus Meropenem [NCT01732250]Phase 4406 participants (Actual)Interventional2013-03-31Completed
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous FL058 and Meropenem Alone and in Combination in Healthy Chinese Subjects [NCT05058105]Phase 140 participants (Actual)Interventional2020-10-08Completed
A Phase 3, Randomized, Double-blind, Active Controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis [NCT03840148]Phase 3661 participants (Actual)Interventional2019-08-07Completed
A Randomized Controlled Trial to Evaluate Fibrin Glue Application in the Treatment of Low-Output Enterocutaneous Fistulas [NCT01828892]30 participants (Anticipated)Interventional2014-03-31Recruiting
Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged Ventilation [NCT04553367]Phase 1/Phase 2200 participants (Actual)Interventional2020-07-02Completed
Piperacillin-tazobactam and Temocillin as Carbapenem-alternatives for the Treatment of Severe Infections Due to Extended-spectrum Beta-lactamase-Producing Gram-negative Enterobacteriaceae in the Intensive Care Unit [NCT05565222]Phase 3600 participants (Anticipated)Interventional2023-03-11Recruiting
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE) [NCT02168946]Phase 377 participants (Actual)Interventional2014-07-31Completed
Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged Ventilation [NCT06072248]Phase 1/Phase 2200 participants (Actual)Interventional2020-07-02Completed
Pilot RCT of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC Beta-lactamase Producing Enterobacter Spp., Citrobacter Freundii, Morganella Morganii, Providencia Spp. or Serratia Marcescens. in Low- [NCT02437045]Phase 4100 participants (Anticipated)Interventional2015-04-30Completed
A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam Compared With Meropenem in Adult Patients With Ventilated Nosocomial Pneumonia [NCT02070757]Phase 3726 participants (Actual)Interventional2014-09-02Completed
A Phase 3, Multicenter, Double-blind, Randomized, Active-controlled Clinical Study to Evaluate the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Chinese Participants With Complicated Intra-abdominal Infect [NCT03830333]Phase 3268 participants (Actual)Interventional2019-03-20Completed
Pharmacokinetics of Meropenem in Patients on Plasma Exchange [NCT05042271]15 participants (Anticipated)Observational2020-01-01Recruiting
TAID Study - A Prospective Interventional Trial on Antibiotics Continuous Infusion at Home [NCT04816968]Phase 150 participants (Anticipated)Interventional2021-09-30Not yet recruiting
A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Efficacy and Safety of Intravenous CXA-201 With That of Meropenem in Complicated Intraabdominal Infections [NCT01445678]Phase 3494 participants (Actual)Interventional2011-12-23Completed
Conservative Treatment of Acute Appendicitis in Children Pilot Trial [NCT01572558]51 participants (Actual)Interventional2012-02-29Completed
Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis: an Open, Randomized, Controlled Clinical Trial [NCT01455246]Phase 2/Phase 332 participants (Actual)Interventional2010-10-31Terminated(stopped due to Decision of independent monitoring committee after interim analysis: Risk of failure significantly higher in ceftazidime group.)
Population Pharmacokinetics of Commonly Used Antimicrobial Agents in Children of Bacterial Meningitis With Augmented Renal Clearance [NCT04771884]300 participants (Anticipated)Observational2020-10-01Recruiting
A Single Blind, Randomised, Multi-centre, Active Controlled, Trial To Evaluate Safety, Tolerability, Pharmacokinetics And Efficacy Of Ceftazidime And Avibactam When Given In Combination With Metronidazole, Compared With Meropenem, In Children From 3 Month [NCT02475733]Phase 283 participants (Actual)Interventional2015-08-01Completed
A Phase 3, Randomized, Multicenter, Double-Blind Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Meropenem Followed by Optional Oral Therapy for the Treatment of Complicated Urinary Tract Infection (cUTI), Including Acute Pyelonephri [NCT02486627]Phase 3609 participants (Actual)Interventional2016-01-11Completed
Phase III, Randomized, Double-Blind, Study Evaluating Efficacy/Safety/Tolerability of Meropenem-Vaborbactam Compared to Piperacillin/Tazobactam in Adult Patients With Complicated Urinary Tract Infections, Including Acute Pyelonephritis [NCT02166476]Phase 3550 participants (Actual)Interventional2014-11-20Completed
Multiple Dose Pharmacokinetic Study of Meropenem in Young Infants (<91 Days) With Suspected or Complicated Intra-abdominal Infections [NCT00621192]Phase 1/Phase 2200 participants (Actual)Interventional2008-06-30Completed
A Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem, Administered Intravenously, Plus Amoxycillin/CA and Faropenem, Administered Orally, Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed, Smear-positi [NCT02349841]Phase 246 participants (Actual)Interventional2014-09-30Completed
Amplification and Selection of Antimicrobial Resistance in the Intestine II [NCT03140826]60 participants (Actual)Observational2018-01-30Completed
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdo [NCT01726023]Phase 3486 participants (Actual)Interventional2013-01-31Completed
A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE) [NCT01970371]Phase 369 participants (Actual)Interventional2014-09-16Completed
Antimicrobial Revision in Patients With Persistent Febrile Neutropenia: A Prospective, Randomized Trial [NCT05784844]Phase 4120 participants (Anticipated)Interventional2024-01-31Not yet recruiting
A Multicenter, Randomized, Double-Blind, Double-Dummy, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With Complicated Urinary Tract Infections, [NCT05204368]Phase 3780 participants (Anticipated)Interventional2023-03-30Not yet recruiting
Comparative Study Between Usage of Meropenem/Gentamicin Versus Ceftazidime/Avibactam in the Treatment of ARDS Induced by Both Lung Trauma and VAP [NCT04402359]200 participants (Actual)Observational [Patient Registry]2018-07-05Completed
Phase Ⅱ, Randomized, Double-Blind,Double-Dummy Study Evaluating Safety,Tolerability,Efficacy of Meropenem-FL058 in Adult Patients With Complicated Urinary Tract Infections, Including Acute Pyelonephritis [NCT05060419]Phase 2150 participants (Anticipated)Interventional2021-10-08Not yet recruiting
An Open Label Study to Assess the Population Pharmacokinetics, Safety, and Practicality of Administering Meropenem as a Prolonged Infusion to Cystic Fibrosis Children Admitted With an Acute Pulmonary Exacerbation [NCT01429259]Phase 430 participants (Actual)Interventional2012-02-29Completed
Evaluation of Meropenem Penetration Across Blood-Brain Barrier in Patients With Central Nervous System Infection After Neurosurgery and Optimization of Meropenem Treatment [NCT02506686]Phase 482 participants (Actual)Interventional2008-09-30Completed
PipEracillin/Tazobactam vs mERoPENem for Treatment of AmpC-producing Bloodstream Infections: an Extension of the Original PETERPEN Trial [NCT05355350]Phase 41,000 participants (Anticipated)Interventional2022-07-01Recruiting
A Single-Center, Randomized, Open-label, Prospective, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI) Plus Vancomycin or Linezolid Versus Standard of Care Plus Vancomycin or Linezolid as Empiric The [NCT02732327]Phase 22 participants (Actual)Interventional2016-05-17Terminated(stopped due to No longer aligned with the revised clinical development plan and commercial strategy)
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdo [NCT01499290]Phase 3493 participants (Actual)Interventional2012-03-31Completed
Randomized Controlled Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME) [NCT01597973]Phase 3467 participants (Actual)Interventional2012-10-06Completed
Comparative Clinical Study Between Colistin-Tigecycline Combined Therapy Versus Colistin-Meropenem Combined Therapy in Treatment of Blood Stream Infections With Multidrug-Resistant Klebsiella Pneumoniae [NCT04489459]Phase 460 participants (Anticipated)Interventional2019-09-21Recruiting
A Phase III, Randomized, Multicentre, Double-blind, Double-dummy, Parallel-group Comparative Study to Determine the Efficacy, Safety And Tolerability of Ceftazidime-Avibactam Versus Meropenem in the Treatment of Nosocomial Pneumonia Including Ventilator-A [NCT01808092]Phase 3969 participants (Actual)Interventional2013-04-30Completed
Open-label Randomized Clinical Trial Comparing Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With Minimal Inhibitory Concentrations for Meropenem Above 32mg/L [NCT04876430]Phase 2/Phase 313 participants (Actual)Interventional2021-05-04Terminated(stopped due to Very low frequency of recruitment)
Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for the Treatment of Diabetic Foot Osteomyelitis (CRO-OSTEOMYELITIS) [NCT02168816]Phase 230 participants (Actual)Interventional2014-03-19Terminated(stopped due to The study was stopped for feasibility (i.e., low recruitment))
Impact of Aggressive Empiric Antibiotic Therapy and Duration of Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Hospitalized Subjects With Pneumonia Requiring Mechanical Ventilation [NCT01570192]Phase 243 participants (Actual)Interventional2010-09-30Terminated(stopped due to NIAID terminated the study due to low subject enrollment)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00621192 (4) [back to overview]Deaths
NCT00621192 (4) [back to overview]Efficacy Success (Alive at Efficacy Visit,Last Culture (if Obtained) From Sterile Body Fluid is Negative for Bacteria (Except Staphylococcus Species) From Start of Study Drug Until Efficacy Visit,Presumptive Clinical Cure Score(PCCS) >7 at Efficacy Visit)
NCT00621192 (4) [back to overview]Meropenem Clearance
NCT00621192 (4) [back to overview]Key Safety Endpoints
NCT00752219 (10) [back to overview]Number of Participants With Clinical Response at the Late Follow-up Visit
NCT00752219 (10) [back to overview]Number of Participants With Clinical Response at the Test of Cure (TOC) Visit
NCT00752219 (10) [back to overview]Number of Participants With Clinical Response in CE Participants at the End of IV Therapy
NCT00752219 (10) [back to overview]Number of Participants With Clinical Response in CE Participants at the Late Follow-up Visit
NCT00752219 (10) [back to overview]Number of Participants With Clinical Response in Clinically Evaluable (CE) Participants at the Test of Cure Visit
NCT00752219 (10) [back to overview]Number of Participants With Microbiological Response at the End of IV Therapy
NCT00752219 (10) [back to overview]Number of Participants With Microbiological Response at the Late Follow-up Visit
NCT00752219 (10) [back to overview]Number of Participants With Microbiological Response at the Test of Cure Visit
NCT00752219 (10) [back to overview]Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00752219 (10) [back to overview]Number of Participants With Clinical Response at the End of Intravenous (IV) Therapy
NCT01110382 (7) [back to overview]The Number of Participants With Favorable Per-participant Microbiological Response
NCT01110382 (7) [back to overview]The Number of Participants With Clinical Cure Rate at Late Follow-Up (LFU) Visit
NCT01110382 (7) [back to overview]Number of Participants With Favorable Per-pathogen Microbiological Outcome Rate at Late Follow-Up (LFU) Visit
NCT01110382 (7) [back to overview]The Number of Participants With Clinical Cure Rate at Test Of Cure (TOC) Visit
NCT01110382 (7) [back to overview]The Number of Participants With Clinical Improvement Rate at End of IV (EIV) Visit
NCT01110382 (7) [back to overview]Number of Participants With Favorable Per-pathogen Microbiological Outcome Rate at End of IV (EIV) Visit
NCT01110382 (7) [back to overview]Number of Participants With Favorable Per-pathogen Microbiological Outcome Rate at Test Of Cure (TOC) Visit
NCT01147640 (2) [back to overview]Clinical Response of CXA 101/Tazobactam and Metronidazole at Test of Cure (TOC) Visit in the Microbiological Modified Intent to Treat (mMITT) Analysis Population
NCT01147640 (2) [back to overview]Microbiological Response of CXA 101/Tazobactam and Metronidazole at the TOC Visit in the Microbiologically Evaluable (ME) Population
NCT01381562 (18) [back to overview]Laboratory Parameters of Interest- Mean Reticulocytes Over the Period of Study Duration
NCT01381562 (18) [back to overview]Number of Participants With Therapeutic Response in MITT Population
NCT01381562 (18) [back to overview]Number of Participants With Clinical Response at Test of Cure Visit (5-9 Days Post-therapy) in Microbiological Evaluable Population.
NCT01381562 (18) [back to overview]Number of Participants With Any Adverse Event
NCT01381562 (18) [back to overview]Mean Change From Baseline in Hemoglobin for Partcipants With Significant Hemoglobin Drop
NCT01381562 (18) [back to overview]Mean Change From Baseline in Hemoglobin for Partcipants With Significant Hemoglobin Drop
NCT01381562 (18) [back to overview]Laboratory Parameters of Interest- Mean Hemoglobin Over the Period of Study Duration
NCT01381562 (18) [back to overview]Laboratory Parameters of Interest- Mean Hemoglobin Over the Period of Study Duration
NCT01381562 (18) [back to overview]Laboratory Parameters of Interest- Mean Reticulocytes Over the Period of Study Duration
NCT01381562 (18) [back to overview]Number of Participants With Therapeutic Response in Microbiological Evaluable Population
NCT01381562 (18) [back to overview]Number of Participants With Normal and Abnormal ECG Findings
NCT01381562 (18) [back to overview]Number of Participants With Clinical Response at Test of Cure Visit (5-9 Days Post-therapy) in Microbiological Intent to Treat (MITT) Population
NCT01381562 (18) [back to overview]Number of Participants With Microbiological Response in MITT Population
NCT01381562 (18) [back to overview]Number of Participants With Microbiological Response in Microbiological Evaluable Population
NCT01381562 (18) [back to overview]Mean Change From Baseline in Hemoglobin for Partcipants With Significant Hemoglobin Drop
NCT01381562 (18) [back to overview]Number of Participants With Clinical Response in MITT Population
NCT01381562 (18) [back to overview]Number of Participants With Clinical Response in Microbiological Evaluable Population
NCT01381562 (18) [back to overview]Number of Participants With Clinically Significant Trends in Vital Signs Over the Period of Study Duration
NCT01429259 (2) [back to overview]Population Pharmacokinetics - Volume of Central Compartment
NCT01429259 (2) [back to overview]Population Pharmacokinetics - Total Body Clearance
NCT01445678 (6) [back to overview]The Percentage of Subjects With Clinical Response at End of Therapy in the ME Population
NCT01445678 (6) [back to overview]The Percentage of Subjects With Clinical Response at End of Therapy (EOT) Visit in the MITT Population
NCT01445678 (6) [back to overview]The Percentage of Subjects With Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population
NCT01445678 (6) [back to overview]The Percentage of Subjects With Microbiological Outcome of Success at the TOC Visit in the Microbiologically Evaluable (ME) Population
NCT01445678 (6) [back to overview]The Percentage of Subjects With Clinical Response at Long Term Follow-Up (LFU) in the MITT Population
NCT01445678 (6) [back to overview]The Percentage of Subjects With Clinical Response at LFU Visit in the ME Population
NCT01499290 (13) [back to overview]Number of Patients Afebrile at Last Observation in the Clinically Evaluable Analysis Set for Patients Who Have Fever at Study Entry
NCT01499290 (13) [back to overview]Clinical Response by Pathogen at TOC for Patients Infected With Ceftazidime-resistant Pathogens in Microbiological Modified Intent to Treat Analysis Set
NCT01499290 (13) [back to overview]Per-patient Microbiological Response in the Microbiologically Modified Intent- To-Treat Analysis Set
NCT01499290 (13) [back to overview]Per-patient Microbiological Response at TOC for Patients Infected With Ceftazidime-resistant Pathogens in mMITT Analysis Set
NCT01499290 (13) [back to overview]Per-pathogen Microbiological Response at TOC in the Microbiologically Modified Intent-To-Treat Analysis Set.
NCT01499290 (13) [back to overview]Favorable Per-pathogen Microbiological Response for Patients Infected With Ceftazidime-resistant Pathogens in mMITT Analysis Set
NCT01499290 (13) [back to overview]Clinical Response by Visit in the Primary Population: Microbiologically Modified Intent-to-Treat (mMITT)
NCT01499290 (13) [back to overview]Clinical Response at the TOC Visit in the Modified Intent-To-Treat Analysis Set (Co-primary Outcome for Rest of World [ROW]).
NCT01499290 (13) [back to overview]Clinical Response at the TOC Visit in the Clinically Evaulable (CE) Analysis Set (Co-primary Outcome for Rest of World [ROW]).
NCT01499290 (13) [back to overview]Clinical Response at the Test of Cure (TOC) Visit in the Microbiologically Modified Intent-To-Treat (mMITT) Analysis Set (Primary Outcome for FDA).
NCT01499290 (13) [back to overview]Clinical Cure at TOC in the Microbiologically Evaluable Analysis Set
NCT01499290 (13) [back to overview]Clinical Cure at TOC in the Extended Microbiologically Evaluable Analysis Set
NCT01499290 (13) [back to overview]Plasma Concentrations for Ceftazidime and Avibactam
NCT01570192 (9) [back to overview]Number of Participants With Suppression and Emergence of Resistance
NCT01570192 (9) [back to overview]Suppression of the Emergence of Resistance in Other Gram-negative Pathogens
NCT01570192 (9) [back to overview]Clinical Response in Subjects Who Received Prior Antibiotics
NCT01570192 (9) [back to overview]Clinical Response
NCT01570192 (9) [back to overview]Mortality
NCT01570192 (9) [back to overview]Mortality
NCT01570192 (9) [back to overview]Occurrence of Repeat Negative Cultures
NCT01570192 (9) [back to overview]Overall Microbiologic Response
NCT01570192 (9) [back to overview]Pretreatment Pathogen Response
NCT01597973 (5) [back to overview]Clinical Failure at the End of Therapy
NCT01597973 (5) [back to overview]Number of Participants Who Develop Colistin Resistance
NCT01597973 (5) [back to overview]Microbiologic Cure at the End of Therapy
NCT01597973 (5) [back to overview]Mortality
NCT01597973 (5) [back to overview]Number of Participants With Toxicities Related to Treatment Medications
NCT01726023 (41) [back to overview]The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Clinically Evaluable (CE) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Clinically Evaluable (CE) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Clinically Evaluable (CE) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Favorable Per-pathogen Microbiological Response in the Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Favorable Per-pathogen Microbiological Response in the Microbiological Response at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Favorable Per-pathogen Microbiological Response at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Favorable Per-pathogen Microbiological Response at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable(ME) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]Plasma Concentrations for Ceftazidime and Avibactam
NCT01726023 (41) [back to overview]The Time to First Defervescence in the Clinically Evaluable (CE) Analysis Set for Patients Who Have Fever at Study Entry.
NCT01726023 (41) [back to overview]The Proportion of Favorable Per-pathogen Microbiological Response at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Favorable Per-pathogen Microbiological Response at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]The Time to First Defervescence in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set for Patients Who Have Fever at Study Entry.
NCT01726023 (41) [back to overview]The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]Safety and Tolerability by Incidence and Severity of Adverse Events and Serious Adverse Events and Mortality.
NCT01726023 (41) [back to overview]Safety and Tolerability: Clinical Laboratory Evaluation Clinical Chemistry.
NCT01726023 (41) [back to overview]Safety and Tolerability by Incidence: Extent of Exposure.
NCT01726023 (41) [back to overview]Safety and Tolerability: Clinical Laboratory Evaluation Hematology.
NCT01726023 (41) [back to overview]Safety and Tolerability:ECG , QTcB and QTcF Intervals
NCT01726023 (41) [back to overview]The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01808092 (49) [back to overview]Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Extended Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients Discharged From Hospital up to Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Clinically Evaluable at TOC Analysis Set (Co-primary Analyses)
NCT01808092 (49) [back to overview]The Number of Favorable Per-pathogen Microbiologic Responses at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Microbiologically Evaluable Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Clinically Modified Intent-to-treat Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Clinically Evaluable Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients With a Favorable Per-patient Microbiologic Response at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients With a Favorable Per-patient Microbiologic Response at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients With a Favorable Per-patient Microbiologic Response at Test-of-cure (TOC) Visit in Extended Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients With a Favorable Per-patient Microbiologic Response at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients With a Favorable Per-patient Microbiologic Response at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients With a Favorable Per-patient Microbiologic Response at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients Discharged From Hospital up to Test-of-cure (TOC) Visit in the Clinically Modified Intent-to-treat Analysis Set
NCT01808092 (49) [back to overview]Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set at End of Treatment Visit
NCT01808092 (49) [back to overview]The Number of Patients Discharged From Hospital up to Test-of-cure (TOC) Visit in the Clinically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set at Test-of-cure Visit
NCT01808092 (49) [back to overview]The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Extended Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set at End of Treatment Visit
NCT01808092 (49) [back to overview]The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Clinically Modified Intent-to-treat Analysis Set (Co-primary Analyses)
NCT01808092 (49) [back to overview]The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Extended Microbiologically Evaluable Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Microbiologically Evaluable Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Microbiologically Modified Intent-to-treat Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Clinically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Clinically Modified Intent-to-treat Analysis Set at End of Treatment Visit
NCT01808092 (49) [back to overview]The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Clinically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Clinically Modified Intent-to-treat Analysis Set at Test-of-cure Visit
NCT01808092 (49) [back to overview]The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients With Death Due to Any Cause (All-cause Mortality) at Test-of-cure (TOC) Visit in Clinically Modified Intent-to-treat Analysis Set at Test-of-cure Visit
NCT01808092 (49) [back to overview]The Number of Patients With Death Due to Any Cause (All-cause Mortality) at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set at Test-of-cure Visit
NCT01808092 (49) [back to overview]The Number of Patients With Death Due to Any Cause (All-cause Mortality) at Test-of-cure (TOC) Visit in the Clinically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]The Number of Patients With Death Due to Any Cause (All-cause Mortality) in Clinically Modified Intent-to-treat Analysis Set at Day 28
NCT01808092 (49) [back to overview]The Number of Patients With Death Due to Any Cause (All-cause Mortality) in Microbiologically Modified Intent-to-treat Analysis Set at Day 28
NCT01808092 (49) [back to overview]The Number of Patients With Death Due to Any Cause (All-cause Mortality) in the Clinically Evaluable at Test-of-cure Analysis Set at Day 28
NCT01808092 (49) [back to overview]The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]The Number of Favorable Per-pathogen Microbiologic Responses at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set at Test-of-cure Visit
NCT01808092 (49) [back to overview]The Number of Favorable Per-pathogen Microbiologic Responses at Test-of-cure (TOC) Visit in Extended Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]The Number of Favorable Per-pathogen Microbiologic Responses at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set at End of Treatment Visit
NCT01808092 (49) [back to overview]The Number of Favorable Per-pathogen Microbiologic Responses at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]The Number of Favorable Per-pathogen Microbiologic Responses at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set at Test-of-cure Visit
NCT01944319 (3) [back to overview]Clinical Success Rate
NCT01944319 (3) [back to overview]Bacteriological Success Rate
NCT01944319 (3) [back to overview]Amount of Used Antibiotics
NCT01970371 (10) [back to overview]Percentage of Patients With All Cause Mortality (ACM) at Day 28 or Significant Disease-Related Complication (SDRC) in the Microbiological Modified Intent to Treat (mMITT) Population in Cohort 1
NCT01970371 (10) [back to overview]Percentage of Patients With ACM at Day 28 in the mMITT Population in Cohort 1
NCT01970371 (10) [back to overview]Percentage of Patients With ACM at Day 14 in the mMITT Population in Cohort 1
NCT01970371 (10) [back to overview]Time to Death Through Day 28 in the mMITT Population in Cohort 1
NCT01970371 (10) [back to overview]Percentage of Patients With Adjudicated Clinical Cure at the Test of Cure (TOC) Visit in the mMITT Population in Cohort 1
NCT01970371 (10) [back to overview]Plasma Pharmacokinetics (PK): Minimum Observed Plasma Drug Concentration (Cmin)
NCT01970371 (10) [back to overview]Plasma Pharmacokinetics (PK): Maximum Observed Plasma Drug Concentration (Cmax)
NCT01970371 (10) [back to overview]Percentage of Patients With Treatment-Emergent Adverse Events (TEAEs)
NCT01970371 (10) [back to overview]Percentage of Patients With Dose Adjustment Due to Therapeutic Drug Management (TDM)
NCT01970371 (10) [back to overview]Plasma Pharmacokinetics (PK): Area Under the Curve From 0 to 24 Hours (AUC 0-24h)
NCT02070757 (13) [back to overview]Percentage of Participants With All Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population - Day 28
NCT02070757 (13) [back to overview]Percentage of Participants Discontinuing Study Drug Due to an Adverse Event (AE)
NCT02070757 (13) [back to overview]Percentage of Participants Who Report 1 or More Adverse Event (AE)
NCT02070757 (13) [back to overview]Percentage of Participants With All Cause Mortality in the Intent-to-Treat (ITT) Population - Day 28
NCT02070757 (13) [back to overview]Percentage of Participants With All-Cause Mortality in the Intent-to-Treat (ITT) Population - Day 14
NCT02070757 (13) [back to overview]Percentage of Participants With Any Serious Adverse Event (SAE)
NCT02070757 (13) [back to overview]Percentage of Participants With Clinical Response of Clinical Cure at the End-of-Therapy (EOT) Visit in the Intent-to-Treat (ITT) Population
NCT02070757 (13) [back to overview]Percentage of Participants With Clinical Response of Clinical Cure at the Late Follow-up (LFU) Visit in the Clinically Evaluable (CE) Population
NCT02070757 (13) [back to overview]Percentage of Participants With Clinical Response of Clinical Cure at the Test-of-Cure (TOC) Visit in the Clinically Evaluable (CE) Population
NCT02070757 (13) [back to overview]Percentage of Participants With Clinical Response of Clinical Cure at the Test-of-Cure (TOC) Visit in the Intent-to-Treat (ITT) Population
NCT02070757 (13) [back to overview]Percentage of Participants With Per-Participant Microbiological Response of Cure or Presumed Cure at the End-of-Therapy (EOT) Visit in the Microbiologically Evaluable (ME) Population
NCT02070757 (13) [back to overview]Percentage of Participants With Per-Participant Microbiological Response of Cure or Presumed Cure at the Test-of-Cure (TOC) Visit in the Microbiologically Evaluable (ME) Population
NCT02070757 (13) [back to overview]Percentage of Participants With Microbiological Response of Eradication or Presumed Eradication, by Pathogen, at the Test-of-Cure (TOC) Visit in the Microbiologically Evaluable (ME) Population (>=10 Isolates at Baseline)
NCT02166476 (15) [back to overview]Proportion Of Participants In The m-MITT Population Who Achieved A Microbiologic Outcome Of Eradication
NCT02166476 (15) [back to overview]Proportion Of Participants In The m-MITT Population With Overall Success
NCT02166476 (15) [back to overview]Proportion Of Participants In The ME Population Who Achieved A Microbiologic Outcome Of Eradication
NCT02166476 (15) [back to overview]Proportion Of Participants In The ME Population With Overall Success
NCT02166476 (15) [back to overview]Proportion Of Participants With A Clinical Outcome Of Cure In The Clinical Evaluable (CE) Population
NCT02166476 (15) [back to overview]Proportion Of Participants With A Clinical Outcome Of Cure In The m-MITT Population
NCT02166476 (15) [back to overview]Proportion Of Participants With A Clinical Outcome Of Cure In The ME Population
NCT02166476 (15) [back to overview]Per-Pathogen Microbiological Outcome (FDA) In The ME Population
NCT02166476 (15) [back to overview]Per-Pathogen Microbiological Outcome (FDA) In The m-MITT Population
NCT02166476 (15) [back to overview]Per-Pathogen Microbiological Outcome (EMA) In The ME Population
NCT02166476 (15) [back to overview]Per-Pathogen Microbiological Outcome (EMA) In The m-MITT Population
NCT02166476 (15) [back to overview]Proportion Of Participants In The Microbiological Modified Intent-To-Treat (m-MITT) Population Who Achieved Overall Success At The End Of Intravenous Treatment Visit
NCT02166476 (15) [back to overview]Proportion Of Participants In The Microbiological Evaluable (ME) Population Who Achieved A Microbiologic Outcome Of Eradication At The TOC Visit
NCT02166476 (15) [back to overview]Proportion Of Participants In The m-MITT Population Who Achieved A Microbiologic Outcome Of Eradication At The Test Of Cure Visit
NCT02166476 (15) [back to overview]Pharmacokinetic (PK) Characterization Of Plasma Exposure Of Meropenem/Vaborbactam
NCT02168946 (16) [back to overview]Proportion of Subjects in the Microbiological Modified Intent-to-Treat (m-MITT) Population With a Clinical Outcome of Cure (All Indications)
NCT02168946 (16) [back to overview]Proportion of Subjects in the mCRE-MITT Population With a Clinical Outcome of Cure (HABP/VABP and Bacteremia)
NCT02168946 (16) [back to overview]Proportion of Subjects in the mCRE-MITT Population With a Clinical Outcome of Cure (cUTI/AP Subjects Only)
NCT02168946 (16) [back to overview]Proportion of Subjects in the mCRE-MITT Population With a Clinical Outcome of Cure (All Indications)
NCT02168946 (16) [back to overview]Proportion of Subjects in the m-MITT Populations With a With a Response of Overall Success (cUTI/AP)
NCT02168946 (16) [back to overview]Proportion of Subjects in the m-MITT Populations With a With a Response of Overall Success (Bacteremia Only)
NCT02168946 (16) [back to overview]Proportion of Subjects in the m-MITT Population With a Microbiological Outcome of Eradication (All Indications)
NCT02168946 (16) [back to overview]Proportion of Subjects in the mCRE-MITT Population With a Microbiological Outcome of Eradication (All Indications)
NCT02168946 (16) [back to overview]Proportion of Subjects in the m-MITT Population With a Clinical Outcome of Cure (HABP/VABP and Bacteremia)
NCT02168946 (16) [back to overview]Proportion of Subjects in the m-MITT Population With a Clinical Outcome of Cure (cUTI/AP)
NCT02168946 (16) [back to overview]The All-cause Mortality Rate in the mCRE-MITT Population (cUTI/AP)
NCT02168946 (16) [back to overview]The All-cause Mortality Rate in the mCRE-MITT Population (All Indications)
NCT02168946 (16) [back to overview]The All-cause Mortality Rate in the m-MITT Population (All Indications)
NCT02168946 (16) [back to overview]Proportion of Subjects in the Microbiological Carbapenem-resistant Enterobacteriaceae Modified Intent-to-Treat (mCRE-MITT) Population With a Response of Overall Success [Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Subjects]
NCT02168946 (16) [back to overview]Proportion of Subjects in the mCRE-MITT Population With a Clinical Outcome of Cure [Complicated Intra-abdominal Infection (cIAI) Subjects Only]
NCT02168946 (16) [back to overview]All-cause Mortality Rate in the mCRE-MITT Population [Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP) and Bacteremia Subjects)
NCT02475733 (26) [back to overview]Percentage of Participants With Creatinine Clearance (CrCl) at Day 7
NCT02475733 (26) [back to overview]Percentage of Participants With Cephalosporin Class Effects and Additional Adverse Events (AEs)
NCT02475733 (26) [back to overview]Percentage of Participants With Abnormal Physical Examination Findings at End of Intravenous Therapy (EOIV) Visit
NCT02475733 (26) [back to overview]Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End of Intravenous Therapy (EOIV) Visit
NCT02475733 (26) [back to overview]Change From Baseline in Respiratory Rate at End of Intravenous Therapy (EOIV) Visit
NCT02475733 (26) [back to overview]Change From Baseline in Pulse Rate at End of Intravenous Therapy (EOIV) Visit
NCT02475733 (26) [back to overview]Change From Baseline in Body Weight at End of Intravenous Therapy (EOIV) Visit
NCT02475733 (26) [back to overview]Change From Baseline in Body Temperature at End of Intravenous Therapy (EOIV) Visit
NCT02475733 (26) [back to overview]Percentage of Participants With Creatinine Clearance (CrCl) at End of Intravenous Therapy (EOIV) Visit
NCT02475733 (26) [back to overview]Percentage of Participants With Favorable Clinical Response (CR) at Test of Cure (TOC) Visit: Intent-to-treat (ITT) Analysis Population
NCT02475733 (26) [back to overview]Percentage of Participants With Favorable Clinical Response (CR) at End of Intravenous Therapy (EOIV) Visit: Intent-to-treat (ITT) Analysis Population
NCT02475733 (26) [back to overview]Percentage of Participants With Favorable Clinical Response (CR) at End of 72 Hours Treatment: Intent-to-treat (ITT) Analysis Population
NCT02475733 (26) [back to overview]Percentage of Participants With Emergent Infections: Microbiological Intent-to-treat (Micro-ITT) Population
NCT02475733 (26) [back to overview]Percentage of Participants With Emergent Infections at Test of Cure (TOC) Visit: Microbiologically Evaluable Population
NCT02475733 (26) [back to overview]Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Microbiologically Evaluable (ME) Population
NCT02475733 (26) [back to overview]Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Clinically Evaluable (CE) Population
NCT02475733 (26) [back to overview]Percentage of Participants With Favorable Microbiological Response: Microbiological Intent-to-treat (Micro-ITT) Population
NCT02475733 (26) [back to overview]Percentage of Participants With Favorable Microbiological Response: Microbiologically Evaluable (ME) Population
NCT02475733 (26) [back to overview]Percentage of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters
NCT02475733 (26) [back to overview]Plasma Concentrations of Ceftazidime and Avibactam
NCT02475733 (26) [back to overview]Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT02475733 (26) [back to overview]Percentage of Participants With Creatinine Clearance (CrCl) at Late Follow-up (LFU) Visit
NCT02475733 (26) [back to overview]Percentage of Participants With Creatinine Clearance (CrCl) at Test of Cure (TOC) Visit
NCT02475733 (26) [back to overview]Percentage of Participants With Electrocardiogram (ECG) Parameter QTcF: > 450, >480 and >500 Millisecond (ms)
NCT02475733 (26) [back to overview]Percentage of Participants With Favorable Clinical Response (CR): Clinically Evaluable (CE) Analysis Population
NCT02475733 (26) [back to overview]Percentage of Participants With Favorable Clinical Response (CR) at End of Treatment (EOT) Visit: Intent-to-treat (ITT) Analysis Population
NCT02486627 (8) [back to overview]Percentage of Patients With Composite of Microbiological Eradication and Clinical Cure in the ME Population at Day 5
NCT02486627 (8) [back to overview]Percentage of Patients With Composite of Microbiological Eradication and Clinical Cure in the ME Population at TOC
NCT02486627 (8) [back to overview]Percentage of Patients With Treatment-Emergent Adverse Events (TEAEs)
NCT02486627 (8) [back to overview]Plasma Pharmacokinetics (PK): Area Under the Curve From 0 to 24 Hours (AUC 0-24h)
NCT02486627 (8) [back to overview]Plasma PK: Maximum Observed Plasma Drug Concentration (Cmax)
NCT02486627 (8) [back to overview]Plasma PK: Minimum Observed Plasma Drug Concentration (Cmin)
NCT02486627 (8) [back to overview]Percentage of Patients With Composite of Microbiological Eradication and Clinical Cure in the mMITT Population at Test of Cure (TOC)
NCT02486627 (8) [back to overview]Percentage of Patients With Composite of Microbiological Eradication and Clinical Cure in the Microbiological Modified ITT (mMITT) Population at Day 5
NCT03019965 (2) [back to overview]Number of Participants With Clinical Response
NCT03019965 (2) [back to overview]Number of Participants With Adverse Events
NCT03032380 (13) [back to overview]Number of Participants With Treatment-Emergent Adverse Events
NCT03032380 (13) [back to overview]Percentage of Participants With Sustained Microbiologic Eradication at Follow-up
NCT03032380 (13) [back to overview]Percentage of Participants With Sustained Clinical Cure at Follow-up (FU)
NCT03032380 (13) [back to overview]Percentage of Participants With Microbiologic Eradication at Test of Cure (TOC)
NCT03032380 (13) [back to overview]Percentage of Participants With Microbiologic Eradication at End of Treatment
NCT03032380 (13) [back to overview]Percentage of Participants With Microbiologic Eradication at Early Assessment
NCT03032380 (13) [back to overview]Percentage of Participants With Clinical Cure at Test of Cure
NCT03032380 (13) [back to overview]Total Hospitalization Time
NCT03032380 (13) [back to overview]All-cause Mortality Rate at Day 14
NCT03032380 (13) [back to overview]All-cause Mortality Rate at Day 28
NCT03032380 (13) [back to overview]All-cause Mortality Rate at the End of Study
NCT03032380 (13) [back to overview]Percentage of Participants With Clinical Cure at Early Assessment (EA)
NCT03032380 (13) [back to overview]Percentage of Participants With Clinical Cure at End of Treatment (EOT)
NCT03174184 (5) [back to overview]AUC for Rifampin
NCT03174184 (5) [back to overview]Distribution of Minimum Inhibitory Concentration (MIC) of Rifampin
NCT03174184 (5) [back to overview]Estimate of the 14-day Early Bactericidal Activity (EBA), Based on Colony Forming Unit Counts, of the Combination of Meropenem and Amoxicillin/Clavulanate, Without Versus With Rifampin
NCT03174184 (5) [back to overview]Estimate the Antimycobacterial Activity Based on Liquid Culture Time-to-positivity
NCT03174184 (5) [back to overview]Frequency of Grade 2 or Higher Adverse Events
NCT03217136 (6) [back to overview]"Percentage of Participants With a Clinical Response of Cure at the End of Treatment (EOT) Visit"
NCT03217136 (6) [back to overview]Number of Participants Experiencing ≥1 Adverse Events (AEs)
NCT03217136 (6) [back to overview]Number of Participants Who Discontinued Study Therapy Due to AE(s)
NCT03217136 (6) [back to overview]Percentage of Participants With Microbiological Eradication at the TOC Visit
NCT03217136 (6) [back to overview]"Percentage of Participants With a Clinical Response of Cure at the Test of Cure (TOC) Visit"
NCT03217136 (6) [back to overview]Percentage of Participants With Microbiological Eradication at the EOT Visit
NCT03230838 (6) [back to overview]Number of Participants With ≥1 Adverse Events (AEs)
NCT03230838 (6) [back to overview]Number of Participants Discontinuing Study Therapy Due to AE
NCT03230838 (6) [back to overview]Percentage of Participants With Microbiological Eradication of All Baseline Pathogens at the Test of Cure Visit
NCT03230838 (6) [back to overview]Percentage of Participants With Microbiological Eradication of All Baseline Pathogens at the End of Treatment Visit
NCT03230838 (6) [back to overview]Percentage of Participants With a Clinical Response of Cure at the Test of Cure Visit
NCT03230838 (6) [back to overview]Percentage of Participants With a Clinical Response of Cure at the End of Treatment Visit
NCT03485950 (24) [back to overview]Number of Participants With Favorable Clinical Response in the ME Analysis Set at LFU.
NCT03485950 (24) [back to overview]Number of Participants With Favorable Clinical Response in the MITT Analysis Set at TOC
NCT03485950 (24) [back to overview]Number of Participants With Infection-related Mortality in the MITT Analysis Set at LFU
NCT03485950 (24) [back to overview]Number of Participants With Favorable Clinical Response in the MITT Analysis Set at Late Follow-Up (LFU)
NCT03485950 (24) [back to overview]Number of Participants With Favorable Microbiological Response in the ME Analysis Set at LFU
NCT03485950 (24) [back to overview]Number of Participants With Favorable Microbiological Response in the ME Analysis Set at EOIV.
NCT03485950 (24) [back to overview]Number of Participants With Infection-related Mortality in the mMITT Analysis Set at LFU.
NCT03485950 (24) [back to overview]Number of Participants With Favorable Clinical Response in the Clinically Evaluable (CE) Analysis Set at EOIV.
NCT03485950 (24) [back to overview]Number of Participants With Infection-related Mortality in the MITT Analysis Set at TOC
NCT03485950 (24) [back to overview]Number of Participants With Favorable Clinical Response in the ME Analysis Set at EOIV.
NCT03485950 (24) [back to overview]Number of Participants With Infection-related Mortality the mMITT Analysis Set at TOC
NCT03485950 (24) [back to overview]30 Day All-cause Mortality in the mMITT Analysis Set
NCT03485950 (24) [back to overview]Number of Participants With Favorable Clinical Response in the ME Analysis Set at TOC
NCT03485950 (24) [back to overview]30 Day All-cause Mortality in the MITT Analysis Set
NCT03485950 (24) [back to overview]Favorable Microbiological Response in the mMITT Analysis Set at TOC.
NCT03485950 (24) [back to overview]Number of Participants With Favorable Clinical Response at End of Inpatient Intravenous Therapy (EOIV)
NCT03485950 (24) [back to overview]Number of Participants With Favorable Clinical Response in the CE Analysis Set at LFU.
NCT03485950 (24) [back to overview]Number of Participants With Favorable Clinical Response in the CE Analysis Set at TOC
NCT03485950 (24) [back to overview]Number of Participants With Favorable Microbiological Response in the mMITT Analysis Set at LFU.
NCT03485950 (24) [back to overview]Number of Participants With Favorable Microbiological Response in the mMITT Analysis Set at EOIV.
NCT03485950 (24) [back to overview]Number of Participants With Favorable Microbiological Response in the ME Analysis Set at TOC.
NCT03485950 (24) [back to overview]Number of Participants With Favorable Clinical Response in the mMITT Analysis Set at Test of Cure (TOC)
NCT03485950 (24) [back to overview]Number of Participants With Favorable Clinical Response in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set at EOIV.
NCT03485950 (24) [back to overview]Number of Participants With Favorable Clinical Response in the mMITT Analysis Set at Late Follow-Up (LFU)
NCT03830333 (9) [back to overview]Percentage of Participants With Clinical Response (Clinical Cure, Clinical Failure, or Indeterminate) at TOC Visit: Intent to Treat (ITT) Population
NCT03830333 (9) [back to overview]Percentage of Participants With Clinical Response (Clinical Cure, Clinical Failure, or Indeterminate) at EOT Visit: ITT Population
NCT03830333 (9) [back to overview]Percentage of Participants With Clinical Response (Clinical Cure or Clinical Failure) at Test of Cure (TOC) Visit: Clinically Evaluable (CE) Population
NCT03830333 (9) [back to overview]Percentage of Participants With Clinical Response (Clinical Cure or Clinical Failure) at End of Therapy (EOT) Visit: CE Population
NCT03830333 (9) [back to overview]Percentage of Participants Who Experienced 1 or More Adverse Events (AEs)
NCT03830333 (9) [back to overview]Percentage of Participants With Favorable Per-Participant Microbiological Response of Eradication or Presumed Eradication at TOC Visit: Expanded Microbiologically Evaluable (EME) Population
NCT03830333 (9) [back to overview]Percentage of Participants With Favorable Microbiological Response of Eradication or Presumed Eradication, by Pathogen, at the TOC Visit: EME Population
NCT03830333 (9) [back to overview]Percentage of Participants That Discontinued Study Treatment Due to an AE
NCT03830333 (9) [back to overview]Percentage of Participants With Favorable Microbiological Response of Eradication or Presumed Eradication, by Pathogen, at the TOC Visit: EME Population
NCT05102162 (10) [back to overview]Mortality Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens
NCT05102162 (10) [back to overview]Percent of Time Free Drug Concentrations Remain Above Four Multiples of the Minimum Inhibitory Concentration (%fT>4xMIC) in the Dosing Interval Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens
NCT05102162 (10) [back to overview]Hospital Length of Stay Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens.
NCT05102162 (10) [back to overview]Percent of Time Free Drug Concentrations Remain Above the Minimum Inhibitory Concentration (%fT>MIC) in the Dosing Interval Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens
NCT05102162 (10) [back to overview]Superinfection Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens.
NCT05102162 (10) [back to overview]Intensive Care Unit (ICU) Length of Stay Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens
NCT05102162 (10) [back to overview]Microbiologic Eradication Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens
NCT05102162 (10) [back to overview]Clinical Cure at Day 7 of Therapy Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens
NCT05102162 (10) [back to overview]Clinical Cure at the End of Therapy Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens
NCT05102162 (10) [back to overview]Gram-negative Bacterial Resistance Emergence Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens

Deaths

(NCT00621192)
Timeframe: Up to 51 days (Recorded from the time of informed consent until 72 hours following the last dose of study drug)

InterventionParticipants (Number)
1. GA <32 Wks; PNA<2 Wks3
2. GA <32 Wks; PNA 91days ≥ 2Wks8
3. GA ≥ 32 Wks; PNA <2 Wks0
4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks0

[back to top]

Efficacy Success (Alive at Efficacy Visit,Last Culture (if Obtained) From Sterile Body Fluid is Negative for Bacteria (Except Staphylococcus Species) From Start of Study Drug Until Efficacy Visit,Presumptive Clinical Cure Score(PCCS) >7 at Efficacy Visit)

"The PCCS was derived by comparing clinical signs and symptoms prior to administration of the first dose of study drug and study Day 28.The elements of the PCCS include Mean BP,Temp,PaO2(mmHg)/FiO2,Lowest serum pH,seizures,Urine output,Cardiovascular inotrope support,C-reactive protein (CRP)and Abdominal girth.~Score - Asymptomatic to Asymptomatic 1;Asymptomatic to Worsening 0;Symptomatic to Worsening 0;Symptomatic to No change 0;Symptomatic to Improved 1;Symptomatic to Asymptomatic 1~If 7 or more of 10 signs received a score of 1, then the infant was considered a presumptive clinical cure.~GA stands for Gestational Age and PNA stands for Postnatal Age." (NCT00621192)
Timeframe: Average of 12 days (3 to 21 days)

InterventionParticipants (Number)
1. GA <32 Wks; PNA<2 Wks29
2. GA <32 Wks; PNA 91days ≥ 2Wks82
3. GA ≥ 32 Wks; PNA <2 Wks26
4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks25

[back to top]

Meropenem Clearance

"Given the limited availability of blood for Pharmacokinetic (PK) assessments in this population a sparse sampling approach was utilized. Subjects were assigned to one of two Dose 1 sample collection schedules, PK-odd and PK-even based on birth date to ensure collection of PK data throughout the dose interval. In addition, PK samples were collected around approximately the 5th dose. Subjects that did not have Dose 1 PK samples could have steady-state (Dose 5) using the Dose 5 PK collection schedule." (NCT00621192)
Timeframe: Up to 7-8hrs post drug administration

InterventionL/h/kg (Mean)
1. GA <32 Wks; PNA<2 Wks0.089
2. GA <32 Wks; PNA 91days ≥ 2Wks0.122
3. GA ≥ 32 Wks; PNA <2 Wks0.135
4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks0.202

[back to top]

Key Safety Endpoints

Safety assessments included death, seizure documentation (including correlation of serum meropenem level and seizures), strictures, perforation, wound dehiscence, short gut, development of extended beta lactamase infection, development of candidiasis, antimicrobial therapy failure (NCT00621192)
Timeframe: Up to 51 days (Adverse Events (AEs) were recorded from the time of informed consent until 72 hours following the last dose of study drug)

,,,
InterventionParticipants (Number)
DeathSeizureStricturesPerforationWound DehiscenceDevelopment of CandidiasisAntimicrobial Therapy Failure
1. GA <32 Wks; PNA<2 Wks3402157
2. GA <32 Wks; PNA 91days ≥ 2Wks83021312
3. GA ≥ 32 Wks; PNA <2 Wks0100102
4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks0200102

[back to top]

Number of Participants With Clinical Response at the Late Follow-up Visit

Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. This clinical response was measured in participants who were ME at baseline. (NCT00752219)
Timeframe: Late follow-up visit: 4 to 6 weeks post-therapy (up to 8 weeks)

Interventionparticipants (Number)
NXL104/Ceftazidime + Metronidazole62
Meropenem71

[back to top]

Number of Participants With Clinical Response at the Test of Cure (TOC) Visit

Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. This clinical response was measured in participants who were microbiologically evaluable (ME) at baseline. (NCT00752219)
Timeframe: Test of cure visit: 2 weeks post-therapy (Day 28)

Interventionparticipants (Number)
NXL104/Ceftazidime + Metronidazole62
Meropenem71

[back to top]

Number of Participants With Clinical Response in CE Participants at the End of IV Therapy

Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. (NCT00752219)
Timeframe: End of IV therapy: From Day 5 to Day 14

Interventionparticipants (Number)
NXL104/Ceftazidime + Metronidazole84
Meropenem87

[back to top]

Number of Participants With Clinical Response in CE Participants at the Late Follow-up Visit

Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. (NCT00752219)
Timeframe: Late follow-up visit: 4 to 6 weeks post-therapy (up to 8 weeks)

Interventionparticipants (Number)
NXL104/Ceftazidime + Metronidazole79
Meropenem84

[back to top]

Number of Participants With Clinical Response in Clinically Evaluable (CE) Participants at the Test of Cure Visit

Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. (NCT00752219)
Timeframe: Test of cure visit: 2 weeks post-therapy (Day 28)

Interventionparticipants (Number)
NXL104/Ceftazidime + Metronidazole80
Meropenem85

[back to top]

Number of Participants With Microbiological Response at the End of IV Therapy

Microbiological response was defined as eradication of pathogen identified (absence of causative pathogens from appropriately obtained specimens at site of infection) or presumptive eradication of pathogens (absence of material to culture in a participant who had responded clinically to treatment). This clinical response was measured in participants who were ME at baseline. (NCT00752219)
Timeframe: End of IV therapy: From Day 5 to Day 14

Interventionparticipants (Number)
NXL104/Ceftazidime + Metronidazole66
Meropenem74

[back to top]

Number of Participants With Microbiological Response at the Late Follow-up Visit

Favorable: eradication (absence of causative pathogens from appropriately obtained specimens at site of infection) or presumptive eradication (absence of material to culture in a patient who had responded clinically to treatment) (NCT00752219)
Timeframe: Late follow-up visit: 4 to 6 weeks post-therapy (up to 8 weeks)

Interventionparticipants (Number)
NXL104/Ceftazidime + Metronidazole62
Meropenem71

[back to top]

Number of Participants With Microbiological Response at the Test of Cure Visit

Microbiological response was defined as eradication of pathogen identified (absence of causative pathogens from appropriately obtained specimens at site of infection) or presumptive eradication of pathogens (absence of material to culture in a participant who had responded clinically to treatment). This clinical response was measured in participants who were ME at baseline. (NCT00752219)
Timeframe: Test of cure visit: 2 weeks post-therapy (Day 28)

Interventionparticipants (Number)
NXL104/Ceftazidime + Metronidazole62
Meropenem71

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 6 weeks after last dose of study treatment that were absent before treatment or that worsened relative to pretreatment state. (NCT00752219)
Timeframe: Baseline up to 6 weeks after last dose of study treatment (up to a maximum of 8 weeks)

,
Interventionparticipants (Number)
AEsSAEs
Meropenem5911
NXL104/Ceftazidime + Metronidazole659

[back to top]

Number of Participants With Clinical Response at the End of Intravenous (IV) Therapy

Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. This clinical response was measured in participants who were ME at baseline. (NCT00752219)
Timeframe: End of IV therapy: From Day 5 to Day 14

Interventionparticipants (Number)
NXL104/Ceftazidime + Metronidazole66
Meropenem74

[back to top]

The Number of Participants With Favorable Per-participant Microbiological Response

Favorable per-participant microbiological response rate was evaluated at the at End of IV (EIV) visit, Test Of Cure (TOC) visit, and Late Follow-Up (LFU) visit. The favorable per-participant microbiological response was considered when all baseline pathogens were eradicated (absence) or presumed eradicated (absence of material to culture in a participant who has a positive clinical response to treatment). (NCT01110382)
Timeframe: EIV (within 24 hours after completion of the last dose of IV study medication therapy), TOC (7 to 14 days after the last dose of study medication therapy), and LFU (28 to 42 days after the last dose of study medication therapy)

,
Interventionparticipants (Number)
EIV visitTOC visitLFU visit
Doripenem211717
Meropenem655

[back to top]

The Number of Participants With Clinical Cure Rate at Late Follow-Up (LFU) Visit

The participants were considered as clinical cure if they had clinical improvement in signs and symptoms of the intra-abdominal infection such that no additional antibacterial therapy or surgical or percutaneous intervention is/was required for the treatment of the index infection, no fever, and a favorable response at End of IV visit. (NCT01110382)
Timeframe: LFU (28 to 42 days after the last dose of study medication therapy)

Interventionparticipants (Number)
Doripenem22
Meropenem6

[back to top]

Number of Participants With Favorable Per-pathogen Microbiological Outcome Rate at Late Follow-Up (LFU) Visit

A total of 24 pathogens in the doripenem group and 6 pathogens in the meropenem group were isolated at baseline from the intra-abdominal culture and were susceptible to the study drug received. The most common pathogens isolated at baseline from the intra-abdominal culture are listed in the table below; the numbers in parenthesis next to each pathogen represent the number of participants with the pathogen isolated in the doripenem and meropenem treatment groups, respectively. The favorable per-pathogen microbiological outcome was considered when all baseline pathogens were eradicated (absence) or presumed eradicated (absence of material to culture in a participant who has a positive clinical response to treatment). (NCT01110382)
Timeframe: LFU (28 to 42 days after the last dose of study medication therapy)

,
Interventionparticipants (Number)
Streptococcus anginosus (13, 0)Escherichia coli (19, 8)Bacteroides fragilis (11, 1)
Doripenem9159
MeropenemNA51

[back to top]

The Number of Participants With Clinical Cure Rate at Test Of Cure (TOC) Visit

The participants were considered as clinical cure if they had clinical improvement in signs and symptoms of the intra-abdominal infection such that no additional antibacterial therapy or surgical or percutaneous intervention is/was required for the treatment of the index infection, no fever, and a favorable response at End of IV visit. (NCT01110382)
Timeframe: TOC (7 to 14 days after the last dose of study medication therapy)

Interventionparticipants (Number)
Doripenem23
Meropenem7

[back to top]

The Number of Participants With Clinical Improvement Rate at End of IV (EIV) Visit

The participants were considered as clinical improved if they had clinical improvement in signs and symptoms of the intra-abdominal infection, no fever, decrease in WBC, and not received any nonstudy antibiotics for the treatment of intra-abdominal infection after IV study drug therapy had begun. (NCT01110382)
Timeframe: EIV (within 24 hours after completion of the last dose of IV study medication therapy)

Interventionparticipants (Number)
Doripenem29
Meropenem8

[back to top]

Number of Participants With Favorable Per-pathogen Microbiological Outcome Rate at End of IV (EIV) Visit

A total of 24 pathogens in the doripenem group and 6 pathogens in the meropenem group were isolated at baseline from the intra-abdominal culture and were susceptible to the study drug received. The most common pathogens isolated from the intra-abdominal culture are listed in the table below; the numbers in parenthesis next to each pathogen represent the number of participants with the pathogen isolated at baseline in the doripenem and meropenem treatment groups, respectively. The favorable per-pathogen microbiological outcome was considered when all baseline pathogens were eradicated (absence) or presumed eradicated (absence of material to culture in a participant who has a positive clinical response to treatment). (NCT01110382)
Timeframe: EIV (within 24 hours after completion of the last dose of IV study medication therapy)

,
Interventionparticipants (Number)
Streptococcus anginosus (13, 0)Escherichia coli (19, 8)Bacteroides fragilis (11, 1)
Doripenem121810
MeropenemNA61

[back to top]

Number of Participants With Favorable Per-pathogen Microbiological Outcome Rate at Test Of Cure (TOC) Visit

A total of 24 pathogens in the doripenem group and 6 pathogens in the meropenem group were isolated at baseline from the intra-abdominal culture and were susceptible to the study drug received. The most common pathogens isolated from the intra-abdominal culture are listed in the table below; the numbers in parenthesis next to each pathogen represent the number of participants with the pathogen isolated at baseline in the doripenem and meropenem treatment groups, respectively. The favorable per-pathogen microbiological outcome was considered when all baseline pathogens were eradicated (absence) or presumed eradicated (absence of material to culture in a participant who has a positive clinical response to treatment). (NCT01110382)
Timeframe: TOC (7 to 14 days after the last dose of study medication therapy)

,
Interventionparticipants (Number)
Streptococcus anginosus (13, 0)Escherichia coli (19, 8)Bacteroides fragilis (11, 1)
Doripenem9159
MeropenemNA51

[back to top]

Clinical Response of CXA 101/Tazobactam and Metronidazole at Test of Cure (TOC) Visit in the Microbiological Modified Intent to Treat (mMITT) Analysis Population

Clinical response is complete resolution or significant improvement of all signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection. (NCT01147640)
Timeframe: Test-of-Cure Visit (7-14 days after End of Therapy [EOT])

Interventionpercentage of subjects (Number)
CXA 101/Tazobactam and Metronidazole83.6
Meropenem With Matching Saline Placebo96.0

[back to top]

Microbiological Response of CXA 101/Tazobactam and Metronidazole at the TOC Visit in the Microbiologically Evaluable (ME) Population

Microbiological response is eradication (absence of the baseline pathogen from a suitable intra-abdominal specimen) or presumed eradication (absence of a suitable intra-abdominal specimen to culture at the TOC visit in a subject who is assessed as a clinical cure at TOC) (NCT01147640)
Timeframe: Test-of-Cure Visit (7-14 days after EOT)

Interventionpercentage of subjects (Number)
CXA 101/Tazobactam and Metronidazole90.6
Meropenem With Matching Saline Placebo95.8

[back to top]

Laboratory Parameters of Interest- Mean Reticulocytes Over the Period of Study Duration

Absolute mean reticulocytes values recorded over the period of duration were reported. (NCT01381562)
Timeframe: Up to 42 days

,
InterventionTrillion cells per Litre (Mean)
Baseline (Day 1)On IV Therapy (Day 3)On IV Therapy (Day 5)On IV Therapy (Day 8)End Of IV TherapyHaematology SafetyTest Of CureEarly Follow upLate Follow up
GSK2251052 1500 mg0.05730.06380.04800.04440.06020.04780.08600.07690.0870
Meropenem 1g0.08100.07250.08700.06500.08720.08150.08460.07960.0828

[back to top]

Number of Participants With Therapeutic Response in MITT Population

Therapeutic response was a measure of the overall efficacy response, and a therapeutic success referred to participants who had been deemed both a 'clinical success' and a 'microbiological success'. All other combinations (other than 'clinical success' + 'microbiological success') were deemed failures for therapeutic response. Therapeutic response was determined programmatically. (NCT01381562)
Timeframe: End of IV therapy (0-24 hours post-therapy); Test of cure (5-9 days post-therapy); Late Follow-up (21-28 days post-therapy)

,,
InterventionParticipants (Count of Participants)
End of IV Therapy, Therapeutic SuccessEnd of IV Therapy, Therapeutic FailureTest of Cure, Therapeutic SuccessTest of Cure, Therapeutic FailureLate Follow-up, Therapeutic SuccessLate Follow-up, Therapeutic Failure
GSK2251052 1500 mg111111
GSK2251052 750 mg313131
Meropenem 1g404040

[back to top]

Number of Participants With Clinical Response at Test of Cure Visit (5-9 Days Post-therapy) in Microbiological Evaluable Population.

Test of cure-clinical success was resolution of signs and symptoms of complicated intra-abdominal infection (cIAI) for participants who were clinical successes at the end of IV therapy visit with no new symptoms recorded that were not present at Baseline and no use of additional antibiotic therapy for cIAI. Test of cure-clinical failure was persistence of signs and symptoms of cIAI recorded at Baseline, or reappearance of signs and symptoms that had previously resolved, or new signs and symptoms recorded that were not present at a previous visit, or receipt of additional or alternate antibiotic therapy for cIAI or participant had died. Test of cure- unable to determine was refusal to consent to a clinical examination, lost to follow-up. Participants who were 'unable to determine' at End of IV therapy were considered 'unable to determine' Test of cure Visit as well. Due to early termination of the study, a Bayesian approach for informal hypothesis testing was not performed. (NCT01381562)
Timeframe: Day 5 to 9 post IV therapy

,,
InterventionParticipants (Count of Participants)
Test of Cure Clinical SuccessEnd of IV Clinical Failure
GSK2251052 1500 mg11
GSK2251052 750 mg31
Meropenem 1g40

[back to top]

Number of Participants With Any Adverse Event

AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE included AEs those result in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition (NCT01381562)
Timeframe: Up to Day 42

,,
InterventionParticipants (Count of Participants)
Any AEAny SAE
GSK2251052 1500 mg43
GSK2251052 750 mg52
Meropenem 1g30

[back to top]

Mean Change From Baseline in Hemoglobin for Partcipants With Significant Hemoglobin Drop

Participants in whom the hemoglobin level dropped by more than 30% from Baseline that was not attributable to acute blood loss were recorded and immediately withdrawn from study treatment. Baseline assessments were recorded on Visit 1 (Day 1) and used as Baseline values. The change from Baseline was calculated by subtracting the Baseline values from Day 42 values. If either the Baseline or post-randomization value was missing, the change from Baseline was set to missing. The mean change from Baseline in hemoglobin for participants with significant hemoglobin drop were reported. (NCT01381562)
Timeframe: Baseline (Day 1) and up to Day 42

Interventiongrams/L (Mean)
On IV Therapy, Day 3On IV Therapy, Day 5On IV Therapy, Day 8On IV Therapy, Day 11End of IV TherapyHematology SafetyTest for CureEarly Follow-upLate Follow-up
GSK2251052 750 mg-7.8-15.03.0-58.0-16.0-10.8-13.3-16.5-9.0

[back to top]

Mean Change From Baseline in Hemoglobin for Partcipants With Significant Hemoglobin Drop

Participants in whom the hemoglobin level dropped by more than 30% from Baseline that was not attributable to acute blood loss were recorded and immediately withdrawn from study treatment. Baseline assessments were recorded on Visit 1 (Day 1) and used as Baseline values. The change from Baseline was calculated by subtracting the Baseline values from Day 42 values. If either the Baseline or post-randomization value was missing, the change from Baseline was set to missing. The mean change from Baseline in hemoglobin for participants with significant hemoglobin drop were reported. (NCT01381562)
Timeframe: Baseline (Day 1) and up to Day 42

Interventiongrams/L (Mean)
On IV Therapy, Day 3On IV Therapy, Day 5On IV Therapy, Day 8End of IV TherapyHematology SafetyTest for CureEarly Follow-upLate Follow-up
GSK2251052 1500 mg-13.31.5-6.0-0.7-8.3-8.76.011.0

[back to top]

Laboratory Parameters of Interest- Mean Hemoglobin Over the Period of Study Duration

Absolute mean hemoglobin values recorded over the period of duration were reported. (NCT01381562)
Timeframe: Up to Day 42

InterventionGram per Litre (Mean)
Baseline (Day 1)On IV Therapy (Day 3)On IV Therapy (Day 5)On IV Therapy (Day 8)On IV Therapy (Day 11)End Of IV TherapyHaematology SafetyTest of cureEarly Follow upLate Follow up
GSK2251052 750 mg142.2134.4127.2148.097.0126.2131.4131.0125.5133.2

[back to top]

Laboratory Parameters of Interest- Mean Hemoglobin Over the Period of Study Duration

Absolute mean hemoglobin values recorded over the period of duration were reported. (NCT01381562)
Timeframe: Up to Day 42

,
InterventionGram per Litre (Mean)
Baseline (Day 1)On IV Therapy (Day 3)On IV Therapy (Day 5)On IV Therapy (Day 8)End Of IV TherapyHaematology SafetyTest of cureEarly Follow upLate Follow up
GSK2251052 1500 mg121.5112.3120.7132.0123.8118.0116.0121.5126.5
Meropenem 1g125.0137.3131.0143.0130.8138.6138.2138.5146.8

[back to top]

Laboratory Parameters of Interest- Mean Reticulocytes Over the Period of Study Duration

Absolute mean reticulocytes values recorded over the period of duration were reported. (NCT01381562)
Timeframe: Up to 42 days

InterventionTrillion cells per Litre (Mean)
Baseline (Day 1)On IV Therapy (Day 3)On IV Therapy (Day 5)On IV Therapy (Day 8)On IV Therapy (Day 11)End Of IV TherapyHaematology SafetyTest Of CureEarly Follow upLate Follow up
GSK2251052 750 mg0.05890.04870.05800.00770.03350.05640.06400.09590.08420.1046

[back to top]

Number of Participants With Therapeutic Response in Microbiological Evaluable Population

Therapeutic response was a measure of the overall efficacy response, and a therapeutic success referred to participants who had been deemed both a 'clinical success' and a 'microbiological success'. All other combinations (other than 'clinical success' + 'microbiological success') were deemed failures for therapeutic response. Therapeutic response was determined programmatically. (NCT01381562)
Timeframe: End of IV therapy (0-24 hours post-therapy); Test of cure (5-9 days post-therapy); Late Follow-up (21-28 days post-therapy)

,,
InterventionParticipants (Count of Participants)
End of IV Therapy, Therapeutic SuccessEnd of IV Therapy, Therapeutic FailureTest of Cure, Therapeutic SuccessTest of Cure, Therapeutic FailureLate Follow-up, Therapeutic SuccessLate Follow-up, Therapeutic Failure
GSK2251052 1500 mg111111
GSK2251052 750 mg313131
Meropenem 1g404040

[back to top]

Number of Participants With Normal and Abnormal ECG Findings

12-lead ECGs was obtained during the study using an ECG machine and performed with the participant in a semi-supine position rested in this position for at least 10 minutes beforehand. Measurements deviated substantially from previous readings were repeated immediately. Number of participants with normal and abnormal ECG findings were reported. (NCT01381562)
Timeframe: Up to Day 42

,,
InterventionParticipants (Count of Participants)
Baseline, Pre-dose 1, NormalBaseline, Pre-dose 1, Unable to evaluateBaseline, Pre-dose 1, AbnormalBaseline, Pre-dose 2, NormalBaseline, Pre-dose 2, AbnormalBaseline, Pre-dose 3, NormalBaseline, Pre-dose 3, AbnormalBaseline, Post-dose , NormalBaseline, Post-dose , AbnormalOn IV Therapy (Day 4), Pre-dose, NormalOn IV Therapy (Day 4), Pre-dose, AbnormalOn IV Therapy (Day 4), Post-dose, NormalEarly Follow-up
GSK2251052 1500 mg4004040314043
GSK2251052 750 mg4014141414155
Meropenem 1g4105050415055

[back to top]

Number of Participants With Clinical Response at Test of Cure Visit (5-9 Days Post-therapy) in Microbiological Intent to Treat (MITT) Population

Test of cure-clinical success was resolution of signs and symptoms of complicated intra-abdominal infection (cIAI) for participants who were clinical successes at the end of IV therapy visit with no new symptoms recorded that were not present at Baseline and no use of additional antibiotic therapy for cIAI. Test of cure-clinical failure was persistence of signs and symptoms of cIAI recorded at Baseline, or reappearance of signs and symptoms that had previously resolved, or new signs and symptoms recorded that were not present at a previous visit, or receipt of additional or alternate antibiotic therapy for cIAI or participant had died. Test of cure- unable to determine was refusal to consent to a clinical examination, lost to follow-up. Participants who were 'unable to determine' at End of IV therapy were considered 'unable to determine' Test of cure Visit as well. Due to early termination of the study, a Bayesian approach for informal hypothesis testing was not performed. (NCT01381562)
Timeframe: Day 5 to 9 post IV therapy

,,
InterventionParticipants (Count of Participants)
Test of Cure Clinical SuccessTest of Cure Clinical Failure
GSK2251052 1500 mg11
GSK2251052 750 mg31
Meropenem 1g40

[back to top]

Number of Participants With Microbiological Response in MITT Population

Microbiological Response at End of IV Therapy was assessed as Microbiological Success (MS) or Microbiological Failure (MF). MS was categorized as microbiological eradication (ME) and presumed microbiological eradication (PME). MF was categorized as microbiological persistence (MP), presumed microbiological persistence (PMP), unable to determine, new infection and colonization. Number of participants with microbiological response in MITT population were reported. (NCT01381562)
Timeframe: End of IV therapy (0-24 hours post-therapy); Test of cure (5-9 days post-therapy); Late Follow-up (21-28 days post-therapy)

,,
InterventionParticipants (Count of Participants)
End of IV Therapy, MS, PMEEnd of IV Therapy, MF, MPEnd of IV Therapy, MF, PMPTest of Cure, MS, PMETest of Cure, MF, PMPLate follow-up, MS, PMELate follow-up, MF, PMP
GSK2251052 1500 mg1101111
GSK2251052 750 mg3013131
Meropenem 1g4004040

[back to top]

Number of Participants With Microbiological Response in Microbiological Evaluable Population

Microbiological Response at End of IV Therapy was assessed as MS or MF. MS was categorized as ME and PME. MF was categorized as MP and PMP, unable to determine, new infection and colonization. Number of participants with microbiological response in microbiological evaluable population were reported. (NCT01381562)
Timeframe: End of IV therapy (0-24 hours post-therapy); Test of cure (5-9 days post-therapy); Late Follow-up (21-28 days post-therapy)

,,
InterventionParticipants (Count of Participants)
End of IV Therapy, MS, PMEEnd of IV Therapy, MF, MPEnd of IV Therapy, MF, PMPTest of Cure, MS, PMETest of Cure, MF, PMPLate follow-up, MS, PMELate follow-up, MF, PMP
GSK2251052 1500 mg1101110
GSK2251052 750 mg3013131
Meropenem 1g4004040

[back to top]

Mean Change From Baseline in Hemoglobin for Partcipants With Significant Hemoglobin Drop

Participants in whom the hemoglobin level dropped by more than 30% from Baseline that was not attributable to acute blood loss were recorded and immediately withdrawn from study treatment. Baseline assessments were recorded on Visit 1 (Day 1) and used as Baseline values. The change from Baseline was calculated by subtracting the Baseline values from Day 42 values. If either the Baseline or post-randomization value was missing, the change from Baseline was set to missing. The mean change from Baseline in hemoglobin for participants with significant hemoglobin drop were reported. (NCT01381562)
Timeframe: Baseline (Day 1) and up to Day 42

Interventiongrams/L (Mean)
On IV Therapy, Day 3On IV Therapy, Day 5End of IV TherapyHematology SafetyTest for CureEarly Follow-upLate Follow-up
Meropenem 1g0.0-1.7-2.310.011.01.520.0

[back to top]

Number of Participants With Clinical Response in MITT Population

Clinical success was defined as resolution or improvement of Baseline signs and symptoms of cIAI, including white blood cell count within normal limits, participant was afebrile and peritoneal findings consistent with cIAI were no longer present with no new symptoms present that were not present at Baseline and no use of additional or alternate antibiotic therapy. Clinical failure was defined as (1) Lack of improvement or worsening in one or more signs and symptoms of cIAI recorded at Baseline, or reappearance of signs and symptoms that had previously resolved, or (2) signs and symptoms recorded that were not present at Baseline, or (3) receipt of additional or alternate antibiotic therapy for cIAI or (4) participant had died, or (5) participant had an adverse event leading to study drug discontinuation and the participant required additional or alternative antibacterial therapy for the current cIAI. (NCT01381562)
Timeframe: End of IV therapy (0-24 hours post-therapy) and Late Follow-up (21-28 days post-therapy)

,,
InterventionParticipants (Count of Participants)
End of IV Therapy, Clinical Success,End of IV Therapy, Clinical FailureLate follow-up, Follow-up Clinical SuccessLate follow-up, End of IV Clinical Failure
GSK2251052 1500 mg1111
GSK2251052 750 mg3131
Meropenem 1g4040

[back to top]

Number of Participants With Clinical Response in Microbiological Evaluable Population

Clinical success was defined as resolution or improvement of Baseline signs and symptoms of cIAI, including white blood cell count within normal limits, participant was afebrile and peritoneal findings consistent with cIAI were no longer present with no new symptoms present that were not present at Baseline and no use of additional or alternate antibiotic therapy. Clinical failure was defined as (1) Lack of improvement or worsening in one or more signs and symptoms of cIAI recorded at Baseline, or reappearance of signs and symptoms that had previously resolved, or (2) signs and symptoms recorded that were not present at Baseline, or (3) receipt of additional or alternate antibiotic therapy for cIAI or (4) participant had died, or (5) participant had an adverse event leading to study drug discontinuation and the participant required additional or alternative antibacterial therapy for the current cIAI. (NCT01381562)
Timeframe: End of IV therapy (0-24 hours post-therapy); Test of cure (5-9 days post-therapy); Late Follow-up (21-28 days post-therapy)

,,
InterventionParticipants (Count of Participants)
End of IV Therapy, Clinical SuccessEnd of IV Therapy, Clinical FailureLate follow-up, Follow-up Clinical SuccessLate follow-up, End of IV Clinical Failure
GSK2251052 1500 mg1110
GSK2251052 750 mg3131
Meropenem 1g4040

[back to top] [back to top]

Population Pharmacokinetics - Volume of Central Compartment

Based on meropenem concentrations, the pharmacokinetics of the study population will be analyzed to determine each patient's volume of the central compartment. (NCT01429259)
Timeframe: During 8 hour dosing interval after 3rd meropenem dose

InterventionL/kg (Mean)
Meropenem 3 Hour Prolonged Infusion0.21

[back to top]

Population Pharmacokinetics - Total Body Clearance

Based on meropenem concentrations, the pharmacokinetics of the study population will be analyzed to determine each patient's total body clearance. (NCT01429259)
Timeframe: 8 hour dosing interval after 3rd meropenem dose

InterventionL/hr/kg (Mean)
Meropenem 3 Hour Prolonged Infusion0.36

[back to top]

The Percentage of Subjects With Clinical Response at End of Therapy in the ME Population

Clinical response is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection. (NCT01445678)
Timeframe: EOT; Within 24 hours of last study drug administration

Interventionpercentage of subjects (Number)
CXA-201 and Metronidazole as Treatment for cIAI97.1
Meropenem as Treatment for cIAI97.5

[back to top]

The Percentage of Subjects With Clinical Response at End of Therapy (EOT) Visit in the MITT Population

Clinical response is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection. (NCT01445678)
Timeframe: EOT; Within 24 hours of last study drug administration

Interventionpercentage of subjects (Number)
CXA-201 and Metronidazole as Treatment for cIAI89.2
Meropenem as Treatment for cIAI92.3

[back to top]

The Percentage of Subjects With Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population

Clinical cure is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection. (NCT01445678)
Timeframe: TOC; 26-30 days after start of study drug administration

Interventionpercentage of subjects (Number)
CXA-201 and Metronidazole as Treatment for cIAI83.0
Meropenem as Treatment for cIAI87.3

[back to top]

The Percentage of Subjects With Microbiological Outcome of Success at the TOC Visit in the Microbiologically Evaluable (ME) Population

Success is eradication (absence of the baseline pathogen in a specimen appropriately obtained from the original site of infection) or presumed eradication (absence of material to culture in a subject who was assessed as a clinical cure) for each baseline pathogen (NCT01445678)
Timeframe: TOC; 26-30 days after start of study drug administration

Interventionpercentage of subjects (Number)
CXA-201 and Metronidazole as Treatment for cIAI94.2
Meropenem as Treatment for cIAI94.7

[back to top]

The Percentage of Subjects With Clinical Response at Long Term Follow-Up (LFU) in the MITT Population

Clinical response is clinical cure at TOC and no signs and symptoms recur or worsen since the TOC visit. (NCT01445678)
Timeframe: LFU; 38 to 45 days after first study drug administration

Interventionpercentage of subjects (Number)
CXA-201 and Metronidazole as Treatment for cIAI82.5
Meropenem as Treatment for cIAI86.6

[back to top]

The Percentage of Subjects With Clinical Response at LFU Visit in the ME Population

Clinical response is clinical cure at TOC and no signs and symptoms recur or worsen since the TOC visit (NCT01445678)
Timeframe: LFU; 38 to 45 days after first study drug administration

Interventionpercentage of subjects (Number)
CXA-201 and Metronidazole as Treatment for cIAI100
Meropenem as Treatment for cIAI99.3

[back to top]

Number of Patients Afebrile at Last Observation in the Clinically Evaluable Analysis Set for Patients Who Have Fever at Study Entry

Time to first defervescence was calculated for patients with a fever (>38ºC) at baseline. Defervescence (≤37.8ºC) was defined as the absence of fever based on the highest temperature recorded on each study day. (NCT01499290)
Timeframe: Test of Cure: 1 to 14 days after start of study drug

InterventionParticipants (Number)
CAZ-AVI + Metronidazole84
Meropenem72

[back to top]

Clinical Response by Pathogen at TOC for Patients Infected With Ceftazidime-resistant Pathogens in Microbiological Modified Intent to Treat Analysis Set

Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. (NCT01499290)
Timeframe: Test of Cure: 28 to 35 days after start of study drug

,,,
InterventionParticipants (Number)
AllCitrobacter freundii complexEnterobacter aerogenesEnterobacter cloacaeEscherichia coliKlebsiella pneumoniaeMorganella morganiiProteus mirabilisSerratia marcescensAlcaligenes faecalisComamonas testosteroniPseudomonas aeruginosa
CAZ-AVI + Metronidazole391021910121112
CAZ-AVI + Metronidazole (Denominator)471032413221112
Meropenem55217319130204
Meropenem (Denominator)642173713130204

[back to top]

Per-patient Microbiological Response in the Microbiologically Modified Intent- To-Treat Analysis Set

"Microbiological responses as per the protocoled criteria: responses other than indeterminate were classified as favorable or unfavorable. Favorable microbiological response assessments included eradication and presumed eradication. Unfavorable microbiological response assessments included persistence, persistence with increasing minimum inhibitory concentration (MIC), and presumed persistence. Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to a surgical review panel (SRP) assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence)." (NCT01499290)
Timeframe: EOT: within 24 hours after last dose of study drug. TOC: 28 to 35 days after start of study drug. LFU 42 to 49 days after start of study drug

,,,,,
InterventionParticipants (Number)
Favourable responseUnfavourable responseIndeterminate
CAZ-AVI + Metronidazole (EOT)3623021
CAZ-AVI + Metronidazole (LFU)3403835
CAZ-AVI + Metronidazole (TOC)3373739
Meropenem (EOT)3791912
Meropenem (LFU)3473231
Meropenem (TOC)3493130

[back to top]

Per-patient Microbiological Response at TOC for Patients Infected With Ceftazidime-resistant Pathogens in mMITT Analysis Set

"Microbiological responses other than indeterminate were classified as favorable or unfavorable. Favorable microbiological response assessments included eradication and presumed eradication. Unfavorable microbiological response assessments included persistence, persistence with increasing minimum inhibitory concentration (MIC), and presumed persistence. Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence)." (NCT01499290)
Timeframe: Test of Cure: 28 to 35 days after start of study drug

,
InterventionParticipants (Number)
FavourableUnfavourableindeterminate
CAZ-AVI + Metronidazole3972
Meropenem5518

[back to top]

Per-pathogen Microbiological Response at TOC in the Microbiologically Modified Intent-To-Treat Analysis Set.

The number of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure. (NCT01499290)
Timeframe: TOC: 28 to 35 days after start of study drug.

,,,
InterventionParticipants (Number)
Citrobacter freundii complexEnterobacter aerogenesEnterobacter cloacaeEscherichia coliKlebsiella oxytocaKlebsiella pneumoniaeProteus mirabilisPseudomonas aeruginosaEnterococcus aviumEnterococcus faecalisEnterococcus faeciumStaphylococcus aureusStreptococcus anginosus groupStreptococcus bovis groupStreptococcus mitis groupBacteroides fragilisBacteroides ovatusBacteroides stercorisBacteroides thetaiotaomicronBacteroides uniformisBacteroides vulgatusClostridium perfringensEggerthella lentaParabacteroides distasonisParvimonas micra
CAZ-AVI + Metronidazole14411218144053082213175921045179184675137
CAZ-AVI + Metronidazole (Denominator)1851327118518358311618723155222102278105167
Meropenem9516249123773410231814506938171216647128
Meropenem (Denominator)1251928515499361528221461711472012579481310

[back to top]

Favorable Per-pathogen Microbiological Response for Patients Infected With Ceftazidime-resistant Pathogens in mMITT Analysis Set

The number of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure. (NCT01499290)
Timeframe: TOC: 28 to 35 days after start of study drug

,,,
InterventionParticipants (Number)
Citrobacter freundii complexEnterobacter aerogenesEnterobacter cloacaeEscherichia coliKlebsiella pneumoniaeMorganella morganiiProteus mirabilisSerratia marcescensAlcaligenes faecalisComamonas testosteroniPseudomonas aeruginosa
CAZ-AVI + Metronidazole1021910121112
CAZ-AVI + Metronidazole (Denominator)2032413221112
Meropenem217319130204
Meropenem (Denominator)2173713130204

[back to top]

Clinical Response by Visit in the Primary Population: Microbiologically Modified Intent-to-Treat (mMITT)

Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. Indeterminate response are where study data were not available for evaluation of efficacy for any reason, including patient lost to follow-up or assessment not undertaken such that a determination of clinical response could not be made, dDeath where cIAI was clearly noncontributory or circumstances that precluded classification as a cure or failure. (NCT01499290)
Timeframe: EOT: within 24 hours after last dose of study drug. TOC: 28 to 35 days after start of study drug. LFU: 42 to 49 days after start of study drug

,,,,,
InterventionParticipants (Number)
Clinical cureClinical failureIndeterminate
CAZ-AVI + Metronidazole (EOT)3613022
CAZ-AVI + Metronidazole (LFU)3403835
CAZ-AVI + Metronidazole (TOC)3373739
Meropenem (EOT)3791912
Meropenem (LFU)3473132
Meropenem (TOC)3493031

[back to top]

Clinical Response at the TOC Visit in the Modified Intent-To-Treat Analysis Set (Co-primary Outcome for Rest of World [ROW]).

The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. Indeterminate response are where study data were not available for evaluation of efficacy for any reason, including patient lost to follow-up or assessment not undertaken such that a determination of clinical response could not be made, dDeath where cIAI was clearly noncontributory or circumstances that precluded classification as a cure or failure. (NCT01499290)
Timeframe: TOC: 28 to 35 days after start of study drug

,
InterventionParticipants (Number)
Clinical cureClinical failureIndeterminate
CAZ-AVI + Metronidazole4294744
Meropenem4443940

[back to top]

Clinical Response at the TOC Visit in the Clinically Evaulable (CE) Analysis Set (Co-primary Outcome for Rest of World [ROW]).

The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. (NCT01499290)
Timeframe: TOC: 28 to 35 days after start of study drug

,
InterventionParticipants (Number)
Clinical cureClinical failure
CAZ-AVI + Metronidazole37634
Meropenem38531

[back to top]

Clinical Response at the Test of Cure (TOC) Visit in the Microbiologically Modified Intent-To-Treat (mMITT) Analysis Set (Primary Outcome for FDA).

The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention is necessary. Indeterminate response are where study data were not available for evaluation of efficacy for any reason, including patient lost to follow-up or assessment not undertaken such that a determination of clinical response could not be made, death where cIAI was clearly noncontributory or circumstances that precluded classification as a cure or failure. Results from two identical protocols D4280C00001 and D4280C00005 combined into a single database with agreement from FDA and EMA. (NCT01499290)
Timeframe: TOC: 28 to 35 days after start of study drug

,
InterventionParticipants (Number)
Clinical cureClinical failureIndeterminate
CAZ-AVI + Metronidazole3373739
Meropenem3493031

[back to top]

Clinical Cure at TOC in the Microbiologically Evaluable Analysis Set

The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. (NCT01499290)
Timeframe: TOC: 28 to 35 days after start of study drug

,
InterventionParticipants (Number)
Clinical cureClinical failure
CAZ-AVI + Metronidazole24421
Meropenem27215

[back to top]

Clinical Cure at TOC in the Extended Microbiologically Evaluable Analysis Set

The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. (NCT01499290)
Timeframe: TOC: 28 to 35 days after start of study drug

,
InterventionParticipants (Number)
Clinical cureClinical failure
CAZ-AVI + Metronidazole24822
Meropenem27816

[back to top]

Plasma Concentrations for Ceftazidime and Avibactam

Blood samples were taken from all patients on Day 3 for the pharmacokinetic evaluation of ceftazidime and avibactam plasma concentrations (NCT01499290)
Timeframe: Anytime within 15 minutes prior to or after stopping study drug, anytime between 30 and 90 minutes after stopping study drug, anytime between 300 minutes and 360 minutes after stopping study drug

Intervention(NG/ML) (Geometric Mean)
CAZ (1)50823.0
AVI (1)9229.4
CAZ (2)40053.1
AVI (2)7163.9
CAZ (3)10967.6
AVI (3)1690.7

[back to top]

Number of Participants With Suppression and Emergence of Resistance

The emergence of resistance is defined as a change of meropenem MIC or aminoglycoside MIC by two tube dilutions (fourfold) from baseline when assessed at the second BAL procedure on day 5/early extubation. Patients are evaluable for this endpoint IF they had baseline BAL and Day 5/early extubation and if they had positive cultures on baseline and Day/EE. (NCT01570192)
Timeframe: up to 28 days after enrollment

Interventionparticipants (Number)
suppression of emergence of resistanceemergence of resistance
I.V. Meropenem51

[back to top]

Suppression of the Emergence of Resistance in Other Gram-negative Pathogens

Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: Day 5/Early Extubation

InterventionParticipants (Count of Participants)
ME Group - Meropenem Plus Aminoglycoside1
ME Group - Meropenem Only1
m-MITT Group - Meropenem Plus Aminoglycoside1
m-MITT Group - Meropenem Only2

[back to top]

Clinical Response in Subjects Who Received Prior Antibiotics

Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment

InterventionParticipants (Count of Participants)
ME Group - Meropenem Plus Aminoglycoside1
ME Group - Meropenem Only2
m-MITT Group - Meropenem Plus Aminoglycoside1
m-MITT Group - Meropenem Only2

[back to top]

Clinical Response

Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment

InterventionParticipants (Count of Participants)
ME Group - Meropenem Plus Aminoglycoside2
MEGroup - Meropenem Only8
m-MITT Group - Meropenem Plus Aminoglycoside2
m-MITT Group - Meropenem Only8

[back to top]

Mortality

Percentage of patients who died by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
ME Group - Meropenem Plus Aminoglycoside1
ME Group - Meropenem Only0
m-MITT Group - Meropenem Plus Aminoglycoside2
m-MITT Group - Meropenem Only2

[back to top]

Mortality

Percentage of patients who died by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
ME Group - Meropenem Plus Aminoglycoside2
ME Group - Meropenem Only1
m-MITT Group - Meropenem Plus Aminoglycoside3
m-MITT Group - Meropenem Only3

[back to top]

Occurrence of Repeat Negative Cultures

Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: Day 5/Early Extubation

InterventionParticipants (Count of Participants)
ME Group - Meropenem Plus Aminoglycoside3
ME Group - Meropenem Only6
m-MITT Group - Meropenem Plus Aminoglycoside3
m-MITT Group - Meropenem Only7

[back to top]

Overall Microbiologic Response

Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment

InterventionParticipants (Count of Participants)
ME Group - Meropenem Plus Aminoglycoside2
ME Group - Meropenem Only6
m-MITT Group - Meropenem Plus Aminoglycoside2
m-MITT Group - Meropenem Only7

[back to top]

Pretreatment Pathogen Response

Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment

InterventionParticipants (Count of Participants)
ME Group - Meropenem Plus Aminoglycoside3
ME Group - Meropenem Only9
m-MITT Group - Meropenem Plus Aminoglycoside3
m-MITT Group - Meropenem Only11

[back to top]

Clinical Failure at the End of Therapy

Clinical failure as defined by either Blood Stream Infection (BSI) or Pneumonia; based on death between 48 hours and end of treatment, medication change from protocol, a positive blood culture after 5 days of blood stream infection treatment, or no improvements in PaO2/FiO2 at end of treatment. (NCT01597973)
Timeframe: 48 hours after end of treatment, that is up to 16 days

InterventionParticipants (Count of Participants)
Colistin and Placebo115
Colistin and a Carbapenem97

[back to top]

Number of Participants Who Develop Colistin Resistance

Determine what treatment regimen (colistin monotherapy (combined with placebo)) or colistin combined a carbapenem (imipenem or meropenem) is more likely to reduce the frequency of emergence of colistin resistance among XDR-GNB isolates during therapy. Measurements of Minimum Inhibitory Concentration of colistin to XDR-GNB. This is shown below as numbers of those subjects who develop colistin resistance and their percentages of the total completed population. (NCT01597973)
Timeframe: patients' resistance data will be collected up to 30 days

InterventionParticipants (Count of Participants)
Colistin and Placebo18
Colistin and a Carbapenem15

[back to top]

Microbiologic Cure at the End of Therapy

Microbiologic cure at the end of therapy as defined by the number of participants who no longer have the causative XDR-GNB pathogens for their BSI or pneumonia identified based on microbiologic testing (NCT01597973)
Timeframe: From 5 days after enrollment up to 14 days following enrollment (i.e. end of treatment)

,
InterventionParticipants (Count of Participants)
CureFailure
Colistin and a Carbapenem10569
Colistin and Placebo11257

[back to top]

Mortality

Determine whether the treatment regimen of colistin combined with a carbapenem (imipenem or meropenem) is associated with a decreased risk for all-cause mortality during the 30 day post-enrollment period compared to colistin combined with a placebo for subjects with bloodstream infection (BSI) and/or pneumonia due to extensively drug-resistant Gram-negative bacilli (XDR-GNB). (NCT01597973)
Timeframe: participants will be followed daily for the duration of hospital stay, an expected average of 4 weeks

,
InterventionParticipants (Count of Participants)
DeadAlive
Colistin and a Carbapenem78133
Colistin and Placebo92122

[back to top] [back to top]

The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated." (NCT01726023)
Timeframe: At the end of treatment (EOT) (within 24 hours after last IV dose)

,
InterventionNumber of patients (Number)
FavorableUnfavorable
Ceftazidime-Avibactam Plus Metronidazole1033
Meropenem1135

[back to top]

The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Clinically Evaluable (CE) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. (NCT01726023)
Timeframe: At the test of cure visit (Day 28 to35)

,
InterventionNumber of patients (Number)
Clinical cureClinical failure
Ceftazidime-Avibactam Plus Metronidazole16611
Meropenem17311

[back to top]

The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. (NCT01726023)
Timeframe: At the late follow up (LFU) (Day 42 to 49)

,
InterventionNumber of patients (Number)
Clinical cureClinical failure
Ceftazidime-Avibactam Plus Metronidazole897
Meropenem1006

[back to top]

The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. (NCT01726023)
Timeframe: At the late follow up (LFU) (Day 42 to 49)

,
InterventionNumber of patients (Number)
Clinical cureClinical failureIndeterminate
Ceftazidime-Avibactam Plus Metronidazole1161017
Meropenem132911

[back to top]

The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. (NCT01726023)
Timeframe: At the late follow up (LFU) (Day 42 to 49)

,
InterventionNumber of patients (Number)
Clinical cureClinical failure
Ceftazidime-Avibactam Plus Metronidazole907
Meropenem1066

[back to top]

The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Clinically Evaluable (CE) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. (NCT01726023)
Timeframe: At late follow up (LFU) visits (Day 42 to 49)

,
InterventionNumber of patients (Number)
Clinical cureClinical failure
Ceftazidime-Avibactam Plus Metronidazole15711
Meropenem16811

[back to top]

The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. (NCT01726023)
Timeframe: At the end of treatment (EOT) (within 24 hours after last IV dose)

,
InterventionNumber of patients (Number)
Clinical cureClinical failure
Ceftazidime-Avibactam Plus Metronidazole1033
Meropenem1135

[back to top]

The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. (NCT01726023)
Timeframe: At the end of treatment (EOT) (within 24 hours after last IV dose)

,
InterventionNumber of patients (Number)
Clinical cureClinical failureIndeterminate
Ceftazidime-Avibactam Plus Metronidazole126611
Meropenem14075

[back to top]

The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. (NCT01726023)
Timeframe: At the end of treatment (EOT) (within 24 hours after last IV dose)

,
InterventionNumber of patients (Number)
Clinical cureClinical failure
Ceftazidime-Avibactam Plus Metronidazole1043
Meropenem1205

[back to top]

The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Clinically Evaluable (CE) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. (NCT01726023)
Timeframe: At the end of treatment (EOT) (within 24 hours after last IV dose)

,
InterventionNumber of patients (Number)
Clinical cureClinical failure
Ceftazidime-Avibactam Plus Metronidazole1837
Meropenem1879

[back to top]

The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated." (NCT01726023)
Timeframe: At the test of cure (TOC) (Day 28 to 35)

,
InterventionNumber of patients (Number)
FavorableUnfavorable
Ceftazidime-Avibactam Plus Metronidazole927
Meropenem1076

[back to top]

The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated." (NCT01726023)
Timeframe: At the test of cure (TOC) (Day 28 to 35)

,
InterventionNumber of patients (Number)
FavorableUnfavorableIndeterminate
Ceftazidime-Avibactam Plus Metronidazole1191014
Meropenem13598

[back to top]

The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated." (NCT01726023)
Timeframe: At the test of cure (TOC) (Day 28 to 35)

,
InterventionNumber of patients (Number)
FavorableUnfavorable
Ceftazidime-Avibactam Plus Metronidazole937
Meropenem1136

[back to top]

The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. (NCT01726023)
Timeframe: At the test of cure (TOC) (Day 28 to 35)

,
InterventionNumber of patients (Number)
Clinical cureClinical failure
Ceftazidime-Avibactam Plus Metronidazole937
Meropenem1136

[back to top]

The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated." (NCT01726023)
Timeframe: At the late follow up (LFU) (Day 42 to 49)

,
InterventionNumber of patients (Number)
FavorableUnfavorableIndeterminate
Ceftazidime-Avibactam Plus Metronidazole1161017
Meropenem132911

[back to top]

The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. (NCT01726023)
Timeframe: At the test of cure (TOC) (Day 28 to 35)

,
InterventionNumber of patients (Number)
Clinical cureClinical failureIndeterminate
Ceftazidime-Avibactam Plus Metronidazole1191014
Meropenem13598

[back to top]

The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. (NCT01726023)
Timeframe: At the test of cure (TOC) (Day 28 to 35)

,
InterventionNumber of patients (Number)
Clinical cureClinical failure
Ceftazidime-Avibactam Plus Metronidazole927
Meropenem1076

[back to top]

The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated." (NCT01726023)
Timeframe: At the end of treatment (EOT) (within 24 hours after last IV dose)

,
InterventionNumber of patients (Number)
FavorableUnfavorableIndeterminate
Ceftazidime-Avibactam Plus Metronidazole126611
Meropenem14075

[back to top]

The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated." (NCT01726023)
Timeframe: At the end of treatment (EOT) (within 24 hours after last IV dose)

,
InterventionNumber of patients (Number)
FavorableUnfavorable
Ceftazidime-Avibactam Plus Metronidazole1043
Meropenem1205

[back to top]

The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Microbiologically Evaluable (ME) Analysis Set.

"The microbiological responses as per the protocoled criteria: responses other than indeterminate were classified as favorable or unfavorable. Favorable microbiological response assessments included eradication and presumed eradication. Unfavorable microbiological response assessments included persistence, persistence with increasing minimum inhibitory concentration (MIC), and presumed persistence. Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence)." (NCT01726023)
Timeframe: At the test of cure (TOC) (Day 28 to 35)

,
InterventionNumber of patients (Number)
FavorableUnfavorable
Ceftazidime-Avibactam Plus Metronidazole221
Meropenem231

[back to top]

The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

"The microbiological responses as per the protocoled criteria: responses other than indeterminate were classified as favorable or unfavorable. Favorable microbiological response assessments included eradication and presumed eradication. Unfavorable microbiological response assessments included persistence, persistence with increasing minimum inhibitory concentration (MIC), and presumed persistence. Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence)." (NCT01726023)
Timeframe: At the test of cure (TOC) (Day 28 to 35)

,
InterventionNumber of patients (Number)
FavorableUnfavorableIndeterminate
Ceftazidime-Avibactam Plus Metronidazole2414
Meropenem2711

[back to top]

The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Extended Microbiologically Evaluable (ME) Analysis Set.

"The microbiological responses as per the protocoled criteria: responses other than indeterminate were classified as favorable or unfavorable. Favorable microbiological response assessments included eradication and presumed eradication. Unfavorable microbiological response assessments included persistence, persistence with increasing minimum inhibitory concentration (MIC), and presumed persistence. Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence)." (NCT01726023)
Timeframe: At the test of cure (TOC) (Day 28 to 35)

,
InterventionNumber of patients (Number)
FavorableUnfavorable
Ceftazidime-Avibactam Plus Metronidazole221
Meropenem251

[back to top]

The Proportion of Favorable Per-pathogen Microbiological Response in the Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure. (NCT01726023)
Timeframe: At the test of cure (TOC) (Day 28 to 35)

,
InterventionParticipants with favorable responses (Number)
Escherichia coli (n=84, 89)Klebsiella oxytoca (n=5, 5)Klebsiella pneumoniae (n=28,35)Pseudomonas aeruginosa (n=17, 20)Streptococcus anginosus group (n=8, 7)Streptococcus mitis group (n=6, 5)Enterococcus faecalis (n=6, 6)Enterococcus faecium (n=4, 7)
Ceftazidime-Avibactam Plus Metronidazole70523147664
Meropenem84531175545

[back to top]

The Proportion of Favorable Per-pathogen Microbiological Response in the Microbiological Response at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure. (NCT01726023)
Timeframe: At the late follow up (LFU) (Day 42 to 49)

,
InterventionParticipants with favorable responses (Number)
Escherichia coli (n=84, 89)Klebsiella pneumoniae (n=28, 35)Pseudomonas aeruginosa (n=17, 20)Klebsiella oxytoca (n=5, 5)Enterococcus faecalis (n=6, 6)Enterococcus faecium (n=4, 7)Streptococcus anginosus group (n=8, 7)Streptococcus mitis group (n=6, 5)
Ceftazidime-Avibactam Plus Metronidazole70221444376
Meropenem82311754555

[back to top]

The Proportion of Favorable Per-pathogen Microbiological Response at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure. (NCT01726023)
Timeframe: At the test of cure (TOC) (Day 28 to 35)

,
InterventionParticipants with favorable responses (Number)
Escherichia coli (n=69, 77)Klebsiella oxytoca (n=5, 5)Klebsiella pneumoniae (n=22, 29)Pseudomonas aeruginosa (n=14, 16)
Ceftazidime-Avibactam Plus Metronidazole6452113
Meropenem7452814

[back to top]

The Proportion of Favorable Per-pathogen Microbiological Response at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable(ME) Analysis Set.

The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure. (NCT01726023)
Timeframe: At the test of cure (TOC) (Day 28 to 35)

,
InterventionParticipants with favorable responses (Number)
Escherichia coli (n=70, 80)Klebsiella oxytoca (n=5, 5)Klebsiella pneumoniae (n=22, 30)Pseudomonas aeruginosa (n=14, 18)
Ceftazidime-Avibactam Plus Metronidazole6552113
Meropenem7752916

[back to top]

The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated." (NCT01726023)
Timeframe: At the late follow up (LFU) (Day 42 to 49)

,
InterventionNumber of patients (Number)
FavorableUnfavorable
Ceftazidime-Avibactam Plus Metronidazole907
Meropenem1066

[back to top]

Plasma Concentrations for Ceftazidime and Avibactam

Blood samples were taken from all patients on Day 3 for the pharmacokinetic evaluation of ceftazidime and avibactam plasma concentrations (NCT01726023)
Timeframe: At Day 3: Anytime within 15 minutes prior to or after stopping study drug, anytime between 30 and 90 minutes after stopping study drug, anytime between 300 minutes and 360 minutes after stopping study drug.

Interventionng/mL (Geometric Mean)
Ceftazidime(1)60300.4
Avibactam(1)10126.9
Ceftazidime(2)46473.9
Avibactam(2)7289.3
Ceftazidime(3)9555.0
Avibactam(3)1207.2

[back to top]

The Time to First Defervescence in the Clinically Evaluable (CE) Analysis Set for Patients Who Have Fever at Study Entry.

Time to first defervescence was calculated for patients with a fever (>38ºC) at baseline. Defervescence (≤37.8ºC) was defined as the absence of fever based on the highest temperature recorded on each study day. Time to first defervescence while on IV study therapy in the CE analysis set at TOC for patients who had fever at study entry is defined as time (in days) from the first dose of IV study therapy to first absence of fever. (NCT01726023)
Timeframe: while on study therapy (from Day 1 to Day 14)

InterventionDays (Median)
Ceftazidime-Avibactam Plus Metronidazole1
Meropenem1.5

[back to top]

The Proportion of Favorable Per-pathogen Microbiological Response at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure. (NCT01726023)
Timeframe: At the late follow up (LFU) (Day 42 to 49)

,
InterventionParticipants with favorable responses (Number)
Escherichia coli (n=69, 77)Klebsiella oxytoca (n=5, 5)Klebsiella pneumoniae (n=22, 29)Pseudomonas aeruginosa (n=14, 16)
Ceftazidime-Avibactam Plus Metronidazole6342113
Meropenem7252714

[back to top]

The Proportion of Favorable Per-pathogen Microbiological Response at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure. (NCT01726023)
Timeframe: At the late follow up (LFU) (Day 42 to 49)

,
InterventionParticipants with favorable responses (Number)
Escherichia coli (n=70, 80)Klebsiella oxytoca (n=5, 5)Klebsiella pneumoniae (n=22, 30)Pseudomonas aeruginosa (n=14, 18)
Ceftazidime-Avibactam Plus Metronidazole6442113
Meropenem7552816

[back to top]

The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure. (NCT01726023)
Timeframe: At the end of treatment (EOT) (within 24 hours after last IV dose)

,
InterventionParticipants with favorable responses (Number)
Escherichia coli (n=69, 77)Klebsiella oxytoca (n=5, 5)Klebsiella pneumoniae (n=22, 29)Pseudomonas aeruginosa (n=14, 16)
Ceftazidime-Avibactam Plus Metronidazole6852114
Meropenem7552814

[back to top]

The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure. (NCT01726023)
Timeframe: At the end of treatment (EOT) (within 24 hours after last IV dose)

,
InterventionParticipants with favorable responses (Number)
Escherichia coli (n=84, 89)Klebsiella oxytoca (n=5, 5)Klebsiella pneumoniae (n=28,35)Pseudomonas aeruginosa (n=17, 20)Streptococcus anginosus grou (n=8, 7)Streptococcus mitis group (n=6, 5)Enterococcus faecalis (n=6, 6)Enterococcus faecium (n=4, 7)
Ceftazidime-Avibactam Plus Metronidazole77522157654
Meropenem86532176555

[back to top]

The Time to First Defervescence in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set for Patients Who Have Fever at Study Entry.

Time to first defervescence was calculated for patients with a fever (>38ºC) at baseline. Defervescence (≤37.8ºC) was defined as the absence of fever based on the highest temperature recorded on each study day. Time to first defervescence while on IV study therapy in the CE analysis set at TOC for patients who had fever at study entry is defined as time (in days) from the first dose of IV study therapy to first absence of fever. (NCT01726023)
Timeframe: while on study therapy (from Day 1 to Day 14)

InterventionDays (Median)
Ceftazidime-Avibactam Plus Metronidazole1
Meropenem2

[back to top]

The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated." (NCT01726023)
Timeframe: At the late follow up (LFU) (Day 42 to 49)

,
InterventionNumber of patients (Number)
FavorableUnfavorable
Ceftazidime-Avibactam Plus Metronidazole897
Meropenem1006

[back to top]

Safety and Tolerability by Incidence and Severity of Adverse Events and Serious Adverse Events and Mortality.

Adverse event data were collected from the screening/consent visit until the late follow-up visit (i.e. Day -1/0 to Day 42). (NCT01726023)
Timeframe: study duration (from screening to Day 49 LFU visit)

,
InterventionNumber of patients (Number)
Any AEAny SAEAny AE leading to discontinuation of IPAny AE of severe intensityTotal number of deathsDeaths due to disease progressionAny AE with outcome=death
Ceftazidime-Avibactam Plus Metronidazole82975220
Meropenem831135101

[back to top]

Safety and Tolerability: Clinical Laboratory Evaluation Clinical Chemistry.

Potentially clinically significant (PCS) post Baseline clinical chemistry values up to LFU (Safety analysis set) (NCT01726023)
Timeframe: study duration (from screening to Day 49 LFU visit)

,
InterventionNumber of patients (Number)
Alanine aminotransferase (μkat/L): PCS (High)Alkaline phosphatase (μkat/L): PCS (Low)Alkaline phosphatase (μkat/L): PCS (High)Aspartate aminotransferase (μkat/L): PCS (High)Bicarbonate (mmol/L) PCS (Low)Bicarbonate (mmol/L): PCS (High)Creatinine (μmol/L): PCS (High)Glucose (non-fasting) (mmol/L): PCS (Low)Glucose (non-fasting) (mmol/L): PCS (High)Gamma-glutamyl transferase (μkat/L):PCS (High)Inorganic phosphorus (mmol/L): PCS (Low)Inorganic phosphorus (mmol/L): PCS (High)Potassium (mmol/L): PCS (Low)Potassium (mmol/L): PCS (High)Total bilirubin (μmol/L): PCS (High)Direct bilirubin (μmol/L): PCS (High)
Ceftazidime-Avibactam Plus Metronidazole3024100012309301
Meropenem8034001014705111

[back to top]

Safety and Tolerability by Incidence: Extent of Exposure.

Duration of exposure is calculated as the difference between the last study therapy date and the first study therapy date converted to days plus 1 day. Actual calculated duration could be shorter or longer than a full day. (NCT01726023)
Timeframe: study duration (from screening to Day 49 LFU visit)

,
InterventionNumber of patients (Number)
1 - 2 days3 - 4 days5 -10 days11 - 14 days>14 days
Ceftazidime-Avibactam Plus Metronidazole106175240
Meropenem55181260

[back to top]

Safety and Tolerability: Clinical Laboratory Evaluation Hematology.

Potentially clinically significant (PCS) post Baseline hematology values up to LFU (Safety analysis set) (NCT01726023)
Timeframe: study duration (from screening to Day 49 LFU visit)

,
InterventionNumber of patients (Number)
Platelet count: PCS (Low)Platelet count: PCS (High)Red blood cell count: PCS (Low)Red blood cell count: PCS (High)White blood cell: PCS (Low)White blood cell: PCS (High)Hemoglobin: PCS (Low)Hemoglobin: PCS (High)Lymphocytes: PCS (Low)Lymphocytes: PCS (High)Neutrophils: PCS (Low)Neutrophils: PCS (High)Eosinophils: PCS (High)Monocytes: PCS (High)Basophils: PCS (High)Direct Coombs test:- at Baseline, + post-BaselineHematocrit (ratio): PCS (Low)Hematocrit (ratio): PCS (High)
Ceftazidime-Avibactam Plus Metronidazole1570147010490001550
Meropenem14130151401128000280

[back to top]

Safety and Tolerability:ECG , QTcB and QTcF Intervals

Shifts in ECG interpretation and changes in QT, QTcB, and QTcF intervals , from baseline to post baseline. (NCT01726023)
Timeframe: EOT visit/any observation on treatment

,
InterventionNumber of patients (Number)
Normal to Abnormal: EOTNormal to Abnormal: Anytime up to EOTReaching a value in QT: ≥450 (ms)Reaching a value in QT: ≥480 (ms)Reaching a value in QT: ≥500 (ms)QT: ≥500 and increase from Baseline ≥60(ms)Increase in QT: ≥30 (ms)Increase in QT: ≥60 (ms)Decrease in QT: ≥30 (ms)Decrease in QT: ≥60 (ms)Reaching a value in QTcB: ≥450(ms)Reaching a value in QTcB: ≥480(ms)Reaching a value in QTcB: ≥500 (ms)QTcB: ≥500 and increase from Baseline ≥60(ms)Increase in QTcB: ≥30 (ms)Increase in QTcB: ≥60 (ms)Decrease in QTcB: ≥30 (ms)Decrease in QTcB: ≥60 (ms)Reaching a value in QTcF: ≥450 (ms)Reaching a value in QTcF: ≥480 (ms)Reaching a value in QTcF: ≥500 (ms)QTcF: ≥500 and increase from Baseline ≥60 (ms)Increase in QTcF: ≥30 (ms)Increase in QTcF: ≥60 (ms)Decrease QTcF: ≥30 (ms)Decrease QTcF: ≥60 (ms)
Ceftazidime-Avibactam Plus Metronidazole1734920011550241257134221242619410424217
Meropenem143010100114442446382127126418000413191

[back to top]

The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure. (NCT01726023)
Timeframe: At the end of treatment (EOT) (within 24 hours after last IV dose)

,
InterventionParticipants with favorable responses (Number)
Escherichia coli (n=70, 80)Klebsiella oxytoca (n=5, 5)Klebsiella pneumoniae (n=22, 30)Pseudomonas aeruginosa (n=14, 18)
Ceftazidime-Avibactam Plus Metronidazole6952114
Meropenem7852916

[back to top]

Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated. Eradication is defined as: source specimen demonstrates absence of the original baseline pathogen. Presumed eradication is defined as: source specimen was not available to culture and the patient was assessed as a clinical cure." (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants (Number)
FavorableUnfavorable
CAZ-AVI219
Meropenem1814

[back to top]

Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Extended Microbiologically Evaluable at Test-of-cure Analysis Set

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated. Eradication is defined as: source specimen demonstrates absence of the original baseline pathogen. Presumed eradication is defined as: source specimen was not available to culture and the patient was assessed as a clinical cure." (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants (Number)
FavorableUnfavorable
CAZ-AVI2314
Meropenem2120

[back to top]

The Number of Patients Discharged From Hospital up to Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set

The number of patients discharged from hospital in microbiologically modified intent-to-treat analysis set. (NCT01808092)
Timeframe: up to 25 days from randomization

,
Interventionparticipants (Number)
Number of patients with admission dateNumber of patients with at least one discharge1 discharge2 discharges>2 discharges
CAZ-AVI170717100
Meropenem182757410

[back to top]

The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Clinically Evaluable at TOC Analysis Set (Co-primary Analyses)

The number of patients meeting the cure criteria: the patient was not a clinical failure at end of treatment and the patient is alive and all signs and symptoms of pneumonia have resolved or improved to an extent that no antibacterial therapy for Nosocomial Pneumonia was taken between end of treatment and test-of-cure inclusive. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants (Number)
Clinical cureClinical failure
CAZ-AVI19958
Meropenem21159

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set

The number of patients with a favorable per-pathogen microbiological response: favorable microbiological response includes: Eradication where, source specimen demonstrates absence of the original baseline pathogen. Presumed eradication where, source specimen was not available to culture and the patient was assessed as a clinical cure. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants with favorable responses (Number)
Enterobacter aerogenes (n=6, 5)Enterobacter cloacae (n=21, 11)Escherichia coli (n=10, 18)Klebsiella pneumoniae (n=37, 47)Proteus mirabilis (n=11, 8)Serratia marcescens (n=12, 8)Haemophilus influenzae (n=9, 12)Pseudomonas aeruginosa (n=31, 28)Staphylococcus aureus (n=13, 19)
CAZ-AVI5181029999134
Meropenem37163865111215

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set

The number of patients with a favorable per-pathogen microbiological response: favorable microbiological response includes: Eradication where, source specimen demonstrates absence of the original baseline pathogen. Presumed eradication where, source specimen was not available to culture and the patient was assessed as a clinical cure. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants with favorable responses (Number)
Enterobacter cloacae (n=5, 5)Escherichia coli (n=4, 4)Klebsiella pneumoniae (n=14, 20)Pseudomonas aeruginosa (n=3, 6)
CAZ-AVI44111
Meropenem44131

[back to top]

The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set

The number of patients meeting the cure criteria: the patient is alive and all signs and symptoms of pneumonia have resolved or improved such that all antibacterial therapies for Nosocomial Pneumonia are stopped. No antibacterial therapy other than those outlined by the protocol has been administered for Nosocomial Pneumonia prior to end of treatment. (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

,
Interventionparticipants (Number)
Clinical cureClinical failureIndeterminate
CAZ-AVI143235
Meropenem161185

[back to top]

The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Microbiologically Evaluable Analysis Set

The number of patients meeting the cure criteria: the patient is alive and all signs and symptoms of pneumonia have resolved or improved such that all antibacterial therapies for Nosocomial Pneumonia are stopped. No antibacterial therapy other than those outlined by the protocol has been administered for Nosocomial Pneumonia prior to end of treatment. (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

,
Interventionparticipants (Number)
Clinical cureClinical failure
CAZ-AVI11012
Meropenem12612

[back to top]

The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable Analysis Set

The number of patients meeting the cure criteria: the patient is alive and all signs and symptoms of pneumonia have resolved or improved such that all antibacterial therapies for Nosocomial Pneumonia are stopped. No antibacterial therapy other than those outlined by the protocol has been administered for Nosocomial Pneumonia prior to end of treatment. (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

,
Interventionparticipants (Number)
Clinical cureClinical failure
CAZ-AVI12518
Meropenem13516

[back to top]

The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Clinically Modified Intent-to-treat Analysis Set

The number of patients meeting the cure criteria: the patient is alive and all signs and symptoms of pneumonia have resolved or improved such that all antibacterial therapies for Nosocomial Pneumonia are stopped. No antibacterial therapy other than those outlined by the protocol has been administered for Nosocomial Pneumonia prior to end of treatment. (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

,
Interventionparticipants (Number)
Clinical cureClinical failureIndeterminate
CAZ-AVI2925014
Meropenem3094516

[back to top]

The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Clinically Evaluable Analysis Set

The number of patients meeting the cure criteria: the patient is alive and all signs and symptoms of pneumonia have resolved or improved such that all antibacterial therapies for Nosocomial Pneumonia are stopped. No antibacterial therapy other than those outlined by the protocol has been administered for Nosocomial Pneumonia prior to end of treatment. (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

,
Interventionparticipants (Number)
Clinical cureClinical failure
CAZ-AVI25338
Meropenem26838

[back to top]

The Number of Patients With a Favorable Per-patient Microbiologic Response at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated. Eradication is defined as: source specimen demonstrates absence of the original baseline pathogen. Presumed eradication is defined as: source specimen was not available to culture and the patient was assessed as a clinical cure." (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants (Number)
FavorableUnfavorableIndeterminate
CAZ-AVI956412
Meropenem1185412

[back to top]

The Number of Patients With a Favorable Per-patient Microbiologic Response at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated. Eradication is defined as: source specimen demonstrates absence of the original baseline pathogen. Presumed eradication is defined as: source specimen was not available to culture and the patient was assessed as a clinical cure." (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants (Number)
FavorableUnfavorable
CAZ-AVI7037
Meropenem8335

[back to top]

The Number of Patients With a Favorable Per-patient Microbiologic Response at Test-of-cure (TOC) Visit in Extended Microbiologically Evaluable at Test-of-cure Analysis Set

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated. Eradication is defined as: source specimen demonstrates absence of the original baseline pathogen. Presumed eradication is defined as: source specimen was not available to culture and the patient was assessed as a clinical cure." (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants (Number)
FavorableUnfavorable
CAZ-AVI8045
Meropenem8942

[back to top]

The Number of Patients With a Favorable Per-patient Microbiologic Response at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated. Eradication is defined as: source specimen demonstrates absence of the original baseline pathogen. Presumed eradication is defined as: source specimen was not available to culture and the patient was assessed as a clinical cure." (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

,
Interventionparticipants (Number)
FavorableUnfavorableIndeterminate
CAZ-AVI128385
Meropenem148315

[back to top]

The Number of Patients With a Favorable Per-patient Microbiologic Response at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated. Eradication is defined as: source specimen demonstrates absence of the original baseline pathogen. Presumed eradication is defined as: source specimen was not available to culture and the patient was assessed as a clinical cure." (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

,
Interventionparticipants (Number)
FavorableUnfavorable
CAZ-AVI9626
Meropenem11226

[back to top]

The Number of Patients With a Favorable Per-patient Microbiologic Response at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable at End of Treatment Analysis Set

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated. Eradication is defined as: source specimen demonstrates absence of the original baseline pathogen. Presumed eradication is defined as: source specimen was not available to culture and the patient was assessed as a clinical cure." (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

,
Interventionparticipants (Number)
FavorableUnfavorable
CAZ-AVI11231
Meropenem12328

[back to top]

The Number of Patients Discharged From Hospital up to Test-of-cure (TOC) Visit in the Clinically Modified Intent-to-treat Analysis Set

The number of patients discharged from hospital in the clinically modified intent-to-treat analysis set. (NCT01808092)
Timeframe: up to 25 days from randomization

,
Interventionparticipants (Number)
Number of patients with admission dateNumber of patients with at least one discharge1 discharge2 discharges>2 discharges
CAZ-AVI35520620150
Meropenem36620620042

[back to top]

Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable at End of Treatment Analysis Set

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated. Eradication is defined as: source specimen demonstrates absence of the original baseline pathogen. Presumed eradication is defined as: source specimen was not available to culture and the patient was assessed as a clinical cure." (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

,
Interventionparticipants (Number)
FavorableUnfavorable
CAZ-AVI319
Meropenem3613

[back to top]

Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated. Eradication is defined as: source specimen demonstrates absence of the original baseline pathogen. Presumed eradication is defined as: source specimen was not available to culture and the patient was assessed as a clinical cure." (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

,
Interventionparticipants (Number)
FavorableUnfavorable
CAZ-AVI267
Meropenem2911

[back to top]

Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set at End of Treatment Visit

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated. Eradication is defined as: source specimen demonstrates absence of the original baseline pathogen. Presumed eradication is defined as: source specimen was not available to culture and the patient was assessed as a clinical cure." (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

,
Interventionparticipants (Number)
FavorableUnfavorableIndeterminate
CAZ-AVI35101
Meropenem39132

[back to top]

The Number of Patients Discharged From Hospital up to Test-of-cure (TOC) Visit in the Clinically Evaluable at Test-of-cure Analysis Set

The number of patients discharged from hospital in the clinically evaluable at test-of-cure analysis set. (NCT01808092)
Timeframe: up to 25 days from randomization

,
Interventionparticipants (Number)
Number of patients with admission dateNumber of patients with at least one discharge1 discharge2 discharges>2 discharges
CAZ-AVI25614814440
Meropenem26615515131

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set at Test-of-cure Visit

The number of patients with a favorable per-pathogen microbiological response: favorable microbiological response includes: Eradication where, source specimen demonstrates absence of the original baseline pathogen. Presumed eradication where, source specimen was not available to culture and the patient was assessed as a clinical cure. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants with favorable responses (Number)
Enterobacter aerogenes (n=4, 2)Enterobacter cloacae (n=6, 6)Escherichia coli (n=6, 5)Klebsiella pneumoniae (n=20, 30)Pseudomonas aeruginosa (n=11, 15)
CAZ-AVI354154
Meropenem254184

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Extended Microbiologically Evaluable at Test-of-cure Analysis Set

The number of patients with a favorable per-pathogen microbiological response: favorable microbiological response includes: Eradication where, source specimen demonstrates absence of the original baseline pathogen. Presumed eradication where, source specimen was not available to culture and the patient was assessed as a clinical cure. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants with favorable responses (Number)
Enterobacter cloacae (n=5, 5)Escherichia coli (n=5, 4)Klebsiella pneumoniae (n=14, 22)Pseudomonas aeruginosa (n=9, 13)
CAZ-AVI44113
Meropenem44143

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set at End of Treatment Visit

The number of patients with a favorable per-pathogen microbiological response: favorable microbiological response includes: Eradication where, source specimen demonstrates absence of the original baseline pathogen. Presumed eradication where, source specimen was not available to culture and the patient was assessed as a clinical cure. (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

,
Interventionparticipants with favorable responses (Number)
Enterobacter aerogenes (n=4, 2)Enterobacter cloacae (n=6, 6)Escherichia coli (n=6, 5)Klebsiella pneumoniae (n=20, 30)Pseudomonas aeruginosa (n=11, 15)
CAZ-AVI365188
Meropenem264267

[back to top]

The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Clinically Modified Intent-to-treat Analysis Set (Co-primary Analyses)

The number of patients meeting the cure criteria: the patient was not a clinical failure at end of treatment and the patient is alive and all signs and symptoms of pneumonia have resolved or improved to an extent that no antibacterial therapy for Nosocomial Pneumonia was taken between end of treatment and test-of-cure inclusive. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants (Number)
Clinical cureClinical failureIndeterminate
CAZ-AVI2457932
Meropenem2707030

[back to top]

The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Extended Microbiologically Evaluable Analysis Set

The number of patients meeting the cure criteria: the patient was not a clinical failure at end of treatment and the patient is alive and all signs and symptoms of pneumonia have resolved or improved to an extent that no antibacterial therapy for Nosocomial Pneumonia was taken between end of treatment and test-of-cure inclusive. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants (Number)
Clinical cureClinical failure
CAZ-AVI9629
Meropenem10328

[back to top]

The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Microbiologically Evaluable Analysis Set

The number of patients meeting the cure criteria: the patient was not a clinical failure at end of treatment and the patient is alive and all signs and symptoms of pneumonia have resolved or improved to an extent that no antibacterial therapy for Nosocomial Pneumonia was taken between end of treatment and test-of-cure inclusive. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants (Number)
Clinical cureClinical failure
CAZ-AVI8522
Meropenem9424

[back to top]

The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Microbiologically Modified Intent-to-treat Analysis Set

The number of patients meeting the cure criteria: the patient was not a clinical failure at end of treatment and the patient is alive and all signs and symptoms of pneumonia have resolved or improved to an extent that no antibacterial therapy for Nosocomial Pneumonia was taken between end of treatment and test-of-cure inclusive. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants (Number)
Clinical cureClinical failureIndeterminate
CAZ-AVI1203714
Meropenem1383412

[back to top]

The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Clinically Evaluable at End of Treatment Analysis Set

The number of patients meeting the cure criteria: the patient is alive and all signs and symptoms of pneumonia have resolved or improved such that all antibacterial therapies for Nosocomial Pneumonia are stopped. No antibacterial therapy other than those outlined by the protocol has been administered for Nosocomial Pneumonia prior to end of treatment. (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

,
Interventionparticipants (Number)
All (n=39, 49)Enterobacteriaceae (n=29, 37)Enterobacter aerogenes (n=4, 2)Enterobacter cloacae (n=6, 5)Escherichia coli (n=6, 4)Klebsiella pneumoniae (n=16, 28)Gram- pathogens not Enterobacteriaceae (n=10,14)Pseudomonas aeruginosa (n=10, 13)
CAZ-AVI35273651688
Meropenem4231233251312

[back to top]

The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Clinically Modified Intent-to-treat Analysis Set at End of Treatment Visit

The number of patients meeting the cure criteria: the patient is alive and all signs and symptoms of pneumonia have resolved or improved such that all antibacterial therapies for Nosocomial Pneumonia are stopped. No antibacterial therapy other than those outlined by the protocol has been administered for Nosocomial Pneumonia prior to end of treatment. (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

,
Interventionparticipants (Number)
All (n=45, 54)Enterobacteriaceae (n=34, 41)Enterobacter aerogenes (n=4, 2)Enterobacter cloacae (n=6, 6)Escherichia coli (n=6, 5)Klebsiella pneumoniae (n=20, 30)Gram- pathogens not Enterobacteriaceae (n=11,16)Pseudomonas aeruginosa (n=11, 15)
CAZ-AVI40323652088
Meropenem4533243261413

[back to top]

The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set

The number of patients meeting the cure criteria: the patient is alive and all signs and symptoms of pneumonia have resolved or improved such that all antibacterial therapies for Nosocomial Pneumonia are stopped. No antibacterial therapy other than those outlined by the protocol has been administered for Nosocomial Pneumonia prior to end of treatment. (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

,
Interventionparticipants (Number)
All (n=32, 40)Enterobacteriaceae (n=28, 35)Enterobacter aerogenes (n=4, 2)Enterobacter cloacae (n=6, 5)Escherichia coli (n=5, 4)Klebsiella pneumoniae (n=16, 26)Gram- pathogens not Enterobacteriaceae (n=4,7)Pseudomonas aeruginosa (n=4, 6)
CAZ-AVI31273651644
Meropenem36312332576

[back to top]

The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Clinically Evaluable at Test-of-cure Analysis Set

The number of patients meeting the cure criteria: the patient was not a clinical failure at end of treatment and the patient is alive and all signs and symptoms of pneumonia have resolved or improved to an extent that no antibacterial therapy for Nosocomial Pneumonia was taken between end of treatment and test-of-cure inclusive. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants (Number)
All (n=36, 41)Enterobacteriaceae (n=27, 30)Enterobacter cloacae (n=5, 5)Escherichia coli (n=5, 4)Klebsiella pneumoniae (n=14, 22)Gram- pathogens not Enterobacteriaceae (n=9,13)Pseudomonas aeruginosa (n=9, 13)
CAZ-AVI2923541266
Meropenem322233171212

[back to top]

The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Clinically Modified Intent-to-treat Analysis Set at Test-of-cure Visit

The number of patients meeting the cure criteria: the patient was not a clinical failure at end of treatment and the patient is alive and all signs and symptoms of pneumonia have resolved or improved to an extent that no antibacterial therapy for Nosocomial Pneumonia was taken between end of treatment and test-of-cure inclusive. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants (Number)
All (n=45, 54)Enterobacteriaceae (n=34, 41)Enterobacter aerogenes (n=4, 2)Enterobacter cloacae (n=6, 6)Escherichia coli (n=6, 5)Klebsiella pneumoniae (n=20, 30)Gram- pathogens not Enterobacteriaceae (n=11,16)Pseudomonas aeruginosa (n=11, 15)
CAZ-AVI35283641677
Meropenem4029243221313

[back to top]

The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set

The number of patients meeting the cure criteria: the patient was not a clinical failure at end of treatment and the patient is alive and all signs and symptoms of pneumonia have resolved or improved to an extent that no antibacterial therapy for Nosocomial Pneumonia was taken between end of treatment and test-of-cure inclusive. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants (Number)
All (n=29, 32)Enterobacteriaceae (n=26, 28)Enterobacter cloacae (n=5, 5)Escherichia coli (n=4, 4)Klebsiella pneumoniae (n=14, 20)Gram- pathogens not Enterobacteriaceae (n=3,6)Pseudomonas aeruginosa (n=3, 6)
CAZ-AVI2523541222
Meropenem2622331766

[back to top]

The Number of Patients With Death Due to Any Cause (All-cause Mortality) at Test-of-cure (TOC) Visit in Clinically Modified Intent-to-treat Analysis Set at Test-of-cure Visit

The number of patients with death due to any cause (all-cause mortality) in clinically modified intent-to-treat analysis set at test-of-cure visit. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants (Number)
Number of patients who died (all cause mortality)Deaths due to disease progressionNumber of patients with any AE with outcome=deathNumber of patients aliveNumber of patients with unknown survival status
CAZ-AVI29101931611
Meropenem256193414

[back to top]

The Number of Patients With Death Due to Any Cause (All-cause Mortality) at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set at Test-of-cure Visit

The number of patients with death due to any cause (all-cause mortality) in microbiologically modified intent-to-treat analysis set at test-of-cure visit. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants (Number)
Number of patients who died (all cause mortality)Deaths due to disease progressionNumber of patients with any AE with outcome=deathNumber of patients aliveNumber of patients with unknown survival status
CAZ-AVI166101532
Meropenem14591700

[back to top]

The Number of Patients With Death Due to Any Cause (All-cause Mortality) at Test-of-cure (TOC) Visit in the Clinically Evaluable at Test-of-cure Analysis Set

The number of patients with death due to any cause (all-cause mortality) in the clinically evaluable at test-of-cure analysis set. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants (Number)
Number of patients who died (all cause mortality)Deaths due to disease progressionNumber of patients with any AE with outcome=deathNumber of patients aliveNumber of patients with unknown survival status
CAZ-AVI11562451
Meropenem8442620

[back to top]

The Number of Patients With Death Due to Any Cause (All-cause Mortality) in Clinically Modified Intent-to-treat Analysis Set at Day 28

The number of patients with death due to any cause (all-cause mortality) in clinically modified intent-to-treat analysis set at day 28. (NCT01808092)
Timeframe: at Day 28 from randomization

,
Interventionparticipants (Number)
Number of patients who died (all cause mortality)Deaths due to disease progressionNumber of patients with any AE with outcome=deathNumber of patients aliveNumber of patients with unknown survival status
CAZ-AVI30102031511
Meropenem276213394

[back to top]

The Number of Patients With Death Due to Any Cause (All-cause Mortality) in Microbiologically Modified Intent-to-treat Analysis Set at Day 28

The number of patients with death due to any cause (all-cause mortality) in microbiologically modified intent-to-treat analysis set at day 28. (NCT01808092)
Timeframe: at Day 28 from randomization

,
Interventionparticipants (Number)
Number of patients who died (all cause mortality)Deaths due to disease progressionNumber of patients with any AE with outcome=deathNumber of patients aliveNumber of patients with unknown survival status
CAZ-AVI176111522
Meropenem165111680

[back to top]

The Number of Patients With Death Due to Any Cause (All-cause Mortality) in the Clinically Evaluable at Test-of-cure Analysis Set at Day 28

The number of patients with death due to any cause (all-cause mortality) in the clinically evaluable at test-of-cure analysis set at day 28. (NCT01808092)
Timeframe: at Day 28 from randomization

,
Interventionparticipants (Number)
Number of patients who died (all cause mortality)Deaths due to disease progressionNumber of patients with any AE with outcome=deathNumber of patients aliveNumber of patients with unknown survival status
CAZ-AVI12572441
Meropenem9452610

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set

The number of patients with a favorable per-pathogen microbiological response: favorable microbiological response includes: Eradication where, source specimen demonstrates absence of the original baseline pathogen. Presumed eradication where, source specimen was not available to culture and the patient was assessed as a clinical cure. (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

,
Interventionparticipants with favorable responses (Number)
Enterobacter aerogenes (n=4, 2)Enterobacter cloacae (n=6, 5)Escherichia coli (n=5, 4)Klebsiella pneumoniae (n=16, 26)Pseudomonas aeruginosa (n=4, 6)
CAZ-AVI365143
Meropenem254231

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable at End of Treatment Analysis Set

The number of patients with a favorable per-pathogen microbiological response: favorable microbiological response includes: Eradication where, source specimen demonstrates absence of the original baseline pathogen. Presumed eradication where, source specimen was not available to culture and the patient was assessed as a clinical cure. (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

,
Interventionparticipants with favorable responses (Number)
Enterobacter aerogenes (n=4, 2)Enterobacter cloacae (n=6, 5)Escherichia coli (n=6, 4)Klebsiella pneumoniae (n=16, 28)Pseudomonas aeruginosa (n=10, 13)
CAZ-AVI365148
Meropenem254256

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set at Test-of-cure Visit

The number of patients with a favorable per-pathogen microbiological response: favorable microbiological response includes: Eradication where, source specimen demonstrates absence of the original baseline pathogen. Presumed eradication where, source specimen was not available to culture and the patient was assessed as a clinical cure. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants with favorable responses (Number)
Enterobacter aerogenes (n=8, 8)Enterobacter cloacae (n=26, 22)Escherichia coli (n=17, 20)Klebsiella pneumoniae (n=59, 71)Proteus mirabilis (n=14, 12)Serratia marcescens (n=15, 13)Haemophilus influenzae (n=16, 25)Pseudomonas aeruginosa (n=58, 47)Staphylococcus aureus (n=24, 34)
CAZ-AVI52113371110142211
Meropenem513165388231825

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses at Test-of-cure (TOC) Visit in Extended Microbiologically Evaluable at Test-of-cure Analysis Set

The number of patients with a favorable per-pathogen microbiological response: favorable microbiological response includes: Eradication where, source specimen demonstrates absence of the original baseline pathogen. Presumed eradication where, source specimen was not available to culture and the patient was assessed as a clinical cure. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants with favorable responses (Number)
Enterobacter aerogenes (n=6, 5)Enterobacter cloacae (n=21, 11)Escherichia coli (n=11, 18)Klebsiella pneumoniae (n=37, 49)Proteus mirabilis (n=11, 8)Serratia marcescens (n=12, 8)Haemophilus influenzae (n=11, 13)Pseudomonas aeruginosa (n=42, 35)Staphylococcus aureus (n=14, 22)
CAZ-AVI51810299911185
Meropenem37163965121417

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set at End of Treatment Visit

The number of patients with a favorable per-pathogen microbiological response: favorable microbiological response includes: Eradication where, source specimen demonstrates absence of the original baseline pathogen. Presumed eradication where, source specimen was not available to culture and the patient was assessed as a clinical cure. (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

,
Interventionparticipants with favorable responses (Number)
Enterobacter aerogenes (n=8, 8)Enterobacter cloacae (n=26, 22)Escherichia coli (n=17, 20)Klebsiella pneumoniae (n=59, 71)Proteus mirabilis (n=14, 12)Serratia marcescens (n=15, 13)Haemophilus influenzae (n=16, 25)Pseudomonas aeruginosa (n=58, 47)Staphylococcus aureus (n=24, 34)
CAZ-AVI62515491212153321
Meropenem52018651011252732

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set

The number of patients with a favorable per-pathogen microbiological response: favorable microbiological response includes: Eradication where, source specimen demonstrates absence of the original baseline pathogen. Presumed eradication where, source specimen was not available to culture and the patient was assessed as a clinical cure. (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

,
Interventionparticipants with favorable responses (Number)
Enterobacter aerogenes (n=6, 7)Enterobacter cloacae (n=22, 17)Escherichia coli (n=13, 18)Klebsiella pneumoniae (n=45, 55)Proteus mirabilis (n=9, 8)Serratia marcescens (n=13, 10)Haemophilus influenzae (n=12, 15)Pseudomonas aeruginosa (n=38, 34)Staphylococcus aureus (n=16, 23)
CAZ-AVI4221338812122214
Meropenem517175168151922

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable at End of Treatment Analysis Set

The number of patients with a favorable per-pathogen microbiological response: favorable microbiological response includes: Eradication where, source specimen demonstrates absence of the original baseline pathogen. Presumed eradication where, source specimen was not available to culture and the patient was assessed as a clinical cure. (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

,
Interventionparticipants with favorable responses (Number)
Enterobacter aerogenes (n=6, 7)Enterobacter cloacae (n=22, 17)Escherichia coli (n=14, 18)Klebsiella pneumoniae (n=46, 57)Proteus mirabilis (n=9, 8)Serratia marcescens (n=13, 10)Haemophilus influenzae (n=14, 16)Pseudomonas aeruginosa (n=50, 41)Staphylococcus aureus (n=18, 26)
CAZ-AVI4221339812143016
Meropenem517175368162425

[back to top]

Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set at Test-of-cure Visit

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated. Eradication is defined as: source specimen demonstrates absence of the original baseline pathogen. Presumed eradication is defined as: source specimen was not available to culture and the patient was assessed as a clinical cure." (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

,
Interventionparticipants (Number)
FavorableUnfavorableIndeterminate
CAZ-AVI27163
Meropenem27234

[back to top]

Clinical Success Rate

"The clinical success or failure of meropenem therapy will be evaluated one week after stop of antibiotic therapy.~Clinical success was defined as cure or improvement of all signs and symptoms caused by the infection and no requirement for additional antibacterial therapy.~Clinical failure was defined as a persistence or worsening of any new clinical sign or symptom, development of any new clinical signs or symptoms of infection, or the requirement for other systemic antimicrobial therapy at the end of meropenem therapy." (NCT01944319)
Timeframe: One week after antibiotic therapy finished.

Interventionparticipants (Number)
Control Group28
Study Group35

[back to top]

Bacteriological Success Rate

"The bacterial success or failure will be evaluated at the end of meropenem therapy.~Bacteriological success including eradication and presumed eradication. Bacteriological failure including persistence and presumed persistence." (NCT01944319)
Timeframe: At the end of meropenem therapy, an average of 10 days.

Interventionparticipants (Number)
Control Group24
Study Group28

[back to top]

Amount of Used Antibiotics

Record the amount of antibiotics usage during antibiotic therapy (NCT01944319)
Timeframe: participants will be followed for the duration of antibiotic therapy, an average of 10 days

Interventiongrams (Median)
Control Group19.0
Study Group15.0

[back to top] [back to top]

Percentage of Patients With ACM at Day 28 in the mMITT Population in Cohort 1

"ACM at Day 28: confirmed date of death within 28 days of the first dose of study drug, irrespective of causality.~Note: Although it is generally expected that results for primary and secondary endpoints will be presented for all arms included at baseline, results for Cohort 2 are not presented here as this Cohort was not part of the primary or key secondary endpoints per the protocol and SAP." (NCT01970371)
Timeframe: Up to Day 28

Interventionpercentage of patients (Number)
Plazomicin in Combination With Meropenem or Tigecycline11.8
Colistin in Combination With Meropenem or Tigecycline40

[back to top]

Percentage of Patients With ACM at Day 14 in the mMITT Population in Cohort 1

"ACM at Day 14 was defined as a confirmed date of death within 14 days of the first dose of study drug, irrespective of causality.~Note: Although it is generally expected that results for primary and secondary endpoints will be presented for all arms included at baseline, results for Cohort 2 are not presented here as this Cohort was not part of the primary or key secondary endpoints per the protocol and SAP." (NCT01970371)
Timeframe: Day 14

Interventionpercentage of patients (Number)
Plazomicin in Combination With Meropenem or Tigecycline5.9
Colistin in Combination With Meropenem or Tigecycline20

[back to top]

Time to Death Through Day 28 in the mMITT Population in Cohort 1

"Time to death through Day 28 is defined as days from first dose of study drug to death from any cause on or before Day 28. Patients who were alive at Day 28 were censored on Day 28. Any patient whose survival status was not known at Day 28 was censored on the last known date alive.~Note: Although it is generally expected that results for primary and secondary endpoints will be presented for all arms included at baseline, results for Cohort 2 are not presented here as this Cohort was not part of the primary or key secondary endpoints per the protocol and SAP." (NCT01970371)
Timeframe: Up to Day 28

,
Interventionpercentage of patients (Number)
% of patients who died by Day 28% of patients censored at 28 days% of patients censored at <28 daysKaplan-Meier estmate of ACM at Day 28
Colistin in Combination With Meropenem or Tigecycline40.060.00.040
Plazomicin in Combination With Meropenem or Tigecycline11.888.20.011.8

[back to top]

Percentage of Patients With Adjudicated Clinical Cure at the Test of Cure (TOC) Visit in the mMITT Population in Cohort 1

"Clinical response (CR) was assessed at end of treatment (EOT) in all patients and at TOC for those who were a clinical cure or had an indeterminate outcome at the most recent visit. Assessment of CR at TOC was not needed for those who were a clinical failure at an earlier visit. Clinical outcomes at both EOT and TOC were independently adjudicated by an external committee. The assessment was confounded by comorbidities and the occurrence of additional infections; thus, adjudicating CR of the baseline CRE infection was influenced by confounding signs and symptoms of unrelated infections or conditions. The difficulty assessing CR supports greater reliance on the more objective mortality-based primary endpoint in these patients.~Note: Although it is generally expected that results for primary and secondary endpoints will be presented for all arms included at baseline, results for Cohort 2 are not presented here as this Cohort was not part of the endpoints per the protocol and SAP." (NCT01970371)
Timeframe: Up to TOC (Day 23)

,
Interventionpercentage of patients (Number)
EOT Visit: Clinical CureEOT Visit: Clinical FailureTOC Visit: Clinical CureTOC Visit: Clinical FailureTOC Visit: Indeterminate Response
Colistin in Combination With Meropenem or Tigecycline455535650
Plazomicin in Combination With Meropenem or Tigecycline64.735.335.358.85.9

[back to top]

Plasma Pharmacokinetics (PK): Minimum Observed Plasma Drug Concentration (Cmin)

PK specimens were collected on Days 1 and 4 using a sparse sampling scheme, and concentration-time data from these PK specimens were pooled with data from specimens collected for TDM. The pooled data were analyzed by population PK modeling, which described PK over the entire course of plazomicin treatment. The protocol allowed dose adjustments based on creatinine clearance; therefore, various dose regimens were used in the study, including regimens with dosing intervals of 12, 24, and 48 hours. To enable a combined summation of exposures across dose regimens, PK exposure parameters for the study were summarized for the first 48 hours of treatment. Thus, while exposures are summarized for the first 48 hours, the reported results considered patient data over the course of plazomicin treatment. (NCT01970371)
Timeframe: 48 hours

Interventionmg/L (Geometric Mean)
Plazomicin2.1

[back to top]

Plasma Pharmacokinetics (PK): Maximum Observed Plasma Drug Concentration (Cmax)

PK specimens were collected on Days 1 and 4 using a sparse sampling scheme, and concentration-time data from these PK specimens were pooled with data from specimens collected for TDM. The pooled data were analyzed by population PK modeling, which described PK over the entire course of plazomicin treatment. The protocol allowed dose adjustments based on creatinine clearance; therefore, various dose regimens were used in the study, including regimens with dosing intervals of 12, 24, and 48 hours. To enable a combined summation of exposures across dose regimens, PK exposure parameters for the study were summarized for the first 48 hours of treatment. Thus, while exposures are summarized for the first 48 hours, the reported results considered patient data over the course of plazomicin treatment. (NCT01970371)
Timeframe: 48 hours

Interventionmg/L (Geometric Mean)
Plazomicin37.1

[back to top]

Percentage of Patients With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered to be drug related. An AE (also referred to as an adverse experience) can be any unfavorable and unintended sign (eg, an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, and it does not imply any judgment about causality. Adverse events also include the exacerbation or worsening of a condition present at screening other than the index infection for which the patient was enrolled in the study. A TEAE is any AE that newly appeared, increased in frequency, or worsened in severity following initiation of study drug. The safety population included all randomized patients who received any amount of study drug. (NCT01970371)
Timeframe: Up to Day 67

Interventionpercentage of patients (Number)
Plazomicin in Combination With Meropenem or Tigecycline88.9
Colistin in Combination With Meropenem or Tigecycline100
Plazomicin in Combination With Adjunctive Antibiotic86.7

[back to top]

Percentage of Patients With Dose Adjustment Due to Therapeutic Drug Management (TDM)

"After the initial plazomicin dose, subsequent doses were adjusted, as directed, with the use of TDM on Day 1, 4, and 8 as needed.~Note: Although it is generally expected that results for primary and secondary endpoints will be presented for all arms included at baseline, results for Cohort 1: Colistin are not presented here as TDM collection does not apply to and was not collected for patients in the colistin arm, as only plazomicin levels were measured." (NCT01970371)
Timeframe: Up to Day 14

Interventionpercentage of patients (Number)
Plazomicin in Combination With Meropenem or Tigecycline77.8
Plazomicin in Combination With Adjunctive Antibiotic86.7

[back to top]

Plasma Pharmacokinetics (PK): Area Under the Curve From 0 to 24 Hours (AUC 0-24h)

PK specimens were collected on Days 1 and 4 using a sparse sampling scheme, and concentration-time data from these PK specimens were pooled with data from specimens collected for TDM. The pooled data were analyzed by population PK modeling, which described PK over the entire course of plazomicin treatment. The protocol allowed dose adjustments based on creatinine clearance; therefore, various dose regimens were used in the study, including regimens with dosing intervals of 12, 24, and 48 hours. To enable a combined summation of exposures across dose regimens, PK exposure parameters for the study were summarized for the first 48 hours of treatment. Thus, while exposures are summarized for the first 48 hours, the reported results considered patient data over the course of plazomicin treatment. (NCT01970371)
Timeframe: 48 hours

Interventionmg*h/L (millgrams times hours per liter) (Geometric Mean)
Plazomicin235

[back to top]

Percentage of Participants With All Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population - Day 28

To compare the all cause mortality rates of participants in the ceftolozane/tazobactam versus meropenem arms in microbiological intent-to-treat (mITT) population. (NCT02070757)
Timeframe: Day 28

InterventionPercentage of Participants (Number)
Ceftolozane/Tazobactam20.1
Meropenem25.5

[back to top]

Percentage of Participants Discontinuing Study Drug Due to an Adverse Event (AE)

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. (NCT02070757)
Timeframe: Up to 14 days after the first dose of study drug (Up to ~Day 15)

InterventionPercentage of Participants (Number)
Ceftolozane/Tazobactam10.2
Meropenem11.7

[back to top]

Percentage of Participants Who Report 1 or More Adverse Event (AE)

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. (NCT02070757)
Timeframe: Up to 35 days after last dose of study drug (Up to ~Day 50)

InterventionPercentage of Participants (Number)
Ceftolozane/Tazobactam85.9
Meropenem83.3

[back to top]

Percentage of Participants With All Cause Mortality in the Intent-to-Treat (ITT) Population - Day 28

To demonstrate the non-inferiority of ceftolozane/tazobactam versus meropenem in stratified adult participants with ventilated nosocomial pneumonia (VNP) (participants with either ventilator-associated bacterial pneumonia [VABP] or ventilated hospital-acquired bacterial pneumonia [HABP]) based on the difference in all-cause mortality rates in the intent to treat (ITT) population using a non-inferiority margin of 10%. The estimated adjusted percentage was a weighted average across all strata, constructed using Mehrotra-Railkar continuity-corrected minimum risk (MRc) stratum weights. (NCT02070757)
Timeframe: Day 28

InterventionPercentage of Participants (Number)
Ceftolozane/Tazobactam24.0
Meropenem25.3

[back to top]

Percentage of Participants With All-Cause Mortality in the Intent-to-Treat (ITT) Population - Day 14

To compare the all cause mortality rates of participants (ceftolozane/tazobactam versus meropenem arms). Participants whose Day 14 mortality outcomes are missing or unknown are analysed as deceased. (NCT02070757)
Timeframe: Day 14

InterventionPercentage of Participants (Number)
Ceftolozane/Tazobactam14.1
Meropenem12.9

[back to top]

Percentage of Participants With Any Serious Adverse Event (SAE)

A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. (NCT02070757)
Timeframe: Up to 35 days after last dose of study drug (Up to ~Day 50)

InterventionPercentage of Participants (Number)
Ceftolozane/Tazobactam42.1
Meropenem35.9

[back to top]

Percentage of Participants With Clinical Response of Clinical Cure at the End-of-Therapy (EOT) Visit in the Intent-to-Treat (ITT) Population

To compare the clinical response rates at the EOT visit for ceftolozane/tazobactam versus meropenem. Clinical response at the EOT visit was defined as cure (complete resolution with no new signs of VNP), failure (progression, relapse or recurrence of VNP) or indeterminate (no evaluable study data). A favorable clinical response is a clinical cure. A missing clinical response will be considered indeterminate. (NCT02070757)
Timeframe: Within 24 hours after last dose of study drug (Up to ~Day 15)

InterventionPercentage of Participants (Number)
Ceftolozane/Tazobactam66.0
Meropenem66.8

[back to top]

Percentage of Participants With Clinical Response of Clinical Cure at the Late Follow-up (LFU) Visit in the Clinically Evaluable (CE) Population

"To compare the clinical response rates at the Late Follow-up (LFU) visit for ceftolozane/tazobactam versus meropenem in the CE population. Clinical response at the LFU visit will be classified as sustained cure, relapse, or indeterminate only in participants deemed a clinical cure at the TOC visit. A favorable clinical response is sustained clinical cure." (NCT02070757)
Timeframe: 28 to 35 days after the last dose of study drug (Up to ~Day 50)

InterventionPercentage of Participants (Number)
Ceftolozane/Tazobactam52.8
Meropenem51.6

[back to top]

Percentage of Participants With Clinical Response of Clinical Cure at the Test-of-Cure (TOC) Visit in the Clinically Evaluable (CE) Population

To compare the clinical response rates of ceftolozane/tazobactam versus meropenem in adult participants with VNP (participants with either ventilator-associated bacterial pneumonia [VABP] or ventilated hospital-acquired bacterial pneumonia [HABP]) at the TOC visit in the CE population. Clinical response at the TOC visit was defined as cure (complete resolution with no new signs of VNP), failure (progression, relapse or recurrence of VNP) or indeterminate (no evaluable study data). A favorable clinical response is a clinical cure. A missing clinical response will be considered indeterminate unless the clinical outcome at the EOT visit was failure. The data-as-observed (DAO) approach was used where participants with missing clinical responses, including indeterminate outcomes, are excluded from the analysis population. (NCT02070757)
Timeframe: 7 to 14 days after last dose of study drug (Up to ~Day 30)

InterventionPercentage of Participants (Number)
Ceftolozane/Tazobactam63.8
Meropenem64.7

[back to top]

Percentage of Participants With Clinical Response of Clinical Cure at the Test-of-Cure (TOC) Visit in the Intent-to-Treat (ITT) Population

To demonstrate the non-inferiority of ceftolozane/tazobactam versus meropenem in adult participants with ventilated nosocomial pneumonia (VNP) at the TOC visit (7 to 14 days after the end-of-therapy [EOT] visit) using a non-inferiority margin of 12.5%. Clinical response at the TOC visit was defined as cure (complete resolution with no new signs of VNP), failure (progression, relapse or recurrence of VNP) or indeterminate (no evaluable study data). A favorable clinical response is a clinical cure. A missing clinical response will be considered indeterminate unless the clinical outcome at the EOT visit was failure. The estimated adjusted percentage was a weighted average across all strata, constructed using Mehrotra-Railkar continuity-corrected minimum risk (MRc) stratum weights. (NCT02070757)
Timeframe: 7 to 14 days after last dose of study drug (Up to ~Day 30)

InterventionPercentage of Participants (Number)
Ceftolozane/Tazobactam54.4
Meropenem53.3

[back to top]

Percentage of Participants With Per-Participant Microbiological Response of Cure or Presumed Cure at the End-of-Therapy (EOT) Visit in the Microbiologically Evaluable (ME) Population

To compare the microbiological response rates of ceftolozane/tazobactam versus meropenem at the EOT visit. The per-participant microbiological response will be determined based on the individual microbiological outcomes for each baseline pathogen. A microbiological response at the EOT visit was defined as cure (baseline pathogens eradicated), failure (baseline pathogen is persistent) or indeterminate (no evaluable respiratory material). A favorable microbiological response is a microbiological cure or presumed cure. The data-as-observed (DAO) approach was used where participants with missing clinical responses, including indeterminate outcomes, are excluded from the analysis population. (NCT02070757)
Timeframe: Within 24 hours after last dose of study drug (Up to ~Day 15)

InterventionPercentage of Participants (Number)
Ceftolozane/Tazobactam80.9
Meropenem78.8

[back to top]

Percentage of Participants With Per-Participant Microbiological Response of Cure or Presumed Cure at the Test-of-Cure (TOC) Visit in the Microbiologically Evaluable (ME) Population

To compare the per-participant microbiological response rates of ceftolozane/tazobactam versus meropenem at the TOC visit in the microbiologically evaluable (ME) population. The per-participant microbiological response will be determined based on the individual microbiological outcomes for each baseline pathogen. A microbiological response at the TOC visit was defined as cure (baseline pathogens eradicated), failure (baseline pathogen is persistent) or indeterminate (no evaluable respiratory material). A favorable microbiological response is a microbiological cure or presumed cure. The data-as-observed (DAO) approach was used where participants with missing clinical responses, including indeterminate outcomes, are excluded from the analysis population. (NCT02070757)
Timeframe: 7 to 14 days after last dose of study drug (Up to ~Day 30)

InterventionPercentage of Participants (Number)
Ceftolozane/Tazobactam70.4
Meropenem62.7

[back to top]

Percentage of Participants With Microbiological Response of Eradication or Presumed Eradication, by Pathogen, at the Test-of-Cure (TOC) Visit in the Microbiologically Evaluable (ME) Population (>=10 Isolates at Baseline)

"To compare the percentage of participants with a microbiological outcome of eradication or presumed eradication, by pathogen. The microbiological outcome was classified as eradication, presumed eradication, persistence, 'presumed persistence, indeterminate or recurrence. Eradication was defined as a ≥1- log reduction in bacterial burden of the original baseline LRT pathogen AND a per pathogen count of ≤10^4 colony-forming unit (CFU)/mL for endotracheal aspirate (ETA) or sputum specimens, ≤10^3 CFU/mL for a bronchoalveolar lavage (BAL) specimen, or ≤10^2 CFU/mL for a protected brush specimen (PBS) from a follow-up LRT culture. Presumed eradication was defined as an absence of material to culture (e.g. inability to obtain a culture in an extubated patient) in a patient deemed a clinical cure." (NCT02070757)
Timeframe: 7 to 14 days after last dose of study drug (Up to ~Day 30)

,
InterventionPercentage of Participants (Number)
Gram-NegativePseudomonas aeruginosaEnterobacteriaceaeEscherichia coliKlebsiella pneumoniaeProteus mirabilisHaemophilus influenzaeEnterobacter cloacaeKlebsiella oxytocaSerratia marcescensAcinetobacter baumannii
Ceftolozane/Tazobactam69.979.368.778.371.463.691.757.187.540.033.3
Meropenem62.455.365.673.966.770.050.075.057.150.080.0

[back to top]

Proportion Of Participants In The m-MITT Population Who Achieved A Microbiologic Outcome Of Eradication

This secondary outcome measure focused on a microbiological outcome of Eradication in the m-MITT population at 5 time points: Day 3, EOIVT, end of treatment (EOT), TOC, and late follow up (LFU). Eradication was defined as a reduction in baseline bacterial pathogen(s) to <10^4 CFU/mL of urine culture (FDA) or <10^3 CFU/mL (EMA), and a negative blood culture for an organism that was identified as a uropathogen (if repeated after positive at baseline blood culture). (NCT02166476)
Timeframe: Day 3, EOIVT (Days 5-14), EOT (Days 10-14), TOC (Days 15-23), and LFU (Days 22-30)

,
InterventionParticipants (Count of Participants)
Day 3: FDAEOIVT: FDAEOT: FDATOC: FDALFU: FDADay 3: EMAEOIVT: EMAEOT: EMATOC: EMALFU: EMA
Meropenem-Vaborbactam189188172132132186188169128129
Piperacillin-Tazobactam16716815811310316416815810598

[back to top]

Proportion Of Participants In The m-MITT Population With Overall Success

This secondary outcome measure focused on the overall success in the ME population at the EOIVT and TOC visits. Overall success at TOC was defined as a clinical outcome of Cured and a microbiologic outcome of Eradication. Overall success at EOIVT was defined as a clinical outcome of Cured or Improvement and a microbiologic outcome of Eradication. Cured was defined as the complete resolution or significant improvement of the baseline signs and symptoms of cUTI or AP. Improvement was defined as lessening, incomplete resolution, or no worsening of the baseline signs and symptoms of cUTI or AP, but continued IV therapy was warranted. Eradication was defined using the FDA's CFU/mL criteria that the bacterial pathogen(s) found at baseline was/were reduced to <10^4 CFU/mL of urine culture and a negative blood culture for an organism that was identified as an uropathogen (if repeated after positive at baseline blood culture). (NCT02166476)
Timeframe: EOIVT (Days 5-14) and TOC (Days 15-23)

,
InterventionParticipants (Count of Participants)
EOIVTTOC
Meropenem-Vaborbactam189143
Piperacillin-Tazobactam171128

[back to top]

Proportion Of Participants In The ME Population Who Achieved A Microbiologic Outcome Of Eradication

This secondary outcome measure focused on a microbiological outcome of Eradication in the ME population at 5 time points: Day 3, EOIVT, EOT, TOC, and LFU. Eradication was defined as a reduction in baseline bacterial pathogen(s) to <10^4 CFU/mL of urine culture (FDA) or <10^3 CFU/mL (EMA), and a negative blood culture for an organism that was identified as an uropathogen (if repeated after positive at baseline blood culture). (NCT02166476)
Timeframe: Day 3, EOIVT (Days 5-14), EOT (Days 10-14), TOC (Days 15-23), and LFU (Days 22-30)

,
InterventionParticipants (Count of Participants)
Day 3: FDAEOIVT: FDAEOT: FDATOC: FDALFU: FDADay 3: EMAEOIVT: EMAEOT: EMATOC: EMALFU: EMA
Meropenem-Vaborbactam177178163122122174178160118120
Piperacillin-Tazobactam1601661561099915716615610294

[back to top]

Proportion Of Participants In The ME Population With Overall Success

This secondary outcome measure focused on the overall success in the ME population at the EOIVT and TOC visits. Overall success was defined as a clinical outcome of Cured or Improvement and a microbiologic outcome of Eradication. Cured was defined as the complete resolution or significant improvement of the baseline signs and symptoms of cUTI or AP. Improvement was defined as lessening, incomplete resolution, or no worsening of the baseline signs and symptoms of cUTI or AP, but continued IV therapy was warranted. Eradication was defined using the FDA's CFU/mL criteria that the bacterial pathogen(s) found at baseline was/were reduced to <10^4 CFU/mL of urine culture and a negative blood culture for an organism that was identified as an uropathogen (if repeated after positive at baseline blood culture). (NCT02166476)
Timeframe: EOIVT (Days 5-14) and TOC (Days 15-23)

,
InterventionParticipants (Count of Participants)
EOIVTTOC
Meropenem-Vaborbactam178134
Piperacillin-Tazobactam165124

[back to top]

Proportion Of Participants With A Clinical Outcome Of Cure In The Clinical Evaluable (CE) Population

This secondary outcome measure focused on a clinical outcome of Cure in the CE population. A clinical outcome of Cure was defined as the following: at EOIVT, the complete resolution or significant improvement of the baseline signs and symptoms of cUTI or AP; at EOT, TOC, and LFU, the complete resolution or significant improvement of the baseline signs and symptoms of cUTI or AP such that no further antimicrobial therapy was warranted. Symptom resolution did not necessarily include baseline symptoms associated with anatomic abnormalities that predisposed to cUTI, such as symptoms associated with the presence of an indwelling urinary catheter. The clinical outcome of Cure was reported only at the EOIVT, EOT, TOC, and LFU visits, and improvement was reported only at the Day 3, EOIVT, and EOT visits. (NCT02166476)
Timeframe: Day 3, EOIVT (Days 5-14), EOT (Days 10-14), TOC (Days 15-23), and LFU (Days 22-30)

,
InterventionParticipants (Count of Participants)
Day 3: ImprovementEOIVT: CureEOIVT: ImprovementEOT: CureEOT: ImprovementTOC: CureLFU: Cure
Meropenem-Vaborbactam243202452357231220
Piperacillin-Tazobactam250206462396224209

[back to top]

Proportion Of Participants With A Clinical Outcome Of Cure In The m-MITT Population

This secondary outcome measure focused on a clinical outcome of Cure in the m-MITT Population. A clinical outcome of Cure was defined as the following: at EOIVT, the complete resolution or significant improvement of the baseline signs and symptoms of cUTI or AP; at EOT, TOC, and LFU, the complete resolution or significant improvement of the baseline signs and symptoms of cUTI or AP such that no further antimicrobial therapy was warranted. Symptom resolution did not necessarily include baseline symptoms associated with anatomic abnormalities that predisposed to cUTI, such as symptoms associated with the presence of an indwelling urinary catheter. The clinical outcome of Cure was reported only at the EOIVT, EOT, TOC, and LFU visits, and improvement was reported only at Day 3, EOIVT, and EOT visits. (NCT02166476)
Timeframe: Day 3, EOIVT (Days 5-14), EOT (Days 10-14), TOC (Days 15-23), and LFU (Days 22-30)

,
InterventionParticipants (Count of Participants)
Day 3: ImprovementEOIVT: CureEOIVT: ImprovementEOT: CureEOT: ImprovementTOC: CureLFU: Cure
Meropenem-Vaborbactam186156331794174166
Piperacillin-Tazobactam171144301673157143

[back to top]

Proportion Of Participants With A Clinical Outcome Of Cure In The ME Population

This secondary outcome measure focused on a clinical outcome of Cure in the ME population. A clinical outcome of Cure was defined as the following: at EOIVT, the complete resolution or significant improvement of the baseline signs and symptoms of cUTI or AP; at EOT, TOC, and LFU, the complete resolution or significant improvement of the baseline signs and symptoms of cUTI or AP such that no further antimicrobial therapy was warranted. Symptom resolution did not necessarily include baseline symptoms associated with anatomic abnormalities that predisposed to cUTI, such as symptoms associated with the presence of an indwelling urinary catheter. The clinical outcome of Cure was reported only at the EOIVT, EOT, TOC, and LFU visits, and improvement was reported only at the Day 3, EOIVT, and EOT visits. (NCT02166476)
Timeframe: Day 3, EOIVT (Days 5-14), EOT (Days 10-14), TOC (Days 15-23), and LFU (Days 22-30)

,
InterventionParticipants (Count of Participants)
Day 3: ImprovementEOIVT: CureEOIVT: ImprovementEOT: CureEOT: ImprovementTOC: CureLFU: Cure
Meropenem-Vaborbactam175148301703164156
Piperacillin-Tazobactam164138301613153139

[back to top]

Per-Pathogen Microbiological Outcome (FDA) In The ME Population

This secondary outcome measure focused on the per-pathogen (E. cloacae, E. faecalis, E. coli, K. pneumoniae) microbiological outcome of Eradication in the ME population at 5 time points: Day 3, EOIVT, EOT, TOC, and LFU. Eradication was defined per the FDA criteria as a reduction in baseline bacterial pathogen(s) to <10^4 CFU/mL of urine culture and a negative blood culture for an organism that was identified as an uropathogen (if repeated after positive at baseline blood culture). (NCT02166476)
Timeframe: Day 3, EOIVT (Days 5-14), EOT (Days 10-14), TOC (Days 15-23), and LFU (Days 22-30)

,
InterventionParticipants (Count of Participants)
Day 3: E. cloacaeEOIVT: E. cloacaeEOT: E. cloacaeTOC: E. cloacaeLFU: E. cloacaeDay 3: E. faecalisEOIVT: E. faecalisEOT: E. faecalisTOC: E. faecalisLFU: E. faecalisDay 3: E. coliEOIVT: E. coliEOT: E. coliTOC: E. coliLFU: E. coliDay 3: K. pneumoniaeEOIVT: K. pneumoniaeEOT: K. pneumoniaeTOC: K. pneumoniaeLFU: K. pneumoniae
Meropenem-Vaborbactam101010981111116911711710884842828261815
Piperacillin-Tazobactam3553214141312101011069971672526241412

[back to top]

Per-Pathogen Microbiological Outcome (FDA) In The m-MITT Population

This secondary outcome measure focused on the per-pathogen (Enterobacter cloacae [E. cloacae], Enterococcus faecalis [E. faecalis], Escherichia coli [E. coli], Klebsiella pneumoniae [K. pneumoniae]) microbiological outcome of Eradication in the m-MITT population at 5 time points: Day 3, EOIVT, EOT, TOC, and LFU. Eradication was defined per the FDA criteria as a reduction in baseline bacterial pathogen(s) to <10^4 CFU/mL of urine culture and a negative blood culture for an organism that was identified as an uropathogen (if repeated after positive at baseline blood culture). (NCT02166476)
Timeframe: Day 3, EOIVT (Days 5-14), EOT (Days 10-14), TOC (Days 15-23), and LFU (Days 22-30)

,
InterventionParticipants (Count of Participants)
Day 3: E. cloacaeEOIVT: E. cloacaeEOT: E. cloacaeTOC: E. cloacaeLFU: E. cloacaeDay 3: E. faecalisEOIVT: E. faecalisEOT: E. faecalisTOC: E. faecalisLFU: E. faecalisDay 3: E. coliEOIVT: E. coliEOT: E. coliTOC: E. coliLFU: E. coliDay 3: K. pneumoniaeEOIVT: K. pneumoniaeEOT: K. pneumoniaeTOC: K. pneumoniaeLFU: K. pneumoniae
Meropenem-Vaborbactam1010109813131371112412311391912929271915
Piperacillin-Tazobactam35532141414121010610710073692626241513

[back to top]

Per-Pathogen Microbiological Outcome (EMA) In The ME Population

This secondary outcome measure focused on the per-pathogen (E. cloacae, E. faecalis, E. coli, K. pneumoniae) microbiological outcome of Eradication in the ME population at 5 time points: Day 3, EOIVT, EOT, TOC, and LFU. Eradication was defined per the EMA criteria as a reduction in baseline bacterial pathogen(s) to <10^3 CFU/mL of urine culture and a negative blood culture for an organism that was identified as an uropathogen (if repeated after positive at baseline blood culture). (NCT02166476)
Timeframe: Day 3, EOIVT (Days 5-14), EOT (Days 10-14), TOC (Days 15-23), and LFU (Days 22-30)

,
InterventionParticipants (Count of Participants)
Day 3: E. cloacaeEOIVT: E. cloacaeEOT: E. cloacaeTOC: E. cloacaeLFU: E. cloacaeDay 3: E. faecalisEOIVT: E. faecalisEOT: E. faecalisTOC: E. faecalisLFU: E. faecalisDay 3: E. coliEOIVT: E. coliEOT: E. coliTOC: E. coliLFU: E. coliDay 3: K. pneumoniaeEOIVT: K. pneumoniaeEOT: K. pneumoniaeTOC: K. pneumoniaeLFU: K. pneumoniae
Meropenem-Vaborbactam101010981111104811711710782832828261815
Piperacillin-Tazobactam355321414131191011069967662326241311

[back to top]

Per-Pathogen Microbiological Outcome (EMA) In The m-MITT Population

This secondary outcome measure focused on the per-pathogen (E. cloacae, E. faecalis, E. coli, K. pneumoniae) microbiological outcome of Eradication in the m-MITT population at 5 time points: Day 3, EOIVT, EOT, TOC, and LFU. Eradication was defined per the EMA criteria as a reduction in baseline bacterial pathogen(s) to <10^3 CFU/mL of urine culture and a negative blood culture for an organism that was identified as an uropathogen (if repeated after positive at baseline blood culture). (NCT02166476)
Timeframe: Day 3, EOIVT (Days 5-14), EOT (Days 10-14), TOC (Days 15-23), and LFU (Days 22-30)

,
InterventionParticipants (Count of Participants)
Day 3: E. cloacaeEOIVT: E. cloacaeEOT: E. cloacaeTOC: E. cloacaeLFU: E. cloacaeDay 3: E. faecalisEOIVT: E. faecalisEOT: E. faecalisTOC: E. faecalisLFU: E. faecalisDay 3: E. coliEOIVT: E. coliEOT: E. coliTOC: E. coliLFU: E. coliDay 3: K. pneumoniaeEOIVT: K. pneumoniaeEOT: K. pneumoniaeTOC: K. pneumoniaeLFU: K. pneumoniae
Meropenem-Vaborbactam101010981313125912412311289902929271915
Piperacillin-Tazobactam3553214141311910610710068682426241412

[back to top]

Proportion Of Participants In The Microbiological Modified Intent-To-Treat (m-MITT) Population Who Achieved Overall Success At The End Of Intravenous Treatment Visit

This was the primary outcome measure for the Food and Drug Administration (FDA). For this composite outcome measure, overall success was achieved with a clinical outcome of Cure or Improvement and microbiologic outcome of Eradication at the end of intravenous treatment (EOIVT). Cure was defined as the complete resolution or significant improvement of the baseline signs and symptoms. Improvement was defined as lessening, incomplete resolution, or no worsening of the baseline signs and symptoms. Eradication was defined using the FDA's colony-forming units (CFU)/mL criteria that the bacterial pathogen(s) found at baseline was/were reduced to <10^4 CFU/mL of urine culture and a negative blood culture for an organism that was identified as an uropathogen (if repeated after positive at baseline blood culture). (NCT02166476)
Timeframe: EOIVT (Days 5-14)

InterventionParticipants (Count of Participants)
Meropenem-Vaborbactam189
Piperacillin-Tazobactam171

[back to top]

Proportion Of Participants In The Microbiological Evaluable (ME) Population Who Achieved A Microbiologic Outcome Of Eradication At The TOC Visit

This was the primary outcome measure for the EMA. For this measure, a microbiologic outcome of Eradication was defined using the EMA's CFU/mL criteria: bacterial pathogen(s) found at baseline was reduced to <10^3 CFU/mL of urine culture and a negative blood culture for an organism that was identified as an uropathogen (if repeated after positive at baseline blood culture). The ME population included all participants who met m-MITT criteria and had a clinical outcome and microbiologic outcome at EOIVT or earlier; received <80% or >120% of expected IV doses; missed no more than 1 IV dose in the first 48 hours, missed no more than 2 consecutive IV doses; received no less than 6 doses for failure or no less than 9 doses for cure. (NCT02166476)
Timeframe: TOC (Days 15-23)

InterventionParticipants (Count of Participants)
Meropenem-Vaborbactam118
Piperacillin-Tazobactam102

[back to top]

Proportion Of Participants In The m-MITT Population Who Achieved A Microbiologic Outcome Of Eradication At The Test Of Cure Visit

This was the primary outcome measure for the European Medicines Agency (EMA). For this measure, a microbiologic outcome of Eradication was defined using the EMA's CFU/mL criteria: bacterial pathogen(s) found at baseline was reduced to <10^3 CFU/mL of urine culture and a negative blood culture for an organism that was identified as an uropathogen (if repeated after positive at baseline blood culture). (NCT02166476)
Timeframe: Test of cure (TOC) (Days 15-23)

InterventionParticipants (Count of Participants)
Meropenem-Vaborbactam128
Piperacillin-Tazobactam105

[back to top]

Pharmacokinetic (PK) Characterization Of Plasma Exposure Of Meropenem/Vaborbactam

"This outcome measure focused on PK assessment of participants in the meropenem/vaborbactam group who met MITT criteria and had at least 1 plasma PK sample drawn. Sparse PK sampling on Day 1 was performed 3-3.5 hours and 5-6 hours after the start of the first 3-h IV study drug infusion. Samples were not collected around the 30-minute infusions. Samples were collected from both groups to maintain the blind; however, only PK samples for the meropenem/vaborbactam group were analyzed. The area under the curve (AUC) was generated using a Population PK model and post hoc estimates of each participants' PK parameters, including AUC0-24, were generated.~The AUC during 24 hours (AUC0-24) for Day 1 and at steady-state are presented in micrograms (ug)·hour/mL." (NCT02166476)
Timeframe: Day 1

Interventionug·hour/mL (Mean)
AUC0-24: Day 1AUC0-24: Steady-State
Meropenem-Vaborbactam803798

[back to top]

Proportion of Subjects in the Microbiological Modified Intent-to-Treat (m-MITT) Population With a Clinical Outcome of Cure (All Indications)

Clinical cure defined as complete resolution or significant improvement of the baseline signs and symptoms, no further antimicrobial warranted. (NCT02168946)
Timeframe: at EOT visit (7-14) and TOC visit (day 12-23)

,
InterventionParticipants (Count of Participants)
EOTTOC
Best Available Therapy76
Vabomere2421

[back to top]

Proportion of Subjects in the mCRE-MITT Population With a Clinical Outcome of Cure (HABP/VABP and Bacteremia)

Clinical cure defined as complete resolution or significant improvement of the baseline signs & symptoms, no further antimicrobial warranted. (NCT02168946)
Timeframe: at EOT visit (7-14) and TOC visit (day 12-23)

,
InterventionParticipants (Count of Participants)
EOTTOC
Best Available Therapy32
Vabomere1012

[back to top]

Proportion of Subjects in the mCRE-MITT Population With a Clinical Outcome of Cure (cUTI/AP Subjects Only)

Clinical cure defined as complete resolution or significant improvement of the baseline signs & symptoms, no further antimicrobial warranted. (NCT02168946)
Timeframe: at EOT visit (7-14) and TOC visit (day 12-23)

,
InterventionParticipants (Count of Participants)
EOTTOC
Best Available Therapy22
Vabomere95

[back to top]

Proportion of Subjects in the mCRE-MITT Population With a Clinical Outcome of Cure (All Indications)

Clinical cure defined as complete resolution or significant improvement of the baseline signs & symptoms, no further antimicrobial warranted. (NCT02168946)
Timeframe: at End of Therapy (EOT) visit (7-14 days) and TOC visit (12-23 days)

,
InterventionParticipants (Count of Participants)
EOTTOC
Best Available Therapy54
Vabomere2119

[back to top]

Proportion of Subjects in the m-MITT Populations With a With a Response of Overall Success (cUTI/AP)

Proportion of subjects in m-MITT Population with response of cure and microbiological eradication or presumed eradication. Eradication defined for cUTI/AP as the demonstration that the bacterial pathogen(s) found at baseline is reduced to <10x4 CFU/mL urine (FDA). Clinical cure defined as complete resolution or significant improvement of the baseline signs & symptoms, no further antimicrobial warranted. (NCT02168946)
Timeframe: at EOT visit (7-14) and TOC visit (day 12-23)

,
InterventionParticipants (Count of Participants)
EOTTOC
Best Available Therapy44
Vabomere104

[back to top]

Proportion of Subjects in the m-MITT Populations With a With a Response of Overall Success (Bacteremia Only)

Proportion of subjects in m-MITT Population with response of cure and microbiological eradication or presumed eradication. Clinical cure defined as complete resolution or significant improvement of the baseline signs & symptoms, no further antimicrobial warranted. (NCT02168946)
Timeframe: at EOT visit (7-14) and TOC visit (day 12-23)

,
InterventionParticipants (Count of Participants)
EOTTOC
Best Available Therapy32
Vabomere88

[back to top]

Proportion of Subjects in the m-MITT Population With a Microbiological Outcome of Eradication (All Indications)

Microbiological eradication defined for cUTI/AP as the demonstration that the bacterial pathogen(s) found at baseline is reduced to <10x4 CFU/mL urine (FDA). (NCT02168946)
Timeframe: at EOT visit (7-14) and TOC visit (day 12-23)

,
InterventionParticipants (Count of Participants)
EOTTOC
Best Available Therapy87
Vabomere2317

[back to top]

Proportion of Subjects in the mCRE-MITT Population With a Microbiological Outcome of Eradication (All Indications)

Includes subjects with microbiologic eradication or presumed eradication as defined: microbiologic eradication of the baseline pathogen or absence of culture result (microbiologic outcome of indeterminate or not assesses) where subject is deemed as clinical cure at that visit. For cUTI/AP subjects, demonstration that the bacterial pathogen(s) found at baseline is reduced to <10x4 CFU/mL urine (FDA). (NCT02168946)
Timeframe: at EOT visit (7-14) and TOC visit (day 12-23)

,
InterventionParticipants (Count of Participants)
EOTTOC
Best Available Therapy65
Vabomere2117

[back to top]

Proportion of Subjects in the m-MITT Population With a Clinical Outcome of Cure (HABP/VABP and Bacteremia)

Clinical cure defined as complete resolution or significant improvement of the baseline signs & symptoms, no further antimicrobial warranted. (NCT02168946)
Timeframe: at EOT visit (7-14) and TOC visit (day 12-23)

,
InterventionParticipants (Count of Participants)
EOTTOC
Best Available Therapy32
Vabomere1213

[back to top]

Proportion of Subjects in the m-MITT Population With a Clinical Outcome of Cure (cUTI/AP)

Clinical cure defined as complete resolution or significant improvement of the baseline signs & symptoms, no further antimicrobial warranted. (NCT02168946)
Timeframe: at EOT visit (7-14) and TOC visit (day 12-23)

,
InterventionParticipants (Count of Participants)
EOTTOC
Best Available Therapy44
Vabomere106

[back to top]

The All-cause Mortality Rate in the mCRE-MITT Population (cUTI/AP)

All Cause Mortality at Day 28 in the mCRE-MITT population (cUTI/AP subjects only) (NCT02168946)
Timeframe: at Day 28

InterventionParticipants (Count of Participants)
Vabomere1
Best Available Therapy0

[back to top]

The All-cause Mortality Rate in the mCRE-MITT Population (All Indications)

All Cause Mortality at Day 28 in the mCRE-MITT population (all indications) (NCT02168946)
Timeframe: at Day 28

InterventionParticipants (Count of Participants)
Vabomere5
Best Available Therapy5

[back to top]

The All-cause Mortality Rate in the m-MITT Population (All Indications)

The All Cause Mortality rate at Day 28 in the m-MITT population (all indications) (NCT02168946)
Timeframe: at Day 28

InterventionParticipants (Count of Participants)
Vabomere5
Best Available Therapy5

[back to top]

Proportion of Subjects in the Microbiological Carbapenem-resistant Enterobacteriaceae Modified Intent-to-Treat (mCRE-MITT) Population With a Response of Overall Success [Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Subjects]

Overall success is defined as clinical cure & microbiological eradication. Eradication defined by FDA as the demonstration that the bacterial pathogen(s) found at baseline is reduced to <10x4 colony forming unit (CFU)/mL urine. Clinical cure defined as complete resolution or significant improvement of the baseline signs & symptoms, no further antimicrobial warranted. (NCT02168946)
Timeframe: at Test of Cure (TOC) visit (Day 12-23)

InterventionParticipants (Count of Participants)
Vabomere4
Best Available Therapy2

[back to top]

Proportion of Subjects in the mCRE-MITT Population With a Clinical Outcome of Cure [Complicated Intra-abdominal Infection (cIAI) Subjects Only]

Clinical cure defined as complete resolution or significant improvement of the baseline signs and symptoms, no further antimicrobial warranted. (NCT02168946)
Timeframe: at TOC visit (Day 12-23)

InterventionParticipants (Count of Participants)
Vabomere2
Best Available Therapy0

[back to top]

All-cause Mortality Rate in the mCRE-MITT Population [Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP) and Bacteremia Subjects)

The All-cause mortality rate at Day 28 in the mCRE-MITT population (HABP/VABP and Bacteremia) (NCT02168946)
Timeframe: Day 28

InterventionParticipants (Count of Participants)
Vabomere4
Best Available Therapy4

[back to top]

Percentage of Participants With Creatinine Clearance (CrCl) at Day 7

CrCl is a measure of glomerular filtration rate (GMFR), an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: <30 mL/min/1.73 m^2, >=30 to <50 mL/min/1.73 m^2, >=50 mL/min/1.73 m^2 to <80 mL/min/1.73 m^2, and >=80 mL/min/1.73 m^2. (NCT02475733)
Timeframe: Day 7

,
Interventionpercentage of participants (Number)
CrCl: <30mL/min/1.73 m^2CrCl: >=30 to <50mL/min/1.73 m^2CrCl: >=50 to <80mL/min/1.73 m^2CrCl: >=80mL/min/1.73 m^2
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole00050.8
Meropenem00059.1

[back to top]

Percentage of Participants With Cephalosporin Class Effects and Additional Adverse Events (AEs)

Percentage of participants with Cephalosporin class effects (defined as adverse event of special interest (AEoSI) within the safety topics (ST) of hypersensitivity/anaphylaxis) and additional AEs (which included AEs of seizures, diarrhea, renal disorder, and liver disorder relevant to the cephalosporin class within the ST and AEs with preferred term in the system organ class of nervous system disorder system organ class based on MedDRA 20.0) were reported in this outcome measure. (NCT02475733)
Timeframe: Baseline until the LFU visit (up to a maximum study duration of 50 days)

,
Interventionpercentage of participants (Number)
AE in the ST of DiarrheaAEoSI in the ST of Hypersensitivity/AnaphylaxisAE in the ST of Liver DisorderAE in the ST of Renal DisorderAEs with PTs in the Nervous System Disorder SOCAE of seizure
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole1.64.9001.60
Meropenem013.6004.50

[back to top]

Percentage of Participants With Abnormal Physical Examination Findings at End of Intravenous Therapy (EOIV) Visit

Physical examination included an assessment of the following: general appearance, skin, head and neck (including ears, eyes, nose and throat), lymph nodes, thyroid, respiratory system, cardiovascular system, abdomen, musculoskeletal system (including spine and extremities), and neurological system. Participants with new or aggravated abnormal physical examination findings with regard to baseline findings were reported. Abnormality in physical examinations were based on blinded observer's discretion. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02475733)
Timeframe: EOIV visit (anytime from Day 4 up to 16)

,
Interventionpercentage of participants (Number)
AbdomenCardiovascular SystemGeneral AppearanceHead and NeckLymph NodesMusculoskeletal SystemNeurological SystemRespiratory SystemSkinThyroid
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole6.601.600003.31.60
Meropenem18.2000000000

[back to top]

Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End of Intravenous Therapy (EOIV) Visit

EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02475733)
Timeframe: Baseline, EOIV visit (anytime from Day 4 up to 16)

,
Interventionmillimeter of mercury (mmHg) (Mean)
SBP: BaselineSBP: Change at EOIVDBP: BaselineDBP: Change at EOIV
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole109.7-4.063.51.3
Meropenem111.6-6.063.1-2.8

[back to top]

Change From Baseline in Respiratory Rate at End of Intravenous Therapy (EOIV) Visit

EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02475733)
Timeframe: Baseline, EOIV visit (anytime from Day 4 up to 16)

,
Interventionbreaths per minute (Mean)
BaselineChange at EOIV
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole22.4-1.3
Meropenem22.9-1.3

[back to top]

Change From Baseline in Pulse Rate at End of Intravenous Therapy (EOIV) Visit

EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02475733)
Timeframe: Baseline, EOIV visit (anytime from Day 4 up to 16)

,
Interventionbeats per minute (Mean)
BaselineChange at EOIV
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole102.1-15.2
Meropenem103.0-15.4

[back to top]

Change From Baseline in Body Weight at End of Intravenous Therapy (EOIV) Visit

EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02475733)
Timeframe: Baseline, EOIV visit (anytime from Day 4 up to 16)

,
Interventionkilograms (Mean)
BaselineChange at EOIV
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole40.58-0.38
Meropenem38.35-1.06

[back to top]

Change From Baseline in Body Temperature at End of Intravenous Therapy (EOIV) Visit

EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02475733)
Timeframe: Baseline, EOIV visit (anytime from Day 4 up to 16)

,
Interventiondegree Celsius (Mean)
BaselineChange at EOIV
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole37.35-0.78
Meropenem37.16-0.60

[back to top]

Percentage of Participants With Creatinine Clearance (CrCl) at End of Intravenous Therapy (EOIV) Visit

CrCl is a measure of GMFR, an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: <30 mL/min/1.73 m^2, >=30 to <50 mL/min/1.73 m^2, >=50 mL/min/1.73 m^2 to <80 mL/min/1.73 m^2, and >=80 mL/min/1.73 m^2. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02475733)
Timeframe: EOIV visit (anytime from Day 4 up to 16)

,
Interventionpercentage of participants (Number)
CrCl: <30mL/min/1.73 m^2CrCl: >=30 to <50mL/min/1.73 m^2CrCl: >=50 to <80mL/min/1.73 m^2CrCl: >=80mL/min/1.73 m^2
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole00082.0
Meropenem00081.8

[back to top]

Percentage of Participants With Favorable Clinical Response (CR) at Test of Cure (TOC) Visit: Intent-to-treat (ITT) Analysis Population

Favorable CR was resolution of all acute signs and symptoms of cIAI, or improvement to such an extent that no further antimicrobial therapy was required. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). (NCT02475733)
Timeframe: TOC visit (up to a maximum study duration of 50 days)

Interventionpercentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole91.8
Meropenem95.5

[back to top]

Percentage of Participants With Favorable Clinical Response (CR) at End of Intravenous Therapy (EOIV) Visit: Intent-to-treat (ITT) Analysis Population

Favorable CR was resolution of all acute signs and symptoms of cIAI or improvement to such an extent that no further antimicrobial therapy was required, or improvement in participants who had switch to oral therapy and met the following criterion: afebrile (temperature <=38.0°C) for at least 24 hours, absence of new and improvement in at least 1 symptom or sign (fever, pain, tenderness, elevated WBCs, elevated c-reative-protein) from baseline and worsening of none. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02475733)
Timeframe: EOIV visit (anytime from Day 4 up to 16)

Interventionpercentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole96.7
Meropenem100

[back to top]

Percentage of Participants With Favorable Clinical Response (CR) at End of 72 Hours Treatment: Intent-to-treat (ITT) Analysis Population

Favorable CR was defined as resolution of all acute signs and symptoms of complicated intra- abdominal infection (cIAIs), or improvement to such an extent that no further antimicrobial therapy was required, or improvement but not enough to switch to oral therapy and still on IV study drug at end of 72 hours and had met following criterion: absence of new signs and symptoms, improvement in at least 1 symptom/sign (fever, pain, tenderness, elevated White Blood Cells [WBCs], elevated c-reactive protein) from baseline and no worsening symptom/sign. (NCT02475733)
Timeframe: End of 72 hours study drug treatment on Day 1

Interventionpercentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole93.4
Meropenem90.9

[back to top]

Percentage of Participants With Emergent Infections: Microbiological Intent-to-treat (Micro-ITT) Population

Emergent infections were categorized as super infections and new infections. Superinfection: An intra-abdominal culture identified pathogen other than a baseline pathogen during the course of active treatment with study therapy along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy. New infection: An intra-abdominal culture identified pathogen other than a baseline pathogen at any time after study treatment had finished along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy. Participants with any (super infections or new infections) of the infections were reported. (NCT02475733)
Timeframe: Baseline up to 50 days

Interventionpercentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole0
Meropenem0

[back to top]

Percentage of Participants With Emergent Infections at Test of Cure (TOC) Visit: Microbiologically Evaluable Population

Emergent Infections was an intra-abdominal culture identified pathogen other than a baseline pathogen during the course of active treatment with study therapy along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy, new infection was an intra-abdominal culture identified pathogen other than a baseline pathogen at any time after study treatment has finished along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). Participants with any (super infections or new infections) of the infections were reported. (NCT02475733)
Timeframe: TOC visit (up to a maximum study duration of 50 days)

Interventionpercentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole0
Meropenem0

[back to top]

Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Microbiologically Evaluable (ME) Population

A participant was said to have clinical relapse if me either 1 of the following criteria: reappearance or worsening of signs and symptoms of cIAI that required further antimicrobial therapy and/or surgery, or death after TOC in which cIAI was contributory. LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral). (NCT02475733)
Timeframe: LFU visit (up to a maximum study duration of 50 days)

Interventionpercentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole0
Meropenem0

[back to top]

Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Clinically Evaluable (CE) Population

A participant was said to have clinical relapse if met either 1 of the following criteria: reappearance or worsening of signs and symptoms of cIAI that required further antimicrobial therapy and/or surgery, or death after TOC in which cIAI was contributory. LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral). (NCT02475733)
Timeframe: LFU visit (up to a maximum study duration of 50 days)

Interventionpercentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole0
Meropenem0

[back to top]

Percentage of Participants With Favorable Microbiological Response: Microbiological Intent-to-treat (Micro-ITT) Population

Favorable microbiological response was achieved when all baseline pathogens were eradicated or presumed eradicated based on investigator's discretion. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. EOT visit occurred within 48 hours after completion of last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study if on oral switch therapy (which occurred within the maximum study treatment duration of 15 days). EOIV visit occurred within 24 hours after completion of last infusion of the study drug. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral). (NCT02475733)
Timeframe: EOIV visit (Day 4 up to 16), EOT visit (up to Day 17), TOC visit (up to a maximum study duration of 50 days) and LFU visit (up to a maximum study duration of 50 days)

,
Interventionpercentage of participants (Number)
EOIVEOTTOCLFU
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole96.090.090.090.0
Meropenem10010094.794.7

[back to top]

Percentage of Participants With Favorable Microbiological Response: Microbiologically Evaluable (ME) Population

Favorable microbiological response was achieved when all baseline pathogens were eradicated or presumed eradicated based on investigator's discretion. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. EOT visit occurred within 48 hours after completion of last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study if on oral switch therapy (which occurred within the maximum study treatment duration of 15 days). TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral). (NCT02475733)
Timeframe: EOIV visit (Day 4 up to 16), EOT visit (up to Day 17), TOC visit (up to a maximum study duration of 50 days) and LFU visit (up to a maximum study duration of 50 days)

,
Interventionpercentage of participants (Number)
EOIVEOTTOCLFU
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole97.591.790.089.2
Meropenem10010093.392.9

[back to top]

Percentage of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters

Criteria for potentially clinically significant laboratory abnormalities: Chemistry (calcium: <0.7*lower limit of normal range [LLN] and >30 percent decrease from baseline [DFB]; alanine aminotransferase [ALT]: >3*upper limit of normal range [ULN] and >300 percent IFB; alanine aminotransferase [AST]: >3*ULN and >300 percent IFB) and hematology (platelets: >2*ULN and >100 percent IFB). LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral). (NCT02475733)
Timeframe: Baseline until the LFU visit (up to a maximum study duration of 50 days)

,
Interventionpercentage of participants (Number)
Chemistry: CalciumChemistry: ALTChemistry: ASTHematology: Platelets
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole1.91.71.83.3
Meropenem0000

[back to top]

Plasma Concentrations of Ceftazidime and Avibactam

(NCT02475733)
Timeframe: 15, 30-90, 300-360 minutes post-dose on Day 3

Interventionnanogram per milliliter (Geometric Mean)
Ceftazidime: 15 minute post-dose on Day 3Ceftazidime: 30-90 minute post-dose on Day 3Ceftazidime:300-360minute post-dose on Day 3Avibactam: 15 minute post-dose on Day 3Avibactam: 30-90 minute post-dose on Day 3Avibactam: 300-360 minute post-dose on Day 3
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole63565.538048.04603.012186.26548.6821.5

[back to top]

Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events between first dose of study drug and up to late follow-up (LFU) visit (20 to 35 days after last dose of study treatment [IV or oral]) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAE and non-SAE. (NCT02475733)
Timeframe: Baseline until the LFU visit (up to a maximum study duration of 50 days)

,
Interventionpercentage of participants (Number)
AEsSAEs
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole52.58.2
Meropenem59.14.5

[back to top]

Percentage of Participants With Creatinine Clearance (CrCl) at Late Follow-up (LFU) Visit

CrCl is a measure of GMFR, an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: <30 mL/min/1.73 m^2, >=30 to <50 mL/min/1.73 m^2, >=50 mL/min/1.73 m^2 to <80 mL/min/1.73 m^2, and >=80 mL/min/1.73 m^2. LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral). (NCT02475733)
Timeframe: LFU visit (up to a maximum study duration of 50 days)

,
Interventionpercentage of participants (Number)
CrCl: <30mL/min/1.73 m^2CrCl: >=30 to <50mL/min/1.73 m^2CrCl: >=50 to <80mL/min/1.73 m^2CrCl: >=80mL/min/1.73 m^2
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole001.66.6
Meropenem0009.1

[back to top]

Percentage of Participants With Creatinine Clearance (CrCl) at Test of Cure (TOC) Visit

CrCl is a measure of GMFR, an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: <30 mL/min/1.73 m^2, >=30 to <50 mL/min/1.73 m^2, >=50 mL/min/1.73 m^2 to <80 mL/min/1.73 m^2, and >=80 mL/min/1.73 m^2. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). (NCT02475733)
Timeframe: TOC visit (up to a maximum study duration of 50 days)

,
Interventionpercentage of participants (Number)
CrCl: <30mL/min/1.73 m^2CrCl: >=30 to <50mL/min/1.73 m^2CrCl: >=50 to <80mL/min/1.73 m^2CrCl: >=80mL/min/1.73 m^2
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole003.342.6
Meropenem00059.1

[back to top]

Percentage of Participants With Electrocardiogram (ECG) Parameter QTcF: > 450, >480 and >500 Millisecond (ms)

ECG parameters included maximum QT intervals using Fridericia's correction (QTcF). Maximum QTcF >450 millisecond (ms); maximum QTcF >480 ms; and maximum QTcF >500 ms. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02475733)
Timeframe: Baseline until the EOIV visit (anytime from Day 4 to 16)

,
Interventionpercentage of participants (Number)
Maximum QTcF Interval : >450 msMaximum QTcF Interval : >480 msMaximum QTcF Interval : >500 ms
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole1.61.60
Meropenem4.54.54.5

[back to top]

Percentage of Participants With Favorable Clinical Response (CR): Clinically Evaluable (CE) Analysis Population

Favorable CR was resolution of all acute signs and symptoms of cIAI, or improvement to such an extent that no further antimicrobial therapy was required, or improvement in participants who had switch to oral therapy and met the following criterion: afebrile (temperature <=38.0°C) for at least 24 hours, absence of new and improvement in at least 1 symptom or sign (fever, pain, tenderness, elevated WBCs, elevated c-reative-protein) from baseline and worsening of none. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. EOT visit occurred within 48 hours after completion of last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study (if on oral switch therapy). TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). (NCT02475733)
Timeframe: End of 72 hours study drug treatment on Day 1, EOIV (anytime from Day 4 up to 16), EOT visit (up to Day 17) and TOC visit (up to a maximum study duration of 50 days)

,
Interventionpercentage of participants (Number)
End 72 hours study medicationEOIVEOTTOC
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole98.098.194.292.9
Meropenem95.010010095.0

[back to top]

Percentage of Participants With Favorable Clinical Response (CR) at End of Treatment (EOT) Visit: Intent-to-treat (ITT) Analysis Population

Favorable CR was resolution of all acute signs and symptoms of cIAI, or improvement to such an extent that no further antimicrobial therapy was required. EOT visit occurred within 48 hours after completion of the last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study (if on oral switch therapy). (NCT02475733)
Timeframe: EOT visit (up to Day 17)

Interventionpercentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole91.8
Meropenem100

[back to top]

Percentage of Patients With Composite of Microbiological Eradication and Clinical Cure in the ME Population at Day 5

Microbiological eradication: urine culture showed the pathogen found at baseline at ≥10^5 CFU/mL was reduced to <10^4 CFU/mL. Clinical Cure Day 5: Marked improvement defined as complete resolution or return to premorbid levels or reduction in severity of all core baseline symptoms with worsening of none, and no new symptoms develop. Failure Day 5: Lack of improvement in core baseline symptoms of cUTI or development of new core symptoms of cUTI; AE requiring the discontinuation of study drug and the patient required alternative non-study antibiotic therapy for the current cUTI. (NCT02486627)
Timeframe: Day 5

,
Interventionpercentage of patients (Number)
Day 5: Composite CureDay 5: Composite Failure
Meropenem94.25.8
Plazomicin89.410.6

[back to top]

Percentage of Patients With Composite of Microbiological Eradication and Clinical Cure in the ME Population at TOC

Microbiological eradication: urine culture showed the pathogen found at baseline at ≥10^5 CFU/mL was reduced to <10^4 CFU/mL. Clinical Cure TOC: Complete resolution or return to premorbid levels of core symptoms of cUTI and no new symptoms develop, and no use of non-study antibiotic therapy for the current cUTI. Failure TOC: Persistence of one or more core symptom of infection or reappearance of or development of new core symptoms that require alternative non-study antibiotic therapy for the current cUTI. (NCT02486627)
Timeframe: Day 17 TOC Visit

,
Interventionpercentage of patients (Number)
TOC: Composite CureTOC: Composite Failure
Meropenem75.124.9
Plazomicin84.915.1

[back to top]

Percentage of Patients With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered to be drug related. An AE (also referred to as an adverse experience) can be any unfavorable and unintended sign (eg, an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, and it does not imply any judgment about causality. Adverse events also include the exacerbation or worsening of a condition present at screening other than the index infection for which the patient was enrolled in the study. A TEAE is any AE that newly appeared, increased in frequency, or worsened in severity following initiation of study drug. (NCT02486627)
Timeframe: Up to Day 32

Interventionpercentage of patients (Number)
Plazomicin19.5
Meropenem21.6

[back to top]

Plasma Pharmacokinetics (PK): Area Under the Curve From 0 to 24 Hours (AUC 0-24h)

PK blood samples were collected on Day 3 (plus or minus 1 day) of study drug administration for the determination of plazomicin concentrations in plazomicin-treated patients. (NCT02486627)
Timeframe: Day 3

Interventionmg*h/L (milligrams times hour per liter) (Geometric Mean)
Plazomicin234

[back to top]

Plasma PK: Maximum Observed Plasma Drug Concentration (Cmax)

PK blood samples were collected on Day 3 (plus or minus 1 day) of study drug administration for the determination of plazomicin concentrations in plazomicin-treated patients. (NCT02486627)
Timeframe: Day 3

Interventionmg/L (Geometric Mean)
Plazomicin46.6

[back to top]

Plasma PK: Minimum Observed Plasma Drug Concentration (Cmin)

PK blood samples were collected on Day 3 (plus or minus 1 day) of study drug administration for the determination of plazomicin concentrations in plazomicin-treated patients. (NCT02486627)
Timeframe: Day 3

Interventionmg/L (Geometric Mean)
Plazomicin0.88

[back to top]

Percentage of Patients With Composite of Microbiological Eradication and Clinical Cure in the mMITT Population at Test of Cure (TOC)

Microbiological eradication was defined as a urine culture that showed the pathogen found at baseline at ≥10^5 CFU/mL was reduced to <10^4 CFU/mL. Clinical Cure at TOC Visit: the complete resolution or return to premorbid levels of core symptoms of cUTI and no new symptoms develop, and no use of non-study antibiotic therapy for the current cUTI. Failure: Persistence of one or more core symptom of infection or reappearance of or development of new core symptoms that require alternative non-study antibiotic therapy for the current cUTI. Indeterminate: Insufficient data are available to allow an evaluation of clinical outcome for any reason. (NCT02486627)
Timeframe: Day 17 TOC Visit

,
Interventionpercentage of patients (Number)
Composite CureComposite FailureIndeterminate
Meropenem70.125.94.1
Plazomicin81.715.23.1

[back to top]

Percentage of Patients With Composite of Microbiological Eradication and Clinical Cure in the Microbiological Modified ITT (mMITT) Population at Day 5

Microbiological eradication was defined as a urine culture that showed the pathogen found at baseline at ≥10^5 colony forming units per milliliter (CFU/mL) was reduced to <10^4 CFU/mL. Clinical Cure at Day 5: marked improvement evidenced by complete resolution or return to premorbid levels or reduction in severity of all core baseline symptoms with worsening of none, and no new symptoms developed. Failure: Lack of improvement in core baseline symptoms of cUTI or development of new core symptoms of cUTI; adverse event (AE) requiring the discontinuation of study drug and the patient required alternative non-study antibiotic therapy for the current cUTI. Indeterminate: Insufficient data are available to allow an evaluation of clinical outcome for any reason. (NCT02486627)
Timeframe: Day 5

,
Interventionpercentage of patients (Number)
Composite CureComposite FailureIndeterminate
Meropenem91.47.61
Plazomicin8810.51.6

[back to top]

Number of Participants With Clinical Response

"Resolution. Disappearance of all signs and symptoms related to the infection.~Failure. Insufficient lessening of the signs and symptoms of infection to qualify as improvement, including death or indeterminate (no evaluation possible, for any reason)." (NCT03019965)
Timeframe: Number of participants with clinical response at 14 days after antibiotic cessation, up to an average of 28 days or the day of your discharge if this occurred before 14 days after antibiotic cessation.

InterventionParticipants (Count of Participants)
Intermittent. Piperacillin/Tazobactam, Imipenem, Meropenem178
Prolonged Infusion. Continuous Piperacillin/Tazobactam, Extended Imipenem, Extended Meropenem169

[back to top]

Number of Participants With Adverse Events

Any harmful, undesirable, potentially serious and life threatening effects occurring during or after administration of the antibiotics proposed in this study (piperacillin / tazobactam, imipenem or meropenem), was evaluated as: none or adverse event classified according to the intensity of the clinical manifestation (severity) as: mild, moderate or severe and for each antibiotic. (NCT03019965)
Timeframe: Number of participants with adverse events evaluated by an physician at the time of administration of antibiotics, up to an average to 24 hours after the study drug cessation.

InterventionParticipants (Count of Participants)
Intermittent. Piperacillin/Tazobactam, Imipenem, Meropenem1
Prolonged Infusion. Continuous Piperacillin/Tazobactam, Extended Imipenem, Extended Meropenem3

[back to top]

Number of Participants With Treatment-Emergent Adverse Events

"The severity of each adverse event (AE) was graded by the investigator according to the following definitions:~Mild: A finding or symptom is minor and does not interfere with usual daily activities.~Moderate: The event causes discomfort and interferes with usual daily activity or affects clinical status.~Severe: The event causes an interruption of the participant's usual daily activities or has a clinically significant effect.~The relationship of each AE to the study treatment was determined by the investigator based on whether the AE could be reasonably explained as having been caused by the study drug (treatment related AE [TRAE]).~An SAE is defined as any AE occurring at any dose that resulted in any of the following outcomes:~Death~Life-threatening condition~Hospitalization or prolongation of existing hospitalization for treatment~Persistent or significant disability/incapacity~Congenital anomaly/birth defect~Other medically important condition" (NCT03032380)
Timeframe: From first dose of study drug through the end of study, up to 42 days.

,
InterventionParticipants (Count of Participants)
Any adverse eventMild adverse eventsModerate adverse eventsSevere adverse eventsTreatment-related adverse eventsSerious adverse eventsTreatment-related serious adverse eventsAEs leading to discontinuation of study drugTRAE leading to discontinuation of study drugAdverse events leading to death
Cefiderocol1303341561454312239
Meropenem1293747451745514235

[back to top]

Percentage of Participants With Sustained Microbiologic Eradication at Follow-up

"Microbiological outcome by Baseline pathogen at Follow-up was determined by the sponsor as either Sustained Eradication, Persistence, Recurrence, or Indeterminate. Overall per-participant microbiological outcome was determined based on the individual microbiological outcomes for each Baseline pathogen.~Sustained eradication: Absence of all Baseline Gram-negative pathogens from an appropriate clinical specimen (sputum, tracheal aspirate, BAL fluid, protected specimen brush, pleural fluid, or lung biopsy) after TOC. If it was not possible to obtain an appropriate clinical culture and the participant had a successful clinical response after TOC, the response was presumed to be eradication." (NCT03032380)
Timeframe: Follow-up (14 days after the end of treatment, Days 21 to 28)

Interventionpercentage of participants (Number)
Cefiderocol43.5
Meropenem38.6

[back to top]

Percentage of Participants With Sustained Clinical Cure at Follow-up (FU)

"Clinical outcome was assessed by the investigator at follow-up as either Sustained Clinical Cure, Relapse, or Indeterminate.~Sustained Clinical Cure: Continued resolution or substantial improvement of Baseline signs and symptoms of pneumonia, such that no antibacterial therapy was required for the treatment of pneumonia in a participant assessed as cured at TOC." (NCT03032380)
Timeframe: Follow-up (14 days after the end of treatment; Day 21 to 28)

Interventionpercentage of participants (Number)
Cefiderocol57.9
Meropenem57.8

[back to top]

Percentage of Participants With Microbiologic Eradication at Test of Cure (TOC)

"Lower respiratory tract specimens (eg, sputum, endotracheal aspiration [ETA], endobronchial culture specimens collected by bronchoalveolar lavage [BAL], or protected specimen brush [PSB], lung biopsy tissue, pleural effusions, etc) were sent to the local microbiology laboratory for isolation and identification of pathogens.~Microbiological outcome by Baseline pathogen at TOC was determined by the sponsor as either Eradication, Persistence, or Indeterminate. Overall per-participant microbiological outcome was determined based on the individual microbiological outcomes for each Baseline pathogen.~Eradication: Absence of all Baseline Gram-negative pathogens from an appropriate clinical specimen (sputum, tracheal aspirate, bronchoalveolar lavage (BAL) fluid, protected specimen brush, pleural fluid, or lung biopsy). If it was not possible to obtain an appropriate clinical culture, and the participant had a successful clinical outcome, the response was presumed as eradication." (NCT03032380)
Timeframe: Test of cure (7 days after end of treatment; equivalent to Study Day 14 to 21)

Interventionpercentage of participants (Number)
Cefiderocol47.6
Meropenem48.0

[back to top]

Percentage of Participants With Microbiologic Eradication at End of Treatment

"Microbiological outcome by Baseline pathogen at End of Treatment was determined by the sponsor as either: Eradication, Persistence, or Indeterminate. Overall per-participant microbiological outcome was determined based on the individual microbiological outcomes for each Baseline pathogen.~Eradication: Absence of all Baseline Gram-negative pathogens from an appropriate clinical specimen (sputum, tracheal aspirate, BAL fluid, protected specimen brush, pleural fluid, or lung biopsy). If it was not possible to obtain an appropriate clinical culture, and the participant had a successful clinical outcome, the response was presumed as eradication." (NCT03032380)
Timeframe: End of treatment, Day 7 to 14

Interventionpercentage of participants (Number)
Cefiderocol63.7
Meropenem66.9

[back to top]

Percentage of Participants With Microbiologic Eradication at Early Assessment

"Microbiological outcome by Baseline pathogen at Early Assessment was determined by the sponsor as either Eradication, Persistence, or Indeterminate. Overall per-participant microbiological outcome was determined based on the individual microbiological outcomes for each Baseline pathogen.~Eradication: Absence of all Baseline Gram-negative pathogens from an appropriate clinical specimen (sputum, tracheal aspirate, BAL fluid, protected specimen brush, pleural fluid, or lung biopsy). If it was not possible to obtain an appropriate clinical culture, and the participant had a successful clinical outcome, the response was presumed as eradication." (NCT03032380)
Timeframe: Early Assessment, Days 3 to 4

Interventionpercentage of participants (Number)
Cefiderocol41.9
Meropenem53.5

[back to top]

Percentage of Participants With Clinical Cure at Test of Cure

"Clinical outcome was assessed by the investigator as either Clinical Cure, Clinical Failure, or Indeterminate.~Clinical Cure: Resolution or substantial improvement of Baseline signs and symptoms of pneumonia, including a reduction in Sequential Organ Failure Assessment (SOFA) and Clinical Pulmonary Infection Score (CPIS) scores, and improvement or lack of progression of chest radiographic abnormalities such that no additional antibacterial therapy was required for the treatment of the current infection." (NCT03032380)
Timeframe: Test of cure (7 days after the end of treatment; equivalent to Study Day 14 to 21)

Interventionpercentage of participants (Number)
Cefiderocol64.8
Meropenem66.7

[back to top]

Total Hospitalization Time

The length of hospital stay attributable to the study-qualifying infection. (NCT03032380)
Timeframe: From first dose of study drug to test of cure (7 days after end of treatment; equivalent to Study Day 14 to 21) and to follow-up (14 days after the end of treatment; Day 21 to 28)

,
Interventiondays (Mean)
Test of CureFollow-up
Cefiderocol11.5413.49
Meropenem11.4712.98

[back to top]

All-cause Mortality Rate at Day 14

"The all-cause mortality (ACM) rate at Day 14 was calculated as the percentage of participants in each treatment group who experienced mortality, regardless of the cause, from the first infusion of study drug up to Day 14.~The Modified Intent-to-Treat Population included all randomized participants who met either of the following criteria:~Evidence of Gram-negative infection of the lower respiratory tract based on a culture, Gram-stain, or other diagnostic test~Evidence of a lower respiratory tract infection but culture or other diagnostic tests did not provide a microbiologic diagnosis" (NCT03032380)
Timeframe: From first dose of study drug to Day 14

Interventionpercentage of participants (Number)
Cefiderocol12.4
Meropenem11.6

[back to top]

All-cause Mortality Rate at Day 28

The all-cause mortality (ACM) rate at Day 28 was calculated as the percentage of participants who experienced mortality, regardless of the cause, from the first dose of study drug up to Day 28. (NCT03032380)
Timeframe: From first dose of study drug to Day 28

Interventionpercentage of participants (Number)
Cefiderocol21.0
Meropenem20.5

[back to top]

All-cause Mortality Rate at the End of Study

The all-cause mortality rate during both the treatment and follow-up period (up to the end of study [EOS] visit) was calculated as the percentage of participants who experienced mortality, regardless of the cause, from the first infusion of study drug up to EOS. If a participant discontinued from the study before EOS and survival information was not available, then the survival status for this endpoint for the participant was considered unknown. (NCT03032380)
Timeframe: From first dose of study drug through end of study (28 days after end of treatment, up to 42 days)

Interventionpercentage of participants (Number)
Cefiderocol26.8
Meropenem23.3

[back to top]

Percentage of Participants With Clinical Cure at Early Assessment (EA)

"Clinical outcome was assessed by the investigator as either Clinical Cure, Clinical Failure, or Indeterminate.~Clinical Cure: Resolution or substantial improvement of Baseline signs and symptoms of pneumonia, including a reduction in Sequential Organ Failure Assessment (SOFA) and Clinical Pulmonary Infection Score (CPIS) scores, and improvement or lack of progression of chest radiographic abnormalities such that no additional antibacterial therapy was required for the treatment of the current infection." (NCT03032380)
Timeframe: Early assessment (Day 3-4 after the start of treatment)

Interventionpercentage of participants (Number)
Cefiderocol82.8
Meropenem83.0

[back to top]

Percentage of Participants With Clinical Cure at End of Treatment (EOT)

"Clinical outcome was assessed by the investigator as either Clinical Cure, Clinical Failure, or Indeterminate.~Clinical Cure: Resolution or substantial improvement of Baseline signs and symptoms of pneumonia, including a reduction in Sequential Organ Failure Assessment (SOFA) and Clinical Pulmonary Infection Score (CPIS) scores, and improvement or lack of progression of chest radiographic abnormalities such that no additional antibacterial therapy was required for the treatment of the current infection." (NCT03032380)
Timeframe: End of treatment (Day 7 to 14)

Interventionpercentage of participants (Number)
Cefiderocol77.2
Meropenem81.0

[back to top]

AUC for Rifampin

Rifampin AUC0-last in Arms A and C (NCT03174184)
Timeframe: 14 days

Interventionh*mg/L (Mean)
Rifampin Resistant A105
Rifampin Susceptible C109

[back to top]

Distribution of Minimum Inhibitory Concentration (MIC) of Rifampin

The distribution of rifampin MIC in the drug-resistant arms (NCT03174184)
Timeframe: 14 days

Interventionmcg/mL (Median)
Rifampin Resistant A1.28
Rifampin Resistant B1.28

[back to top]

Estimate of the 14-day Early Bactericidal Activity (EBA), Based on Colony Forming Unit Counts, of the Combination of Meropenem and Amoxicillin/Clavulanate, Without Versus With Rifampin

The Early Bactericidal Activity (EBA) over a 14 days period (EBA0-14), as determined by the median rate of change in log10 Colony Forming Units (CFU) per mL sputum. A non-linear mixed effects model of log10 CFU/mL sputum on time was developed using aggregated participant data for each treatment arm. A basic model was developed based on mono- or bi-exponential bacterial killing functions. Afterwards, covariate modelling to identify relationships between demographics, disease severity, secondary pharmacokinetic summary indices (area under the curve from time 0 to last measured concentration (AUC0-last) and maximum observed plasma concentration (Cmax), and model parameters describing log10 CFU/mL sputum over time was performed. Finally, the treatment regimen was tested using different functions supported by the graphical analysis. (NCT03174184)
Timeframe: 14 days

Interventionrate of change in log10 CFU/mL/day (Mean)
Rifampin Resistant A-0.06
Rifampin Resistant B-0.11
Rifampin Susceptible C-0.14
Rifampin Susceptible D-0.12
Rifampin Susceptible E-0.05
Rifampin Susceptible F-0.02

[back to top]

Estimate the Antimycobacterial Activity Based on Liquid Culture Time-to-positivity

Change in time-to-positivity in Mycobacteria Growth Indicator Tube (MGIT) liquid media over 14 days of treatment (EBA0-14(TTP)) (time to positivity) for the study treatments. The Early Bactericidal Activity (EBA) over a 14 days period (EBA0-14), as determined by the median rate of change in TTP (expressed in log10 hours/day). A non-linear mixed effects model of log10 hours/day on time was developed using aggregated participant data for each treatment arm. A basic model was developed based on mono- or bi-exponential bacterial killing functions. Afterwards, covariate modelling to identify relationships between demographics, disease severity, secondary pharmacokinetic summary indices (area under the curve from time 0 to last measured concentration (AUC0-last) and maximum observed plasma concentration (Cmax), and model parameters describing TTP over time was performed. Finally, the treatment regimen was tested using different functions supported by the graphical analysis. (NCT03174184)
Timeframe: 14 days

Interventionrate of change in log10 hours/day (Mean)
Rifampin Resistant A0.19
Rifampin Resistant B0.31
Rifampin Susceptible C0.53
Rifampin Susceptible D0.20
Rifampin Susceptible E0.09
Rifampin Susceptible F0.09

[back to top]

Frequency of Grade 2 or Higher Adverse Events

Grade 2 or higher Adverse Events (AE) that constitute any untoward medical occurrence in a study participant and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. (NCT03174184)
Timeframe: From the time a study participant receives the first dose of study drug through the final study visit, up to 28 days

InterventionEvents (Number)
Rifampin Resistant A28
Rifampin Resistant B15
Rifampin Susceptible C5
Rifampin Susceptible D8
Rifampin Susceptible E3
Rifampin Susceptible F7

[back to top]

"Percentage of Participants With a Clinical Response of Cure at the End of Treatment (EOT) Visit"

"The percentage of participants who had a clinical outcome of cure at the time of the EOT visit is presented. The cure clinical outcome was defined as complete resolution or marked improvement in signs and symptoms of the complicated intra-abdominal infection (cIAI) or return to pre-infection signs and symptoms such that no further antibiotic therapy (intravenous or oral) or surgical or drainage procedure is required for treatment of the cIAI. Participants who were missing clinical response data were considered treatment failures." (NCT03217136)
Timeframe: Up to approximately 27 days

InterventionPercentage of participants (Number)
Ceftolozane/Tazobactam + Metronidazole80.0
Meropenem95.2

[back to top]

Number of Participants Experiencing ≥1 Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. The number of participants who experienced an AE is presented. (NCT03217136)
Timeframe: Up to approximately 75 days

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam + Metronidazole56
Meropenem13

[back to top]

Number of Participants Who Discontinued Study Therapy Due to AE(s)

An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. The number of participants who discontinued study treatment due to an AE is presented. (NCT03217136)
Timeframe: Up to approximately 18 days

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam + Metronidazole2
Meropenem0

[back to top]

Percentage of Participants With Microbiological Eradication at the TOC Visit

The percentage of participants who achieved either eradication or presumed eradication of each baseline infecting pathogen by the time of the TOC visit is presented. Eradication was defined as absence of the baseline pathogen(s) in a postbaseline specimen appropriately obtained from the original site of infection. Presumed eradication was defined as absence of material to culture in a participant who is assessed as having partial improvement, or clinical cure. In the event of multiple baseline pathogens, the least favorable microbiological response from all possible baseline pathogens was used. (NCT03217136)
Timeframe: Up to approximately 39 days

InterventionPercentage of participants (Number)
Ceftolozane/Tazobactam + Metronidazole84.1
Meropenem100

[back to top]

"Percentage of Participants With a Clinical Response of Cure at the Test of Cure (TOC) Visit"

"The percentage of participants who had a clinical outcome of cure at the time of the TOC visit is presented. The cure clinical outcome was defined as complete resolution or marked improvement in signs and symptoms of the complicated intra-abdominal infection (cIAI) or return to pre-infection signs and symptoms such that no further antibiotic therapy (intravenous or oral) or surgical or drainage procedure is required for treatment of the cIAI. Participants who were missing clinical response data were considered treatment failures." (NCT03217136)
Timeframe: Up to approximately 39 days

InterventionPercentage of participants (Number)
Ceftolozane/Tazobactam + Metronidazole80.0
Meropenem100.0

[back to top]

Percentage of Participants With Microbiological Eradication at the EOT Visit

The percentage of participants who achieved either eradication or presumed eradication of each baseline infecting pathogen by the time of the EOT visit is presented. Eradication was defined as absence of the baseline pathogen(s) in a postbaseline specimen appropriately obtained from the original site of infection. Presumed eradication was defined as absence of material to culture in a participant who is assessed as having partial improvement, or clinical cure. In the event of multiple baseline pathogens, the least favorable microbiological response from all possible baseline pathogens was used. (NCT03217136)
Timeframe: Up to approximately 27 days

InterventionPercentage of participants (Number)
Ceftolozane/Tazobactam + Metronidazole84.1
Meropenem94.7

[back to top]

Number of Participants With ≥1 Adverse Events (AEs)

An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. (NCT03230838)
Timeframe: Up to Day 88

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam59
Meropenem20

[back to top]

Number of Participants Discontinuing Study Therapy Due to AE

An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. (NCT03230838)
Timeframe: Up to Day 15

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam1
Meropenem0

[back to top]

Percentage of Participants With Microbiological Eradication of All Baseline Pathogens at the Test of Cure Visit

Microbiological eradication of all baseline pathogens is defined as a postbaseline urine culture shows all uropathogens found at baseline at ≥10^5 colony-forming units (CFU)/mL are reduced to <10^4 CFU/mL. The 95% CIs of each treatment are unstratified Wilson CIs. (NCT03230838)
Timeframe: Up to Test of Cure Visit (up to 35 days)

InterventionPercentage of participants (Number)
Ceftolozane/Tazobactam84.5
Meropenem87.5

[back to top]

Percentage of Participants With Microbiological Eradication of All Baseline Pathogens at the End of Treatment Visit

Microbiological eradication of all baseline pathogens is defined as a postbaseline urine culture shows all uropathogens found at baseline at ≥10^5 colony-forming units (CFU)/mL are reduced to <10^4 CFU/mL. The 95% CIs of each treatment are unstratified Wilson CIs. (NCT03230838)
Timeframe: Up to 48 hours after last oral dose (up to 19 days)

InterventionPercentage of participants (Number)
Ceftolozane/Tazobactam93.0
Meropenem95.8

[back to top]

Percentage of Participants With a Clinical Response of Cure at the Test of Cure Visit

Clinical response of cure is complete resolution or marked improvement in signs and symptoms of the complicated urinary tract infection (cUTI) or return to pre-infection signs and symptoms, such that no further antibiotic therapy (IV or oral) is required for the treatment of the cUTI. The 95% confidence intervals (CIs) of each treatment are unstratified Wilson CIs. (NCT03230838)
Timeframe: Up to Test of Cure Visit (up to 35 days)

InterventionPercentage of participants (Number)
Ceftolozane/Tazobactam88.7
Meropenem95.8

[back to top]

Percentage of Participants With a Clinical Response of Cure at the End of Treatment Visit

Clinical response of cure is complete resolution or marked improvement in signs and symptoms of the cUTI or return to pre-infection signs and symptoms, such that no further antibiotic therapy (IV or oral) is required for the treatment of the cUTI. The 95% CIs of each treatment are unstratified Wilson CIs. (NCT03230838)
Timeframe: Up to 48 hours after last oral dose (up to 19 days)

InterventionPercentage of participants (Number)
Ceftolozane/Tazobactam94.4
Meropenem100.0

[back to top]

Number of Participants With Favorable Clinical Response in the ME Analysis Set at LFU.

The secondary efficacy outcome is favorable clinical response of the patients in the ME (Microbiologically Evaluable) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate. (NCT03485950)
Timeframe: 35 to 42 days after the start of inpatient IV study drug

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam Arm2
Standard of Care (SOC) Arm1

[back to top]

Number of Participants With Favorable Clinical Response in the MITT Analysis Set at TOC

The secondary efficacy outcome is favorable clinical response of the patients in the MITT (Modified Intent-To-Treat) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate. (NCT03485950)
Timeframe: 21 to 28 days after the start of inpatient IV study drug

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam Arm34
Standard of Care (SOC) Arm28

[back to top] [back to top]

Number of Participants With Favorable Clinical Response in the MITT Analysis Set at Late Follow-Up (LFU)

The secondary efficacy outcome is favorable clinical response of the patients in the MITT (Modified Intent-To-Treat) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate. (NCT03485950)
Timeframe: 35 to 42 days after the start of inpatient IV study drug

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam Arm33
Standard of Care (SOC) Arm26

[back to top]

Number of Participants With Favorable Microbiological Response in the ME Analysis Set at LFU

The secondary efficacy outcome is favorable microbiological response of the patients in the ME (Microbiologically Evaluable) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate. (NCT03485950)
Timeframe: 35 to 42 days after the start of inpatient IV study drug

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam Arm2
Standard of Care (SOC) Arm1

[back to top]

Number of Participants With Favorable Microbiological Response in the ME Analysis Set at EOIV.

The secondary efficacy outcome is favorable clinical response of the patients in the ME (Microbiologically Evaluable) Analysis Set at end of inpatient intravenous therapy (EOIV). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate. (NCT03485950)
Timeframe: Within 72 hours after administration of the last dose of inpatient IV study drug

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam Arm2
Standard of Care (SOC) Arm1

[back to top] [back to top]

Number of Participants With Favorable Clinical Response in the Clinically Evaluable (CE) Analysis Set at EOIV.

The secondary efficacy outcome is favorable clinical response of the patients in the CE (Clinically Evaluable) Analysis Set at end of inpatient intravenous therapy (EOIV). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate. (NCT03485950)
Timeframe: Within 72 hours after administration of the last dose of inpatient IV study drug.

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam Arm29
Standard of Care (SOC) Arm32

[back to top] [back to top]

Number of Participants With Favorable Clinical Response in the ME Analysis Set at EOIV.

The secondary efficacy outcome is favorable clinical response of the patients in the ME (Microbiologically Evaluable) Analysis Set at end of inpatient intravenous therapy (EOIV). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate. (NCT03485950)
Timeframe: Within 72 hours after administration of the last dose of inpatient IV study drug.

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam Arm2
Standard of Care (SOC) Arm1

[back to top] [back to top]

30 Day All-cause Mortality in the mMITT Analysis Set

The secondary efficacy outcome is all-cause mortality of the patients in the mMITT (microbiological Modified Intent-To-Treat) Analysis Set, which is mortality within 30 days after the last dose of inpatient IV study drug. (NCT03485950)
Timeframe: 30 days after the last dose of inpatient IV study drug

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam Arm0
Standard of Care (SOC) Arm0

[back to top]

Number of Participants With Favorable Clinical Response in the ME Analysis Set at TOC

The secondary efficacy outcome is favorable clinical response of the patients in the ME (Microbiologically Evaluable) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate. (NCT03485950)
Timeframe: 21 to 28 days after the start of inpatient IV study drug.

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam Arm2
Standard of Care (SOC) Arm1

[back to top]

30 Day All-cause Mortality in the MITT Analysis Set

The secondary efficacy outcome is all-cause mortality of the patients in the MITT (Modified Intent-To-Treat) Analysis Set, which is mortality within 30 days after the last dose of inpatient IV study drug. (NCT03485950)
Timeframe: 30 days after the last dose of inpatient IV study drug

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam Arm2
Standard of Care (SOC) Arm2

[back to top]

Favorable Microbiological Response in the mMITT Analysis Set at TOC.

The secondary efficacy outcome is favorable microbiological response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate. (NCT03485950)
Timeframe: 21 to 28 days after the start of inpatient IV study drug

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam Arm3
Standard of Care (SOC) Arm2

[back to top]

Number of Participants With Favorable Clinical Response at End of Inpatient Intravenous Therapy (EOIV)

Resolution of all acute signs and symptoms of the primary infection or improvement to such an extent that no additional antibacterial therapy is required (ie, except for protocol-allowed adjunctive therapies and/or oral or IV switch) and such that no more than 14 days of total antibacterial therapy is required. (NCT03485950)
Timeframe: Within 72 hours after administration of the last dose of inpatient IV study drug

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam Arm41
Standard of Care (SOC) Arm36

[back to top]

Number of Participants With Favorable Clinical Response in the CE Analysis Set at LFU.

The secondary efficacy outcome is favorable clinical response of the patients in the CE (Clinically Evaluable) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate. (NCT03485950)
Timeframe: 35 to 42 days after the start of inpatient IV study drug

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam Arm27
Standard of Care (SOC) Arm24

[back to top]

Number of Participants With Favorable Clinical Response in the CE Analysis Set at TOC

The secondary efficacy outcome is favorable clinical response of the patients in the CE (Clinically Evaluable) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate. (NCT03485950)
Timeframe: 21 to 28 days after the start of inpatient IV study drug

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam Arm28
Standard of Care (SOC) Arm26

[back to top]

Number of Participants With Favorable Microbiological Response in the mMITT Analysis Set at LFU.

The secondary efficacy outcome is favorable microbiological response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate. (NCT03485950)
Timeframe: 35 to 42 days after the start of inpatient IV study drug.

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam Arm3
Standard of Care (SOC) Arm2

[back to top]

Number of Participants With Favorable Microbiological Response in the mMITT Analysis Set at EOIV.

The secondary efficacy outcome is favorable microbiological response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at end of inpatient intravenous therapy (EOIV). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate. (NCT03485950)
Timeframe: Within 72 hours after administration of the last dose of inpatient IV study drug

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam Arm3
Standard of Care (SOC) Arm2

[back to top]

Number of Participants With Favorable Microbiological Response in the ME Analysis Set at TOC.

The secondary efficacy outcome is favorable microbiological response of the patients in the ME (Microbiologically Evaluable) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate. (NCT03485950)
Timeframe: 21 to 28 days after the start of inpatient IV study drug

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam Arm2
Standard of Care (SOC) Arm1

[back to top]

Number of Participants With Favorable Clinical Response in the mMITT Analysis Set at Test of Cure (TOC)

The secondary efficacy outcome is favorable clinical response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate. (NCT03485950)
Timeframe: 21 to 28 days after the start of inpatient IV study drug.

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam Arm3
Standard of Care (SOC) Arm1

[back to top]

Number of Participants With Favorable Clinical Response in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set at EOIV.

The secondary efficacy outcome is favorable clinical response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at end of inpatient intravenous therapy (EOIV). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate. (NCT03485950)
Timeframe: Within 72 hours after administration of the last dose of inpatient IV study drug.

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam Arm3
Standard of Care (SOC) Arm1

[back to top]

Number of Participants With Favorable Clinical Response in the mMITT Analysis Set at Late Follow-Up (LFU)

The secondary efficacy outcome is favorable clinical response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate. (NCT03485950)
Timeframe: 35 to 42 days after the start of inpatient IV study drug

InterventionParticipants (Count of Participants)
Ceftolozane/Tazobactam Arm3
Standard of Care (SOC) Arm1

[back to top]

Percentage of Participants With Clinical Response (Clinical Cure, Clinical Failure, or Indeterminate) at TOC Visit: Intent to Treat (ITT) Population

"Clinical response was classified as cure, failure, or indeterminate. Clinical cure (favorable) was defined as complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure is required for the index infection. Clinical failure (unfavorable) was defined as death related to IAI at any time point; persisting or recurrent infection within the abdomen requiring additional intervention to cure; need for treatment with additional antibiotics for ongoing IAI symptoms; or post-surgical wound infection that requires additional antimicrobial therapy and/or non-routing wound care. Indeterminate (unfavorable) was defined as participants for whom study data were not available for evaluation of efficacy for any reason. The percentage of participants with clinical response of clinical cure, clinical failure, or indeterminate at TOC was summarized." (NCT03830333)
Timeframe: Up to approximately Day 30

,
InterventionPercentage of Participants (Number)
Clinical Cure (favorable)Clinical Failure (unfavorable)Indeterminate (unfavorable)
Ceftolozane/Tazobactam + Metronidazole85.114.20.7
Meropenem + Placebo89.69.70.7

[back to top]

Percentage of Participants With Clinical Response (Clinical Cure, Clinical Failure, or Indeterminate) at EOT Visit: ITT Population

"Clinical response was classified as cure, failure, or indeterminate. Clinical cure (favorable) was defined as complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure is required for the index infection. Clinical failure (unfavorable) was defined as death related to IAI at any time point; persisting or recurrent infection within the abdomen requiring additional intervention to cure; need for treatment with additional antibiotics for ongoing IAI symptoms; or post-surgical wound infection that requires additional antimicrobial therapy and/or non-routing wound care. Indeterminate (unfavorable) was defined as participants for whom study data are not available for evaluation of efficacy for any reason. The percentage of participants with clinical response of clinical cure, clinical failure, or indeterminate at EOT was summarized." (NCT03830333)
Timeframe: Up to approximately Day 15

,
InterventionPercentage of Participants (Number)
Clinical Cure (favorable)Clinical Failure (unfavorable)Indeterminate (unfavorable)
Ceftolozane/Tazobactam + Metronidazole92.57.50.0
Meropenem + Placebo94.04.51.5

[back to top]

Percentage of Participants With Clinical Response (Clinical Cure or Clinical Failure) at Test of Cure (TOC) Visit: Clinically Evaluable (CE) Population

"Clinical response was classified as cure or failure. Clinical cure (favorable) was defined as complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure is required for the index infection. Clinical failure (unfavorable) was defined as death related to IAI at any time point; persisting or recurrent infection within the abdomen requiring additional intervention to cure; need for treatment with additional antibiotics for ongoing IAI symptoms; or post-surgical wound infection that requires additional antimicrobial therapy and/or non-routing wound care. The percentage of participants with clinical response of clinical cure or clinical failure at TOC was summarized." (NCT03830333)
Timeframe: Up to approximately Day 30

,
InterventionPercentage of Participants (Number)
Clinical Cure (favorable)Clinical Failure (unfavorable)
Ceftolozane/Tazobactam + Metronidazole95.24.8
Meropenem + Placebo93.16.9

[back to top]

Percentage of Participants With Clinical Response (Clinical Cure or Clinical Failure) at End of Therapy (EOT) Visit: CE Population

"Clinical response was classified as cure or failure. Clinical cure (favorable) was defined as complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure is required for the index infection. Clinical failure (unfavorable) was defined as death related to IAI at any time point; persisting or recurrent infection within the abdomen requiring additional intervention to cure; need for treatment with additional antibiotics for ongoing IAI symptoms; or post-surgical wound infection that requires additional antimicrobial therapy and/or non-routing wound care. The percentage of participants with clinical response of clinical cure or clinical failure at EOT was summarized." (NCT03830333)
Timeframe: Up to approximately Day 15

,
InterventionPercentage of Participants (Number)
Clinical Cure (favorable)Clinical Failure (unfavorable)
Ceftolozane/Tazobactam + Metronidazole98.11.9
Meropenem + Placebo96.63.4

[back to top]

Percentage of Participants Who Experienced 1 or More Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant administered a pharmaceutical product that did not necessarily have to have a causal relationship with this treatment. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. The percentage of participants who experienced 1 or more AEs were summarized. (NCT03830333)
Timeframe: Up to approximately Day 30

InterventionPercentage of Participants (Number)
Ceftolozane/Tazobactam + Metronidazole50.0
Meropenem + Placebo50.7

[back to top]

Percentage of Participants With Favorable Per-Participant Microbiological Response of Eradication or Presumed Eradication at TOC Visit: Expanded Microbiologically Evaluable (EME) Population

An overall microbiological response was determined by the Sponsor for each participant based on individual microbiological responses for each baseline bacterial pathogen. A favorable individual microbiological response was eradication (absence of the baseline bacterial pathogen in a specimen appropriately obtained from the original site of infection) or presumed eradication (absence of material to culture in a participant who is assessed as a clinical cure). In order for the participant to have a favorable overall microbiological response, each individual baseline bacterial pathogen must have had a favorable microbiological outcome. The percentage of participants with a favorable per-participant microbiological response of eradication or presumed eradication was reported for the TOC visit. (NCT03830333)
Timeframe: Up to approximately Day 30

InterventionPercentage of Participants (Number)
Ceftolozane/Tazobactam + Metronidazole94.4
Meropenem + Placebo93.2

[back to top]

Percentage of Participants With Favorable Microbiological Response of Eradication or Presumed Eradication, by Pathogen, at the TOC Visit: EME Population

A microbiological response was determined for each bacterial pathogen isolated at baseline by the Sponsor. Favorable microbiological responses included eradication (absence of the baseline bacterial pathogen in a specimen appropriately obtained from the original site of infection) or presumed eradication (absence of material to culture in a participant who is assessed as a clinical cure). The percentage of participants with a favorable microbiological response of eradication or presumed eradication was reported per pathogen for the TOC visit. (NCT03830333)
Timeframe: Up to approximately Day 30

InterventionPercentage of Participants (Number)
Gram-negative aerobesAll EnterobacteriaceaeOther Enterobacter spp.Escherichia coliKlebsiella oxytocaKlebsiella pneumoniaeMorganella morganiiPseudomonas aeruginosaGram-positive aerobesGram-negative anaerobesGram-positive anaerobes
Meropenem + Placebo95.095.0100.095.7100.090.9100.0100.088.2100.0100.0

[back to top]

Percentage of Participants That Discontinued Study Treatment Due to an AE

An AE was any untoward medical occurrence in a participant administered a pharmaceutical product that did not necessarily have to have a causal relationship with this treatment. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. The percentage of participants who had study drug discontinued during the study due to an AE was summarized. (NCT03830333)
Timeframe: Up to Day 14

InterventionPercentage of Participants (Number)
Ceftolozane/Tazobactam + Metronidazole2.2
Meropenem + Placebo2.2

[back to top]

Percentage of Participants With Favorable Microbiological Response of Eradication or Presumed Eradication, by Pathogen, at the TOC Visit: EME Population

A microbiological response was determined for each bacterial pathogen isolated at baseline by the Sponsor. Favorable microbiological responses included eradication (absence of the baseline bacterial pathogen in a specimen appropriately obtained from the original site of infection) or presumed eradication (absence of material to culture in a participant who is assessed as a clinical cure). The percentage of participants with a favorable microbiological response of eradication or presumed eradication was reported per pathogen for the TOC visit. (NCT03830333)
Timeframe: Up to approximately Day 30

InterventionPercentage of Participants (Number)
Gram-negative aerobesAll EnterobacteriaceaeCitrobacter freundii complexCitrobacter koseriEnterobacter aerogenesEnterobacter cloacae complexEscherichia coliKlebsiella pneumoniaeProteus mirabilisAeromonas hydrophilaPseudomonas aeruginosaGram-positive aerobesGram-positive anaerobes
Ceftolozane/Tazobactam + Metronidazole94.093.8100.0100.0100.0100.093.8100.050.0100.075.080.0100.0

[back to top]

Mortality Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens

(NCT05102162)
Timeframe: 4 weeks

InterventionParticipants (Count of Participants)
Continuous Antibiotic Dose Over 24 Hours Arm2
Intermittent Antibiotic Dose Over 30 Minutes2

[back to top]

Percent of Time Free Drug Concentrations Remain Above Four Multiples of the Minimum Inhibitory Concentration (%fT>4xMIC) in the Dosing Interval Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens

Beta-lactam bactericidal efficacy depends upon the percentage of time that free drug concentrations remain above the minimum inhibitory concentration (%fT>MIC) of the pathogen within the dosing interval. Pre-clinical animal studies demonstrate 40-70% fT>MIC is needed for adequate bacterial killing. However, clinical studies suggest higher exposures may be needed, potentially 100%fT>MIC to 100%fT>4xMIC. Patients had beta-lactam concentrations measured as part of therapeutic drug monitoring. Drug exposures were determined using a Bayesian-based software. Infusion arms were compared to determine if %fT>4xMIC was different between infusion arms. (NCT05102162)
Timeframe: 4 weeks

InterventionPercentage of time (Median)
Continuous Antibiotic Dose Over 24 Hours Arm100
Intermittent Antibiotic Dose Over 30 Minutes100

[back to top]

Hospital Length of Stay Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens.

(NCT05102162)
Timeframe: 4 weeks (may extend beyond depending on patient length of stay in hospital)

InterventionDays (Median)
Continuous Antibiotic Dose Over 24 Hours Arm27
Intermittent Antibiotic Dose Over 30 Minutes18

[back to top]

Percent of Time Free Drug Concentrations Remain Above the Minimum Inhibitory Concentration (%fT>MIC) in the Dosing Interval Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens

Beta-lactam bactericidal efficacy depends upon the percentage of time that free drug concentrations remain above the minimum inhibitory concentration (%fT>MIC) of the pathogen within the dosing interval. Pre-clinical animal studies demonstrate 40-70% fT>MIC is needed for adequate bacterial killing. However, clinical studies suggest higher exposures may be needed, potentially 100%fT>MIC to 100%fT>4xMIC. Patients had beta-lactam concentrations measured as part of therapeutic drug monitoring. Drug exposures were determined using a Bayesian-based software. Infusion arms were compared to determine if %fT>MIC was different between infusion arms. (NCT05102162)
Timeframe: 4 weeks

InterventionPercentage of time (Median)
Continuous Antibiotic Dose Over 24 Hours Arm100
Intermittent Antibiotic Dose Over 30 Minutes100

[back to top]

Superinfection Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens.

Superinfection is defined as the growth of resistant Gram-negative bacteria during the follow-up period which was not isolated in baseline culture. Respiratory cultures during the follow up period were assessed for Gram-negative isolates resistant to the beta-lactams of interest that were not present in the initial respiratory cultures. (NCT05102162)
Timeframe: 4 weeks

InterventionBacteria isolates (Number)
Continuous Antibiotic Dose Over 24 Hours Arm0
Intermittent Antibiotic Dose Over 30 Minutes0

[back to top]

Intensive Care Unit (ICU) Length of Stay Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens

(NCT05102162)
Timeframe: 4 weeks (may extend beyond depending on patient length of stay in ICU)

InterventionDays (Median)
Continuous Antibiotic Dose Over 24 Hours Arm23
Intermittent Antibiotic Dose Over 30 Minutes9

[back to top]

Microbiologic Eradication Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens

Microbiologic eradication is defined as the absence of bacterial growth during the follow-up period with no subsequent positive culture from any site. Respiratory cultures during the follow up period were assessed for the absence of bacterial growth. (NCT05102162)
Timeframe: 4 weeks

InterventionBacteria isolates (Number)
Continuous Antibiotic Dose Over 24 Hours Arm1
Intermittent Antibiotic Dose Over 30 Minutes4

[back to top]

Clinical Cure at Day 7 of Therapy Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens

Clinical cure is the resolution of infection-related symptoms at day 7 of therapy, including normalization of body temperature and white blood cell (WBC) count and taking the patient off mechanical ventilation or vasopressors, and non-initiation of a new antibiotic within 48 hours of stopping the original antibiotic. (NCT05102162)
Timeframe: 7 Days

InterventionParticipants (Count of Participants)
Continuous Antibiotic Dose Over 24 Hours Arm0
Intermittent Antibiotic Dose Over 30 Minutes5

[back to top]

Clinical Cure at the End of Therapy Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens

Clinical cure is the resolution of infection-related symptoms at the end of therapy, including normalization of body temperature and white blood cell (WBC) count and taking the patient off mechanical ventilation or vasopressors, and non-initiation of a new antibiotic within 48 hours of stopping the original antibiotic. End of therapy could occur up to 4 weeks after enrollment. (NCT05102162)
Timeframe: 4 weeks

InterventionParticipants (Count of Participants)
Continuous Antibiotic Dose Over 24 Hours Arm3
Intermittent Antibiotic Dose Over 30 Minutes8

[back to top]

Gram-negative Bacterial Resistance Emergence Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens

Bacterial resistance is defined as new numeric increases (>/=2 fold) in the bacterial MIC during the follow-up period compared to the baseline when starting beta-lactam therapy. MICs were collected from respiratory samples and compared from study enrollment to end of the follow-up period for at least a 2 fold increase in MIC. (NCT05102162)
Timeframe: 4 weeks

InterventionBacteria isolates (Number)
Continuous Antibiotic Dose Over 24 Hours Arm4
Intermittent Antibiotic Dose Over 30 Minutes8

[back to top]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
acetylcarnitine
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.		4.911O-acylcarnitinehuman metabolite
gamma-aminobutyric acid
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.		1.9810amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
acetic acid
Acetic Acid: Product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed). acetic acid : A simple monocarboxylic acid containing two carbons.		2.0510monocarboxylic acidantimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent
acetamide
acetimidic acid : A carboximidic acid that is acetic acid in which the carbonyl oxygen is replaced by an imino group.		2.0510acetamides;
carboximidic acid;
monocarboxylic acid amide;
N-acylammonia
adenine
[no description available]		2.42206-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
allantoin
[no description available]		2.0510imidazolidine-2,4-dione;
ureas		Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite;
vulnerary
ammonium hydroxide
azane : Saturated acyclic nitrogen hydrides having the general formula NnHn+2.		4.911azane;
gas molecular entity;
mononuclear parent hydride		EC 3.5.1.4 (amidase) inhibitor;
metabolite;
mouse metabolite;
neurotoxin;
NMR chemical shift reference compound;
nucleophilic reagent;
refrigerant
quinacrine
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.		2.4520acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
beta-alanine
[no description available]		4.9281amino acid zwitterion;
beta-amino acid		agonist;
fundamental metabolite;
human metabolite;
inhibitor;
neurotransmitter
benzoic acid
Benzoic Acid: A fungistatic compound that is widely used as a food preservative. It is conjugated to GLYCINE in the liver and excreted as hippuric acid.. benzoic acid : A compound comprising a benzene ring core carrying a carboxylic acid substituent.. aromatic carboxylic acid : Any carboxylic acid in which the carboxy group is directly bonded to an aromatic ring.		2.1310benzoic acidsalgal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite
betaine
glycine betaine : The amino acid betaine derived from glycine.		3.5920amino-acid betaine;
glycine derivative		fundamental metabolite
1-butanol
1-Butanol: A four carbon linear hydrocarbon that has a hydroxy group at position 1.. butan-1-ol : A primary alcohol that is butane in which a hydrogen of one of the methyl groups is substituted by a hydroxy group. It it produced in small amounts in humans by the gut microbes.		2.4110alkyl alcohol;
primary alcohol;
short-chain primary fatty alcohol		human metabolite;
mouse metabolite;
protic solvent
carnitine
[no description available]		5.3431amino-acid betainehuman metabolite;
mouse metabolite
methane
Methane: The simplest saturated hydrocarbon. It is a colorless, flammable gas, slightly soluble in water. It is one of the chief constituents of natural gas and is formed in the decomposition of organic matter. (Grant & Hackh's Chemical Dictionary, 5th ed). methane : A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC).		5.1421alkane;
gas molecular entity;
mononuclear parent hydride;
one-carbon compound		bacterial metabolite;
fossil fuel;
greenhouse gas
citric acid, anhydrous
Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.. citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.		2.8330tricarboxylic acidantimicrobial agent;
chelator;
food acidity regulator;
fundamental metabolite
coumarin
2H-chromen-2-one: coumarin derivative		2.4520coumarinsfluorescent dye;
human metabolite;
plant metabolite
salicylic acid
Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).		2.0510monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite
bupropion
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.. bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.		4.0740aromatic ketone;
monochlorobenzenes;
secondary amino compound		antidepressant;
environmental contaminant;
xenobiotic
malic acid
malic acid : A 2-hydroxydicarboxylic acid that is succinic acid in which one of the hydrogens attached to a carbon is replaced by a hydroxy group.. 2-hydroxydicarboxylic acid : Any dicarboxylic acid carrying a hydroxy group on the carbon atom at position alpha to the carboxy group.		2.21102-hydroxydicarboxylic acid;
C4-dicarboxylic acid		food acidity regulator;
fundamental metabolite
1-aminocyclopropane-1-carboxylic acid
1-aminocyclopropanecarboxylic acid : A non-proteinogenic alpha-amino acid consisting of cyclopropane having amino and carboxy substituents both at the 1-position.		2.0210amino acid zwitterion;
monocarboxylic acid;
non-proteinogenic alpha-amino acid		ethylene releasers;
plant metabolite
aminocaproic acid
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.		4.0640amino acid zwitterion;
epsilon-amino acid;
omega-amino fatty acid		antifibrinolytic drug;
hematologic agent;
metabolite
fosmidomycin
fosmidomycin: from Streptomyces lavendulae; RN given refers to parent cpd; structure in second source. fosmidomycin : Propylphosphonic acid in which one of the hydrogens at position 3 is substituted by a formyl(hydroxy)amino group. An antibiotic obtained from Streptomyces lavendulae, it specifically inhibits DXP reductoisomerase (EC 1.1.1.267), a key enzyme in the non-mevalonate pathway of isoprenoid biosynthesis.		2.0610hydroxamic acid;
phosphonic acids		antimicrobial agent;
bacterial metabolite;
EC 1.1.1.267 (1-deoxy-D-xylulose-5-phosphate reductoisomerase) inhibitor
creatine
[no description available]		5.5231glycine derivative;
guanidines;
zwitterion		geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical
lactic acid
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.		3.84302-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
dimethyl sulfoxide
Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.		2.0510sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
formaldehyde
paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy		2.0510aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
glycine
[no description available]		2.7430alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
glycerol
Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.		2.0510alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
alpha-glycerophosphoric acid
[no description available]		2.1310glycerol monophosphatealgal metabolite;
human metabolite
hydrogen carbonate
Bicarbonates: Inorganic salts that contain the -HCO3 radical. They are an important factor in determining the pH of the blood and the concentration of bicarbonate ions is regulated by the kidney. Levels in the blood are an index of the alkali reserve or buffering capacity.. hydrogencarbonate : The carbon oxoanion resulting from the removal of a proton from carbonic acid.		2.4420carbon oxoanioncofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
dalteparin
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)		2.3110
hydroquinone
[no description available]		2.0510benzenediol;
hydroquinones		antioxidant;
carcinogenic agent;
cofactor;
Escherichia coli metabolite;
human xenobiotic metabolite;
mouse metabolite;
skin lightening agent
iodine
Iodine: A nonmetallic element of the halogen group that is represented by the atomic symbol I, atomic number 53, and atomic weight of 126.90. It is a nutritionally essential element, especially important in thyroid hormone synthesis. In solution, it has anti-infective properties and is used topically.. diiodine : Molecule comprising two covalently bonded iodine atoms with overall zero charge..		2.1510diatomic iodinenutrient
thioctic acid
Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.		2.4110dithiolanes;
heterocyclic fatty acid;
thia fatty acid		fundamental metabolite;
geroprotector
methanol
Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.		3.0120alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound		amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite
inositol
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.		2.0510cyclitol;
hexol
melatonin
[no description available]		2.0810acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
niacinamide
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.		2.0510pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
niacin
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.. vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).. nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.		3.8730pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3		antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
nitrates
Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.		4.911monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species
orotic acid
Orotic Acid: An intermediate product in PYRIMIDINE synthesis which plays a role in chemical conversions between DIHYDROFOLATE and TETRAHYDROFOLATE.. orotic acid : A pyrimidinemonocarboxylic acid that is uracil bearing a carboxy substituent at position C-6.		2.0510pyrimidinemonocarboxylic acidEscherichia coli metabolite;
metabolite;
mouse metabolite
4-aminobenzoic acid
4-Aminobenzoic Acid: An aminobenzoic acid isomer that combines with pteridine and GLUTAMIC ACID to form FOLIC ACID. The fact that 4-aminobenzoic acid absorbs light throughout the UVB range has also resulted in its use as an ingredient in SUNSCREENS.. 4-ammoniobenzoate : A zwitterion obtained by transfer of a proton from the carboxy to the amino group of 4-aminobenzoic acid.. 4-aminobenzoic acid : An aminobenzoic acid in which the amino group is para to the carboxy group.		2.0510aminobenzoic acid;
aromatic amino-acid zwitterion		allergen;
Escherichia coli metabolite;
plant metabolite
phenol
[no description available]		2.0510phenolsantiseptic drug;
disinfectant;
human xenobiotic metabolite;
mouse metabolite
phenylacetic acid
phenylacetic acid : A monocarboxylic acid that is toluene in which one of the hydrogens of the methyl group has been replaced by a carboxy group.		2.0510benzenes;
monocarboxylic acid;
phenylacetic acids		allergen;
Aspergillus metabolite;
auxin;
EC 6.4.1.1 (pyruvate carboxylase) inhibitor;
Escherichia coli metabolite;
human metabolite;
plant growth retardant;
plant metabolite;
Saccharomyces cerevisiae metabolite;
toxin
picolinic acid
picolinic acid: iron-chelating agent that inhibits DNA synthesis; may interfere with iron-dependent production of stable free organic radical which is essential for ribonucleotide reductase formation of deoxyribonucleotides; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7206. picolinic acid : A pyridinemonocarboxylic acid in which the carboxy group is located at position 2. It is an intermediate in the metabolism of tryptophan.		2.5720pyridinemonocarboxylic acidhuman metabolite;
MALDI matrix material
pyrazinamide
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.		4.350monocarboxylic acid amide;
N-acylammonia;
pyrazines		antitubercular agent;
prodrug
pyrazole
1H-pyrazole : The 1H-tautomer of pyrazole.		7.3110pyrazole
pyridoxal phosphate
Pyridoxal Phosphate: This is the active form of VITAMIN B 6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (PYRIDOXAMINE).. pyridoxal 5'-phosphate : The monophosphate ester obtained by condensation of phosphoric acid with the primary hydroxy group of pyridoxal.		2.0510methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6 phosphate		coenzyme;
cofactor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
pyridoxine
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source. vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).		3.5920hydroxymethylpyridine;
methylpyridines;
monohydroxypyridine;
vitamin B6		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
pyruvic acid
Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed). pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.		2102-oxo monocarboxylic acidcofactor;
fundamental metabolite
sulfites
Sulfites: Inorganic salts of sulfurous acid.. sulfites : Any sulfurous acid derivative that is a salt or an ester of sulfurous acid.. organosulfonate oxoanion : An organic anion obtained by deprotonation of the sufonate group(s) of any organosulfonic acid.. sulfite : A sulfur oxoanion that is the conjugate base of hydrogen sulfite (H2SO3).		2.1110divalent inorganic anion;
sulfur oxide;
sulfur oxoanion
spermine
[no description available]		2.110polyazaalkane;
tetramine		antioxidant;
fundamental metabolite;
immunosuppressive agent
taurine
[no description available]		7.0110amino sulfonic acid;
zwitterion		antioxidant;
Escherichia coli metabolite;
glycine receptor agonist;
human metabolite;
mouse metabolite;
nutrient;
radical scavenger;
Saccharomyces cerevisiae metabolite
thiamine
thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.		3.5920primary alcohol;
vitamin B1		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
2-mercaptoacetate
[no description available]		2.0510sulfur-containing carboxylic acid
tryptamine
[no description available]		2.1310aminoalkylindole;
aralkylamino compound;
indole alkaloid;
tryptamines		human metabolite;
mouse metabolite;
plant metabolite
uracil
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder		2.0510pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		2.0510isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
catechin
[no description available]		2.0510hydroxyflavan
octoclothepine
octoclothepine: major tranquilizer with action similar to those of the phenothiazines; used in schizophrenic & manic psychoses; minor decriptor (77-86); on-line & INDEX MEDICUS search DIBENZOTHIEPINS (77-86); RN given refers to parent cpd without isomeric designation		2.1510dibenzothiepine
menthol
Menthol: A monoterpene cyclohexanol produced from mint oils.		2.0510p-menthane monoterpenoid;
secondary alcohol		volatile oil component
1,10-phenanthroline
1,10-phenanthroline: RN given refers to parent cpd; inhibits Zn-dependent metalloproteinases		2.7730phenanthrolineEC 2.7.1.1 (hexokinase) inhibitor;
EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor
1-(3-chlorophenyl)piperazine
1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure. 1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.		2.4620monochlorobenzenes;
N-arylpiperazine		drug metabolite;
environmental contaminant;
serotonergic agonist;
xenobiotic
1-anilino-8-naphthalenesulfonate
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.		210aminonaphthalene;
naphthalenesulfonic acid		fluorescent probe
2-methyl-5-ht
2-methyl-5-HT: M-receptor agonist		2.1310tryptaminesserotonergic agonist
enprofylline
enprofylline : Xanthine bearing a propyl substituent at position 3. A bronchodilator, it is used for the symptomatic treatment of asthma and chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.		2.4520oxopurineanti-arrhythmia drug;
anti-asthmatic drug;
bronchodilator agent;
non-steroidal anti-inflammatory drug
3-nitrobenzeneboronic acid
[no description available]		2.4110
p-chloromercuribenzoic acid
p-Chloromercuribenzoic Acid: An organic mercurial used as a sulfhydryl reagent.		2.2510chlorine molecular entity;
mercuribenzoic acid
phenytoin
[no description available]		4.2550imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
5-methoxytryptamine
5-Methoxytryptamine: Serotonin derivative proposed as potentiator for hypnotics and sedatives.. 5-methoxytryptamine : A member of the class of tryptamines that is the methyl ether derivative of serotonin.		2.1310aromatic ether;
primary amino compound;
tryptamines		5-hydroxytryptamine 2A receptor agonist;
5-hydroxytryptamine 2B receptor agonist;
5-hydroxytryptamine 2C receptor agonist;
antioxidant;
cardioprotective agent;
human metabolite;
mouse metabolite;
neuroprotective agent;
radiation protective agent;
serotonergic agonist
oxyquinoline
Oxyquinoline: An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics.. quinolin-8-ol : A monohydroxyquinoline that is quinoline substituted by a hydroxy group at position 8. Its fungicidal properties are used for the control of grey mould on vines and tomatoes.		2.4110monohydroxyquinolineantibacterial agent;
antifungal agrochemical;
antiseptic drug;
iron chelator
tacrine
Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.		3.1550acridines;
aromatic amine		EC 3.1.1.7 (acetylcholinesterase) inhibitor
acebutolol
Acebutolol: A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.. acebutolol : An ether that is the 2-acetyl-4-(butanoylamino)phenyl ether of the primary hydroxy group of 3-(propan-2-ylamino)propane-1,2-diol.		4.460aromatic amide;
ethanolamines;
ether;
monocarboxylic acid amide;
propanolamine;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympathomimetic agent
acetaminophen
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.		6.6791acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
acetazolamide
Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)		4.2650monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
acetohexamide
Acetohexamide: A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide.. acetohexamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is replaced by a p-acetylphenylsulfonyl group, while a hydrogen attached to the other nitrogen is replaced by a cyclohexyl group.		2.0510acetophenones;
N-sulfonylurea		hypoglycemic agent;
insulin secretagogue
acetohydroxamic acid
acetohydroxamic acid: urease inhibitor. oxime : Compounds of structure R2C=NOH derived from condensation of aldehydes or ketones with hydroxylamine. Oximes from aldehydes may be called aldoximes; those from ketones may be called ketoximes.. N-hydroxyacetimidic acid : A carbohydroximic acid consisting of acetimidic acid having a hydroxy group attached to the imide nitrogen.. acetohydroxamic acid : A member of the class of acetohydroxamic acids that is acetamide in which one of the amino hydrogens has been replaced by a hydroxy group.		3.8530acetohydroxamic acids;
carbohydroximic acid		algal metabolite;
EC 3.5.1.5 (urease) inhibitor
alaproclate
alaproclate: specific 5-hydroxytryptamine uptake inhibitors; RN given refers to (DL)-isomer		3.2310alpha-amino acid ester
albendazole
[no description available]		3.8730aryl sulfide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		anthelminthic drug;
microtubule-destabilising agent;
tubulin modulator
albuterol
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.. albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).		4.4160phenols;
phenylethanolamines;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic
alendronate
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.		3.56201,1-bis(phosphonic acid);
primary amino compound		bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
alfuzosin
alfuzosin: structure given in first source		3.8630monocarboxylic acid amide;
quinazolines;
tetrahydrofuranol		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
alosetron
alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.		3.5820imidazoles;
pyridoindole		antiemetic;
gastrointestinal drug;
serotonergic antagonist
alprazolam
Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238). alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.		4.0640organochlorine compound;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic
alprenolol
Alprenolol: One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.. alprenolol : A secondary alcohol that is propan-2-ol substituted by a 2-allylphenoxy group at position 1 and an isopropylamino group at position 3. It is a beta-adrenergic antagonist used as a antihypertensive, anti-arrhythmia and a sympatholytic agent.		2.9740secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
altretamine
Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.		3.5620triamino-1,3,5-triazine
amantadine
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source		4.2550adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
ambenonium
ambenonium : A symmetrical oxalamide-based bis-quaternary ammonium ion having ethyl and 2-chlorobenzyl groups attached to the nitrogens.		3.2310quaternary ammonium ionEC 3.1.1.8 (cholinesterase) inhibitor
ambroxol
Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.		2.5220aromatic amine
diatrizoic acid
Diatrizoate: A commonly used x-ray contrast medium. As DIATRIZOATE MEGLUMINE and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.. amidotrizoic acid : A member of the class of benzoic acids that is benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, mainly as its N-methylglucamine and sodium salts, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography.		3.8730acetamides;
benzoic acids;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
amifostine anhydrous
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.. amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.		3.5620diamine;
organic thiophosphate		antioxidant;
prodrug;
radiation protective agent
aminoglutethimide
Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.. aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.		2.7430dicarboximide;
piperidones;
substituted aniline		adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
pimagedine
pimagedine: diamine oxidase & nitric oxide synthase inhibitor; an advanced glycosylation end product inhibitor; used in the treatment of diabetic complications; structure. aminoguanidine : A one-carbon compound whose unique structure renders it capable of acting as a derivative of hydrazine, guanidine or formamide.		2.0510guanidines;
one-carbon compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 1.4.3.4 (monoamine oxidase) inhibitor
p-aminohippuric acid
p-Aminohippuric Acid: The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.. p-aminohippurate : A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group.. p-aminohippuric acid : An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow.		3.5420N-acylglycineDaphnia magna metabolite
theophylline
[no description available]		9.6780dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
2-aminothiazole
2-aminothiazole: RN given refers to parent cpd; structure. 1,3-thiazol-2-amine : A primary amino compound that is 1,3-thiazole substituted by an amino group at position 2.		2.6101,3-thiazoles;
primary amino compound
amiodarone
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.		4.54701-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug
dan 2163
[no description available]		2.4720aromatic amide;
aromatic amine;
benzamides;
pyrrolidines;
sulfone		environmental contaminant;
second generation antipsychotic;
xenobiotic
amitriptyline
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.. amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.		4.5470carbotricyclic compound;
tertiary amine		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic
amlexanox
amlexanox: SRA-A antagonist;structure given in first source. amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.		2.4520monocarboxylic acid;
pyridochromene		anti-allergic agent;
anti-ulcer drug;
non-steroidal anti-inflammatory drug
amlodipine
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.		4.6780dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound		antihypertensive agent;
calcium channel blocker;
vasodilator agent
amobarbital
Amobarbital: A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565). amobarbital : A member of the class of barbiturates that is pyrimidine-2,4,6(1H,3H,5H)-trione substituted by a 3-methylbutyl and an ethyl group at position 5. Amobarbital has been shown to exhibit sedative and hypnotic properties.		2.0510barbiturates
amoxapine
Amoxapine: The N-demethylated derivative of the antipsychotic agent LOXAPINE that works by blocking the reuptake of norepinephrine, serotonin, or both; it also blocks dopamine receptors. Amoxapine is used for the treatment of depression.. amoxapine : A dibenzooxazepine compound having a chloro substituent at the 2-position and a piperazin-1-yl group at the 11-position.		3.8530dibenzooxazepineadrenergic uptake inhibitor;
antidepressant;
dopaminergic antagonist;
geroprotector;
serotonin uptake inhibitor
amsacrine
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.		2.9840acridines;
aromatic ether;
sulfonamide		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
anastrozole
[no description available]		4.0840nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
anethole trithione
Anethole Trithione: Choleretic used to allay dry mouth and constipation due to tranquilizers.		2.0510methoxybenzenes
anthralin
Anthralin: An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.. anthralin : An anthracene compound derived by the substitution of -OH groups for hydrogen at C-1 and C-8, and with an oxo group at C-9.		2.4720anthracenesantipsoriatic
antipyrine
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29). antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.		3.1550pyrazoloneantipyretic;
cyclooxygenase 3 inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
apraclonidine
apraclonidine: relieves postoperative intraocular pressure following trabeculoplasty; RN given refers to parent cpd. apraclonidine : An imidazoline that is 2-amino 4,5-dihydro-1H-imidazoline in which one of the exocyclic amino hydrogens has been replaced by a 4-amino-2,6-dichlorophenyl group.		2.0210dichlorobenzene;
guanidines;
imidazolines		alpha-adrenergic agonist;
antiglaucoma drug;
beta-adrenergic agonist;
diagnostic agent;
ophthalmology drug
aspirin
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.		4.7790benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
astemizole
Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.		2.4520benzimidazoles;
piperidines		anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist
atenolol
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.		4.5470ethanolamines;
monocarboxylic acid amide;
propanolamine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic
azathioprine
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed). azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.		4.4160aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine		antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug
azelaic acid
nonanedioic acid : An alpha,omega-dicarboxylic acid that is heptane substituted at positions 1 and 7 by carboxy groups.		2.0210alpha,omega-dicarboxylic acid;
dicarboxylic fatty acid		antibacterial agent;
antineoplastic agent;
dermatologic drug;
plant metabolite
azelastine
azelastine: azeptin is azelastine hydrochloride; structure; eye drop formulation effective in relieving symptoms of allergic conjunctivitis; do not confuse with 5-loxin which is an extract of Boswellia. azelastine : A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position.		2.7330monochlorobenzenes;
phthalazines;
tertiary amino compound		anti-allergic agent;
anti-asthmatic drug;
bronchodilator agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
H1-receptor antagonist;
platelet aggregation inhibitor
aztreonam
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.. aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.		8.12460
baclofen
[no description available]		9.9560amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound		central nervous system depressant;
GABA agonist;
muscle relaxant
barbital
5,5-diethylbarbituric acid : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by two ethyl groups. Formerly used as a hypnotic (sleeping aid).		2.0510barbituratesdrug allergen
bendazac
bendazac : A monocarboxylic acid that is glycolic acid in which the hydrogen attached to the 2-hydroxy group is replaced by a 1-benzyl-1H-indazol-3-yl group. Although it has anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties and has been used for the treatment of various inflammatory skin disorders, its principal effect is to inhibit the denaturation of proteins. Its lysine salt is used in the management of cataracts.		3.5920indazoles;
monocarboxylic acid		non-steroidal anti-inflammatory drug;
radical scavenger
bendroflumethiazide
Bendroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810). bendroflumethiazide : A sulfonamide consisting of 7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by a trifluoromethyl group and that at position 3 is substituted by a benzyl group.		3.2310benzothiadiazine;
sulfonamide		antihypertensive agent;
diuretic
benserazide
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.. benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.		2.0610carbohydrazide;
catechols;
primary alcohol;
primary amino compound		antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
benzbromarone
Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.		4.27501-benzofurans;
aromatic ketone		uricosuric drug
benzocaine
Benzocaine: A surface anesthetic that acts by preventing transmission of impulses along NERVE FIBERS and at NERVE ENDINGS.. dextran sulfate sodium : An organic sodium salt of dextran sulfate. It induces colitis in mice.. benzocaine : A benzoate ester having 4-aminobenzoic acid as the acid component and ethanol as the alcohol component. A surface anaesthetic, it is used to suppress the gag reflex, and as a lubricant and topical anaesthetic on the larynx, mouth, nasal cavity, respiratory tract, oesophagus, rectum, urinary tract, and vagina.		2.0810benzoate ester;
substituted aniline		allergen;
antipruritic drug;
sensitiser;
topical anaesthetic
benzothiazide
benzothiazide: structure. benzthiazide : 7-Sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by chlorine and that at position 3 is substituted by a benzylsulfanylmethyl group. A diuretic, it is used to treat hypertension and edema.		2.1510benzothiadiazine;
sulfonamide		antihypertensive agent;
diuretic
bepridil
Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.. bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.		2.0210pyrrolidines;
tertiary amine		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
betaxolol
[no description available]		4.4260propanolamineantihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
bethanechol
Bethanechol: A slowly hydrolyzing muscarinic agonist with no nicotinic effects. Bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, HEART RATE changes, and BRONCHIAL SPASM.. bethanechol : The carbamic acid ester of 2-methylcholine. A slowly hydrolysed muscarinic agonist with no nicotinic effects, it is used as its chloride salt to increase smooth muscle tone, as in the gastrointestinal tract following abdominal surgery, treatment of gastro-oesophageal reflux disease, and as an alternative to catheterisation in the treatment of non-obstructive urinary retention.		3.2310carbamate ester;
quaternary ammonium ion		muscarinic agonist
bevantolol
bevantolol: structure given in first source. bevantolol : A propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by 3-methylphenyl and one of the hydrogens attached to the nitrogen is substituted by 2-(3,4-dimethoxyphenyl)ethyl. A beta1 adrenoceptor antagonist, it has been shown to be as effective as other beta-blockers for the treatment of angina pectoris and hypertension.		2.4520propanolamineanti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
calcium channel blocker
bicalutamide
bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.		4.0840(trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol
bay h 4502
bifonazole : A racemate comprising equimolar amounts of R- and S-bifonazole. It is a broad spectrum antifungal drug used for the treatment of fungal skin and nail infections.. 1-[biphenyl-4-yl(phenyl)methyl]imidazole : A member of the class of imidazoles carrying an alpha-(biphenyl-4-yl)benzyl substituent at position 1.		2.4720biphenyls;
imidazoles
biperiden
Biperiden: A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.. biperiden : A member of the class of piperidines that is N-propylpiperidine in which the methyl hydrogens have been replaced by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease.		3.5820piperidines;
tertiary alcohol;
tertiary amino compound		antidote to sarin poisoning;
antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist;
parasympatholytic
bisacodyl
Bisacodyl: A diphenylmethane stimulant laxative used for the treatment of CONSTIPATION and for bowel evacuation. (From Martindale, The Extra Pharmacopoeia, 30th ed, p871)		3.6120diarylmethane
bisoprolol
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.		4.2550secondary alcohol;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
brimonidine
[no description available]		2.0210imidazoles;
quinoxaline derivative;
secondary amine		adrenergic agonist;
alpha-adrenergic agonist;
antihypertensive agent
bromazepam
Bromazepam: One of the BENZODIAZEPINES that is used in the treatment of ANXIETY DISORDERS.		2.4520organic molecular entity
bromhexine
Bromhexine: A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744). bromhexine : A substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive cough (i.e. a cough characterised by the production of sputum).		2.0610organobromine compound;
substituted aniline;
tertiary amino compound		mucolytic
bromopride
bromopride: RN given refers to parent cpd; structure		2.7530benzamides
bromisovalum
Bromisovalum: A sedative and mild hypnotic with potentially toxic effects.. bromisoval : A racemate comprising equimolar amounts of (R)- and (S)-bromisoval. It was previously used for its hypnotic and sedative properties but the use of bromides is now deprecated due to the possibility of the toxic accumulation of bromine in the body.. 2-bromo-N-carbamoyl-3-methylbutanamide : An N-acylurea that is urea in which one of the hydrogens is replaced by a 2-bromo-3-methybutanoyl group.		2.0510N-acylurea;
organobromine compound
bronopol
[no description available]		2.0810nitro compound
brotizolam
brotizolam: structure		2.4520organic molecular entity
buflomedil
buflomedil: RN given refers to parent cpd; synonym LL 1656 refers to HCl; structure		2.4520aromatic ketone
bumetanide
[no description available]		4.4160amino acid;
benzoic acids;
sulfonamide		diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
bunazosin
bunazosin: structure		2.0410quinazolines
bupivacaine
Bupivacaine: A widely used local anesthetic agent.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.. bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.		2.7430aromatic amide;
piperidinecarboxamide;
tertiary amino compound
buspirone
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.. buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.		4.0740azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines		anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist
busulfan
[no description available]		4.6780methanesulfonate esteralkylating agent;
antineoplastic agent;
carcinogenic agent;
insect sterilant;
teratogenic agent
secbutabarbital
secbutabarbital: Butabarbital (a synonym for Secbutabarbital) should be distinguished from Butobarbital		3.2310barbiturates
butalbital
butalbital: management of butalbital withdrawal can be simplified by using a phenobarbital-loading protocol; RN given refers to parent cpd. butalbital : A member of the class of barbiturates that is barbituric acid in which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. Frequently combined with other medicines, such as aspirin, paracetamol and codeine, it is used for treatment of pain and headache.		2.0510barbituratesanalgesic;
sedative
butenafine
butenafine: studied on experimental dermatophytosis. butenafine : Trimethylamine in which hydrogen atoms attached to different methyl groups are substituted by 1-naphthyl and 4-tert-butylphenyl groups. It is an inhibitor of squalene epoxidase, an enzyme responsible for the creation of sterols needed in fungal cell membranes, and is used as its hydrochloride salt for treatment of dermatological fungal infections.		2.0210naphthalenes;
tertiary amine		antifungal drug;
EC 1.14.13.132 (squalene monooxygenase) inhibitor
caffeine
[no description available]		4.6680purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		4.4160aromatic ether;
nitrile;
polyether;
tertiary amino compound
metrizoate
Metrizoic Acid: A diagnostic radiopaque that usually occurs as the sodium salt.		2.4520monocarboxylic acidradioopaque medium
candesartan cilexetil
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects		2.5520biphenyls
candesartan
candesartan: a nonpeptide angiotensin II receptor antagonist. candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.		3.2310benzimidazolecarboxylic acid;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
carbamazepine
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.		4.2650dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
carbinoxamine
carbinoxamine: Note: tradenames that start with Histex refer to more than one drug. carbinoxamine : An organochlorine compound that is 2-(4-chlorobenzyl)pyridine in which one of the benzylic hydrogens is substituted by 2-(dimethylamino)ethoxy group. It is an ethanolamine-type antihistamine, used as its maleate salt for treating hay fever, as well as mild cases of Parkinson's disease.		3.2310monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist
carisoprodol
Carisoprodol: A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202). carisoprodol : A carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm.		3.5920carbamate estermuscle relaxant
carmustine
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.		3.1550N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
carprofen
carprofen: RN given refers to cpd without isomeric designation. carprofen : Propanoic acid in which one of the methylene hydrogens is substituted by a 6-chloro-9H-carbazol-2-yl group. A non-steroidal anti-inflammatory drug, it is no longer used in human medicine but is still used for treatment of arthritis in elderly dogs.		2.4720carbazoles;
organochlorine compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug;
photosensitizing agent
carteolol
Carteolol: A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.		2.0210quinolone;
secondary alcohol		anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
carvedilol
[no description available]		4.4160carbazoles;
secondary alcohol;
secondary amino compound		alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent
carbonyl cyanide m-chlorophenyl hydrazone
Carbonyl Cyanide m-Chlorophenyl Hydrazone: A proton ionophore. It is commonly used as an uncoupling agent and inhibitor of photosynthesis because of its effects on mitochondrial and chloroplast membranes.. CCCP : A member of the class of monochlorobenzenes that is benzene substituted by 2-(1,3-dinitrilopropan-2-ylidene)hydrazinyl and chloro groups at positions 1 and 3, respectively. It is a mitochondrial depolarizing agent that induces reactive oxygen species mediated cell death.		5.6551hydrazone;
monochlorobenzenes;
nitrile		antibacterial agent;
geroprotector;
ionophore
cefuroxime
Cefuroxime: Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.. cefuroxime : A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain.		6.13152carbamate ester;
cephalosporin
celecoxib
[no description available]		3.8730organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
cefixime
Cefixime: A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases.. cefixime : A third-generation cephalosporin antibiotic bearing vinyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is used in the treatment of gonorrhoea, tonsilitis, pharyngitis, bronchitis, and urinary tract infections.		4.2450
cetirizine
Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.. cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.		3.8530ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines		anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic
cgs 15943
9-chloro-2-(2-furyl)-(1,2,4)triazolo(1,5-c)quinazolin-5-imine: non-xanthine triazoloquinazoline adenosine antagonist. CGS 15943 : A member of the class of triazoloquinazolines that is [1,2,4]triazolo[1,5-c]quinazoline substited at positions 2, 5 and 9 by furan-2-yl, amino and chloro groups respectively. A potent antagonist at adenosine A1 and adenosine A2A receptors.		3.1710aromatic amine;
biaryl;
furans;
organochlorine compound;
primary amino compound;
quinazolines;
triazoloquinazoline		adenosine A1 receptor antagonist;
adenosine A2A receptor antagonist;
antineoplastic agent;
central nervous system stimulant
chloral hydrate
[no description available]		2.0510aldehyde hydrate;
ethanediol;
organochlorine compound		general anaesthetic;
mouse metabolite;
sedative;
xenobiotic
chlorambucil
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.		4.2650aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
chlorcyclizine
chlorcyclizine: was heading 1964-94 (Prov 1964-73); CHLOROCYCLIZINE & HISTACHLORAZINE were see CHLORCYCLIZINE 1977-94; use PIPERAZINES to search CHLORCYCLIZINE 1966-94; histamine H1-blocker used both orally and topically in allergies and also for the prevention of motion sickness		3.2310diarylmethane
chlordiazepoxide
Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.. chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.		4.2650benzodiazepine
chlormezanone
Chlormezanone: A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm.. chlormezanone : A 1,3-thiazine that is 1,3-thiazinan-4-one S,S-dioxide in which a hydrogen at position 2 is substituted by a 4-chlorophenyl group and the hydrogen attached to the nitrogen is substituted by methyl. A non-benzodiazepine muscle relaxant, it was used in the management of anxiety and in the treatment of muscle spasms until being discontinued worldwide by its manufacturer in 1996, due to rare but serious cutaneous reactions.		3.85301,3-thiazine;
lactam;
monochlorobenzenes;
sulfone		antipsychotic agent;
anxiolytic drug;
muscle relaxant
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		9.5570aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
chlorothiazide
Chlorothiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812). thiazide : Heterocyclic compound with sulfur and nitrogen in the ring.. chlorothiazide : 4H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position is substituted by chlorine and that at position 7 is substituted by a sulfonamide group. A diuretic, it is used for treatment of oedema and hypertension.		3.5920benzothiadiazineantihypertensive agent;
diuretic
chloroxine
chloroxine : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 have been substituted by chlorine. A synthetic antibacterial prepared by chlorination of quinolin-8-ol, it is used for the treatment of dandruff and seborrhoeic dermatitis of the scalp.		2.4110monohydroxyquinoline;
organochlorine compound		antibacterial agent;
antifungal drug;
antiseborrheic
chloroxylenol
chloroxylenol: topical antiseptic; RN given refers to parent cpd; structure. 4-chloro-3,5-dimethylphenol : A member of the class of phenols that is 3,5-xylenol which is substituted at position 4 by chlorine. It is bactericidal against most Gram-positive bacteria but less effective against Staphylococci and Gram-negative bacteria, and often inactive against Pseudomonas species. It is ineffective against bacterial spores.		2.0510monochlorobenzenes;
phenols		antiseptic drug;
disinfectant;
molluscicide
chlorpheniramine
Chlorpheniramine: A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.. chlorphenamine : A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma.		4.2650monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor
chlorpromazine
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.		4.4260organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
chlorpropamide
Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277). chlorpropamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification.		4.4260monochlorobenzenes;
N-sulfonylurea		hypoglycemic agent;
insulin secretagogue
chlorthalidone
Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.		4.0840isoindoles;
monochlorobenzenes;
sulfonamide
chlorzoxazone
Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202). chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.		3.87301,3-benzoxazoles;
heteroaryl hydroxy compound;
organochlorine compound		muscle relaxant;
sedative
cifenline
[no description available]		2.7530diarylmethane
ciclopirox
[no description available]		2.4520cyclic hydroxamic acid;
hydroxypyridone antifungal drug;
pyridone		antibacterial agent;
antiseborrheic
ciglitazone
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes. ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.		2.0810aromatic ether;
thiazolidinone		antineoplastic agent;
insulin-sensitizing drug
cilostazol
[no description available]		3.8830lactam;
tetrazoles		anticoagulant;
bronchodilator agent;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
fibrin modulating drug;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent
cimetidine
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.		4.4260aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
cinoxacin
Cinoxacin: Synthetic antimicrobial related to OXOLINIC ACID and NALIDIXIC ACID and used in URINARY TRACT INFECTIONS.. cinoxacin : A member of the class of cinnolines that is 6,7-methylenedioxycinnolin-4(1H)-one bearing an ethyl group at position 1 and a carboxylic acid group at position 3. An analogue of oxolinic acid, it has similar antibacterial actions. It was formerly used for the treatment of urinary tract infections.		2.4420cinnolines;
oxacycle;
oxo carboxylic acid		antibacterial drug;
antiinfective agent
ciprofibrate
[no description available]		2.4720cyclopropanes;
monocarboxylic acid;
organochlorine compound		antilipemic drug
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		15.531611aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
cisapride
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed). cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.		2.7430benzamides
citalopram
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.		4.41602-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound
clioquinol
Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.. 5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.		2.4720monohydroxyquinoline;
organochlorine compound;
organoiodine compound		antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antiprotozoal drug;
chelator;
copper chelator
clobazam
Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.. clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.		2.47201,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
GABA modulator
clofazimine
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619). clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.		4.4460monochlorobenzenes;
phenazines		dye;
leprostatic drug;
non-steroidal anti-inflammatory drug
clofibrate
angiokapsul: contains clofibrate & insoitolnicotinate		4.2750aromatic ether;
ethyl ester;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist
clomiphene
[no description available]		3.8730tertiary amineestrogen antagonist;
estrogen receptor modulator
clomipramine
Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.		4.0740dibenzoazepineanticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor
clonazepam
Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.. clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.		4.06401,4-benzodiazepinone;
monochlorobenzenes		anticonvulsant;
anxiolytic drug;
GABA modulator
clonidine
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.		4.2550clonidine;
imidazoline
4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide
[no description available]		2.0810sulfonamide
chlorazepate
clorazepic acid : A 1,4-benzodiazepinone in which the oxo group is at position 2, and which is substituted at positions 3, 5, and 7 by carboxy, phenyl and chloro groups, respectively.		3.84301,4-benzodiazepinoneanticonvulsant;
anxiolytic drug;
GABA modulator;
prodrug
clotiazepam
clotiazepam: was heading 1975-94 (see under AZEPINES 1978-90; was Y 6047 see under AZEPINES 1975-77); Y 6047 was see CLOTIAZEPAM 1978-94; use AZEPINES to search CLOTIAZEPAM 1975-94; thienodiazepine derivative with actions similar to those of benzodiazepines		2.0510organic molecular entity
clotrimazole
[no description available]		4.6240conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes		antiinfective agent;
environmental contaminant;
xenobiotic
cloxyquin
cloxyquin: has antitubercular activity; structure in first source		2.4110organochlorine compound;
quinolines
cromolyn
cromoglycic acid : A dicarboxylic acid that is the bis-chromone derivative of glycerol. It is effective as a mast cell stabilizer.		2.4720chromones;
dicarboxylic acid		anti-asthmatic drug;
calcium channel blocker
cyclandelate
Cyclandelate: A direct-acting SMOOTH MUSCLE relaxant used to dilate BLOOD VESSELS.. cyclandelate : The ester obtained by formal condensation of mandelic acid and 3,3,5-tricyclohexanol. It is a direct-acting smooth muscle relaxant used to dilate blood vessels.		2.0510carboxylic ester;
secondary alcohol		vasodilator agent
cyclobenzaprine
cyclobenzaprine: RN given refers to parent cpd; Lisseril is synonymous for HCl; structure. cyclobenzaprine : 5-Methylidene-5H-dibenzo[a,d]cycloheptene in which one of the hydrogens of the methylidene group is substituted by a 2-(dimethylamino)ethyl group. A centrally acting skeletal muscle relaxant, it is used as its hydrochloride salt in the symptomatic treatment of painful muscle spasm.		3.5620carbotricyclic compoundantidepressant;
muscle relaxant;
tranquilizing drug
cyclofenil
Cyclofenil: A gonadal stimulant and inducer of ovulation. It is used in the treatment of infertility and amenorrhea, but is thought to be less effective than CLOMIPHENE.		3.2310organic molecular entity
cyproheptadine
Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.. cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.		3.5920piperidines;
tertiary amine		anti-allergic agent;
antipruritic drug;
gastrointestinal drug;
H1-receptor antagonist;
serotonergic antagonist
danthron
danthron: structure. chrysazin : A dihydroxyanthraquinone that is anthracene-9,10-dione substituted by hydroxy groups at positions 1 and 8.		2.0510dihydroxyanthraquinoneapoptosis inducer;
plant metabolite
dapi
DAPI: RN given refers to parent cpd.		2.0510indolesfluorochrome
dapsone
[no description available]		4.4260substituted aniline;
sulfone		anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug
deferoxamine
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.		9.0540acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore
desipramine
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.		4.0840dibenzoazepine;
secondary amino compound		adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor
nordazepam
Nordazepam: An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.. nordazepam : A 1,4-benzodiazepinone having phenyl and chloro substituents at positions 5 and 7 respectively; it has anticonvulsant, anxiolytic, muscle relaxant and sedative properties but is used primarily in the treatment of anxiety.		2.46201,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
GABA modulator;
human metabolite;
sedative
amphetamine
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.		3.8630primary amine
eflornithine
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.		2.4620alpha-amino acid;
fluoroamino acid		trypanocidal drug
diazepam
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.		4.41601,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
diazoxide
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.. diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.		4.2650benzothiadiazine;
organochlorine compound;
sulfone		antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent
diclofenac
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.		4.6580amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
ddt
1,1-bis(p-chlorophenyl)-2,2,2-trichloroethane: structure in first source		2.0510benzenoid aromatic compound;
chlorophenylethane;
monochlorobenzenes;
organochlorine insecticide		bridged diphenyl acaricide;
carcinogenic agent;
endocrine disruptor;
persistent organic pollutant
dichlorphenamide
Dichlorphenamide: A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.. diclofenamide : A sulfonamide that is benzene-1,3-disulfonamide in which the hydrogens at positions 4 and 5 are substituted by chlorine. An oral carbonic anhydrase inhibitor, it partially suppresses the secretion (inflow) of aqueous humor in the eye and so reduces intraocular pressure. It is used for the treatment of glaucoma.		3.2310dichlorobenzene;
sulfonamide		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
ophthalmology drug
dicyclomine
Dicyclomine: A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms.. dicyclomine : The ester resulting from the formal condensation of 1-cyclohexylcyclohexanecarboxylic acid with 2-(diethylamino)ethanol. An anticholinergic, it is used as the hydrochloride to treat or prevent spasm in the muscles of the gastrointestinal tract, particularly that associated with irritable bowel syndrome.		3.2310carboxylic ester;
tertiary amine		antispasmodic drug;
muscarinic antagonist;
parasympatholytic
pentetic acid
Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.		3.2310pentacarboxylic acidcopper chelator
diflunisal
Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.. diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.		4.0640monohydroxybenzoic acid;
organofluorine compound		non-narcotic analgesic;
non-steroidal anti-inflammatory drug
dimercaprol
Dimercaprol: An anti-gas warfare agent that is effective against Lewisite (dichloro(2-chlorovinyl)arsine) and formerly known as British Anti-Lewisite or BAL. It acts as a chelating agent and is used in the treatment of arsenic, gold, and other heavy metal poisoning.. dimercaprol : A dithiol that is propane-1,2-dithiol in which one of the methyl hydrogens is replaced by a hydroxy group. a chelating agent originally developed during World War II as an experimental antidote against the arsenic-based poison gas Lewisite, it has been used clinically since 1949 for the treatment of poisoning by arsenic, mercury and gold. It can also be used for treatment of poisoning by antimony, bismuth and possibly thallium, and (with sodium calcium edetate) in cases of acute leaad poisoning. Administration is by (painful) intramuscular injection of a suspension of dimercaprol in peanut oil, typically every 4 hours for 2-10 days depending on the toxicity. In the past, dimercaprol was also used for the treatment of Wilson's disease, a severely debilitating genetic disorder in which the body tends to retain copper, with resultant liver and brain injury.		3.2310dithiol;
primary alcohol		chelator
diphenhydramine
Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.. diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.. antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.		6.3361ether;
tertiary amino compound		anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative
diphenyleneiodonium
diphenyleneiodonium: structure in first source; NADPH oxidase inhibitor. dibenziodolium : An organic cation that is fluorene in which the methylene group is replaced by a positively charged iodine.		2.1510organic cation
dipivefrin
dipivefrin: used in treatment of both primary & open angle glaucoma; RN given refers to (+-)-isomer. dipivefrin : The dipivalate ester of (+-)-epinephrine (racepinephrine). A pro-drug of epinephrine, the hydrochloride is used topically as eye drops to reduce intra-ocular pressure in the treatment of open-angle glaucoma or ocular hypertension.		2.0210ethanolamines;
pivalate ester		adrenergic agonist;
antiglaucoma drug;
ophthalmology drug;
prodrug;
sympathomimetic agent
dipyridamole
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.		4.0940piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol		adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
disopyramide
Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.. disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.		4.5370monocarboxylic acid amide;
pyridines;
tertiary amino compound		anti-arrhythmia drug
disulfiram
[no description available]		9.780organic disulfide;
organosulfur acaricide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor
valproic acid
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.		7.81490branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
thiorphan
Thiorphan: A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms.		2.2510N-acyl-amino acid
domperidone
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.		2.7530benzimidazoles;
heteroarylpiperidine		antiemetic;
dopaminergic antagonist
donepezil
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.		3.8830aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent
doxapram
Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225). doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.		3.5820morpholines;
pyrrolidin-2-ones		central nervous system stimulant
doxazosin
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.. doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.		3.8430aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines		alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent
doxepin
Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.. doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.		4.4160dibenzooxepine;
tertiary amino compound		antidepressant
doxylamine
Doxylamine: Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in PARKINSONISM.		3.2310pyridines;
tertiary amine		anti-allergic agent;
antiemetic;
antitussive;
cholinergic antagonist;
H1-receptor antagonist;
histamine antagonist;
sedative
droperidol
Droperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in conjunction with an opioid analgesic such as FENTANYL to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593). droperidol : An organofluorine compound that is haloperidol in which the hydroxy group has been eliminated with the introduction of a double bond in the piperidine ring, and the 4-chlorophenyl group has been replaced by a benzimidazol-2-on-1-yl group. It is used in the management of chemotherapy-induced nausea and vomiting, and in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon.		3.8530aromatic ketone;
benzimidazoles;
organofluorine compound		anaesthesia adjuvant;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
dyphylline
Dyphylline: A THEOPHYLLINE derivative with broncho- and vasodilator properties. It is used in the treatment of asthma, cardiac dyspnea, and bronchitis.. dyphylline : An oxopurine that is theophylline bearing a 2,3-dihydroxypropyl group at the 7 position. It has broncho- and vasodilator properties, and is used in the treatment of asthma, cardiac dyspnea, and bronchitis. It is also an ingredient in preparations that have been promoted for coughs.		3.8530oxopurine;
propane-1,2-diols		bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
muscle relaxant;
vasodilator agent
ebastine
[no description available]		2.0810organic molecular entity
ebselen
ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.		2.8630benzoselenazoleanti-inflammatory drug;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 3.5.4.1 (cytosine deaminase) inhibitor;
EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor;
enzyme mimic;
ferroptosis inhibitor;
genotoxin;
hepatoprotective agent;
neuroprotective agent;
radical scavenger
econazole
Econazole: An imidazole derivative that is commonly used as a topical antifungal agent.. econazole : A racemate composed of equimolar amounts of (R)- and (S)-econazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections.. 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 4-chlorobenzyl group.		7.9840dichlorobenzene;
ether;
imidazoles;
monochlorobenzenes
edrophonium
Edrophonium: A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.. edrophonium : A quaternary ammonium ion that is N-ethyl-N,N-dimethylanilinium in which one of the meta positions is substituted by a hydroxy group. It is a reversible inhibitor of cholinesterase, with a rapid onset (30-60 seconds after injection) but a short duration of action (5-15 minutes). The chloride salt is used in myasthenia gravis both diagnostically and to distinguish between under- or over-treatment with other anticholinesterases. It has also been used for the reversal of neuromuscular blockade in anaesthesia, and for the management of poisoning due to tetrodotoxin, a neuromuscular blocking toxin found in puffer fish and other marine animals.		3.2310phenols;
quaternary ammonium ion		antidote;
diagnostic agent;
EC 3.1.1.8 (cholinesterase) inhibitor
embelin
embelin: from Embelia fruit (Myrsinaceae). embelin : A member of the class of dihydroxy-1,4-benzoquinones that is 2,5-dihydroxy-1,4-benzoquinone which is substituted by an undecyl group at position 3. Isolated from Lysimachia punctata and Embelia ribes, it exhibits antimicrobial, antineoplastic and inhibitory activity towards hepatitis C protease.		3.1410dihydroxy-1,4-benzoquinonesantimicrobial agent;
antineoplastic agent;
hepatitis C protease inhibitor;
plant metabolite
enflurane
Enflurane: An extremely stable inhalation anesthetic that allows rapid adjustments of anesthesia depth with little change in pulse or respiratory rate.. enflurane : An ether in which the oxygen atom is connected to 2-chloro-1,1,2-trifluoroethyl and difluoromethyl groups.		2.4420ether;
organochlorine compound;
organofluorine compound		anaesthetic
enoxacin
Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.. enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.		2.96401,8-naphthyridine derivative;
amino acid;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-arylpiperazine;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor
estazolam
Estazolam: A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than DIAZEPAM or NITRAZEPAM.. estazolam : A triazolo[4,3-a][1,4]benzodiazepine having a phenyl group at position 6 and a chloro substituent at position 8. A short-acting benzodiazepine with general properties similar to diazepam, it is given by mouth as a hypnotic in the short-term management of insomnia.		3.8530triazoles;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA modulator
ethacrynic acid
Ethacrynic Acid: A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.. etacrynic acid : An aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor.		4.0840aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid		EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic
ethosuximide
Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.. ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.		3.8630dicarboximide;
pyrrolidinone		anticonvulsant;
geroprotector;
T-type calcium channel blocker
ethotoin
ethotoin: was heading 1966-94 (see under HYDANTOINS 1966-90); use HYDANTOINS to search ETHOTOIN 1966-94. ethotoin : An imidazolidine-2,4-dione that is hydantoin substituted by ethyl and phenyl at positions 3 and 5, respectively. An antiepileptic, it is less toxic than phenytoin but also less effective.		3.2310imidazolidine-2,4-dioneanticonvulsant
ethoxzolamide
Ethoxzolamide: A carbonic anhydrase inhibitor used as diuretic and in glaucoma. It may cause hypokalemia.. ethoxzolamide : A sulfonamide that is 1,3-benzothiazole-2-sulfonamide which is substituted by an ethoxy group at position 6. A carbonic anhydrase inhibitor, it has been used in the treatment of glaucoma, and as a diuretic.		2.0510aromatic ether;
benzothiazoles;
sulfonamide		antiglaucoma drug;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
etidronate
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.. etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.		3.85301,1-bis(phosphonic acid)antineoplastic agent;
bone density conservation agent;
chelator
etilefrine
Etilefrine: A phenylephrine-related beta-1 adrenergic and alpha adrenergic agonist used as a cardiotonic and antihypotensive agent.		2.4520phenols
etodolac
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).. etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.		4.0740monocarboxylic acid;
organic heterotricyclic compound		antipyretic;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
brl 42810
[no description available]		4.26502-aminopurines;
acetate ester		antiviral drug;
prodrug
felbamate
Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.. felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.		4.2650carbamate esteranticonvulsant;
neuroprotective agent
4-biphenylylacetic acid
biphenyl-4-ylacetic acid : A monocarboxylic acid in which one of the alpha-hydrogens is substituted by a biphenyl-4-yl group. An active metabolite of fenbufen, it is used as a topical medicine to treat muscle inflammation and arthritis.		2.0810biphenyls;
monocarboxylic acid		non-steroidal anti-inflammatory drug
felodipine
Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.. felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.		4.4160dichlorobenzene;
dihydropyridine;
ethyl ester;
methyl ester		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
fenfluramine
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.. fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.		2.0210(trifluoromethyl)benzenes;
secondary amino compound		appetite depressant;
serotonergic agonist;
serotonin uptake inhibitor
fenofibrate
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE		4.140aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
fenoldopam
Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.		3.2310benzazepinealpha-adrenergic agonist;
antihypertensive agent;
dopamine agonist;
dopaminergic antagonist;
vasodilator agent
fenoprofen
Fenoprofen: A propionic acid derivative that is used as a non-steroidal anti-inflammatory agent.. fenoprofen : A monocarboxylic acid that is propanoic acid in which one of the hydrogens at position 2 is substituted by a 3-phenoxyphenyl group. A non-steroidal anti-inflammatory drug, the dihydrate form of the calcium salt is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.		3.2310monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
berotek
Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.. fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.		2.4620resorcinols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent
fenspiride
fenspiride: was heading 1975-94 (see under SPIRO COMPOUNDS 1975-90); use SPIRO COMPOUNDS to search FENSPIRIDE 1975-94; bronchodilator agent used in asthma		2.0410azaspiro compound
fentanyl
Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.		3.1350anilide;
monocarboxylic acid amide;
piperidines		adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
fexofenadine
fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl. fexofenadine : A piperidine-based anti-histamine compound.		3.5620piperidines;
tertiary amine		anti-allergic agent;
H1-receptor antagonist
fipexide
fipexide: regulates dopaminergic systems at macromolecular level		3.2310benzodioxoles
flavoxate
Flavoxate: A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist.. flavoxate : A carboxylic ester resulting from the formal condensation of 3-methylflavone-8-carboxylic acid with 2-(1-piperidinyl)ethanol.		3.2310carboxylic ester;
flavones;
piperidines;
tertiary amino compound		antispasmodic drug;
muscarinic antagonist;
parasympatholytic
flecainide
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.. flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).		4.2550aromatic ether;
monocarboxylic acid amide;
organofluorine compound;
piperidines		anti-arrhythmia drug
fleroxacin
Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.. fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.		2.9640difluorobenzene;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
quinolines		antibacterial drug;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
fluconazole
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.		7.47211conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
flucytosine
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.		4.4160aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone		prodrug
flufenamic acid
Flufenamic Acid: An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16). flufenamic acid : An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders.		2.0510aromatic amino acid;
organofluorine compound		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
fluphenazine
[no description available]		3.5620N-alkylpiperazine;
organofluorine compound;
phenothiazines		anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug
flumazenil
Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.. flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.		4.4160ethyl ester;
imidazobenzodiazepine;
organofluorine compound		antidote to benzodiazepine poisoning;
GABA antagonist
flunitrazepam
Flunitrazepam: A benzodiazepine with pharmacologic actions similar to those of DIAZEPAM that can cause ANTEROGRADE AMNESIA. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.. flunitrazepam : A 1,4-benzodiazepinone that is nitrazepam substituted by a methyl group at position 1 and by a fluoro group at position 2'. It is a potent hypnotic, sedative, and amnestic drug used to treat chronic insomnia.		2.45201,4-benzodiazepinone;
C-nitro compound;
monofluorobenzenes		anxiolytic drug;
GABAA receptor agonist;
sedative
fluorescite
fluorescein (acid form) : A xanthene dye that is highly fluorescent and commonly used as a fluorescent tracer.		3.8730benzoic acids;
cyclic ketone;
hydroxy monocarboxylic acid;
organic heterotricyclic compound;
phenols;
xanthene dye		fluorescent dye;
radioopaque medium
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		9.7690nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
fluoxetine
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.		4.2650(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound
fluphenazine depot
fluphenazine decanoate : The prodrug of fluphenazine, an antipsychotic drug used for the symptomatic management of psychosis in patients with schizophrenia.		2.0210decanoate ester;
N-alkylpiperazine;
organofluorine compound;
phenothiazines		dopaminergic antagonist;
phenothiazine antipsychotic drug;
prodrug
fluphenazine enanthate
[no description available]		2.0210phenothiazines
flurazepam
Flurazepam: A benzodiazepine derivative used mainly as a hypnotic.. flurazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a 2-(diethylamino)ethyl group, 2-fluorophenyl group and chloro group at positions 1, 5 and 7, respectively. It is a partial agonist of GABAA receptors and used for the treatment of insomnia.		3.23101,4-benzodiazepinone;
monofluorobenzenes;
organochlorine compound;
tertiary amino compound		anticonvulsant;
anxiolytic drug;
GABAA receptor agonist;
sedative
flurbiprofen
Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.. flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.		3.8530fluorobiphenyl;
monocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
flutamide
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.		4.2650(trifluoromethyl)benzenes;
monocarboxylic acid amide		androgen antagonist;
antineoplastic agent
fomepizole
Fomepizole: A pyrazole and competitive inhibitor of ALCOHOL DEHYDROGENASE that is used for the treatment of poisoning by ETHYLENE GLYCOL or METHANOL.. fomepizole : A member of the class of pyrazoles that is 1H-pyrazole substituted by a methyl group at position 4.		3.5920pyrazolesantidote;
EC 1.1.1.1 (alcohol dehydrogenase) inhibitor;
protective agent
foscarnet
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.		4.4160carboxylic acid;
one-carbon compound;
phosphonic acids		antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor
furosemide
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.		4.86100chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic
gabapentin
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.. gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.		4.2450gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic
gabexate
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.		3.8230benzoate ester
gemfibrozil
[no description available]		4.0840aromatic etherantilipemic drug
gentamicin
Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.		10.66883
glafenine
Glafenine: An anthranilic acid derivative with analgesic properties used for the relief of all types of pain.. glafenine : A carboxylic ester that is 2,3-dihydroxypropyl anthranilate in which the amino group is substituted by a 7-chloroquinolin-4-yl group. A non-steroidal anti-inflammatory drug, glafenine and its hydrochloride salt were used for the relief of all types of pain, but high incidence of anaphylactic reactions resulted in their withdrawal from the market.		3.8730aminoquinoline;
carboxylic ester;
glycol;
organochlorine compound;
secondary amino compound		inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
gliclazide
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.		2.4720N-sulfonylureahypoglycemic agent;
insulin secretagogue;
radical scavenger
glimepiride
glimepiride: structure given in first source		4.2550sulfonamide
glipizide
Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.. glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.		4.2550aromatic amide;
monocarboxylic acid amide;
N-sulfonylurea;
pyrazines		EC 2.7.1.33 (pantothenate kinase) inhibitor;
hypoglycemic agent;
insulin secretagogue
glutethimide
Glutethimide: A hypnotic and sedative. Its use has been largely superseded by other drugs.		2.0510piperidines
glyburide
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.		4.4160monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent
2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester
[no description available]		3.2310benzenes
gossypol
Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.		2.0510
granisetron
[no description available]		4.0640aromatic amide;
indazoles
guaiazulene
guaiazulene: structure		2.0510sesquiterpene
guaifenesin
Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.		4.1540methoxybenzenes
guanethidine
Guanethidine: An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.. guanethidine : A member of the class of guanidines in which one of the hydrogens of the amino group has been replaced by a 2-azocan-1-ylethyl group.. guanethidine sulfate : A organic sulfate salt composed of two molecules of guanethidine and one of sulfuric acid.		3.2310azocanes;
guanidines		adrenergic antagonist;
antihypertensive agent;
sympatholytic agent
guanfacine
Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.		4.2550acetamides
guanidine
Guanidine: A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.. guanidine : An aminocarboxamidine, the parent compound of the guanidines.		3.2310carboxamidine;
guanidines;
one-carbon compound
fasudil
fasudil: intracellular calcium antagonist; structure in first source. fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.		2.0510isoquinolines;
N-sulfonyldiazepane		antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent
haloperidol
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.		4.4160aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
halothane
[no description available]		2.4420haloalkane;
organobromine compound;
organochlorine compound;
organofluorine compound		inhalation anaesthetic
hexachlorophene
Hexachlorophene: A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797). hexachlorophene : An organochlorine compound that is diphenylmethane in which each of the phenyl groups is substituted by chlorines at positions 2, 3, and 5, and by a hydroxy group at position 6. An antiseptic that is effective against Gram-positive organisms, it is used in soaps and creams for the treatment of various skin disorders. It is also used in agriculture as an acaricide and fungicide, but is not approved for such use within the European Union.		2.0510bridged diphenyl fungicide;
polyphenol;
trichlorobenzene		acaricide;
antibacterial agent;
antifungal agrochemical;
antiseptic drug
miltefosine
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.		2.0510phosphocholines;
phospholipid		anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor
hexestrol
[no description available]		2.0510stilbenoid
hexetidine
Hexetidine: A bactericidal and fungicidal antiseptic. It is used as a 0.1% mouthwash for local infections and oral hygiene. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797)		2.0510organic heteromonocyclic compound;
organonitrogen heterocyclic compound
hexobarbital
Hexobarbital: A barbiturate that is effective as a hypnotic and sedative.. hexobarbital : A member of the class of barbiturates taht is barbituric acid substituted at N-1 by methyl and at C-5 by methyl and cyclohex-1-enyl groups.		2.7430barbiturates
ethidium
Ethidium: A trypanocidal agent and possible antiviral agent that is widely used in experimental cell biology and biochemistry. Ethidium has several experimentally useful properties including binding to nucleic acids, noncompetitive inhibition of nicotinic acetylcholine receptors, and fluorescence among others. It is most commonly used as the bromide.. ethidium : The fluorescent compound widely used in experimental cell biology and biochemistry to reveal double-stranded DNA and RNA.		2.1110phenanthridinesfluorochrome;
intercalator
hycanthone
Hycanthone: Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE.. hycanthone : A thioxanthen-9-one compound having a hydroxymethyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. It was formerly used (particularly as the monomethanesulfonic acid salt) as a schistosomicide for individual or mass treatement of infection with Schistosoma haematobium and S. mansoni, but due to its toxicity and concern about possible carcinogenicity, it has been replaced by other drugs such as praziquantel.		2.0710thioxanthenesmutagen;
schistosomicide drug
hydralazine
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.		4.2650azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines		antihypertensive agent;
vasodilator agent
hydrochlorothiazide
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.		4.2650benzothiadiazine;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
hydroflumethiazide
Hydroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822). hydroflumethiazide : A benzothiadiazine consisting of a 3,4-dihydro-HH-1,2,4-benzothiadiazine bicyclic system dioxygenated on sulfur and carrying trifluoromethyl and aminosulfonyl groups at positions 6 and 7 respectively. A diuretic with actions and uses similar to those of hydrochlorothiazide.		3.8730benzothiadiazine;
thiazide		antihypertensive agent;
diuretic
hydroxychloroquine
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970). hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.		4.1440aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug
hydroxyurea
[no description available]		4.4160one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
hydroxyzine
Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.		4.0740hydroxyether;
monochlorobenzenes;
N-alkylpiperazine		anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist
hypericin
[no description available]		2.0410
ibuprofen
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine		4.6580monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
phenelzine
Phenelzine: One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC.		4.0740primary amine
lidocaine
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.		4.4160benzenes;
monocarboxylic acid amide;
tertiary amino compound		anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic
alverine
alverine : A tertiary amine having one ethyl and two 3-phenylprop-1-yl groups attached to the nitrogen. An antispasmodic that acts directly on intestinal and uterine smooth muscle, it is used (particularly as the citrate salt) in the treatment of irritable bowel syndrome.		2.0510tertiary amineantispasmodic drug
idebenone
[no description available]		2.05101,4-benzoquinones;
primary alcohol		antioxidant;
ferroptosis inhibitor
ifosfamide
[no description available]		4.4160ifosfamidesalkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic
imipramine
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.		4.4260dibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
amrinone
Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.. amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.		4.4160bipyridinesEC 3.1.4.* (phosphoric diester hydrolase) inhibitor
indapamide
Indapamide: A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. indapamide : A sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine.		4.0840indoles;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		4.7690aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
iodixanol
iodixanol: dimeric contrast media; structure given in first source. iodixanol : A dimeric, non-ionic, water-soluble, radiographic contrast agent, used particularly in coronary angiography.		2.0210organoiodine compoundradioopaque medium
iohexol
Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.. iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.		3.1550benzenedicarboxamide;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
iopromide
iopromide: structure given in first source. iopromide : A dicarboxylic acid diamide that consists of N-methylisophthalamide bearing three iodo substituents at positions 2, 4 and 6, a methoxyacetyl substituent at position 5 and two 2,3-dihydroxypropyl groups attached to the amide nitrogens. A water soluble x-ray contrast agent for intravascular administration.		2.7330dicarboxylic acid diamide;
organoiodine compound		environmental contaminant;
nephrotoxic agent;
radioopaque medium;
xenobiotic
iothalamic acid
Iothalamic Acid: A contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine (IOTHALAMATE MEGLUMINE) salts.		2.4620organic molecular entity
iodipamide
Iodipamide: A water-soluble radiographic contrast media for cholecystography and intravenous cholangiography.. adipiodone : An organoiodine compound that is 3-amino-2,4,6-triiodobenzoic acid in which one of the amino hydrogens is substituted by a 6-(3-carboxy-2,4,6-triiodoanilino)-6-oxohexanoyl group. It is a water-soluble radiographic contrast media for cholecystography and intravenous cholangiography.		2.0510benzoic acids;
organoiodine compound;
secondary carboxamide		radioopaque medium
iotroxic acid
iotroxic acid: RN given refers to parent cpd; structure		2.0610organic molecular entity
ioversol
[no description available]		3.5620amidobenzoic acid
iproniazid
[no description available]		4.140carbohydrazide;
pyridines
avapro
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.		4.0840azaspiro compound;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
isocarboxazid
Isocarboxazid: An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)		3.5920benzenes
isoflurane
Isoflurane: A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.		2.4420organofluorine compoundinhalation anaesthetic
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		5.86160carbohydrazideantitubercular agent;
drug allergen
2-propanol
2-Propanol: An isomer of 1-PROPANOL. It is a colorless liquid having disinfectant properties. It is used in the manufacture of acetone and its derivatives and as a solvent. Topically, it is used as an antiseptic.. propan-2-ol : A secondary alcohol that is propane in which one of the hydrogens attached to the central carbon is substituted by a hydroxy group.		2.0510secondary alcohol;
secondary fatty alcohol		protic solvent
isoproterenol
Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.		3.8630catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
isoxsuprine
Isoxsuprine: A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.		3.5920alkylbenzene
isradipine
Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.		4.4160benzoxadiazole;
dihydropyridine;
isopropyl ester;
methyl ester
itraconazole
[no description available]		5.0670piperazines
ketamine
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.		4.0840cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic
ketanserin
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.		2.9740aromatic ketone;
organofluorine compound;
piperidines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
ketoconazole
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.		4.2650dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
ketoprofen
Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.		4.460benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
ketorolac
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed). ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.. 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.		4.460amino acid;
aromatic ketone;
monocarboxylic acid;
pyrrolizines;
racemate		analgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
khellin
Khellin: A vasodilator that also has bronchodilatory action. It has been employed in the treatment of angina pectoris, in the treatment of asthma, and in conjunction with ultraviolet light A, has been tried in the treatment of vitiligo. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1024). khellin : A furanochrome in which the basic tricyclic skeleton is substituted at positions 4 and 9 with methoxy groups and at position 7 with a methyl group. A major constituent of the plant Ammi visnaga it is a herbal folk medicine used for various illnesses, its main effect being as a vasodilator.		2.0510furanochromone;
organic heterotricyclic compound;
oxacycle		anti-asthmatic agent;
bronchodilator agent;
cardiovascular drug;
vasodilator agent
labetalol
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.. labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.. 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.		4.5470benzamides;
benzenes;
phenols;
primary carboxamide;
salicylamides;
secondary alcohol;
secondary amino compound
lamotrigine
[no description available]		4.26501,2,4-triazines;
dichlorobenzene;
primary arylamine		anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic
lansoprazole
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.		4.5470benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
beta-lapachone
beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase. beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.		2.0510benzochromenone;
orthoquinones		anti-inflammatory agent;
antineoplastic agent;
plant metabolite
leflunomide
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.		3.8730(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide		antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor
letrozole
[no description available]		4.0840nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
lofepramine
Lofepramine: A psychotropic IMIPRAMINE derivative that acts as a tricyclic antidepressant and possesses few anticholinergic properties. It is metabolized to DESIPRAMINE.		2.4720aromatic ketone;
dibenzoazepine;
monochlorobenzenes;
tertiary amino compound		antidepressant
lomefloxacin
lomefloxacin: structure given in first source. lomefloxacin : A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.		9.0440fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antimicrobial agent;
antitubercular agent;
photosensitizing agent
lomustine
[no description available]		3.8730N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
loperamide
Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.. loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.		3.5920monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol		anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist
loratadine
Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.. loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.		3.8530benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide		anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist
lorazepam
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.		3.8530benzodiazepine
losartan
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position		4.460biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist
loxapine
Loxapine: An antipsychotic agent used in SCHIZOPHRENIA.		3.5620dibenzooxazepineantipsychotic agent;
dopaminergic antagonist
malathion
Malathion: A wide spectrum aliphatic organophosphate insecticide widely used for both domestic and commercial agricultural purposes.. malathion : A racemate comprising equimolar amounts of (R) and (S)-malathion. It is a broad spectrum organophosphate proinsecticide used to control a wide range of pests including Coleoptera, Diptera, fruit flies, mosquitos and spider mites.. diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate : A diester that is diethyl succinate in which position 2 is substituted by a (dimethoxyphosphorothioyl)thio group.		2.0510diester;
ethyl ester;
organic thiophosphate
diisopropyl 1,3-dithiol-2-ylidenemalonate
diisopropyl 1,3-dithiol-2-ylidenemalonate: structure in first source		2.0510isopropyl ester
maprotiline
Maprotiline: A bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.		4.2650anthracenes
mazindol
Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.		2.0510organic molecular entity
mebendazole
Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.		4.4160aromatic ketone;
benzimidazoles;
carbamate ester		antinematodal drug;
microtubule-destabilising agent;
tubulin modulator
mecamylamine
Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.		3.620primary aliphatic amine
mechlorethamine
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.		3.2310nitrogen mustard;
organochlorine compound		alkylating agent
meclizine
Meclizine: A histamine H1 antagonist used in the treatment of motion sickness, vertigo, and nausea during pregnancy and radiation sickness.		3.8730diarylmethane
meclofenamic acid
Meclofenamic Acid: A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.. meclofenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis.		3.5620aminobenzoic acid;
organochlorine compound;
secondary amino compound		analgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
meclofenoxate
Meclofenoxate: An ester of DIMETHYLAMINOETHANOL and para-chlorophenoxyacetic acid.		2.0510monocarboxylic acid
mefenamic acid
Mefenamic Acid: A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.. mefenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis.		4.2650aminobenzoic acid;
secondary amino compound		analgesic;
antipyretic;
antirheumatic drug;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
mefloquine hydrochloride
[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol : An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4.		2.0210organofluorine compound;
piperidines;
quinolines;
secondary alcohol
memantine
[no description available]		3.2310adamantanes;
primary aliphatic amine		antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist
vitamin k 3
Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.		2.05101,4-naphthoquinones;
vitamin K		angiogenesis inhibitor;
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human urinary metabolite;
nutraceutical
mepenzolate
mepenzolic acid: anticholinergic, antispasmodic agent; RN given refers to parent cpd; structure		3.2310diarylmethane
meperidine
Meperidine: A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.. pethidine : A piperidinecarboxylate ester that is piperidine which is substituted by a methyl group at position 1 and by phenyl and ethoxycarbonyl groups at position 4. It is an analgesic which is used for the treatment of moderate to severe pain, including postoperative pain and labour pain.		4.4160ethyl ester;
piperidinecarboxylate ester;
tertiary amino compound		antispasmodic drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
mephenytoin
Mephenytoin: An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias.. mephenytoin : An imidazolidine-2,4-dione (hydantoin) in which the imidazolidine nucleus carries a methyl group at N-3 and has ethyl and phenyl substituents at C-5. An anticonvulsant, it is no longer available in the USA or the UK but is still studied largely because of its interesting hydroxylation polymorphism.		3.5920imidazolidine-2,4-dioneanticonvulsant
mepivacaine
Mepivacaine: A local anesthetic that is chemically related to BUPIVACAINE but pharmacologically related to LIDOCAINE. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168). mepivacaine : A piperidinecarboxamide in which N-methylpipecolic acid and 2,6-dimethylaniline have combined to form the amide bond. It is used as a local amide-type anaesthetic.		4.0840piperidinecarboxamidedrug allergen;
local anaesthetic
meprobamate
Meprobamate: A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of ANXIETY DISORDERS, and also for the short-term management of INSOMNIA but has largely been superseded by the BENZODIAZEPINES. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603)		3.8630organic molecular entity
mesalamine
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed). mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.		4.0640amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols		non-steroidal anti-inflammatory drug
mesoridazine
Mesoridazine: A phenothiazine antipsychotic with effects similar to CHLORPROMAZINE.. mesoridazine : A phenothiazine substituted at position 2 (para to the S atom) by a methylsulfinyl group, and on the nitrogen by a 2-(1-methylpiperidin-2-yl)ethyl group.		3.2310phenothiazines;
sulfoxide;
tertiary amino compound		dopaminergic antagonist;
first generation antipsychotic
metaproterenol
Metaproterenol: A beta-2 adrenergic agonist used in the treatment of ASTHMA and BRONCHIAL SPASM.. orciprenaline : A racemate composed of equimolar amounts of (R)- and (S)-orciprenaline. Used (as its sulfate salt) to relax the airway muscles and improve breathing for patients suffering from asthma or bronchitis.. 5-[1-hydroxy-2-(isopropanylamino)ethyl]benzene-1,3-diol : A member of the class of resorcinols bearing an additional 1-hydroxy-2-(isopropanylamino)ethyl substituent at position 5 of resorcinol itself.		3.5920aralkylamino compound;
phenylethanolamines;
resorcinols;
secondary alcohol;
secondary amino compound
metformin
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.		4.5470guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
methadone
Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3). methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.. 6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.		4.0840benzenes;
diarylmethane;
ketone;
tertiary amino compound
methapyrilene
Methapyrilene: Histamine H1 antagonist with sedative action used as a hypnotic and in allergies.. methapyrilene : A member of the class of ethylenediamine derivatives that is ethylenediamine in which one of the nitrogens is substituted by two methyl groups, and the other nitrogen is substituted by a 2-pyridyl group and a (2-thienyl)methyl group.		2.0410ethylenediamine derivativeanti-allergic agent;
carcinogenic agent;
H1-receptor antagonist;
sedative
methazolamide
Methazolamide: A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.		3.2310sulfonamide;
thiadiazoles
methocarbamol
Methocarbamol: A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206). methocarbamol : A racemate comprising equimolar amounts of (R)- and (S)-methocarbamol. A centrally acting skeletal muscle relaxant, it is used as an adjunct in the short-term symptomatic treatment of painful muscle spasm. The (R)-enantiomer is more active than the (S)-enantiomer.. 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate : A carbamate ester that is glycerol in which one of the primary alcohol groups has been converted to its 2-methoxyphenyl ether while the other has been converted to the corresponding carbamate ester.		3.620aromatic ether;
carbamate ester;
secondary alcohol
methoxsalen
Methoxsalen: A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation.. methoxsalen : A member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis.		3.5920aromatic ether;
psoralens		antineoplastic agent;
cross-linking reagent;
dermatologic drug;
photosensitizing agent;
plant metabolite
methoxyflurane
Methoxyflurane: An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with NITROUS OXIDE to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180). methoxyflurane : An ether in which the two groups attached to the central oxygen atom are methyl and 2,2-dichloro-1,1-difluoroethyl.		2.0510ether;
organochlorine compound;
organofluorine compound		hepatotoxic agent;
inhalation anaesthetic;
nephrotoxic agent;
non-narcotic analgesic
methyclothiazide
Methyclothiazide: A thiazide diuretic with properties similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)		3.2310benzothiadiazine
methyl salicylate
methyl salicylate: used in over-the-counter liniments, ointments, lotions for relief of musculoskeletal aches and pains; has hemolytic effect on human & sheep erythrocytes; RN given refers to parent cpd; structure in Merck Index, 9th ed, #5990. methyl salicylate : A benzoate ester that is the methyl ester of salicylic acid.		2.0510benzoate ester;
methyl ester;
salicylates		flavouring agent;
insect attractant;
metabolite
methylphenidate
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.. methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.. methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.		4.0840beta-amino acid ester;
methyl ester;
piperidines
methyprylon
methyprylon: was heading 1973-94 (see under HYPNOTICS AND SEDATIVES 1963-72); use PIPERIDONES to search METHYPRYLON 1973-94		2.0510organic molecular entity
metoclopramide
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.		4.4160benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound		antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic
metolazone
Metolazone: A quinazoline-sulfonamide derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. metolazone : A quinazoline that consists of 1,2,3,4-tetrahydroquinazolin-4-one bearing additional methyl, 2-tolyl, sulfamyl and chloro substituents at positions 2, 3, 6 and 7 respectively. A quinazoline diuretic, with properties similar to thiazide diuretics.		4.0840organochlorine compound;
quinazolines;
sulfonamide		antihypertensive agent;
diuretic;
ion transport inhibitor
metoprolol
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.. metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.		4.5370aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound		antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic
metronidazole
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.		14.277316C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
metyrapone
Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.. metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.		3.5920aromatic ketoneantimetabolite;
diagnostic agent;
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
mexiletine
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.. mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.		4.2550aromatic ether;
primary amino compound		anti-arrhythmia drug
mianserin
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.. mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.		2.4620dibenzoazepineadrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist
miconazole
Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion.. 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group.. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.		3.6120dichlorobenzene;
ether;
imidazoles
midazolam
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.		4.4160imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
midodrine
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.. midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.		3.8530amino acid amide;
aromatic ether;
secondary alcohol		alpha-adrenergic agonist;
prodrug;
sympathomimetic agent;
vasoconstrictor agent
milrinone
[no description available]		4.0740bipyridines;
nitrile;
pyridone		cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
minoxidil
Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371). minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.		4.4160dialkylarylamine;
tertiary amino compound
mirtazapine
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.		4.5570benzazepine;
tetracyclic antidepressant		alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
oneirogen;
serotonergic antagonist
mitotane
Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.		3.5920diarylmethane
mitoxantrone
Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.		4.460dihydroxyanthraquinoneanalgesic;
antineoplastic agent
moclobemide
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.. moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.		2.7530benzamides;
monochlorobenzenes;
morpholines		antidepressant;
environmental contaminant;
xenobiotic
modafinil
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.. modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.. 2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.		3.8730monocarboxylic acid amide;
sulfoxide
moxisylyte
Moxisylyte: An alpha-adrenergic blocking agent that is used in Raynaud's disease. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312)		3.8730monoterpenoid
muscimol
Muscimol: A neurotoxic isoxazole isolated from species of AMANITA. It is obtained by decarboxylation of IBOTENIC ACID. Muscimol is a potent agonist of GABA-A RECEPTORS and is used mainly as an experimental tool in animal and tissue studies.. muscimol : A member of the class of isoxazoles that is 1,2-oxazol-3(2H)-one substituted by an aminomethyl group at position 5. It has been isolated from mushrooms of the genus Amanita.		2.420alkaloid;
isoxazoles;
primary amino compound		fungal metabolite;
GABA agonist;
oneirogen;
psychotropic drug
deet
N,N-diethyl-m-toluamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of m-toluic acid with the nitrogen of diethylamine. First developed by the U.S. Army in 1946 for use by military personnel in insect-infested areas, it is the most widely used insect repellent worldwide.		2.0510benzamides;
monocarboxylic acid amide		environmental contaminant;
insect repellent;
xenobiotic
acecainide
Acecainide: A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure.. N-acetylprocainamide : A benzamide obtained via formal condensation of 4-acetamidobenzoic acid and 2-(diethylamino)ethylamine.		2.7530acetamides;
benzamides		anti-arrhythmia drug
ethylmaleimide
Ethylmaleimide: A sulfhydryl reagent that is widely used in experimental biochemical studies.		2.1110maleimidesanticoronaviral agent;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.1.1 (hexokinase) inhibitor
apnea
Apnea: A transient absence of spontaneous respiration.		2.0610purine nucleoside
nabumetone
Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.. nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.		3.8530methoxynaphthalene;
methyl ketone		cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
nadolol
[no description available]		3.6120tetralins
nalidixic acid
[no description available]		5.161401,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor
naratriptan
naratriptan: structure given in first source		3.8530heteroarylpiperidine;
sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent
nefazodone
nefazodone: may be useful as an opiate adjunct		4.5470aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles		alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor
nefopam
Nefopam: Non-narcotic analgesic chemically similar to ORPHENADRINE. Its mechanism of action is unclear. It is used for the relief of acute and chronic pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p26). nefopam : A racemate comprising equal amounts of (R)- and (S)-nefopam. The hydrochloride is a centrally acting non-opiate analgesic commonly used for the treatment of moderate to severe pain.. 5-methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine : A member of the class of benzoxazocines that is 3,4,5,6-tetrahydro-1H-2,5-benzoxazocine substituted by phenyl and methyl groups at positions 1 and 5 respectively.		2.4620benzoxazocine;
tertiary amino compound
neostigmine
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.. neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.		2.0810quaternary ammonium ionantidote to curare poisoning;
EC 3.1.1.7 (acetylcholinesterase) inhibitor
nevirapine
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.		4.5470cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
nialamide
Nialamide: An MAO inhibitor that is used as an antidepressive agent.		3.5920organonitrogen compound;
organooxygen compound
nicardipine
Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.. nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.. 2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.		4.460benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound
niceritrol
Niceritrol: An ester of nicotinic acid that lowers cholesterol and triglycerides in total plasma and in the VLD- and LD-lipoprotein fractions.		2.0510organic molecular entity
nifedipine
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.		4.5470C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
niflumic acid
Niflumic Acid: An analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.		2.0510aromatic carboxylic acid;
pyridines
nilutamide
[no description available]		4.0740(trifluoromethyl)benzenes;
C-nitro compound;
imidazolidinone		androgen antagonist;
antineoplastic agent
nimesulide
nimesulide: structure. nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.		4.140aromatic ether;
C-nitro compound;
sulfonamide		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
nimodipine
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.. nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.		4.53702-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester		antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent
nisoldipine
Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.. nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.. methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.		4.5470C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
methyl ester
nitrazepam
Nitrazepam: A benzodiazepine derivative used as an anticonvulsant and hypnotic.. nitrazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the treatment of epileptic spasms in infants (West's syndrome).		2.97401,4-benzodiazepinone;
C-nitro compound		anticonvulsant;
antispasmodic drug;
drug metabolite;
GABA modulator;
sedative
nitrendipine
Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.. nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.		3.1550C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester		antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent
nitroglycerin
Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.		3.5920nitroglycerolexplosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic
nizatidine
[no description available]		4.25501,3-thiazoles;
C-nitro compound;
carboxamidine;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
cholinergic drug;
H2-receptor antagonist
nomifensine
Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266). nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.		3.8530isoquinolinesdopamine uptake inhibitor
masoprocol
nordihydroguaretic acid: antioxidant compound found in the creosote bush (Larrea tridentata)		2.4420catechols;
lignan;
tetrol		antioxidant;
ferroptosis inhibitor;
geroprotector;
plant metabolite
norfloxacin
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.		5.97190fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
nortriptyline
Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.. nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.		4.4160organic tricyclic compound;
secondary amine		adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite
ofloxacin
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.		8.963823-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
omeprazole
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.		5.2790aromatic ether;
benzimidazoles;
pyridines;
sulfoxide
ondansetron
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.		4.2550carbazoles
orphenadrine
Orphenadrine: A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.. orphenadrine : A tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol.		3.8730ether;
tertiary amino compound		antidyskinesia agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic
oxamniquine
Oxamniquine: An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs. (From Martindale, The Extra Pharmacopoeia, 31st ed, p121). oxamniquine : A racemate comprising equimolar amounts of (R)- and (S)-oxamniquine. An anthelmintic, it is administered orally for the treatment of schistomiasis caused by Schistosoma mansoni (but not by other Schistosoma species); intramuscular administration is no longer used as it causes severe pain at the injection site.. {2-[(isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl}methanol : A member of the class of quinolines that is 1,2,3,4-tetrahydroquinoline which is substituted at positions 2, 6, and 7 by (isopropylamino)methyl, hydroxymethyl, and nitro groups, respectively.		2.0510aromatic primary alcohol;
C-nitro compound;
quinolines;
secondary amino compound
oxaprozin
Oxaprozin: An oxazole-propionic acid derivative, cyclooxygenase inhibitor, and non-steroidal anti-inflammatory drug that is used in the treatment of pain and inflammation associated with of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; and ARTHRITIS, JUVENILE.. oxaprozin : A monocarboxylic acid that is a propionic acid derivative having a 4,5-diphenyl-1,3-oxazol-2-yl substituent at position 3. It is non-steroidal anti-inflammatory drug commonly used to relieve the pain and inflammatory responses associated with osteoarthritis and rheumatoid arthritis.		4.08401,3-oxazoles;
monocarboxylic acid		analgesic;
non-steroidal anti-inflammatory drug
oxazepam
Oxazepam: A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia.. oxazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5.		4.08401,4-benzodiazepinone;
organochlorine compound		anxiolytic drug;
environmental contaminant;
xenobiotic
oxethazaine
[no description available]		2.0510amino acid amide
oxiracetam
oxiracetam: structure in first source		2.0410organonitrogen compound;
organooxygen compound
oxolinic acid
quinolone antibiotic : An organonitrogen heterocyclic antibiotic whose structure contains a quinolone or quinolone-related skeleton.		2.0410aromatic carboxylic acid;
organic heterotricyclic compound;
oxacycle;
quinolinemonocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antifungal agent;
antiinfective agent;
antimicrobial agent;
enzyme inhibitor
oxprenolol
Oxprenolol: A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.		2.0510aromatic ether
oxybenzone
oxybenzone : A hydroxybenzophenone that is benzophenone which is substituted at the 2- and 4-positions of one of the benzene rings by hydroxy and methoxy groups respectively.		2.0510hydroxybenzophenone;
monomethoxybenzene		dermatologic drug;
environmental contaminant;
protective agent;
ultraviolet filter;
xenobiotic
oxybutynin
oxybutynin: RN given refers to parent cpd. oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.		4.0940acetylenic compound;
carboxylic ester;
racemate;
tertiary alcohol;
tertiary amino compound		antispasmodic drug;
calcium channel blocker;
local anaesthetic;
muscarinic antagonist;
muscle relaxant;
parasympatholytic
oxyphenbutazone
Oxyphenbutazone: A non-steroidal anti-inflammatory drug. Oxyphenbutazone eyedrops have been used abroad in the management of postoperative ocular inflammation, superficial eye injuries, and episcleritis. (From AMA, Drug Evaluations Annual, 1994, p2000) It had been used by mouth in rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis but such use is no longer considered justified owing to the risk of severe hematological adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p27). oxyphenbutazone : A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome.		2.4720phenols;
pyrazolidines		antimicrobial agent;
antineoplastic agent;
antipyretic;
drug metabolite;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite
aminosalicylic acid
Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.. 4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.		3.8730aminobenzoic acid;
phenols		antitubercular agent
pamidronate
[no description available]		4.2550phosphonoacetic acid
pantoprazole
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.. pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.		4.2850aromatic ether;
benzimidazoles;
organofluorine compound;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
environmental contaminant;
xenobiotic
papaverine
Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.		4.0840benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines		antispasmodic drug;
vasodilator agent
pemoline
Pemoline: A central nervous system stimulant used in fatigue and depressive states and to treat hyperkinetic disorders in children.. pemoline : A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted by an amino group at position 2 and by a phenyl group at position 5. A central nervous system stimulant, it was used to treat hyperactivity disorders in children, but withdrawn from use following reports of serious hepatotoxicity.		4.08401,3-oxazolescentral nervous system stimulant
pentamidine
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.		4.2550aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic
pentobarbital
Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.		3.8630barbituratesGABAA receptor agonist
pentoxifylline
[no description available]		4.2550oxopurine
perazine
Perazine: A phenothiazine antipsychotic with actions and uses similar to those of CHLORPROMAZINE. Extrapyramidal symptoms may be more common than other side effects.. perazine : A phenothiazine derivative in which 10H-phenothiazinecarries a 3-(4-methylpiperazin-1-yl)propyl substituent at the N-10 position.		2.0510N-alkylpiperazine;
N-methylpiperazine;
phenothiazines		dopaminergic antagonist;
phenothiazine antipsychotic drug
perhexiline
Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.		3.620piperidinescardiovascular drug
perphenazine
Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.		4.4160N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines		antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug
phenacetin
Saridon: contains phenacetin, caffeine, propyphenazone & pyrithyldione		2.7530acetamides;
aromatic ether		cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug
phenobarbital
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.		4.2650barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
phenolphthalein
Phenolphthalein: An acid-base indicator which is colorless in acid solution, but turns pink to red as the solution becomes alkaline. It is used medicinally as a cathartic.		2.0510phenols
phenoxybenzamine
Phenoxybenzamine: An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.		3.8730aromatic amine
phentermine
Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.		3.620primary amineadrenergic agent;
appetite depressant;
central nervous system drug;
central nervous system stimulant;
dopaminergic agent;
sympathomimetic agent
4-phenylbutyric acid
4-phenylbutyric acid: RN refers to the parent cpd. 4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.		3.2310monocarboxylic acidantineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug
phenylbutazone
Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.		2.4720pyrazolidinesantirheumatic drug;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
phthalylsulfathiazole
phthalylsulfathiazole: minor descriptor (63-86); on-line & INDEX MEDICUS search SULFATHIAZOLES (66-86); RN given refers to parent cpd. phthalylsulfathiazole : A sulfonamide incorporating 2-carboxybenzamido and 1,3-thiazol-2-yl moieties that is a broad-spectrum antibiotic indicated in the treatment of dysentery, colitis, gastroenteritis and intestinal surgery.		2.06101,3-thiazoles;
dicarboxylic acid monoamide;
sulfonamide antibiotic;
sulfonamide
moxonidine
moxonidine: structure given in first source		2.9740organohalogen compound;
pyrimidines
pimobendan
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source		2.0410benzimidazoles;
pyridazinone		cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
pinacidil
Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed)		2.0510pyridines
pindolol
Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638). pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.		4.2550indoles;
secondary amine		antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
serotonergic antagonist;
vasodilator agent
pioglitazone
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.		3.8830aromatic ether;
pyridines;
thiazolidinediones		antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic
pipemidic acid
Pipemidic Acid: Antimicrobial against Gram negative and some Gram positive bacteria. It is protein bound and concentrated in bile and urine and used for gastrointestinal, biliary, and urinary infections.. pipemidic acid : A pyridopyrimidine that is 5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid substituted at position 2 by a piperazin-1-yl group and at position 8 by an ethyl group. A synthetic broad-spectrum antibacterial, it is used for treatment of gastrointestinal, biliary, and urinary infections.		3.6120amino acid;
monocarboxylic acid;
N-arylpiperazine;
pyridopyrimidine;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor
piperazine
[no description available]		2.0510azacycloalkane;
piperazines;
saturated organic heteromonocyclic parent		anthelminthic drug
piracetam
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.		3.3920organonitrogen compound;
organooxygen compound
pirbuterol
pirbuterol: structure		2.4420pyridines
piretanide
piretanide: potent inhibitor of chloride transport; structure		2.4520aromatic ether
piribedil
Piribedil: A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist.		2.0810N-arylpiperazine
polythiazide
[no description available]		3.2310benzothiadiazine
practolol
Practolol: A beta-1 adrenergic antagonist that has been used in the emergency treatment of CARDIAC ARRYTHMIAS.. practolol : N-(4-Hydroxyphenyl)acetamide in which the hydrogen of the phenolic hydroxy group is substituted by a 3-(isopropylaminoamino)-2-hydroxypropyl group. A selective beta blocker, it has been used in the emergency treatment of cardiac arrhythmias.		2.0510acetamides;
ethanolamines;
propanolamine;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
beta-adrenergic antagonist
duodote
duodote: consists of atropine and pralidoxime chloride; for treating those exposed to organophosphorus-containing nerve agents		3.2310pyridinium ionantidote to organophosphate poisoning;
antidote to sarin poisoning;
cholinergic drug;
cholinesterase reactivator
ono 1078
pranlukast: SRS-A antagonist; leukotriene D4 receptor antagonist		3.6620chromones
pyranoprofen
pyranoprofen: RN given refers to unlabled parent cpd; structure given in first source		2.0810pyridochromene
prazepam
Prazepam: A benzodiazepine that is used in the treatment of ANXIETY DISORDERS.		2.0210benzodiazepine
praziquantel
azinox: Russian drug		4.0840isoquinolines
prazosin
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.		4.4160aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
prilocaine
Prilocaine: A local anesthetic that is similar pharmacologically to LIDOCAINE. Currently, it is used most often for infiltration anesthesia in dentistry.. prilocaine : An amino acid amide in which N-propyl-DL-alanine and 2-methylaniline have combined to form the amide bond; used as a local anaesthetic.		2.0410amino acid amide;
monocarboxylic acid amide		anticonvulsant;
local anaesthetic
primaquine
Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.		4.0840aminoquinoline;
aromatic ether;
N-substituted diamine		antimalarial
primidone
Primidone: A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite.. primidone : A pyrimidone that is dihydropyrimidine-4,6(1H,5H)-dione substituted by an ethyl and a phenyl group at position 5. It is used as an anticonvulsant for treatment of various types of seizures.		4.0840pyrimidoneanticonvulsant;
environmental contaminant;
xenobiotic
probenecid
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.		5.971benzoic acids;
sulfonamide		uricosuric drug
probucol
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).. probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.		2.0510dithioketal;
polyphenol		anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug
procainamide
Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.		4.4160benzamidesanti-arrhythmia drug;
platelet aggregation inhibitor;
sodium channel blocker
procarbazine
Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.. procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.		3.8530benzamides;
hydrazines		antineoplastic agent
prochlorperazine
Prochlorperazine: A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612). prochlorperazine : A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position.		4.2750N-alkylpiperazine;
N-methylpiperazine;
organochlorine compound;
phenothiazines		alpha-adrenergic antagonist;
antiemetic;
cholinergic antagonist;
dopamine receptor D2 antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic
procyclidine
Procyclidine: A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.. procyclidine : A tertiary alcohol that consists of propan-1-ol substituted by a cyclohexyl and a phenyl group at position 1 and a pyrrolidin-1-yl group at position 3.		3.8730pyrrolidines;
tertiary alcohol		antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist
promazine
Promazine: A phenothiazine with actions similar to CHLORPROMAZINE but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic.. promazine : A phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position.		2.0410phenothiazines;
tertiary amine		antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
serotonergic antagonist
promethazine
Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.. promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.		4.2650phenothiazines;
tertiary amine		anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative
propafenone
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.. propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.		4.2450aromatic ketone;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug
propantheline
Propantheline: A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.		3.2310xanthenes
propofol
Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.. propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.		4.0640phenolsanticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative
propranolol
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.		9.7890naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
protriptyline
Protriptyline: Tricyclic antidepressant similar in action and side effects to IMIPRAMINE. It may produce excitation.		3.2310carbotricyclic compoundantidepressant
pyridinolcarbamate
Pyridinolcarbamate: A drug that has been given by mouth in the treatment of atherosclerosis and other vascular disorders, hyperlipidemias, and thrombo-embolic disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1408)		2.0510pyridines
pyridostigmine
[no description available]		4.0840pyridinium ion
pyrilamine
Pyrilamine: A histamine H1 antagonist. It has mild hypnotic properties and some local anesthetic action and is used for allergies (including skin eruptions) both parenterally and locally. It is a common ingredient of cold remedies.. mepyramine : An ethylenediamine derivative that is ethylenediamine in which one of the amino nitrogens is substituted by two methyl groups and the remaining amino nitrogen is substituted by a 4-methoxybenzyl and a pyridin-2-yl group.		2.0710aromatic ether;
ethylenediamine derivative		H1-receptor antagonist
pyrimethamine
Maloprim: contains above 2 cpds		3.8630aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
sch 16134
quazepam: structure given in first source		3.5620benzodiazepine
quetiapine
[no description available]		3.5920dibenzothiazepine;
N-alkylpiperazine;
N-arylpiperazine		adrenergic antagonist;
dopaminergic antagonist;
histamine antagonist;
second generation antipsychotic;
serotonergic antagonist
rabeprazole
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.		3.8530benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
raloxifene
raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.		3.6201-benzothiophenes;
aromatic ketone;
N-oxyethylpiperidine;
phenols		bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
ranitidine
[no description available]		3.4470aralkylamine
opc 12759
rebamipide: structure in first source; RN refers to (+-)-isomer; inhibits gastric xanthine oxidase		2.0510secondary carboxamide
riluzole
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.		4.0840benzothiazoles
rimantadine
Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.		3.5620alkylamine
risperidone
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.. risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.		9.55701,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist
rizatriptan
rizatriptan: structure given in first source; RN given refers to benzoate		3.8530tryptaminesanti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
rofecoxib
[no description available]		2.4720butenolide;
sulfone		analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
ropinirole
[no description available]		3.2310indolones;
tertiary amine		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
dopamine agonist
s-methylisothiopseudouronium
S-methylisothiopseudouronium: inhibits nitric oxide synthase; structure in first source		2.0110
saccharin
Saccharin: Flavoring agent and non-nutritive sweetener.. saccharin : A 1,2-benzisothiazole having a keto-group at the 3-position and two oxo substituents at the 1-position. It is used as an artificial sweetening agent.		2.06101,2-benzisothiazole;
N-sulfonylcarboxamide		environmental contaminant;
sweetening agent;
xenobiotic
salicylamide
salamide: a major impurity of hydrochlorothiazide; structure in first source		2.0510phenols;
salicylamides		antirheumatic drug;
non-narcotic analgesic
salmeterol xinafoate
salmeterol : A racemate consisting of equal parts of (R)- and (S)-salmeterol. It is a potent and selective beta2-adrenoceptor agonist (EC50 = 5.3 nM). Unlike other beta2 agonists, it binds to the exo-site domain of beta2 receptors, producing a slow onset of action and prolonged activation.. 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol : A phenol having a hydroxymethyl group at C-2 and a 1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl group at C-4; derivative of phenylethanolamine.		2.0210ether;
phenols;
primary alcohol;
secondary alcohol;
secondary amino compound
salicylsalicylic acid
salicylsalicylic acid: structure. salsalate : A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes.		3.2310benzoate ester;
benzoic acids;
phenols;
salicylates		antineoplastic agent;
antirheumatic drug;
EC 3.5.2.6 (beta-lactamase) inhibitor;
hypoglycemic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
secobarbital
Secobarbital: A barbiturate that is used as a sedative. Secobarbital is reported to have no anti-anxiety activity.. secobarbital : A member of the class of barbiturates that is barbituric acid in which the hydrogens at position 5 are substituted by prop-2-en-1-yl and pentan-2-yl groups.		3.2310barbituratesanaesthesia adjuvant;
GABA modulator;
sedative
sevoflurane
Sevoflurane: A non-explosive inhalation anesthetic used in the induction and maintenance of general anesthesia. It does not cause respiratory irritation and may also prevent PLATELET AGGREGATION.. sevoflurane : An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups.		2.4420ether;
organofluorine compound		central nervous system depressant;
inhalation anaesthetic;
platelet aggregation inhibitor
sibutramine
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride		3.5920organochlorine compound;
tertiary amino compound		anti-obesity agent;
serotonin uptake inhibitor
sulfadiazine
Sulfadiazine: One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.. sulfadiazine : A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.. diazine : The parent structure of the diazines.		4.4160pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
antimicrobial agent;
antiprotozoal drug;
coccidiostat;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic
risedronic acid
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.		4.2650pyridines
sotalol
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.. sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.		4.6680ethanolamines;
secondary alcohol;
secondary amino compound;
sulfonamide		anti-arrhythmia drug;
beta-adrenergic antagonist;
environmental contaminant;
xenobiotic
4-phenylbutyric acid, sodium salt
sodium phenylbutyrate : The organic sodium salt of 4-phenylbutyric acid. A prodrug for phenylacetate, it is used to treat urea cycle disorders.		2.0510organic sodium saltEC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector;
neuroprotective agent;
orphan drug;
prodrug
imatinib
[no description available]		4.0840aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines		antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
vorinostat
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).		4.0840dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
succinylcholine
Succinylcholine: A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for.. succinylcholine : A quaternary ammonium ion that is the bis-choline ester of succinic acid.		3.2310quaternary ammonium ion;
succinate ester		drug allergen;
muscle relaxant;
neuromuscular agent
succinylsulfathiazole
succinylsulfathiazole: intestinal antimicrobial agent; structure		2.06101,3-thiazoles
sulconazole
sulconazole: RN given refers to cpd with unspecified isomeric designation; structure given in first source. sulconazole : A racemate comprising equimolar amounts of (R)- and (S)-sulconazole. An antifungal agent with activity against Candida species, it is used (generally as the nitrate salt) for the topical treatment of fungal skin infections.. 1-{2-[(4-chlorobenzyl)sulfanyl]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole : A member of the class of imidazoles that is 1-ethyl-1H-imidazole in which one of the hydrogens of the methyl group is replaced by a (4-chlorobenzyl)sulfanediyl group while a second is replaced by a 2,4-dichlorophenyl group.		2.0210dichlorobenzene;
imidazoles;
monochlorobenzenes;
organic sulfide
sulfadimethoxine
Sulfadimethoxine: A sulfanilamide that is used as an anti-infective agent.. sulfadimethoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 2- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position.		2.0510aromatic ether;
pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
antimicrobial agent;
drug allergen;
environmental contaminant;
xenobiotic
sulfamerazine
[no description available]		2.0510pyrimidines;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen
sulfameter
Sulfameter: Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections.. sulfamethoxydiazine : A sulfonamide consisting of pyrimidine having a methoxy substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 2-position.		2.0510pyrimidines;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
leprostatic drug;
renal agent
sulfamethazine
Sulfamethazine: A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.. sulfamethazine : A sulfonamide consisting of pyrimidine with methyl substituents at the 4- and 6-positions and a 4-aminobenzenesulfonamido group at the 2-position.		2.0510pyrimidines;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
antiinfective agent;
antimicrobial agent;
carcinogenic agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
ligand;
xenobiotic
sulfamethizole
Sulfamethizole: A sulfathiazole antibacterial agent.. sulfamethizole : A sulfonamide consisting of a 1,3,4-thiadiazole nucleus with a methyl substituent at C-5 and a 4-aminobenzenesulfonamido group at C-2.		3.5920sulfonamide antibiotic;
sulfonamide;
thiadiazoles		antiinfective agent;
antimicrobial agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfamethoxazole
Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208). sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.		4.09140isoxazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
antiinfective agent;
antimicrobial agent;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
epitope;
P450 inhibitor;
xenobiotic
sulfanilamide
[no description available]		2.0510substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
drug allergen;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
sulfanitran
[no description available]		2.0810sulfonamide
sulfaphenazole
Sulfaphenazole: A sulfonilamide anti-infective agent.. sulfaphenazole : A sulfonamide that is sulfanilamide in which the sulfonamide nitrogen is substituted by a 1-phenyl-1H-pyrazol-5-yl group. It is a selective inhibitor of cytochrome P450 (CYP) 2C9 isozyme, and antibacterial agent.		2.4720primary amino compound;
pyrazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor;
P450 inhibitor
sulfapyridine
Sulfapyridine: Antibacterial, potentially toxic, used to treat certain skin diseases.. sulfapyridine : A sulfonamide consisting of pyridine with a 4-aminobenzenesulfonamido group at the 2-position.		2.0510pyridines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
dermatologic drug;
drug allergen;
environmental contaminant;
xenobiotic
sulfasalazine
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.		4.2650
sulfathiazole
Sulfathiazole: A sulfathiazole compound that is used as a short-acting anti-infective agent. It is no longer commonly used systemically due to its toxicity, but may still be applied topically in combination with other drugs for the treatment of vaginal and skin infections, and is still used in veterinary medicine.. sulfathiazole : A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position.		3.23101,3-thiazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic
sulfinpyrazone
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.		2.7430pyrazolidines;
sulfoxide		uricosuric drug
sulfisoxazole
Sulfisoxazole: A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.. sulfisoxazole : A sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms.		2.7530isoxazoles;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
drug allergen
2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol
[no description available]		3.5920alkylbenzene
sulpiride
Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed). sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.		2.9740benzamides;
N-alkylpyrrolidine;
sulfonamide		antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
sultopride
[no description available]		2.0610salicylamides
sumatriptan
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.. sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.		4.2550sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent
suprofen
Suprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic.. suprofen : An aromatic ketone that is thiophene substituted at C-2 by a 4-(1-carboxyethyl)benzoyl group.		2.9540aromatic ketone;
monocarboxylic acid;
thiophenes		antirheumatic drug;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
suramin
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.		2.7430naphthalenesulfonic acid;
phenylureas;
secondary carboxamide		angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
gatifloxacin
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.		4.17160N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
tazarotene
tazarotene: a topical acetylenic retinoid; a topical kerytolytic. tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.		2.4520acetylenic compound;
ethyl ester;
pyridines;
retinoid;
thiochromane		keratolytic drug;
prodrug;
teratogenic agent
tegafur
[no description available]		2.0510organohalogen compound;
pyrimidines
temazepam
Temazepam: A benzodiazepine that acts as a GAMMA-AMINOBUTYRIC ACID modulator and anti-anxiety agent.		3.8530benzodiazepine
temozolomide
[no description available]		4.0840imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
terazosin
Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia		4.4160furans;
piperazines;
primary amino compound;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
terbutaline
Terbutaline: A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.. terbutaline : A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group.		4.4260phenylethanolamines;
resorcinols		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hypoglycemic agent;
sympathomimetic agent;
tocolytic agent
terfenadine
Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.		2.7430diarylmethane
tetracaine
Tetracaine: A potent local anesthetic of the ester type used for surface and spinal anesthesia.. tetracaine : A benzoate ester in which 4-N-butylbenzoic acid and 2-(dimethylamino)ethanol have combined to form the ester bond; a local ester anaesthetic (ester caine) used for surface and spinal anaesthesia.		2.0510benzoate ester;
tertiary amino compound		local anaesthetic
thalidomide
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.		3.8630phthalimides;
piperidones
thiabendazole
Tresaderm: dermatologic soln containing dexamethasone, thiabendazole & neomycin sulfate		3.59201,3-thiazoles;
benzimidazole fungicide;
benzimidazoles		antifungal agrochemical;
antinematodal drug
thioridazine
Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.. thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.		4.5940phenothiazines;
piperidines		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
thiotepa
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).		4.2550aziridines
tiapride
[no description available]		2.0810benzamides
tiaprofenic acid
tiaprofenic acid: RN given refers to parent cpd; structure. tiaprofenic acid : An aromatic ketone that is thiophene substituted at C-2 by benzoyl and at C-4 by a 1-carboxyethyl group.		2.0510aromatic ketone;
monocarboxylic acid;
thiophenes		drug allergen;
non-steroidal anti-inflammatory drug
ticlopidine
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.. ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.		4.0740monochlorobenzenes;
thienopyridine		anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
tilorone
Tilorone: An antiviral agent used as its hydrochloride. It is the first recognized synthetic, low-molecular-weight compound that is an orally active interferon inducer, and is also reported to have antineoplastic and anti-inflammatory actions.. tilorone : A member of the class of fluoren-9-ones that is 9H-fluoren-9-one which is substituted by a 2-(diethylamino)ethoxy group at positions 2 and 7. It is an interferon inducer and a selective alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonist. Its hydrochloride salt is used as an antiviral drug.		2.0810aromatic ether;
diether;
fluoren-9-ones;
tertiary amino compound		anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
interferon inducer;
nicotinic acetylcholine receptor agonist
tinidazole
Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.. tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.		4.2650imidazolesantiamoebic agent;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
tioconazole
tioconazole : A racemate comprising equimolar amounts of (R)- and (S)-tioconazole.. 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole : A member of the class of imidazoles that comprises 2-(2,4-dichlorophenyl)ethylimidazole carrying an additional (2-chloro-3-thienyl)methoxy substituent at position 2.		2.0210dichlorobenzene;
ether;
imidazoles;
thiophenes
tiopronin
Tiopronin: Sulfhydryl acylated derivative of GLYCINE.		3.8530N-acyl-amino acid
tizanidine
tizanidine: RN given refers to parent cpd; structure. tizanidine : 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.		4.4160benzothiadiazole;
imidazoles		alpha-adrenergic agonist;
muscle relaxant
nikethamide
Nikethamide: A central nervous system stimulant. It was formerly used in the treatment of barbiturate overdose but is now considered to be of no value for such purposes and may be dangerous. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1229)		2.0810pyridinecarboxamide
tolazamide
Tolazamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE.. tolazamide : An N-sulfonylurea that is 1-tosylurea in which a hydrogen attached to the nitrogen at position 3 is replaced by an azepan-1-yl group. A hypoglycemic agent, it is used for the treatment of type 2 diabetes mellitus.		3.5920N-sulfonylureahypoglycemic agent;
potassium channel blocker
tolbutamide
Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.		4.4260N-sulfonylureahuman metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker
tolmetin
Tolmetin: A non-steroidal anti-inflammatory agent (ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL) similar in mode of action to INDOMETHACIN.. tolmetin : A monocarboxylic acid that is (1-methylpyrrol-2-yl)acetic acid substituted at position 5 on the pyrrole ring by a 4-methylbenzoyl group. Used in the form of its sodium salt dihydrate as a nonselective nonsteroidal anti-inflammatory drug.		3.2310aromatic ketone;
monocarboxylic acid;
pyrroles		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
tolnaftate
[no description available]		2.0810monothiocarbamic esterantifungal drug
tolperisone
Tolperisone: A centrally acting muscle relaxant that has been used for the symptomatic treatment of spasticity and muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1211)		2.0510aromatic ketone
tosufloxacin
tosufloxacin: quinolone anti-infective agent; structure given in first source. tosufloxacin : A racemate comprising equimolar amounts of (R)- and (S)-tosufloxacin.. 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 3-aminopyrrolidin-1-yl substituents at positions 1, 6 and 7 respectively.		3.81211,8-naphthyridine derivative;
amino acid;
aminopyrrolidine;
monocarboxylic acid;
organofluorine compound;
primary amino compound;
quinolone antibiotic;
tertiary amino compound
ultram
2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol : A tertiary alcohol that is cyclohexanol substituted at positions 1 and 2 by 3-methoxyphenyl and dimethylaminomethyl groups respectively.		4.2550aromatic ether;
tertiary alcohol;
tertiary amino compound
tranexamic acid
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.		3.8630amino acid
trapidil
Trapidil: A coronary vasodilator agent.		2.0610triazolopyrimidines
trazodone
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309). trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.		4.2550monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine		adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
triamterene
Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.. triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.		4.0840pteridinesdiuretic;
sodium channel blocker
triazolam
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.		4.0640triazolobenzodiazepinesedative
triclosan
[no description available]		2.0510aromatic ether;
dichlorobenzene;
monochlorobenzenes;
phenols		antibacterial agent;
antimalarial;
drug allergen;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
fungicide;
persistent organic pollutant;
xenobiotic
trientine
Trientine: An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.. TETA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 8 and 11 of a fouteen-membered ring are each substituted with a carboxymethyl group.. 2,2,2-tetramine : A polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens.		2.0210polyazaalkane;
tetramine		copper chelator
trifluoperazine
[no description available]		3.5620N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines		antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug
triflupromazine
Triflupromazine: A phenothiazine used as an antipsychotic agent and as an antiemetic.. triflupromazine : A member of the class of phenothiazines that is 10H-phenothiazine having a trifluoromethyl subsitituent at the 2-position and a 3-(dimethylamino)propyl group at the N-10 position.		2.0510organofluorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
trihexyphenidyl
Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.		3.2310amine
trimethadione
Trimethadione: An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378). trimethadione : An oxazolidinone that is 1,3-oxazolidine-2,4-dione substituted by methyl groups at positions 3, 5 and 5. It is an antiepileptic agent.		4.0640oxazolidinoneanticonvulsant;
geroprotector
trimethobenzamide
trimethobenzamide: major descriptor (64-84); on-line search BENZAMIDES (64-84); Index Medicus search TRIMETHOBENZAMIDE (64-84); RN given refers to parent cpd. trimethobenzamide : The amide obtained by formal condensation of 3,4,5-trihydroxybenzoic acid with 4-[2-(N,N-dimethylamino)ethoxy]benzylamine. It is used to prevent nausea and vomitting in humans.		3.2310benzamides;
tertiary amino compound		antiemetic
trimethoprim
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.		6.12220aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
trimetrexate
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.		4.0640
trimipramine
Trimipramine: Tricyclic antidepressant similar to IMIPRAMINE, but with more antihistaminic and sedative properties.. trimipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant.		3.8430dibenzoazepine;
tertiary amino compound		antidepressant;
environmental contaminant;
xenobiotic
troglitazone
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.		4.2650chromanes;
thiazolidinone		anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent
thenoyltrifluoroacetone
Thenoyltrifluoroacetone: Chelating agent and inhibitor of cellular respiration.		2.0810
tyramine
[no description available]		3.2310monoamine molecular messenger;
primary amino compound;
tyramines		EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter
delavirdine
Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.		3.2310aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide		antiviral drug;
HIV-1 reverse transcriptase inhibitor
undecylenic acid
undecylenic acid: a fatty acid with a terminal double bond. 10-undecenoic acid : An undecenoic acid having its double bond in the 10-position. It is derived from castor oil and is used for the treatment of skin problems.. undecenoic acid : A C11, straight-chain fatty acid carrying a C=C double bond at any position.		2.0810undecenoic acidantifungal drug;
plant metabolite
urapidil
[no description available]		2.7530piperazines
venlafaxine
venlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group.		4.5470cyclohexanols;
monomethoxybenzene;
tertiary alcohol;
tertiary amino compound		adrenergic uptake inhibitor;
analgesic;
antidepressant;
dopamine uptake inhibitor;
environmental contaminant;
serotonin uptake inhibitor;
xenobiotic
vesnarinone
[no description available]		2.0510organic molecular entity
vigabatrin
[no description available]		3.8730gamma-amino acidanticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
viloxazine
Viloxazine: A morpholine derivative used as an antidepressant. It is similar in action to IMIPRAMINE.		2.0410aromatic ether
pirinixic acid
pirinixic acid: structure		2.0810aryl sulfide;
organochlorine compound;
pyrimidines
ici 204,219
zafirlukast: a leukotriene D4 receptor antagonist		4.2650carbamate ester;
indoles;
N-sulfonylcarboxamide		anti-asthmatic agent;
leukotriene antagonist
zaleplon
zaleplon: an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; a hypnotic with less marked effect on psychomotor functions compared to lorazepam. zaleplon : A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.		4.0840nitrile;
pyrazolopyrimidine		anticonvulsant;
anxiolytic drug;
central nervous system depressant;
sedative
zolpidem
Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.. zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.		4.460imidazopyridinecentral nervous system depressant;
GABA agonist;
sedative
zomepirac
zomepirac: RN given refers to parent cpd; structure		2.4420aromatic ketone;
monocarboxylic acid;
monochlorobenzenes;
pyrroles		cardiovascular drug;
non-steroidal anti-inflammatory drug
zonisamide
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.. zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.		3.61201,2-benzoxazoles;
sulfonamide		anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker
zopiclone
zopiclone: S(+)-enantiomer of racemic zopiclone; azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; was term of zopiclone 2004-2007. zopiclone : A pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position.		2.7530monochloropyridine;
pyrrolopyrazine		central nervous system depressant;
sedative
guanidine hydrochloride
[no description available]		2.0510one-carbon compound;
organic chloride salt		protein denaturant
hydrocortisone acetate
hydrocortisone acetate: RN given refers to cpd without isomeric designation		2.0510cortisol ester;
tertiary alpha-hydroxy ketone
cortisone acetate
Cortisone Acetate: The acetate ester of cortisone that is used mainly for replacement therapy in adrenocortical insufficiency and in the treatment of many allergic and inflammatory disorders.		3.5920corticosteroid hormone
mitomycin
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.		4.1140mitomycinalkylating agent;
antineoplastic agent
prednisolone
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.		6.0514011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
estriol
hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone. chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.		2.472016alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid		estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite
reserpine
Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.		3.8730alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
cephaloridine
Cephaloridine: A cephalosporin antibiotic.. cefaloridine : A cephalosporin compound having pyridinium-1-ylmethyl and 2-thienylacetamido side-groups. A first-generation semisynthetic derivative of cephalosporin C.		4.05140beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
phentolamine
Phentolamine: A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.. phentolamine : A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used for the treatment of hypertension.		3.5920imidazoles;
phenols;
substituted aniline;
tertiary amino compound		alpha-adrenergic antagonist;
vasodilator agent
sorbitol
D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).		3.5920glucitolcathartic;
Escherichia coli metabolite;
food humectant;
human metabolite;
laxative;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite;
sweetening agent
floxuridine
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.		2.7430nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent
piperonyl butoxide
[no description available]		2.0510benzodioxolespesticide synergist
bromouracil
Bromouracil: 5-Bromo-2,4(1H,3H)-pyrimidinedione. Brominated derivative of uracil that acts as an antimetabolite, substituting for thymine in DNA. It is used mainly as an experimental mutagen, but its deoxyriboside (BROMODEOXYURIDINE) is used to treat neoplasms.. 5-bromouracil : A pyrimidine having keto groups at the 2- and 4-positions and a bromo group at the 5-position. Used mainly as an experimental mutagen.		2.0510nucleobase analogue;
pyrimidines		mutagen
3,3',5-triiodothyroacetic acid
tiratricol : A monocarboxylic acid that is (4-hydroxy-3,5-diiodophenyl)acetic acid in which the phenolic hydroxy group has been replaced by a 4-hydroxy-3-iodophenoxy group. It is a thyroid hormone analogue that has been used in the treatment of thyroid hormone resistance syndrome.		2.0510
histamine dihydrochloride
Ceplene: Tradename for histamine dihydrochloride.		2.0510
thyroxine
Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.. thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.		3.59202-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine		antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone
dextroamphetamine
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.. (S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.		3.59201-phenylpropan-2-amineadrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent
carbachol
Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.		2.0510ammonium salt;
carbamate ester		cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic
norethindrone acetate
norethisterone acetate : A 3-oxo Delta(4)-steroid that is norethisterone in which the hydroxy group has been converted to its acetate ester.		2.05103-oxo-Delta(4) steroid;
acetate ester;
terminal acetylenic compound		progestin;
synthetic oral contraceptive
spironolactone
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827). spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.		3.85303-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester		aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
cyclobarbital
cyclobarbital: was heading 1977-94 (see under BARBITURATES 1977-90); CYCLOBARBITONE, HEXEMAL, & TETRAHYDROPHENOBARBITAL were see CYCLOBARBITAL 1977-94; use BARBITURATES to search CYCLOBARBITAL 1977-94; short to intermediate duration barbiturate used as hypnotic and sedative		2.0510barbiturates
allobarbital
allobarbital: was heading 1976-94 (see under BARBITURATES 1976-90); ALLOBARBITONE, DIALLYLBARBITAL, DIALLYLBARBITURIC ACID, & DIALLYLMAL were see ALLOBARBITAL 1976-94; use BARBITURATES to search ALLOBARBITAL 1976-94; a barbiturate derivative with effects of intermediate duration; at lower doses, it is used as a sedative; at higher doses, it displays hypnotic effects		2.0510barbiturates
penicillamine
Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.. penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.		4.0840non-proteinogenic alpha-amino acid;
penicillamine		antirheumatic drug;
chelator;
copper chelator;
drug allergen
trichlorfon
Trichlorfon: An organochlorophosphate cholinesterase inhibitor that is used as an insecticide for the control of flies and roaches. It is also used in anthelmintic compositions for animals. (From Merck, 11th ed). trichlorfon : A phosphonic ester that is dimethyl phosphonate in which the hydrogen atom attched to the phosphorous is substituted by a 2,2,2-trichloro-1-hydroxyethyl group.		2.0510organic phosphonate;
organochlorine compound;
phosphonic ester		agrochemical;
anthelminthic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
insecticide
cysteine
[no description available]		3.2310cysteine zwitterion;
cysteine;
L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid		EC 4.3.1.3 (histidine ammonia-lyase) inhibitor;
flour treatment agent;
human metabolite
prednisone
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.		5.269011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug
estrone
Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.		3.592017-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
oxandrolone
Oxandrolone: A synthetic hormone with anabolic and androgenic properties.		3.592017beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid;
oxa-steroid		anabolic agent;
androgen
dehydroepiandrosterone
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.. dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.		2.051017-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
androstanoid		androgen;
human metabolite;
mouse metabolite
nad
[no description available]		2.0510NADgeroprotector
penicillin g
Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.		9.47672penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope
metaraminol
Metaraminol: A sympathomimetic agent that acts predominantly at alpha-1 adrenergic receptors. It has been used primarily as a vasoconstrictor in the treatment of HYPOTENSION.. metaraminol : A member of the class of phenylethanolamines that is 2-amino-1-phenylethanol substituted by a methyl group at position 2 and a phenolic hydroxy group at position 1. A sympathomimetic agent , it is used in the treatment of hypotension.		2.0710phenylethanolaminesalpha-adrenergic agonist;
sympathomimetic agent;
vasoconstrictor agent
pilocarpine
Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.. (+)-pilocarpine : The (+)-enantiomer of pilocarpine.		3.8530pilocarpineantiglaucoma drug
pentylenetetrazole
Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.. pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.		3.1350organic heterobicyclic compound;
organonitrogen heterocyclic compound
triiodothyronine
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.. 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.		3.87302-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine		human metabolite;
mouse metabolite;
thyroid hormone
isoflurophate
Isoflurophate: A di-isopropyl-fluorophosphate which is an irreversible cholinesterase inhibitor used to investigate the NERVOUS SYSTEM.		2.0610dialkyl phosphate
biguanides
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.. biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.		3.2310guanidines
carbon tetrachloride
Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.		2.0810chlorocarbon;
chloromethanes		hepatotoxic agent;
refrigerant
cantharidin
Cantharidin: A toxic compound, isolated from the Spanish fly or blistering beetle (Lytta (Cantharis) vesicatoria) and other insects. It is a potent and specific inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). This compound can produce severe skin inflammation, and is extremely toxic if ingested orally.. cantharidin : A monoterpenoid with an epoxy-bridged cyclic dicarboxylic anhydride structure secreted by many species of blister beetle, and most notably by the Spanish fly, Lytta vesicatoria. Natural toxin inhibitor of protein phosphatases 1 and 2A.		7.0110cyclic dicarboxylic anhydride;
monoterpenoid		EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
herbicide
alanine
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.		2.0310alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
serine
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.		2.7930L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
chloramphenicol
Amphenicol: Chloramphenicol and its derivatives.		6.71410C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
aspartic acid
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.		2.520aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter
glutamine
Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.		3.8530amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
lysine
Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.		2.730aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
cetrimonium bromide
cetyltrimethylammonium bromide : The organic bromide salt that is the bromide salt of cetyltrimethylammonium; one of the components of the topical antiseptic cetrimide.		2.0510organic bromide salt;
quaternary ammonium salt		detergent;
surfactant
vincristine
[no description available]		4.2450acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
physostigmine
Physostigmine: A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.		3.5920carbamate ester;
indole alkaloid		antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic
sucrose
Saccharum: A plant genus of the family POACEAE widely cultivated in the tropics for the sweet cane that is processed into sugar.		2.4920glycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent
ethinyl estradiol
Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.		3.155017-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
testosterone propionate
Testosterone Propionate: An ester of TESTOSTERONE with a propionate substitution at the 17-beta position.. androgen : A sex hormone that stimulates or controls the development and maintenance of masculine characteristics in vertebrates by binding to androgen receptors.		2.4420steroid ester
tubocurarine
Tubocurarine: A neuromuscular blocker and active ingredient in CURARE; plant based alkaloid of Menispermaceae.. tubocurarine : A benzylisoquinoline alkaloid muscle relaxant which constitutes the active component of curare.. isoquinoline alkaloid : Any alkaloid that has a structure based on an isoquinoline nucleus. They are derived from the amino acids like tyrosine and phenylalanine.		2.0810bisbenzylisoquinoline alkaloiddrug allergen;
muscle relaxant;
nicotinic antagonist
apomorphine
Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.		4.0840aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
aminopyrine
Aminopyrine: A pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of AGRANULOCYTOSIS. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of CYTOCHROME P-450 metabolic activity in LIVER FUNCTION TESTS.. aminophenazone : A pyrazolone that is 1,2-dihydro-3H-pyrazol-3-one substituted by a dimethylamino group at position 4, methyl groups at positions 1 and 5 and a phenyl group at position 2. It exhibits analgesic, anti-inflammatory, and antipyretic properties.		2.7630pyrazolone;
tertiary amino compound		antipyretic;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
methyltestosterone
Methyltestosterone: A synthetic hormone used for androgen replacement therapy and as an hormonal antineoplastic agent (ANTINEOPLASTIC AGENTS, HORMONAL).. methyltestosterone : A 17beta-hydroxy steroid that is testosterone bearing a methyl group at the 17alpha position.		3.592017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
enone		anabolic agent;
androgen;
antineoplastic agent
tetrabenazine
9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one : A benzoquinolizine that is 1,2,3,4,4a,9,10,10a-octahydrophenanthrene in which the carbon at position 10a is replaced by a nitrogen and which is substituted by an isobutyl group at position 2, an oxo group at position 3, and methoxy groups at positions 6 and 7.		3.5920benzoquinolizine;
cyclic ketone;
tertiary amino compound
adenosine diphosphate
Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.		210adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite
cephalothin
Cephalothin: A cephalosporin antibiotic.. cefalotin : A semisynthetic, first-generation cephalosporin antibiotic with acetoxymethyl and (2-thienylacetyl)nitrilo moieties at positions 3 and 7, respectively, of the core structure. Administered parenterally during surgery and to treat a wide spectrum of blood infections.		5.14430azabicycloalkene;
beta-lactam antibiotic allergen;
carboxylic acid;
cephalosporin;
semisynthetic derivative;
thiophenes		antibacterial drug;
antimicrobial agent
uridine
[no description available]		2.0510uridinesdrug metabolite;
fundamental metabolite;
human metabolite
kanamycin a
Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.		5.45180kanamycinsbacterial metabolite
galactose
galactopyranose : The pyranose form of galactose.		2.1310D-galactose;
galactopyranose		Escherichia coli metabolite;
mouse metabolite
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		3.89120monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
phenylephrine
Phenylephrine: An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent.. phenylephrine : A member of the class of the class of phenylethanolamines that is (1R)-2-(methylamino)-1-phenylethan-1-ol carrying an additional hydroxy substituent at position 3 on the phenyl ring.		2.0510phenols;
phenylethanolamines;
secondary amino compound		alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent
levodopa
Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease		3.1450amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug
edetic acid
Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.		5.34160ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector
cysteamine
Cysteamine: A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS.. cysteamine : An amine that consists of an ethane skeleton substituted with a thiol group at C-1 and an amino group at C-2.		3.2310amine;
thiol		geroprotector;
human metabolite;
mouse metabolite;
radiation protective agent
acetylcholine chloride
acetylcholine chloride : The chloride salt of acetylcholine, and a parasympatomimetic drug.		3.2310quaternary ammonium salt
mepazine
mepazine: major descriptor (66-85); on-line search PHENOTHIAZINES (66-85); Index Medicus search MEPAZINE (66-85); RN given refers to parent cpd. pacatal : A phenothiazine derivative in which 10H-phenothiazine has an N-methylpiperidin-4-ylmethyl substituent at the N-10 position.		3.2310phenothiazines
adenosine monophosphate
Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.		2.4110adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
methicillin
Methicillin: One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.. methicillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.		3.84110penicillin allergen;
penicillin		antibacterial drug
niridazole
Niridazole: An antischistosomal agent that has become obsolete.		2.05101,3-thiazoles;
C-nitro compound
cloxacillin
Cloxacillin: A semi-synthetic antibiotic that is a chlorinated derivative of OXACILLIN.. cloxacillin : A semisynthetic penicillin antibiotic carrying a 3-(2-chlorophenyl)-5-methylisoxazole-4-carboxamido group at position 6.		5.82160penicillin allergen;
penicillin;
semisynthetic derivative		antibacterial agent;
antibacterial drug
bretylium tosylate
Bretylium Tosylate: An agent that blocks the release of adrenergic transmitters and may have other actions. It was formerly used as an antihypertensive agent, but is now proposed as an anti-arrhythmic.. bretylium tosylate : The tosylate salt of bretylium. It blocks noradrenaline release from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation.		2.0210organosulfonate salt;
quaternary ammonium salt		adrenergic antagonist;
anti-arrhythmia drug;
antihypertensive agent
zoxazolamine
Zoxazolamine: A uricosuric and muscle relaxant. Zoxazolamine acts centrally as a muscle relaxant, but the mechanism of its action is not understood.		2.0710benzoxazole
leucine
Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.		4.0640amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
calcium acetate
calcium acetate: a principal compound used as phosphate binders in patients with chronic renal failure; used like sevelamer. calcium acetate : The calcium salt of acetic acid. It is used, commonly as a hydrate, to treat hyperphosphataemia (excess phosphate in the blood) in patients with kidney disease: the calcium ion combines with dietary phosphate to form (insoluble) calcium phosphate, which is excreted in the faeces.		3.2310calcium saltchelator
carbaryl
Carbaryl: A carbamate insecticide and parasiticide. It is a potent anticholinesterase agent belonging to the carbamate group of reversible cholinesterase inhibitors. It has a particularly low toxicity from dermal absorption and is used for control of head lice in some countries.. carbaryl : A carbamate ester obtained by the formal condensation of 1-naphthol with methylcarbamic acid.		2.0510carbamate ester;
naphthalenes		acaricide;
agrochemical;
carbamate insecticide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant growth retardant
lactose
Lactose: A disaccharide of GLUCOSE and GALACTOSE in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.. lactose : A glycosylglucose disaccharide, found most notably in milk, that consists of D-galactose and D-glucose fragments bonded through a beta-1->4 glycosidic linkage. The glucose fragment can be in either the alpha- or beta-pyranose form, whereas the galactose fragment can only have the beta-pyranose form.. beta-lactose : The beta-anomer of lactose.		2.5220lactose
methionine
Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.		3.5920aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
Mebutamate
[no description available]		2.0510organic molecular entity
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		4.2750alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
mebanazine
mebanazine: RN given refers to parent cpd without isomeric designation; structure		3.2310benzenes
oxacillin
Oxacillin: An antibiotic similar to FLUCLOXACILLIN used in resistant staphylococci infections.. oxacillin : A penicillin antibiotic carrying a 5-methyl-3-phenylisoxazole-4-carboxamide group at position 6beta.		7.75281penicillinantibacterial agent;
antibacterial drug
triamcinolone diacetate
triamcinolone diacetate: lysyl oxidase antagonist; Polcortolon may also refers to triamcinolone		2.0810corticosteroid hormone
norethindrone
Norethindrone: A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION.. norethisterone : A 17beta-hydroxy steroid that is testosterone in which the hydrogen at position 17 is replaced by an ethynyl group and in which the methyl group attached to position 10 is replaced by hydrogen.		2.051017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol		progestin;
synthetic oral contraceptive
norethynodrel
Norethynodrel: A synthetic progestational hormone with actions and uses similar to those of PROGESTERONE. It has been used in the treatment of functional uterine bleeding and ENDOMETRIOSIS. As a contraceptive (CONTRACEPTIVE AGENTS), it has usually been administered in combination with MESTRANOL.		2.0510oxo steroid
cycloserine
Cycloserine: Antibiotic substance produced by Streptomyces garyphalus.. D-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has R configuration. It is an antibiotic produced by Streptomyces garyphalus or S. orchidaceus and is used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed. An analogue of D-alanine, it interferes with bacterial cell wall synthesis in the cytoplasm by competitive inhibition of L-alanine racemase (which forms D-alanine from L-alanine) and D-alanine--D-alanine ligase (which incorporates D-alanine into the pentapeptide required for peptidoglycan formation and bacterial cell wall synthesis).		4.64404-amino-1,2-oxazolidin-3-one;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic;
zwitterion		antiinfective agent;
antimetabolite;
antitubercular agent;
metabolite;
NMDA receptor agonist
benziodarone
benziodarone: minor descriptor (75-89); on-line & INDEX MEDICUS search BENZOFURANS (68-89) & IODOBENZOATES (74)		3.5920aromatic ketone
ampicillin
Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.		10.631541beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
mannitol
[no description available]		4.1140mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent
cytarabine
[no description available]		4.4160beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
trifluridine
Trifluridine: An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557). trifluridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis.		2.4820nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor
histidine
Histidine: An essential amino acid that is required for the production of HISTAMINE.. L-histidine : The L-enantiomer of the amino acid histidine.. histidine : An alpha-amino acid that is propanoic acid bearing an amino substituent at position 2 and a 1H-imidazol-4-yl group at position 3.		2.1710amino acid zwitterion;
histidine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
medroxyprogesterone acetate
[no description available]		2.743020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester		adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive
mestranol
[no description available]		2.743017beta-hydroxy steroid;
aromatic ether;
terminal acetylenic compound		prodrug;
xenoestrogen
methaqualone
Methaqualone: A quinazoline derivative with hypnotic and sedative properties. It has been withdrawn from the market in many countries because of problems with abuse. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604). methaqualone : A member of the class of quinazolines that is quinazolin-4-one substituted at positions 2 and 3 by methyl and o-tolyl groups respectively. A depressant that increases the activity of the GABA receptors in the brain and nervous system, it is used as a sedative and hypnotic medication. It became popular as a recreational drug and club drug in the late 1960s and 1970s.		2.0510quinazolinesGABA agonist;
sedative
trypan blue
VisionBlue: A trypan blue ophthalmic solution.		2.0510
chlorquinaldol
Chlorquinaldol: Local anti-infective agent used for skin, gastrointestinal, and vaginal infections with fungi, protozoa, and certain bacteria. In animals, it causes central nervous system damage and is not administered parenterally. It is also used as antiseptic, fungistat, or deodorant.. chlorquinaldol : A monohydroxyquinoline that is quinolin-8-ol which is substituted by a methyl group at position 2 and by chlorine at positions 5 and 7. An antifungal and antibacterial, it was formerly used for topical treatment of skin conditions and vaginal infections.		2.4110monohydroxyquinoline;
organochlorine compound		antibacterial drug;
antiprotozoal drug;
antiseptic drug
cordycepin
[no description available]		2.05103'-deoxyribonucleoside;
adenosines		antimetabolite;
nucleoside antibiotic
tryptophan
Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.		2.4320erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
arginine
Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.		3.8830arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
bromoethane
bromoethane : A bromoalkane that is ethane carrying a bromo substituent. It is an alkylating agent used as a chemical intermediate in various organic syntheses.		2.0510bromoalkane;
bromohydrocarbon;
volatile organic compound		alkylating agent;
carcinogenic agent;
local anaesthetic;
refrigerant;
solvent
ethylene oxide
Ethylene Oxide: A colorless and flammable gas at room temperature and pressure. Ethylene oxide is a bactericidal, fungicidal, and sporicidal disinfectant. It is effective against most micro-organisms, including viruses. It is used as a fumigant for foodstuffs and textiles and as an agent for the gaseous sterilization of heat-labile pharmaceutical and surgical materials. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p794). oxirane : A saturated organic heteromonocyclic parent that is a three-membered heterocycle of two carbon atoms and one oxygen atom.		7.0610gas molecular entity;
oxacycle;
saturated organic heteromonocyclic parent		allergen;
mouse metabolite;
mutagen
trichloroacetic acid
Trichloroacetic Acid: A strong acid used as a protein precipitant in clinical chemistry and also as a caustic for removing warts.. trichloroacetic acid : A monocarboxylic acid that is acetic acid in which all three methyl hydrogens are substituted by chlorine.		2.0510monocarboxylic acid;
organochlorine compound		carcinogenic agent;
metabolite;
mouse metabolite
perflutren
Definity: a fluorocarbon-filled ultrasonic contrast agent; Definity is tradename. octafluoropropane : A fluorocarbon that is propane in which all of the hydrogens have been replaced by fluorines.		3.2310fluoroalkane;
fluorocarbon
triamcinolone acetonide
Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.		2.753011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
fluoxymesterone
Fluoxymesterone: An anabolic steroid that has been used in the treatment of male HYPOGONADISM, delayed puberty in males, and in the treatment of breast neoplasms in women.		3.231011beta-hydroxy steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid;
fluorinated steroid		anabolic agent;
antineoplastic agent
bromcresol green
Bromcresol Green: An indicator and reagent. It has been used in serum albumin determinations and as a pH indicator.		2.2110benzofurans
allylpropymal
allylpropymal: RN given refers to parent cpd. aprobarbital : A member of the class of barbiturates that is pyrimidine-2,4,6(1H,3H,5H)-trione substituted by an isopropyl and a prop-1-en-3-yl group at position 5.		2.0510barbiturates
phencyclidine
Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.		2.7330benzenes;
piperidines		anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug
butobarbital
butobarbital: Butobarbital should be distinguished from Butabarbital (a synonym for Secbutabarbital)		2.0510barbiturates
methsuximide
methsuximide: anticonvulsant effective in petit mal & psychomotor epilepsy; has a number of unpleasant & toxic side effects; minor descriptor (75-86); on-line & INDEX MEDICUS search SUCCINIMIDES (75-86); RN given refers to parent cpd without isomeric designation		3.2310organic molecular entity
tromethamine
Tromethamine: An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)		3.2310primary amino compound;
triol		buffer
3-mercaptopropionic acid
3-Mercaptopropionic Acid: An inhibitor of glutamate decarboxylase. It decreases the GAMMA-AMINOBUTYRIC ACID concentration in the brain, thereby causing convulsions.. 3-mercaptopropanoic acid : A mercaptopropanoic acid that is propanoic acid carrying a sulfanyl group at position 3.		2.0510mercaptopropanoic acidalgal metabolite
isoprene
isoprene: used in manufacture of ''synthetic'' rubber, butyl rubber; copolymer in production of elastomers; structure. isoprene : A hemiterpene with the formula CH2=C(CH3)CH=CH2; the monomer of natural rubber and a common structure motif to the isoprenoids, a large class of other naturally occurring compounds.		2.6320alkadiene;
hemiterpene;
volatile organic compound		plant metabolite
trichloroethylene
Trichloroethylene: A highly volatile inhalation anesthetic used mainly in short surgical procedures where light anesthesia with good analgesia is required. It is also used as an industrial solvent. Prolonged exposure to high concentrations of the vapor can lead to cardiotoxicity and neurological impairment.. triol : A chemical compound containing three hydroxy groups.		2.0510chloroethenesinhalation anaesthetic;
mouse metabolite
propionamide
[no description available]		2.2110monocarboxylic acid amide;
primary fatty amide
dichloroacetic acid
[no description available]		2.0410monocarboxylic acid;
organochlorine compound		astringent;
marine metabolite
methylmethacrylate
Methylmethacrylate: The methyl ester of methacrylic acid. It polymerizes easily to form POLYMETHYL METHACRYLATE. It is used as a bone cement.. methyl methacrylate : An enoate ester having methacrylic acid as the carboxylic acid component and methanol as the alcohol component.		3.5911enoate ester;
methyl ester		allergen;
polymerisation monomer
dehydrocholic acid
Dehydrocholic Acid: A semisynthetic bile acid made from cholic acid. It is used as a cholagogue, hydrocholeretic, diuretic, and as a diagnostic aid.. 3,7,12-trioxo-5beta-cholanic acid : An oxo-5beta-cholanic acid in which three oxo substituents are located at positions 3, 7 and 12 on the cholanic acid skeleton.		2.051012-oxo steroid;
3-oxo-5beta-steroid;
7-oxo steroid;
oxo-5beta-cholanic acid		gastrointestinal drug
taurocholic acid
Taurocholic Acid: The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.. taurocholate : An organosulfonate oxoanion that is the conjugate base of taurocholic acid.. taurocholic acid : A bile acid taurine conjugate of cholic acid that usually occurs as the sodium salt of bile in mammals.		2.9640amino sulfonic acid;
bile acid taurine conjugate		human metabolite
rhodamine b
rhodamine B: RN & N1 from 9th CI Form Index; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7973; TETRAETHYLRHODAMINE was see RHODAMINES 1975-93; use RHODAMINES to search TETRAETHYLRHODAMINE 1975-93. rhodamine B : An organic chloride salt having N-[9-(2-carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene]-N-ethylethanaminium as the counterion. An amphoteric dye commonly used as a fluorochrome.		2.1510organic chloride salt;
xanthene dye		fluorescent probe;
fluorochrome;
histological dye
methylprednisolone
Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.		6.271406-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic
rotenone
Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.		2.0810organic heteropentacyclic compound;
rotenones		antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin
8-hydroxyquinoline-5-sulfonic acid
8-hydroxyquinoline-5-sulfonic acid: RN given refers to parent cpd		2.4110
benzoic anhydride
2-benzoylbenzoic acid: structure in first source		2.1110
pyocyanine
Pyocyanine: Antibiotic pigment produced by Pseudomonas aeruginosa.. pyocyanine : An iminium betaine that is 5-methylphenazin-5-ium which is substituted at position 1 by an oxidanidyl group. An antibiotic pigment produced by Pseudomonas aeruginosa.		2.4520iminium betaine;
phenazines		antibacterial agent;
bacterial metabolite;
biological pigment;
virulence factor
brompheniramine
Brompheniramine: Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.. brompheniramine : Pheniramine in which the hydrogen at position 4 of the phenyl substituent is substituted by bromine. A histamine H1 receptor antagonist, brompheniramine is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.		3.2310organobromine compound;
pyridines		anti-allergic agent;
H1-receptor antagonist
acriflavine chloride
3,6-diamino-10-methylacridinium chloride : The 10-methochloride salt of 3,6-diaminoacridine. Note that a mixture of this compound with 3,6-diaminoacridine (proflavine) is known as acriflavine or neutral acriflavine.		2.0310organic chloride saltantibacterial agent;
antiseptic drug;
carcinogenic agent;
histological dye;
intercalator
penicillin v
Penicillin V: A broad-spectrum penicillin antibiotic used orally in the treatment of mild to moderate infections by susceptible gram-positive organisms.. phenoxymethylpenicillin : A penicillin compound having a 6beta-(phenoxyacetyl)amino side-chain.		4.3860penicillin allergen;
penicillin
isosorbide dinitrate
Isosorbide Dinitrate: A vasodilator used in the treatment of ANGINA PECTORIS. Its actions are similar to NITROGLYCERIN but with a slower onset of action.		4.0740glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent
penicillanic acid
Penicillanic Acid: A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed). penicillanic acid : A penam that consists of 3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane bearing a carboxy group at position 2 and having (2S,5R)-configuration.		15.9412918penicillanic acids
xylitol
xylooligosaccharide: structure in first source. pentitol : An alditol obtained by reduction of any pentose.. xylooligosaccharide : An oligosaccharide comprised of xylose residues.		2.2510
thymol
Thymol: A phenol obtained from thyme oil or other volatile oils used as a stabilizer in pharmaceutical preparations, and as an antiseptic (antibacterial or antifungal) agent.. thymol : A phenol that is a natural monoterpene derivative of cymene.		2.4110monoterpenoid;
phenols		volatile oil component
pseudoephedrine
Pseudoephedrine: A phenethylamine that is an isomer of EPHEDRINE which has less central nervous system effects and usage is mainly for respiratory tract decongestion.. pseudoephedrine : A member of the class of the class of phenylethanolamines that is (1S)-2-(methylamino)-1-phenylethan-1-ol in which the pro-S hydrogen at position 2 is replaced by a methyl group.		3.2310phenylethanolamines;
secondary alcohol;
secondary amino compound		anti-asthmatic drug;
bronchodilator agent;
central nervous system drug;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
diethylpropion
Diethylpropion: A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290). diethylpropion : An aromatic ketone that is propiophenone in which one of the hydrogens alpha- to the carbonyl is substituted by a diethylamino group. A central stimulant and indirect-acting sympathomimetic, it is an appetite depressant and is used as the hydrochloride as an anoretic in the short term management of obesity.		3.2310aromatic ketone;
tertiary amine		appetite depressant
isatin
tribulin: endogenous MONOAMINE OXIDASE inhibitory activity extractable into ethyl acetate found in brain and many mammalian tissues and fluids; ISATIN is a major component; produced in excess following alcohol withdrawal;		2.610indoledioneEC 1.4.3.4 (monoamine oxidase) inhibitor;
plant metabolite
pyronine
Pyronine: Xanthene dye used as a bacterial and biological stain. Synonyms: Pyronin; Pyronine G; Pyronine Y. Use also for Pyronine B. which is diethyl-rather than dimethylamino-.. pyronin Y : An organic chloride salt having 6-(dimethylamino)-N,N-dimethyl-3H-xanthen-3-iminium as the cation. Used with methyl green to selectively demonstrate RNA (red) in contrast to DNA (green) with the Unna-Pappenheim method.		2.0510iminium salt;
organic chloride salt		histological dye
synephrine
[no description available]		2.0510ethanolamines;
phenethylamine alkaloid;
phenols		alpha-adrenergic agonist;
plant metabolite
benzoyl peroxide
Benzoyl Peroxide: A peroxide derivative that has been used topically for BURNS and as a dermatologic agent in the treatment of ACNE and POISON IVY DERMATITIS. It is used also as a bleach in the food industry.		2.0510carbonyl compound
benzonatate
benzonatate: structure in Merck Index, 9th ed, #1107. benzonatate : The ester obtained by formal condensation of 4-butylaminobenzoic acid with nonaethylene glycol monomethyl ether. Structurally related to procaine and benzocaine, it has an anaesthetic effect on the stretch sensors in the lungs, and is used as a non-narcotic cough suppressant.		3.2310benzoate ester;
secondary amino compound;
substituted aniline		anaesthetic;
antitussive
acrylonitrile
[no description available]		3.4111aliphatic nitrile;
volatile organic compound		antifungal agent;
carcinogenic agent;
fungal metabolite;
mutagen;
polar aprotic solvent
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		4.4651pyrrole;
secondary amine
furan
furan : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing four carbons and one oxygen, with formula C4H4O. It is a toxic, flammable, low-boiling (31degreeC) colourless liquid.		2.0510furans;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		carcinogenic agent;
hepatotoxic agent;
Maillard reaction product
ergotamine
Ergotamine: A vasoconstrictor found in ergot of Central Europe. It is a serotonin agonist that has been used as an oxytocic agent and in the treatment of MIGRAINE DISORDERS.. ergotamine : A peptide ergot alkaloid that is dihydroergotamine in which a double bond replaces the single bond between positions 9 and 10.		2.4520peptide ergot alkaloidalpha-adrenergic agonist;
mycotoxin;
non-narcotic analgesic;
oxytocic;
serotonergic agonist;
vasoconstrictor agent
estradiol dipropionate
estradiol dipropionate: RN given refers to (17beta)-isomer; RN for cpd without isomeric designation not in Chemline 7/83		2.0210steroid ester
methylergonovine
Methylergonovine: A homolog of ERGONOVINE containing one more CH2 group. (Merck Index, 11th ed)		3.2310ergoline alkaloid
neostigmine bromide
neostigmine bromide : The bromide salt of neostigmine.		2.7530bromide salt
phenformin
Phenformin: A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). phenformin : A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a 2-phenylethyl group. It was used as an anti-diabetic drug but was later withdrawn from the market due to potential risk of lactic acidosis.		2.4720biguanidesantineoplastic agent;
geroprotector;
hypoglycemic agent
mephobarbital
Mephobarbital: A barbiturate that is metabolized to PHENOBARBITAL. It has been used for similar purposes, especially in EPILEPSY, but there is no evidence mephobarbital offers any advantage over PHENOBARBITAL.. mephobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by ethyl and phenyl groups.		2.0510barbituratesanticonvulsant
1-amino-2-naphthol-4-sulfonic acid
4-amino-3-hydroxynaphthalene-1-sulfonic acid: reagent for removal of chromium(VI) from aqueous solution		2.4110aminonaphthalene;
naphthalenesulfonic acid		mutagen
hexachlorobenzene
Hexachlorobenzene: An agricultural fungicide and seed treatment agent.. hexachlorobenzene : A member of the class of chlorobenzenes that is benzene in which all of the hydrogens are replaced by chlorines. An agricultural fungicide introduced in the mid-1940s and formerly used as a seed treatment, its use has been banned since 1984 under the Stockholm Convention on Persistent Organic Pollutants.		2.0510aromatic fungicide;
chlorobenzenes		antifungal agrochemical;
carcinogenic agent;
persistent organic pollutant
trinitrotoluene
Trinitrotoluene: A 2,4,6-trinitrotoluene, which is an explosive chemical that can cause skin irritation and other toxic consequences.. 2,4,6-trinitrotoluene : A trinitrotoluene having the nitro groups at positions 2, 4 and 6.		2.0510trinitrotolueneexplosive
framycetin
Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.		2.9640aminoglycosideallergen;
antibacterial drug;
Escherichia coli metabolite
pyrazolanthrone
pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.		2.0510anthrapyrazole;
aromatic ketone;
cyclic ketone		antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector
meglumine
Meglumine: 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium.. N-methylglucamine : A hexosamine that is D-glucitol in which the hydroxy group at position 1 is substituted by the nitrogen of a methylamino group. A crystalline base, it is used in preparing salts of certain acids for use as diagnostic radiopaque media, while its antimonate is used as an antiprotozoal in the treatment of leishmaniasis.		2.0510hexosamine;
secondary amino compound
cinchophen
cinchophen: was heading 1963-94; ACIPHENOCHINOLIUM was see CHINOPHEN 1978-94; use QUINOLINES to search CINCHOPHEN 1966-94		3.5920quinolines
indolebutyric acid
indolebutyric acid: RN given refers to parent cpd. indole-3-butyric acid : A indol-3-yl carboxylic acid that is butanoic acid carrying a 1H-indol-3-yl substituent at position 1.		2.8130indol-3-yl carboxylic acidauxin;
plant hormone;
plant metabolite
yohimbine
Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.. yohimbine : An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.		2.0510methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist
nafcillin
Nafcillin: A semi-synthetic antibiotic related to penicillin.. nafcillin : A penicillin in which the substituent at position 6 of the penam ring is a (2-ethoxy-1-naphthoyl)amino group.		4.2650penicillin allergen;
penicillin		antibacterial drug
mequinol
mequinol: depigmenting agent; RN given refers to parent cpd		2.0510methoxybenzenes;
phenols		metabolite
methohexital
Methohexital: An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.. methohexital : A barbiturate, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by allyl and 1-methylpent-2-ynyl groups.		3.8430acetylenic compound;
barbiturates		drug allergen;
intravenous anaesthetic
quinestrol
Quinestrol: The 3-cyclopentyl ether of ETHINYL ESTRADIOL. After gastrointestinal absorption, it is stored in ADIPOSE TISSUE, slowly released, and metabolized principally to the parent compound. It has been used in ESTROGEN REPLACEMENT THERAPY. (From AMA Drug Evaluations Annual, 1992, p1011)		2.051017-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
dydrogesterone
[no description available]		2.051020-oxo steroid;
3-oxo-Delta(4) steroid		progestin
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		3.5320azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
adamantane
Adamantane: A tricyclo bridged hydrocarbon.		2.0710adamantanes;
polycyclic alkane
isoxazoles
Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.		3.5420isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
oxazoles
Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.		2.72201,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
thiazoles
[no description available]		3.6801,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
1,2,4-triazole
1,2,4-triazole: RN given refers to 1H-1,2,4-triazole		2.41101,2,4-triazole
pyrazines
Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.		2.4110diazine;
pyrazines		Daphnia magna metabolite
ephedrine
Ephedrine: A phenethylamine found in EPHEDRA SINICA. PSEUDOEPHEDRINE is an isomer. It is an alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used for asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.. (-)-ephedrine : A phenethylamine alkaloid that is 2-phenylethanamine substituted by a methyl group at the amino nitrogen and a methyl and a hydroxy group at position 2 and 1 respectively.		3.5920phenethylamine alkaloid;
phenylethanolamines		bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
chlormadinone acetate
Chlormadinone Acetate: An orally active synthetic progestational hormone used often in combinations as an oral contraceptive (CONTRACEPTIVES, ORAL).		2.0510corticosteroid hormone
pirinitramide
Pirinitramide: A diphenylpropylamine with intense narcotic analgesic activity of long duration. It is a derivative of MEPERIDINE with similar activity and usage.		2.4520nitrile
edrophonium bromide
[no description available]		2.0410
2,3-dimercaptosuccinic acid
[no description available]		2.0510
paraoxon
[no description available]		2.610aryl dialkyl phosphate;
organophosphate insecticide		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
mouse metabolite
estradiol 17 beta-cypionate
[no description available]		2.0210steroid ester
evans blue
Evans Blue: An azo dye used in blood volume and cardiac output measurement by the dye dilution method. It is very soluble, strongly bound to plasma albumin, and disappears very slowly.. Evans blue : An organic sodium salt that is the tetrasodium salt of 6,6'-{(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis[diazene-2,1-diyl]}bis(4-amino-5-hydroxynaphthalene-1,3-disulfonate). It is sometimes used as a counterstain, especially in fluorescent methods to suppress background autofluorescence.		2.0510organic sodium saltfluorochrome;
histological dye;
sodium channel blocker;
teratogenic agent
testosterone enanthate
[no description available]		2.4420heptanoate ester;
sterol ester		androgen
aminophylline
Aminophylline: A drug combination that contains THEOPHYLLINE and ethylenediamine. It is more soluble in water than theophylline but has similar pharmacologic actions. It's most common use is in bronchial asthma, but it has been investigated for several other applications.. aminophylline : A mixture comprising of theophylline and ethylenediamine in a 2:1 ratio.		3.8730mixturebronchodilator agent;
cardiotonic drug
azacitidine
Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.		3.8630N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent
phenyramidol
phenyramidol: considered as a drug that possibly causes hepatotoxicity		2.0510aminopyridine
carbutamide
Carbutamide: A sulfonylurea antidiabetic agent with similar actions and uses to CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277)		2.0510benzenes;
sulfonamide
galantamine
Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.. galanthamine : A benzazepine alkaloid isolated from certain species of daffodils.		4.0840benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound		antidote to curare poisoning;
cholinergic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite
nandrolone decanoate
Nandrolone Decanoate: Decanoic acid ester of nandrolone that is used as an anabolic agent to prevent or treat WASTING SYNDROME associated with severe chronic illness or HIV infection (HIV WASTING SYNDROME). It may also be used in the treatment of POSTMENOPAUSAL OSTEOPOROSIS.		3.5920steroid ester
bucladesine
[no description available]		2.05103',5'-cyclic purine nucleotide;
butanamides;
butyrate ester		agonist;
cardiotonic drug;
vasodilator agent
procarbazine hydrochloride
procarbazine hydrochloride : A hydrochloride obtained by combining procarbazine with one equivalent of hydrochloric acid. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.		2.0810hydrochlorideantineoplastic agent
betamethasone
Betamethasone: A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)		3.145011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic agent;
anti-inflammatory drug;
immunosuppressive agent
perflubron
perflubron: potential anti-obesity compound; reduces food adsorption; 8-carbon perfluorocarbon radiopaque compound; an oral contrast agent for use with MRI to enhance delineation of the bowel distinguishing it from adjacent organs. perflubron : A haloalkane that is perfluorooctane in which a fluorine attached to one of the terminal carbons has been replaced by a bromine.		2.0510haloalkane;
organobromine compound;
perfluorinated compound		blood substitute;
radioopaque medium
cyproterone acetate
[no description available]		2.051020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
chlorinated steroid;
steroid ester		androgen antagonist;
geroprotector;
progestin
dextropropoxyphene
Dextropropoxyphene: A narcotic analgesic structurally related to METHADONE. Only the dextro-isomer has an analgesic effect; the levo-isomer appears to exert an antitussive effect.. propoxyphene : A racemate of the (1R,2R)- and (1S,2R)- diastereoisomers.. dextropropoxyphene : The (1S,2R)-(+)-diastereoisomer of propoxyphene.		3.86301-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoatemu-opioid receptor agonist;
opioid analgesic
ketobemidone
ketobemidone: structure		2.0410piperidines
glycyrrhetinic acid
[no description available]		2.4720cyclic terpene ketone;
hydroxy monocarboxylic acid;
pentacyclic triterpenoid		immunomodulator;
plant metabolite
chenodeoxycholic acid
Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.. chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3.		3.8530bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
fusarium
Fusarium: A mitosporic Hypocreales fungal genus, various species of which are important parasitic pathogens of plants and a variety of vertebrates. Teleomorphs include GIBBERELLA.		2.0510
plumbagin
plumbagin: a superoxide anion generator. plumbagin : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogens at positions 2 and 5 are substituted by methyl and hydroxy groups, respectively.		2.1310hydroxy-1,4-naphthoquinone;
phenols		anticoagulant;
antineoplastic agent;
immunological adjuvant;
metabolite
emetine
Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.		2.0810isoquinoline alkaloid;
pyridoisoquinoline		antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor
dihydralazine
Dihydralazine: 1,4-Dihydrazinophthalazine. An antihypertensive agent with actions and uses similar to those of HYDRALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p354)		2.0510phthalazines
phenylpropanolamine
Phenylpropanolamine: A sympathomimetic that acts mainly by causing release of NOREPINEPHRINE but also has direct agonist activity at some adrenergic receptors. It is most commonly used as a nasal vasoconstrictor and an appetite depressant.. phenylpropanolamine : An amphetamine in which the parent 1-phenylpropan-2-amine skeleton is substituted at position 1 with an hydroxy group. A decongestant and appetite suppressant, it is commonly used in prescription and over-the-counter cough and cold preparations.. (-)-norephedrine : An amphetamine that is propylbenzene substituted by a hydroxy group at position 1 and by an amino group at position 2 (the 1R,2S-stereoisomer). It is a plant alkaloid.		2.0510amphetamines;
phenethylamine alkaloid		plant metabolite
carvacrol
carvacrol : A phenol that is a natural monoterpene derivative of cymene. An inhibitor of bacterial growth, it is used as a food additive. Potent activator of the human ion channels transient receptor potential V3 (TRPV3) and A1 (TRPA1).		7.4110botanical anti-fungal agent;
p-menthane monoterpenoid;
phenols		agrochemical;
antimicrobial agent;
flavouring agent;
TRPA1 channel agonist;
volatile oil component
dipicolinic acid
dipicolinic acid : A pyridinedicarboxylic acid carrying two carboxy groups at positions 2 and 6.		3.360pyridinedicarboxylic acidbacterial metabolite
4-hydroxybutyric acid
4-hydroxybutyric acid: was an entry term to Sodium Oxybate (74-98). 4-hydroxybutyric acid : A 4-hydroxy monocarboxylic acid that is butyric acid in which one of the hydrogens at position 4 is replaced by a hydroxy group.		3.23104-hydroxy monocarboxylic acid;
hydroxybutyric acid		general anaesthetic;
GHB receptor agonist;
neurotoxin;
sedative
dihydroergotamine
Dihydroergotamine: A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.. dihydroergotamine : Ergotamine in which a single bond replaces the double bond between positions 9 and 10. A semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine, it is used (as the methanesulfonic or tartaric acid salts) for the treatment of migraine and orthostatic hypotension.		3.8730ergot alkaloid;
semisynthetic derivative		dopamine agonist;
non-narcotic analgesic;
serotonergic agonist;
sympatholytic agent;
vasoconstrictor agent
podophyllotoxin
Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.		2.4420furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
hesperidin
Hesperidin: A flavanone glycoside found in CITRUS fruit peels.. hesperidin : A disaccharide derivative that consists of hesperetin substituted by a 6-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.		2.05103'-hydroxyflavanones;
4'-methoxyflavanones;
dihydroxyflavanone;
disaccharide derivative;
flavanone glycoside;
monomethoxyflavanone;
rutinoside		mutagen
medroxyprogesterone
[no description available]		3.231017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		contraceptive drug;
progestin;
synthetic oral contraceptive
dimenhydrinate
gravinol: has antioxidant and ant-inflammatory activities; structure in first source		3.6120diarylmethane
azomycin
azomycin: RN given refers to parent cpd with specified locant; structure		4.3450C-nitro compound;
imidazoles		antitubercular agent
chlormethiazole
Chlormethiazole: A sedative and anticonvulsant often used in the treatment of alcohol withdrawal. Chlormethiazole has also been proposed as a neuroprotective agent. The mechanism of its therapeutic activity is not entirely clear, but it does potentiate GAMMA-AMINOBUTYRIC ACID receptors response and it may also affect glycine receptors.		2.7430thiazoles
methamphetamine
Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.		4.0840amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
levocarnitine
(R)-carnitine : The (R)-enantiomer of carnitine.		3.5620carnitineantilipemic drug;
nootropic agent;
nutraceutical;
Saccharomyces cerevisiae metabolite;
water-soluble vitamin (role)
malondialdehyde
Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.		2.9340dialdehydebiomarker
sulfanilylurea
sulfanilylurea: antimicrobial agent; structure		3.2310benzenes;
sulfonamide
gentian violet
Gentian Violet: A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.. crystal violet : An organic chloride salt that is the monochloride salt of crystal violet cation. It has been used in creams for the topical treatment of bacterial and fungal infections, being effective against some Gram-positive bacteria (notably Staphylococcus species) and some pathogenic fungi (including Candida species) but use declined following reports of animal carcinogenicity. It has also been used for dying wood, silk, and paper, as well as a histological stain.		3.0240organic chloride saltanthelminthic drug;
antibacterial agent;
antifungal agent;
antiseptic drug;
histological dye
1-naphthylisothiocyanate
1-Naphthylisothiocyanate: A tool for the study of liver damage which causes bile stasis and hyperbilirubinemia acutely and bile duct hyperplasia and biliary cirrhosis chronically, with changes in hepatocyte function. It may cause skin and kidney damage.		2.0810isothiocyanateinsecticide
hematoporphyrin
Hematoporphyrins: Iron-free derivatives of heme with 4 methyl groups, 2 hydroxyethyl groups and 2 propionic acid groups attached to the pyrrole rings. Some of these PHOTOSENSITIZING AGENTS are used in the PHOTOTHERAPY of malignant NEOPLASMS.. hematoporphyrin : A dicarboxylic acid that is protoporphyrin in which the vinyl groups at positions 7 and 12 are replaced by 1-hydroxyethyl groups.		2.0510
lithium carbonate
Lithium Carbonate: A lithium salt, classified as a mood-stabilizing agent. Lithium ion alters the metabolism of BIOGENIC MONOAMINES in the CENTRAL NERVOUS SYSTEM, and affects multiple neurotransmission systems.		2.0410carbonate salt;
lithium salt		antimanic drug
lactulose
[no description available]		3.8730glycosylfructosegastrointestinal drug;
laxative
3-hydroxyflavone
3-hydroxyflavone: structure given in first source. flavonol : A monohydroxyflavone that is the 3-hydroxy derivative of flavone.		2.4110flavonols;
monohydroxyflavone
megestrol acetate
[no description available]		2.743020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
pamabrom
[no description available]		3.2310
Methyl 2-benzoylbenzoate
methyl 2-benzoylbenzoate: a photoinitiator; structure in first source		2.1110benzophenones
acetylcysteine
N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.		4.2650acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
phendimetrazine
phendimetrazine: minor descriptor (66-86); file maintained to MORPHOLINES (66-86); on-line & INDEX MEDICUS search MORPHOLINES (66-86); RN given refers to parent cpd without isomeric designation		2.0710
benzydamine
Benzydamine: A benzyl-indazole having analgesic, antipyretic, and anti-inflammatory effects. It is used to reduce post-surgical and post-traumatic pain and edema and to promote healing. It is also used topically in treatment of RHEUMATIC DISEASES and INFLAMMATION of the mouth and throat.. benzydamine : A member of the class of indazoles carrying benzyl and 3-(dimethylamino)propyl groups at positions 1 and 3 respectively. A locally-acting nonsteroidal anti-inflammatory drug that also exhibits local anaesthetic and analgesic properties.		2.0610aromatic ether;
indazoles;
tertiary amino compound		analgesic;
central nervous system stimulant;
hallucinogen;
local anaesthetic;
non-steroidal anti-inflammatory drug
erythromycin stearate
[no description available]		2.0510aminoglycoside
erythromycin
Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.		13.28351cyclic ketone;
erythromycin
dibutyldichlorotin
[no description available]		2.0610
biphenyl-3-carboxylic acid
biphenyl-3-carboxylic acid: structure in first source		2.1310
hydroxychloroquine sulfate
[no description available]		2.0810
levonorgestrel
Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.		4.074017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin;
synthetic oral contraceptive
8-hydroxy-2-methylquinoline
8-hydroxy-2-methylquinoline: structure in first source		2.4110hydroxyquinoline
lormetazepam
lormetazepam: RN given refers to cpd with specified locant for methyl group; structure given in first source. lormetazepam : A 1,4-benzodiazepinone compound having a methyl substituent at the 1-position, a hydroxy substituent at the 3-position, a 2-chlorophenyl group at the 5-position and a chloro substituent at the 7-position.		2.45201,4-benzodiazepinone;
organochlorine compound		sedative
vinblastine
[no description available]		2.9640
diphenoxylate
Diphenoxylate: A MEPERIDINE congener used as an antidiarrheal, usually in combination with ATROPINE. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity.. diphenoxylate : A piperidinecarboxylate ester that is the ethyl ester of difenoxin.		3.2310ethyl ester;
nitrile;
piperidinecarboxylate ester;
tertiary amine		antidiarrhoeal drug
4-phenylpyridine
[no description available]		2.1310phenylpyridine
estradiol valerate
[no description available]		2.4420steroid ester
ammonium bicarbonate
ammonium bicarbonate: see also record for ammonium carbonate (di-NH4 salt)		2.1110organooxygen compound
ethambutol hydrochloride
ethambutol dihydrochloride : The dihydrchloride salt of ethambutol. A bacteriostatic antimycobacterial drug, it is effective against Mycobacterium tuberculosis and some other mycobacteria. It is used in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol dihydrochloride is used alone.		2.0810hydrochlorideantitubercular agent
ethambutol
Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.		4.890ethanolamines;
ethylenediamine derivative		antitubercular agent;
environmental contaminant;
xenobiotic
ethidium bromide
[no description available]		2.4420organic bromide saltgeroprotector;
intercalator;
trypanocidal drug
cadmium sulfide
[no description available]		2.1510cadmium molecular entity
zinc oxide
Zinc Oxide: A mild astringent and topical protectant with some antiseptic action. It is also used in bandages, pastes, ointments, dental cements, and as a sunblock.		3.0120zinc molecular entity
antimycin a
[no description available]		2.0810benzamides;
formamides;
macrodiolide;
phenols		antifungal agent;
mitochondrial respiratory-chain inhibitor;
piscicide
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		14.932355glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
d-alpha tocopherol
Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.		3.5920alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite
pregnenolone carbonitrile
Pregnenolone Carbonitrile: A catatoxic steroid and microsomal enzyme inducer having significant effects on the induction of cytochrome P450. It has also demonstrated the potential for protective capability against acetaminophen-induced liver damage.		2.0810aliphatic nitrile
ibufenac
ibufenac: used in the treatment of rheumatism; also possesses antipyretic properties; minor descriptor (75-84); on-line & Index Medicus search PHENYLACETATES (75-84); RN given refers to parent cpd. ibufenac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 4-isobutylphenyl group. Although it was shown to be effective in treatment of rheumatoid arthritis, the clinical use of ibufenac was discontinued due to hepatotoxic side-effects.		3.2310monocarboxylic acidEC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
metylperon
metylperon: RN given refers to parent cpd		2.4620aromatic ketone
metaxalone
[no description available]		3.2310aromatic ether
spectinomycin
Spectinomycin: An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of GONORRHEA.. spectinomycin dihydrochloride : A hydrochloride obtained by combining spectinomycin with two molar equivalents of hydrochloric acid. An antibiotic that is active against gram-negative bacteria and used (as its pentahydrate) to treat gonorrhea.. spectinomycin : A pyranobenzodioxin and antibiotic that is active against gram-negative bacteria and used (as its dihydrochloride pentahydrate) to treat gonorrhea. It is produced by the bacterium Streptomyces spectabilis.		4.0840cyclic acetal;
cyclic hemiketal;
cyclic ketone;
pyranobenzodioxin;
secondary alcohol;
secondary amino compound		antibacterial drug;
antimicrobial agent;
bacterial metabolite
dronabinol
Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.. Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.		4.0640benzochromene;
diterpenoid;
phytocannabinoid;
polyketide		cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic
amiloride
Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.		3.8730aromatic amine;
guanidines;
organochlorine compound;
pyrazines		diuretic;
sodium channel blocker
pimozide
Pimozide: A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403). pimozide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group.		4.0740benzimidazoles;
heteroarylpiperidine;
organofluorine compound		antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
benperidol
Benperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It has been used in the treatment of aberrant sexual behavior. (From Martindale, The Extra Pharmacopoeia, 30th ed, p567)		2.0410aromatic ketone
betamethasone valerate
Betamethasone Valerate: The 17-valerate derivative of BETAMETHASONE. It has substantial topical anti-inflammatory activity and relatively low systemic anti-inflammatory activity.. betamethasone valerate : A steroid ester that is betamethasone in which the hydroxy group at the 17alpha position has been converted to the corresponding pentanoate ester.		2.021011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
primary alpha-hydroxy ketone;
steroid ester		anti-inflammatory drug
guanoxan
guanoxan: was MH 1976-92 (see under GUANIDINES 1976-90); use GUANIDINES to search GUANOXAN 1976-92; antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage		2.0610benzodioxine
methylprednisolone hemisuccinate
Methylprednisolone Hemisuccinate: A water-soluble ester of METHYLPREDNISOLONE used for cardiac, allergic, and hypoxic emergencies.		2.0210corticosteroid hormone;
hemisuccinate
dexbrompheniramine
dexbrompheniramine : The (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.		3.2310brompheniramineanti-allergic agent;
H1-receptor antagonist
sulfadoxine
Sulfadoxine: A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.. sulfadoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 5- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. In combination with the antiprotozoal pyrimethamine (CHEBI:8673) it is used as an antimalarial.		2.4720pyrimidines;
sulfonamide		antibacterial drug;
antimalarial
acadesine
[no description available]		2.05101-ribosylimidazolecarboxamide;
aminoimidazole;
nucleoside analogue		antineoplastic agent;
platelet aggregation inhibitor
chlordesmethyldiazepam
[no description available]		2.0410benzodiazepine
stavudine
Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase		4.5470dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
doxifluridine
doxifluridine : A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase.		2.7430organofluorine compound;
pyrimidine 5'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
prodrug
dicloxacillin
Dicloxacillin: One of the PENICILLINS which is resistant to PENICILLINASE.. dicloxacillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]formyl group.		4.2750dichlorobenzene;
penicillin		antibacterial drug
fluorescein-5-isothiocyanate
Fluorescein-5-isothiocyanate: Fluorescent probe capable of being conjugated to tissue and proteins. It is used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.. fluorescein 5-isothiocyanate : The 5-isomer of fluorescein isothiocyanate. Acts as a fluorescent probe capable of being conjugated to tissue and proteins; used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.		2.110fluorescein isothiocyanate
sabinene
sabinene: RN given refers to cpd without isomeric designation. sabinene : A thujene that is a bicyclic monoterpene isolated from the essential oils of various plant species.		2.0710thujeneplant metabolite
dithiothreitol
1,4-dimercaptobutane-2,3-diol : A glycol that is butane-2,3-diol in which a hydrogen from each of the methyl groups is replaced by a thiol group.. 1,4-dithiothreitol : The threo-diastereomer of 1,4-dimercaptobutane-2,3-diol.		1.98101,4-dimercaptobutane-2,3-diol;
butanediols;
dithiol;
glycol;
thiol		chelator;
human metabolite;
reducing agent
cyclacillin
Cyclacillin: A cyclohexylamido analog of PENICILLANIC ACID.		2.0210penicillinantibacterial drug
iproclozide
iproclozide: structure		2.0510aromatic ether
megestrol
Megestrol: A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.. megestrol : A 3-oxo Delta(4)-steroid that is pregna-4,6-diene-3,20-dione substituted by a methyl group at position 6 and a hydroxy group at position 17.		3.231017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
tranylcypromine
Tranylcypromine: A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311). tranylcypromine : A racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).. (1R,2S)-tranylcypromine : A 2-phenylcyclopropan-1-amine that is the (1R,2S)-enantiomer of tranylcypromine.		2.02102-phenylcyclopropan-1-amine
streptomycin
[no description available]		5.77150antibiotic antifungal drug;
antibiotic fungicide;
streptomycins		antibacterial drug;
antifungal agrochemical;
antimicrobial agent;
antimicrobial drug;
bacterial metabolite;
protein synthesis inhibitor
nitroxoline
nitroxoline: structure in Merck Index, 9th ed, #6475; RN given refers to parent cpd. nitroxoline : A monohydroxyquinoline in which the hydroxy group is positioned at C-8 with a nitro group trans to it at C-5.		3.0130C-nitro compound;
monohydroxyquinoline		antifungal agent;
antiinfective agent;
antimicrobial agent;
renal agent
cladribine
[no description available]		4.4160organochlorine compound;
purine 2'-deoxyribonucleoside		antineoplastic agent;
immunosuppressive agent
beclomethasone
[no description available]		2.442011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
corticosteroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic drug;
anti-inflammatory drug
carbenicillin
Carbenicillin: Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.. carbenicillin : A penicillin antibiotic having a 6beta-2-carboxy-2-phenylacetamido side-chain.		5.85170penicillin allergen;
penicillin		antibacterial drug
carbenicillin disodium
[no description available]		2.0510organic sodium salt
vantocil
polihexanide: RN given refers to parent cpd		3.2310
dehydroemetine
dehydroemetine: was MH 1991-94 (see under EMETINE 1976-90); use EMETINE to search DEHYDROEMETINE 1976-94; amebicide, derivative of emetine. dehydroemetine : A pyridoisoquinoline which was developed in response to the cardiovascular toxicity associated with emetine and results from the dehydrogenation of the heterotricylic ring of emetine. It is an antiprotozoal agent and displays antimalarial, antiamoebic, and antileishmanial properties.		2.0510aromatic ether;
isoquinolines;
pyridoisoquinoline		antileishmanial agent;
antimalarial;
antiprotozoal drug
estradiol enanthate
[no description available]		2.0210steroid ester
benorilate
benorilate: was heading 1980-94 (see under SALICYLATES 1980-90); was BENORYLATE see under SALICYLATES 1975-79; BENORYLATE was see BENORILATE 1980-94; use SALICYLATES to search BENORILATE 1980-90 & BENORYLATE 1975-79; an ester of aspirin and paracetamol with analgesic, antipyretic, and anti-inflammatory activity used in the treatment of rheumatoid diseases; it has less severe side effects than aspirin		2.0510carbonyl compound
trimetazidine
Trimetazidine: A vasodilator used in angina of effort or ischemic heart disease.		2.0510aromatic amine
metocurine
metocurine: from Chinese herb Cyclea hainanensis Mrr		2.0810isoquinolines
floxacillin
Floxacillin: Antibiotic analog of CLOXACILLIN.. flucloxacillin : A penicillin compound having a 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido] side-chain.		5.17130penicillin allergen;
penicillin		antibacterial drug
clomacran
clomacran: RN given refers to parent cpd; structure		3.2310acridines
beclomethasone dipropionate
beclomethasone dipropionate : A steroid ester comprising beclomethasone having propionyl groups at the 17- and 21-positions.		2.041011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
corticosteroid;
enone;
glucocorticoid;
propanoate ester;
steroid ester		anti-arrhythmia drug;
anti-asthmatic drug;
anti-inflammatory drug;
prodrug
vidarabine
adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.		2.0510beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
betamethasone-17,21-dipropionate
[no description available]		2.021011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
propanoate ester;
steroid ester		antipsoriatic
methenamine hippurate
methenamine hippurate: both parts of molecule contribute to its antibacterial action		3.2310N-acylglycine
olsalazine
olsalazine: cpd with 2 salicylate molecules linked together by an azo bond. olsalazine : An azobenzene that consists of two molecules of 4-aminosalicylic acid joined by an azo linkage. A prodrug for mesalazine, an anti-inflammatory drug, it is used (as the disodium salt) in the treatment of inflammatory bowel disease.		4.0740azobenzenes;
dicarboxylic acid		non-steroidal anti-inflammatory drug;
prodrug
tiadenol
tiadenol: structure		2.0510aliphatic sulfide
terodiline
[no description available]		2.4520diarylmethane
1-(4-carboxyphenyl)-3,3-dimethyltriazene
1-(4-carboxyphenyl)-3,3-dimethyltriazene: RN given refers to parent cpd		2.0410
etidronate disodium
etidronate disodium : An organic sodium salt resulting from the replacement of two protons from etidronic acid (one from from each of the phosphonic acid groups) by sodium ions.		2.0810organic sodium saltantineoplastic agent;
bone density conservation agent;
chelator
platinum
Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.		2.2110elemental platinum;
nickel group element atom;
platinum group metal atom
ruthenium
Ruthenium: A hard, brittle, grayish-white rare earth metal with an atomic symbol Ru, atomic number 44, and atomic weight 101.07. It is used as a catalyst and hardener for PLATINUM and PALLADIUM.		2.2510iron group element atom;
platinum group metal atom
silver
Silver: An element with the atomic symbol Ag, atomic number 47, and atomic weight 107.87. It is a soft metal that is used medically in surgical instruments, dental prostheses, and alloys. Long-continued use of silver salts can lead to a form of poisoning known as ARGYRIA.		8.1340copper group element atom;
elemental silver		Escherichia coli metabolite
terbium
Terbium: An element of the rare earth family of metals. It has the atomic symbol Tb, atomic number 65, and atomic weight 158.92.		2.1510f-block element atom;
lanthanoid atom
titanium
Titanium: A dark-gray, metallic element of widespread distribution but occurring in small amounts with atomic number, 22, atomic weight, 47.867 and symbol, Ti; specific gravity, 4.5; used for fixation of fractures.		2.2110titanium group element atom
cadmium
Cadmium: An element with atomic symbol Cd, atomic number 48, and atomic weight 112.41. It is a metal and ingestion will lead to CADMIUM POISONING.. elemental cadmium : An element in the zinc group of the periodic table with atomic number 48, atomic mass 112, M.P. 321degreeC, and B.P. 765degreeC). An odourless, tasteless, and highly poisonous soft, ductile, lustrous metal with electropositive properties. It has eight stable isotopes: (106)Cd, (108)Cd,(110)Cd, (111)Cd, (112)Cd, (113)Cd, (114)Cd and (116)Cd, with (112)Cd and (114)Cd being the most common.		7.8220cadmium molecular entity;
zinc group element atom
gold
Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.		2.610copper group element atom;
elemental gold
zirconium
Zirconium: A rather rare metallic element with atomic number 40, atomic weight 91.224, and symbol Zr.		2.1510titanium group element atom
cupric chloride
cupric chloride: RN given refers to unlabeled parent cpd. copper(II) chloride : An inorganic chloride of copper in which the metal is in the +2 oxidation state.		2.1710copper molecular entity;
inorganic chloride		EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor
zalcitabine
Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.		3.1550pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
acetylglucosamine
Acetylglucosamine: The N-acetyl derivative of glucosamine.. N-acetyl-beta-D-glucosamine : An N-acetyl-D-glucosamine having beta-configuration at the anomeric centre.		2.1510N-acetyl-D-glucosamineepitope
metocurine iodide
[no description available]		2.4520aromatic ether
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		2.4720delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
zinc sulfate
Zinc Sulfate: A compound given in the treatment of conditions associated with zinc deficiency such as acrodermatitis enteropathica. Externally, zinc sulfate is used as an astringent in lotions and eye drops. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995). zinc sulfate : A metal sulfate compound having zinc(2+) as the counterion.		2.610metal sulfate;
zinc molecular entity		fertilizer
sodium sulfate
[no description available]		4.911inorganic sodium salt
sodium thiosulfate
sodium thiosulfate: do not confuse synonym sodium hyposulfite with sodium hyposulfite, synonym for di-Na salt of dithionous acid. sodium thiosulfate : An inorganic sodium salt composed of sodium and thiosulfate ions in a 2:1 ratio.		3.2310inorganic sodium saltantidote to cyanide poisoning;
antifungal drug;
nephroprotective agent
calcium sulfate
Calcium Sulfate: A calcium salt that is used for a variety of purposes including: building materials, as a desiccant, in dentistry as an impression material, cast, or die, and in medicine for immobilizing casts and as a tablet excipient. It exists in various forms and states of hydration. Plaster of Paris is a mixture of powdered and heat-treated gypsum.		2.4110calcium salt;
inorganic calcium salt
ancitabine
Ancitabine: Congener of CYTARABINE that is metabolized to cytarabine and thereby maintains a more constant antineoplastic action.. ancitabine : An organic heterotricyclic compound resulting from the formal condensation of the oxo group of cytidine to the 2' position with loss of water to give the corresponding cyclic ether. A prodrug, it is metabolised to the antineoplastic agent cytarabine, so is used to maintain a more constant antineoplastic action.		2.2510diol;
organic heterotricyclic compound		antimetabolite;
antineoplastic agent;
prodrug
cadmium nitrate
cadmium nitrate: RN given refers to parent cpd. cadmium nitrate : An inorganic nitrate salt having Cd(2+) as the counterion.		2.4110cadmium salt;
inorganic nitrate salt		carcinogenic agent;
genotoxin;
hepatotoxic agent
trolamine salicylate
Arthritis: Acute or chronic inflammation of JOINTS.		2.4820
stanozolol
Stanozolol: A synthetic steroid that has anabolic and androgenic properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1194). stanozolol : An organic heteropentacyclic compound resulting from the formal condensation of the 3-keto-aldehyde moiety of oxymetholone with hydrazine. Like oxymetholone, it is a synthetic anabolic steroid. It has both anabolic and androgenic properties, and has been used to treat hereditary angioedema and various vascular disorders. It has also been widely abused by professional athletes.		2.051017beta-hydroxy steroid;
anabolic androgenic steroid;
organic heteropentacyclic compound;
tertiary alcohol		anabolic agent;
androgen
clodronic acid
Clodronic Acid: A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification.. clodronic acid : An organochlorine compound that is methylene chloride in which both hydrogens are replaced by phosphonic acid groups. It inhibits bone resorption and soft tissue calcification, and is used (often as the disodium salt tetrahydrate) as an adjunct in the treatment of severe hypercalcaemia associated with malignancy, and in the management of osteolytic lesions and bone pain associated with skeletal metastases.		2.05101,1-bis(phosphonic acid);
one-carbon compound;
organochlorine compound		antineoplastic agent;
bone density conservation agent
ammonium chloride
Ammonium Chloride: An acidifying agent that has expectorant and diuretic effects. Also used in etching and batteries and as a flux in electroplating.. ammonium chloride : An inorganic chloride having ammonium as the counterion.		2.0310ammonium salt;
inorganic chloride		ferroptosis inhibitor
mafenide acetate
[no description available]		2.0810carboxylic acid
reproterol
reproterol: RN given refers to cpd without isomeric designation; structure		2.0610oxopurine
titanium dioxide
titanium dioxide: used medically as protectant against externally caused irritation & sunlight; high concentrations of dust may cause irritation to respiratory tract; RN given refers to titanium oxide (TiO2); structure. titanium dioxide : A titanium oxide with the formula TiO2. A naturally occurring oxide sourced from ilmenite, rutile and anatase, it has a wide range of applications.		4.911titanium oxidesfood colouring
apazone
Apazone: An anti-inflammatory agent used in the treatment of rheumatoid arthritis. It also has uricosuric properties and has been used to treat gout.. apazone : A member of the class of benzotriazines that is 1,2-dihydro-1,2,4-benzotriazine bearing a dimethylamino substitutent at position 3 and a methyl substituent at position 7 and in which the nitrogens at positions 1 and 2 are both acylated by a carboxy group of propylmalonic acid.		2.0410benzotriazinesnon-steroidal anti-inflammatory drug;
uricosuric drug
diacerein
diacerein: chelates with bivalent metals; a quinone which possesses redox properties; metabolized to active rhein; proposed mechanisms include inhibiting IL1 and metalloproteinases; called a slow acting symptomatic drug in osteoarthritis; no effect of cyclooxygenase;		2.0810anthraquinone
xipamide
Xipamide: A sulfamoylbenzamide analog of CLOPAMIDE. It is diuretic and saluretic with antihypertensive activity. It is bound to PLASMA PROTEINS, thus has a delayed onset and prolonged action.		2.0510benzamides
selegiline
Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.		4.460selegiline;
terminal acetylenic compound		geroprotector
selegiline hydrochloride, (r)-isomer
[no description available]		2.0810hydrochloride;
terminal acetylenic compound		antiparkinson drug;
dopaminergic agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor
levamisole
Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.		2.44206-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazoleantinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator
clemastine
Clemastine: A histamine H1 antagonist used as the hydrogen fumarate in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.. clemastine : 2-[(2R)-1-Methylpyrrolidin-2-yl]ethanol in which the hydrogen of the hydroxy group is substituted by a 1-(4-chlorophenyl)-1-phenylethyl group (R configuration). An antihistamine with antimuscarinic and moderate sedative properties, it is used as its fumarate salt for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions.		3.620monochlorobenzenes;
N-alkylpyrrolidine		anti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist
thiamphenicol
[no description available]		2.4720monocarboxylic acid amide;
sulfone		antimicrobial agent;
immunosuppressive agent
pancuronium bromide
pancuronium bromide : A bromide salt consisting of two bromide ions and one pancuronium dication.		2.0810bromide saltcholinergic antagonist;
muscle relaxant;
nicotinic antagonist
pizotyline
Pizotyline: Serotonin antagonist used against MIGRAINE DISORDERS and vascular headaches.. pizotifen : A benzocycloheptathiophene that is 9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thiophene 4-ylidene)-1-methylpiperidine which is joined from the 4 position to the 4 position of an N-methylpiperidine moiety by a double bond. It is a sedating antihistamine, with strong serotonin antagonist and weak antimuscarinic activity. It is generally used as the malate salt for the treatment of migraine and the prevention of headache attacks during cluster periods.		2.0510benzocycloheptathiophenehistamine antagonist;
muscarinic antagonist;
serotonergic antagonist
cephalexin
Cephalexin: A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.. cephalexin : A semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract.		10.390beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
isosorbide-5-mononitrate
isosorbide-5-mononitrate: for prevention of angina pectoris; structure given in first source; a Russian drug		3.1350glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent
ornidazole
Ornidazole: A nitroimidazole antiprotozoal agent used in ameba and trichomonas infections. It is partially plasma-bound and also has radiation-sensitizing action.. ornidazole : A C-nitro compound that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by 3-chloro-2-hydroxypropyl and methyl groups, respectively. It is used in the treatment of susceptible protozoal infections and for the treatment of anaerobic bacterial infections.		2.0810C-nitro compound;
imidazoles;
organochlorine compound;
secondary alcohol		antiamoebic agent;
antibacterial drug;
antiinfective agent;
antiprotozoal drug;
antitrichomonal drug;
epitope
fluorides
[no description available]		2.1310halide anion;
monoatomic fluorine
danazol
Danazol: A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.		4.265017beta-hydroxy steroid;
terminal acetylenic compound		anti-estrogen;
estrogen antagonist;
geroprotector
fenclozic acid
fenclozic acid: an analgesic & antipyretic with anti-inflammatory properties; minor descriptor (75-86); on-line & INDEX MEDICUS search THIAZOLES (75-86); RN given refers to parent cpd		3.2310
laxagetten 4,4'-diacetoxydiphenylpyridylemethane
[no description available]		3.2310
daunorubicin
Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.		3.8530aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite
cephapirin
Cephapirin: Cephalosporin antibiotic, partly plasma-bound, that is effective against gram-negative and gram-positive organisms.. cephapirin : A cephalosporin with acetoxymethyl and 2(pyridin-4-ylsulfanyl)acetamido substituents at positions 3 and 7, respectively, of the cephem skeleton. It is used (as its sodium salt) as an antibiotic, being effective against gram-negative and gram-positive organisms.		2.4320cephalosporinantibacterial drug
fludarabine phosphate
fludarabine phosphate: structure given in first source. fludarabine phosphate : A purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas.		3.6120nucleoside analogue;
organofluorine compound;
purine arabinonucleoside monophosphate		antimetabolite;
antineoplastic agent;
antiviral agent;
DNA synthesis inhibitor;
immunosuppressive agent;
prodrug
alclofenac
alclofenac: was heading 1975-94 (was see under PHENYLACETATES 1975-90); use PHENYLACETATES to search ALCLOFENAC 1975-94; an anti-inflammatory agent used in the treatment of rheumatoid arthritis; acts also as an analgesic and an antipyretic. alclofenac : An aromatic ether in which the ether oxygen links an allyl group to the 4-position of (3-chlorophenyl)acetic acid.A non-steroidal anti-inflammatory drug, it was withdrawn from the UK market in 1979 due to concerns with its association with vasculitis and rash.		3.2310aromatic ether;
monocarboxylic acid;
monochlorobenzenes		drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
carbimazole
Carbimazole: An imidazole antithyroid agent. Carbimazole is metabolized to METHIMAZOLE, which is responsible for the antithyroid activity.. carbimazole : A member of the class of imidazoles that is methimazole in which the nitrogen bearing a hydrogen is converted into its ethoxycarbonyl derivative. A prodrug for methimazol, carbimazole is used for the treatment of hyperthyroidism.		2.47201,3-dihydroimidazole-2-thiones;
carbamate ester		antithyroid drug;
prodrug
bromocriptine
Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.		4.0740indole alkaloidantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		2.6320benzenes;
phenyl acetates
triamcinolone
Triamcinolone: A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739). triamcinolone : A C21-steroid hormone that is 1,4-pregnadiene-3,20-dione carrying four hydroxy substituents at positions 11beta, 16alpha, 17alpha and 21 as well as a fluoro substituent at position 9. Used in the form of its 16,17-acetonide to treat various skin infections.		2.472011beta-hydroxy steroid;
16alpha-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
oxyphenisatin
[no description available]		3.5920indoles
tetrachloroethylene
Tetrachloroethylene: A chlorinated hydrocarbon used as an industrial solvent and cooling liquid in electrical transformers. It is a potential carcinogen.		2.0510chlorocarbon;
chloroethenes		nephrotoxic agent
fludrocortisone
Fludrocortisone: A synthetic mineralocorticoid with anti-inflammatory activity.		3.231011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
fluorinated steroid;
mineralocorticoid		adrenergic agent;
anti-inflammatory drug
ursodeoxycholic acid
Ursodeoxycholic Acid: An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.. ursodeoxycholic acid : A bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones.. ursodeoxycholate : A bile acid anion that is the conjugate base of ursodeoxycholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.		3.8530bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
pregnanolone
Pregnanolone: A pregnane found in the urine of pregnant women and sows. It has anesthetic, hypnotic, and sedative properties.. 3alpha-hydroxy-5beta-pregnan-20-one : The 3alpha-stereoisomer of 3-hydroxy-5beta-pregnan-20-one.		2.04103-hydroxy-5beta-pregnan-20-one;
3alpha-hydroxy steroid		human metabolite;
intravenous anaesthetic;
sedative
butylated hydroxytoluene
2,6-di-tert-butyl-4-methylphenol : A member of the class of phenols that is 4-methylphenol substituted by tert-butyl groups at positions 2 and 6.		2.0710phenolsantioxidant;
ferroptosis inhibitor;
food additive;
geroprotector
isothiuronium
Isothiuronium: An undecenyl THIOUREA which may have topical anti-inflammatory activity.		2.0110
metipranolol
Metipranolol: A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.. metipranolol : 3-(Propan-2-ylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by a 4-acetoxy-2,3,5-trimethylphenoxy group. A non-cardioselective beta-blocker, it is used to lower intra-ocular pressure in the management of open-angle glaucoma.		2.0210acetate ester;
aromatic ether;
propanolamine;
secondary amino compound		anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist
benzonidazole
benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.		2.5220C-nitro compound;
imidazoles;
monocarboxylic acid amide		antiprotozoal drug
halazepam
halazepam: structure		2.0210organic molecular entity
butachlor
butachlor : An aromatic amide that is 2-choro-N-(2,6-diethylphenyl)acetamide in which the amide nitrogen has been replaced by a butoxymethyl group.		2.0510aromatic amide;
organochlorine compound;
tertiary carboxamide		environmental contaminant;
herbicide;
xenobiotic
du-21220
Ritodrine: An adrenergic beta-2 agonist used to control PREMATURE LABOR.. 4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol : A secondary amino compound that is 4-(2-amino-1-hydroxypropyl)phenol in which one of the hydrogens attached to the nitrogen is replaced by a 2-(4-hydroxyphenyl)ethyl group.		2.4320benzyl alcohols;
polyphenol;
secondary alcohol;
secondary amino compound
transferrin
Transferrin: An iron-binding beta1-globulin that is synthesized in the LIVER and secreted into the blood. It plays a central role in the transport of IRON throughout the circulation. A variety of transferrin isoforms exist in humans, including some that are considered markers for specific disease states.		2.2110
rose bengal b disodium salt
[no description available]		2.0510
glutamic acid
Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.		2.4820glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
dexchlorpheniramine
dexchlorpheniramine: RN given refers to parent cpd(S)-isomer		3.2310chlorphenamine
ribostamycin
Ribostamycin: A broad-spectrum antimicrobial isolated from Streptomyces ribosifidicus.. ribostamycin : An amino cyclitol glycoside that is 4,6-diaminocyclohexane-1,2,3-triol having a 2,6-diamino-2,6-dideoxy-alpha-D-glucosyl residue attached at position 1 and a beta-D-ribosyl residue attached at position 2. It is an antibiotic produced by Streptomyces ribosidificus (formerly S. thermoflavus).		7.4220amino cyclitol glycoside;
aminoglycoside antibiotic		antibacterial drug;
antimicrobial agent;
metabolite
clometacin
clometacin: structure		3.2310N-acylindole
cefazolin
Cefazolin: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.. cefazolin : A first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively.		7.2370beta-lactam antibiotic allergen;
cephalosporin;
tetrazoles;
thiadiazoles		antibacterial drug
amoxicillin
Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.		8.07890penicillin allergen;
penicillin		antibacterial drug
timolol
(S)-timolol (anhydrous) : The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.		4.5470timololanti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist
indoramin
Indoramin: An alpha-1 adrenergic antagonist that is commonly used as an antihypertensive agent.		2.4620tryptamines
almitrine
Almitrine: A respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep.. almitrine : A triamino-1,3,5-triazine compound having allylamino substituents at the 2- and 4-positions and a 4-(bis(p-fluorophenyl)methyl)-1-piperazinyl group at the 6-position.		2.0610piperazines;
triamino-1,3,5-triazine		central nervous system stimulant
nicergoline
Nicergoline: An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It may ameliorate cognitive deficits in CEREBROVASCULAR DISORDERS.		2.0510organic heterotetracyclic compound;
organonitrogen heterocyclic compound
oxcarbazepine
Oxcarbazepine: A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4.. oxcarbazepine : A dibenzoazepine derivative, having a carbamoyl group at the ring nitrogen, substituted with an oxo group at C-4 of the azepeine ring which is also hydrogenated at C-4 and C-5. It is a anticholinergic anticonvulsant and mood stabilizing drug, used primarily in the treatment of epilepsy.		3.8730cyclic ketone;
dibenzoazepine		anticonvulsant;
drug allergen
carbidopa
carbidopa (anhydrous) : 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa.		3.6120catechols;
hydrazines;
monocarboxylic acid		antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
toloxatone
toloxatone: oxazolidinone derivative; psychotropic drug; structure. toloxatone : A racemate consisting of equimolar amounts of (R)- and (S)-toloxatone. It is a reversible monoamine oxidase A inhibitor and antidepressant.. 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one : A member of the class of oxazolidinones that is 5-(hydroxymethyl)-1,3-oxazolidin-2-one substituted by a 3-methylphenyl group at position 3.		2.4520oxazolidinone;
primary alcohol;
toluenes
moricizine
Moricizine: An antiarrhythmia agent used primarily for ventricular rhythm disturbances.. moricizine : A phenothiazine substituted on the nitrogen by a 3-(morpholin-4-yl)propanoyl group, and at position 2 by an (ethoxycarbonyl)amino group.		3.8530carbamate ester;
morpholines;
phenothiazines		anti-arrhythmia drug
amineptin
amineptin: used in treatment of neuroses with psychoasthenic, anxio-phobic & depressive manifestations; synonym S 1694 refers to HCl; structure. amineptine : A carbocyclic fatty acid that is 5-aminoheptanoic acid in which one of the hydrogens attached to the nitrogen is replaced by a 10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl group. A tricyclic antidepressant, it was never approved in the US and was withdrawn from the French market in 1999 due to concerns over abuse, dependence and severe acne.		3.5920amino acid;
carbocyclic fatty acid;
carbotricyclic compound;
secondary amino compound		antidepressant;
dopamine uptake inhibitor
bitolterol
bitolterol: RN given refers to parent cpd; structure. bitolterol : The di-4-toluate ester of (+-)-N-tert-butylnoradrenaline (colterol). A pro-drug for colterol, a beta2-adrenergic receptor agonist, bitolterol is used as its methanesulfonate salt for relief of bronchospasm in conditions such as asthma, chronic bronchitis and emphysema.		2.0210carboxylic ester;
diester;
ethanolamines;
secondary alcohol;
secondary amino compound		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
prodrug
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		9.7790azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
feprazone
Feprazone: A pyrazole that has analgesic, anti-inflammatory, and antipyretic properties. It has been used in mild to moderate pain, fever, and inflammation associated with musculoskeletal and joint disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p15)		2.0810organic molecular entity
pirprofen
pirprofen: anti-inflammatory agent used in therapy of rheumatoid arthritis; prostaglandin synthetase inhibitor; more potent than indomethacin; structure		3.8730pyrroline
sisomicin
Sisomicin: Antibiotic produced by Micromonospora inyoensis. It is closely related to gentamicin C1A, one of the components of the gentamicin complex (GENTAMICINS).		8.71151amino cyclitol glycoside;
aminoglycoside antibiotic;
beta-L-arabinoside;
monosaccharide derivative
amdinocillin
Amdinocillin: An amidinopenicillanic acid derivative with broad spectrum antibacterial action.. mecillinam : A penicillin in which the 6beta substituent is [(azepan-1-yl)methylidene]amino; an extended-spectrum penicillin antibiotic that binds specifically to penicillin binding protein 2 (PBP2), and is only considered to be active against Gram-negative bacteria.		3.4670penicillinantibacterial drug;
antiinfective agent
tobramycin
Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.		12.371217amino cyclitol glycosideantibacterial agent;
antimicrobial agent;
toxin
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		4.4160taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
etoposide
[no description available]		4.86100beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
dobutamine
Dobutamine: A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.. dobutamine : A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure.		4.2850catecholamine;
secondary amine		beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent
ticarcillin
Ticarcillin: An antibiotic derived from penicillin similar to CARBENICILLIN in action.. ticarcillin : A penicillin compound having a 6beta-[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino side-group.		10.28500penicillin allergen;
penicillin		antibacterial drug
trimazosin
trimazosin: RN given refers to parent cpd; structure		2.0410N-arylpiperazine
penbutolol
Penbutolol: A nonselective beta-blocker used as an antihypertensive and an antianginal agent.		3.5620ethanolamines
ribavirin
Rebetron: Rebetron is tradename		4.41601-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
adinazolam
adinazolam: structure in first source. adinazolam : A triazolo[4,3-a][1,4]benzodiazepine having a dimethylaminomethyl group at the 1-position, a phenyl group at the 6-position and a chloro substituent at the 8-position.		2.4520triazolobenzodiazepineanticonvulsant;
antidepressant;
anxiolytic drug;
sedative
amikacin
Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.		17.1124819alpha-D-glucoside;
amino cyclitol glycoside;
aminoglycoside;
carboxamide		antibacterial drug;
antimicrobial agent;
nephrotoxin
tolamolol
[no description available]		2.0410
cephradine
Cephradine: A semi-synthetic cephalosporin antibiotic.. cephradine : A first-generation cephalosporin antibiotic with a methyl substituent at position 3, and a (2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetamido substituent at position 7, of the cephem skeleton.		3.8530beta-lactam antibiotic allergen;
cephalosporin		antibacterial drug
ticrynafen
Ticrynafen: A novel diuretic with uricosuric action. It has been proposed as an antihypertensive agent.. tienilic acid : An aromatic ketone that is 2,3-dichlorophenoxyacetic acid in which the hydrogen at position 4 on the benzene ring is replaced by a thiophenecarbonyl group. A loop diuretic used to treat hypertension, it was withdrawn from the market in 1982 due to links with hepatitis.		3.8730aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid;
thiophenes		antihypertensive agent;
hepatotoxic agent;
loop diuretic
guanadrel
guanadrel: RN given refers to parent cpd; structure. guanadrel : A spiroketal resulting from the formal condensation of the keto group of cyclohexanone with the hydroxy groups of 1-(2,3-dihydroxypropyl)guanidine. A postganglionic adrenergic blocking agent formerly used (generally as the sulfate salt) for the management of hypertension, it has been largely superseded by other drugs less likely to cause orthostatic hypotension (dizzy spells on standing up or stretching).		2.0210guanidines;
spiroketal		adrenergic antagonist;
antihypertensive agent
methyldopa
Methyldopa: An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.. alpha-methyl-L-dopa : A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring.		4.5470L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		alpha-adrenergic agonist;
antihypertensive agent;
hapten;
peripheral nervous system drug;
sympatholytic agent
tocainide
Tocainide: An antiarrhythmic agent which exerts a potential- and frequency-dependent block of SODIUM CHANNELS.. tocainide : A monocarboxylic acid amide in which 2,6-dimethylphenylaniline and isobutyric acid have combined to form the amide bond; used as a local anaesthetic.		2.7330monocarboxylic acid amideanti-arrhythmia drug;
local anaesthetic;
sodium channel blocker
sulbenicillin
Sulbenicillin: Semisynthetic penicillin-type antibiotic.. sulbenicillin : A penicillin antibiotic having a 6beta-[phenyl(sulfo)acetamido] side-chain.		2.4520penicillin
bezafibrate
[no description available]		2.0510aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
sq-11725
Nadolol: A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.. nadolol : Nadolol is a diastereoisomeric mixture consisting of equimolar amounts of the four possible 2,3-cis-isomers of 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol.		3.1450
diltiazem
Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.		4.54705-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetateantihypertensive agent;
calcium channel blocker;
vasodilator agent
levobunolol
Levobunolol: The L-Isomer of bunolol.. levobunolol : A cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma.		2.0210aromatic ether;
cyclic ketone;
propanolamine		antiglaucoma drug;
beta-adrenergic antagonist
vecuronium bromide
Vecuronium Bromide: Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.. vecuronium bromide : The organic bromide salt of a 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidinino- and 16beta-N-methylpiperidinium substituents.		2.7330organic bromide salt;
quaternary ammonium salt		muscle relaxant;
neuromuscular agent;
nicotinic antagonist
vecuronium
vecuronium : A 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidino- and 16beta-N-methylpiperidinium substituents.		3.2310acetate ester;
androstane;
quaternary ammonium ion		drug allergen;
muscle relaxant;
neuromuscular agent;
nicotinic antagonist
benoxaprofen
benoxaprofen: RN given refers to parent cpd; structure. benoxaprofen : A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group. It was used as a non-steroidal anti-inflammatory drug until 1982 when it was withdrawn from the market due to adverse side-effects including liver necrosis, photosensitivity, and carcinogenicity in animals.		3.59201,3-benzoxazoles;
monocarboxylic acid;
monochlorobenzenes		antipsoriatic;
antipyretic;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
hepatotoxic agent;
nephrotoxin;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
protein kinase C agonist
permethrin
hemoglobin Atlanta-Coventry: Leu replaced by Pro at beta75 and Leu deleted at beta141		2.4420cyclopropanecarboxylate ester;
cyclopropanes		agrochemical;
ectoparasiticide;
pyrethroid ester acaricide;
pyrethroid ester insecticide;
scabicide
exifone
[no description available]		3.2310benzophenones
pirfenidone
pirfenidone : A pyridone that is 2-pyridone substituted at positions 1 and 5 by phenyl and methyl groups respectively. An anti-inflammatory drug used for the treatment of idiopathic pulmonary fibrosis.		2.0510pyridoneantipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
mefloquine
(-)-(11S,2'R)-erythro-mefloquine : An optically active form of [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol having (-)-(11S,2'R)-erythro-configuration. An antimalarial agent, used in racemic form, which acts as a blood schizonticide; its mechanism of action is unknown.		3.2310[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanolantimalarial
desogestrel
Desogestrel: A synthetic progestational hormone used often as the progestogenic component of combined oral contraceptive agents (ORAL CONTRACEPTIVES, COMBINED).		2.051017beta-hydroxy steroid;
terminal acetylenic compound		contraceptive drug;
progestin;
synthetic oral contraceptive
meptazinol
Meptazinol: A narcotic antagonist with analgesic properties. It is used for the control of moderate to severe pain.		2.4520azepanes
muzolimine
Muzolimine: A pyrazole diuretic with long duration and high capacity of action. It was proposed for kidney failure and hypertension but was withdrawn worldwide because of severe neurological effects.		2.0510dichlorobenzene
nitazoxanide
nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug		3.8630benzamides;
carboxylic ester
sufentanil
Sufentanil: An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent.. sufentanil : An anilide resulting from the formal condensation of the aryl amino group of 4-(methoxymethyl)-N-phenyl-1-[2-(2-thienyl)ethyl]piperidin-4-amine with propanoic acid.		4.0640anilide;
ether;
piperidines;
thiophenes		anaesthesia adjuvant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
acarbose
[no description available]		3.6120tetrasaccharide derivativeEC 3.2.1.1 (alpha-amylase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
geroprotector;
hypoglycemic agent
torsemide
Torsemide: A pyridine and sulfonamide derivative that acts as a sodium-potassium chloride symporter inhibitor (loop diuretic). It is used for the treatment of EDEMA associated with CONGESTIVE HEART FAILURE; CHRONIC RENAL INSUFFICIENCY; and LIVER DISEASES. It is also used for the management of HYPERTENSION.. torasemide : An N-sulfonylurea obtained by formal condensation of [(3-methylphenyl)amino]pyridine-3-sulfonic acid with the free amino group of N-isopropylurea. It is a potent loop diuretic used for the treatment of hypertension and edema in patients with congestive heart failure.		4.2550aminopyridine;
N-sulfonylurea;
secondary amino compound		antihypertensive agent;
loop diuretic
medroxalol
medroxalol: RN given refers to parent cpd without isomeric designation		2.0410salicylamides
epirubicin
Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.		5.1850aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
cefmetazole
Cefmetazole: A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.. cefmetazole : A second-generation cephalosporin antibiotic having N(1)-methyltetrazol-5-ylthiomethyl, {[(cyanomethyl)sulfanyl]acetyl}amino and methoxy side-groups at positions 3, 7beta and 7alpha respectively of the parent cephem bicyclic structure.		5.79112cephalosporinantibacterial drug
desflurane
Desflurane: A fluorinated ether that is used as a volatile anesthetic for maintenance of general anesthesia.		2.4420organofluorine compoundinhalation anaesthetic
lorcainide
[no description available]		2.7530acetamides
idarubicin
Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.		4.0640anthracycline antibiotic;
deoxy hexoside;
monosaccharide derivative
ceforanide
ceforanide: RN given refers to (6R-(trans))-isomer. ceforanide : A second-generation cephalosporin antibiotic with {[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl and 2-(aminomethyl)phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is effective against many coliforms, including Escherichia coli, Klebsiella, Enterobacter and Proteus, and most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.		2.0410cephalosporinantibacterial drug
cefonicid
Cefonicid: A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.. cefonicid : A cephalosporin bearing {[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl and (R)-2-hydroxy-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		2.4720cephalosporinantibacterial drug
piperacillin
Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.		17.9434916penicillin allergen;
penicillin		antibacterial drug
cefotiam
Cefotiam: One of the CEPHALOSPORINS that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.. cefotiam : A cephalosporin with ({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl and (2-amino-1,3-thiazol-4-yl)acetamido substituents at positions 3 and 7, respectively, of the cephem skeleton. A third generation beta-lactam cephalosporin antibiotic, it is active against a broad spectrum of both Gram positive and Gram negative bacteria.		2.7430beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
paroxetine
Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.		4.460aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines		antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
captopril
Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.		10.38170alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cefoperazone
Cefoperazone: Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections.. cefoperazone : A semi-synthetic parenteral cephalosporin with a tetrazolyl moiety that confers beta-lactamase resistance.		8.5352cephalosporinantibacterial drug
staurosporine
[no description available]		2.0810indolocarbazole alkaloid;
organic heterooctacyclic compound		apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector
foscarnet sodium
trisodium phosphonoformate : The trisodium salt of phosphonoformic acid. It is used as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.		2.4720one-carbon compound;
organic sodium salt		antiviral drug
lodoxamide
[no description available]		2.0210organonitrogen compound;
organooxygen compound
atracurium
Atracurium: A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.. atracurium : A diester compound consisting of pentane-1,5-diol with both hydroxyls bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups.		3.8430diester;
quaternary ammonium ion		muscle relaxant;
nicotinic antagonist
atracurium besylate
atracurium besylate : The bisbenzenesulfonate salt of atracurium.		2.0810organosulfonate salt;
quaternary ammonium salt		muscle relaxant;
nicotinic antagonist
butoconazole
butoconazole: RN given refers to parent cpd; structure. butoconazole : A member of the class of imidazoles that is 1H-imidazole in which the hydrogen attached to the nitrogen is substituted by a 4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)sulfanyl]butyl group. An antifungal agent, it is used as its nitrate salt in gynaecology for treatment of vulvovaginal infections caused by Candida species, particularly Candida albicans.		2.0210aryl sulfide;
conazole antifungal drug;
dichlorobenzene;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes
moxalactam
Moxalactam: Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.. moxalactam : A broad-spectrum oxacephem antibiotic in which the oxazine ring is substituted with a tetrazolylthiomethyl group and the azetidinone ring carries methoxy and 2-carboxy-2-(4-hydroxyphenyl)acetamido substituents.		9.14150cephalosporin;
oxacephem		antibacterial drug
nicorandil
Nicorandil: A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase.. nicorandil : A pyrimidinecarboxamide that is nicotinamide in which one of the hydrogens attached to the carboxamide nitrogen is replaced by a 2-(nitrooxy)ethyl group. It has both nitrate-like and ATP-sensitive potassium channel activator properties, and is used for the prevention and treatment of angina pectoris.		2.4720nitrate ester;
pyridinecarboxamide		potassium channel opener;
vasodilator agent
endralazine
BQ 22-708: RN given refers to parent cpd		2.0410benzamides
naftifine
naftifine: allylamine der; RN given refers to unlabeled parent cpd. naftifine : A tertiary amine in which the nitrogen is substituted by methyl, alpha-naphthylmethyl, and (1E)-cinnamyl groups. It is used (usually as its hydrochloride salt) for the treatment of fungal skin infections.		2.0210allylamine antifungal drug;
naphthalenes;
tertiary amine		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
sterol biosynthesis inhibitor
pergolide
Pergolide: A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES.. pergolide : A diamine that is ergoline in which the beta-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.		3.5620diamine;
methyl sulfide;
organic heterotetracyclic compound		antiparkinson drug;
dopamine agonist
pergolide mesylate
pergolide mesylate : A methanesulfonate salt obtained from pergolide by mixing eqimolar amount of pergolide and methanesulfonic acid. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.		2.0810methanesulfonate saltantiparkinson drug;
dopamine agonist;
geroprotector
cefadroxil anhydrous
Cefadroxil: Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.. cefadroxil : A cephalosporin bearing methyl and (2R)-2-amino-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		4.4160cephalosporinantibacterial drug
encainide
Encainide: One of the ANTI-ARRHYTHMIA AGENTS, it blocks VOLTAGE-GATED SODIUM CHANNELS and slows conduction within the His-Purkinje system and MYOCARDIUM.. encainide : 4-Methoxy-N-phenylbenzamide in which the hydrogen at the 2 position of the phenyl group is substituted by a 2-(1-methylpiperidin-2-yl)ethyl group. A class Ic antiarrhythmic, the hydrochloride was used for the treatment of severe or life-threatening ventricular arrhythmias, but it was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack and was withdrawn from the market.		2.9540benzamides;
piperidines		anti-arrhythmia drug;
sodium channel blocker
talniflumate
talniflumate: an anti-inflammatory molecule for the treatment of cystic fibrosis, chronic obstructive pulmonary disease and asthma		2.0810benzofurans
fenoldopam mesylate
[no description available]		2.0810benzazepine
nedocromil
Nedocromil: A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with ASTHMA, including EOSINOPHILS; NEUTROPHILS; MACROPHAGES; MAST CELLS; MONOCYTES; AND PLATELETS.		2.4420dicarboxylic acid;
organic heterotricyclic compound		anti-allergic agent;
anti-asthmatic drug;
non-steroidal anti-inflammatory drug
fialuridine
[no description available]		3.2310
cefaclor anhydrous
Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN.. cefaclor : A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		5.23150cephalosporinantibacterial drug;
drug allergen
pefloxacin
Pefloxacin: A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.. pefloxacin : A quinolone that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6 and 7 by ethyl, carboxy, fluorine, and 4-methylpiperazin-1-yl groups, respectively.		4.460fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
N-arylpiperazine;
quinolone antibiotic;
quinolone		antibacterial drug;
antiinfective agent;
DNA synthesis inhibitor
alfentanil
Alfentanil: A short-acting opioid anesthetic and analgesic derivative of FENTANYL. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.. alfentanil : A member of the class of piperidines that is piperidine having a 2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl group at the 1-position as well as N-phenylpropanamido- and methoxymethyl groups at the 4-position.		4.2450monocarboxylic acid amide;
piperidines		central nervous system depressant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
peripheral nervous system drug
miglustat
miglustat: a glucosylceramide synthase inhibitor. miglustat : A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group.		3.5920piperidines;
tertiary amino compound		anti-HIV agent;
EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
haloperidol decanoate
[no description available]		3.2310organic molecular entity
cefotetan
Cefotetan: A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.. cefotetan : A semi-synthetic second-generation cephamycin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl, methoxy and {[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino groups at the 3, 7alpha, and 7beta positions, respectively, of the cephem skeleton. It is resistant to a wide range of beta-lactamases and is active against a broad spectrum of aerobic and anaerobic Gram-positive and Gram-negative microorganisms.		6.39121
recainam
recainam: structure given in first source		2.9640
lovastatin
Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).		4.6680delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug
flupirtine
flupirtine: RN given refers to parent cpd without isomeric designation		2.7530aminopyridine
tolrestat
tolrestat: RN & structure given in first source		3.5920naphthalenesEC 1.1.1.21 (aldehyde reductase) inhibitor
enoximone
Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.		2.9740aromatic ketone
stepronin
[no description available]		2.0810N-acyl-amino acid
piritrexim
piritrexim: RN given refers to parent cpd; structure given in first source		2.0510
levocabastine
levocabastine: for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis		2.0210piperidines
simvastatin
Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.		4.2650delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug
idazoxan
Idazoxan: A benzodioxane-linked imidazole that has alpha-2 adrenoceptor antagonist activity.. idazoxan : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group.		2.4620benzodioxine;
imidazolines		alpha-adrenergic antagonist
remoxipride
Remoxipride: An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.		2.9740dimethoxybenzene
balsalazide
balsalazide: a mesalamine 5-aminosalicylate prodrug; 99% of ingested drug remains intact through the stomach and is delivered to and activated in the colon; used for inflammatory bowel disease, ulcerative colitis and radiation-induced proctosigmoiditis but avoided in patients with known hypersensitivity reaction to salicylates or mesalamine; structure in first source. balsalazide : A monohydroxybenzoic acid consisting of 5-aminosalicylic acid (mesalazine) linked to 4-aminobenzoyl-beta-alanine via an azo bond.		3.2310
pravastatin
Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).. pravastatin : A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.		4.54703-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic)		anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic
cabergoline
Cabergoline: An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE.. cabergoline : An N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia.		3.8530N-acylureaantineoplastic agent;
antiparkinson drug;
dopamine agonist
bambuterol
bambuterol: selective inhibitor of butyrylcholinesterase & acetylcholinesterase. bambuterol : A carbamate ester that is terbutaline in which both of the phenolic hydroxy groups have been protected as the corresponding N,N-dimethylcarbamates. A long acting beta-adrenoceptor agonist used in the treatment of asthma, it is a prodrug for terbutaline.		2.0410carbamate ester;
phenylethanolamines		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
prodrug;
sympathomimetic agent;
tocolytic agent
atomoxetine hydrochloride
Atomoxetine Hydrochloride: A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.. atomoxetine hydrochloride : The hydrochloride salt of atomoxetine.		2.4720hydrochlorideadrenergic uptake inhibitor;
antidepressant
atomoxetine
atomoxetine : A secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents.		3.8530aromatic ether;
secondary amino compound;
toluenes		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
xenobiotic
quinapril
Quinapril: A tetrahydroisoquinoline derivative and ANGIOTENSIN CONVERTING ENZYME inhibitor that is used in the treatment of HYPERTENSION and HEART FAILURE.. quinapril : A member of the class of isoquinolines that is (3S)-2-L-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in which the alpha-amino group of the alanyl residue has been substituted by a 1-ethoxycarbonyl-4-phenylbutan-2-yl group (the all-S isomer). A prodrug for quinaprilat (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) used (generally as the hydrochloride salt) for the treatment of hypertension and congestive heart failure.		4.0840dicarboxylic acid monoester;
ethyl ester;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
alpidem
[no description available]		3.620imidazoles
raloxifene hydrochloride
Raloxifene Hydrochloride: A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.. raloxifene hydrochloride : A hydrochloride salt resulting from the reaction of equimolar amounts of raloxifene and hydrogen chloride.		2.4110hydrochloridebone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
gepirone
gepirone: RN given refers to parent cpd; structure given in first source		2.0510N-arylpiperazine
mifepristone
Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.		3.87303-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound		abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive
amifloxacin
amifloxacin: structure in UD		2.0210quinolines
trospectomycin
trospectomycin: active against Neisseria gonorrhoeae; RN refers to 2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9beta,9alpha,9aalpha,10abeta)-(9CI)-isomer		2.0410dioxanes
fosphenytoin
fosphenytoin: structure given in first & second source		3.5620imidazolidine-2,4-dione
salmeterol xinafoate
Salmeterol Xinafoate: A selective ADRENERGIC BETA-2 RECEPTOR agonist that functions as a BRONCHODILATOR when administered by inhalation. It is used to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.		2.0810naphthoic acid
ranolazine
Ranolazine: An acetanilide and piperazine derivative that functions as a SODIUM CHANNEL BLOCKER and prevents the release of enzymes during MYOCARDIAL ISCHEMIA. It is used in the treatment of ANGINA PECTORIS.. N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide : An aromatic amide obtained by formal condensation of the carboxy group of 2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetic acid with the amino group of 2,6-dimethylaniline.. ranolazine : A racemate comprising equal amounts of (R)- and (S)-ranolazine. Used for treatment of chronic angina.		3.2310aromatic amide;
monocarboxylic acid amide;
monomethoxybenzene;
N-alkylpiperazine;
secondary alcohol
finasteride
Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.		4.41603-oxo steroid;
aza-steroid;
delta-lactam		androgen antagonist;
antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
imiquimod
Imiquimod: A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS.. imiquimod : An imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.		2.0810imidazoquinolineantineoplastic agent;
interferon inducer
sematilide
sematilide: RN refers to HCl; structure given in first source		2.4520
esmolol
methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate : A methyl ester that is methyl 3-(4-hydroxyphenyl)propanoate in which the hydrogen attached to the phenolic hydroxy group is substituted by a 2-hydroxy-3-(isopropylamino)propyl group.. esmolol : A racemate comprising equimolar amounts of (R)- and (S)-esmolol. A cardioselective and short-acting beta1 receptor blocker with rapid onset but lacking intrinsic sympathomimetic and membrane-stabilising properties, it is used as the hydrochloride salt in the management of supraventricular arrhythmias, and for the control of hypertension and tachycardia during surgery. While the S enantiomer possesses all of the heart rate control, both enantiomers contribute to lowering blood pressure.		3.8430aromatic ether;
ethanolamines;
methyl ester;
secondary alcohol;
secondary amino compound
clinafloxacin
clinafloxacin: structure given in first source; RN given is for monoHCl		2.9340quinolines
sertindole
sertindole : A phenylindole that is 1H-indole which is substituted on the nitrogen by a p-chlorophenyl group, at position 5 by chlorine, and at position 3 by a piperidin-4-yl group, which is itself substituted on the nitrogen by a 2-(2-oxoimidazolidin-1-yl)ethyl group.		2.0810heteroarylpiperidine;
imidazolidinone;
organochlorine compound;
organofluorine compound;
phenylindole		alpha-adrenergic antagonist;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic antagonist
adapalene
Adapalene: A naphthalene derivative that has specificity for RETINOIC ACID RECEPTORS. It is used as a DERMATOLOGIC AGENT for the treatment of ACNE.. adapalene : A naphthoic acid that is CD437 in which the phenolic hydroxy group has been converted to its methyl ether.		2.4520adamantanes;
monocarboxylic acid;
naphthoic acid		dermatologic drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
non-steroidal anti-inflammatory drug
adefovir
adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.		4.08406-aminopurines;
ether;
phosphonic acids		antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent
loxiglumide
loxiglumide: cholecystokinin receptor antagonist; RN refers to (+-)-isomer; structure in first source		2.0410organic molecular entity
aromasil
[no description available]		3.612017-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor;
environmental contaminant;
xenobiotic
sparfloxacin
[no description available]		3.4170fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone
zileuton
[no description available]		4.26501-benzothiophenes;
ureas		anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug
tebufelone
tebufelone: structure given in first source		2.0210
clopidogrel
Clopidogrel: A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION.. clopidogrel : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer). A P2Y12 receptor antagonist, it is used to inhibit blood clots and prevent heart attacks.		3.930methyl ester;
monochlorobenzenes;
thienopyridine		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
cidofovir anhydrous
Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.		4.5470phosphonic acids;
pyrimidone		anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent
tiagabine
Tiagabine: A nipecotic acid derivative that acts as a GABA uptake inhibitor and anticonvulsant agent. It is used in the treatment of EPILEPSY, for refractory PARTIAL SEIZURES.. tiagabine : A piperidinemonocarboxylic acid that is (R)-nipecotic acid in which the hydrogen attached to the nitrogen has been replaced by a 1,1-bis(3-methyl-2-thienyl)but-1-en-4-yl group. A GABA reuptake inhibitor, it is used (generally as the hydrochloride salt) for the treatment of epilepsy.		3.8530beta-amino acid;
piperidinemonocarboxylic acid;
tertiary amino compound;
thiophenes		anticonvulsant;
GABA reuptake inhibitor
mibefradil
Mibefradil: A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE.		2.4620tetralinsT-type calcium channel blocker
topotecan
Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.		4.0640pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
tenidap
tenidap: structure given in first source; RN refers to (Z)-isomer		2.0610
bromfenac
bromfenac: bromfenac sodium is the active cpd; structure in first source. bromfenac : Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure.		4.4260aromatic amino acid;
benzophenones;
organobromine compound;
substituted aniline		non-narcotic analgesic;
non-steroidal anti-inflammatory drug
gemcitabine hydrochloride
[no description available]		2.0810hydrochloride;
organofluorine compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral drug;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
immunosuppressive agent;
radiosensitizing agent
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		4.0640organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
ibutilide
ibutilide: RN & structure in first source; RN refers to the fumarate salt		4.0640benzenes;
organic amino compound
aripiprazole
Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.. aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.		3.8730aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone		drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist
remifentanil
Remifentanil: A piperidine-propionate derivative and opioid analgesic structurally related to FENTANYL. It functions as a short-acting MU OPIOID RECEPTOR agonist, and is used as an analgesic during induction or maintenance of general anesthesia, following surgery, during childbirth, and in mechanically ventilated patients under intensive care.. remifentanil : A piperidinecarboxylate ester that is methyl piperidine-4-carboxylate in which the hydrogen attached to the nitrogen is substituted by a 3-methoxy-3-oxopropyl group and the hydrogen at position 4 is substituted the nitrogen of N-propanoylaniline.		4.0640alpha-amino acid ester;
anilide;
monocarboxylic acid amide;
piperidinecarboxylate ester		intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
sedative
atorvastatin calcium anhydrous
[no description available]		2.0810organic calcium salt
atorvastatin
[no description available]		4.0740aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic)		environmental contaminant;
xenobiotic
lamivudine
[no description available]		4.6580monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
duloxetine hydrochloride
Duloxetine Hydrochloride: A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.. (S)-duloxetine hydrochloride : A duloxetine hydrochloride in which the duloxetine moiety has S configuration.		2.0810duloxetine hydrochlorideantidepressant
duloxetine
[no description available]		3.5920duloxetine
irinotecan
[no description available]		4.460carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
valsartan
Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.		4.6680biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
ibandronic acid
Ibandronic Acid: Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.		3.5820
ziprasidone
ziprasidone: a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone. ziprasidone : A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.		4.08401,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines		antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist
zanamivir
Zanamivir: A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.		2.4520guanidinesantiviral agent;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
zolmitriptan
zolmitriptan: an antimigraine compound; a serotonin (5HT)-1D receptor agonist. zolmitriptan : A member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine.		4.0840oxazolidinone;
tryptamines		anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
adefovir dipivoxil
bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine: structure given in first source. adefovir pivoxil : An organic phosphonate that is the dipivoxil ester of adefovir. A prodrug for adefovir, an HIV-1 reverse transcriptase inhibitor, adefovir pivoxil is used to treat chronic hepatitis B viral infection.		2.47206-aminopurines;
carbonate ester;
ether;
organic phosphonate		antiviral drug;
DNA synthesis inhibitor;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent;
prodrug
emtricitabine
Emtricitabine: A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS.. emtricitabine : An organofluorine compound that is 5-fluorocytosine substituted at the 1 position by a 2-(hydroxymethyl)-1,3-oxathiolan-5-yl group (2R,5S configuration). It is used in combination therapy for the treatment of HIV-1 infection.		3.6120monothioacetal;
nucleoside analogue;
organofluorine compound;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
tasosartan
tasosartan: angiotensin II antagonist; structure given in first source		3.2310biphenyls
tiludronic acid
tiludronic acid: a bone resorption inhibitor; an antihypercalcemic agent; used in the tratment of Paget's disease; used in the treatment and prevention of osteoporosis; structure given in first source		3.5620organochlorine compound
tirofiban
Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME.. tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group.		3.8530L-tyrosine derivative;
piperidines;
sulfonamide		anticoagulant;
fibrin modulating drug;
platelet glycoprotein-IIb/IIIa receptor antagonist
capecitabine
Capecitabine: A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.. capecitabine : A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers.		3.5920carbamate ester;
cytidines;
organofluorine compound		antimetabolite;
antineoplastic agent;
prodrug
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		3.8530adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
acridine orange
Acridine Orange: A cationic cytochemical stain specific for cell nuclei, especially DNA. It is used as a supravital stain and in fluorescence cytochemistry. It may cause mutations in microorganisms.. acridine orange : Fluorescent dye useful for cell cycle determination. It is cell-permeable, and interacts with DNA and RNA by intercalation or electrostatic attractions respectively.. acridine orange free base : A member of the class of aminoacridines that is acridine carrying two dimethylamino substituents at positions 3 and 6. The hydrochloride salt is the fluorescent dye 'acridine orange', used for cell cycle determination.		2.0510aminoacridines;
aromatic amine;
tertiary amino compound		fluorochrome;
histological dye
paroxetine hydrochloride
paroxetine hydrochloride : The hydrochloride salt of paroxetine. It is an antidepressant drug.		2.0810hydrochlorideantidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
bupropion hydrochloride
[no description available]		2.0810aromatic ketone
cisatracurium
cisatracurium: RN refers to (1R-(1alpha,2alpha(1'R*,2'R*)))-isomer. cisatracurium : A diester that is the (1R,1'R,2R,2'R)-diastereoisomer of atracurium, a quaternary ammonium ion consisting of pentane-1,5-diol with both hydroxy functions bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups. The active species in the skeletal muscle relaxant cisatracurium besylate.		2.0410diester;
quaternary ammonium ion		muscle relaxant;
nicotinic antagonist
halofuginone
[no description available]		2.0510quinazolines
trazodone hydrochloride
Triticum: A plant genus of the family POACEAE that is the source of EDIBLE GRAIN. A hybrid with rye (SECALE CEREALE) is called TRITICALE. The seed is ground into FLOUR and used to make BREAD, and is the source of WHEAT GERM AGGLUTININS.. trazodone hydrochloride : A hydrochloride salt prepared from equimolar amounts of trazodone and hydrogen chloride.		2.0810hydrochlorideadrenergic antagonist;
antidepressant;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
fosinoprilat
fosinoprilat: active phosphinic acid metabolite of prodrug fosenopril, which is activated by esterases in vivo; structure given in first source; binds zinc with phosphinic acid group. fosinoprilat : A phosphinic acid-containing N-acyl derivative of (4S)-cyclohexyl-L-proline. An inhibitor of angiotensin converting enzyme (ACE), it is used as the phosphinate ester pro-drug fosinopril for treatment of hypertension and chronic heart failure.		2.0410L-proline derivative;
phosphinic acids		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
ortho-cept
ethinyl estradiol-desogestrel combination: Ethinyl Estradiol and Desogestrell given in fixed proportions; has proved to be an effective & well-tolerated oral contraceptive, which improves cycle control & has a beneficial effect on acne		2.0510
trovafloxacin
trovafloxacin: a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity. trovafloxacin : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.		10.1380
cefprozil
[no description available]		4.2550cephalosporin;
semisynthetic derivative		antibacterial drug
doxazosin mesylate
Cardura: Trade name in United States.		2.0810methanesulfonate saltgeroprotector
methylprednisolone aceponate
methylprednisolone aceponate: RN given for (6alpha,11beta)-isomer		2.0210corticosteroid hormone
dexamethasone 17-valerate
dexamethasone 17-valerate: RN given refers to (11beta,16alpha)-isomer; structure		2.021021-hydroxy steroid
dexamethasone dipropionate
[no description available]		2.0210corticosteroid hormone
4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
[no description available]		2.0510stilbenoid
efavirenz
efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.		3.8730acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
nelfinavir
Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.		3.8730aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound		antineoplastic agent;
HIV protease inhibitor
doxapram hydrochloride
[no description available]		2.0510hydrochloridecentral nervous system stimulant
mevastatin
mevastatin: antifungal metabolite from Penicillium brevicopactum; potent inhibitory activity to sterol synthesis; structure. mevastatin : A carboxylic ester that is pravastatin that is lacking the allylic hydroxy group. A hydroxymethylglutaryl-CoA reductase inhibitor (statin) isolated from Penicillium citrinum and from Penicillium brevicompactum, its clinical use as a lipid-regulating drug ceased following reports of toxicity in animals.		2.08102-pyranones;
carboxylic ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		antifungal agent;
apoptosis inducer;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
fungal metabolite;
Penicillium metabolite
bupivacaine hydrochloride
bupivacaine hydrochloride (anhydrous) : A racemate composed of equimolar amounts of dextrobupivacaine hydrochloride and levobupivacaine hydrochloride. The monohydrate form is commonly used as a local anaesthetic.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide hydrochloride : A hydrochloride obtained by combining 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide with one molar equivalent of hydrochloric acid.		2.0810hydrochloride;
racemate		adrenergic antagonist;
amphiphile;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
local anaesthetic
fenofibric acid
fenofibric acid: RN given refers to parent cpd without isomeric designation; structure. fenofibric acid : A monocarboxylic acid that is 2-methylpropanoic acid substituted by a 4-(4-chlorobenzoyl)phenoxy group at position 2. It is a metabolite of the drug fenofibrate.		3.2310aromatic ketone;
chlorobenzophenone;
monocarboxylic acid		drug metabolite;
marine xenobiotic metabolite
1,5-anhydroglucitol
1,5-anhydroglucitol: structure. 1,5-anhydro-D-glucitol : An anhydro sugar of D-glucitol.		2.0510anhydro sugarhuman metabolite
betulinic acid
[no description available]		2.0510hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
plerixafor
plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.		3.6120azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound		anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant
amprenavir
[no description available]		3.8730carbamate ester;
sulfonamide;
tetrahydrofuryl ester		antiviral drug;
HIV protease inhibitor
oseltamivir
Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.		3.9130acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic
kasugamycin
kasugamycin: experimental antimicrobial agent from Streptomyces kausugaensis; used in pseudomonas infections; interfers with protein synthesis in susceptible Escherichia coli. kasugamycin : An amino cyclitol glycoside that is isolated from Streptomyces kasugaensis and exhibits antibiotic and fungicidal properties.		3.1710
ticlopidine hydrochloride
[no description available]		2.0810hydrochloride
epirubicin hydrochloride
[no description available]		2.0810
glutathione disulfide
Glutathione Disulfide: A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.		2.0510glutathione derivative;
organic disulfide		Escherichia coli metabolite;
mouse metabolite
iopamidol
Iopamidol: A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures.. iopamidol : A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a (2S)-2-hydroxypropanamido group at the 5-position.		2.4320benzenedicarboxamide;
organoiodine compound;
pentol		environmental contaminant;
radioopaque medium;
xenobiotic
histamine phosphate
histamine phosphate : A phosphate salt that is the diphosphate salt of histamine.		3.2310phosphate salthistamine agonist
cephalosporin c
cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.		19.1729240cephalosporinfungal metabolite
imipramine n-oxide
imipramine N-oxide: RN given refers to parent cpd; structure		2.0410dibenzooxazepine
tilbroquinol
[no description available]		3.2310organohalogen compound;
quinolines
bendamustine
[no description available]		3.5920benzimidazoles
erdosteine
[no description available]		2.0510N-acyl-amino acid
ritipenem
ritipenem: carbapenem antibiotic; structure given in first source		2.0210
droxicam
droxicam: structure given in first source. droxicam : An organic heterotricyclic compound that is 2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide substituted at positions 3 and 5 by pyridin-2-yl and methyl groups respectively. A prodrug of piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.		3.2310organic heterotricyclic compound;
pyridines		cyclooxygenase 1 inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor;
prodrug
terizidone
terizidone: minor descriptor (1975-1984); on-line & Index Medicus search OXAZOLES (1975-1984); RN given refers to parent cpd without isomeric designation		3.2110
flomoxef
flomoxef: structure given in first source; RN given refers to sodium salt. flomoxef : A second-generation oxacephem antibiotic in which the oxazine ring is substituted at C-3 with a hydroxyethyl-substituted tetrazolylthiomethyl group and the azetidinone ring carries 7alpha-methoxy and 7beta-{2-[(difluoromethyl)thiomethyl]acetamido} substituents.		3.2760N-acyl-amino acid;
organonitrogen heterocyclic antibiotic;
oxacephem		antibacterial drug
ebrotidine
ebrotidine: an H2-receptor antagonist and gastric mucosa protector		3.2310sulfonamide
fropenem
[no description available]		5.12130faropenem
mizolastine
[no description available]		2.0510benzimidazoles
dexloxiglumide
dexloxiglumide: a CCK receptor antagonist; structure given in first source		2.4520glutamic acid derivative
intoplicine
intoplicine: structure in first source		2.4520pyridoindole
pazufloxacin
[no description available]		9.8471quinolines
repaglinide
[no description available]		4.0840piperidines
telmisartan
Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.		4.2650benzimidazoles;
biphenyls;
carboxybiphenyl		angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic
inogatran
inogatran: a direct low molecular weight thrombin inhibitor		2.0210
dexfenfluramine
Dexfenfluramine: The S-isomer of FENFLURAMINE. It is a serotonin agonist and is used as an anorectic. Unlike fenfluramine, it does not possess any catecholamine agonist activity.. (S)-fenfluramine : The S-enantiomer of fenfluramine. It stimulates the release of serotonin and selectively inhibits its reuptake, but unlike fenfluramine it does not possess catecholamine agonist activity. It was formerly given by mouth as the hydrochloride in the treatment of obesity, but, like fenfluramine, was withdrawn wolrdwide following reports of valvular heart defects.		2.7330fenfluramineappetite depressant;
serotonergic agonist;
serotonin uptake inhibitor
2-methoxyestradiol
2-methoxy-17beta-estradiol : A 17beta-hydroxy steroid, being 17beta-estradiol methoxylated at C-2.		2.051017beta-hydroxy steroid;
3-hydroxy steroid		angiogenesis modulating agent;
antimitotic;
antineoplastic agent;
human metabolite;
metabolite;
mouse metabolite
ethinyl estradiol-17-sulfate
ethinyl estradiol-17-sulfate: RN given refers to the (17alpha)-isomer		2.0410
1,7-phenanthroline
[no description available]		2.3110phenanthroline
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		3.98401,2,3-triazole
miconazole nitrate
miconazole nitrate : A racemate composed of equimolar amounts of (R)- and (S)-miconazole nitrate. An antifungal used for the treatment of athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.		2.0810
ethinylestradiol-3-sulfate
ethinylestradiol-3-sulfate: binds to albumin at 2 sites		2.041017beta-hydroxy steroid;
steroid sulfate		antineoplastic agent;
estrogen
medetomidine
Medetomidine: An agonist of RECEPTORS, ADRENERGIC ALPHA-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of DEXMEDETOMIDINE.		2.0510imidazoles
sertraline
Sertraline: A selective serotonin uptake inhibitor that is used in the treatment of depression.. sertraline : A member of the class of tetralins that is tetralin which is substituted at positions 1 and 4 by a methylamino and a 3,4-dichlorophenyl group, respectively (the S,S diastereoisomer). A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as the hydrochloride salt as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder.		4.0740dichlorobenzene;
secondary amino compound;
tetralins		antidepressant;
serotonin uptake inhibitor
picosulfate sodium
picosulfate sodium: contains two active ingredients, sodium picosulfate and magnesium citrate, which are both laxatives; structure		2.0510aryl sulfate;
pyridines
cefcanel
cefcanel: RN given refers to (6R-(6 alpha,7 beta(R*)))-isomer; structure		2.0410
arbekacin
arbekacin: structure given in first source. arbekacin : A kanamycin that is kanamycin B bearing an N-(2S)-4-amino-2-hydroxybutyryl group on the aminocyclitol ring.		3.360aminoglycoside;
kanamycins		antibacterial agent;
antibacterial drug;
antimicrobial agent;
protein synthesis inhibitor
zoledronic acid
Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.		4.08401,1-bis(phosphonic acid);
imidazoles		bone density conservation agent
epristeride
epristeride: structure given in first source		2.4520steroid acid
talinolol
[no description available]		2.4520ureas
artemisinin
(+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.		2.0810organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite
brinzolamide
brinzolamide: an antiglaucoma agent		2.0810sulfonamide;
thienothiazine		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
dienogest
[no description available]		2.051017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
aliphatic nitrile;
steroid hormone		progesterone receptor agonist;
progestin;
synthetic oral contraceptive
drospirenone
drospirenone: a progestational compound with antimineralocorticoid and antiandrogenic activity; structure given in first source		2.08103-oxo-Delta(4) steroid;
steroid lactone		aldosterone antagonist;
contraceptive drug;
progestin
artemether
Artemether: An artemisinin derivative that is used in the treatment of MALARIA.. artemether : An artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.		2.0810artemisinin derivative;
cyclic acetal;
organic peroxide;
semisynthetic derivative;
sesquiterpenoid		antimalarial
morphazinamide
morphazinamide: RN given refers to parent cpd; RN in Chemline for mono-HCL: 1473-73-0; structure in Merck Index		2.0510morpholines;
pyrazines;
secondary carboxamide
bromopyruvate
3-bromopyruvic acid : A 2-oxo monocarboxylic acid that is pyruvic acid in which one of the methyl hydrogens is replaced by bromine. Synthetic brominated derivative and structural analog of pyruvic acid. Highly reactive alkylating agent. Anti-cancer drug		2.31102-oxo monocarboxylic acid;
organobromine compound;
oxo carboxylic acid		alkylating agent;
antineoplastic agent
denaverine
denaverine: RN given refers to parent cpd; structure		2.0410diarylmethane
cefminox
cefminox : A second-generation cephamycin antibiotic having [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl and 2-{[(2S)-2-amino-2-carboxyethyl]sulfanyl}acetamido side-groups located respectively at positions 3 and 7beta of the cephem nucleus. A broad-spectrum bactericide, it is especially effective against Gram-negative and anaerobic bacteria.		2.0410cephamycin;
tetrazoles
pafenolol
pafenolol: structure given in first source		2.0610
acamprosate
Acamprosate: Structural analog of taurine that is used for the prevention of relapse in individuals with ALCOHOLISM.. acamprosate : An organosulfonic acid that is propane-1-sulfonic acid substituted by an acetylamino group at position 3.		3.5920acetamides;
organosulfonic acid		environmental contaminant;
neurotransmitter agent;
xenobiotic
isaxonine
isaxonine: promotes nerve growth		3.2310aminopyrimidine
enrofloxacin
Enrofloxacin: A fluoroquinolone antibacterial and antimycoplasma agent that is used in veterinary practice.. enrofloxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid substituted by an oxo group at position 4, a fluoro group at position 6, a cyclopropyl group at position 1 and a 4-ethylpiperazin-1-yl group at position 7. It is a veterinary antibacterial agent used for the treatment of pets.		2.4110cyclopropanes;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone		antibacterial agent;
antimicrobial agent;
antineoplastic agent
diprafenone
diprafenone: structure given in first source		2.4520aromatic compound
erythromycin propionate
erythromycin propionate: form in which erythromycin estolate is principally absorbed		2.0210erythromycin derivative
nebivolol
2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol] : A member of the class of chromanes that is 2,2'-iminodiethanol in which one hydrogen attached to each hydroxy-bearing carbon is replaced by a 6-fluorochroman-2-yl group.		3.5820chromanes;
diol;
organofluorine compound;
secondary alcohol;
secondary amino compound
uk 68798
[no description available]		4.2750aromatic ether;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
potassium channel blocker
ljc 10627
biapenem: structure given in first source. biapenem : A carbapenem antibiotic in which the azetidine and pyrroline rings carry 1-hydroxymethyl and pyrazolo[1,2-a][1,2,4]triazolium-6-ylthio substituents respectively.		7.68471carbapenems;
organic sulfide;
pyrazolotriazole		antibacterial drug
hp 873
iloperidone: an atypical, negative symptom antipsychotic agent. iloperidone : A member of the class of piperidines that is the 4-acetyl-2-methoxyphenyl ether of 3-(piperidin-1-yl)propan-1-ol which is substituted at position 4 of the piperidine ring by a 6-fluoro-1,2-benzoxazol-3-yl group. A member of the group of second generation antipsychotics (also known as an atypical antipsychotics), it is used for the treatment of schizophrenia.		3.61201,2-benzoxazoles;
aromatic ether;
aromatic ketone;
methyl ketone;
monoamine;
organofluorine compound;
piperidines;
tertiary amino compound		dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist
dexrazoxane
Dexrazoxane: The (+)-enantiomorph of razoxane.		4.4260razoxaneantineoplastic agent;
cardiovascular drug;
chelator;
immunosuppressive agent
masoprocol
Masoprocol: A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils.. masoprocol : The meso-form of nordihydroguaiaretic acid. An antioxidant found in the creosote bush, Larrea divaricata, it is a potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. It also inhibits (though to a lesser extent) formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase.		3.1410nordihydroguaiaretic acidantineoplastic agent;
hypoglycemic agent;
lipoxygenase inhibitor;
metabolite
loxapine succinate
[no description available]		2.0810succinate saltgeroprotector
sanfetrinem
sanfetrinem: orally absorbed hexetil ester of GV-104326		2.4220
fenoxypropazine
[no description available]		3.2310aromatic ether
antebate
betamethasone butyrate propionate: a topical corticosteroid		2.0210corticosteroid hormone
voriconazole
Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.		5.44170conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug		P450 inhibitor
betamipron
[no description available]		2.7430organonitrogen compound;
organooxygen compound
bufuralol
bufuralol: RN given refers to cpd without isomeric designation; structure		2.4520benzofurans
uroxatral
[no description available]		2.0810hydrochloride
aceclofenac
[no description available]		3.6120amino acid;
carboxylic ester;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
secnidazole
[no description available]		2.1710C-nitro compound;
imidazoles;
secondary alcohol		epitope
nitrefazole
[no description available]		3.2310imidazoles
panipenem
panipenem: synthetic cpd; structure given in first source		8.43401organic molecular entity
perindoprilat
perindoprilat : A dipeptide obtained by formal condensation of one of the carboxy groups of N-[(1S)-1-carboxyethyl]-L-norvaline with the amino group of (2S,3aS,7aS)-octahydroindole-2-carboxylic acid. The major active metabolite of perindopril.		2.0410dicarboxylic acid;
dipeptide;
L-alanine derivative;
organic heterobicyclic compound		antihypertensive agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cyclobutyrol
cyclobutyrol: RN given refers to parent cpd; structure. cyclobutyrol : A hydroxy monocarboxylic acid in which the hydroxy group is geminal to a 1-carboxypropyl group on a cyclohexane ring.		2.0510hydroxy monocarboxylic acidbile therapy drug
thiocolchicoside
[no description available]		2.0810glycoside
terlipressin
terlivaz: first FDA approved injection to improve kidney function in adults with hepatorenal syndrome (HRS) with rapid reduction in kidney function.		2.0510polypeptide
7-hydroxystaurosporine
[no description available]		2.0410
methotrimeprazine
Methotrimeprazine: A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604). methotrimeprazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a (2R)-3-(dimethylamino)-2-methylpropyl group and a methoxy group at positions 10 and 2 respectively.		2.0410phenothiazines;
tertiary amine		anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist
isoflavone
[no description available]		2.0510isoflavones
clevudine
[no description available]		2.0510
gentamicin c1
[no description available]		2.7620
gentamicin c1a
[no description available]		3.4760gentamycin C
9-aminocamptothecin
[no description available]		2.0410pyranoindolizinoquinoline
sch 34343
Sch 34343: structure given in first source; RN given refers to (5R-(5alpha,6alpha))-isomer		2.9340
pd 131628
PD 131628: CI-990 is L-alanylamide prodrug of PD-131628; structure given in first source		1.9810
topsentin
topsentin: structure given in first source; a marine natural product		2.0210
squalamine
squalamine: from dogfish shark Squalus acanthias; structure given in first source		2.0410bile acid
5-nitro-1,10-phenanthroline
5-nitro-1,10-phenanthroline: structure in first source		3.5110
1,10-phenanthroline-5,6-dione
1,10-phenanthroline-5,6-dione: has antineoplastic, intercalating, and trypanocidal activities; structure given in first source		2.3110
tetrandrine
tetrandrine: a bisbenzylisoquinoline that exhibits antifibrogenic activity		2.0510bisbenzylisoquinoline alkaloid;
isoquinolines
doripenem
Doripenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS.		14.371336carbapenems
oxazolidin-2-one
Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.		7.41201carbamate ester;
oxazolidinone		metabolite
8-hydroxy-2-quinolinecarboxylic acid
[no description available]		2.4110quinolines
indole-5-carboxylic acid
[no description available]		2.1310indolecarboxylic acidplant metabolite
atovaquone
Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.. atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.		4.0640hydroxy-1,2-naphthoquinone
4-carboxybiphenyl ether
4-carboxybiphenyl ether: structure given in first source. 4-phenoxybenzoic acid : A phenoxybenzoic acid in which the phenoxy group is para to the carboxy group.		2.1310phenoxybenzoic acid
rivastigmine
[no description available]		4.0840carbamate ester;
tertiary amino compound		cholinergic drug;
EC 3.1.1.8 (cholinesterase) inhibitor;
neuroprotective agent
frovatriptan
[no description available]		3.8530carbazoles
eletriptan
eletriptan: 5-HT(1B/1D) receptor agonist; structure in first source. eletriptan : An N-alkylpyrrolidine, that is N-methylpyrrolidine in which the pro-R hydrogen at position 2 is replaced by a {5-[2-(phenylsulfonyl)ethyl]-1H-indol-3-yl}methyl group.		3.5820indoles;
N-alkylpyrrolidine;
sulfone		non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
rosiglitazone
[no description available]		4.4260aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
tamiflu
[no description available]		2.0810phosphate salt
bexarotene
[no description available]		3.6120benzoic acids;
naphthalenes;
retinoid		antineoplastic agent
s20098
[no description available]		2.0810acetamides
flunisolide
flunisolide: flunisolide HFA is a formulation of flunisolide using hydrofluoroalkane (HFA) as propellant in place of chlorofluorocarbon (CFC) ones		2.964011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic ketal;
fluorinated steroid;
primary alpha-hydroxy ketone		anti-asthmatic drug;
anti-inflammatory drug;
immunosuppressive agent
ketorolac tromethamine
Ketorolac Tromethamine: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.. ketorolac tromethamine : An organoammonium salt resulting from the mixture of equimolar amounts of ketorolac and tromethamine (tris). It has potent non-sedating analgesic and moderate anti-inflammatory effects. It is used in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis.		2.0810organoammonium saltanalgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor
clarithromycin
Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.		8.51252macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
valproic acid glucuronide
valproic acid glucuronide: major metabolite of valproic acid		2.1310glucosiduronic acid
nicotine
(S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.		3.29603-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
moexipril
[no description available]		3.8530peptide
gliquidone
gliquidone: structure; RN given refers to parent cpd		2.0810isoquinolines
3-aminobenzeneboronic acid
[no description available]		3.0140
mci 9038
[no description available]		3.5820peptide
lopinavir
[no description available]		3.2450amphetamines;
dicarboxylic acid diamide		anticoronaviral agent;
antiviral drug;
HIV protease inhibitor
glycidyl nitrate
glycidyl nitrate: a nitric oxide donor; structure in first source. peptidoglycan : A peptidoglycosaminoglycan formed by alternating residues of beta-(1->4)-linked N-acetylglucosamine and N-acetylmuramic acid {2-amino-3-O-[(S)-1-carboxyethyl]-2-deoxy-D-glucose} residues. Attached to the carboxy group of the muramic acid is a peptide chain of three to five amino acids.		4.11130
2,8-dihydroxyquinoline
[no description available]		2.4110dihydroxyquinoline;
monohydroxyquinoline;
quinolone
moxifloxacin hydrochloride
moxifloxacin hydrochloride : A hydrochloride comprising equimolar amounts of moxifloxacin and hydrogen chloride.		2.0810hydrochlorideantibacterial drug
fulvestrant
Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.		3.612017beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide		antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist
mizoribine
[no description available]		2.0810imidazolesanticoronaviral agent
imipenem, anhydrous
Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.		21.0391840beta-lactam antibiotic allergen;
carbapenems;
zwitterion		antibacterial drug
sr141716
[no description available]		2.4720amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles		anti-obesity agent;
appetite depressant;
CB1 receptor antagonist
bosentan anhydrous
Bosentan: A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.		4.0840primary alcohol;
pyrimidines;
sulfonamide		antihypertensive agent;
endothelin receptor antagonist
selenomethionine
[no description available]		2.0510amino acid zwitterion;
selenomethionine		plant metabolite
sivelestat
sivelestat: inhibitor of neutrophil elastase; structure given in first source		2.0310N-acylglycine;
pivalate ester
racecadotril
racecadotril: parenterally active enkephalinase inhibitor		2.0810N-acyl-amino acid
perindopril
Perindopril: An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure.. perindopril : An alpha-amino acid ester that is the ethyl ester of N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvaline		3.5920alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
asulacrine
asulacrine: derivative of amsacrine; structure given in first source		2.0410acridines
hydroxycotinine
hydroxycotinine: metabolite of nicotine; RN given refers to (S)-isomer; structure. trans-3-hydroxycotinine : An N-alkylpyrrolidine that is cotinine substituted at position C-3 by a hydroxy group (the 3R,5S-diastereomer).		2.0410N-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid
fingolimod
fingolimod : An aminodiol that consists of propane-1,3-diol having amino and 2-(4-octylphenyl)ethyl substituents at the 2-position. It is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis. A prodrug, fingolimod is phosphorylated by sphingosine kinase to active metabolite fingolimod-phosphate, a structural analogue of sphingosine 1-phosphate.		2.0510aminodiol;
primary amino compound		antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
quinaprilat
quinaprilat: metabolite of quinapril. quinaprilat : A dicarboxylic acid resulting from the hydrolysis of the ethyl ester group of quinapril to give the corresponding dicarboxylic acid. The active angiotensin-converting enzyme inhibitor (ACE inhibitor) of the prodrug quinapril.		2.4520dicarboxylic acid;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
vasodilator agent
2-hydroxyimipramine
2-hydroxyimipramine: RN given refers to parent cpd		2.4520dibenzoazepine
ecteinascidin 743
[no description available]		2.4520acetate ester;
azaspiro compound;
bridged compound;
hemiaminal;
isoquinoline alkaloid;
lactone;
organic heteropolycyclic compound;
organic sulfide;
oxaspiro compound;
polyphenol;
tertiary amino compound		alkylating agent;
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
marine metabolite
1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Platelet Activating Factor: A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION.. 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine : A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine betaine which has hexadecyl as the alkyl group. PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis.		3.13102-acetyl-1-alkyl-sn-glycero-3-phosphocholineantihypertensive agent;
beta-adrenergic antagonist;
bronchoconstrictor agent;
hematologic agent;
vasodilator agent
tadalafil
[no description available]		3.6120benzodioxoles;
pyrazinopyridoindole		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
florfenicol
florfenicol: structure given in first source. florfenicol : A carboxamide that is the N-dichloroacetyl derivative of (1R,2S)-2-amino-3-fluoro-1-[4-(methanesulfonyl)phenyl]propan-1-ol. A synthetic veterinary antibiotic that is used for treatment of bovine respiratory disease and foot rot; also used in aquaculture.		2.8220organochlorine compound;
organofluorine compound;
secondary alcohol;
secondary carboxamide;
sulfone		antimicrobial agent
panipenem-betamipron
panipenem-betamipron: useful perenteral antibiotic against respiratory tract infections; structure given in first source		4.9281
paliperidone
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one : A member of the class of pyridopyrimidines that is 9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.. paliperidone : A racemate comprising equimolar amounts of (R)- and (S)-paliperidone. Paliperidone is the primary active metabolite of the older antipsychotic risperidone and is used for treatment of schizophrenia.		3.23101,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine;
secondary alcohol
nitisinone
[no description available]		3.5920(trifluoromethyl)benzenes;
C-nitro compound;
cyclohexanones;
mesotrione		EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor
plavix
[no description available]		2.0810azaheterocycle sulfate salt;
organoammonium sulfate salt		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
marimastat
marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary. marimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide.		2.0510hydroxamic acid;
secondary carboxamide		antineoplastic agent;
matrix metalloproteinase inhibitor
clofarabine
[no description available]		3.8730adenosines;
organofluorine compound		antimetabolite;
antineoplastic agent
pramipexole
Pramipexole: A benzothiazole derivative and dopamine agonist with antioxidant properties that is used in the treatment of PARKINSON DISEASE and RESTLESS LEGS SYNDROME.. pramipexole : A member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively.		3.6120benzothiazoles;
diamine		antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
radical scavenger
valdecoxib
[no description available]		3.6120isoxazoles;
sulfonamide		antipyretic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
mitiglinide
mitiglinide: a rapid and short-acting hypoglycemic agent; acts on sulfonylurea receptor closing KATP channels; considered one of the glinides-an imprecise grouping; structure given in first source		2.0510benzenes;
monocarboxylic acid
celastrol
[no description available]		2.4110monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory drug;
antineoplastic agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Hsp90 inhibitor;
metabolite
imatinib mesylate
imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.		2.0510methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
almotriptan
almotriptan : An indole compound having a 2-(dimethylamino)ethyl group at the 3-position and a (pyrrolidin-1-ylsulfonyl)methyl group at the 5-position.		4.0840indoles;
sulfonamide;
tertiary amine		non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
mk 0663
[no description available]		2.4620bipyridines;
organochlorine compound;
sulfone		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
tazobactam
Tazobactam: A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria.. tazobactam : A member of the class of penicillanic acids that is sulbactam in which one of the exocyclic methyl hydrogens is replaced by a 1,2,3-triazol-1-yl group; used (in the form of its sodium salt) in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections.		16.4313316penicillanic acids;
triazoles		antiinfective agent;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
gefitinib
[no description available]		4.0840aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine: structure given in first source; a selective A(3) adenosine receptor agonist. 3-iodobenzyl-5'-N-methylcarboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by N-ethylcarboxamido and one of the hydrogens of the exocyclic amino function is substituted by a 3-iodobenzyl group.		2.0510adenosines;
monocarboxylic acid amide;
organoiodine compound		adenosine A3 receptor agonist
polymyxin b nonapeptide
[no description available]		2.4920
desloratadine
desloratadine: major metabolite of loratadine. desloratadine : Loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis and chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness.		3.6120benzocycloheptapyridineanti-allergic agent;
cholinergic antagonist;
drug metabolite;
H1-receptor antagonist
garenoxacin
garenoxacin: a des-fluoro(6) quinolone with antibacterial activity. garenoxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid that is substituted by a cyclopropyl group at position 1, an oxo group at position 4, a (1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl group at position 7, and a difluoromethoxy group at position 8.		2.520aromatic ether;
cyclopropanes;
isoindoles;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic		antibacterial drug;
non-steroidal anti-inflammatory drug
1,4,7-triazacyclononane-n,n',n''-triacetic acid
1,4,7-triazacyclononane-N,N',N''-triacetic acid: structure given in first source		2.2110
desvenlafaxine
O-desmethylvenlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-hydroxyphenyl group. It is a metabolite of the drug venlafaxine.		3.2310cyclohexanols;
phenols;
tertiary amino compound		antidepressant;
drug metabolite;
marine xenobiotic metabolite
methotrexate
[no description available]		4.7790dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
cefbuperazone
cefbuperazone: RN given refers to parent cpd(6R-(6alpha,7alpha,7(2R*,3S*)))-isomer; structure. cefbuperazone : A second-generation cephamycin antibiotic having [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl and {N-[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]-D-threonyl}amino side groups located at positions 3 and 7beta respectively.		2.0410cephalosporin;
peptide
tamsulosin
[no description available]		3.85305-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamidealpha-adrenergic antagonist;
antineoplastic agent
rufinamide
rufinamide: for treatment of Lennox-Gastaut syndrome; structure in first source		3.2310aromatic amide;
heteroarene
antiprimod
azaspirane: structure given in first source		2.0510
sulperazone
sulperazone: combination of above two cpds		3.8621
sulbactam
[no description available]		7.66752penicillanic acids
olmesartan medoxomil
Olmesartan Medoxomil: An ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to manage HYPERTENSION.		3.8730biphenyls
dexpanthenol
dexpanthenol: The alcohol of pantothenic acid		3.2310amino alcohol;
monocarboxylic acid amide		cholinergic drug;
provitamin
fosamprenavir
fosamprenavir: a prodrug of the protease inhibitor amprenavir. fosamprenavir : A sulfonamide with a structure based on that of sulfanilamide substituted on the sulfonamide nitrogen by a (2R,3S)-4-phenyl-2-(phosphonooxy)-3-({[(3S)-tetrahydrofuran-3-yloxy]carbonyl}amino)butyl group. It is a pro-drug of the HIV protease inhibitor and antiretroviral drug amprenavir.		3.2310sulfonamideprodrug
ilomastat
CS 610: matrix metalloproteinase inhibitor; structure in first source. ilomastat : An N-acyl-amino acid obtained by formal condensation of the carboxy group of (2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the amino group of N-methyl-L-tryptophanamide. A cell permeable broad-spectrum matrix metalloproteinase (MMP) inhibitor		2.0510hydroxamic acid;
L-tryptophan derivative;
N-acyl-amino acid		anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
EC 3.4.24.24 (gelatinase A) inhibitor;
neuroprotective agent
abiraterone
[no description available]		2.08103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
pyridines		antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
centa
CENTA: structure; beta-lactamase chromogenic cephalosporin reagent		2.1310
febuxostat
Febuxostat: A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment of HYPERURICEMIA in patients with chronic GOUT.. febuxostat : A 1,3-thiazolemonocarboxylic acid that is 4-methyl-1,3-thiazole-5-carboxylic acid which is substituted by a 3-cyano-4-(2-methylpropoxy)phenyl group at position 2. It is an orally-active, potent, and selective xanthine oxidase inhibitor used for the treatment of chronic hyperuricaemia in patients with gout.		3.61201,3-thiazolemonocarboxylic acid;
aromatic ether;
nitrile		EC 1.17.3.2 (xanthine oxidase) inhibitor
dilevalol
(R,R)-labetalol : A 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide that has 1R,2R-configuration.		2.04102-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide
carbapenems
[no description available]		19.6458834
xylose
xylopyranose: structure in first source		2.6120D-xylose
beta-lactams
2-azetidinone: structure in first source. azetidin-2-one : An unsubstituted beta-lactam compound.. beta-lactam : A lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon.		16.141886beta-lactam antibiotic allergen;
beta-lactam
escitalopram
Escitalopram: S-enantiomer of CITALOPRAM. Belongs to a class of drugs known as SELECTIVE SEROTONIN REUPTAKE INHIBITORS, used to treat depression and generalized anxiety disorder.. escitalopram : A 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has S-configuration at the chiral centre. It is the active enantiomer of citalopram.		3.23101-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrileantidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
lexapro
Lexapro: Trade name of escitalopram, the active S-enantiomer of the racemic citalopram.		2.0810
10-propargyl-10-deazaaminopterin
10-propargyl-10-deazaaminopterin: structure in first source. pralatrexate : A pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma.		3.2310N-acyl-L-glutamic acid;
pteridines;
terminal acetylenic compound		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
docetaxel
[no description available]		2.9540hydrate;
secondary alpha-hydroxy ketone		antineoplastic agent
docetaxel anhydrous
Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.		3.6120secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
irofulven
irofulven: structure in first source		2.0410cyclohexenones
atazanavir
atazanavir : A heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV).		3.5920carbohydrazideantiviral drug;
HIV protease inhibitor
ym 872
YM 872: structure in first source		2.0410
levofloxacin
Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.		13.4713539-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
ezetimibe
Ezetimibe: An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.. ezetimibe : A beta-lactam that is azetidin-2-one which is substituted at 1, 3, and 4 by p-fluorophenyl, 3-(p-fluorophenyl)-3-hydroxypropyl, and 4-hydroxyphenyl groups, respectively (the 3R,3'S,4S enantiomer).		3.8730azetidines;
beta-lactam;
organofluorine compound		anticholesteremic drug;
antilipemic drug;
antimetabolite
ertapenem
Ertapenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.. ertapenem : Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract.		14.881963carbapenemcarboxylic acid;
pyrrolidinecarboxamide		antibacterial drug
phenylalanylarginine
phenylalanylarginine: RN given refers to all (L)-isomer. Phe-Arg : A dipeptide composed of L-phenylalanine and L-arginine joined by a peptide linkage.		2.110dipeptidemetabolite
dx 8951
[no description available]		2.0410pyranoindolizinoquinoline
cox 189
lumiracoxib: a COX-2 inhibitor. lumiracoxib : An amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity.		3.6120amino acid;
monocarboxylic acid;
organochlorine compound;
organofluorine compound;
secondary amino compound		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
cilomilast
[no description available]		2.4520methoxybenzenes
conivaptan
conivaptan : The amide resulting from the formal condensation of 4-[(biphenyl-2-ylcarbonyl)amino]benzoic acid with the benzazepine nitrogen of 2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine. It is an antagonist for two of the three types of arginine vasopressin (AVP) receptors, V1a and V2. It is used as its hydrochloride salt for the treatment of hyponatraemia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).		3.5820benzazepineaquaretic;
vasopressin receptor antagonist
cariporide
cariporide: a selective sodium-hydrogen exchange subtype 1 inhibitor; structure in first source		2.0510
tezosentan
tezosentan: structure in first source		2.4520
1,1'-biphenyl-4-yl-boronic acid
[no description available]		2.4110
sabarubicin
sabarubicin: structure given in first source		2.0410
moxifloxacin
Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.		10.05412aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
pralnacasan
pralnacasan: NSAID, ICE inhibitor & metastasis inhibitor; RN & structure in first source		3.2310
clevidipine
clevidipine: a calcium channel blocker and antihypertensive agent; structure in first source		3.5820dihydropyridine
jtt 501
JTT 501: an insulin sensitizer; structure in first source		2.0510
solifenacin
[no description available]		3.8530isoquinolines
dexmethylphenidate
dexmethylphenidate : A methyl phenyl(piperidin-2-yl)acetate in which both stereocentres have R configuration. It is the active enantiomer in the racemic drug methylphenidate.		3.2310methyl phenyl(piperidin-2-yl)acetateadrenergic agent
hyoscyamine
Hyoscyamine: The 3(S)-endo isomer of atropine.. (S)-atropine : An atropine with a 2S-configuration.		2.0710tropane alkaloid
xamoterol
Xamoterol: A phenoxypropanolamine derivative that is a selective beta-1-adrenergic agonist.		2.7530morpholines
naproxen
Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.		6.6891methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
cinacalcet
cinacalcet : A secondary amino compound that is (1R)-1-(naphthalen-1-yl)ethanamine in which one of the hydrogens attached to the nitrogen is substituted by a 3-[3-(trifluoromethyl)phenyl]propyl group.		3.2310(trifluoromethyl)benzenes;
naphthalenes;
secondary amino compound		calcimimetic;
P450 inhibitor
lubiprostone
[no description available]		3.2310
olmesartan
olmesartan: an active metabolite of CS 866		2.0710biphenylyltetrazoleangiotensin receptor antagonist;
antihypertensive agent
telbivudine
[no description available]		3.6120pyrimidine 2'-deoxyribonucleosideantiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
cyc 202
seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.		2.05102,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
an-69
AN-69: copolymer of acrylonitrile & sodium methallylsulfonate used in hemodialysis		3.4111
abanoquil
[no description available]		2.0410
tetraphenylphosphonium chloride
[no description available]		2.0510
paromomycin
Paromomycin: An aminoglycoside antibacterial and antiprotozoal agent produced by species of STREPTOMYCES.. paromomycin : An amino cyclitol glycoside that is the 1-O-(2-amino-2-deoxy-alpha-D-glucopyranoside) and the 3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranoside of 4,6-diamino-2,3-dihydroxycyclohexane (the 1R,2R,3S,4R,6S diastereoisomer). It is obtained from various Streptomyces species. A broad-spectrum antibiotic, it is used (generally as the sulfate salt) for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis.		3.5920amino cyclitol glycoside;
aminoglycoside antibiotic		anthelminthic drug;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
anidulafungin
Anidulafungin: Echinocandin antifungal agent that is used in the treatment of CANDIDEMIA and CANDIDIASIS.. anidulafungin : A semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis.		3.5820antibiotic antifungal drug;
azamacrocycle;
echinocandin;
heterodetic cyclic peptide;
semisynthetic derivative
avasimibe
[no description available]		2.0510monoterpenoid
17 alpha-hydroxyprogesterone caproate
17 alpha-Hydroxyprogesterone Caproate: Hydroxyprogesterone derivative that acts as a PROGESTIN and is used to reduce the risk of recurrent MISCARRIAGE and of PREMATURE BIRTH. It is also used in combination with ESTROGEN in the management of MENSTRUATION DISORDERS.		3.2310corticosteroid hormone
varenicline
Varenicline: A benzazepine derivative that functions as an ALPHA4-BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION.. varenicline : An organic heterotetracyclic compound that acts as a partial agonist for nicotinic cholinergic receptors and is used (in the form of its tartate salt) as an aid to giving up smoking.		3.2310
biotin
vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.		2.0510biotins;
vitamin B7		coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite
temocillin
temocillin: beta-lactam antibiotic with unusual spectrum of antibacterial activity & exceptional stability to bacterial beta-lactamases; RN given refers to di-Na salt (2S-(2alpha,5alpha,6alpha))-isomer; structure in first source. temocillin : A penicillin compound having a 6alpha-methoxy and 6beta-[2-carboxy(thiophen-3-yl)acetamido side-groups.		7.36121penicillin
fiduxosin
fiduxosin: fiduxosin (ABT-980) is the (3aR,9bR)-isomer; structure in first source		3.2310
atropine
tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.		4.4260
lignin
Lignin: The most abundant natural aromatic organic polymer found in all vascular plants. Lignin together with cellulose and hemicellulose are the major cell wall components of the fibers of all wood and grass species. Lignin is composed of coniferyl, p-coumaryl, and sinapyl alcohols in varying ratios in different plant species. (From Merck Index, 11th ed). lignin : A polyphenylpropanoid derived from three monolignol monomers: trans-p-coumaryl alcohol, coniferol and trans-sinapyl alcohol. There is extensive cross-linking and no defined primary structure.		4.911
ropivacaine
Ropivacaine: An anilide used as a long-acting local anesthetic. It has a differential blocking effect on sensory and motor neurons.. ropivacaine : The piperidinecarboxamide obtained by the formal condensation of N-propylpipecolic acid and 2,6-dimethylaniline.. (S)-ropivacaine : A piperidinecarboxamide-based amide-type local anaesthetic (amide caine) in which (S)-N-propylpipecolic acid and 2,6-dimethylaniline are combined to form the amide bond.		2.4320piperidinecarboxamide;
ropivacaine		local anaesthetic
erlotinib
[no description available]		3.2310aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
topsentin a
topsentin A: number of carbony group = 1 for topsentin A and no carbonyl group for nortopsentin B and D; structure in first source		2.0210
melagatran
[no description available]		2.4520azetidines;
carboxamidine;
dicarboxylic acid monoamide;
non-proteinogenic alpha-amino acid;
secondary amino compound		anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
serine protease inhibitor
oxytocin, asp(5)-
[no description available]		2.0510
carboxyebselen
carboxyebselen: a nitric oxide synthase inhibitor		2.1710
etravirine
[no description available]		3.2310aminopyrimidine;
aromatic ether;
dinitrile;
organobromine compound		antiviral agent;
HIV-1 reverse transcriptase inhibitor
aspergillomarasmine a
[no description available]		2.520
troleandomycin
Troleandomycin: A macrolide antibiotic that is similar to ERYTHROMYCIN.. troleandomycin : A semi-synthetic macrolide antibiotic obtained by acetylation of the three free hydroxy groups of oleandomycin. Troleandomycin is only found in individuals that have taken the drug.		2.4720acetate ester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyketide;
semisynthetic derivative		EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor;
xenobiotic
dronedarone
Dronedarone: A non-iodinated derivative of amiodarone that is used for the treatment of ARRHYTHMIA.. dronedarone : A member of the class of 1-benzofurans used for the treatment of cardiac arrhythmias.		3.23101-benzofurans;
aromatic ether;
aromatic ketone;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
environmental contaminant;
xenobiotic
tesaglitazar
tesaglitazar: structure in first source		2.4520
ramelteon
ramelteon: melatonin MT1/MT2 receptor agonist		3.6120indanes
lapatinib
[no description available]		3.2310furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
darunavir
Darunavir: An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.. darunavir : An N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors.		3.6220carbamate ester;
furofuran;
sulfonamide		antiviral drug;
HIV protease inhibitor
deferasirox
Deferasirox: A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA.. deferasirox : A member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patients receiving long-term blood transfusions.		3.8730benzoic acids;
monocarboxylic acid;
phenols;
triazoles		iron chelator
bms204352
BMS204352: a calcium-sensitive opener of maxi-K potassium channels; structure in first source		2.4620
fosfluconazole
fosfluconazole: prodrug of fluconazole		4.1231conazole antifungal drug;
triazole antifungal drug;
triazoles		prodrug
tbc-11251
sitaxsentan: endothelin A receptor antagonist; structure in first source		3.8730benzodioxoles
tolvaptan
[no description available]		3.6120benzazepine;
benzenedicarboxamide		aquaretic;
vasopressin receptor antagonist
sorafenib
[no description available]		3.2310(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
colistimethate sodium
[no description available]		7.8530
lenalidomide
[no description available]		4.4530aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
regadenoson
[no description available]		3.2310purine nucleoside
lacosamide
Lacosamide: An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.		3.6120N-acyl-amino acid
cp 101,606
traxoprodil mesylate: a selective NMDA antagonist; structure given in first source		2.4520
sitosterol, (3beta)-isomer
Sobatum: tradename; active fraction of Solanum trilobatum; reduces side-effects of radiation-induced toxicity. sitosterol : A member of the class of phytosterols that is stigmast-5-ene substituted by a beta-hydroxy group at position 3.		2.05103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
C29-steroid;
phytosterols;
stigmastane sterol		anticholesteremic drug;
antioxidant;
mouse metabolite;
plant metabolite;
sterol methyltransferase inhibitor
deoxycholic acid
Deoxycholic Acid: A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.. deoxycholic acid : A bile acid that is 5beta-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 12 respectively.		2.0510bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human blood serum metabolite
estradiol 3-benzoate
17beta-estradiol 3-benzoate : A benzoate ester resulting from the formal condensation of benzoic acid with the phenolic hydroxy group of 17beta-estradiol.		2.021017beta-hydroxy steroid;
benzoate ester		estrogen receptor agonist;
xenoestrogen
vincaleukoblastine
[no description available]		3.6120acetate ester;
indole alkaloid fundamental parent;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
immunosuppressive agent;
microtubule-destabilising agent;
plant metabolite
vincristine sulfate
[no description available]		2.0810organic sulfate saltantineoplastic agent;
geroprotector
benzarone
benzarone: antihemorrhagic agent; structure		3.59201-benzofurans
nsc-89199
estramustine phosphate : A steroid phosphate which is the 17-O-phospho derivative of estramustine.		2.0410carbamate ester;
organochlorine compound;
steroid phosphate
estramustine
Estramustine: A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.. estramustine : A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid.		3.853017beta-hydroxy steroid;
carbamate ester;
organochlorine compound		alkylating agent;
antineoplastic agent;
radiation protective agent
phenethicillin
phenethicillin: minor descriptor (85); major descriptor (63-84); on-line search PENICILLIN, PHENOXYMETHYL/AA (66-85); Index Medicus search PHENETHICILLIN (63-84); RN given refers to (2S-(2alpha,5alpha,6beta))-isomer. phenethicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-phenoxypropanamido group.		2.0410penicillin allergen;
penicillin
noscapine
Noscapine: A naturally occurring opium alkaloid that is a centrally acting antitussive agent.. (-)-noscapine : A benzylisoquinoline alkaloid that is 1,2,3,4-tetrahydroisoquinoline which is substituted by a 4,5-dimethoxy-3-oxo-1,3-dihydro-2-benzofuran-1-yl group at position 1, a methylenedioxy group at positions 6-7 and a methoxy group at position 8. Obtained from plants of the Papaveraceae family, it lacks significant painkilling properties and is primarily used for its antitussive (cough-suppressing) effects.		2.0510aromatic ether;
benzylisoquinoline alkaloid;
cyclic acetal;
isobenzofuranone;
organic heterobicyclic compound;
organic heterotricyclic compound;
tertiary amino compound		antineoplastic agent;
antitussive;
apoptosis inducer;
plant metabolite
homoharringtonine
Homoharringtonine: Semisynthetic derivative of harringtonine that acts as a protein synthesis inhibitor and induces APOPTOSIS in tumor cells. It is used in the treatment of MYELOID LEUKEMIA, CHRONIC.. omacetaxine mepesuccinate : A cephalotaxine-derived alkaloid ester obtained from Cephalotaxus harringtonia; used for the treatment of chronic or accelerated phase chronic myeloid leukaemia.		2.0510alkaloid ester;
enol ether;
organic heteropentacyclic compound;
tertiary alcohol		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
protein synthesis inhibitor
acivicin
[no description available]		2.4420isoxazoles;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		antileishmanial agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor;
glutamine antagonist;
metabolite
wortmannin
[no description available]		2.0810acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound		anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
menthofuran
menthofuran: RN given refers to cpd without isomeric designation; derives from cyclization of pulegone. menthofuran : A monoterpenoid that is 4,5,6,7-tetrahydro-1-benzofuran substituted by methyl groups at positions 3 and 6.		2.07101-benzofurans;
monoterpenoid		nematicide;
plant metabolite
trimethoprim, sulfamethoxazole drug combination
Trimethoprim, Sulfamethoxazole Drug Combination: A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.. co-trimoxazole : A two-component mixture comprising trimethoprim and sulfamethoxazole.		10.23562
o-(chloroacetylcarbamoyl)fumagillol
O-(Chloroacetylcarbamoyl)fumagillol: Semisynthetic analog of fumagillin (a cyclohexane-sesquiterpene antibiotic isolated from ASPERGILLUS FUMIGATUS) that inhibits angiogenesis.. O-(chloroacetylcarbamoyl)fumagillol : A carbamate ester that is fumagillol in which the hydroxy group has been converted to the corresponding N-(chloroacetyl)carbamate derivative.		2.0510carbamate ester;
organochlorine compound;
semisynthetic derivative;
sesquiterpenoid;
spiro-epoxide		angiogenesis inhibitor;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
methionine aminopeptidase 2 inhibitor;
retinoic acid receptor alpha antagonist
bortezomib
[no description available]		4.850amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
ritonavir
Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.		4.59701,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
tizoxanide
tizoxanide: major metabolite of nitazoxanide; structure in first source		2.0310salicylamides
nu 6027
[no description available]		3.5110
bromodeoxytopsentin
bromodeoxytopsentin: from sponge Topsentia pachastrelloides; structure in first source. bromodeoxytopsentin : An aromatic ketone that is imidazole which is substituted by a 1H-indole-3-carbonyl group and a 6-bromo-1H-indol-3-yl group at positions 2 and 4, respectively. Isolated from the Mediterranean shallow-water sponge, Topsentia genetrix. It is a potent inhibitor of MRSA pyruvate kinase and exhibits antibacterial properties.		2.0210aromatic ketone;
bromoindole;
imidazoles;
indole alkaloid		antibacterial agent;
EC 2.7.1.40 (pyruvate kinase) inhibitor;
marine metabolite
nexavar
[no description available]		2.0510organosulfonate salt
carboplatin
[no description available]		2.6120
rimiterol
rimiterol: was heading 1977-94 (see under CATECHOLS 1977-90); use CATECHOLS to search RIMITEROL 1977-94; predominantly a beta 2 stimulant, therefore affects the cardiovascular system less than isoproterenol, but its action is of shorter duration than that of albuterol		2.0610catechols
glucosamine
D-glucosamine : An amino sugar whose structure comprises D-glucose having an amino substituent at position 2.. 2-amino-2-deoxy-D-glucopyranose : A D-glucosamine whose structure comprises D-glucopyranose having an amino substituent at position 2.		2.0510D-glucosamineEscherichia coli metabolite;
geroprotector;
mouse metabolite
raffinose
Raffinose: A trisaccharide occurring in Australian manna (from Eucalyptus spp, Myrtaceae) and in cottonseed meal.. raffinose : A trisaccharide composed of alpha-D-galactopyranose, alpha-D-glucopyranose and beta-D-fructofuranose joined in sequence by 1->6 and 1<->2 glycosidic linkages, respectively.		2.0610raffinose family oligosaccharide;
trisaccharide		mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
epiglucan
epiglucan: a highly side-chain/branched alkali-insoluble cell wall glucan from fungus such as Epicoccum nigrum, Botrytis cinerea, ascomycetes & basidiomycetes; also isolated S-4001 from Lei Wan (polyporus mylitiae), HA-beta-glucan from mushroom Pleutotus ostreatus (Fr.) Quel., and translam from seaweed Laminaria cichorioides; with commercially important functional properties including emulsification and friction reduction.		2.1310
oxytocin
Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.		3.5920heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
laminaran
beta-1,3-glucan: component of fungal cell walls; also used as antitumor polysaccharide; unspecified D usually means BETA-GLUCANS; beta-1,3-D-glucan is also available; glucan phosphate is also available; biosynthesis is inhibited by echinocandins (cyclic hexapeptides). laminarin : A polysaccharide composed of beta-(1->3)-linked glucose residues containing sporadic beta-(1->6)-linkages as branch points or inter-residue linkages and 2-3% D-mannitol at some reducing termini.		2.1310
ouabain
Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.		2.061011alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone		anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite
pentostatin
Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.. pentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia.		3.8530coformycinsantimetabolite;
antineoplastic agent;
Aspergillus metabolite;
bacterial metabolite;
EC 3.5.4.4 (adenosine deaminase) inhibitor
quinidine
Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.		4.6580cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
thienamycin
thienamycin: beta-lactam antibiotic; RN given refers to cpd without isomeric designation		210carbapenems
sq 27860
carbapenem-3-carboxylic acid: from species of Serratia & Erwinia; carbapenam antibiotic; structure given in first source. 1-carbapenem-3-carboxylic acid : A carbapenemcarboxylic acid that is the 3-carboxy derivative of 2,3-didehydro-1-carbapenam.		2.0410alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid
griseofulvin
Griseofulvin: An antifungal agent used in the treatment of TINEA infections.. griseofulvin : An oxaspiro compound produced by Penicillium griseofulvum. It is used by mouth as an antifungal drug for infections involving the scalp, hair, nails and skin that do not respond to topical treatment.		4.6401-benzofurans;
antibiotic antifungal drug;
benzofuran antifungal drug;
organochlorine compound;
oxaspiro compound		antibacterial agent;
Penicillium metabolite
cefoxitin
Cefoxitin: A semisynthetic cephamycin antibiotic resistant to beta-lactamase.. cefoxitin : A semisynthetic cephamycin antibiotic which, in addition to the methoxy group at the 7alpha position, has 2-thienylacetamido and carbamoyloxymethyl side-groups. It is resistant to beta-lactamase.		10.72963beta-lactam antibiotic allergen;
cephalosporin;
cephamycin;
semisynthetic derivative		antibacterial drug
digitoxin
Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain.		2.7530cardenolide glycosideEC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
moxalactam disodium
[no description available]		2.0210
saquinavir
Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.		4.2550L-asparagine derivative;
quinolines		antiviral drug;
HIV protease inhibitor
pancuronium
Pancuronium: A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than CURARE but has less effect on the circulatory system and on histamine release.. pancuronium : A steroid ester in which a 5alpha-androstane skeleton is C-3alpha- and C-17beta-disubstituted with acetoxy groups and 2beta- and 16beta-disubstituted with 1-methylpiperidinium-1-yl groups. It is a non-depolarizing curare-mimetic muscle relaxant.		3.5820acetate ester;
steroid ester		cholinergic antagonist;
muscle relaxant;
nicotinic antagonist
rocuronium
Rocuronium: An androstanol non-depolarizing neuromuscular blocking agent. It has a mono-quaternary structure and is a weaker nicotinic antagonist than PANCURONIUM.. rocuronium : A 5alpha-androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents.		2.04103alpha-hydroxy steroid;
acetate ester;
androstane;
morpholines;
quaternary ammonium ion;
tertiary amino compound		drug allergen;
muscle relaxant;
neuromuscular agent
abacavir
abacavir: a carbocyclic nucleoside with potent selective anti-HIV activity. abacavir : A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.		3.85302,6-diaminopurinesantiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor
netilmicin
Netilmicin: Semisynthetic 1-N-ethyl derivative of SISOMYCIN, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity.		6142
trimethaphan camsylate
trimethaphan camsylate : The (S)-camphorsulfonate salt of trimethaphan.		2.0510
perindopril erbumine
[no description available]		2.0810addition compoundantihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
miglitol
[no description available]		4.0840piperidines
metyrosine
alpha-methyl-L-tyrosine : An L-tyrosine derivative that consists of L-tyrosine bearing an additional methyl substituent at position 2. An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma.		3.8530L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		antihypertensive agent;
EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor
rocuronium bromide
rocuronium bromide : The organic bromide salt of a 5alpha androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents.		2.4520organic bromide salt;
quaternary ammonium salt		muscle relaxant;
neuromuscular agent
erythromycin estolate
Erythromycin Estolate: A macrolide antibiotic, produced by Streptomyces erythreus. It is the lauryl sulfate salt of the propionic ester of erythromycin. This erythromycin salt acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.		2.0510aminoglycoside sulfate salt;
erythromycin derivative		enzyme inhibitor
terconazole
terconazole: structure & RN for (cis)-isomer from first source. terconazole : A racemate consisting of equimolar amounts of (2R,4S)- and (2S,4R)-terconazole. It has broad-spectrum antifungal activitiy and is used for the treatment of vaginal yeast infections (Candida).. (2R,4S)-terconazole : A 1-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine in which positions 2 and 4 of the 1,3-dioxolane moiety have R and S configuration, respectively.		2.02101-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine
bacampicillin
bacampicillin: ester prodrug that is hydrolyzed to ampicillin after its absorption from the gastrointestinal tract; RN given refers to parent cpd; structure. bacampicillin : A penicillanic acid ester that is the 1-ethoxycarbonyloxyethyl ester of ampicillin. It is a semi-synthetic, microbiologically inactive prodrug of ampicillin.		2.0210penicillanic acid esterprodrug
linezolid
[no description available]		10.25872acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
indican
[no description available]		2.3110beta-D-glucoside;
exopolysaccharide;
indolyl carbohydrate
cyclopamine
[no description available]		2.0510piperidinesglioma-associated oncogene inhibitor
1-deoxy-d-xylulose 5-phosphate
deoxyxylulose phosphate: structure in first source. 1-deoxy-D-xylulose 5-phosphate : The 5-phospho derivative of 1-deoxy-D-xylulose.		2.1310xylulose phosphateEscherichia coli metabolite
phenylalanine arginine beta-naphthylamide
phenylalanine arginine beta-naphthylamide: a drug efflux pump inhibitor; structure in first source		2.1110peptide
devazepide
Devazepide: A derivative of benzodiazepine that acts on the cholecystokinin A (CCKA) receptor to antagonize CCK-8's (SINCALIDE) physiological and behavioral effects, such as pancreatic stimulation and inhibition of feeding.. devazepide : An indolecarboxamide obtained by formal condensation of the carboxy group of indole-2-carboxylic acid with the exocyclic amino group of (3S)-3-amino-1-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one. A cholecystokinin antagonist used for treatment of gastrointestinal disorders.		2.05101,4-benzodiazepinone;
indolecarboxamide		antineoplastic agent;
apoptosis inducer;
cholecystokinin antagonist;
gastrointestinal drug
clindamycin phosphate
[no description available]		3.2310
pemirolast potassium salt
[no description available]		2.0810
eplerenone
Eplerenone: A spironolactone derivative and selective ALDOSTERONE RECEPTOR antagonist that is used in the management of HYPERTENSION and CONGESTIVE HEART FAILURE, post-MYOCARDIAL INFARCTION.		3.61203-oxo-Delta(4) steroid;
epoxy steroid;
gamma-lactone;
methyl ester;
organic heteropentacyclic compound;
oxaspiro compound;
steroid acid ester		aldosterone antagonist;
antihypertensive agent
tolterodine
[no description available]		4.0840tertiary amineantispasmodic drug;
muscarinic antagonist;
muscle relaxant
doxorubicin hydrochloride
[no description available]		2.0510anthracycline
erythromycin ethylsuccinate
Erythromycin Ethylsuccinate: A macrolide antibiotic, produced by Streptomyces erythreus. This compound is an ester of erythromycin base and succinic acid. It acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin ethylsuccinate : A erythromycin derivative that is erythromycin A in which the hydroxy group at position 3R is substituted by a (4-ethoxy-4-oxobutanoyl)oxy group. It is used for the treatment of a wide variety of bacterial infections.		2.4420cyclic ketone;
erythromycin derivative;
ethyl ester;
succinate ester
amcinonide
amcinonide: structure		2.021011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
acetate ester;
corticosteroid;
fluorinated steroid;
spiroketal		anti-inflammatory drug
betamethasone acetate
[no description available]		2.021011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
acetate ester;
fluorinated steroid;
steroid ester;
tertiary alpha-hydroxy ketone
ao 128
AO 128: alpha-glucosidase inhibitor; structure given in first source		2.4720organic molecular entity
sultamicillin
sultamicillin: contains ampicillin & sulbactam		7.22152penicillanic acid ester
loteprednol etabonate
Loteprednol Etabonate: An androstadiene derivative corticosteroid that is used as an ANTI-ALLERGIC AGENT for the treatment of inflammatory and allergic eye conditions.		2.081011beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
etabonate ester;
organochlorine compound;
steroid acid ester;
steroid ester		anti-inflammatory drug
darifenacin
darifenacin : 2-[(3S)-1-Ethylpyrrolidin-3-yl]-2,2-diphenylacetamide in which one of the hydrogens at the 2-position of the ethyl group is substituted by a 2,3-dihydro-1-benzofuran-5-yl group. It is a selective antagonist for the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions, and is used as the hydrobromide salt in the management of urinary incontinence.		3.58201-benzofurans;
monocarboxylic acid amide;
pyrrolidines		antispasmodic drug;
muscarinic antagonist
fluticasone propionate
fluticasone propionate : A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity.		2.462011beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
corticosteroid;
fluorinated steroid;
propanoate ester;
steroid ester;
thioester		adrenergic agent;
anti-allergic agent;
anti-asthmatic drug;
anti-inflammatory drug;
bronchodilator agent;
dermatologic drug
betadex
beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.		2.5220cyclodextrin
acarbose
[no description available]		2.9640amino cyclitol;
glycoside
tretinoin
Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.		4.2650retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
farnesol
Farnesol: A colorless liquid extracted from oils of plants such as citronella, neroli, cyclamen, and tuberose. It is an intermediate step in the biological synthesis of cholesterol from mevalonic acid in vertebrates. It has a delicate odor and is used in perfumery. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed). (2-trans,6-trans)-farnesol : The (2-trans,6-trans)-stereoisomer of farnesol.. farnesol : A farnesane sesquiterpenoid that is dodeca-2,6,10-triene substituted by methyl groups at positions 3, 7 and 11 and a hydroxy group at position 1.		2.3110farnesolplant metabolite
resveratrol
trans-resveratrol : A resveratrol in which the double bond has E configuration.		4.911resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
retinol
Vitamin A: Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of CAROTENOIDS found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products.. vitamin A : Any member of a group of fat-soluble retinoids produced via metabolism of provitamin A carotenoids that exhibit biological activity against vitamin A deficiency. Vitamin A is involved in immune function, vision, reproduction, and cellular communication.. all-trans-retinol : A retinol in which all four exocyclic double bonds have E- (trans-) geometry.. retinol : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraen-1-ol substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).		3.5920retinol;
vitamin A		human metabolite;
mouse metabolite;
plant metabolite
alpha-D-fructofuranose 1,6-bisphosphate
alpha-D-fructofuranose 1,6-bisphosphate : A D-fructofuranose 1,6-bisphosphate with an alpha-configuration at the anomeric position.		2.0510D-fructofuranose 1,6-bisphosphate
docosahexaenoate
efalex: a mixture of fish oil and primrose oil; used as a high-docosahexaenoic acid fatty acid supplement. docosahexaenoic acid : Any C22 polyunsaturated fatty acid containing six double bonds.. docosahexaenoate : A polyunsaturated fatty acid anion that is the conjugate base of docosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.. all-cis-docosa-4,7,10,13,16,19-hexaenoic acid : A docosahexaenoic acid having six cis-double bonds at positions 4, 7, 10, 13, 16 and 19.		2.0510docosahexaenoic acid;
omega-3 fatty acid		algal metabolite;
antineoplastic agent;
Daphnia tenebrosa metabolite;
human metabolite;
mouse metabolite;
nutraceutical
oleic acid
Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed). oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry.		2.5320octadec-9-enoic acidantioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent
tacrolimus
Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.		9.4460macrolide lactambacterial metabolite;
immunosuppressive agent
cerivastatin
cerivastatin: cerivastatin is the ((E)-(+))-isomer; structure given in first source. cerivastatin : (3R,5S)-3,5-dihydroxyhept-6-enoic acid in which the (7E)-hydrogen is substituted by a 4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl group. Formerly used (as its sodium salt) to lower cholesterol and prevent cardiovascular disease, it was withdrawn from the market worldwide in 2001 following reports of a severe form of muscle toxicity.		2.7430dihydroxy monocarboxylic acid;
pyridines;
statin (synthetic)
rosuvastatin
rosuvastatin : A dihydroxy monocarboxylic acid that is (6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl} hept-6-enoic acid carrying two hydroxy substituents at positions 3 and 5 (the 3R,5S-diastereomer).		4.0840dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrimidines;
statin (synthetic);
sulfonamide		anti-inflammatory agent;
antilipemic drug;
cardioprotective agent;
CETP inhibitor;
environmental contaminant;
xenobiotic
cocaine
Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.		2.9640benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
eicosapentaenoic acid
icosapentaenoic acid : Any straight-chain, C20 polyunsaturated fatty acid having five C=C double bonds.. all-cis-5,8,11,14,17-icosapentaenoic acid : An icosapentaenoic acid having five cis-double bonds at positions 5, 8, 11, 14 and 17.		2.0510icosapentaenoic acid;
omega-3 fatty acid		anticholesteremic drug;
antidepressant;
antineoplastic agent;
Daphnia galeata metabolite;
fungal metabolite;
micronutrient;
mouse metabolite;
nutraceutical
mycophenolic acid
Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.		3.85302-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic
mupirocin
Mupirocin: A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.. mupirocin : An alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections.		2.7330alpha,beta-unsaturated carboxylic ester;
epoxide;
monocarboxylic acid;
oxanes;
secondary alcohol;
triol		antibacterial drug;
bacterial metabolite;
protein synthesis inhibitor
clindamycin
Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.		12.92787
brivudine
brivudine: anti-herpes agent		2.0610
fosfomycin
Fosfomycin: An antibiotic produced by Streptomyces fradiae.. fosfomycin : A phosphonic acid having an (R,S)-1,2-epoxypropyl group attached to phosphorus.		11.03572epoxide;
phosphonic acids		antimicrobial agent;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
zithromax
Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.		7.01380macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
drf 2725
ragaglitazar: a phenoxazine analogue of phenyl propanoic acid; Ragaglitazar is a coligand of PPARalpha and PPARgamma		2.0510
diethylstilbestrol
Diethylstilbestrol: A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed). diethylstilbestrol : An olefinic compound that is trans-hex-3-ene in which the hydrogens at positions 3 and 4 have been replaced by p-hydroxyphenyl groups.		2.4720olefinic compound;
polyphenol		antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen
bms 214662
7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine: a farnesyltransferase inhibitor; structure in first source. BMS-214662 : A member of the class of benzodiazepines that is 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine substituted by (1H-imidazol-5-yl)methyl, benzyl, (thiophen-2-yl)sulfonyl, and cyano groups at positions 1, 3R, 4 and 7, respectively. It is a potent inhibitor of farnesyltransferase (IC50 = 1.35nM) which was under clinical development for the treatment of solid tumors.		2.0410benzenes;
benzodiazepine;
imidazoles;
nitrile;
sulfonamide;
thiophenes		antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
octreotide
[no description available]		3.2310
eptifibatide
[no description available]		3.5820homodetic cyclic peptide;
macrocycle;
organic disulfide		anticoagulant;
platelet aggregation inhibitor
alitretinoin
Alitretinoin: A retinoid that is used for the treatment of chronic hand ECZEMA unresponsive to topical CORTICOSTEROIDS. It is also used to treat cutaneous lesions associated with AIDS-related KAPOSI SARCOMA.		2.0510retinoic acidantineoplastic agent;
keratolytic drug;
metabolite;
retinoid X receptor agonist
gs 4071
GS 4071: The acid form.. oseltamivir acid : A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid which is substituted at positions 3, 4, and 5 by pentan-3-yloxy, acetamido, and amino groups, respectively (the 3R,4R,5S enantiomer). An antiviral drug, it is used as the corresponding ethyl ester prodrug, oseltamivir, to slow the spread of influenza.		2.4520acetate ester;
amino acid;
cyclohexenecarboxylic acid;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
marine xenobiotic metabolite
decitabine
[no description available]		4.26502'-deoxyribonucleoside
sm 8668
Sch 39304: Sch 42427 is the active entantiomer of the antifungal agent Sch 39304 which consists of Sch 42426 & Sch 42427; Sch 42426, the (S,S)-isomer, is inactive		2.0410
teniposide
[no description available]		4.4160aromatic ether;
beta-D-glucoside;
cyclic acetal;
furonaphthodioxole;
gamma-lactone;
monosaccharide derivative;
phenols;
thiophenes		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
troxacitabine
troxacitabine: shows good anti-HIV activity without cytotoxicity		2.0410carbohydrate derivative;
nucleobase-containing molecular entity
valrubicin
[no description available]		2.0810anthracycline;
trifluoroacetamide
pa 824
pretomanid: nitroimidazopyran derived from 5-nitroimidazoles; a prodrug that requires activation by a bacterial F420-depedent glucose-6-phosphate dehydrogenase (Fgd) and nitroreductase to activate components that then inhibit bacterial mycolic acid and protein synthesis; structure in first source		3.8930
ketoconazole
(2R,4S)-ketoconazole : A cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2R,4S)-configuration.		3.3110cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
cefamandole
Cefamandole: Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate.. cefamandole : A cephalosporin compound having (R)-mandelamido and N-methylthiotetrazole side-groups.		3.2760cephalosporin;
semisynthetic derivative		antibacterial drug
dactinomycin
Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)		4.0740actinomycinmutagen
tiazofurin
tiazofurin: RN given refers to (beta-D)-isomer; structure given in first source. tiazofurine : A C-glycosyl compound that is 1,3-thiazole-4-carboxamide in which the hydrogen at position 2 has been replaced by a beta-D-ribofuranosyl group. It is metabolised to thiazole-4-carboxamide adenine dinucleotide (TAD), a selective inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase).		2.73301,3-thiazoles;
C-glycosyl compound;
monocarboxylic acid amide		antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
prodrug
5-carboxy-8-hydroxyquinoline
5-carboxy-8-hydroxyquinoline: a JmjC histone demethylase inhibitor; structure in first source		2.4110quinolines
melphalan
Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.		6.5881L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
sitafloxacin
[no description available]		2.7430fluoroquinolone antibiotic;
quinolines;
quinolone antibiotic
tenofovir
tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.		4.0840nucleoside analogue;
phosphonic acids		antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor
u 100480
U 100480: structure given in first source		3.5110
posaconazole
[no description available]		3.6120aromatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles		trypanocidal drug
l 743,872
[no description available]		4.7280
dibekacin
Dibekacin: Analog of KANAMYCIN with antitubercular as well as broad-spectrum antimicrobial properties.. dibekacin : A kanamycin that is kanamycin B lacking the 3- and 4-hydroxy groups on the 2,6-diaminosugar ring.		2.9640kanamycinsantibacterial agent;
protein synthesis inhibitor
rubitecan
rubitecan: RN refers to (+-)-isomer; anti-HIV agent; DNA Topoisomerases, Type I inhibitor. rubitecan : A pyranoindolizinoquinoline that is camptothecin in which the hydrogen at position 9 has been replaced by a nitro group. It is a prodrug for 9-aminocamptothecin.		2.4720C-nitro compound;
delta-lactone;
pyranoindolizinoquinoline;
semisynthetic derivative;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
micafungin
Micafungin: A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.. micafungin : A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.		5.9871antibiotic antifungal drug;
echinocandin		antiinfective agent
abt 492
WQ 3034: structure in first source		4.0330
favipiravir
favipiravir : A member of the class of pyrazines that is pyrazine substituted by aminocarbonyl, hydroxy and fluoro groups at positions 2, 3 and 6, respectively. It is an anti-viral agent that inhibits RNA-dependent RNA polymerase of several RNA viruses and is approved for the treatment of influenza in Japan.		7.4110hydroxypyrazine;
organofluorine compound;
primary carboxamide		anticoronaviral agent;
antiviral drug;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor
riboflavin
vitamin B2 : Any member of a group of vitamers that belong to the chemical structural class called flavins that exhibit biological activity against vitamin B2 deficiency. Symptoms associated with vitamin B2 deficiency include glossitis, seborrhea, angular stomaitis, cheilosis and photophobia. The vitamers include riboflavin and its phosphate derivatives (and includes their salt, ionised and hydrate forms).		3.5920flavin;
vitamin B2		anti-inflammatory agent;
antioxidant;
cofactor;
Escherichia coli metabolite;
food colouring;
fundamental metabolite;
human urinary metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite
n,n'-ethylenediamine disuccinic acid
N,N'-ethylenediamine disuccinic acid: from Actinomycetes MG417-CF17; structure given in first source		2.4110
sodium bicarbonate
Sodium Bicarbonate: A white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.		3.5920one-carbon compound;
organic sodium salt		antacid;
food anticaking agent
sodium acetate, anhydrous
Sodium Acetate: The trihydrate sodium salt of acetic acid, which is used as a source of sodium ions in solutions for dialysis and as a systemic and urinary alkalizer, diuretic, and expectorant.		2.0510organic sodium saltNMR chemical shift reference compound
sodium benzoate
Sodium Benzoate: The sodium salt of BENZOIC ACID. It is used as an antifungal preservative in pharmaceutical preparations and foods. It may also be used as a test for liver function.. sodium benzoate : An organic sodium salt resulting from the replacement of the proton from the carboxy group of benzoic acid by a sodium ion.		2.0510organic sodium saltalgal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite
arsenic trioxide
Tetraarsenic Oxide: A form of As2O3 that exists as As4O6 in the solid state. It dissociates to As2O3 upon heating to the vapor phase above 800 degrees Celsius.		3.2310arsenic oxideantineoplastic agent;
insecticide
dipyrone
Dipyrone: A drug that has analgesic, anti-inflammatory, and antipyretic properties. It is the sodium sulfonate of AMINOPYRINE.. metamizole sodium : An organic sodium salt of antipyrine substituted at C-4 by a methyl(sulfonatomethyl)amino group, commonly used as a powerful analgesic and antipyretic.		3.9121organic sodium saltanti-inflammatory agent;
antipyretic;
antirheumatic drug;
cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug;
prodrug
ditiocarb sodium
[no description available]		2.0510organic molecular entity
sch 22219
alclometasone dipropionate : A prednisolone compound having an alpha-chloro substituent at the 7-position, an alpha-methyl substituent at the 16-position and O-propanoyl groups at the 17- and 21-positions.		2.021011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
glucocorticoid;
propanoate ester;
steroid ester		anti-inflammatory drug
sr 90107
fondaparinux sodium : An organic sodium salt, being the decasodium salt of fondaparinux.		3.2310
carbenoxolone
[no description available]		2.0510
cefpiramide
cefpiramide: antipseudomonal cephalosporin derivative. cefpiramide : A third-generation cephalosporin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl and (R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It has a broad spectrum of antibacterial activity.		2.420carboxylic acid;
cephalosporin		antibacterial drug
meglumine iodipamide
[no description available]		3.2310organoammonium saltradioopaque medium
isomethyleugenol
Methylation: Addition of methyl groups. In histo-chemistry methylation is used to esterify carboxyl groups and remove sulfate groups by treating tissue sections with hot methanol in the presence of hydrochloric acid. (From Stedman, 25th ed)		1.9910isomethyleugenol
thyrotropin-releasing hormone
PR 546: no other info available 9/89. protirelin : A tripeptide composed of L-pyroglutamyl, L-histidyl and L-prolinamide residues joined in sequence.		3.2310peptide hormone;
tripeptide		human metabolite
discodermolide
[no description available]		2.0510diterpenoid
cannabidiol
Cannabidiol: Compound isolated from Cannabis sativa extract.. cannabidiol : An cannabinoid that is cyclohexene which is substituted by a methyl group at position 1, a 2,6-dihydroxy-4-pentylphenyl group at position 3, and a prop-1-en-2-yl group at position 4.		2.0510olefinic compound;
phytocannabinoid;
resorcinols		antimicrobial agent;
plant metabolite
arginine vasopressin
Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.. argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6.		3.6120vasopressincardiovascular drug;
hematologic agent;
mitogen
s 1033
[no description available]		3.2310(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
mezlocillin
Mezlocillin: Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.. mezlocillin : A penicillin in which the substituent at position 6 of the penam ring is a (2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido group.		8.1350penicillin allergen;
penicillin		antibacterial drug
amygdalin
(R)-amygdalin : An amygdalin in which the stereocentre on the cyanohydrin function has R-configuration.		2.0610amygdalinantineoplastic agent;
apoptosis inducer;
plant metabolite
cefsulodin
Cefsulodin: A pyridinium-substituted semisynthetic, broad-spectrum antibacterial used especially for Pseudomonas infections in debilitated patients.. cefsulodin : A pyridinium-substituted semi-synthetic, broad-spectrum, cephalosporin antibiotic.		1.9810cephalosporin;
organosulfonic acid;
primary carboxamide		antibacterial drug
trilostane
trilostane: inhibits conversion of pregnenolone to progesterone; adrenal blocking agent used in treatment of Cushing's syndrome. trilostane : An epoxy steroid that is 3,17beta-dihydroxy-5alpha-androst-2-ene-2-carbonitrile in which the oxygen of the epoxy group is joined to the 4alpha and 5 alpha positions.		2.081017beta-hydroxy steroid;
3-hydroxy steroid;
androstanoid;
epoxy steroid;
nitrile		abortifacient;
antineoplastic agent;
EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor
cholinophyllin
[no description available]		2.0210
tropisetron
Tropisetron: An indole derivative and 5-HT3 RECEPTOR antagonist that is used for the prevention of nausea and vomiting.. tropisetron : An indolyl carboxylate ester obtained by formal condensation of the carboxy group of indole-3-carboxylic acid with the hydroxy group of tropine.		2.0410indolyl carboxylic acid
leuprolide acetate
leuprolide acetate : An acetate salt obtained by combining the nonapeptide leuprolide with acetic acid. A long lasting GnRH analog, LH-Rh agonist. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.		2.0810acetate saltantineoplastic agent;
gonadotropin releasing hormone agonist
leuprolide
Leuprolide: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.. leuprolide : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.		2.4620oligopeptideanti-estrogen;
antineoplastic agent;
gonadotropin releasing hormone agonist
fludarabine
[no description available]		2.4320purine nucleoside
propylthiouracil
Propylthiouracil: A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534). 6-propyl-2-thiouracil : A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group.		4.6680pyrimidinethioneantidote to paracetamol poisoning;
antimetabolite;
antioxidant;
antithyroid drug;
carcinogenic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
hormone antagonist
ipratropium bromide anhydrous
[no description available]		2.0210
ipratropium
[no description available]		2.0710
prothionamide
Prothionamide: Antitubercular agent similar in action and side effects to ETHIONAMIDE. It is used mostly in combination with other agents.		2.0510pyridines
etomidate
Etomidate: Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.. etomidate : The ethyl ester of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid. It is an intravenous general anaesthetic with no analgesic activity.		4.0640ethyl ester;
imidazoles		intravenous anaesthetic;
sedative
mercaptopurine
Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.		4.5470aryl thiol;
purines;
thiocarbonyl compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent
levosulpiride
(S)-(-)-sulpiride : An optically active form of sulpiride having (S)-configuration. The active enantiomer of the racemic drug sulpiride. Selective D2-like dopamine antagonist (Ki values are ~ 0.015. ~ 0.013, 1, ~ 45 and ~ 77 muM at D2, D3, D4, D1 and D5 receptors respectively).		2.0810sulpirideantidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
1-(1-naphthylmethyl)piperazine
[no description available]		2.0610
pyrantel
Pyrantel: A depolarizing neuromuscular-blocking agent, that causes persistent nicotinic activation resulting in spastic paralysis of susceptible nematodes. It is a drug of second-choice after benzimidazoles for treatment of ascariasis, hookworm, and pinworm infections, being effective after a single dose. (From Smith and Reynard, Textbook of Pharmacology, 1992, p920). pyrantel : A carboxamidine that is 1,4,5,6-tetrahydropyrimidine that is substituted at position 1 by a methyl group and at position 2 by an (E)-2-(2-thienyl)vinyl group. It is used, particularly as the embonate [4,4'-methylenebis(3-hydroxy-2-naphthoate)] salt, as an anthelmintic that is effective against intestinal nematodes including threadworms, roundworms and hookworms, and is included in the WHO 'Model List of Essential Medicines'.		3.23101,4,5,6-tetrahydropyrimidines;
carboxamidine;
thiophenes		antinematodal drug
n-benzoylalanine
N-benzoylalanine: RN given refers to parent cpd (L-Ala)-isomer. N-benzoylalanine : An N-acylamino acid that is the N-benzoyl derivative of alanine.. N-benzoyl-L-alanine : An N-acyl-L-alanine resulting from the formal condensation of L-alanine with the carboxy group of benzoic acid.		2.0310N-acyl-L-alanine;
N-benzoylalanine		metabolite
cotinine
Cotinine: The N-glucuronide conjugate of cotinine is a major urinary metabolite of NICOTINE. It thus serves as a biomarker of exposure to tobacco SMOKING. It has CNS stimulating properties.. (-)-cotinine : An N-alkylpyrrolidine that consists of N-methylpyrrolidinone bearing a pyridin-3-yl substituent at position C-5 (the 5S-enantiomer). It is an alkaloid commonly found in Nicotiana tabacum.		2.0410N-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid		antidepressant;
biomarker;
human xenobiotic metabolite;
plant metabolite
thiothixene
[no description available]		3.5620N-methylpiperazineanticoronaviral agent
eszopiclone
Eszopiclone: A pyridine, pyrazine, and piperazine derivative that is used as a HYPNOTIC AND SEDATIVE in the treatment of INSOMNIA.. eszopiclone : The (5S)- (active) enantiomer of zopiclone. Unlike almost all other hypnotic sedatives, which are approved only for the relief of short-term (6-8 weeks) insomnia, eszopiclone is approved by the U.S. Food and Drug Administration for long-term use.		3.6120zopiclonecentral nervous system depressant;
sedative
rhodanine
2-mercaptothiazolinone: metabolite in urine from persons exposed to CS2; structure		2.110thiazolidinone
benztropine
Benztropine: A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.. benzatropine : Tropane in which a hydrogen at position 3 is substituted by a diphenylmethoxy group (endo-isomer). An acetylcholine receptor antagonist, it is used (particularly as its methanesulphonate salt) in the treatment of Parkinson's disease, and to reduce parkinsonism and akathisia side effects of antipsychotic treatments.		3.5620diarylmethane
methimazole
Methimazole: A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.. methimazole : A member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen.		4.29501,3-dihydroimidazole-2-thionesantithyroid drug
cinnarizine
Cinnarizine: A piperazine derivative having histamine H1-receptor and calcium-channel blocking activity with vasodilating and antiemetic properties but it induces PARKINSONIAN DISORDERS.		2.0810diarylmethane;
N-alkylpiperazine;
olefinic compound		anti-allergic agent;
antiemetic;
calcium channel blocker;
geroprotector;
H1-receptor antagonist;
histamine antagonist;
muscarinic antagonist
sulindac
Sulindac: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.. sulindac : A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.		4.2650monocarboxylic acid;
organofluorine compound;
sulfoxide		analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent
capsaicin
ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.		2.0510capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
enclomiphene
Enclomiphene: The trans or (E)-isomer of clomiphene.		2.0210
terbinafine
[no description available]		3.8530acetylenic compound;
allylamine antifungal drug;
enyne;
naphthalenes;
tertiary amine		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor;
sterol biosynthesis inhibitor
epalrestat
epalrestat : A monocarboxylic acid that is 1,3-thiazolidine which is substituted on the nitrogen by a carboxymethyl group, at positions 2 and 4 by thioxo and oxo groups, respectively, and at position 5 by a 2-methyl-3-phenylprop-2-en-1-ylidene group. It is an inhibitor of aldose reductase (which catalyses the conversion of glucose to sorbitol) and is used for the treatment of some diabetic complications, including neuropathy.		2.0810monocarboxylic acid;
thiazolidines		EC 1.1.1.21 (aldehyde reductase) inhibitor
drotaverin
drotaverin: Hungarian drug; RN given refers to parent cpd; structure		2.7530isoquinolines
thioguanine anhydrous
Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.		3.85302-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent
tacrine hydrochloride
[no description available]		2.0510
sodium propionate
sodium propionate: was term of propionic acid (1986-2006). sodium propionate : An organic sodium salt comprising equal numbers of sodium and propionate ions.		2.0510organic sodium saltantifungal drug;
food preservative
D-fructopyranose
[no description available]		2.520cyclic hemiketal;
D-fructose;
fructopyranose		sweetening agent
succimer
Succimer: A mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them.. succimer : A sulfur-containing carboxylic acid that is succinic acid bearing two mercapto substituents at positions 2 and 3. A lead chelator used as an antedote to lead poisoning.		3.5620dicarboxylic acid;
dithiol;
sulfur-containing carboxylic acid		chelator
digoxin
Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.		4.2650cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
streptozocin
[no description available]		4.0740
tamoxifen
[no description available]		5.5480stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
ethionamide
Ethionamide: A second-line antitubercular agent that inhibits mycolic acid synthesis.. ethionamide : A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.		4.6140pyridines;
thiocarboxamide		antilipemic drug;
antitubercular agent;
fatty acid synthesis inhibitor;
leprostatic drug;
prodrug
cancidas
[no description available]		3.5820
5-nitro-8-(1-pyrrolidinyl)quinoline
[no description available]		2.4110nitro compound;
quinolines
fusidic acid
Fusidic Acid: An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed). It acts by inhibiting translocation during protein synthesis.. fusidic acid : A steroid antibiotic that is isolated from the fermentation broth of Fusidium coccineum.		3.457011alpha-hydroxy steroid;
3alpha-hydroxy steroid;
alpha,beta-unsaturated monocarboxylic acid;
steroid acid;
steroid antibiotic;
sterol ester		EC 2.7.1.33 (pantothenate kinase) inhibitor;
Escherichia coli metabolite;
protein synthesis inhibitor
lincomycin
Lincomycin: An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.. lincomycin : A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis.		4.350carbohydrate-containing antibiotic;
L-proline derivative;
monocarboxylic acid amide;
pyrrolidinecarboxamide;
S-glycosyl compound		antimicrobial agent;
bacterial metabolite
valinomycin
Valinomycin: A cyclododecadepsipeptide ionophore antibiotic produced by Streptomyces fulvissimus and related to the enniatins. It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid linked alternately to form a 36-membered ring. (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies.. valinomycin : A twelve-membered cyclodepsipeptide composed of three repeating D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl units joined in sequence. An antibiotic found in several Streptomyces strains.		2.0810cyclodepsipeptide;
macrocycle		antimicrobial agent;
antiviral agent;
bacterial metabolite;
potassium ionophore
thiopental
Thiopental: A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration.. thiopental : A barbiturate, the structure of which is that of 2-thiobarbituric acid substituted at C-5 by ethyl and sec-pentyl groups.		2.4520barbituratesanticonvulsant;
drug allergen;
environmental contaminant;
intravenous anaesthetic;
sedative;
xenobiotic
estrone sulfate
estrone sulfate: sulfoconjugated estrone; RN given refers to parent cpd		2.051017-oxo steroid;
steroid sulfate		human metabolite;
mouse metabolite
ranitidine
Ranitidine: A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.. ranitidine : A member of the class of furans used to treat peptic ulcer disease (PUD) and gastroesophageal reflux disease.		3.2310C-nitro compound;
furans;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic
aplaviroc
aplaviroc: a spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1; structure in first source		3.2310
hmr 3647
[no description available]		4.94110
latoconazole
latoconazole: RN refers to cpd without isomeric designation; latoconazole is (E)-isomer; structure given in first source		2.0810conazole antifungal drug;
imidazole antifungal drug
maraviroc
[no description available]		3.6120tropane alkaloid
toremifene citrate
[no description available]		2.0810stilbenoidanticoronaviral agent
toremifene
Toremifene: A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.		3.5920aromatic ether;
organochlorine compound;
tertiary amine		antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
telaprevir
[no description available]		2.0510cyclopentapyrrole;
cyclopropanes;
oligopeptide;
pyrazines		antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic
nelarabine
nelarabine: prodrug of ara-G. nelarabine : A purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G).		3.8730beta-D-arabinoside;
monosaccharide derivative;
purine nucleoside		antineoplastic agent;
DNA synthesis inhibitor;
prodrug
2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine
[no description available]		2.4520aromatic ether
dermatan sulfate
Dermatan Sulfate: A naturally occurring glycosaminoglycan found mostly in the skin and in connective tissue. It differs from CHONDROITIN SULFATE A (see CHONDROITIN SULFATES) by containing IDURONIC ACID in place of glucuronic acid, its epimer, at carbon atom 5. (from Merck, 12th ed). alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S : An oligosaccharide sulfate that is 2-acetamido-2-deoxy-4-O-sulfo-beta-D-galactopyranose in which the hydroxy group at position 3 has been converted to the corresponding alpha-L-idopyranuronoside.. dermatan sulfate : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated beta1->4-linked L-iduronyl-(alpha1->3)-N-acetyl-D-galactosamine units.		3.2310amino disaccharide;
glycosylgalactose derivative;
iduronic acids;
oligosaccharide sulfate
dezocine
dezocine: potent analgesic; RN given refers to ((5R-(5alpha,11alpha,13S*)))-isomer (dezocin); structure. dezocine : (7S,8S)-7-Amino-8-methyl-5,6,7,8-tetrahydronaphthalen-2-ol in which the hydrogen at position 8 and one of the hydrogens at position 6 are substituted by each end of a tetramethylene bridge. A synthetic opioid analgesic, it has mixed opiod agonist and antagonist properties. Although it is used for pain management, it can produce opioid withdrawal syndrome in patients already dependent on other opioids, and its clinical application is limited by side effects such as dizziness.		2.0210phenols;
primary amino compound		opioid analgesic
dapiprazole
[no description available]		2.0210N-alkylpiperazine;
N-arylpiperazine;
pyridines		alpha-adrenergic antagonist;
antipsychotic agent;
miotic;
ophthalmology drug
droloxifene
[no description available]		2.0510stilbenoid
dolasetron
[no description available]		3.5820indolyl carboxylic acid
or 1259
[no description available]		2.4520hydrazone;
nitrile;
pyridazinone		anti-arrhythmia drug;
cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
vasodilator agent
gestodene
Gestodene: synthetic steroid with progestational activity; RN given refers to (17alpha)-isomer		2.7530steroidestrogen
orlistat
Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.		3.8730beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative		anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor
idoxifene
idoxifene: structure given in first source		2.0510stilbenoid
quinine
[no description available]		4.2750cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
methyldithiocarbazate
methyldithiocarbazate: structure		2.610
glycodeoxycholic acid
Glycodeoxycholic Acid: A bile salt formed in the liver by conjugation of deoxycholate with glycine, usually as the sodium salt. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and choleretic.. glycodeoxycholic acid : A bile acid glycine conjugate of deoxycholic acid.		2.0110bile acid glycine conjugatehuman metabolite
isepamicin
[no description available]		2.7430
ifetroban
ifetroban: thromboxane receptor antagonist; structure given in first source; a 7-oxabicyclo(2.2.1)heptane derivative		2.4420benzenes;
monocarboxylic acid
hamacanthine a
hamacanthine A: a dihydropyrazinonediylbis(indole) alkaloid from deep-water marine sponge Hamacantha sp.; structure in first source. hamacanthin A : A member of the class of pyrazinones that is 5,6-dihydropyrazin-2(1H)-one substituted at positions 3 and 6 by 6-bromo-1H-indol-3-yl groups. It is an antifungal drug isolated from deep water marine sponge Hamacantha sp.		2.0310
lamifiban
lamifiban: a nonpeptide glycoprotein IIb/IIIa antagonist; prevents platelet loss during experimental cardiopulmonary bypass		2.4420N-acylglycine
fospropofol
[no description available]		3.2310alkylbenzene
azilect
[no description available]		2.0810
rasagiline
[no description available]		3.2310indanes;
secondary amine;
terminal acetylenic compound		EC 1.4.3.4 (monoamine oxidase) inhibitor;
neuroprotective agent
dasatinib
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).		3.61201,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
carbonyl 3-chlorophenylhydrazone
carbonyl 3-chlorophenylhydrazone: inhibitor of ATP synthesis; inhibits iron-containing nitrile hydratases		2.8430
zd 6474
CH 331: structure in first source		2.0510aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine		antineoplastic agent;
tyrosine kinase inhibitor
telavancin
telavancin: an anti-infective agent; structure in first source. telavancin : A glycopeptide that is vancomycin substituted at position N-3'' by a 2-(decylamino)ethyl group and at position C-29 by a (phosphonomethyl)aminomethyl group. Used as its hydrochloride salt for treatment of adults with complicated skin and skin structure infections caused by bacteria.		7.9840glycopeptideantibacterial drug;
antimicrobial agent
silybin
[no description available]		2.0510
susalimod
susalimod: analogue of sulphasalazine, was designed for use in the treatment of rheumatoid arthritis		2.0210
sodium dodecyl sulfate
Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.. sodium dodecyl sulfate : An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.		3.2350organic sodium saltdetergent;
protein denaturant
galactomannan
galactomannan: a galectin inhibitor. galactomannan : A heteroglycan consisting of a mannan backbone with galactose side groups.		2.1310oligosaccharide
chloramine-t
chloramine-T: RN given refers to unlabeled parent cpd. chloramine T : An organic sodium salt derivative of toluene-4-sulfonamide with a chloro substituent in place of an amino hydrogen.		2.0510organic sodium saltallergen;
antifouling biocide;
disinfectant
naphthoquinones
Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.		2.1310
digitoxigenin
Digitoxigenin: 3 beta,14-Dihydroxy-5 beta-card-20(22)enolide. A cardenolide which is the aglycon of digitoxin. Synonyms: Cerberigenin; Echujetin; Evonogenin; Thevetigenin.. digitoxigenin : A 5beta-cardenolide that is 5beta-cardanolide with hydroxy substituents at the 3beta- and 14beta-positions and double bond unsaturation at C(20)-C(22).		2.61014beta-hydroxy steroid;
3beta-hydroxy steroid
sitagliptin
sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.		4.0840triazolopyrazine;
trifluorobenzene		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
environmental contaminant;
hypoglycemic agent;
serine proteinase inhibitor;
xenobiotic
flosequinan
[no description available]		2.4420quinolines
tolcapone
Tolcapone: A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated.. tolcapone : Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase.		4.26502-nitrophenols;
benzophenones;
catechols		antiparkinson drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
sq 109
N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine: has antitubercular activity		3.6520
quercetin
[no description available]		3.04407-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		2.0510prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
dinoprost
Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.		2.0510monocarboxylic acid;
prostaglandins Falpha		human metabolite;
mouse metabolite
tylosin
[no description available]		2.4110aldehyde;
disaccharide derivative;
enone;
leucomycin;
macrolide antibiotic;
monosaccharide derivative		allergen;
bacterial metabolite;
environmental contaminant;
xenobiotic
calcitriol
dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes		4.0840D3 vitamins;
hydroxycalciol;
triol		antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical
beta carotene
beta Carotene: A carotenoid that is a precursor of VITAMIN A. Beta carotene is administered to reduce the severity of photosensitivity reactions in patients with erythropoietic protoporphyria (PORPHYRIA, ERYTHROPOIETIC).. provitamin A : A provitamin that can be converted into vitamin A by enzymes from animal tissues.		2.0510carotenoid beta-end derivative;
cyclic carotene		antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A
alprostadil
[no description available]		2.9740prostaglandins Eanticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent
vitamin d 2
Ergocalciferols: Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.. vitamin D2 : A vitamin D supplement and has been isolated from alfalfa.		3.6120hydroxy seco-steroid;
seco-ergostane;
vitamin D		bone density conservation agent;
nutraceutical;
plant metabolite;
rodenticide
cholecalciferol
Cholecalciferol: Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24.. calciol : A hydroxy seco-steroid that is (5Z,7E)-9,10-secocholesta-5,7,10(19)-triene in which the pro-S hydrogen at position 3 has been replaced by a hydroxy group. It is the inactive form of vitamin D3, being hydroxylated in the liver to calcidiol (25-hydroxyvitamin D3), which is then further hydroxylated in the kidney to give calcitriol (1,25-dihydroxyvitamin D3), the active hormone.		2.0510D3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
steroid hormone		geroprotector;
human metabolite
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		10.93180antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
clavulanic acid
Clavulanic Acid: A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.. clavulanate : The conjugate base of clavulanic acid.. clavulanic acid : Antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes.		6.67640oxapenamantibacterial drug;
anxiolytic drug;
bacterial metabolite;
EC 3.5.2.6 (beta-lactamase) inhibitor
pulmicort
Budesonide: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.. budesonide : A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.		4.547011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic acetal;
glucocorticoid;
primary alpha-hydroxy ketone		anti-inflammatory drug;
bronchodilator agent;
drug allergen
oxymetholone
Oxymetholone: A synthetic hormone with anabolic and androgenic properties. It is used mainly in the treatment of anemias. According to the Fourth Annual Report on Carcinogens (NTP 85-002), this compound may reasonably be anticipated to be a carcinogen. (From Merck Index, 11th ed). oxymetholone : A 3-oxo-5alpha- steroid that is 4,5alpha-dihydrotestosterone which is substituted by a hydroxymethylidene group at position 2 and by a methyl group at the 17alpha position. A synthetic androgen, it was mainly used for the treatment of anaemias until being replaced by treatments with fewer side effects.		3.8730
eprosartan
eprosartan: angiotensin II receptor antagonist. eprosartan : A member of the class of imidazoles and thiophenes that is an angiotensin II receptor antagonist used for the treatment of high blood pressure.		4.0840dicarboxylic acid;
imidazoles;
thiophenes		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
montelukast
montelukast: a leukotriene D4 receptor antagonist		4.2650aliphatic sulfide;
monocarboxylic acid;
quinolines		anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist
mivacurium
Mivacurium: An isoquinoline derivative that is used as a short-acting non-depolarizing agent.		3.5820isoquinolines
brompheniramine maleate
brompheniramine maleate : The maleic acid salt of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.		2.0810maleate saltanti-allergic agent
dexchlorpheniramine maleate
[no description available]		2.0810organic molecular entity
olopatadine
[no description available]		2.0210
hemabate
carboprost tromethamine : The tromethamine salt of carboprost. It is used as an abortifacient agent that is effective in both the first and second trimesters of pregnancy.		3.2310
mycophenolate mofetil
mycophenolate mofetil : A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.		3.8730carboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound		anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug
bw b1090u
[no description available]		2.0210isoquinolines
entacapone
entacapone: structure given in first source. entacapone : A monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group.		4.26502-nitrophenols;
catechols;
monocarboxylic acid amide;
nitrile		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
paricalcitol
[no description available]		3.8530hydroxy seco-steroid;
seco-cholestane		antiparathyroid drug
astaxanthine
astaxanthine: a keto form of carotene; pigment in flesh of Scottish salmon (Salmo salar) crustacoa-lobster (Homarus gammarus, flamingo feathers; structure; a carotenoid without vitamin A activity, has shown anti-oxidant and anti-inflammatory activities. astaxanthin : A carotenone that consists of beta,beta-carotene-4,4'-dione bearing two hydroxy substituents at positions 3 and 3' (the 3S,3'S diastereomer). A carotenoid pigment found mainly in animals (crustaceans, echinoderms) but also occurring in plants. It can occur free (as a red pigment), as an ester, or as a blue, brown or green chromoprotein.		2.0510carotenol;
carotenone		animal metabolite;
anticoagulant;
antioxidant;
food colouring;
plant metabolite
humulene
humulene: structure given in first source. (1E,4E,8E)-alpha-humulene : The (1E,4E,8E)-isomer of alpha-humulene.		4.911alpha-humulene
baicalein
[no description available]		8.0120trihydroxyflavoneangiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger
diosmin
[no description available]		2.0510dihydroxyflavanone;
disaccharide derivative;
glycosyloxyflavone;
monomethoxyflavone;
rutinoside		anti-inflammatory agent;
antioxidant
fisetin
[no description available]		7.41103'-hydroxyflavonoid;
7-hydroxyflavonol;
tetrahydroxyflavone		anti-inflammatory agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
metabolite;
plant metabolite
cynarine
cynarine: active principle of the artichoke; functions primarily as a cholagogue and choleretic and also as antilipemic agent		2.0510alkyl caffeate ester;
quinic acid		plant metabolite
sdz psc 833
valspodar: nonimmunosuppressive cyclosporin analog which is a potent multidrug resistance modifier; 7-10 fold more potent than cyclosporin A; a potent P glycoprotein inhibitor; MW 1215		2.4520homodetic cyclic peptide
l 660,711
[no description available]		2.4520quinolines
coenzyme q10
coenzyme Q10: Ubiquinone ring with a chain of 10 isoprene units; redox equilibrium with ubiqunol serving in mitochondrial inner membrane to transfer electrons; presence during reconstitution of acetylcholine receptor into phospholipid vesicles yields vesicles active in catalyzing carbamylcholine-sensitive Na+ flux; coenzyme Q10 depletion has been noted with use of statins. coenzyme Q10 : A ubiquinone having a side chain of 10 isoprenoid units. In the naturally occurring isomer, all isoprenyl double bonds are in the E- configuration.		2.0510ubiquinonesantioxidant;
ferroptosis inhibitor;
human metabolite
cerulenin
Cerulenin: An epoxydodecadienamide isolated from several species, including ACREMONIUM, Acrocylindrum, and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.. cerulenin : An epoxydodecadienamide isolated from several species, including Acremonium, Acrocylindrum and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.		2.7220epoxide;
monocarboxylic acid amide		antifungal agent;
antiinfective agent;
antilipemic drug;
antimetabolite;
antimicrobial agent;
fatty acid synthesis inhibitor
miocamycin
Miocamycin: A macrolide antibiotic that has a wide antimicrobial spectrum and is particularly effective in respiratory and genital infections.		2.0110
rokitamycin
rokitamycin: structure in first source		7.0110organic molecular entity
travoprost
Travoprost: A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.. travoprost : The isopropyl ester of prostaglandin F2alpha in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. A synthetic analogue of prostaglandin F2alpha, ophthalmic solutions of travoprost are used as a topical medication for controlling the progression of open-angle glaucoma and ocular hypertension, by reducing intraocular pressure. It is a pro-drug; the isopropyl ester group is hydrolysed by esterases in the cornea to the biologically active free acid, fluprostenol.		2.0810(trifluoromethyl)benzenes;
isopropyl ester;
prostaglandins Falpha		antiglaucoma drug;
antihypertensive agent;
ophthalmology drug;
prodrug;
prostaglandin receptor agonist
tranilast
tranilast: antiallergic drug; potent inhibitor of homologous passive cutaneous anaphylaxis. tranilast : An amidobenzoic acid that is anthranilic acid in which one of the anilino hydrogens is replaced by a 3,4-dimethoxycinnamoyl group.		2.4720amidobenzoic acid;
cinnamamides;
dimethoxybenzene;
secondary carboxamide		anti-allergic agent;
anti-asthmatic drug;
antineoplastic agent;
aryl hydrocarbon receptor agonist;
calcium channel blocker;
hepatoprotective agent;
nephroprotective agent
7432 s
Ceftibuten: A cephalosporin antibacterial agent that is used in the treatment of infections, including urinary-tract and respiratory-tract infections.. ceftibuten : A third-generation cephalosporin antibiotic with a [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino substituent at the 7 position of the cephem skeleton. An orally-administered agent, ceftibuten is used as the dihydrate to treat urinary-tract and respiratory-tract infections.		3.8530cephalosporin;
dicarboxylic acid		antibacterial drug
imipenem
[no description available]		2.7230carbapenems
etretinate
retinoid : Oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.		2.7430enoate ester;
ethyl ester;
retinoid		keratolytic drug
isotretinoin
Isotretinoin: A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects.. isotretinoin : A retinoic acid that is all-trans-retinoic acid in which the double bond which is alpha,beta- to the carboxy group is isomerised to Z configuration. A synthetic retinoid, it is used for the treatment of severe cases of acne and other skin diseases.		4.0840retinoic acidantineoplastic agent;
keratolytic drug;
teratogenic agent
misoprostol
Misoprostol: A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties.. misoprostol : A diastereoisomeric mixture composed of approximately equal amounts of a double racemate of four of the sixteen possible diastereoisomers of methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate that is racemic prostaglandin E1 which is lacking the hydroxy group at position 15, but which has an additional hydroxy group at position 16. It is a synthetic prostaglandin E1 analogue, used in the treatment of gastric and duodenal ulcers. A weak abortifacient, it is also used for cervical ripening prior to surgical termination of pregnancy. The (11R,16S)-diastereoisomer is the pharmacologically active form.		2.4420
ketotifen fumarate
ketotifen fumarate : An organoammonium salt consisting of equimolar amounts of ketotifen(1+) and fumarate(1-) ions. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is a non-bronchodilator anti-asthmatic drug.		2.0810organoammonium saltanti-asthmatic drug;
H1-receptor antagonist
epoprostenol
[no description available]		3.5620prostaglandins Imouse metabolite
indocyanine green
[no description available]		3.58201,1-diunsubstituted alkanesulfonate;
benzoindole;
cyanine dye
dinoprost tromethamine
[no description available]		2.0810organic molecular entity
s 1108
S 1108: structure given in first source; an oral cephem antibiotic and prodrug of S-1006		2.2110
ozagrel
ozagrel: RN refers to (E)-isomer		2.0510cinnamic acids
triprolidine
Triprolidine: Histamine H1 antagonist used in allergic rhinitis; ASTHMA; and URTICARIA. It is a component of COUGH and COLD medicines. It may cause drowsiness.. triprolidine : An N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms of uticaria, rhinitis, and various pruritic skin disorders.		3.2310N-alkylpyrrolidine;
olefinic compound;
pyridines		H1-receptor antagonist
pitavastatin
pitavastatin : A dihydroxy monocarboxylic acid that is (6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]hept-6-enoic acid in which the two hydroxy groups are located at positions 3 and 5 (the 3R,5S-stereoisomer). Used as its calcium salt for treatment of hypercholesterolemia (elevated levels of cholesterol in the blood) on patients unable to sufficiently lower their cholesterol levels by diet and exercise.		3.5920cyclopropanes;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
quinolines;
statin (synthetic)		antioxidant
rosuvastatin calcium
S 4522: structure in first source		2.0810N-acyl-15-methylhexadecasphinganine-1-phosphoethanolamine;
organic calcium salt		anti-inflammatory agent;
cardioprotective agent;
CETP inhibitor
terbinafine hydrochloride
terbinafine hydrochloride : A hydrochloride obtained by reaction of terbinafine with one molar equivalent of hydrogen chloride.		2.0810allylamine antifungal drug;
hydrochloride		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor
ethamolin
monoethanolamine oleate: used for treatment of pyogenic granuloma		3.2310long-chain fatty acid
betamethasone benzoate
[no description available]		2.021021-hydroxy steroid
alatrofloxacin mesylate
[no description available]		3.5920
codeine
[no description available]		4.2650morphinane alkaloid;
organic heteropentacyclic compound		antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic
cyclosporine
ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF		4.4260homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
natamycin
[no description available]		2.4720antibiotic antifungal drug;
dicarboxylic acid monoester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyene antibiotic		antifungal agrochemical;
antimicrobial food preservative;
apoptosis inducer;
bacterial metabolite;
ophthalmology drug
acitretin
Acitretin: An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.. acitretin : A retinoid that consists of 3,7-dimethylnona-2,4,6,8-tetraenoic acid having a 4-methoxy-2,3,6-trimethylphenyl group attached at position 9.		3.8730acitretin;
alpha,beta-unsaturated monocarboxylic acid;
retinoid		keratolytic drug
cyproterone
Cyproterone: An anti-androgen that, in the form of its acetate (CYPROTERONE ACETATE), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.		2.071017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
chlorinated steroid;
tertiary alpha-hydroxy ketone		androgen antagonist
dorzolamide
dorzolamide: topically effective ocular hypotensive carbonic anhydrase inhibitor; RN refers to mono-HCl (4S-trans)-isomer. dorzolamide : 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide in which hydrogens at the 4 and 6 positions are substituted by ethylamino and methyl groups, respectively (4S, trans-configuration). A carbonic anhydrase inhibitor, it is used as the hydrochloride in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension.		2.0210sulfonamide;
thiophenes		antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
dothiepin
[no description available]		2.0510dothiepin
estropipate
estropipate: used therapeutically in menopausal patients		3.2310piperazinium salt;
steroid sulfate
hydrocodone
Hydrocodone: Narcotic analgesic related to CODEINE, but more potent and more addicting by weight. It is used also as cough suppressant.. hydrocodone : A morphinane-like compound that is a semi-synthetic opioid synthesized from codeine.		2.0710morphinane-like compound;
organic heteropentacyclic compound		antitussive;
mu-opioid receptor agonist;
opioid analgesic
hydromorphone
Hydromorphone: An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.. hydromorphone : A morphinane alkaloid that is a hydrogenated ketone derivative of morphine. A semi-synthetic drug, it is a centrally acting pain medication of the opioid class.		4.0740morphinane alkaloid;
organic heteropentacyclic compound		mu-opioid receptor agonist;
opioid analgesic
levetiracetam
Levetiracetam: A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.. levetiracetam : A pyrrolidinone and carboxamide that is N-methylpyrrolidin-2-one in which one of the methyl hydrogens is replaced by an aminocarbonyl group, while another is replaced by an ethyl group (the S enantiomer). An anticonvulsant, it is used for the treatment of epilepsy in both human and veterinary medicine.		5.0140pyrrolidin-2-onesanticonvulsant;
environmental contaminant;
xenobiotic
ly 163892
loracarbef: 1-carbacephem antibiotic; has a broad spectrum of antimicrobial activity; structure given in first source; carbacephems differ from cephalosporins in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. loracarbef : A synthetic "carba" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria.		3.8430carbacephem;
zwitterion		antibacterial drug;
antimicrobial agent
nabilone
nabilone: cannabinol deriv; RN given refers to cpd without isomeric designation; structure		3.2310
nalmefene
nalmefene: RN given refers to 5-alpha isomer		2.9640morphinane alkaloid
nalorphine
Nalorphine: A narcotic antagonist with some agonist properties. It is an antagonist at mu opioid receptors and an agonist at kappa opioid receptors. Given alone it produces a broad spectrum of unpleasant effects and it is considered to be clinically obsolete.		2.0510morphinane alkaloid
naloxone
Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.		4.2650morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
oxycodone
Oxycodone: A semisynthetic derivative of CODEINE.. oxycodone : A semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.		4.0840organic heteropentacyclic compound;
semisynthetic derivative		antitussive;
mu-opioid receptor agonist;
opioid analgesic
oxymorphone
Oxymorphone: An opioid analgesic with actions and uses similar to those of MORPHINE, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092)		3.8730morphinane alkaloid
vitamin k 1
Vitamin K 1: A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity.. phylloquinone : A member of the class of phylloquinones that consists of 1,4-naphthoquinone having methyl and phytyl groups at positions 2 and 3 respectively. The parent of the class of phylloquinones.		3.2310phylloquinones;
vitamin K		cofactor;
human metabolite;
plant metabolite
sirolimus
Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.		3.8630antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
topiramate
Topiramate: A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.. topiramate : A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.		4.4260cyclic ketal;
ketohexose derivative;
sulfamate ester		anticonvulsant;
sodium channel blocker
trospium chloride
trospium chloride : An organic chloride salt of trospium. It is an antispasmodic drug used for the treatment of overactive bladder.		3.2310
alvocidib
alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.		2.4520dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound		antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
seocalcitol
seocalcitol: structure given in first source		2.0510
fenretinide
Fenretinide: A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.. 4-hydroxyphenyl retinamide : A retinoid obtained by formal condensation of the carboxy group of all-trans retinoic acid and the anilino group of 4-hydroxyaniline. Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids.		2.0510monocarboxylic acid amide;
retinoid		antineoplastic agent;
antioxidant
geldanamycin
[no description available]		2.05101,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound		antimicrobial agent;
antineoplastic agent;
antiviral agent;
cysteine protease inhibitor;
Hsp90 inhibitor
calcipotriene
[no description available]		2.0210cyclopropanes;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
triol		antipsoriatic;
drug allergen
morphine
Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.		5.0570morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
demycarosylturimycin h
[no description available]		2.4720
acipimox
acipimox: lipolysis inhibitor		2.0810pyrazinecarboxylic acid
atosiban
[no description available]		2.0810oligopeptide
benzphetamine
Benzphetamine: A sympathomimetic agent with properties similar to DEXTROAMPHETAMINE. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222). benzphetamine : Dextroamphetamine in which the the hydrogens attached to the amino group are substituted by a methyl and a benzyl group. A sympathomimetic agent with properties similar to dextroamphetamine, it is used as its hydrochloride salt in the treatment of obesity.		3.2310amphetamines;
tertiary amine		adrenergic uptake inhibitor;
appetite depressant;
dopamine uptake inhibitor;
sympathomimetic agent
bimatoprost
Bimatoprost: A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.		2.0810monocarboxylic acid amideantiglaucoma drug;
antihypertensive agent
cicaprost
cicaprost: RN given refers to (3aS-(2E,3aalpha,4alpha(3R*,4R*),5beta,6aalpha))-isomer		2.0410monoterpenoid
clobetasol
Clobetasol: A derivative of PREDNISOLONE with high glucocorticoid activity and low mineralocorticoid activity. Absorbed through the skin faster than FLUOCINONIDE, it is used topically in treatment of PSORIASIS but may cause marked adrenocortical suppression.. clobetasol : A 3-oxo-Delta(1),Delta(4)-steroid that is 16beta-methylpregna-1,4-diene-3,20-dione bearing hydroxy groups at the 11beta and 17alpha positions, fluorine at position 9, and a chlorine substituent at position 21. It is used as its 17alpha-propionate ester to treat various skin disorders, including exzema and psoriasis.		2.021011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
fluorinated steroid;
glucocorticoid;
tertiary alpha-hydroxy ketone		anti-inflammatory drug;
SMO receptor agonist
deamino arginine vasopressin
Deamino Arginine Vasopressin: A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.		3.2310heterodetic cyclic peptidediagnostic agent;
renal agent;
vasopressin receptor agonist
dexmedetomidine
[no description available]		3.5820medetomidinealpha-adrenergic agonist;
analgesic;
non-narcotic analgesic;
sedative
fluticasone
Fluticasone: A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.. fluticasone : A trifluorinated corticosteroid used in the form of its propionate ester for treatment of allergic rhinitis.		2.021011beta-hydroxy steroid;
17alpha-hydroxy steroid;
3-oxo-Delta(4) steroid;
corticosteroid;
fluorinated steroid;
thioester		anti-allergic agent;
anti-asthmatic drug
goserelin
Goserelin: A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.		3.2310organic molecular entity
halobetasol
halobetasol: used in ointment to treat psoriasis; Ulobetasol cream contains 0.05% 6-fluoroclobetasol 17-propionate		2.0210corticosteroid hormone
iloprost
Iloprost: An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.. iloprost : A carbobicyclic compound that is prostaglandin I2 in which the endocyclic oxygen is replaced by a methylene group and in which the (1E,3S)-3-hydroxyoct-1-en-1-yl side chain is replaced by a (3R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl group. A synthetic analogue of prostacyclin, it is used as the trometamol salt (generally by intravenous infusion) for the treatment of peripheral vascular disease and pulmonary hypertension.		2.7330carbobicyclic compound;
monocarboxylic acid;
secondary alcohol		platelet aggregation inhibitor;
vasodilator agent
latanoprost
Latanoprost: A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.. latanoprost : A prostaglandin Falpha that is the isopropyl ester prodrug of latanoprost free acid. Used in the treatment of open-angle glaucoma and ocular hypertension.		2.4520isopropyl ester;
prostaglandins Falpha;
triol		antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
prodrug
nalbuphine
Nalbuphine: A narcotic used as a pain medication. It appears to be an agonist at KAPPA RECEPTORS and an antagonist or partial agonist at MU RECEPTORS.		4.2550organic heteropentacyclic compoundmu-opioid receptor antagonist;
opioid analgesic
nateglinide
Nateglinide: A phenylalanine and cyclohexane derivative that acts as a hypoglycemic agent by stimulating the release of insulin from the pancreas. It is used in the treatment of TYPE 2 DIABETES.. nateglinide : An N-acyl-D-phenylalanine resulting from the formal condensation of the amino group of D-phenylalanine with the carboxy group of trans-4-isopropylcyclohexanecarboxylic acid. An orally-administered, rapidly-absorbed, short-acting insulinotropic agent, it is used for the treatment of type 2 diabetes mellitus.		4.2750phenylalanine derivative
rimexolone
[no description available]		2.021020-oxo steroid
vinorelbine
[no description available]		4.2550acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
ring assembly;
vinca alkaloid		antineoplastic agent;
photosensitizing agent
silodosin
silodosin: an alpha(1a)-adrenoceptor-selective antagonist; structure given in first source		3.2310indolecarboxamide
furazolidone
[no description available]		2.0510
fluvoxamine
Fluvoxamine: A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.. fluvoxamine : An oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder.		4.0740(trifluoromethyl)benzenes;
5-methoxyvalerophenone O-(2-aminoethyl)oxime		antidepressant;
anxiolytic drug;
serotonin uptake inhibitor
semaxinib
semaxanib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is replaced by a 3,5-dimethylpyrrol-2-yl group.		2.0510olefinic compound;
oxindoles;
pyrroles		angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
orantinib
orantinib: an antiangiogenic agent. orantinib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is substituted by a 2-(2-carboxyethyl)-3,5-dimethylpyrrol-3-yl group. It is an ATP-competitive inhibitor of the tyrosine kinase activity of fibroblast growth factor receptor 1.		2.0510
su 11248
[no description available]		3.2310monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
romidepsin
depsipeptide : A natural or synthetic compound having a sequence of amino and hydroxy carboxylic acid residues (usually alpha-amino and alpha-hydroxy acids), commonly but not necessarily regularly alternating.		2.0410cyclodepsipeptide;
heterocyclic antibiotic;
organic disulfide		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid : A dihydroxy monocarboxylic acid that is N-isopropylindole which is substituted at position 3 by a p-fluorophenyl group and at position 2 by a 6-carboxy-3,5-dihydroxyhex-1-en-1-yl group. It has four possible diastereoisomers.		4.460dihydroxy monocarboxylic acid;
indoles;
organofluorine compound
molsidomine
[no description available]		2.4720ethyl ester;
morpholines;
oxadiazole;
zwitterion		antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent
oxiconazole
oxiconazole: RN given refers to parent cpd(Z)-isomer; structure given in first source. oxiconazole : An oxime O-ether that is the 2,4-dichlorobenzyl ether of the oxime obtained by formal condensation of hydroxylamine with the carbonyl group of acetopnenone in which the phenyl group is substituted by chlorines at positions 2 and 4, and in which one of the hydrogens of the methyl group is replaced by a 1H-imidazol-1-yl group. An antifungal agent, it is used (generally as the nitrate salt) in creams and powders for the topical treatment of fungal skin infections.		2.0210conazole antifungal drug;
dichlorobenzene;
imidazole antifungal drug;
imidazoles;
oxime O-ether		antiinfective agent
levorphanol
Levorphanol: A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection.		3.2310morphinane alkaloid
bismuth
Bismuth: A metallic element that has the atomic symbol Bi, and atomic number 83. Its principal isotope is Bismuth 209.		5.321metal atom;
pnictogen
naltrexone
Naltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.. naltrexone : An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.		4.2450cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound		antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic
morphine-6-glucuronide
morphine-6-glucuronide: RN given refers to (5alpha,6alpha)-isomer		2.0410morphinane alkaloid
dextromethorphan
Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.		3.59206-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthreneantitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic
gallium
Gallium: A rare, metallic element designated by the symbol, Ga, atomic number 31, and atomic weight 69.72.. gallium atom : A metallic element predicted as eka-aluminium by Mendeleev in 1870 and discovered by Paul-Emile Lecoq de Boisbaudran in 1875. Named in honour of France (Latin Gallia) and perhaps also from the Latin gallus cock, a translation of Lecoq.		2.2510boron group element atom
butorphanol
Butorphanol: A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.. butorphanol : Levorphanol in which a hydrogen at position 14 of the morphinan skeleton is substituted by hydroxy and one of the hydrogens of the N-methyl group is substituted by cyclopropyl. A semi-synthetic opioid agonist-antagonist analgesic, it is used as its (S,S)-tartaric acid salt for relief or moderate to severe pain.		4.4160morphinane alkaloidantitussive;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
cefodizime
cefodizime: RN given refers to (6R-(6alpha,7beta(Z)))-isomer. cefodizime : A cephalosporin compound having 5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl}methyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.		2.73301,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
EC 1.14.18.1 (tyrosinase) inhibitor
methylnaltrexone
methylnaltrexone: RN given refers to parent cpd(5alpha)-isomer		2.0410phenanthrenes
cefixime
[no description available]		4.85100cephalosporinantibacterial drug;
drug allergen
lisinopril
Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.		4.5470dipeptideEC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
benazepril
benazepril: structure given in first source. benazepril : A benzazepine that is benazeprilat in which the carboxy group of the 2-amino-4-phenylbutanoic acid moiety has been converted to the corresponding ethyl ester. It is used (generally as its hydrochloride salt) as a prodrug for the angiotensin-converting enzyme inhibitor benazeprilat in the treatment of hypertension and heart failure.		3.8530benzazepine;
dicarboxylic acid monoester;
ethyl ester;
lactam		EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
ramipril
Ramipril: A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.. ramipril : A dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure.. quark : Quarks comprise one of two classes of the fundamental particles. Quarks possess fractional electric charges and are not observed in free state. The word "quark" first appears in James Joyce's Finnegans Wake and has been chosen by Murray Gell-Mann as a name for fundamental building blocks of particles.		4.2650azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid monoester;
dipeptide;
ethyl ester		bradykinin receptor B2 agonist;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor;
prodrug
verteporfin
(2R,2(1)S)-8-ethenyl-2(1),2(2)-bis(methoxycarbonyl)-17-(3-methoxy-3-oxopropyl)-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13-propanoic acid : The 2(1),2(2),17-trimethyl ester of (2R,2(1)S)-2(1),2(2)-dicarboxy-8-ethenyl-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13,17-dipropanoic acid.		3.2310
indinavir sulfate
Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.		4.5470dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide		HIV protease inhibitor
zimeldine
Zimeldine: One of the SEROTONIN UPTAKE INHIBITORS formerly used for depression but was withdrawn worldwide in September 1983 because of the risk of GUILLAIN-BARRE SYNDROME associated with its use. (From Martindale, The Extra Pharmacopoeia, 29th ed, p385)		3.2310styrenes
bedaquiline
bedaquiline: a diarylquinoline Antitubercular Agent. bedaquiline : A quinoline-based antimycobacterial drug used (as its fumarate salt) for the treatment of pulmonary multi-drug resistant tuberculosis by inhibition of ATP synthase, an enzyme essential for the replication of the mycobacteria.		430aromatic ether;
naphthalenes;
organobromine compound;
quinolines;
tertiary alcohol;
tertiary amino compound		antitubercular agent;
ATP synthase inhibitor
enalapril maleate
enalapril maleate : The maleic acid salt of enalapril. It contains one molecule of maleic acid for each molecule of enalapril. Following oral administration, the ethyl ester group of enalapril is hydrolysed to afford the corresponding carboxylic acid, enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is thus a prodrug for enalaprilat (which, unlike enalapril, is not absorbed by mouth), and its maleate is used in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients.		2.4820maleate saltantihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
enalapril
Enalapril: An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.. enalapril : A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration).		3.8530dicarboxylic acid monoester;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug
nitrofurazone
Nitrofurazone: A topical anti-infective agent effective against gram-negative and gram-positive bacteria. It is used for superficial WOUNDS AND INJURIES and skin infections. Nitrofurazone has also been administered orally in the treatment of TRYPANOSOMIASIS.. nitrofurazone : A semicarbazone resulting from the formal condensation of semicarbazide with 5-nitrofuraldehyde. A broad spectrum antibacterial drug, although with little activity against Pseudomonas species, it is used as a local application for burns, ulcers, wounds and skin infections.		2.0510
trientine hydrochloride
[no description available]		3.2310
artocarpin lectin
artocarpin lectin: a mannose-specific lectin; from the seeds of Artocarpus integrifolia; a homotetramic protein distinct from jacalin, another jackfruit lectin; MW 65 kDa; devoid of covalently-attached carbohydrates; consists of 4 isolectins with pI 5 - 6.5; do not confuse with artocarpin flavone. artocarpin : A trihydroxyflavone that is flavone substituted by hydroxy groups at positions 5, 2', and 4', a methoxy group at position 7, a prenyl group at position 3 and a (1E)-3-methylbut-1-enyl group at position 6. Isolated from Artocarpus heterophyllus and Artocarpus integrifolia, it exhibits antineoplastic activity.		2.4110monomethoxyflavone;
trihydroxyflavone		antineoplastic agent;
metabolite
n-methylscopolamine bromide
scopolamine methobromide : A quaternary ammonium salt resulting from the reaction of the amino group of scopolamine with methyl bromide.		3.2310
aztreonam
[no description available]		2.3110
beryllium
Beryllium: An element with the atomic symbol Be, atomic number 4, and atomic weight 9.01218. Short exposure to this element can lead to a type of poisoning known as BERYLLIOSIS.. beryllium atom : Alkaline earth metal atom with atomic number 4.		4.911alkaline earth metal atom;
elemental beryllium;
metal allergen		adjuvant;
carcinogenic agent;
epitope
bleomycin
[no description available]		3.5920bleomycinantineoplastic agent;
metabolite
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.		2.7330cysteiniumfundamental metabolite
enalaprilat anhydrous
Enalaprilat: The active metabolite of ENALAPRIL and one of the potent, intravenously administered, ANGIOTENSIN-CONVERTING ENZYME INHIBITORS. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.. enalaprilat dihydrate : The dihydrate form of enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor that is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is administered by intravenous injection.. enalaprilat (anhydrous) : Enalapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid. Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor and is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is given by intravenous injection, usually as the dihydrate.		4.2650dicarboxylic acid;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
imidapril
imidapril: structure given in first source. imidapril : A member of the class of imidazolidines that is (4S)-1-methyl-2-oxoimidazolidine-4-carboxylic acid in which the hydrogen of the imidazolidine nitrogen has been substituted by (1S)-1-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}ethyl group. It is the prodrug for imidaprilat, an ACE inhibitor used for the treatment of chronic heart failure.		2.0510dicarboxylic acid monoester;
dipeptide;
ethyl ester;
imidazolidines;
N-acylurea;
secondary amino compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
sulindac sulfone
sulindac sulfone: inhibits K-ras-dependent cyclooxygenase-2; sulfated analog of indomethacin;; CP248 is an antineoplastic agent that fosters microtubule depolymerization; structure in first source. sulindac sulfone : A sulfone metabolite of sulindac that inhibits cell growth by inducing apoptosis independently of cyclooxygenase inhibition. It inhibits the development and induces regression of premalignant adenomatous polyps. Lipoxygenase and Cox-2 inhibitor.		2.0510monocarboxylic acid;
organofluorine compound;
sulfone		apoptosis inducer;
cyclooxygenase 2 inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
ximelagatran
ximelagatran: prodrug (via hydroxylation) of melagatran & a direct thrombin inhibitor; liver toxicity concerns so AZD0837 being developed to replace this. ximelagatran : A member of the class of azetidines that is melagatran in which the carboxylic acid group has been converted to the corresponding ethyl ester and in which the amidine group has been converted into the corresponding amidoxime. A prodrug for melagatran, ximelagatran was the first orally available direct thrombin inhibitor to be brought to market as an anticoagulant, but was withdrawn in 2006 following reports of it causing liver damage.		3.5920amidoxime;
azetidines;
carboxamide;
ethyl ester;
hydroxylamines;
secondary amino compound;
secondary carboxamide;
tertiary carboxamide		anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
prodrug;
serine protease inhibitor
cefuroxime
[no description available]		6.354803-(carbamoyloxymethyl)cephalosporin;
furans;
oxime O-ether		drug allergen
ceftriaxone
[no description available]		9.315611,2,4-triazines;
1,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 3.5.2.6 (beta-lactamase) inhibitor
cefepime
Cefepime: A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.. cefepime : A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		17.2530411cephalosporin;
oxime O-ether		antibacterial drug
hr 810
cefpirome: structure in first source. cefpirome : A fourth-generation cephalosporin antibiotic having 6,7-dihydro-5H-cyclopenta[b]pyridinium-1-ylmethyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.		7.37200cephalosporin;
cyclopentapyridine
pafuramidine
pafuramidine: a prodrug of furamidine		3.2310
ceftazidime
[no description available]		17.171701cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
trandolapril
trandolapril : A heterobicylic compound that is (2S,3aR,7aS)-1-[(2S)-2-aminopropanoyl]octahydro-1H-indole-2-carboxylic acid in which the hydrogen of the amino group is substituted by a (2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl group. It is a angiotensin-converting enzyme inhibitor and a prodrug used for the treatment of hypertension.		4.2650dicarboxylic acid monoester;
dipeptide;
ethyl ester;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
pregabalin
Pregabalin: A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.. pregabalin : A gamma-amino acid that is gamma-aminobutyric acid (GABA) carrying an isobutyl substitutent at the beta-position (the S-enantiomer). Binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues.		3.6120gamma-amino acidanticonvulsant;
calcium channel blocker
cefetamet
cefetamet: active against Neisseria gonorrhoeae; structure given in first source. cefetamet : A cephalosporin compound having methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side-groups; a cephalosporin antibiotic active against Neisseria gonorrhoeae.		2.4520cephalosporin
alvimopan anhydrous
alvimopan: mu opioid receptor antagonist; intended to treat constipation in patients taking opiates for pain		3.6120peptide
(6R,7R)-7-[[(2R)-2-carboxy-2-(4-hydroxyphenyl)-1-oxoethyl]amino]-7-methoxy-3-[[(1-methyl-5-tetrazolyl)thio]methyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
[no description available]		2.5820dicarboxylic acid;
secondary carboxamide
oxyfedrine
Oxyfedrine: A drug used in the treatment of angina pectoris, heart failure, conduction defects, and myocardial infarction. It is a partial agonist at beta adrenergic receptors and acts as a coronary vasodilator and cardiotonic agent.		2.0610aromatic ketone
aliskiren
aliskiren: orally active nonpeptidic renin inhibitor. aliskiren : A monomethoxybenzene compound having a 3-methoxypropoxy group at the 2-position and a multi-substituted branched alkyl substituent at the 4-position.		3.2310monocarboxylic acid amide;
monomethoxybenzene		antihypertensive agent
guanabenz acetate
[no description available]		2.0510dichlorobenzenegeroprotector
guanabenz
Guanabenz: An alpha-2 selective adrenergic agonist used as an antihypertensive agent.		2.4420dichlorobenzene
famotidine
[no description available]		4.54701,3-thiazoles;
guanidines;
sulfonamide		anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
cefotaxime
Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.		13.3416581,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen
aztreonam
[no description available]		9.841250beta-lactam antibiotic allergen;
monobactam		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
proguanil
Proguanil: A biguanide compound which metabolizes in the body to form cycloguanil, an anti-malaria agent.. proguanil : A biguanide compound which has isopropyl and p-chlorophenyl substituents on the terminal N atoms. A prophylactic antimalarial drug, it works by inhibiting the enzyme dihydrofolate reductase, which is involved in the reproduction of the malaria parasites Plasmodium falciparum and P. vivax within the red blood cells.		2.0510biguanides;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
cci 15641
[no description available]		2.4520cephalosporin
rifamycin sv
rifamycin SV: RN given refers to parent cpd; structure in Merck Index, 9th ed, #8009. rifamycin SV : A member of the class of rifamycins that exhibits antibiotic and antitubercular properties.		2.0510acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterotetracyclic compound;
polyphenol;
rifamycins		antimicrobial agent;
antitubercular agent;
bacterial metabolite
ginkgolide b
[no description available]		2.0410
ro 42-5892
remikiren : An L-histidine derivative that is L-histidine in which one of the amino hydrogens is replaced by a (2S)-2-[(2-methylpropane-2-sulfonyl)methyl]-3-phenylpropanoyl group and the carboxy group is replaced by a [(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino group. It is a renin inhibitor which was under development for the treatment of hypertension (now discontinued).		2.0210cyclopropanes;
diol;
L-histidine derivative;
secondary carboxamide;
sulfone		antihypertensive agent;
EC 3.4.23.15 (renin) inhibitor;
peptidomimetic;
vasodilator agent
selenium
Selenium: An element with the atomic symbol Se, atomic number 34, and atomic weight 78.97. It is an essential micronutrient for mammals and other animals but is toxic in large amounts. Selenium protects intracellular structures against oxidative damage. It is an essential component of GLUTATHIONE PEROXIDASE.		4.911chalcogen;
nonmetal atom		micronutrient
cefpodoxime
[no description available]		4.7790carboxylic acid;
cephalosporin		antibacterial drug
palonosetron
Palonosetron: Isoquinoline and quinuclidine derivative that acts as a 5-HT3 RECEPTOR antagonist. It is used in the prevention of nausea and vomiting induced by cytotoxic chemotherapy, and for the prevention of post-operative nausea and vomiting.. palonosetron : An organic heterotricyclic compound that is an antiemetic used (as its hydrochloride salt) in combination with netupitant (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy.		3.9130azabicycloalkane;
delta-lactam;
organic heterotricyclic compound		antiemetic;
serotonergic antagonist
epoprostenol sodium
[no description available]		2.0510prostanoid
tenofovir disoproxil fumarate
tenofovir disoproxil fumarate : A fumarate salt prepared from equimolar amounts of tenofovir disoproxil and fumaric acid. It is used in combination therapy for the treatment of HIV infection.		2.0810fumarate saltantiviral drug;
HIV-1 reverse transcriptase inhibitor;
prodrug
psammaplin a
psammaplin A: isolated from marine sponges Poecillastra and Jaspis; structure in second source		2.0110
cefatrizine
Cefatrizine: Orally active semisynthetic cephalosporin antibiotic with broad-spectrum activity.. cefatrizine : A cephalosporin compound having (1H-1,2,3-triazol-4-ylsulfanyl)methyl and [(2R)-2-amino-2-(4-hydroxyphenyl)]acetamido side-groups. An antibacterial drug first prepared in the 1970s, it has more recently been found to be an inhibitor of eukaryotic elongation factor-2 kinase (eEF2K), which is known to regulate apoptosis, autophagy and ER stress in many types of human cancers.		2.7430amino acid amide;
carboxylic acid;
cephalosporin;
phenols;
semisynthetic derivative;
triazoles		antibacterial drug;
EC 2.7.11.20 (elongation factor 2 kinase) inhibitor
eniporide
eniporide: inhibits NHE-1 isoform; structure in first source		2.0410
dexbrompheniramine maleate
dexbrompheniramine maleate : The maleic acid salt of the (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.		2.0810brompheniramine maleateanti-allergic agent;
H1-receptor antagonist
cilastatin
[no description available]		15.627832carboxamide;
L-cysteine derivative;
non-proteinogenic L-alpha-amino acid;
organic sulfide		EC 3.4.13.19 (membrane dipeptidase) inhibitor;
environmental contaminant;
protease inhibitor;
xenobiotic
s 1006
S 1006: structure given in first source. cefcapene : A cephalosporin compound having (carbamoyloxy)methyl and N-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)pent-2-enoyl]amino side-groups. It is used (generally as the corresponnding pivaloyloxymethyl ester prodrug) as an oral antibacterial.		2.05101,3-thiazoles;
carbamate ester;
carboxylic acid;
cephalosporin;
enamide;
secondary carboxamide		antibacterial drug
nitrocefin
nitrocefin: chromogenic cephalosporin used for detection of beta-lactamase activity; Cefinase is name for nitrocefin on paper disc; RN given refers to (6R-(3(E),6 alpha,7 beta))-isomer; structure for mono-Na salt in second source		9.46210
rifaximin
[no description available]		3.8630acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterohexacyclic compound;
rifamycins;
semisynthetic derivative		antimicrobial agent;
gastrointestinal drug;
orphan drug
brl 28500
ticarcillin-clavulanic acid: combination of ticarcillin and clavulanic acid; used against gram-negative rods		2.9740
mycaminosyltylonolide
mycaminosyltylonolide: structure given in first source. 5-O-mycaminosyltylonolide : A macrolide antibiotic that is tylonolide having a beta-D-mycaminosyl residue attached at position 5.		2.4110aldehyde;
enone;
macrolide antibiotic;
monosaccharide derivative
cefditoren pivoxil
[no description available]		3.14501,3-thiazoles;
cephams;
oxime O-ether;
pivaloyloxymethyl ester		antibacterial drug;
prodrug
everolimus
[no description available]		3.6120cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol		anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
2-(3-methanesulfonylamino-1-propenyl)pyrrolidin-4-ylthiol-6-(1-hydroxyethyl)-1-methyl-1-carbapen-2-em-3-carboxylic acid
DA 1131: structure in first source		2.0110
ixabepilone
[no description available]		3.86301,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle		antineoplastic agent;
microtubule-destabilising agent
gavestinel
[no description available]		2.0210
dirithromycin
[no description available]		2.0210macrolide antibioticprodrug
azlocillin
Azlocillin: A semisynthetic ampicillin-derived acylureido penicillin.. azlocillin : A semisynthetic penicillin having a 6beta-{(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl}amino side-group. It is an antibiotic used in treating infections caused by Pseudomonas aeruginosa, Escherichia coli and Haemophilus influenzae.		3.4270penicillin allergen;
penicillin;
semisynthetic derivative		antibacterial drug
opc-67683
OPC-67683: an antitubercular agent		2.4110piperidines
verlukast
verlukast: LTD4 receptor antagonist		2.0410
cefpodoxime proxetil
cefpodoxime proxetil: structure given in first source; prodrug for cefpodoxime. cefpodoxime proxetil : The 1-[(isopropoxycarbonyl)oxy]ethyl (proxetil) ester prodrug of cefpodoxime. After swallowing, hydrolysis of the ester group occurs in the intestinal epithelium, to release active cefpodoxime in the bloodstream. It is used to treat acute otitis media, pharyngitis, and sinusitis.		2.7430carboxylic acid;
carboxylic ester;
cephalosporin		antibacterial drug;
prodrug
ceftizoxime
[no description available]		4.3960cephalosporinantibacterial drug
cefclidin
cefclidin: structure given in first source. cefclidin : A fourth-generation cephalosporin antibiotic having (4-carbamoyl-1-azoniabicyclo[2.2.2]octan-1-yl)methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.		2.0210cephalosporin;
thiadiazoles
1-methyl-d-lysergic acid butanolamide
[no description available]		3.2310ergot alkaloid;
monocarboxylic acid amide		serotonergic antagonist;
sympatholytic agent;
vasoconstrictor agent
carumonam
carumonam: structure given in first source; RN given refers to (2S-(2alpha,3alpha(Z))-isomer. carumonam : An N-sulfonated monobactam antibiotic.		2.9740monobactamantibacterial drug
fluphenazine
[no description available]		2.0810
dantrolene sodium
dantrolene sodium (anhydrous) : The anhydrous sodium salt of dantrolene.		2.0510
nitrofurantoin
Nitrofurantoin: A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.. nitrofurantoin : An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.		5.31160imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic		antibacterial drug;
antiinfective agent;
hepatotoxic agent
nifurtimox
Nifurtimox: A nitrofuran thiazine that has been used against TRYPANOSOMIASIS.		2.0510nitrofuran antibiotic
eritoran
eritoran : A lipid A derivative used for the treatment of severe sepsis.		2.0410lipid As
dantrolene
[no description available]		4.0740
roxithromycin
(E)-roxithromycin : A major geometrical isomer of roxithromycin.		2.4720roxithromycinenvironmental contaminant;
xenobiotic
cefdinir
[no description available]		4.5470cephalosporin;
ketoxime		antibacterial drug
etonogestrel
[no description available]		3.231017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin
bisoprolol, fumarate (1:1) salt
[no description available]		2.0810
artesunate
artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether		2.4620artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid		antimalarial;
antineoplastic agent;
ferroptosis inducer
evernimicin
[no description available]		210
beraprost
beraprost: stable prostacyclin analog; structure given in first source. beraprost : An organic heterotricyclic compound that is (3aS,8bS)-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan in which the hydrogens at positions 1R, 2R and 5 are replaced by (3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl, hydroxy and 3-carboxypropyl groups, respectively. It is a prostaglandin receptor agonist which is approved to treat pulmonary arterial hypertension in Asia.		2.0510enyne;
monocarboxylic acid;
organic heterotricyclic compound;
secondary alcohol;
secondary allylic alcohol		anti-inflammatory agent;
antihypertensive agent;
platelet aggregation inhibitor;
prostaglandin receptor agonist;
vasodilator agent
lanreotide
[no description available]		2.0510
etoposide phosphate
[no description available]		2.0810furonaphthodioxole
dexniguldipine
niguldipine: structure given in first source; clinical modulator of multidrug resistance		2.0410diarylmethane
ciclesonide
ciclesonide: nasal spray approved for seasonal and perennial allergic rhinitis		2.0810organic molecular entity
napsagatran
napsagatran: structure given in first source		2.4420
temsirolimus
[no description available]		3.8730macrolide lactam
dutasteride
Dutasteride: A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.. dutasteride : An aza-steroid that is inasteride in which the tert-butyl group is replaced by a 2,5-bis(trifluoromethyl)phenyl group. A synthetic 4-azasteroid, dutasteride is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5alpha-reductase, an intracellular enzyme that converts testosterone to 5alpha-dihydrotestosterone. Dutasteride is used for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate gland.		3.6120(trifluoromethyl)benzenes;
aza-steroid;
delta-lactam		antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
tekturna
[no description available]		2.0810fumarate saltantihypertensive agent
lu 208075
ambrisentan: an ET(A) receptor antagonist and antihypertensive agent; studied for use in pulmonary arterial hypertension		3.5920diarylmethane
bms188797
[no description available]		2.0410
bibx 1382bs
BIBX 1382BS: an ErbB receptor kinase inhibitor; no further information available 4/2001		3.2310substituted aniline
vildagliptin
[no description available]		2.0810amino acid amide
fesoterodine
fesoterodine: a muscarinic antagonist for treatment of overactive bladder		3.2310diarylmethane
isoborneol
isoborneol: RN given refers to cpd without isomeric designation; structure		2.110borneol
acetylcarnitine
O-acetyl-L-carnitine : An O-acyl-L-carnitine where the acyl group specified is acetyl. It facilitates movement of acetyl-CoA into the matrices of mammalian mitochondria during the oxidation of fatty acids.		2.0510O-acetylcarnitine;
saturated fatty acyl-L-carnitine		human metabolite;
Saccharomyces cerevisiae metabolite
chlorhexidine
Chlorhexidine: A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.. chlorhexidine : A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge.		4.140biguanides;
monochlorobenzenes		antibacterial agent;
antiinfective agent
sgd 301-76
[no description available]		2.0810conazole antifungal drug;
imidazole antifungal drug;
organic nitrate salt		antiinfective agent
fluvoxamine maleate
[no description available]		2.0810(trifluoromethyl)benzenes
thioacetazone
Thioacetazone: A thiosemicarbazone that is used in association with other antimycobacterial agents in the initial and continuation phases of antituberculosis regimens. Thiacetazone containing regimens are less effective than the short-course regimen recommended by the International Union Against Tuberculosis and are used in some developing countries to reduce drug costs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p217). thiosemicarbazone : A hydrazone resulting from the formal condensation of an aldehyde or ketone with the non-thioacylated nitrogen of thiosemicarbazide or its substituted derivatives.		2.0810
s 1743
Esomeprazole: The S-isomer of omeprazole.. esomeprazole : A 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole that has S configuration at the sulfur atom. An inhibitor of gastric acid secretion, it is used (generally as its sodium or magnesium salt) for the treatment of gastro-oesophageal reflux disease, dyspepsia, peptic ulcer disease, and Zollinger-Ellison syndrome.		2.0710magnesium saltanti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
cefmenoxime
Cefmenoxime: A cephalosporin antibiotic that is administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. The drug has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.. cefmenoxime : A third-generation cephalosporin antibiotic, bearing a 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino group at the 7beta-position and a [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl group at the 3-position.		210cephalosporinantibacterial drug
azimilide
azimilide: structure given in first source; RN given refers to dihydrochloride		2.0410imidazolidine-2,4-dione
nifurtoinol
nifurtoinol : An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group and at position 3 by a hydroxymethyl group.		2.0510hydrazone;
imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic		antibacterial drug;
antiinfective agent;
hepatotoxic agent
cefozopran
[no description available]		2.9540cephalosporin;
imidazopyridazine;
thiadiazoles
gemifloxacin
Gemifloxacin: A naphthyridine and fluoroquinolone derivative antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used for the treatment of community-acquired pneumonia and acute bacterial infections associated with chronic bronchitis.. gemifloxacin : A 1,4-dihydro-1,8-naphthyridine with a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a substituted pyrrolin-1-yl group at the 7-position.		3.57201,8-naphthyridine derivative;
fluoroquinolone antibiotic;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
topoisomerase IV inhibitor
desacetylcefotaxime
desacetylcefotaxime: RN given refers to parent cpd (6R-(6alpha,7alpha(Z)))-isomer		2.0510
dexlansoprazole
Dexlansoprazole: The R-isomer of lansoprazole that is used to treat severe GASTROESOPHAGEAL REFLUX DISEASE.		3.6120benzimidazoles;
sulfoxide
gemifloxacin mesylate
gemifloxacin mesylate : The mesylate salt of gemifloxacin.		2.0810methanesulfonate saltantimicrobial agent;
topoisomerase IV inhibitor
fosinopril
[no description available]		3.8530
armodafinil
armodafinil : A 2-[(diphenylmethyl)sulfinyl]acetamide that has R configuration at the sulfur atom. Like its racemate, modafinil, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. Peak concentration in the blood later occurs later following administration than with modafinil, so it is thought that armodafinil may be more effective than modafinil in treating people with excessive daytime sleepiness.		3.23102-[(diphenylmethyl)sulfinyl]acetamidecentral nervous system stimulant;
eugeroic
tebipenem
tebipenem: an oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae; structure in first source		4.5770
lexipafant
lexipafant: an imidazolyl derivative which forms part of a fused heterocyclic system		3.1310
eflucimibe
eflucimibe: a powerful and systemic acylcoenzyme A: cholesterol acyltransferase inhibitor		2.0510
amoxicillin-potassium clavulanate combination
Amoxicillin-Potassium Clavulanate Combination: A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.		9.84362
tomopenem
[no description available]		3.5480
vidofludimus
vidofludimus: a dihydroorotate dehydrogenase inhibitor; structure in first source		2.610
lenvatinib
lenvatinib : A member of the class of quinolines that is the carboxamide of 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxylic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine.		4.911aromatic amide;
aromatic ether;
cyclopropanes;
monocarboxylic acid amide;
monochlorobenzenes;
phenylureas;
quinolines		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist;
orphan drug;
vascular endothelial growth factor receptor antagonist
sincalide
Sincalide: An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.		3.2310oligopeptide
avibactam
avibactam : A member of the class of azabicycloalkanes that is (2S,5R)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide in which the amino hydrogen at position 6 is replaced by a sulfooxy group. Used (in the form of its sodium salt) in combination with ceftazidime pentahydrate for the treatment of complicated urinary tract infections including pyelonephritis.		7.72361azabicycloalkane;
hydroxylamine O-sulfonic acid;
monocarboxylic acid amide;
ureas		antibacterial drug;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
tapentadol
Tapentadol: An opioid analgesic, MU OPIOID RECEPTOR agonist, and noradrenaline reuptake inhibitor that is used in the treatment of moderate to severe pain, and of pain associated with DIABETIC NEUROPATHIES.		3.2310alkylbenzene
etomoxir
[no description available]		2.0510aromatic ether
bb-83698
BB-83698: peptide deformylase inhibitor		2.0410
ppi-0903
ceftaroline : A cephalosporin that is the active metabolite of the prodrug ceftaroline fosamil. Used for the treatment of adults with acute bacterial skin and skin structure infections.		3.37601,3-thiazoles;
cephalosporin;
iminium betaine;
organic phosphoramidate;
oxime O-ether;
thiadiazoles		antibacterial drug;
antimicrobial agent;
prodrug
pentagastrin
Pentagastrin: A synthetic pentapeptide that has effects like gastrin when given parenterally. It stimulates the secretion of gastric acid, pepsin, and intrinsic factor, and has been used as a diagnostic aid.		3.5920organic molecular entity
cefditoren
cefditoren: structure given in first source; RN given refers to the (6R-(3(Z),6alpha,7beta(Z)))-isomer. cefditoren : A broad spectrum, third-generation cephalosporin antibiotic with (Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. Generally administered as its orally absorbed pivaloyloxymethyl ester prodrug, it is used for the treatment of mild to moderate infections caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, and uncomplicated skin and skin-structure infections.		4.3960carboxylic acid;
cephalosporin		antibacterial drug
rwj 54428
RWJ 54428: structure in first source		2.0510
rivaroxaban
Rivaroxaban: A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.. rivaroxaban : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-chlorothiophene-2-carboxylic acid with the amino group of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one. An anticoagulant used for prophylaxis of venous thromboembolism in patients with knee or hip replacement surgery.		2.5220aromatic amide;
lactam;
monocarboxylic acid amide;
morpholines;
organochlorine compound;
oxazolidinone;
thiophenes		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor
zotarolimus
zotarolimus: synthetic analog of rapamycin; structure in first source		2.0410lactam;
macrolide
lipid a
Lipid A: Lipid A is the biologically active component of lipopolysaccharides. It shows strong endotoxic activity and exhibits immunogenic properties.. lipid A : The glycolipid moiety of bacterial lipopolysaccharide (R can be either hydrogen or a fatty acyl group).		2.1510dodecanoate ester;
lipid A;
tetradecanoate ester		Escherichia coli metabolite
l 084
L 084: an oral carbapenem with a 1-(1,3-thiazolin-2-yl)azetidin-3-ylthio group at the C-2 position; structure in first source		2.0810carbapenems;
pivaloyloxymethyl ester
gentamicin sulfate
[no description available]		7.03721
bn 52020
[no description available]		2.0410
hki 272
[no description available]		2.0810nitrile;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor
tofacitinib
tofacitinib : A pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis.		2.0810N-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound		antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
rhodamine 123
[no description available]		2.0510organic chloride salt;
xanthene dye		fluorochrome
cp 70429
sulopenem: a penem antibiotic		3.250
2-phenylbenzothiazole
PBT2 compound: a metal-protein-attenuating compound that may be useful in treating Alzheimer's disesae		2.4110
fidaxomicin
Fidaxomicin: A narrow-spectrum macrolide antibacterial agent that is used in the treatment of diarrhea associated with CLOSTRIDIUM DIFFICILE INFECTION.. fidaxomicin : An 18-membered macrolide that is a fermentation product obtained from the Actinomycete Dactylosporangium aurantiacum. A narrow spectrum antibiotic used for treatment of Clostridium difficile-related infections.		2.4420
pazopanib
pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.		3.6120aminopyrimidine;
indazoles;
sulfonamide		angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
azd 6244
AZD 6244: a MEK inhibitor		2.0510benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
furanone c-30
furanone C-30: structure in first source		2.2510
prasugrel hydrochloride
Prasugrel Hydrochloride: A piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.. prasugrel hydrochloride : A racemate comprising equal amounts of (R)- and (S)-prasugrel hydrochloride. Used to prevent blood clots in people with acute coronary syndrome who are undergoing a procedure after a recent heart attack or stroke, and in people with certain disorders of the heart or blood vessels.		3.2310
me1036
ME1036: structure in first source		2.0410
anoplin
anoplin: an antimicrobial peptide from the venom of the solitary wasp Anoplius samariensis; peptide sequence in first source		2.3110
ici 213689
ICI 213689: a meropenem metabolite		4.4651
afn 1252
API 1252: inhibits bacterial enoyl-ACP reductase; structure in first source		2.0510
norvancomycin
norvancomycin: glycopeptide; adverse reactions tend to occur in older patients, those who use other antibiotic concomitantly or those who receive this agent longer than 14 days		7.610
homatropine methylbromide
homatropine methylbromide: RN given refers to bromide (endo-(+-))-isomer		2.0710
amg 009
AMG 009: an anti-inflammatory agent; structure in first source		2.0810
vinflunine
vinflunine: inhibits tubulin assembly; structure in first source. vinflunine : An organic heteropentacyclic compound and an organic heterotetracyclic compound that is vinorelbine in which the tetrahydropyridine moiety of the heterotetracyclic part of the molecule has been redced to the corresponding piperidine, and in which the ethyl group attached to this ring has been replaced by a 1,1-difluoroethyl group.		2.0510acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
semisynthetic derivative;
vinca alkaloid		antineoplastic agent
cefotaxime sodium
[no description available]		2.0810organic sodium salt
baci-im
[no description available]		3.9130homodetic cyclic peptide;
polypeptide;
zwitterion		antibacterial agent;
antimicrobial agent
oleanderolide
oleanderolide: oleanane-type triterpene from Nerium oleander; structure in first source		2.610
l 749345
L 749345: structure given in first source. ertapenem sodium : The monosodium salt of ertapenem. It is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract. It is more stable to renal dehydropeptidase I tham imipenem, and so unlike imipenem, its use with cilastatin, which inhibits the enzyme, is not required.		2.0110organic sodium saltantibacterial drug
ar-709
[no description available]		2.0410
polymyxin b(1)
[no description available]		3.340
tedizolid
DA 7157: an anti-infective agent; structure in first source. tedizolid : A member of the class of pyridines that is pyridine which is substituted by a 2-methyl-2H-tetrazol-5-yl group at position 2 and by a 2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl group at position 5. It is used as its phosphate pro-drug used for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis.		8.1130carbamate ester;
organofluorine compound;
oxazolidinone;
primary alcohol;
pyridines;
tetrazoles		antimicrobial agent;
drug metabolite;
protein synthesis inhibitor
bms 477118
[no description available]		3.2310adamantanes;
azabicycloalkane;
monocarboxylic acid amide;
nitrile;
tertiary alcohol		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
nystatin a1
Nystatin: Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.. nystatin : A heterogeneous mixture of polyene compounds produced by cultures of Streptomyces noursei. It mainly consists of three biologically active components designated nystatin A1, nystatin A2, and nystatin A3. It is used to treat oral and dermal fungal infections.. nystatin A1 : A polyene macrolide antibiotic; part of the nystatin complex produced by several Streptomyces species. It is an antifungal antibiotic used for the treatment of topical fungal infections caused by a broad spectrum of fungal pathogens comprising yeast-like and filamentous species.		3.8430nystatins
tedizolid phosphate
tedizolid phosphate: a prodrug of DA-7157; structure in first source. tedizolid phosphate : A phosphate monoester resulting from the formal condensation of equimolar amounts of phosphoric acid with the hydroxy group of tedizolid . It is a prodrug of tedizolid, used for the treatment of acute bacterial skin infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis.		7.2510carbamate ester;
organofluorine compound;
oxazolidinone;
phosphate monoester;
pyridines;
tetrazoles		antimicrobial agent;
prodrug;
protein synthesis inhibitor
milnacipran
[no description available]		3.2310acetamides
vindesine
[no description available]		2.0410
cefdinir
Cefdinir: A third-generation oral cephalosporin antibacterial agent that is used to treat bacterial infections of the respiratory tract and skin.. cefdinir : A cephalosporin compound having 7beta-2-(2-amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino- and 3-vinyl side groups.		210
losartan potassium
Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.		2.5520
moxestrol
moxestrol: RN given refers to (11beta,17alpha)-isomer; structure		2.02103-hydroxy steroid
dextrothyroxine
[no description available]		2.3110
scopolamine hydrobromide
[no description available]		3.5820
dactolisib
dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.		2.0810imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
virginiamycin
Virginiamycin: A cyclic polypeptide antibiotic complex from Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others. It consists of 2 major components, VIRGINIAMYCIN FACTOR M1 and virginiamycin Factor S1. It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry.. virginiamycin : A mixture of cyclic polypeptide streptogramin antibiotics produced by Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others. The two major components are virginiamycin M1 (also known as pristinamycin IIA) and virginiamycin S1. Virginiamycin has been widely used as a growth promotion agent in livestock and has been to have bacteriostatic activity against Gram-positive organisms such as staphylococci and streptococci.		2.9340
pf 03491390
[no description available]		2.0510
rifamycins
[no description available]		2.0710
sch 29482
Sch 29482: penem antibiotic; bactericidal & stable to beta-lactamases; structure given in first source		1.9710
curcumol
[no description available]		4.911sesquiterpenoid
rabeprazole sodium
[no description available]		2.0810organic sodium salt
nad
NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.		4.911organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
ach 702
ACH 702: an anti-tubercular agent; structure in first source		2.0510
amodiaquine hydrochloride
[no description available]		2.4720
bisaramil
[no description available]		2.0410
ceruletide
Ceruletide: A specific decapeptide obtained from the skin of Hila caerulea, an Australian amphibian. Caerulein is similar in action and composition to CHOLECYSTOKININ. It stimulates gastric, biliary, and pancreatic secretion; and certain smooth muscle. It is used in paralytic ileus and as diagnostic aid in pancreatic malfunction.. ceruletide : A decapeptide comprising 5-oxoprolyl, glutamyl, aspartyl, O-sulfotyrosyl, threonyl, glycyl, tryptopyl, methionyl, aspartyl and phenylalaninamide residues in sequence. Found in the skins of certain Australian amphibians, it is an analogue of the gastrointestinal peptide hormone cholecystokinin and stimulates gastric, biliary, and pancreatic secretion. It is used in cases of paralysis of the intestine (paralytic ileus) and as a diagnostic aid in pancreatic malfunction.		2.0110oligopeptidediagnostic agent;
gastrointestinal drug
bivalirudin
bivalirudin: designed to bind to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition. bivalirudin : A synthetic peptide of 20 amino acids, comprising D-Phe, Pro, Arg, Pro, Gly, Gly, Gly, Gly, Asn, Gly, Asp, Phe, Glu, Glu, Ile, Pro, Glu, Glu, Tyr, and Leu in sequence. A congener of hirudin (a naturally occurring drug found in the saliva of the medicinal leech), it a specific and reversible inhibitor of thrombin, and is used as an anticoagulant.		3.6120polypeptideanticoagulant;
EC 3.4.21.5 (thrombin) inhibitor
somatostatin
[no description available]		2.0810heterodetic cyclic peptide;
peptide hormone
teicoplanin
teicoplanin A2-1 : A teicoplanin A2 that has (4Z)-dec-4-enoyl as the variable N-acyl group.		2.4520
tannins
gallotannin : A class of hydrolysable tannins obtained by condensation of the carboxy group of gallic acid (and its polymeric derivatives) with the hydroxy groups of a monosaccharide (most commonly glucose).		5.0221tannin
magainin 2 peptide, xenopus
magainin 2 peptide, Xenopus: from skin of Xenopus laevis; 23-amino acid sequence given in first source; differs from magainin 1 by substitution of Lys instead of Gly at position 10 & Asn instead of Lys at position 22; also used to prevent development of malarial oocysts in mosquito vector; Z-12 is magainin 2 with Lys and Phe residues replaced with their respective D-isomers; homologue of the Xenopus laevis cement; GenBank AF004262 (mouse), AF007791, AF038451-2 (human)		210
enfuvirtide
Enfuvirtide: A synthetic 36-amino acid peptide that corresponds to the heptad repeat sequence of HIV-1 gp41. It blocks HIV cell fusion and viral entry and is used with other anti-retrovirals for combination therapy of HIV INFECTIONS and AIDS.. enfuvirtide : A synthetic 36-amino acid peptide consisting of N-acetyltyrosyl, threonyl, seryl, leucyl, isoleucyl, histidyl, seryl, leucyl, isoleucyl, alpha-glutamyl, alpha-glutamyl, seryl, glutaminyl, asparaginyl, glutaminyl, glutaminyl, alpha-glutamyl, lysyl, asparaginyl, alpha-glutamyl, alpha-glutamyl, alpha-glutamyl, leucyl, leucyl, alpha-glutamyl, leucyl, alpha-aspartyl, lysyl, tryptophyl, alanyl, seryl, leucyl, tryptophyl, asparaginyl, tryptophyl, and phenylalaninamide residues joined in sequence. An HIV fusion inhibitor, it was the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It interferes with entry of HIV into cells by binding to the gp41 sub-unit of the viral envelope glycoprotein, so inhibiting fusion of viral and cellular membranes.		3.2310
cecropin p1-li
cecropin P1-LI: antibacterial peptide isolated from porcine intestine; has immunoreactivity in epithelial cells of duodenum & glucagon cells of the pancreas		210
ganirelix
[no description available]		3.2310polypeptide
protegrin-1
protegrin-1: GenBank X84094		2.4110
ceca1 protein, drosophila
[no description available]		2.1310
teriparatide
[no description available]		3.2310polypeptide
forapin
Forapin: used as ointment for treatment of myositis & arthritis; contains bee venom, salicylate, nicotinate & vanillylnonamide		3.0730peptidyl amide;
polypeptide		animal metabolite;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.13 (protein kinase C) inhibitor;
hepatoprotective agent;
neuroprotective agent;
venom
salmon calcitonin
[no description available]		3.2310heterodetic cyclic peptide;
peptide hormone;
polypeptide		bone density conservation agent;
metabolite
tannins
Tannins: Polyphenolic compounds with molecular weights of around 500-3000 daltons and containing enough hydroxyl groups (1-2 per 100 MW) for effective cross linking of other compounds (ASTRINGENTS). The two main types are HYDROLYZABLE TANNINS and CONDENSED TANNINS. Historically, the term has applied to many compounds and plant extracts able to render skin COLLAGEN impervious to degradation. The word tannin derives from the Celtic word for OAK TREE which was used for leather processing.		4.911
ly-146032
[no description available]		4.5470heterodetic cyclic peptide;
lipopeptide antibiotic;
lipopeptide;
macrocycle;
macrolide		antibacterial drug;
bacterial metabolite;
calcium-dependent antibiotics
dalbavancin
[no description available]		2.0410carbohydrate acid derivative;
glycopeptide;
monosaccharide derivative;
semisynthetic derivative		antibacterial drug;
antimicrobial agent
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide: FE-200486 is the acetate salt		3.2310polypeptide
exenatide
[no description available]		3.2310
warfarin sodium
warfarin sodium : A racemate comprising equal amounts of (R)- and (S)-warfarin sodium. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.		2.0810
endothelin-1
Endothelin-1: A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)		2.4110
pravastatin sodium
pravastatin sodium : An organic sodium salt that is the sodium salt of pravastatin. A reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), it is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.		2.0810organic sodium salt;
statin (semi-synthetic)		anticholesteremic drug
alendronate sodium
[no description available]		2.0810
cilastatin, imipenem drug combination
Cilastatin, Imipenem Drug Combination: Combination of imipenem and cilastatin that is used in the treatment of bacterial infections; cilastatin inhibits renal dehydropeptidase I to prolong the half-life and increase the tissue penetration of imipenem, enhancing its efficacy as an anti-bacterial agent.		12.824212
sl 80.0750
[no description available]		2.0810
lucifer yellow
lucifer yellow: RN given refers to di-Li salt		2.0610organic lithium saltfluorochrome
chitosan
[no description available]		7.9830
mesna
Mesna: A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.		4.2750organosulfonic acid
methallyl sulfonate
[no description available]		3.4111
cerivastatin sodium
cerivastatin sodium : The sodium salt of cerivastatin. Formerly used to lower cholesterol and prevent cardiovascular disease, it was withdrawn from the market worldwide in 2001 following reports of a severe form of muscle toxicity.		2.0510organic sodium salt;
statin (synthetic)
clavulanate potassium
potassium clavulanate : A potassium salt having clavulanate as the counterion. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes and has only weak anitbiotic activity when administered alone. However it can be used in combination with amoxicillin trihydrate (under the trade name Augmentin) for treatment of a variety of bacterial infections, where it prevents antibiotic inactivation by microbial lactamases.		2.0810potassium saltantibacterial drug;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
cefamandole nafate
[no description available]		2.0210organic sodium saltantibacterial drug;
prodrug
sodium bisulfite
sodium bisulfite: has been used externally for parasitic skin diseases and as gastrointestinal antiseptic; structure. sodium hydrogensulfite : An inorganic sodium salt having hydrogensulfite as the counterion.		2.1110inorganic sodium salt;
sulfite salt		allergen;
food antioxidant;
food colour retention agent;
mutagen;
reducing agent
sodium lactate
Sodium Lactate: The sodium salt of racemic or inactive lactic acid. It is a hygroscopic agent used intravenously as a systemic and urinary alkalizer.. sodium lactate : An organic sodium salt having lactate as the counterion.		3.2310lactate salt;
organic sodium salt		food acidity regulator;
food preservative
piperacillin sodium
[no description available]		2.0810organic sodium salt
monensin
[no description available]		2.0510
sodium iothalamate
[no description available]		3.2310
oxacillin sodium
[no description available]		2.4720organic sodium salt
sodium diatrizoate
histopaque: used for separating mononuclear & other cells. sodium amidotrizoate : The sodium salt of a benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, often as a mixture with the meglumine salt, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography.		2.0510organic sodium salt;
organoiodine compound		radioopaque medium
cefazolin sodium
cefazolin sodium : A cephalosporin organic sodium salt having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups.		2.0810organic sodium salt
ro13-9904
Ceftriaxone: A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.. ceftriaxone : A third-generation cephalosporin compound having 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetylamino and [(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl side-groups.		13.251046
azlocillin sodium
[no description available]		2.0810organic sodium salt
piperacillin, tazobactam drug combination
Piperacillin, Tazobactam Drug Combination: An antibiotic combination product of piperacillin and tazobactam, a penicillanic acid derivative with enhanced beta-lactamase inhibitory activity, that is used for the intravenous treatment of intra-abdominal, pelvic, and skin infections and for community-acquired pneumonia of moderate severity. It is also used for the treatment of PSEUDOMONAS AERUGINOSA INFECTIONS.		16.3516317
bli-489
BLI-489: structure in first source		7.4110
quinupristin-dalfopristin
quinupristin-dalfopristin: RP 59500 is a combination of RP 57669 & RP 54476, which are water soluble derivatives of pristinamycin IA & pristinamycin IIB, respectively		7.9340organic molecular entity
bo 2727
BO 2727: structure in first source		2.940carbapenems
tildipirosin
20,23-dipiperidinyl-mycaminosyl-tylonolide: a veterinary antibiotic		2.4110
nxl 104
avibactam sodium : An organic sodium salt that is the monosodium salt of avibactam. Used in combination with ceftazidime pentahydrate for the treatment of complicated urinary tract infections including pyelonephritis.		2.2110organic sodium saltantibacterial drug;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
pc190723
PC190723: Antibacterial; an inhibitor of FtsZ with potent and selective anti-staphylococcal activity including methicillin- and multi-drug-resistant Staphylococcus aureus; structure in first source		2.2110
cetrorelix
cetrorelix: LHRH antagonist. cetrorelix : A synthetic ten-membered oligopeptide comprising N-acetyl-3-(naphthalen-2-yl)-D-alanyl, 4-chloro-D-phenylalanyl, 3-(pyridin-3-yl)-D-alanyl, L-seryl, L-tyrosyl, N(5)-carbamoyl-D-ornithyl, L-leucyl, L-arginyl, L-prolyl, and D-alaninamide residues coupled in sequence. A gonadotrophin-releasing hormone (GnRH) antagonist, it is used for treatment of infertility and of hormone-sensitive cancers of the prostate and breast.		3.5820oligopeptideantineoplastic agent;
GnRH antagonist
mannans
[no description available]		2.1310
btz 043
[no description available]		3.5110
achn 490
plazomicin: structure in first source		8.5111
mk-7655
relebactam: structure in first source		6.91250
quad pill
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination: A pharmaceutical preparation of the ANTI-HIV AGENTS elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate that is used in the treatment of HIV INFECTIONS.		2.4110
piperidines
Piperidines: A family of hexahydropyridines.		2.3110
an2728
crisaborole: NSAID, Dermatologic Agent; structure in first source. crisaborole : A member of the class of benzoxaboroles that is 5-hydroxy-1,3-dihydro-2,1-benzoxaborole in which the phenolic hydrogen has been replaced by a 4-cyanophenyl group. A phosphodiesterase 4 inhibitor that is used for treatment of mild to moderate atopic dermatitis in children and adults.		2.3110aromatic ether;
benzoxaborole;
nitrile		antipsoriatic;
non-steroidal anti-inflammatory drug;
phosphodiesterase IV inhibitor
letermovir
letermovir: has antiviral activity; structure in first source		2.1710
colistin
Colistin: Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.. colistin : A multi-component mixture comprising mostly of colistin A (R = Me) and B (R = H), with small amounts of colistin C and other polymyxins, produced by certain strains of Bacillus polymyxa var. colistinus. An antibiotic, it is used as its sulfate salt (for oral or topical use) or as the sodium salt of the N-methylsulfonic acid derivative (the injectable form) in the treatment of severe Gram-negative infections, partiularly those due to Pseudomonas aeruginosa.		15.4317511
fr 264205
ceftolozane: cephalosporin anti-bacterial agent with enhanced activity against Pseudomonas aeruginosa. ceftolozane : A fifth-generation cephalosporin antibiotic having (5-amino-4-{[(2-aminoethyl)carbamoyl]amino}-1-methyl-1H-pyrazol-2-ium-2-yl)methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of infections with gram-negative bacteria that have become resistant to conventional antibiotics.		11.83287
bocillin fl
BOCILLIN FL: used for detecting pencillin-binding proteins; structure in first source		2.4720
bal 30072
BAL 30072: a siderophore with antibacterial activity; structure in first source		3.790
natriuretic peptide, brain
Natriuretic Peptide, Brain: A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS.		2.0310polypeptide
heme
Heme: The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins.. ferroheme : Any iron(II)--porphyrin coordination complex.. ferroheme b : Heme b in which the iron has oxidation state +2.. heme : A heme is any tetrapyrrolic chelate of iron.		2.4110
cefteram
cefteram: structure given in first source. cefteram : A cephalosporin compound having (5-methyl-2H-tetrazol-2-yl)methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side-groups; a third-generation cephalosporin antibiotic.		210
ascorbic acid
Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.		3.930ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
raltegravir
[no description available]		3.23101,2,4-oxadiazole;
dicarboxylic acid amide;
hydroxypyrimidine;
monofluorobenzenes;
pyrimidone;
secondary carboxamide		antiviral drug;
HIV-1 integrase inhibitor
novobiocin
Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.		3.3460carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols		antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent
tetracycline
Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.		7.16430
chlortetracycline
Chlortetracycline: A TETRACYCLINE with a 7-chloro substitution.. chlortetracycline : A member of the class of tetracyclines with formula C22H23ClN2O8 isolated from Streptomyces aureofaciens.		2.4520
oxytetracycline, anhydrous
Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.		4.2650
minocycline
Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.		10.14781
dicumarol
Dicumarol: An oral anticoagulant that interferes with the metabolism of vitamin K. It is also used in biochemical experiments as an inhibitor of reductases.		2.0510hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
Hsp90 inhibitor;
vitamin K antagonist
piroxicam
[no description available]		4.2650benzothiazine;
monocarboxylic acid amide;
pyridines		analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
roquinimex
roquinimex: structure in first source		2.4620aromatic amide
acenocoumarol
Acenocoumarol: A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233). acenocoumarol : A hydroxycoumarin that is warfarin in which the hydrogen at position 4 of the phenyl substituent is replaced by a nitro group.		2.0510C-nitro compound;
hydroxycoumarin;
methyl ketone		anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
meclocycline
[no description available]		2.0210
mobic
Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.		4.26501,3-thiazoles;
benzothiazine;
monocarboxylic acid amide		analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
mobiflex
tenoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries.		2.9740heteroaryl hydroxy compound;
monocarboxylic acid amide;
pyridines;
thienothiazine		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
isoxicam
isoxicam : A monocarboxylic acid amide that is piroxicam in which the pyrid-2-yl group is replaced by a 5-methyl-1,2-oxazol-3-yl group. A non-steroidal anti-inflammatory drug, it was withdrawn from the market in the 1980s following its association with cases of Stevens-Johnson syndrome.		2.7530benzothiazine;
isoxazoles;
monocarboxylic acid amide		antirheumatic drug;
non-steroidal anti-inflammatory drug
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		5.03120benzenes;
hydroxycoumarin;
methyl ketone
demeclocycline
Demeclocycline: A TETRACYCLINE analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.. demeclocycline : Tetracycline which lacks the methyl substituent at position 7 and in which the hydrogen para- to the phenolic hydroxy group is substituted by chlorine. Like tetracycline, it is an antibiotic, but being excreted more slowly, effective blood levels are maintained for longer. It is used (mainly as the hydrochloride) for the treatment of Lyme disease, acne and bronchitis, as well as for hyponatraemia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective.		3.5820
phenprocoumon
Phenprocoumon: Coumarin derivative that acts as a long acting oral anticoagulant.. phenprocoumon : A hydroxycoumarin that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenylpropyl group.		2.0510hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
tipranavir
tipranavir: inhibits HIV-1 protease. tipranavir : A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor.		3.2310sulfonamideantiviral drug;
HIV protease inhibitor
rolitetracycline
Rolitetracycline: A pyrrolidinylmethyl TETRACYCLINE.. rolitetracycline : A derivative of tetracycline in which the amide function is substituted with a pyrrolidinomethyl group.		2.4520
sudoxicam
sudoxicam: proposed ant-inflammatory agent; minor descriptor (75-86); on-line & INDEX MEDICUS search THIAZINES (75-86)		2.0210
minocycline hydrochloride
[no description available]		2.0810
tigecycline
[no description available]		11.761271
lornoxicam
lornoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 6-chloro-4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain, primarily resulting from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica and other inflammations.		2.4720heteroaryl hydroxy compound;
monocarboxylic acid amide;
organochlorine compound;
pyridines;
thienothiazine		antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
omadacycline
omadacycline: demonstrated in vitro activity against a broad range of Gram-positive and select Gram-negative pathogens; structure in first source		9.2130tetracyclines
eravacycline
eravacycline: has antibacterial activity		11.35174tetracyclines
rpx7009
RPX7009: a beta-lactamase inhibitor; structure in first source		12.82823
calca protein, human
CALCA protein, human: RefSeq NM_001741		4.1331
transforming growth factor beta
Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.		4.911
pbtz169
macozinone: an antitubercular agent; structure in first source		3.5110
ceritinib
ceritinib: an anaplastic lymphoma kinase inhibitor. ceritinib : A member of the class of aminopyrimidines that is 2,6-diamino-5-chloropyrimidine in which the amino groups at positions 2 and 6 are respectively carrying 2-methoxy-4-(piperidin-4-yl)-5-methylphenyl and 2-(isopropylsulfonyl)phenyl substituents. Used for the treatment of ALK-positive metastatic non-small cell lung cancer.		3.5110aminopyrimidine;
aromatic ether;
organochlorine compound;
piperidines;
secondary amino compound;
sulfone		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
ajmaline
[no description available]		2.0510
colistin sulfate
[no description available]		2.0310
agar
Agar: A complex sulfated polymer of galactose units, extracted from Gelidium cartilagineum, Gracilaria confervoides, and related red algae. It is used as a gel in the preparation of solid culture media for microorganisms, as a bulk laxative, in making emulsions, and as a supporting medium for immunodiffusion and immunoelectrophoresis.. agar : A complex mixture of polysaccharides extracted from species of red algae. Its two main components are agarose and agaropectin. Agarose is the component responsible for the high-strength gelling properties of agar, while agaropectin provides the viscous properties.		4.01120
4,6-dichloro-n-(4,4-dimethylcyclohexyl)-1h-indole-2-carboxamide
4,6-dichloro-N-(4,4-dimethylcyclohexyl)-1H-indole-2-carboxamide: structure in first source		3.5110
fertinex
[no description available]		3.2310
cefiderocol
cefiderocol: structure in first source. cefiderocol : A fourth-generation siderophore cephalosporin antibiotic having {1-[2-(2-chloro-3,4-dihydroxybenzamido)ethyl]pyrrolidinium-1-yl}methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino side groups located at positions 3 and 7 respectively, developed to combat a variety of bacterial pathogens, including beta-lactam- and carbapenem-resistant organisms.		10.41272carboxylic acid;
cephalosporin		antibacterial drug;
siderophore
teixobactin
teixobactin: isolated from an Aquabacteria soil bacterium. teixobactin : A cyclodepsipeptide that is isolated from the previously unculturable bacterial species Eleftheria terrae and is active against gram-positive bacteria.		2.1110cyclodepsipeptide;
macrocycle;
peptide antibiotic		antibacterial agent
daptomycin
[no description available]		6.16101
cyclosporine
Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).		4.5540
lactoferrin
Lactoferrin: An iron-binding protein that was originally characterized as a milk protein. It is widely distributed in secretory fluids and is found in the neutrophilic granules of LEUKOCYTES. The N-terminal part of lactoferrin possesses a serine protease which functions to inactivate the TYPE III SECRETION SYSTEM used by bacteria to export virulence proteins for host cell invasion.		4.911
muramidase
Muramidase: A basic enzyme that is present in saliva, tears, egg white, and many animal fluids. It functions as an antibacterial agent. The enzyme catalyzes the hydrolysis of 1,4-beta-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in peptidoglycan and between N-acetyl-D-glucosamine residues in chitodextrin. EC 3.2.1.17.		2.4110
exudates
Malaysia: A parliamentary democracy with a constitutional monarch in southeast Asia, consisting of 11 states (West Malaysia) on the Malay Peninsula and two states (East Malaysia) on the island of BORNEO. It is also called the Federation of Malaysia. Its capital is Kuala Lumpur. Before 1963 it was the Union of Malaya. It reorganized in 1948 as the Federation of Malaya, becoming independent from British Malaya in 1957 and becoming Malaysia in 1963 as a federation of Malaya, Sabah, Sarawak, and Singapore (which seceded in 1965). The form Malay- probably derives from the Tamil malay, mountain, with reference to its geography. (From Webster's New Geographical Dictionary, 1988, p715 & Room, Brewer's Dictionary of Names, 1992, p329)		3.680
entecavir
entecavir (anhydrous) : Guanine substituted at the 9 position by a 4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl group. A synthetic analogue of 2'-deoxyguanosine, it is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. Entecavir is phosphorylated intracellularly to the active triphosphate form, which competes with deoxyguanosine triphosphate, the natural substrate of hepatitis B virus reverse transcriptase, inhibiting every stage of the enzyme's activity, although it has no activity against HIV. It is used for the treatment of chronic hepatitis B.		3.87302-aminopurines;
oxopurine;
primary alcohol;
secondary alcohol		antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		4.881002-aminopurines;
oxopurine		antimetabolite;
antiviral drug
guanosine diphosphate
Guanosine Diphosphate: A guanine nucleotide containing two phosphate groups esterified to the sugar moiety.		210guanosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor
guanosine triphosphate
Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.		210guanosine 5'-phosphate;
purine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor
guanine
[no description available]		2.25102-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
inosinic acid
Inosine Monophosphate: Inosine 5'-Monophosphate. A purine nucleotide which has hypoxanthine as the base and one phosphate group esterified to the sugar moiety.		2.5320inosine phosphate;
purine ribonucleoside 5'-monophosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite
inosine
[no description available]		2.0510inosines;
purines D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
folic acid
folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.		3.5920folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient
neopterin
[no description available]		2.4110
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		10.35851cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
clozapine
Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.		4.5470benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
dacarbazine
(E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.		4.2750dacarbazine
didanosine
Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.		4.6580purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
ganciclovir
[no description available]		4.981102-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
valtrex
[no description available]		2.0810organic molecular entity
valacyclovir
Valacyclovir: A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.		3.5620L-valyl esterantiviral drug
sildenafil
sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.		4.0840piperazines;
pyrazolopyrimidine;
sulfonamide		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
olanzapine
Olanzapine: A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.. olanzapine : A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4.		4.2650benzodiazepine;
N-arylpiperazine;
N-methylpiperazine		antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor
penciclovir
penciclovir : A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration.		3.15502-aminopurines;
propane-1,3-diols		antiviral drug
oxypurinol
Oxypurinol: A xanthine oxidase inhibitor.. alloxanthine : A pyrazolopyrimidine that is 4,5,6,7-tetrahydro-H-pyrazolo[3,4-d]pyrimidine substituted by oxo groups at positions 4 and 6.		2.0510pyrazolopyrimidinedrug metabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor
raltitrexed
[no description available]		2.4720N-acyl-amino acid
vardenafil
vardenafil : The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine.		3.8530imidazotriazine;
N-alkylpiperazine;
N-sulfonylpiperazine		EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
allopurinol
Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.		4.5470nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger
citrovorum factor
[no description available]		3.6120tetrahydrofolic acid
leucovorin
5-formyltetrahydrofolic acid : A formyltetrahydrofolic acid in which the formyl group is located at position 5.		4.0840formyltetrahydrofolic acidEscherichia coli metabolite;
mouse metabolite
rifapentine
rifapentine: cyclopentyl derivative of rifampicin		3.6120N-alkylpiperazine;
N-iminopiperazine;
rifamycins		antitubercular agent;
leprostatic drug
alanosine
[no description available]		2.0510
bl 4162a
anagrelide: imidazoquinazoline derivative which lowers platelet count probably by inhibiting thrombopoiesis and reduces platelet aggregation; used for thrombocythemia; structure in first source. anagrelide : A 1,5-dihydroimidazo[2,1-]quinazoline having an oxo substituent at the 2-position and chloro substituents at the 6- and 7-positions.		3.5920imidazoquinazolineanticoagulant;
antifibrinolytic drug;
cardiovascular drug;
platelet aggregation inhibitor
tegaserod
tegaserod: a nonbenzamide 5-hydroxytryptamine(4) agonist; used in treatment of irritable bowel syndrome; marketing suspended 2007 in US due to higher incidence of MI, stroke, and unstable angina; structure given in first source		3.8530carboxamidine;
guanidines;
hydrazines;
indoles		gastrointestinal drug;
serotonergic agonist
pemetrexed
pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).		3.2310N-acyl-L-glutamic acid;
pyrrolopyrimidine		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
tirapazamine
Tirapazamine: A triazine derivative that introduces breaks into DNA strands in hypoxic cells, sensitizing tumor cells to the cytotoxic activity of other drugs and radiation.. tirapazamine : A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4.		2.4520aromatic amine;
benzotriazines;
N-oxide		antibacterial agent;
antineoplastic agent;
apoptosis inducer
pelrinone
pelrinone: structure given in first source		2.0210
sildenafil citrate
Sildenafil Citrate: A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.. sildenafil citrate : The citrate salt of sildenafil.		2.0810citrate saltEC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
valganciclovir
Valganciclovir: A ganciclovir prodrug and antiviral agent that is used to treat CYTOMEGALOVIRUS RETINITIS in patients with AIDS, and for the prevention of CYTOMEGALOVIRUS INFECTIONS in organ transplant recipients who have received an organ from a CMV-positive donor.. valganciclovir : The L-valinyl ester of ganciclovir, into which it is rapidly converted by intestinal and hepatic esterases. It is a synthetic analogue of 2'-deoxyguanosine.		3.6220L-valyl ester;
purines		antiviral drug;
prodrug
aprepitant
Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.		3.8730(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles		antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist
fosaprepitant
fosaprepitant: a pro-drug form of aprepitant. fosaprepitant : A morpholine derivative that is the (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl ether of (3-{[(2R,3S)-3-(4-fluorophenyl)-2-hydroxymorpholin-4-yl]methyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid.		3.2310(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
phosphoramide;
triazoles		antiemetic;
neurokinin-1 receptor antagonist;
prodrug
tegaserod maleate
[no description available]		2.0810maleate saltserotonergic agonist
ceftobiprole
ceftobiprole: BAL5788 is Ceftobiprole medocaril sodium. ceftobiprole : A fifth-generation cephalosporin antibiotic having (E)-[(3'R)-2-oxo[1,3'-bipyrrolidin]-3-ylidene]methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP).		9.761cephalosporin;
thiadiazoles		antimicrobial agent
rifabutin
[no description available]		4.4160
3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin
KRM 1648: structure in first source		2.0310phenoxazine
levomefolate calcium
levomefolate calcium: an ingredient in Contraceptives, Oral, Combined. levomefolate calcium : An organic calcium salt of (6S)-5-methyltetrahydrofolic acid.		3.2310organic calcium saltantidepressant
lipoteichoic acid
lipoteichoic acid: lipopolysaccharides with an acyl group anchored to the cell membrane of gram-positive bacteria; functions as an adhesion molecule to facilitate the binding of bacteria to cells, colonization, and invasion; interacts with CD14 to induce NF-κB activation and inflammatory cytokine production; can function as surface antigen; inhibits remineraliztion of artificial lesions and surface-softened enamels;. lipoteichoic acid : A teichoic acid which is covalently bound to a lipid.		2.4920
eye
[no description available]		2.0310
abaloparatide
abaloparatide: synthetic analog of human PTHrP (Parathyroid Hormone-Related Protein)		2.1710
dactinomycin
cefozopran: RN given refers to the (6R-(6alpha,7beta(Z)))-isomer; RN for cpd without isomeric designation not available 10/91. cefozopran : A fourth-generation cephalosporin antibiotic having imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.		5.771
ConditionIndicatedRelationship StrengthStudiesTrials
E coli Infections
[description not available]		014.6811114
Group A Strep Infection
[description not available]		08.4252
Escherichia coli Infections
Infections with bacteria of the species ESCHERICHIA COLI.		014.6811114
Streptococcal Infections
Infections with bacteria of the genus STREPTOCOCCUS.		08.4252
Cancer of Colon
[description not available]		02.0110
Cancer of Lung
[description not available]		04.8471
Cancer of Ovary
[description not available]		02.0110
Cancer of Skin
[description not available]		02.0110
Central Nervous System Neoplasm
[description not available]		02.0110
Colonic Neoplasms
Tumors or cancer of the COLON.		02.0110
Lung Neoplasms
Tumors or cancer of the LUNG.		04.8471
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		02.0110
Skin Neoplasms
Tumors or cancer of the SKIN.		02.0110
Central Nervous System Neoplasms
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.		02.0110
Adverse Drug Event
[description not available]		07.42151
Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.		07.42151
Haemophilus Infections
Infections with bacteria of the genus HAEMOPHILUS.		05.73112
Cystic Fibrosis of Pancreas
[description not available]		011.47517
B cepacia Infection
[description not available]		06.46151
Cystic Fibrosis
An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.		011.47517
Infections, Pseudomonas
[description not available]		015.6428610
Infections, Respiratory
[description not available]		012.174114
Pseudomonas Infections
Infections with bacteria of the genus PSEUDOMONAS.		020.6428610
Respiratory Tract Infections
Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.		012.174114
Cerebral Nocardiosis
[description not available]		05.34200
Bacterial Infections, Gram-Positive
[description not available]		010415
Gram-Positive Bacterial Infections
Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.		010415
Ventilator-Associated Pneumonia
[description not available]		011.414219
Pneumonia, Ventilator-Associated
Serious INFLAMMATION of the LUNG in patients who required the use of PULMONARY VENTILATOR. It is usually caused by bacterial CROSS INFECTION in hospitals.		113.414219
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		07.84631
Infections, Klebsiella
[description not available]		015.6322710
Klebsiella Infections
Infections with bacteria of the genus KLEBSIELLA.		015.6322710
Community Acquired Infection
[description not available]		010.72346
Health Care Associated Infection
[description not available]		016.4420220
Cross Infection
Any infection which a patient contracts in a health-care institution.		016.4420220
Cronobacter Infections
[description not available]		014.861801
Enterobacteriaceae Infections
Infections with bacteria of the family ENTEROBACTERIACEAE.		116.861801
Bacteremia
The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.		117.5514714
Acinetobacter Infections
Infections with bacteria of the genus ACINETOBACTER.		013.361776
Critical Illness
A disease or state in which death is possible or imminent.		018.1419327
Infections, Serratia
[description not available]		05.96170
Flavobacteriaceae Infections
Infections with bacteria of the family FLAVOBACTERIACEAE.		02.7530
Antibiotic-Associated Colitis
[description not available]		02.9740
Enterocolitis, Pseudomembranous
An acute inflammation of the INTESTINAL MUCOSA that is characterized by the presence of pseudomembranes or plaques in the SMALL INTESTINE (pseudomembranous enteritis) and the LARGE INTESTINE (pseudomembranous colitis). It is commonly associated with antibiotic therapy and CLOSTRIDIUM DIFFICILE colonization.		02.9740
Bacterial Disease
[description not available]		018.3622853
Bacterial Infections
Infections by bacteria, general or unspecified.		120.3622853
Diabetic Feet
[description not available]		03.0640
Diabetic Foot
Common foot problems in persons with DIABETES MELLITUS, caused by any combination of factors such as DIABETIC NEUROPATHIES; PERIPHERAL VASCULAR DISEASES; and INFECTION. With the loss of sensation and poor circulation, injuries and infections often lead to severe foot ulceration, GANGRENE and AMPUTATION.		08.0640
Infections, Pneumococcal
[description not available]		05.5151
Pneumococcal Infections
Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.		05.5151
Infections, Staphylococcal
[description not available]		09.06543
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		09.06543
Bacterial Infections, Gram-Negative
[description not available]		016.4314719
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		09.6105
Gram-Negative Bacterial Infections
Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.		123.4314719
Bacterial Skin Diseases
[description not available]		08.02144
Skin Diseases, Bacterial
Skin diseases caused by bacteria.		08.02144
Bacteroides Infections
Infections with bacteria of the genus BACTEROIDES.		05.23170
Infectious Skin Diseases
[description not available]		06.3153
Skin Diseases, Infectious
Skin diseases caused by bacteria, fungi, parasites, or viruses.		06.3153
Acute Liver Injury, Drug-Induced
[description not available]		06.08101
Chemical and Drug Induced Liver Injury
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.		06.08101
Campylobacter Infection
[description not available]		06.22170
Bacillus anthracis Infection
[description not available]		02.9940
Anthrax
An acute infection caused by the spore-forming bacteria BACILLUS ANTHRACIS. It commonly affects hoofed animals such as sheep and goats. Infection in humans often involves the skin (cutaneous anthrax), the lungs (inhalation anthrax), or the gastrointestinal tract. Anthrax is not contagious and can be treated with antibiotics.		02.9940
Diabetic Glomerulosclerosis
[description not available]		02.0510
Chronic Kidney Failure
[description not available]		08.4201
Diabetic Nephropathies
KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.		02.0510
Kidney Failure, Chronic
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.		08.4201
Actinomycetoma
[description not available]		02.0510
Mycetoma
A chronic progressive subcutaneous infection caused by species of fungi (eumycetoma), or actinomycetes (actinomycetoma). It is characterized by tumefaction, abscesses, and tumor-like granules representing microcolonies of pathogens, such as MADURELLA fungi and bacteria ACTINOMYCETES, with different grain colors.		02.0510
Blood Poisoning
[description not available]		017.6417435
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.		119.6417435
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Tuberculosis, Drug-Resistant
[description not available]		06.09250
Tuberculosis, Multidrug-Resistant
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.		06.09250
Fungal Diseases
[description not available]		04.9781
Mycoses
Diseases caused by FUNGI.		04.9781
Extravascular Hemolysis
[description not available]		03.2250
Hemolysis
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.		03.2250
Koch's Disease
[description not available]		05.1590
Tuberculosis
Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.		112.1590
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310
Absence Seizure
[description not available]		010.56351
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		010.56351
Dermatoses
[description not available]		04.1431
Skin Diseases
Diseases involving the DERMIS or EPIDERMIS.		04.1431
Congenital Zika Syndrome
[description not available]		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
Bacterial Pneumonia
[description not available]		015.028524
Pneumonia, Bacterial
Inflammation of the lung parenchyma that is caused by bacterial infections.		117.028524
Thrombopenia
[description not available]		05.8881
Thrombocytopenia
A subnormal level of BLOOD PLATELETS.		010.8881
Swine Diseases
Diseases of domestic swine and of the wild boar of the genus Sus.		02.3110
Endotoxin Shock
[description not available]		013.36599
Shock, Septic
Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.		115.36599
Hospital Acquired Pneumonia
[description not available]		08.5787
Healthcare-Associated Pneumonia
Infection of the lung often accompanied by inflammation that is acquired through an interaction within a healthcare institution often through a therapeutic experience (e.g., use of catheters or ventilators).		013.5787
Aura
[description not available]		06.38140
Epilepsy
A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)		011.38140
Drug Overdose
Accidental or deliberate use of a medication or street drug in excess of normal dosage.		04.140
Infections, Soft Tissue
[description not available]		06.49124
Soft Tissue Infections
Infections of non-skeletal tissue, i.e., exclusive of bone, ligaments, cartilage, and fibrous tissue. The concept is usually referred to as skin and soft tissue infections and usually subcutaneous and muscle tissue are involved. The predisposing factors in anaerobic infections are trauma, ischemia, and surgery. The organisms often derive from the fecal or oral flora, particularly in wounds associated with intestinal surgery, decubitus ulcer, and human bites. (From Cecil Textbook of Medicine, 19th ed, p1688)		06.49124
Acute Kidney Failure
[description not available]		012.44506
Acute Kidney Injury
Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.		012.44506
Kidney Failure
A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.		08.57141
Burns
Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.		05.5141
Renal Insufficiency
Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.		08.57141
Co-infection
[description not available]		05.8110
2019 Novel Coronavirus Disease
[description not available]		04.1110
Inflammatory Response Syndrome, Systemic
[description not available]		05.0631
Amnionitis
[description not available]		04.0220
Embryopathies
[description not available]		03.6420
Premature Rupture of Fetal Membranes
[description not available]		04.0220
Chorioamnionitis
INFLAMMATION of the placental membranes (CHORION; AMNION) and connected tissues such as fetal BLOOD VESSELS and UMBILICAL CORD. It is often associated with intrauterine ascending infections during PREGNANCY.		04.0220
Fetal Membranes, Premature Rupture
Spontaneous tearing of the membranes surrounding the FETUS any time before the onset of OBSTETRIC LABOR. Preterm PROM is membrane rupture before 37 weeks of GESTATION.		04.0220
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		09.64213
Systemic Inflammatory Response Syndrome
A systemic inflammatory response to a variety of clinical insults, characterized by two or more of the following conditions: (1) fever		05.0631
Allergy, Drug
[description not available]		06.87231
Drug Hypersensitivity
Immunologically mediated adverse reactions to medicinal substances used legally or illegally.		06.87231
Febrile Neutropenia
Fever accompanied by a significant reduction in the number of NEUTROPHILS.		09.62184
Graft-Versus-Host Disease
[description not available]		05.5351
Graft vs Host Disease
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.		05.5351
Innate Inflammatory Response
[description not available]		04.4780
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		04.4780
Encephalopathy, Toxic
[description not available]		04.2760
Brain Disorders
[description not available]		05.3170
Acute Bacterial Prostatitis
[description not available]		02.8330
Brain Diseases
Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.		05.3170
Prostatitis
Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.		07.8330
Extensively Drug-Resistant Tuberculosis
Tuberculosis resistant to ISONIAZID and RIFAMPIN and at least three of the six main classes of second-line drugs (AMINOGLYCOSIDES; polypeptide agents; FLUOROQUINOLONES; THIOAMIDES; CYCLOSERINE; and PARA-AMINOSALICYLIC ACID) as defined by the CDC.		05.11150
Infectious Diseases
[description not available]		04.6180
Benign Neoplasms
[description not available]		010.393014
Communicable Diseases
An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.		16.6180
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		010.393014
Neonatal Early-Onset Sepsis
[description not available]		06.7463
Neonatal Sepsis
Blood infection that occurs in an infant younger than 90 days old. Early-onset sepsis is seen in the first week of life and most often appears within 24 hours of birth. Late-onset occurs after 1 week and before 3 months of age.		113.7463
Intra-Abdominal Infections
[description not available]		013.933518
Intraabdominal Infections
Infection within the PERITONEAL CAVITY. A frequent cause is an ANASTOMOTIC LEAK following surgery.		115.933518
Cerebromeningitis
[description not available]		03.9640
Urinary Tract Infections
Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.		117.559122
Experimental Lung Inflammation
Inflammation of any part, segment or lobe, of the lung parenchyma.		09.56474
Pneumonia
Infection of the lung often accompanied by inflammation.		111.56474
Apoplexy
[description not available]		02.5720
Infarct
[description not available]		02.6620
Stroke
A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)		02.5720
Atypical Mycobacterial Infection, Disseminated
[description not available]		04.4470
Respiration Disorders
Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available.		02.4110
Brain Abscess
A circumscribed collection of purulent exudate in the brain, due to bacterial and other infections. The majority are caused by spread of infected material from a focus of suppuration elsewhere in the body, notably the PARANASAL SINUSES, middle ear (see EAR, MIDDLE); HEART (see also ENDOCARDITIS, BACTERIAL), and LUNG. Penetrating CRANIOCEREBRAL TRAUMA and NEUROSURGICAL PROCEDURES may also be associated with this condition. Clinical manifestations include HEADACHE; SEIZURES; focal neurologic deficits; and alterations of consciousness. (Adams et al., Principles of Neurology, 6th ed, pp712-6)		06.73370
Infective Endocarditis
[description not available]		04.6650
Abnormality, Heart
[description not available]		03.620
Atrial Septal Defect
[description not available]		03.3310
Pulmonary Hypertension
[description not available]		03.3310
Infections, Pasteurellaceae
[description not available]		03.620
Endocarditis
Inflammation of the inner lining of the heart (ENDOCARDIUM), the continuous membrane lining the four chambers and HEART VALVES. It is often caused by microorganisms including bacteria, viruses, fungi, and rickettsiae. Left untreated, endocarditis can damage heart valves and become life-threatening.		04.6650
Heart Defects, Congenital
Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.		03.620
Hypertension, Pulmonary
Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.		03.3310
Fractures, Compound
[description not available]		02.5120
Brucella Infection
[description not available]		02.4110
Pyrexia
[description not available]		013.797125
Brucellosis
Infection caused by bacteria of the genus BRUCELLA mainly involving the MONONUCLEAR PHAGOCYTE SYSTEM. This condition is characterized by fever, weakness, malaise, and weight loss.		02.4110
Fever
An abnormal elevation of body temperature, usually as a result of a pathologic process.		013.797125
Cerebral Ventriculitis
Inflammation of CEREBRAL VENTRICLES.		03.6480
Primary Peritonitis
[description not available]		010.773511
Peritonitis
INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.		010.773511
Enteritis
Inflammation of any segment of the SMALL INTESTINE.		02.4110
Clostridioides difficile Infection
[description not available]		07.04101
Clostridium Infections
Infections with bacteria of the genus CLOSTRIDIUM and closely related CLOSTRIDIOIDES species.		07.04101
Cytokine Release Syndrome
A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.		02.4110
Palsy
[description not available]		02.4110
Listeria Cerebritis
[description not available]		04.5790
Paralysis
A general term most often used to describe severe or complete loss of muscle strength due to motor system disease from the level of the cerebral cortex to the muscle fiber. This term may also occasionally refer to a loss of sensory function. (From Adams et al., Principles of Neurology, 6th ed, p45)		02.4110
Abscess, Abdominal
[description not available]		07.67135
Abdominal Abscess
An abscess located in the abdominal cavity, i.e., the cavity between the diaphragm above and the pelvis below. (From Dorland, 27th ed)		012.67135
Disseminated Fungal Infection
[description not available]		02.4110
Osteomyelitis
INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA.		18.11260
Acquired Immune Deficiency Syndrome
[description not available]		02.4110
P carinii Pneumonia
[description not available]		02.4110
HIV Coinfection
[description not available]		04.3760
Acquired Immunodeficiency Syndrome
An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.		02.4110
Pneumonia, Pneumocystis
A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.		02.4110
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		04.3760
Cutaneous Fistula
An abnormal passage or communication leading from an internal organ to the surface of the body.		02.4110
Bancroftian Elephantiasis
[description not available]		02.4110
Elephantiasis, Filarial
Parasitic infestation of the human lymphatic system by WUCHERERIA BANCROFTI or BRUGIA MALAYI. It is also called lymphatic filariasis.		02.4110
Burkholderia pseudomallei Infection
[description not available]		08.97471
Infectious Myelitis
[description not available]		02.4110
Kahler Disease
[description not available]		03.5520
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.		03.5520
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		06.2111
Pachymeningitis
[description not available]		07.54160
Meningitis
Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6)		111.38320
Agranulocytosis
A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).		04.5351
Neutropenia
A decrease in the number of NEUTROPHILS found in the blood.		013.936625
Candida Infection
[description not available]		04.06120
Candidiasis
Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)		09.06120
Airflow Obstruction, Chronic
[description not available]		05.1831
ER-Negative PR-Negative HER2-Negative Breast Cancer
[description not available]		04.7211
Disbacteriosis
[description not available]		05.0721
Carcinoma, Squamous Cell of Head and Neck
[description not available]		04.7211
Acute Confusional Senile Dementia
[description not available]		04.7211
ADDH
[description not available]		04.7211
Bleb
[description not available]		05.5832
Breast Cancer
[description not available]		04.9921
Diabetes Mellitus, Adult-Onset
[description not available]		06.8381
Lassitude
[description not available]		04.9921
Cancer of Head
[description not available]		04.921
Hepatocellular Carcinoma
[description not available]		04.7211
Blood Pressure, High
[description not available]		05.3941
Cancer of Liver
[description not available]		04.7211
Eperythrozoonosis
[description not available]		04.7211
Angiogenesis, Pathologic
[description not available]		04.7211
Paratyphoid Fever
A prolonged febrile illness commonly caused by several Paratyphi serotypes of SALMONELLA ENTERICA. It is similar to TYPHOID FEVER but less severe.		05.1331
Symptom Cluster
[description not available]		05.7641
Low Back Ache
[description not available]		05.1731
Squamous Cell Carcinoma of Head and Neck
The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.		04.7211
Alcohol Drinking
Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.		04.7211
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		04.7211
Anorexia
The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.		04.7211
Anxiety
Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.		04.7211
Asthenia
Clinical sign or symptom manifested as debility, or lack or loss of strength and energy.		04.7211
Attention Deficit Disorder with Hyperactivity
A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-V)		04.7211
Breast Neoplasms
Tumors or cancer of the human BREAST.		04.9921
Cardiovascular Diseases
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.		04.7211
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		05.2941
Depression
Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.		04.7211
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		06.8381
Diabetic Retinopathy
Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.		04.7211
Fatigue
The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.		04.9921
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)		04.921
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		04.7211
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		05.3941
Liver Neoplasms
Tumors or cancer of the LIVER.		04.7211
Syndrome
A characteristic symptom complex.		05.7641
Low Back Pain
Acute or chronic pain in the lumbar or sacral regions, which may be associated with musculo-ligamentous SPRAINS AND STRAINS; INTERVERTEBRAL DISK DISPLACEMENT; and other conditions.		05.1731
Pulmonary Disease, Chronic Obstructive
A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.		05.1831
Suicidal Ideation
A risk factor for suicide attempts and completions, it is the most common of all suicidal behavior, but only a minority of ideators engage in overt self-harm.		04.7211
Triple Negative Breast Neoplasms
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.		04.7211
Necrotizing Pyelonephritis
[description not available]		08.63112
Pyelonephritis
Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA.		110.63112
Chronic Kidney Diseases
[description not available]		04.1340
Renal Insufficiency, Chronic
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)		04.1340
Cirrhosis, Liver
[description not available]		06.71102
Liver Cirrhosis
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.		06.71102
Bacterial Meningitides
[description not available]		013.838210
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		02.610
Meningitis, Bacterial
Bacterial infections of the leptomeninges and subarachnoid space, frequently involving the cerebral cortex, cranial nerves, cerebral blood vessels, spinal cord, and nerve roots.		115.838210
Diabetes Mellitus
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.		03.250
Allergic Reaction
[description not available]		02.9330
Hypersensitivity
Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.		02.9330
Chemical and Drug Induced Liver Injury, Chronic
Liver disease lasting six months or more, caused by an adverse effect of a drug or chemical. The adverse effect may be caused by drugs, drug metabolites, chemicals from the environment, or an idiosyncratic response.		02.610
Enteric Fever
[description not available]		04.83100
Typhoid Fever
An acute systemic febrile infection caused by SALMONELLA TYPHI, a serotype of SALMONELLA ENTERICA.		09.83100
Lemierre Disease
[description not available]		03.2450
Fusobacterium Infections
Infections with bacteria of the genus FUSOBACTERIUM.		03.81100
Bile Duct Obstruction
[description not available]		03.0740
Cholangitis
Inflammation of the biliary ductal system (BILE DUCTS); intrahepatic, extrahepatic, or both.		05.3741
Cholestasis
Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).		03.0740
Blastocystis hominis Infections
[description not available]		02.610
Neonatal Death
The death of a live-born INFANT less than 28 days of age.		02.610
Infections, Prosthesis-Related
[description not available]		07.47191
Hematologic Malignancies
[description not available]		08.36124
Hematologic Neoplasms
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.		110.36124
Drug Abuse, Intravenous
[description not available]		02.610
Bacterial Endocarditides
[description not available]		06.72200
Endocarditis, Bacterial
Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use.		06.72200
Infant, Newborn, Diseases
Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts.		02.5220
Eosinophilia, Tropical
[description not available]		05.9731
Eosinophilia
Abnormal increase of EOSINOPHILS in the blood, tissues or organs.		05.9731
Drug-Induced Stevens Johnson Syndrome
[description not available]		02.7530
Stevens-Johnson Syndrome
Rare cutaneous eruption characterized by extensive KERATINOCYTE apoptosis resulting in skin detachment with mucosal involvement. It is often provoked by the use of drugs (e.g., antibiotics and anticonvulsants) or associated with PNEUMONIA, MYCOPLASMA. It is considered a continuum of Toxic Epidermal Necrolysis.		07.7530
Acid Aspiration Syndrome
[description not available]		04.3541
Pneumonia, Aspiration
A type of lung inflammation resulting from the aspiration of food, liquid, or gastric contents into the upper RESPIRATORY TRACT.		04.3541
Pus
[description not available]		03.3260
Chronic Primary Open Angle Glaucoma
[description not available]		03.5720
Infectious Endophthalmitis
Infectious condition of the internal eye.		04.1250
Complication, Postoperative
[description not available]		09.88353
Bacterial Eye Infections
[description not available]		04.5480
Glaucoma, Open-Angle
Glaucoma in which the angle of the anterior chamber is open and the trabecular meshwork does not encroach on the base of the iris.		03.5720
Intraocular Pressure
The pressure of the fluids in the eye.		02.3110
Endophthalmitis
Suppurative inflammation of the tissues of the internal structures of the eye frequently associated with an infection.		09.1250
Postoperative Complications
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.		09.88353
Encephalitis Infection
[description not available]		03.4820
Abscess
Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.		012.96201
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		08.31630
Chronic Illness
[description not available]		04.9881
Recrudescence
[description not available]		09.89282
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		04.9881
ALS - Amyotrophic Lateral Sclerosis
[description not available]		02.2510
Ache
[description not available]		02.7730
Amyotrophic Lateral Sclerosis
A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)		02.2510
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		02.7730
Allergic Contact Dermatitis
[description not available]		07.4620
Dermatitis, Allergic Contact
A contact dermatitis due to allergic sensitization to various substances. These substances subsequently produce inflammatory reactions in the skin of those who have acquired hypersensitivity to them as a result of prior exposure.		02.4620
Gas Gangrene
A severe condition resulting from bacteria invading healthy muscle from adjacent traumatized muscle or soft tissue. The infection originates in a wound contaminated with bacteria of the genus CLOSTRIDIUM. C. perfringens accounts for the majority of cases (over eighty percent), while C. noyvi, C. septicum, and C. histolyticum cause most of the other cases.		02.5220
Hospital-Acquired Condition
[description not available]		02.5820
Delusional Disorder
Disorder with presentation of a facade of coldness with characteristic pervasive mistrust and suspiciousness of others.		02.2110
Arthritides, Bacterial
[description not available]		05.7471
Idiopathic Inflammatory Myopathies
[description not available]		03.4120
Myositis
Inflammation of a muscle or muscle tissue.		03.4120
Cardiac Diseases
[description not available]		02.5120
Heart Diseases
Pathological conditions involving the HEART including its structural and functional abnormalities.		02.5120
Infection, Wound
[description not available]		04.03130
Paralysis, Legs
[description not available]		03.5720
Muscle Spasm
[description not available]		03.1710
Injuries, Spinal Cord
[description not available]		03.5120
Paraplegia
Severe or complete loss of motor function in the lower extremities and lower portions of the trunk. This condition is most often associated with SPINAL CORD DISEASES, although BRAIN DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; NEUROMUSCULAR DISEASES; and MUSCULAR DISEASES may also cause bilateral leg weakness.		03.5720
Spasm
An involuntary contraction of a muscle or group of muscles. Spasms may involve SKELETAL MUSCLE or SMOOTH MUSCLE.		03.1710
Spinal Cord Injuries
Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).		03.5120
Infection
[description not available]		010.79163
Infections
Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.		112.79163
Cardiac Failure
[description not available]		04.0340
Acute Hypercapnic Respiratory Failure
[description not available]		02.8330
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		04.0340
Respiratory Insufficiency
Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed)		14.8330
Infections, Listeria
[description not available]		03.5880
Brill-Symmers Disease
[description not available]		02.2510
Lymphoma, Follicular
Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.		02.2510
Hepatic Failure
[description not available]		03.1710
Complications, Infectious Pregnancy
[description not available]		07.3282
Liver Failure
Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)		03.1710
Entamoeba histolytica Infection
[description not available]		02.2510
Travel Sickness
[description not available]		02.5920
Abscess, Amebic, Hepatic
[description not available]		02.5220
Fever of Unknown Origin
Fever in which the etiology cannot be ascertained.		02.2510
Canine Diseases
[description not available]		02.8430
Cat Diseases
Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used.		02.2510
Experimental Pneumococcal Meningitis
[description not available]		05.24190
Meningitis, Pneumococcal
An acute purulent infection of the meninges and subarachnoid space caused by Streptococcus pneumoniae, most prevalent in children and adults over the age of 60. This illness may be associated with OTITIS MEDIA; MASTOIDITIS; SINUSITIS; RESPIRATORY TRACT INFECTIONS; sickle cell disease (ANEMIA, SICKLE CELL); skull fractures; and other disorders. Clinical manifestations include FEVER; HEADACHE; neck stiffness; and somnolence followed by SEIZURES; focal neurologic deficits (notably DEAFNESS); and COMA. (From Miller et al., Merritt's Textbook of Neurology, 9th ed, p111)		05.24190
Back Ache
[description not available]		02.7730
Erythema Nodosum
An erythematous eruption commonly associated with drug reactions or infection and characterized by inflammatory nodules that are usually tender, multiple, and bilateral. These nodules are located predominantly on the shins with less common occurrence on the thighs and forearms. They undergo characteristic color changes ending in temporary bruise-like areas. This condition usually subsides in 3-6 weeks without scarring or atrophy.		02.2510
Panniculitis, Nodular Nonsuppurative
A form of panniculitis characterized by recurrent episodes of fever accompanied by the eruption of single or multiple erythematous subcutaneous nodules on the lower extremities. They normally resolve, but tend to leave depressions in the skin. The condition is most often seen in women, alone or in association with other disorders.		02.2510
Back Pain
Acute or chronic pain located in the posterior regions of the THORAX; LUMBOSACRAL REGION; or the adjacent regions.		02.7730
Infections, Proteus
[description not available]		03.1950
Fasciitis, Necrotizing
A fulminating bacterial infection of the deep layers of the skin and FASCIA. It can be caused by many different organisms, with STREPTOCOCCUS PYOGENES being the most common.		04.71100
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		05.871
Communicable Diseases, Emerging
Infectious diseases that are novel in their outbreak ranges (geographic and host) or transmission mode.		02.7830
Orientia tsutsugamushi Infection
[description not available]		02.2510
Scrub Typhus
An acute infectious disease caused by ORIENTIA TSUTSUGAMUSHI. It is limited to eastern and southeastern Asia, India, northern Australia, and the adjacent islands. Characteristics include the formation of a primary cutaneous lesion at the site of the bite of an infected mite, fever lasting about two weeks, and a maculopapular rash.		02.2510
Infections, Coronavirus
[description not available]		02.6620
Acute Lymphoid Leukemia
[description not available]		03.2250
Pneumonia, Viral
Inflammation of the lung parenchyma that is caused by a viral infection.		02.9430
Coronavirus Infections
Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).		02.6620
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.		03.2250
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		08.17161
Cauda Equina Syndrome
Compressive lesion affecting the nerve roots of the CAUDA EQUINA (e.g., compression, herniation, inflammation, rupture, or stenosis), which controls the function of the bladder and bowel. Symptoms may include neurological dysfunction of bladder or bowels, loss of sexual sensation and altered sensation or paralysis in the lower extremities.		02.2510
Liver Dysfunction
[description not available]		04.2460
Liver Diseases
Pathological processes of the LIVER.		04.2460
Infections, Neisseriaceae
[description not available]		04.551
Behavior Disorders
[description not available]		02.5320
Mental Disorders
Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.		02.5320
Adenopathy
[description not available]		03.1710
Mediastinal Diseases
Disorders of the mediastinum, general or unspecified.		03.8920
Mucositis
An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).		03.1710
Abscess, Hepatic
[description not available]		04.9880
Colicky Pain
[description not available]		05.5551
Emphysema
A pathological accumulation of air in tissues or organs.		05.0590
Liver Abscess
Solitary or multiple collections of PUS within the liver as a result of infection by bacteria, protozoa, or other agents.		04.9880
Abdominal Pain
Sensation of discomfort, distress, or agony in the abdominal region.		05.5551
Erythrophagocytic Lymphohistiocytosis, Familial
[description not available]		04.1550
Infections, Salmonella
[description not available]		04.4370
Lymphohistiocytosis, Hemophagocytic
A group of related disorders characterized by LYMPHOCYTOSIS; HISTIOCYTOSIS; and hemophagocytosis. The two major forms are familial and reactive.		04.1550
Infarct of the Spleen
[description not available]		02.5420
Aspergillus Infection
[description not available]		03.0340
Aspergillosis
Infections with fungi of the genus ASPERGILLUS.		03.0340
Antibody Deficiency Syndrome
[description not available]		03.9721
Immunologic Deficiency Syndromes
Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.		03.9721
Chylopericardium
[description not available]		02.5720
Pleuropericarditis
Inflammation of both the PERICARDIUM and the PLEURA.		02.9840
Pericardial Effusion
Fluid accumulation within the PERICARDIUM. Serous effusions are associated with pericardial diseases. Hemopericardium is associated with trauma. Lipid-containing effusion (chylopericardium) results from leakage of THORACIC DUCT. Severe cases can lead to CARDIAC TAMPONADE.		02.5720
Pericarditis
Inflammation of the PERICARDIUM from various origins, such as infection, neoplasm, autoimmune process, injuries, or drug-induced. Pericarditis usually leads to PERICARDIAL EFFUSION, or CONSTRICTIVE PERICARDITIS.		02.9840
Keratitis
Inflammation of the cornea.		02.5820
Cerebrospinal Fluid Drainage
[description not available]		02.2510
Colitis Gravis
[description not available]		02.5220
Bordetella Infections
Infections with bacteria of the genus BORDETELLA.		02.7230
Colitis, Ulcerative
Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.		02.5220
Polyomavirus Infections
Infections with POLYOMAVIRUS, which are often cultured from the urine of kidney transplant patients. Excretion of BK VIRUS is associated with ureteral strictures and CYSTITIS, and that of JC VIRUS with progressive multifocal leukoencephalopathy (LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL).		02.3110
Duncan Disease
[description not available]		02.3110
Fibroma, Shope
[description not available]		02.3110
Lymphoproliferative Disorders
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.		02.3110
Hypermelanosis
[description not available]		02.6120
Alopecia Cicatrisata
[description not available]		02.3110
Pancytopenia
Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets.		02.3110
Ectopic Pregnancy
[description not available]		02.3110
Consciousness, Loss of
[description not available]		02.3110
Alopecia
Absence of hair from areas where it is normally present.		02.3110
Pregnancy, Ectopic
A potentially life-threatening condition in which EMBRYO IMPLANTATION occurs outside the cavity of the UTERUS. Most ectopic pregnancies (		02.3110
Hyperpigmentation
Excessive pigmentation of the skin, usually as a result of increased epidermal or dermal melanin pigmentation, hypermelanosis. Hyperpigmentation can be localized or generalized. The condition may arise from exposure to light, chemicals or other substances, or from a primary metabolic imbalance.		02.6120
Cavernous Sinus Thrombophlebitis
[description not available]		02.3110
Mucorales Infection
[description not available]		02.3110
Eye Foreign Bodies
Inanimate objects that become enclosed in the eye.		02.3110
Mucormycosis
Infection in humans and animals caused by any fungus in the order MUCORALES (e.g., RHIZOPUS; MUCOR; CUNNINGHAMELLA; APOPHYSOMYCES; ABSIDIA; SAKSENAEA and RHIZOMUCOR) There are many clinical types associated with infection including central nervous system, lung, gastrointestinal tract, skin, orbit and paranasal sinuses. In humans, it usually occurs as an OPPORTUNISTIC INFECTION.		02.3110
Dermatitis Medicamentosa
[description not available]		04.9950
Exanthem
[description not available]		07.9940
Exanthema
Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.		07.9940
Hemorrhagic Shock
[description not available]		02.3110
Acute Respiratory Distress Syndrome
[description not available]		08.0240
Respiratory Distress Syndrome
A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.		08.0240
Neisseria gonorrhoeae Infection
[description not available]		03.3420
Gonorrhea
Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, NEISSERIA GONORRHOEAE, was isolated by Neisser in 1879.		03.3420
Petechiae
Pinhead size (3 mm) skin discolorization due to hemorrhage.		02.5920
Anguilluliasis
[description not available]		02.3110
Purpura
Purplish or brownish red discoloration, easily visible through the epidermis, caused by hemorrhage into the tissues. When the size of the discolorization is		02.5920
Strongyloidiasis
Infection with nematodes of the genus STRONGYLOIDES. The presence of larvae may produce pneumonitis and the presence of adult worms in the intestine could lead to moderate to severe diarrhea.		02.3110
Food Poisoning
[description not available]		02.3110
Autosomal Recessive Chronic Granulomatous Disease
[description not available]		03.4320
Granulomatous Disease, Chronic
A defect of leukocyte function in which phagocytic cells ingest but fail to digest bacteria, resulting in recurring bacterial infections with granuloma formation. When chronic granulomatous disease is caused by mutations in the CYBB gene, the condition is inherited in an X-linked recessive pattern. When chronic granulomatous disease is caused by CYBA, NCF1, NCF2, or NCF4 gene mutations, the condition is inherited in an autosomal recessive pattern.		03.4320
Ascites
Accumulation or retention of free fluid within the peritoneal cavity.		010.1531
Brachial Paresis
[description not available]		02.830
MODS
[description not available]		08.0784
Multiple Organ Failure
A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.		08.0784
Gall Bladder Diseases
[description not available]		02.1510
Delayed Graft Function
General dysfunction of an organ occurring immediately following its transplantation. The term most frequently refers to renal dysfunction following KIDNEY TRANSPLANTATION.		02.1510
Anemia, Hemolytic, Acquired
[description not available]		02.7930
Gasser Syndrome
[description not available]		02.7830
Congenital Thrombotic Thrombocytopenic Purpura
[description not available]		02.7630
Anemia, Hemolytic
A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red blood cells (ERYTHROCYTES).		02.7930
Hemolytic-Uremic Syndrome
A syndrome that is associated with microvascular diseases of the KIDNEY, such as RENAL CORTICAL NECROSIS. It is characterized by hemolytic anemia (ANEMIA, HEMOLYTIC); THROMBOCYTOPENIA; and ACUTE RENAL FAILURE.		02.7830
Purpura, Thrombotic Thrombocytopenic
An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases.		02.7630
Communicable Diseases, Imported
Infectious diseases originating in one geographically delineated ecosystem that are carried (by travel or immigration) to another geographically delineated ecosystem by an infected individual, animal, or disease vector.		02.1510
Catheter-Associated Infections
[description not available]		03.6280
Flaccid Quadriplegia
[description not available]		02.520
Brain Hemorrhage, Cerebral
[description not available]		02.8130
Cerebral Hemorrhage
Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.		02.8130
Chloroma
[description not available]		02.5120
Sarcoma, Myeloid
An extramedullary tumor of immature MYELOID CELLS or MYELOBLASTS. Granulocytic sarcoma usually occurs with or follows the onset of ACUTE MYELOID LEUKEMIA.		02.5120
Orphan Diseases
Rare diseases that have not been well studied.		02.830
Ecthyma
An ulcerative pyoderma usually caused by group A beta-hemolytic streptococcal infection at the site of minor trauma. (Dorland, 27th ed)		02.5820
Birth Weight
The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.		02.1510
Leishmaniasis, American
[description not available]		02.1510
Leishmaniasis, Cutaneous
An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.		02.1510
Autoimmune Thrombocytopenia
[description not available]		02.1510
Purpura, Thrombocytopenic, Idiopathic
Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.		02.1510
Libman-Sacks Disease
[description not available]		02.4720
Lupus Erythematosus, Systemic
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.		02.4720
Spondylitis
Inflammation of the SPINE. This includes both arthritic and non-arthritic conditions.		02.7530
Phlegmon
[description not available]		06.15111
Cellulitis
An acute, diffuse, and suppurative inflammation of loose connective tissue, particularly the deep subcutaneous tissues, and sometimes muscle, which is most commonly seen as a result of infection of a wound, ulcer, or other skin lesions.		06.15111
Grippe
[description not available]		02.8130
Influenza, Human
An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.		02.8130
Facial Palsy
[description not available]		02.1510
Bone Inflammation
[description not available]		02.5220
Berger Disease
[description not available]		02.1510
Aortitis
Inflammation of the wall of the AORTA.		02.1510
Glomerulonephritis, IGA
A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.		02.1510
Pott Puffy Tumor
Infection of the FRONTAL BONE often as a complication of FRONTAL SINUSITIS or trauma to the frontal bone and skull. It is characterized by subperiosteal abscess with OSTEOMYELITIS.		02.5220
Abscess, Epidural
[description not available]		04.0950
Aspergilloses, Bronchopulmonary
[description not available]		02.1710
DRESS Syndrome
[description not available]		02.1710
Pulmonary Aspergillosis
Infections of the respiratory tract with fungi of the genus ASPERGILLUS.		02.1710
Bilophila Infections
[description not available]		03.0910
Adult Fanconi Syndrome
[description not available]		02.5720
Neurilemoma
[description not available]		02.1510
Infection, Postoperative Wound
[description not available]		07.24192
Neurilemmoma
A neoplasm that arises from SCHWANN CELLS of the cranial, peripheral, and autonomic nerves. Clinically, these tumors may present as a cranial neuropathy, abdominal or soft tissue mass, intracranial lesion, or with spinal cord compression. Histologically, these tumors are encapsulated, highly vascular, and composed of a homogenous pattern of biphasic fusiform-shaped cells that may have a palisaded appearance. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp964-5)		02.1510
Soft Tissue Neoplasms
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.		02.1510
Histiocytic Necrotising Lymphadenitis
[description not available]		02.4720
Central Retinal Edema, Cystoid
[description not available]		02.5720
Autoimmune Thyroiditis
[description not available]		02.1710
Macular Edema
Fluid accumulation in the outer layer of the MACULA LUTEA that results from intraocular or systemic insults. It may develop in a diffuse pattern where the macula appears thickened or it may acquire the characteristic petaloid appearance referred to as cystoid macular edema. Although macular edema may be associated with various underlying conditions, it is most commonly seen following intraocular surgery, venous occlusive disease, DIABETIC RETINOPATHY, and posterior segment inflammatory disease. (From Survey of Ophthalmology 2004; 49(5) 470-90)		02.5720
Disease Exacerbation
[description not available]		05.7871
Embolism, Pulmonary
[description not available]		02.1710
Pleural Diseases
Diseases involving the PLEURA.		02.1710
Bronchial Fistula
An abnormal passage or communication between a bronchus and another part of the body.		02.1710
Pulmonary Embolism
Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.		02.1710
Acute Disease
Disease having a short and relatively severe course.		011.16276
Adenocarcinoma, Basal Cell
[description not available]		02.5420
Superior Vena Cava Obstruction
[description not available]		02.2110
Thoracic Diseases
Disorders affecting the organs of the thorax.		02.2110
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.5420
Carcinoma, Non-Small Cell Lung
[description not available]		02.1710
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.1710
Pleural Effusion
Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself.		0840
Meningitis, Meningococcal, Serogroup A
[description not available]		02.7330
Infections, Meningococcal
[description not available]		02.7630
Meningitis, Meningococcal
A fulminant infection of the meninges and subarachnoid fluid by the bacterium NEISSERIA MENINGITIDIS, producing diffuse inflammation and peri-meningeal venous thromboses. Clinical manifestations include FEVER, nuchal rigidity, SEIZURES, severe HEADACHE, petechial rash, stupor, focal neurologic deficits, HYDROCEPHALUS, and COMA. The organism is usually transmitted via nasopharyngeal secretions and is a leading cause of meningitis in children and young adults. Organisms from Neisseria meningitidis serogroups A, B, C, Y, and W-135 have been reported to cause meningitis. (From Adams et al., Principles of Neurology, 6th ed, pp689-701; Curr Opin Pediatr 1998 Feb;10(1):13-8)		02.7330
Meningococcal Infections
Infections with bacteria of the species NEISSERIA MENINGITIDIS.		02.7630
Radius Fractures
Fractures of the RADIUS.		02.1710
Aspiration, Respiratory
[description not available]		02.1710
Foreign Bodies
Inanimate objects that become enclosed in the body.		02.7830
Empyema, Thoracic
[description not available]		02.8430
Empyema, Pleural
Suppurative inflammation of the pleural space.		02.8430
Arterial Inflammation
[description not available]		02.1710
Arterial Diseases, Carotid
[description not available]		02.1710
Infections, Helicobacter
[description not available]		03.9540
Carotid Artery Diseases
Pathological conditions involving the CAROTID ARTERIES, including the common, internal, and external carotid arteries. ATHEROSCLEROSIS and TRAUMA are relatively frequent causes of carotid artery pathology.		02.1710
Helicobacter Infections
Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.		03.9540
Necrotizing Pneumonia
[description not available]		02.1710
Abscess, Pulmonary
[description not available]		03.6630
Lung Abscess
Solitary or multiple collections of PUS within the lung parenchyma as a result of infection by bacteria, protozoa, or other agents.		03.6630
Carcinoma, Epidermoid
[description not available]		02.5720
Cancer of Esophagus
[description not available]		02.1710
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		02.5720
Esophageal Neoplasms
Tumors or cancer of the ESOPHAGUS.		02.1710
Gastritis
Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders.		04.8550
Bacteroidaceae Infections
Infections with bacteria of the family BACTEROIDACEAE.		02.1710
Aqueductal Stenosis
[description not available]		04.4780
Corynebacterium Infections
Infections with bacteria of the genus CORYNEBACTERIUM.		02.2110
Actinomycetales Infections
Infections with bacteria of the order ACTINOMYCETALES.		04.150
Bilateral Headache
[description not available]		03.570
Headache
The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.		03.570
Acute Cholecystitis
[description not available]		02.1710
Acute Edematous Pancreatitis
[description not available]		04.3570
Pancreatitis
INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.		16.3570
Cholecystitis, Acute
Acute inflammation of the GALLBLADDER wall. It is characterized by the presence of ABDOMINAL PAIN; FEVER; and LEUKOCYTOSIS. Gallstone obstruction of the CYSTIC DUCT is present in approximately 90% of the cases.		02.1710
Gangrene
Death and putrefaction of tissue usually due to a loss of blood supply.		03.0140
Hepatitis
INFLAMMATION of the LIVER.		02.1710
Acute Generalised Exanthematous Pustulosis
[description not available]		02.1710
Adult Premature Aging Syndrome
[description not available]		02.1710
Delayed Hypersensitivity
[description not available]		02.7830
Benign Meningeal Neoplasms
[description not available]		02.7930
Meningeal Neoplasms
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.		02.7930
Breathlessness
[description not available]		02.8330
Dyspnea
Difficult or labored breathing.		02.8330
Colonic Diseases
Pathological processes in the COLON region of the large intestine (INTESTINE, LARGE).		04.1530
Constriction, Pathological
[description not available]		03.920
Constriction, Pathologic
The condition of an anatomical structure's being constricted beyond normal dimensions.		03.920
Intestinal Obstruction
Any impairment, arrest, or reversal of the normal flow of INTESTINAL CONTENTS toward the ANAL CANAL.		03.0910
Cyst
[description not available]		07.8230
ADPKD
[description not available]		02.7930
Polycystic Kidney, Autosomal Dominant
Kidney disorders with autosomal dominant inheritance and characterized by multiple CYSTS in both KIDNEYS with progressive deterioration of renal function.		02.7930
Cancer of Eye
[description not available]		02.2110
Malignant Melanoma
[description not available]		02.2110
Acute Myelogenous Leukemia
[description not available]		03.6890
Cancer, Second Primary
[description not available]		02.2110
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.2110
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		03.6890
Cancer of Stomach
[description not available]		02.2110
Stomach Neoplasms
Tumors or cancer of the STOMACH.		02.2110
Cerebral Intraventricular Haemorrhage
[description not available]		02.2110
Bacterial Infections, Central Nervous System
[description not available]		03.3920
Blood Clot
[description not available]		02.2110
Thrombosis
Formation and development of a thrombus or blood clot in the blood vessel.		02.2110
Equine Diseases
[description not available]		02.2110
Empyema
Presence of pus in a hollow organ or body cavity.		02.2110
Autoimmune Disease
[description not available]		02.2110
Deficiency, Factor 5
[description not available]		02.2110
Autoimmune Diseases
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.		02.2110
Complications of Diabetes Mellitus
[description not available]		04.7261
Leucocythaemia
[description not available]		05.2943
Dysmyelopoietic Syndromes
[description not available]		05.5832
Chemotherapy-Induced Febrile Neutropenia
FEVER accompanied by a significant reduction in NEUTROPHIL count associated with CHEMOTHERAPY.		06.0633
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		010.2943
Myelodysplastic Syndromes
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.		05.5832
Keratitis, Ulcerative
[description not available]		03.1210
Corneal Ulcer
Loss of epithelial tissue from the surface of the cornea due to progressive erosion and necrosis of the tissue; usually caused by bacterial, fungal, or viral infection.		03.1210
Albers-Schoenberg Disease
[description not available]		02.2110
Osteopetrosis
Excessive formation of dense trabecular bone leading to pathological fractures; OSTEITIS; SPLENOMEGALY with infarct; ANEMIA; and extramedullary hemopoiesis (HEMATOPOIESIS, EXTRAMEDULLARY).		02.2110
Respiratory Tract Fistula
An abnormal passage communicating between any component of the respiratory tract or between any part of the respiratory system and surrounding organs.		02.2110
Acute Infectious Thyroiditis
[description not available]		02.2110
Necrotizing Enterocolitis
[description not available]		03.9121
Enterocolitis, Necrotizing
ENTEROCOLITIS with extensive ulceration (ULCER) and NECROSIS. It is observed primarily in LOW BIRTH WEIGHT INFANT.		03.9121
Pneumonia, Pneumococcal
A febrile disease caused by STREPTOCOCCUS PNEUMONIAE.		02.9540
Earache
Pain in the ear.		02.830
External Ear Inflammation
[description not available]		02.5120
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		04.9580
Otitis Externa
Inflammation of the OUTER EAR including the external EAR CANAL, cartilages of the auricle (EAR CARTILAGE), and the TYMPANIC MEMBRANE.		02.5120
Cyanosis
A bluish or purplish discoloration of the skin and mucous membranes due to an increase in the amount of deoxygenated hemoglobin in the blood or a structural defect in the hemoglobin molecule.		02.2110
Methemoglobinemia
The presence of methemoglobin in the blood, resulting in cyanosis. A small amount of methemoglobin is present in the blood normally, but injury or toxic agents convert a larger proportion of hemoglobin into methemoglobin, which does not function reversibly as an oxygen carrier. Methemoglobinemia may be due to a defect in the enzyme NADH methemoglobin reductase (an autosomal recessive trait) or to an abnormality in hemoglobin M (an autosomal dominant trait). (Dorland, 27th ed)		02.2110
Sinusitis, Maxillary
[description not available]		03.4720
Maxillary Sinusitis
Inflammation of the NASAL MUCOSA in the MAXILLARY SINUS. In many cases, it is caused by an infection of the bacteria HAEMOPHILUS INFLUENZAE; STREPTOCOCCUS PNEUMONIAE; or STAPHYLOCOCCUS AUREUS.		03.4720
Brain Inflammation
[description not available]		02.2110
Encephalitis
Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition.		02.2110
Altered Level of Consciousness
[description not available]		03.520
Cough
A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.		02.5720
Amaurosis
[description not available]		02.4920
Cranial Nerve II Diseases
[description not available]		02.0810
Blindness
The inability to see or the loss or absence of perception of visual stimuli. This condition may be the result of EYE DISEASES; OPTIC NERVE DISEASES; OPTIC CHIASM diseases; or BRAIN DISEASES affecting the VISUAL PATHWAYS or OCCIPITAL LOBE.		02.4920
Optic Nerve Diseases
Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect.		02.0810
Fasciitis
Inflammation of the fascia. There are three major types: 1, Eosinophilic fasciitis, an inflammatory reaction with eosinophilia, producing hard thickened skin with an orange-peel configuration suggestive of scleroderma and considered by some a variant of scleroderma; 2, Necrotizing fasciitis (FASCIITIS, NECROTIZING), a serious fulminating infection (usually by a beta hemolytic streptococcus) causing extensive necrosis of superficial fascia; 3, Nodular/Pseudosarcomatous /Proliferative fasciitis, characterized by a rapid growth of fibroblasts with mononuclear inflammatory cells and proliferating capillaries in soft tissue, often the forearm; it is not malignant but is sometimes mistaken for fibrosarcoma.		02.0810
Wounds, Penetrating
Wounds caused by objects penetrating the skin.		02.0810
Pulmonary Consumption
[description not available]		02.9840
Tuberculosis, Pulmonary
MYCOBACTERIUM infections of the lung.		14.9840
Bacteriuria
The presence of bacteria in the urine which is normally bacteria-free. These bacteria are from the URINARY TRACT and are not contaminants of the surrounding tissues. Bacteriuria can be symptomatic or asymptomatic. Significant bacteriuria is an indicator of urinary tract infection.		02.7730
Glanders
A contagious disease of horses that can be transmitted to humans. It is caused by BURKHOLDERIA MALLEI and characterized by ulceration of the respiratory mucosa and an eruption of nodules on the skin.		02.4820
Urinary Lithiasis
[description not available]		02.0810
Colitis, Granulomatous
[description not available]		02.4720
Crohn Disease
A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.		02.4720
Urolithiasis
Formation of stones in any part of the URINARY TRACT, usually in the KIDNEY; URINARY BLADDER; or the URETER.		02.0810
Thrombocythemia
[description not available]		04.2720
Morbid Obesity
[description not available]		06.0652
Obesity, Morbid
The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.		06.0652
Pyuria
The presence of white blood cells (LEUKOCYTES) in the urine. It is often associated with bacterial infections of the urinary tract. Pyuria without BACTERIURIA can be caused by TUBERCULOSIS, stones, or cancer.		02.110
Adenovirus Infections
[description not available]		0310
Adenoviridae Infections
Virus diseases caused by the ADENOVIRIDAE.		0310
Caries, Dental
[description not available]		03.0110
Epileptiform Neuralgia
[description not available]		03.0110
Ethmoid Sinusitis
Inflammation of the NASAL MUCOSA in the ETHMOID SINUS. It may present itself as an acute (infectious) or chronic (allergic) condition.		03.0110
Abscess, Intracranial, Subdural
[description not available]		04.2660
Dental Caries
Localized destruction of the tooth surface initiated by decalcification of the enamel followed by enzymatic lysis of organic structures and leading to cavity formation. If left unchecked, the cavity may penetrate the enamel and dentin and reach the pulp.		03.0110
Trigeminal Neuralgia
A syndrome characterized by recurrent episodes of excruciating pain lasting several seconds or longer in the sensory distribution of the TRIGEMINAL NERVE. Pain may be initiated by stimulation of trigger points on the face, lips, or gums or by movement of facial muscles or chewing. Associated conditions include MULTIPLE SCLEROSIS, vascular anomalies, ANEURYSMS, and neoplasms. (Adams et al., Principles of Neurology, 6th ed, p187)		03.0110
Gallstone Disease
[description not available]		03.3620
Emphysema, Mediastinal
[description not available]		02.110
Cholelithiasis
Presence or formation of GALLSTONES in the BILIARY TRACT, usually in the gallbladder (CHOLECYSTOLITHIASIS) or the common bile duct (CHOLEDOCHOLITHIASIS).		03.3620
Aneurysm, Bacterial
[description not available]		02.7830
Gout
Metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of URIC ACID calculi.		02.110
Hyperuricemia
Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.		02.110
Infections, Tick-Borne
[description not available]		02.0810
Bunyaviridae Infections
Virus diseases caused by the BUNYAVIRIDAE.		02.0810
Hematochezia
The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.		03.6530
Colitis, Ischemic
Inflammation of the COLON due to colonic ISCHEMIA resulting from alterations in systemic circulation or local vasculature.		03.0110
Liposclerotic Mesenteritis
[description not available]		03.0110
Gastrointestinal Hemorrhage
Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.		03.6530
Spinal Diseases
Diseases involving the SPINE.		02.4620
Concomitant Strabismus
[description not available]		02.110
Cellulitis, Orbital
[description not available]		02.4920
Strabismus
Misalignment of the visual axes of the eyes. In comitant strabismus the degree of ocular misalignment does not vary with the direction of gaze. In noncomitant strabismus the degree of misalignment varies depending on direction of gaze or which eye is fixating on the target. (Miller, Walsh & Hoyt's Clinical Neuro-Ophthalmology, 4th ed, p641)		02.110
Delirium of Mixed Origin
[description not available]		02.1110
Delirium
A disorder characterized by CONFUSION; inattentiveness; disorientation; ILLUSIONS; HALLUCINATIONS; agitation; and in some instances autonomic nervous system overactivity. It may result from toxic/metabolic conditions or structural brain lesions. (From Adams et al., Principles of Neurology, 6th ed, pp411-2)		07.1110
Autoimmune Diabetes
[description not available]		02.110
Diabetes Mellitus, Type 1
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.		02.110
Cane-Cutter Fever
[description not available]		02.110
Glomerular Necrosis
[description not available]		02.110
Leptospirosis
Infections with bacteria of the genus LEPTOSPIRA.		02.110
Diathesis
[description not available]		02.9740
Pleurisy
INFLAMMATION of PLEURA, the lining of the LUNG. When PARIETAL PLEURA is involved, there is pleuritic CHEST PAIN.		07.4420
Hypogammaglobulinemia
[description not available]		03.6730
Agammaglobulinemia
An immunologic deficiency state characterized by an extremely low level of generally all classes of gamma-globulin in the blood.		03.6730
Adenoma, Basal Cell
[description not available]		02.110
Cancer of Pituitary
[description not available]		02.110
Adenoma
A benign epithelial tumor with a glandular organization.		02.110
Pituitary Neoplasms
Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.		02.110
Polyarthritis
[description not available]		02.4820
Arthritis
Acute or chronic inflammation of JOINTS.		02.4820
Kidney Stones
[description not available]		02.110
Kidney Calculi
Stones in the KIDNEY, usually formed in the urine-collecting area of the kidney (KIDNEY PELVIS). Their sizes vary and most contains CALCIUM OXALATE.		02.110
Myoclonic Jerk
[description not available]		02.4520
Perforated Appendicitis
[description not available]		07.1294
Appendicitis
Acute inflammation of the APPENDIX. Acute appendicitis is classified as simple, gangrenous, or perforated.		114.1294
Sinus Infections
[description not available]		02.5220
Sinusitis
Inflammation of the NASAL MUCOSA in one or more of the PARANASAL SINUSES.		02.5220
Retinal Dystrophies
A group of disorders involving predominantly the posterior portion of the ocular fundus, due to degeneration in the sensory layer of the RETINA; RETINAL PIGMENT EPITHELIUM; BRUCH MEMBRANE; CHOROID; or a combination of these tissues.		02.1110
Pancreatic Diseases
Pathological processes of the PANCREAS.		02.110
Cancer of Prostate
[description not available]		02.4920
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.4920
Infantile Respiratory Distress Syndrome
[description not available]		02.110
Respiratory Distress Syndrome, Newborn
A condition of the newborn marked by DYSPNEA with CYANOSIS, heralded by such prodromal signs as dilatation of the alae nasi, expiratory grunt, and retraction of the suprasternal notch or costal margins, mostly frequently occurring in premature infants, children of diabetic mothers, and infants delivered by cesarean section, and sometimes with no apparent predisposing cause.		02.110
Candidiasis, Invasive
An important nosocomial fungal infection with species of the genus CANDIDA, most frequently CANDIDA ALBICANS. Invasive candidiasis occurs when candidiasis goes beyond a superficial infection and manifests as CANDIDEMIA, deep tissue infection, or disseminated disease with deep organ involvement.		03.511
A-Thalassemia
[description not available]		02.1110
Discitis
Inflammation of an INTERVERTEBRAL DISC or disk space which may lead to disk erosion. Until recently, discitis has been defined as a nonbacterial inflammation and has been attributed to aseptic processes (e.g., chemical reaction to an injected substance). However, recent studies provide evidence that infection may be the initial cause, but perhaps not the promoter, of most cases of discitis. Discitis has been diagnosed in patients following discography, myelography, lumbar puncture, paravertebral injection, and obstetrical epidural anesthesia. Discitis following chemonucleolysis (especially with chymopapain) is attributed to chemical reaction by some and to introduction of microorganisms by others.		02.7730
Abscess, Psoas
[description not available]		02.4620
alpha-Thalassemia
A disorder characterized by reduced synthesis of the alpha chains of hemoglobin. The severity of this condition can vary from mild anemia to death, depending on the number of genes deleted.		02.1110
Rheumatoid Arthritis
[description not available]		03.6930
Cytomegalic Inclusion Disease
[description not available]		02.5220
Edema, Pulmonary
[description not available]		02.1110
Intestinal Perforation
Opening or penetration through the wall of the INTESTINES.		05.2741
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		03.6930
Cytomegalovirus Infections
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.		02.5220
Pulmonary Edema
Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening.		02.1110
Acne Inversa
[description not available]		02.1110
Kidney, Polycystic
[description not available]		02.1110
Polycystic Kidney Diseases
Hereditary diseases that are characterized by the progressive expansion of a large number of tightly packed CYSTS within the KIDNEYS. They include diseases with autosomal dominant and autosomal recessive inheritance.		02.1110
Hidradenitis Suppurativa
A chronic suppurative and cicatricial disease of the apocrine glands occurring chiefly in the axillae in women and in the groin and anal regions in men. It is characterized by poral occlusion with secondary bacterial infection, evolving into abscesses which eventually rupture. As the disease becomes chronic, ulcers appear, sinus tracts enlarge, fistulas develop, and fibrosis and scarring become evident.		07.1110
Anti-MuSK Myasthenia Gravis
[description not available]		02.1110
Opportunistic Infections
An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.		07.67133
Carcinoma, Thymic
[description not available]		02.1110
Cancer of the Thymus
[description not available]		02.5220
Myasthenia Gravis
A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.		02.1110
Thymoma
A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed)		02.1110
Thymus Neoplasms
Tumors or cancer of the THYMUS GLAND.		02.5220
Emergencies
Situations or conditions requiring immediate intervention to avoid serious adverse results.		04.0650
Asystole
[description not available]		02.1110
Rupture, Spontaneous
Tear or break of an organ, vessel or other soft part of the body, occurring in the absence of external force.		04.5451
Splenic Rupture
Rupture of the SPLEEN due to trauma or disease.		02.1110
Cytomegalovirus
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.		02.1110
Heart Arrest
Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.		02.1110
Acute Necrotizing Pancreatitis
[description not available]		013.36173
Aseptic Meningitis
[description not available]		02.1110
Meningitis, Aseptic
A syndrome characterized by headache, neck stiffness, low grade fever, and CSF lymphocytic pleocytosis in the absence of an acute bacterial pathogen. Viral meningitis is the most frequent cause although MYCOPLASMA INFECTIONS; RICKETTSIA INFECTIONS; diagnostic or therapeutic procedures; NEOPLASTIC PROCESSES; septic perimeningeal foci; and other conditions may result in this syndrome. (From Adams et al., Principles of Neurology, 6th ed, p745)		02.1110
Overweight
A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.		07.1110
Anthracosis
A diffuse parenchymal lung disease caused by accumulation of inhaled CARBON or coal dust. The disease can progress from asymptomatic anthracosis to massive lung fibrosis. This lung lesion usually occurs in coal MINERS, but can be seen in urban dwellers and tobacco smokers.		02.1110
Gastroenteritis
INFLAMMATION of any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Causes of gastroenteritis are many including genetic, infection, HYPERSENSITIVITY, drug effects, and CANCER.		02.1110
Rotavirus Infections
Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice.		02.1110
Atresia, Biliary
[description not available]		02.1110
Biliary Atresia
Progressive destruction or the absence of all or part of the extrahepatic BILE DUCTS, resulting in the complete obstruction of BILE flow. Usually, biliary atresia is found in infants and accounts for one third of the neonatal cholestatic JAUNDICE.		02.1110
Pyoderma Gangrenosum
An idiopathic, rapidly evolving, and severely debilitating disease occurring most commonly in association with chronic ulcerative colitis. It is characterized by the presence of boggy, purplish ulcers with undermined borders, appearing mostly on the legs. The majority of cases are in people between 40 and 60 years old. Its etiology is unknown.		02.5320
Common Variable Hypogammaglobulinemia
[description not available]		02.1110
Common Variable Immunodeficiency
Heterogeneous group of immunodeficiency syndromes characterized by hypogammaglobulinemia of most isotypes, variable B-cell defects, and the presence of recurrent bacterial infections.		02.1110
Carcinoma, Oat Cell
[description not available]		02.1110
Local Neoplasm Recurrence
[description not available]		02.1110
Carcinoma, Small Cell
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)		02.1110
Vesicoureteral Reflux
[description not available]		02.1110
Vesico-Ureteral Reflux
Retrograde flow of urine from the URINARY BLADDER into the URETER. This is often due to incompetence of the vesicoureteral valve leading to ascending bacterial infection into the KIDNEY.		02.1110
Cranial Airocele
[description not available]		02.1110
Hematoma, Subdural, Chronic
Accumulation of blood in the SUBDURAL SPACE with delayed onset of neurological symptoms. Symptoms may include loss of consciousness, severe HEADACHE, and deteriorating mental status.		02.1110
Bites
[description not available]		02.7430
Infections, Pasteurella
[description not available]		02.1110
Sinusitis, Sphenoid
[description not available]		02.1110
Pericementitis
[description not available]		02.1110
Periodontitis
Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology)		02.1110
Cranial Nerve XII Diseases
[description not available]		02.1110
Sore Throat
[description not available]		03.3720
Pharyngitis
Inflammation of the throat (PHARYNX).		03.3720
Haverhill Fever
[description not available]		02.1110
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
[description not available]		02.1110
Lymphoma, Mantle-Cell
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).		02.1110
Pneumoperitoneum
A condition with trapped gas or air in the PERITONEAL CAVITY, usually secondary to perforation of the internal organs such as the LUNG and the GASTROINTESTINAL TRACT, or to recent surgery. Pneumoperitoneum may be purposely introduced to aid radiological examination.		02.7930
Bowel Incontinence
[description not available]		02.1310
Fecal Incontinence
Failure of voluntary control of the anal sphincters, with involuntary passage of feces and flatus.		02.1310
Respiratory Syndrome, Acute, Severe
[description not available]		02.1310
Severe Acute Respiratory Syndrome
A viral disorder characterized by high FEVER, dry COUGH, shortness of breath (DYSPNEA) or breathing difficulties, and atypical PNEUMONIA. A virus in the genus CORONAVIRUS is the suspected agent.		02.1310
Chronic Pancreatitis
[description not available]		02.1110
Pancreatitis, Chronic
INFLAMMATION of the PANCREAS that is characterized by recurring or persistent ABDOMINAL PAIN with or without STEATORRHEA or DIABETES MELLITUS. It is characterized by the irregular destruction of the pancreatic parenchyma which may be focal, segmental, or diffuse.		02.1110
Infections, Vibrio
[description not available]		02.1110
Lock Jaw
[description not available]		02.1110
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		06.7951
Escherichia coli Meningitis
[description not available]		02.9540
Abscess, Retropharyngeal
[description not available]		02.1110
Ischemia
A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.		02.1310
Enlarged Liver
[description not available]		02.1510
Enlarged Spleen
[description not available]		02.5420
Panuveitis
Inflammation in which both the anterior and posterior segments of the uvea are involved and a specific focus is not apparent. It is often severe and extensive and a serious threat to vision. Causes include systemic diseases such as tuberculosis, sarcoidosis, and syphilis, as well as malignancies. The intermediate segment of the eye is not involved.		02.1510
Central Nervous System Infection
[description not available]		02.7830
Pink Eye
[description not available]		02.1310
Conjunctivitis
INFLAMMATION of the CONJUNCTIVA.		02.1310
Prostatic Diseases
Pathological processes involving the PROSTATE or its component tissues.		05.0631
Bullous Dermatoses
[description not available]		02.1310
Foot Dermatoses
Skin diseases of the foot, general or unspecified.		02.1310
Femur Neck Fractures
[description not available]		03.0410
Pseudarthrosis
A pathologic entity characterized by deossification of a weight-bearing long bone, followed by bending and pathologic fracture, with inability to form normal BONY CALLUS leading to existence of the false joint that gives the condition its name. (Dorland, 27th ed)		03.0410
Hydronephrosis, Infected
[description not available]		03.0410
Femoral Neck Fractures
Fractures of the short, constricted portion of the thigh bone between the femur head and the trochanters. It excludes intertrochanteric fractures which are HIP FRACTURES.		03.0410
Granulomatosis, Wegener's
[description not available]		03.4220
Granulomatosis with Polyangiitis
A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN.		03.4220
Cancer of Pharynx
[description not available]		02.1510
Pharyngeal Neoplasms
Tumors or cancer of the PHARYNX.		02.1510
Dysphagia
[description not available]		02.1310
Esophageal Stricture
[description not available]		02.1310
Deglutition Disorders
Difficulty in SWALLOWING which may result from neuromuscular disorder or mechanical obstruction. Dysphagia is classified into two distinct types: oropharyngeal dysphagia due to malfunction of the PHARYNX and UPPER ESOPHAGEAL SPHINCTER; and esophageal dysphagia due to malfunction of the ESOPHAGUS.		02.1310
Esophageal Stenosis
A stricture of the ESOPHAGUS. Most are acquired but can be congenital.		02.1310
Acute Autoimmune Neuropathy
[description not available]		02.1310
Peripheral Nerve Diseases
[description not available]		02.1310
Splenic Diseases
Diseases involving the SPLEEN.		02.4620
Peripheral Nervous System Diseases
Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.		02.1310
Guillain-Barre Syndrome
An acute inflammatory autoimmune neuritis caused by T cell- mediated cellular immune response directed towards peripheral myelin. Demyelination occurs in peripheral nerves and nerve roots. The process is often preceded by a viral or bacterial infection, surgery, immunization, lymphoma, or exposure to toxins. Common clinical manifestations include progressive weakness, loss of sensation, and loss of deep tendon reflexes. Weakness of respiratory muscles and autonomic dysfunction may occur. (From Adams et al., Principles of Neurology, 6th ed, pp1312-1314)		02.1310
Patent Foramen Ovale
[description not available]		03.0410
Foramen Ovale, Patent
A condition in which the FORAMEN OVALE in the ATRIAL SEPTUM fails to close shortly after birth. This results in abnormal communications between the two upper chambers of the heart. An isolated patent ovale foramen without other structural heart defects is usually of no hemodynamic significance.		03.0410
Encephalopathy, Traumatic
[description not available]		04.4311
Benign Neoplasms, Brain
[description not available]		05.0831
Brain Injuries, Traumatic
A form of acquired brain injury which occurs when a sudden trauma causes damage to the brain.		04.4311
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		05.0831
Keratitis, Acanthamoeba
[description not available]		03.0410
Acanthamoeba Keratitis
Infection of the cornea by an ameboid protozoan which may cause corneal ulceration leading to blindness.		03.0410
Injuries, Multiple
[description not available]		02.1510
Astrocytoma, Grade IV
[description not available]		02.1310
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		02.1310
Hypertriglyceridemia
A condition of elevated levels of TRIGLYCERIDES in the blood.		08.0410
Germinoblastoma
[description not available]		03.5311
Lymphoma
A general term for various neoplastic diseases of the lymphoid tissue.		08.5311
Pyomyositis
An intramuscular suppuration of the large skeletal muscle groups. It is associated with INFECTION such as STAPHYLOCOCCUS AUREUS and PYODERMA. It was known as a tropical disease but is increasing among the immunocompromised (IMMUNOCOMPROMISED HOST). Symptoms include muscle pain, FEVER, and leucocytosis. It has been diagnosed by MRI SCANS.		03.1850
Leukemia, Pre-B-Cell
[description not available]		02.1310
Thyroid Diseases
Pathological processes involving the THYROID GLAND.		02.1310
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.		02.1310
Icterus
[description not available]		02.4920
Spherocytosis, Hereditary
A group of familial congenital hemolytic anemias characterized by numerous abnormally shaped erythrocytes which are generally spheroidal. The erythrocytes have increased osmotic fragility and are abnormally permeable to sodium ions.		02.1310
Jaundice
A clinical manifestation of HYPERBILIRUBINEMIA, characterized by the yellowish staining of the SKIN; MUCOUS MEMBRANE; and SCLERA. Clinical jaundice usually is a sign of LIVER dysfunction.		02.4920
Otitis Media, Purulent
[description not available]		02.1510
Otitis Media, Suppurative
Inflammation of the middle ear with purulent discharge.		02.1510
Infant, Premature, Diseases
Diseases that occur in PREMATURE INFANTS.		05.2562
Erythema Multiforme
A skin and mucous membrane disease characterized by an eruption of macules, papules, nodules, vesicles, and/or bullae with characteristic bull's-eye lesions usually occurring on the dorsal aspect of the hands and forearms.		02.1510
Bleeding
[description not available]		02.1510
Hemorrhage
Bleeding or escape of blood from a vessel.		02.1510
Mediastinitis
Inflammation of the mediastinum, the area between the pleural sacs.		02.830
Skin Ulcer
An ULCER of the skin and underlying tissues.		02.7830
Capillary Leak Syndrome
A condition characterized by recurring episodes of fluid leaking from capillaries into extra-vascular compartments causing hematocrit to rise precipitously. If not treated, generalized vascular leak can lead to generalized EDEMA; SHOCK; cardiovascular collapse; and MULTIPLE ORGAN FAILURE.		02.1510
Muscle Pain
[description not available]		02.1510
Anaphylactic Reaction
[description not available]		03.4220
Blood Pressure, Low
[description not available]		02.1510
Circulatory Collapse
[description not available]		02.4820
Emesis
[description not available]		05.7942
Anaphylaxis
An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death.		03.4220
Hypotension
Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.		02.1510
Shock
A pathological condition manifested by failure to perfuse or oxygenate vital organs.		02.4820
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		05.7942
Myalgia
Painful sensation in the muscles.		02.1510
Acute Relapsing Multiple Sclerosis
[description not available]		02.1510
Multiple Sclerosis, Relapsing-Remitting
The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)		02.1510
Cruveilhier-Baumgarten Syndrome
Liver cirrhosis with intrahepatic portal obstruction, HYPERTENSION, and patent UMBILICAL VEINS.		02.0510
Hypertension, Portal
Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.		02.0510
Adnexitis
Inflammation of the uterine appendages (ADNEXA UTERI) including infection of the FALLOPIAN TUBES (SALPINGITIS), the ovaries (OOPHORITIS), or the supporting ligaments (PARAMETRITIS).		04.7221
Pelvic Inflammatory Disease
A spectrum of inflammation involving the female upper genital tract and the supporting tissues. It is usually caused by an ascending infection of organisms from the endocervix. Infection may be confined to the uterus (ENDOMETRITIS), the FALLOPIAN TUBES; (SALPINGITIS); the ovaries (OOPHORITIS), the supporting ligaments (PARAMETRITIS), or may involve several of the above uterine appendages. Such inflammation can lead to functional impairment and infertility.		04.7221
Cerebellar Diseases
Diseases that affect the structure or function of the cerebellum. Cardinal manifestations of cerebellar dysfunction include dysmetria, GAIT ATAXIA, and MUSCLE HYPOTONIA.		02.4420
Anemia
A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.		02.9440
Foreign-Body Reaction
Chronic inflammation and granuloma formation around irritating foreign bodies.		02.0410
Alkalosis
A pathological condition that removes acid or adds base to the body fluids.		07.0410
Mycoplasma dispar Infection
[description not available]		02.0510
Moraxella Infections
[description not available]		02.0410
Craniofacial Dysarthrosis
[description not available]		02.0410
Bed Sores
[description not available]		02.0410
Pressure Ulcer
An ulceration caused by prolonged pressure on the SKIN and TISSUES when one stays in one position for a long period of time, such as lying in bed. The bony areas of the body are the most frequently affected sites which become ischemic (ISCHEMIA) under sustained and constant pressure.		02.0410
Lactic Acidosis
[description not available]		02.0410
Acidosis, Lactic
Acidosis caused by accumulation of lactic acid more rapidly than it can be metabolized. It may occur spontaneously or in association with diseases such as DIABETES MELLITUS; LEUKEMIA; or LIVER FAILURE.		02.0410
Anuria
Absence of urine formation. It is usually associated with complete bilateral ureteral (URETER) obstruction, complete lower urinary tract obstruction, or unilateral ureteral obstruction when a solitary kidney is present.		03.6330
Rhabdomyolysis
Necrosis or disintegration of skeletal muscle often followed by myoglobinuria.		02.0410
Alcohol Abuse
[description not available]		02.4220
Calciphylaxes
[description not available]		02.0510
Alcoholism
A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)		02.4220
Liver Abscess, Pyogenic
Single or multiple areas of PUS due to bacterial infection within the hepatic parenchyma. It can be caused by a variety of BACTERIA, local or disseminated from infections elsewhere such as in APPENDICITIS; CHOLECYSTITIS; PERITONITIS; and after LIVER TRANSPLANTATION.		02.4520
Fungemia
The presence of fungi circulating in the blood. Opportunistic fungal sepsis is seen most often in immunosuppressed patients with severe neutropenia or in postoperative patients with intravenous catheters and usually follows prolonged antibiotic therapy.		02.0510
Bronchial Pneumonia
[description not available]		04.131
EBV Infections
[description not available]		02.0510
Infections, Parvoviridae
[description not available]		02.0510
Epstein-Barr Virus Infections
Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).		02.0510
Actinomyces Infections
[description not available]		02.0510
Lipodystrophy, Intestinal
[description not available]		06.0861
Leukocytopenia
[description not available]		02.4620
Leukopenia
A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).		02.4620
Abdomen, Acute
A clinical syndrome with acute abdominal pain that is severe, localized, and rapid in onset. Acute abdomen may be caused by a variety of disorders, injuries, or diseases.		02.0510
Botulism, Infantile
[description not available]		02.0510
Botulism
A disease caused by potent protein NEUROTOXINS produced by CLOSTRIDIUM BOTULINUM which interfere with the presynaptic release of ACETYLCHOLINE at the NEUROMUSCULAR JUNCTION. Clinical features include abdominal pain, vomiting, acute PARALYSIS (including respiratory paralysis), blurred vision, and DIPLOPIA. Botulism may be classified into several subtypes (e.g., food-borne, infant, wound, and others). (From Adams et al., Principles of Neurology, 6th ed, p1208)		02.0510
Aneurysm, Thoracic Aortic
[description not available]		02.0510
Aortic Aneurysm, Thoracic
An abnormal balloon- or sac-like dilatation in the wall of the THORACIC AORTA. This proximal descending portion of aorta gives rise to the visceral and the parietal branches above the aortic hiatus at the diaphragm.		02.0510
Cecitis
[description not available]		02.0510
Proctitis
INFLAMMATION of the MUCOUS MEMBRANE of the RECTUM, the distal end of the large intestine (INTESTINE, LARGE).		02.0510
Cranial Nerve Diseases
Disorders of one or more of the twelve cranial nerves. With the exception of the optic and olfactory nerves, this includes disorders of the brain stem nuclei from which the cranial nerves originate or terminate.		02.0510
Bowel Diseases, Inflammatory
[description not available]		03.4411
Inflammatory Bowel Diseases
Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.		03.4411
Acute Brain Injuries
[description not available]		02.4120
Disease, Pulmonary
[description not available]		02.6930
Brain Injuries
Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.		02.4120
Lung Diseases
Pathological processes involving any part of the LUNG.		02.6930
Empyema, Gall Bladder
[description not available]		02.0510
Cholecystitis
Inflammation of the GALLBLADDER; generally caused by impairment of BILE flow, GALLSTONES in the BILIARY TRACT, infections, or other diseases.		02.0510
Genetic Diseases, X-Chromosome Linked
[description not available]		02.9710
Malabsorption Syndromes
General term for a group of MALNUTRITION syndromes caused by failure of normal INTESTINAL ABSORPTION of nutrients.		02.9710
Endomyometritis
Inflammation of both the ENDOMETRIUM and the MYOMETRIUM, usually caused by infections after a CESAREAN SECTION.		02.0610
Endometritis
Inflammation of the ENDOMETRIUM, usually caused by intrauterine infections. Endometritis is the most common cause of postpartum fever.		02.0610
Bile Duct Diseases
Diseases in any part of the ductal system of the BILIARY TRACT from the smallest BILE CANALICULI to the largest COMMON BILE DUCT.		02.0510
Left Heart Hypoplasia Syndrome
[description not available]		02.1510
Hypoplastic Left Heart Syndrome
A condition caused by underdevelopment of the whole left half of the heart. It is characterized by hypoplasia of the left cardiac chambers (HEART ATRIUM; HEART VENTRICLE), the AORTA, the AORTIC VALVE, and the MITRAL VALVE. Severe symptoms appear in early infancy when DUCTUS ARTERIOSUS closes.		02.1510
Abdominal Aortic Aneurysm
[description not available]		02.0610
Atherogenesis
[description not available]		02.0610
Endoleak
Postoperative hemorrhage from an endovascular AORTIC ANEURYSM repaired with endoluminal placement of stent grafts (BLOOD VESSEL PROSTHESIS IMPLANTATION). It is associated with pressurization, expansion, and eventual rupture of the aneurysm.		02.0610
Aortic Aneurysm, Abdominal
An abnormal balloon- or sac-like dilatation in the wall of the ABDOMINAL AORTA which gives rise to the visceral, the parietal, and the terminal (iliac) branches below the aortic hiatus at the diaphragm.		02.0610
Atherosclerosis
A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.		02.0610
Abscess, Subdiaphragmatic
[description not available]		02.0510
Myositis, Multiple
[description not available]		02.0610
Polymyositis
Diseases characterized by inflammation involving multiple muscles. This may occur as an acute or chronic condition associated with medication toxicity (DRUG TOXICITY); CONNECTIVE TISSUE DISEASES; infections; malignant NEOPLASMS; and other disorders. The term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. The illness may occur at any age, but is most frequent in the fourth to sixth decade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. Muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (Adams et al., Principles of Neurology, 6th ed, pp1404-9)		02.0610
Haemophilus influenzae Meningitis Type B
[description not available]		03.1250
Hematoma
A collection of blood outside the BLOOD VESSELS. Hematoma can be localized in an organ, space, or tissue.		02.4720
Rodent Diseases
Diseases of rodents of the order RODENTIA. This term includes diseases of Sciuridae (squirrels), Geomyidae (gophers), Heteromyidae (pouched mice), Castoridae (beavers), Cricetidae (rats and mice), Muridae (Old World rats and mice), Erethizontidae (porcupines), and Caviidae (guinea pigs).		02.0610
Myelopathy
[description not available]		02.0610
Spinal Cord Diseases
Pathologic conditions which feature SPINAL CORD damage or dysfunction, including disorders involving the meninges and perimeningeal spaces surrounding the spinal cord. Traumatic injuries, vascular diseases, infections, and inflammatory/autoimmune processes may affect the spinal cord.		02.0610
Cystitis
Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.		02.0610
Cerebral Ischemia
[description not available]		04.5930
Brain Ischemia
Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.		04.5930
Gastric Fistula
Abnormal passage communicating with the STOMACH.		02.0610
Digestive System Fistula
An abnormal passage communicating between any components of the digestive system, or between any part of the digestive system and surrounding organ(s).		02.0610
Genetic Predisposition
[description not available]		02.9810
Central Nervous System Disease
[description not available]		03.3920
Immune Reconstitution Disease
[description not available]		02.9810
Central Nervous System Diseases
Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.		03.3920
Aneurysm, Ruptured
The tearing or bursting of the weakened wall of the aneurysmal sac, usually heralded by sudden worsening pain. The great danger of a ruptured aneurysm is the large amount of blood spilling into the surrounding tissues and cavities, causing HEMORRHAGIC SHOCK.		02.9810
Hemorrhage, Subarachnoid
[description not available]		03.6630
Subarachnoid Hemorrhage
Bleeding into the intracranial or spinal SUBARACHNOID SPACE, most resulting from INTRACRANIAL ANEURYSM rupture. It can occur after traumatic injuries (SUBARACHNOID HEMORRHAGE, TRAUMATIC). Clinical features include HEADACHE; NAUSEA; VOMITING, nuchal rigidity, variable neurological deficits and reduced mental status.		03.6630
Hangman Fracture
[description not available]		02.0710
Spinal Fractures
Broken bones in the vertebral column.		02.0710
Apnea
A transient absence of spontaneous respiration.		02.0610
Convulsions, Grand Mal
[description not available]		02.0610
Epilepsy, Tonic-Clonic
A generalized seizure disorder characterized by recurrent major motor seizures. The initial brief tonic phase is marked by trunk flexion followed by diffuse extension of the trunk and extremities. The clonic phase features rhythmic flexor contractions of the trunk and limbs, pupillary dilation, elevations of blood pressure and pulse, urinary incontinence, and tongue biting. This is followed by a profound state of depressed consciousness (post-ictal state) which gradually improves over minutes to hours. The disorder may be cryptogenic, familial, or symptomatic (caused by an identified disease process). (From Adams et al., Principles of Neurology, 6th ed, p329)		02.0610
Lung Injury, Acute
[description not available]		02.0710
Acute Lung Injury
A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).		07.0710
Dejerine-Roussy Syndrome
[description not available]		02.0610
Scoliosis
An appreciable lateral deviation in the normally straight vertical line of the spine. (Dorland, 27th ed)		02.0610
Cholera Infantum
[description not available]		04.6432
Hypoalbuminemia
A condition in which albumin level in blood (SERUM ALBUMIN) is below the normal range. Hypoalbuminemia may be due to decreased hepatic albumin synthesis, increased albumin catabolism, altered albumin distribution, or albumin loss through the urine (ALBUMINURIA).		02.0710
Ankylosing Spondylarthritis
[description not available]		02.0610
Emphysema, Subcutaneous
[description not available]		02.0610
Spondylitis, Ankylosing
A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions.		02.0610
Infections, Legionella pneumophila
[description not available]		02.4820
Interstitial Nephritis
[description not available]		07.4820
Nephritis, Interstitial
Inflammation of the interstitial tissue of the kidney. This term is generally used for primary inflammation of KIDNEY TUBULES and/or surrounding interstitium. For primary inflammation of glomerular interstitium, see GLOMERULONEPHRITIS. Infiltration of the inflammatory cells into the interstitial compartment results in EDEMA, increased spaces between the tubules, and tubular renal dysfunction.		02.4820
Aneurysm, Anterior Cerebral Artery
[description not available]		02.0710
Carotid Artery Dissection, Internal
[description not available]		02.0710
Intracranial Aneurysm
Abnormal outpouching in the wall of intracranial blood vessels. Most common are the saccular (berry) aneurysms located at branch points in CIRCLE OF WILLIS at the base of the brain. Vessel rupture results in SUBARACHNOID HEMORRHAGE or INTRACRANIAL HEMORRHAGES. Giant aneurysms (		02.0710
Cancer of Muscle
[description not available]		02.0610
Ileal Diseases
Pathological development in the ILEUM including the ILEOCECAL VALVE.		02.9910
Cholecystoduodenal Fistula
[description not available]		02.9910
Urinary Bladder Fistula
An abnormal passage in the URINARY BLADDER or between the bladder and any surrounding organ.		02.9910
Carcinoma, Small Cell Lung
[description not available]		02.0710
Dyskinesia Syndromes
[description not available]		02.4220
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Disorder characterized by symptoms of CATATONIA; HYPOVENTILATION; DYSKINESIAS; ENCEPHALITIS; and SEIZURES followed by a reduced CONSCIOUSNESS. It is often followed by a viral-like prodrome. Many cases are self-limiting and respond well to IMMUNOMODULATORY THERAPIES against the NMDA RECEPTORS antibodies.		02.0710
Movement Disorders
Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.		02.4220
Small Cell Lung Carcinoma
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).		02.0710
Brain Dead
[description not available]		02.0610
African Lymphoma
[description not available]		02.0710
Burkitt Lymphoma
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.		02.0710
Brain Damage, Chronic
A condition characterized by long-standing brain dysfunction or damage, usually of three months duration or longer. Potential etiologies include BRAIN INFARCTION; certain NEURODEGENERATIVE DISORDERS; CRANIOCEREBRAL TRAUMA; ANOXIA, BRAIN; ENCEPHALITIS; certain NEUROTOXICITY SYNDROMES; metabolic disorders (see BRAIN DISEASES, METABOLIC); and other conditions.		02.9910
Facial Dermatoses
Skin diseases involving the FACE.		02.4420
Blood Diseases
[description not available]		05.5832
Hematologic Diseases
Disorders of the blood and blood forming tissues.		05.5832
Anemia, Hypoplastic
[description not available]		04.3340
Anemia, Aplastic
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.		04.3340
Piriformis Muscle Syndrome
A chronic PELVIC PAIN characterized by pain deep in the buttock that may radiate to posterior aspects of the leg. It is caused by the piriformis muscle compressing or irritating the SCIATIC NERVE due to trauma, hypertrophy, inflammation or anatomic variations.		02.0710
Neuralgia, Sciatic
[description not available]		02.0710
Sciatica
A condition characterized by pain radiating from the back into the buttock and posterior/lateral aspects of the leg. Sciatica may be a manifestation of SCIATIC NEUROPATHY; RADICULOPATHY (involving the SPINAL NERVE ROOTS; L4, L5, S1, or S2, often associated with INTERVERTEBRAL DISK DISPLACEMENT); or lesions of the CAUDA EQUINA.		02.0710
Frontal Sinusitis
Inflammation of the NASAL MUCOSA in the FRONTAL SINUS. In many cases, it is caused by an infection of the bacteria STREPTOCOCCUS PNEUMONIAE or HAEMOPHILUS INFLUENZAE.		02.0810
Plasmodium falciparum Malaria
[description not available]		02.0710
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.0710
Hematoma, Subdural, Acute
Accumulation of blood in the SUBDURAL SPACE with acute onset of neurological symptoms. Symptoms may include loss of consciousness, severe HEADACHE, and deteriorating mental status.		02.9910
Anterior Cervical Pain
[description not available]		02.0710
Chills
The sudden sensation of being cold. It may be accompanied by SHIVERING.		02.0710
Neck Pain
Discomfort or more intense forms of pain that are localized to the cervical region. This term generally refers to pain in the posterior or lateral regions of the neck.		02.0710
Nephrotic Syndrome
A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.		0310
Infections, Mycobacterium
[description not available]		02.9210
Mycobacterium Infections
Infections with bacteria of the genus MYCOBACTERIUM.		02.9210
Cellulitis, Pelvic
[description not available]		03.3911
Parametritis
Inflammation of the parametrium, the connective tissue of the pelvic floor, extending from the subserous coat of the uterus laterally between the layers of the BROAD LIGAMENT.		03.3911
Alcoholic Hepatitis
[description not available]		02.0110
Hepatitis, Alcoholic
INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.		02.0110
Serum Sickness
Immune complex disease caused by the administration of foreign serum or serum proteins and characterized by fever, lymphadenopathy, arthralgia, and urticaria. When they are complexed to protein carriers, some drugs can also cause serum sickness when they act as haptens inducing antibody responses.		07.0110
Cholesteatoma
A non-neoplastic mass of keratin-producing squamous EPITHELIUM, frequently occurring in the MENINGES; bones of the skull, and most commonly in the MIDDLE EAR and MASTOID region. Cholesteatoma can be congenital or acquired. Cholesteatoma is not a tumor nor is it associated with high CHOLESTEROL.		02.0110
Pemphigoid
[description not available]		02.0110
Pemphigoid, Bullous
A chronic and relatively benign subepidermal blistering disease usually of the elderly and without histopathologic acantholysis.		02.0110
Pancreatic Insufficiency
[description not available]		02.0110
Nasal Polyps
Focal accumulations of EDEMA fluid in the NASAL MUCOSA accompanied by HYPERPLASIA of the associated submucosal connective tissue. Polyps may be NEOPLASMS, foci of INFLAMMATION, degenerative lesions, or malformations.		02.0110
Exocrine Pancreatic Insufficiency
A malabsorption condition resulting from greater than 10% reduction in the secretion of pancreatic digestive enzymes (LIPASE; PROTEASES; and AMYLASE) by the EXOCRINE PANCREAS into the DUODENUM. This condition is often associated with CYSTIC FIBROSIS and with chronic PANCREATITIS.		02.0110
Histiocytosis, Non-Langerhans-Cell
Group of disorders which feature accumulations of active HISTIOCYTES and LYMPHOCYTES, but where the histiocytes are not LANGERHANS CELLS. The group includes HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; SINUS HISTIOCYTOSIS; xanthogranuloma; reticulohistiocytoma; JUVENILE XANTHOGRANULOMA; xanthoma disseminatum; as well as the lipid storage diseases (SEA-BLUE HISTIOCYTE SYNDROME; and NIEMANN-PICK DISEASES).		02.0110
Granulocytic Leukemia
[description not available]		03.411
B-Cell Chronic Lymphocytic Leukemia
[description not available]		03.411
Leukemia, Myeloid
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.		03.411
Leukemia, Lymphocytic, Chronic, B-Cell
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.		03.411
Middle Ear Inflammation
[description not available]		03.6230
Cranial Nerve III Diseases
[description not available]		02.9310
Otitis Media
Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE.		03.6230
Tachyarrhythmia
[description not available]		02.0210
Atrioventricular Nodal Re-Entrant Tachycardia
[description not available]		02.0210
Tachycardia
Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.		02.0210
Tachycardia, Ventricular
An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).		02.0210
Diffuse Mixed Small and Large Cell Lymphoma
[description not available]		04.3422
Lymphoma, Non-Hodgkin
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.		04.3422
Chronic Bronchitis
[description not available]		02.0110
Bronchitis, Chronic
A subcategory of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. The disease is characterized by hypersecretion of mucus accompanied by a chronic (more than 3 months in 2 consecutive years) productive cough. Infectious agents are a major cause of chronic bronchitis.		02.0110
Acquired Meningomyelocele
[description not available]		02.0210
Sigmoid Colon Diseases
[description not available]		02.0210
Air Embolism
[description not available]		02.0210
Ileitis
Inflammation of any segment of the ILEUM and the ILEOCECAL VALVE.		02.0210
Adult Neuroaxonal Dystrophy
[description not available]		02.0210
Moniliasis, Oral
[description not available]		02.0310
Candidiasis, Oral
Infection of the mucous membranes of the mouth by a fungus of the genus CANDIDA. (Dorland, 27th ed)		02.0310
Uremia
A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.		03.630
Anemia, Sideroblastic
Anemia characterized by the presence of erythroblasts containing excessive deposits of iron in the marrow.		02.0210
Infections, Yersinia
[description not available]		02.0210
Acute Hemolytic Transfusion Reaction
[description not available]		02.0210
Iron Overload
An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989)		02.0210
Transfusion Reaction
Complications of BLOOD TRANSFUSION. Included adverse reactions are common allergic and febrile reactions; hemolytic (delayed and acute) reactions; and other non-hemolytic adverse reactions such as infections and adverse immune reactions related to immunocompatibility.		02.0210
Cardiac Hypertrophy
Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.		02.0310
Acute Q Fever
[description not available]		02.0310
Cardiomegaly
Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.		02.0310
Adult-Onset Still Disease
[description not available]		02.4320
Still's Disease, Adult-Onset
Systemic-onset rheumatoid arthritis in adults. It differs from classical rheumatoid arthritis in that it is more often marked by acute febrile onset, and generalized lymphadenopathy and hepatosplenomegaly are more prominent.		02.4320
Leg Dermatoses
A nonspecific term used to denote any cutaneous lesion or group of lesions, or eruptions of any type on the leg. (From Stedman, 25th ed)		02.0310
Deep Vein Thrombosis
[description not available]		03.3520
Venous Thrombosis
The formation or presence of a blood clot (THROMBUS) within a vein.		03.3520
Fistula
Abnormal communication most commonly seen between two internal organs, or between an internal organ and the surface of the body.		02.0310
Idiopathic Parkinson Disease
[description not available]		02.0310
Parkinson Disease
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)		02.0310
Spinal Stenosis
Narrowing of the spinal canal.		02.0310
Cardiac Tamponade
Compression of the heart by accumulated fluid (PERICARDIAL EFFUSION) or blood (HEMOPERICARDIUM) in the PERICARDIUM surrounding the heart. The affected cardiac functions and CARDIAC OUTPUT can range from minimal to total hemodynamic collapse.		02.0310
Muscle Disorders
[description not available]		02.0310
Muscular Diseases
Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE.		02.0310
Angioblastic Meningioma
[description not available]		02.0210
Meningioma
A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)		02.0210
Amputation, Traumatic
Loss of a limb or other bodily appendage by accidental injury.		02.0310
Absence Status
[description not available]		02.0310
Status Epilepticus
A prolonged seizure or seizures repeated frequently enough to prevent recovery between episodes occurring over a period of 20-30 minutes. The most common subtype is generalized tonic-clonic status epilepticus, a potentially fatal condition associated with neuronal injury and respiratory and metabolic dysfunction. Nonconvulsive forms include petit mal status and complex partial status, which may manifest as behavioral disturbances. Simple partial status epilepticus consists of persistent motor, sensory, or autonomic seizures that do not impair cognition (see also EPILEPSIA PARTIALIS CONTINUA). Subclinical status epilepticus generally refers to seizures occurring in an unresponsive or comatose individual in the absence of overt signs of seizure activity. (From N Engl J Med 1998 Apr 2;338(14):970-6; Neurologia 1997 Dec;12 Suppl 6:25-30)		07.0310
Atopic Hypersensitivity
[description not available]		04.1131
Arthritis, Post-Infectious
[description not available]		02.0310
Intestinal Diseases
Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.		02.0310
Arthritis, Reactive
An aseptic, inflammatory arthritis developing secondary to a primary extra-articular infection, most typically of the GASTROINTESTINAL TRACT or UROGENITAL SYSTEM. The initiating trigger pathogens are usually SHIGELLA; SALMONELLA; YERSINIA; CAMPYLOBACTER; or CHLAMYDIA TRACHOMATIS. Reactive arthritis is strongly associated with HLA-B27 ANTIGEN.		02.0310
Cardiomyopathies, Primary
[description not available]		02.0310
Oliguria
Decreased URINE output that is below the normal range. Oliguria can be defined as urine output of less than or equal to 0.5 or 1 ml/kg/hr depending on the age.		02.0310
Cardiomyopathies
A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).		02.0310
Leukemia, Megakaryocytic
[description not available]		02.0410
Leukemia, Megakaryoblastic, Acute
An acute myeloid leukemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. MYELOFIBROSIS or increased bone marrow RETICULIN is common.		02.0410
Familial Waldenstrom's Macroglobulinaemia
[description not available]		02.0310
Waldenstrom Macroglobulinemia
A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.		02.0310
Deficiency, Factor 10
[description not available]		02.0410
Factor X Deficiency
Blood coagulation disorder usually inherited as an autosomal recessive trait, though it can be acquired. It is characterized by defective activity in both the intrinsic and extrinsic pathways, impaired thromboplastin time, and impaired prothrombin consumption.		02.0410
Cancer of Testis
[description not available]		02.0310
Testicular Neoplasms
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.		02.0310
Benign Infantile Myoclonic Epilepsy
[description not available]		02.0410
Epilepsies, Myoclonic
A clinically diverse group of epilepsy syndromes characterized either by myoclonic seizures or by myoclonus in association with other seizure types. Myoclonic epilepsy syndromes are divided into three subtypes based on etiology: familial, cryptogenic, and symptomatic.		02.0410
Diseases in Twins
Disorders affecting TWINS, one or both, at any age.		02.9510
Wounds, Gunshot
Disruption of structural continuity of the body as a result of the discharge of firearms.		02.0410
Dehiscence, Surgical Wound
[description not available]		02.0410
Diverticulitis
Inflammation of a DIVERTICULUM or diverticula.		02.0410
Female Genital Diseases
[description not available]		06.5754
Genital Diseases, Female
Pathological processes involving the female reproductive tract (GENITALIA, FEMALE).		06.5754
Nervous System Disorders
[description not available]		03.3711
Nervous System Diseases
Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.		03.3711
Ulcer
A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.		03.3711
Meningitis, Viral
Viral infections of the leptomeninges and subarachnoid space. TOGAVIRIDAE INFECTIONS; FLAVIVIRIDAE INFECTIONS; RUBELLA; BUNYAVIRIDAE INFECTIONS; ORBIVIRUS infections; PICORNAVIRIDAE INFECTIONS; ORTHOMYXOVIRIDAE INFECTIONS; RHABDOVIRIDAE INFECTIONS; ARENAVIRIDAE INFECTIONS; HERPESVIRIDAE INFECTIONS; ADENOVIRIDAE INFECTIONS; JC VIRUS infections; and RETROVIRIDAE INFECTIONS may cause this form of meningitis. Clinical manifestations include fever, headache, neck pain, vomiting, PHOTOPHOBIA, and signs of meningeal irritation. (From Joynt, Clinical Neurology, 1996, Ch26, pp1-3)		03.3711
Obstructive Lung Diseases
[description not available]		04.6921
Bronchitis
Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.		04.9931
Lung Diseases, Obstructive
Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.		04.6921
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		06.3731
Bordetella pertussis Infection, Respiratory
[description not available]		01.9910
Whooping Cough
A respiratory infection caused by BORDETELLA PERTUSSIS and characterized by paroxysmal coughing ending in a prolonged crowing intake of breath.		01.9910
Alcoholic Cirrhosis
[description not available]		03.3811
Liver Cirrhosis, Alcoholic
FIBROSIS of the hepatic parenchyma due to chronic excess ALCOHOL DRINKING.		03.3811
Weight Reduction
[description not available]		01.9910
Weight Loss
Decrease in existing BODY WEIGHT.		01.9910
Brain Swelling
[description not available]		01.9910
Brain Edema
Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)		01.9910
Mastoiditis
Inflammation of the honeycomb-like MASTOID BONE in the skull just behind the ear. It is usually a complication of OTITIS MEDIA.		06.9910
Paraneoplastic Syndromes
In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products.		01.9910
Pleural Effusion, Malignant
Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells.		01.9910
Bronchiectasis
Persistent abnormal dilatation of the bronchi.		08.3911
Peritoneal Diseases
Pathological processes involving the PERITONEUM.		03.3911
Cardiovascular Stroke
[description not available]		0210
Myocardial Infarction
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).		0210
Pulmonary Sarcoidosis
[description not available]		0210
Sarcoidosis, Pulmonary
Sarcoidosis affecting predominantly the lungs, the site most frequently involved and most commonly causing morbidity and mortality in sarcoidosis. Pulmonary sarcoidosis is characterized by sharply circumscribed granulomas in the alveolar, bronchial, and vascular walls, composed of tightly packed cells derived from the mononuclear phagocyte system. The clinical symptoms when present are dyspnea upon exertion, nonproductive cough, and wheezing. (Cecil Textbook of Medicine, 19th ed, p431)		0210
Bone Marrow Diseases
Diseases involving the BONE MARROW.		0210
Linear Skull Fracture
[description not available]		0210
Convalescence
The period of recovery following an illness.		0210
Borrelia hermsii Infection
[description not available]		03.3911
Dermatitis, Occupational
A recurrent contact dermatitis caused by substances found in the work place.		0210
Sicca Syndrome
[description not available]		02.0110
Sjogren's Syndrome
Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis.		02.0110
Microbial Superinvasion
[description not available]		03.3911
Lymphatic Diseases
Diseases of LYMPH; LYMPH NODES; or LYMPHATIC VESSELS.		03.3611
Leukemia, Lymphocytic, T Cell
[description not available]		03.3611
Leukemia, T-Cell
A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.		03.3611